"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02273739","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",,"Completed","No Results Available","Solid Tumor|Glioma|Angioimmunoblastic T-cell Lymphoma|Intrahepatic Cholangiocarcinoma|Chondrosarcoma","Drug: AG-221","Safety/tolerability: incidence of adverse events|Maximum Tolerated Dose and/or the recommended Phase II dose of AG-221 in subjects with advanced solid tumors, including glioma, and AITL|Identification and Description of Dose Limiting Toxicities associated with AG-221 in subjects with advanced solid tumors, including glioma, and with AITL|Pharmacokinetic profiles including max concentration (Cmax), time to maximum concentration (Tmax), AUC, and elimination half-life|Pharmacodynamic relationship between levels of AG-221 and 2-HG|Clinical Activity according to RECIST v1.1 (2009), RANO (2010), and IWG for malignant lymphoma (2007)","Celgene|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG221-C-003","October 24, 2014","June 30, 2016","June 30, 2016","October 24, 2014",,"October 30, 2018","Los Angeles, California, United States|Los Angeles, California, United States|Miami, Florida, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Omaha, Nebraska, United States|New York, New York, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Bordeaux, France|Villejuif Cedex, France",,"https://ClinicalTrials.gov/show/NCT02273739"
2,"NCT02103335","Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma in Relapse|Refractory Multiple Myeloma|Multiple Myeloma","Drug: pomalidomide|Drug: marizomib|Drug: low-dose dexamethasone","Maximum tolerated dose and/or recommended Phase 2 dose|Adverse events|Response rate","Celgene|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPI-0052-107","June 5, 2014","October 3, 2016","November 30, 2016","April 3, 2014",,"November 22, 2017","University of Chicago Medical Center, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Alfred Hospital, Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02103335"
3,"NCT03983239","Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects",,"Recruiting","No Results Available","Healthy Volunteers","Drug: Fedratinib|Drug: Rifampin|Drug: Efavirenz","Fedratinib Pharmacokinetic - Cmax|Fedratinib Pharmacokinetic - Tmax|Fedratinib Pharmacokinetic - AUC0-t|Fedratinib Pharmacokinetic - AUC0-∞|Fedratinib Pharmacokinetic - t1/2|Fedratinib Pharmacokinetic - CL/F|Fedratinib Pharmacokinetic - Vz/F|Adverse Events (AEs)","Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FEDR-CP-002|U1111-1233-7946","December 15, 2019","December 15, 2020","December 15, 2020","June 12, 2019",,"October 18, 2019","Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03983239"
4,"NCT03983161","A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment",,"Not yet recruiting","No Results Available","Healthy Volunteers|Hepatic Impairment","Drug: Fedratinib","Fedratinib Pharmacokinetic (PK): AUC0-t|Fedratinib Pharmacokinetic (PK): AUC0-∞|Fedratinib Pharmacokinetic (PK): Cmax|Fedratinib Pharmacokinetic (PK): Tmax|Fedratinib Pharmacokinetic (PK): t1/2|Fedratinib Pharmacokinetic (PK): CL/F|Fedratinib Pharmacokinetic (PK): Vz/F|Adverse Events (AEs)","Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FEDR-CP-001|U1111-1233-7820","December 15, 2019","December 15, 2021","December 15, 2021","June 12, 2019",,"October 15, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, United States|Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03983161"
5,"NCT03952039","An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","FREEDOM2","Recruiting","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera|Myelofibrosis","Drug: FEDRATINIB|Drug: Best Available Therapy (BAT)","Proportion of subjects who have ≥ 35% SVR at end of cycle 6|Proportion of subjects with ≥ 50% reduction in total symptom scores measured by MFSAF at end of cycle 6|Proportion of subjects who have ≥ 25% reduction in spleen volume at the end of cycle 6|Adverse Events (AEs)|Proportion of subjects who have ≥ 50% reduction in spleen size by palpation at end of cycle 6|Durability of Spleen Volume Response by MRI/CT (DR)|Duration of ≥ 50 % reduction in spleen size by palpation for subjects with a palpable spleen at least 5 cm below the left costal margin (LCM) at baseline|Duration of ≥ 50% reduction in total symptom scores measured by MFSAF|Time from randomization to death due to any reason or disease progression (modified IWG-MRT 2013 including ≥ 25% increase in spleen volume by MRI/CT)|Gastrointestinal Adverse Events|Wernicke encephalopathy (WE) events|Health-Related Quality of Life (HRQoL)|EQ-5D-5L|Overall Survival (OS)","Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","192","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FEDR-MF-002|U1111-1223-2962|2018-003411-21","September 9, 2019","November 24, 2021","May 24, 2025","May 16, 2019",,"October 22, 2019","Saint Vincent's Hospital, Darlinghurst, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Frankston Hospital, Frankston, Victoria, Australia|Eastern Health Clinical School, Box Hill, Australia|Alfred Hospital, Melbourne, Australia|Medizinische Universitat Innsbruck, Innsbruck, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Hanusch Krankenhaus, Wien, Austria|AZ Sint-Jan AV Brugge, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Centre Hospitalier de Jolimont-Lobbes, La Louvière-(Haine St-Paul), Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liege - Sart Tilman, Liège, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Peking University People's Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Fujian Medical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China|Shanghai Ruijin Hospital, Shanghai, China|Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China|Henan Cancer Hospital, Zhengzhou, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia|Vseobecna Fakultni Nemocnice v Praze, Prague 2, Czechia|CHU d'Angers, Angers, France|CHRU de Brest - Hopital Morvan, Brest, France|Centre Hospitalier de Lens, Lens Cedex, France|CHRU Claude Huriez, Lille, France|CHU Nice Hopital de L'Archet 2, Nice Cedex 3, France|Centre Hospitalier Universitaire de Nimes - Hopital Universitaire Caremeau, Nimes Cedex 9, France|Hopital Saint Louis, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud - Hospices Civils de Lyon Groupement Hospitalier Sud, Pierre-Benite, France|CHU Strasbourg - Hopital Civil, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Unviversitatsklinikum Aachen, Aachen, Germany|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Universitaetsklinikum Halle Saale, Halle, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Magdeburg A oeR, Magdeburg, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|Johannes Wiesling Klinikum Minden, Minden, Germany|TU München - Klinikum rechts der Isar, München, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Semmelweis Egyetem, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Szegedi Tudomanyegyetem - Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Cork University Hospital, Cork, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|St. James' Hospital, Dublin, Ireland|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST Spedali Civili P.O. di Brescia, Brescia, Italy|Azienda Ospedaliero - Universitaria ""Policlinico - Vittorio Emanuele"" - Ospedale Gaspare Rodolico, Catania, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|IRCSS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy|Ospedale Cardarelli, Naples, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Universita Cattololica del Sacro Cuore, Roma, Italy|Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Italy|Policlinico Umberto I - Università La Sapienza, Rome, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul St Marys Hospital College of Medicine The Catholic University of Korea, Seoul, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|UMC Maastricht, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Oddzial Kliniczny Kliniki Hematologii, Krakow, Poland|Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Instytut Hematologii i Transfuzjologii w Warszawie, Warszawa, Poland|Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego, Wroclaw, Poland|Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin, Moscow, Russian Federation|Semashko Central Clinical Hospital #2 under OJSC Russian Railways, Moscow, Russian Federation|Russian Research Institute of Hematology and Transfusiology of the Federal Biomedical Agency, Saint Petersburg, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St Petersburg, Russian Federation|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital Universitario Cruces, Barakaldo, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, United Kingdom|United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom|Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, United Kingdom|Imperial College Hammersmith Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|The Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03952039"
6,"NCT03755518","An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","FREEDOM","Recruiting","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera|Myelofibrosis","Drug: FEDRATINIB","Proportion of subjects who have a ≥ 35% SVR at end of Cycle 6|Adverse Event(s)|Proportion of subjects who have ≥ 50% reduction in spleen size by|Symptom response rate (SRR)|To evaluate durability of spleen volume response (DR)|To evaluate the durability of spleen response by palpation (DRP)|Durability of symptoms response (DSR)|Gastrointestinal Adverse Events|Wernicke encephalopathy (WE) events|Wernicke encephalopathy (WE) thiamine monitoring","Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","110","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FEDR-MF-001|U1111-1223-2862|2018-002237-38","March 27, 2019","June 6, 2022","June 6, 2022","November 28, 2018",,"October 1, 2019","Mayo Clinic Phoenix, Phoenix, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Baptist Health - Miami Cardiac & Vascular Institute, Miami, Florida, United States|Augusta University - Georgia Cancer Center, Augusta, Georgia, United States|Rush University Medical Center - University Cardiovascular Surgeons, Chicago, Illinois, United States|The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois, United States|Advocate Medical Group, Park Ridge, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|St. Agnes - Medical Center, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, P.C., Bethesda, Maryland, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington Univ School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|North Carolina Women's Hospital, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|UC Health Barrett Cancer Center, Cincinnati, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|UT Health - San Antonio, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Wisconsin Medical School, Madison, Wisconsin, United States|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03755518"
7,"NCT03723148","Individual Patient Compassionate Use of Fedratinib",,"Available","No Results Available","Myelofibrosis","Drug: Oral Fedratinib",,"Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","All","18 Years and older   (Adult, Older Adult)",,,"Industry|Other","Expanded Access:Individual Patients",,"FEDR",,,,"October 29, 2018",,"October 22, 2019","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03723148"
8,"NCT01163071","A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas",,"Terminated","No Results Available","Advanced Solid Tumors","Drug: ABI-011","DLT's and MTD Safety and Toxicity profile|Safety and toxicity profile of repeated dosing of ABI-011|Evaluate plasma PK of ABI-011 on this schedule|Assess biological activity and PD of ABI-011|Make preliminary assessment of tumor response|Assess biological activity/exploratory during treatment C1, C2, EOS","Celgene|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA601","March 1, 2011","September 23, 2011","September 23, 2011","July 15, 2010",,"November 14, 2019","Karmanos Cancer Center Institute, Detroit, Michigan, United States|CTRC @ The Utah Health Science Center @ San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01163071"
9,"NCT00106431","A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)",,"Completed","Has Results","Cutaneous T-cell Lymphoma","Drug: romidepsin (depsipeptide, FK228)","The Percent of Patients (Pts) With Objective Disease Response|Duration of Objective Disease Response|Time to Objective Disease Response|Time to Disease Progression|Decrease in Pruritus Visual Analogue Scale (VAS) Score of ≥30 mm or a Score of 0 for at Least 2 Consecutive Cycles.|Duration of Objective Disease Control (ODC)|Percent of Pts With Objective Disease Control","Celgene|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GPI-04-0001","January 1, 2005","June 1, 2008","December 1, 2008","March 25, 2005","April 23, 2010","October 30, 2019","UCLA Jonsson Cancer Center, Los Angeles, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Pennsylvania Abrahamson Cancer Center, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Research Site, Multiple Locations, France|Research Site, Multiple Locations, Germany|Research Site, Multiple Locations, Poland|Research Site, Multiple Locations, Russian Federation|Research Site, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00106431"
10,"NCT04149678","Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites",,"Recruiting","No Results Available","Healthy Volunteers","Drug: Ozanimod|Drug: Cyclosporine","Pharmacokinetic - Cmax|Pharmacokinetic - AUC∞|Pharmacokinetic - AUClast|Adverse Events (AEs)|Pharmacokinetic - Tmax|Pharmacokinetic - CL/F|Pharmacokinetic - Vz/F|Pharmacokinetic - t1/2","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC-1063-CP-001|U1111-1239-1156","October 4, 2019","November 13, 2019","December 28, 2019","November 4, 2019",,"November 4, 2019","ICON Early Phase Services, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04149678"
11,"NCT04143724","Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Subjects Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.",,"Not yet recruiting","No Results Available","Beta-Thalassemia","Drug: ACE-536","Determination of the Recommended Dose|Pharmacokinetics - Cmax|Pharmacokinetics - AUC|To evaluate the change in RBC transfusion burden|To evaluate the change in hemoglobin levels over the course of the study|Safety Adverse Events (AEs)|Frequency of antidrug antibodies and its effect on safety|Exposure-response relationships for measures of activities and toxicity","Celgene|Acceleron Pharma, Inc.","All","6 Months to 18 Years   (Child, Adult)","Phase 2","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-B-THAL-004|U1111-1241-4168|2019-000208-13","November 1, 2019","December 4, 2021","September 2, 2026","October 29, 2019",,"October 29, 2019","Children's Hospital of Los Angeles, Los Angeles, California, United States|Universitatsklinikum Ulm, Ulm, Germany|General Children's Hospital ""Agia Sophia"", Athens, Greece|Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite, Genoa, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano, Italy|Siriraj Hospital Mahidol University, Bangkok, Thailand|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT04143724"
12,"NCT04140305","Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)","ENLIGHTEN","Not yet recruiting","No Results Available","Multiple Sclerosis","Drug: RPC-1063","Proportion of subjects with an increase in raw score of ≥ 4 points or 10% from baseline (improved)|Proportion of subjects with a decrease in raw score of ≥ 4 points or 10% from baseline (worsened)|Proportion of subjects with a raw score change from baseline who do not meet the improved or worsened definition (stable)|Proportion of subjects with an increase in raw score of ≥ 3 points from baseline|Proportion of subjects with a decrease in raw score of ≥ 3 points from baseline|Change from baseline in Symbol Digit Modalities Test (SMDT)|Percent change from baseline in thalamic, cortical grey matter, whole brain, lateral ventricular, and MOV volumes|Proportion of subjects free of gadolinium enhancing (GdE) lesions over 3 years|GdE lesion volume over 3 years|Number of unique new or enlarging hyperintense T2-weighted lesions and their volume from baseline to Year 3|Number of unique new or enlarging hypointense T1 weighted lesions and their volume from baseline to Year 3|Treatment Satisfaction Questionnaire for Medication (TSQM v1.4)|Work Productivity and Activity Impairment-Multiple Sclerosis (WPAI-MS)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Hospital Anxiety and Depression Scale (HADS)|Annualized relapse rate (ARR)|Timed 25-foot Walk (T25W)|Nine-hole Peg Test (9-HPT)|Expanded Disability Status Scale (EDSS)|Adverse Events (AEs)","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC-1063-MS-001|U1111-1240-5667","January 5, 2020","October 1, 2024","December 30, 2024","October 25, 2019",,"October 25, 2019",,,"https://ClinicalTrials.gov/show/NCT04140305"
13,"NCT04139226","A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole",,"Recruiting","No Results Available","Healthy Volunteers","Drug: CC-11050","Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC 0-∞|Pharmacokinetics - AUC 0-t|Pharmacokinetics - AUC 0-24|Pharmacokinetics - AUC 0-12|Pharmacokinetics - t1/2|Pharmacokinetics - Accumulation index (Rac)|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","42","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-11050-CP-010|U1111-1240-5519","August 28, 2019","February 14, 2020","March 31, 2020","October 25, 2019",,"October 25, 2019","ICON Early Phase Services, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04139226"
14,"NCT04097704","Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort",,"Recruiting","No Results Available","Hepatic Insufficiency",,"Percentage of subjects whose primary saliva sample yields DNA that meets modified PharmacoScan® workflow acceptability criteria|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"28","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NDS-CP-003|U1111-1237-0411","September 4, 2019","October 15, 2019","October 15, 2019","September 20, 2019",,"September 20, 2019","Clinical Pharmacology of Miami, LLC, Miami, Florida, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, United States|Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04097704"
15,"NCT04096105","Japanese Pharmacokinetic Bridging Study for CC-93538",,"Not yet recruiting","No Results Available","Healthy Volunteers","Drug: CC-93538","Pharmacokinetics - AUC0-last|Pharmacokinetics - AUC0-∞|Pharmacokinetics - Cmax|Pharmacokinetics - tmax|Pharmacokinetics - t½|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Adverse Events (AEs)|Immunogenicity profile for CC-93538","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-93538-CP-001|U1111-1238-7252","October 2, 2019","March 4, 2020","March 4, 2020","September 19, 2019",,"September 19, 2019","Anaheim Clinical Trials, LLC, Anaheim, California, United States",,"https://ClinicalTrials.gov/show/NCT04096105"
16,"NCT04089527","Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: CC-95775","Dose Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Non-tolerated Dose (NTD)|Adverse Events (AEs)|Pharmacokinetics - Cmax of CC-95775|Pharmacokinetics - AUC of CC-95775|Pharmacokinetics - Tmax of CC-95775|Pharmacokinetics - t1/2 of CC-95775|Pharmacokinetics - CL/F of CC-95775|Pharmacokinetics - Vz/F of CC-95775|Evaluate the pharmacodynamic (PD) effects of CC-95775 on gene expression in peripheral blood and in tumor tissue.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-95775-ST-001|U1111-1238-6062|2019-001092-36","October 31, 2019","June 18, 2023","June 18, 2023","September 13, 2019",,"October 22, 2019","Institut Curie, Paris, France|Hopital Saint Louis, Paris, France|Centre Eugene Marquis, Rennes, France|Hospital de Madrid Norte- Sanchinarro, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT04089527"
17,"NCT04064060","A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials",,"Recruiting","No Results Available","Myelodysplastic Syndromes (MDS)|Beta-thalassemia|Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis","Drug: Luspatercept","Adverse Events (AEs)|Number of subjects progressing to high/very high risk MDS or AML.|Percentage of subjects progressing to high/very high risk MDS or AML|Number of subjects developing other malignancies/pre-malignancies|Percentage of subjects developing other malignancies/pre-malignancies|Overall Survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","665","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-LTFU-001|U1111-1235-8123|2018-002915-93","August 12, 2019","January 24, 2028","January 24, 2028","August 21, 2019",,"October 22, 2019","Childrens Hospital Los Angeles RHU, Los Angeles, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Stanford Cancer Center, Stanford, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Weill Cornell Medical College, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Prince of Wales Hospital, Randwick, Australia|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|AZ Sint-Jan AV Brugge, Brugge, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|UZ Leuven, Leuven, Belgium|University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Haematological Diseases - Sofia, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHU d'Angers, Angers, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Universitaire de Grenoble Hopital Albert Michallon, La Tronche, France|CHRU de Lille-Hopital Claude Huriez, Lille, France|Hôpitaux de La Timone, Marseille Cedex 9, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|Hopital civil, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Hopital Bretonneau, Tours, France|Medizinisches Versorgungszentrum (MVZ) Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Marien Hospital, Dusseldorf, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, München, Germany|Aghia Sophia' Children's General Hospital of Athens, Athens, Greece|Laiko General Hospital of Athens - Center of Thalassemia, Athens, Greece|General Hospital Georgios Gennimatas of Athens, Athens, Greece|University General Hospital of Patras, Rio Patras, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|HaEmek Medical Center, Afula, Israel|Rambam Health Corporation, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Rabin Medical Center, Petah Tikva, Israel|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Italy|Presidio Ospedaliero Antonio Perrino, Brindisi, Italy|Azienda Sanitaria Locale (ASL) Cagliari - Ospedale Regionale per le Microcitemie, Cagliari, Italy|Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna, Ferrara, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite, Genoa, Italy|Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Milano, Italy|Azienda Ospedaliero Universitaria Di Modena Policlinico, Modena, Italy|AORN A Cardarelli, Napoli, Italy|AOU dell'Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy|Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Di Calabria, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Ospedale di Circolo di Varese, Varese, Italy|Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy|Chronic Care Center, Hazmieh, Lebanon|Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia|Hospital Pulau Pinang c/o Penang Medical College, Georgetown, Malaysia|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Hospital Universitario Cruces, Barakaldo, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Seville, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Skanes Universitetssjukhus Lund, Lund, Sweden|Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Siriraj Hospital Mahidol University, Bangkok, Thailand|Chiang Mai University - Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|University Hospital Farhat Hached, Sousse, Tunisia|Bone Marrow Transplant Center, Tunis, Tunisia|Aziza Othmana Hospital, Tunis, Tunisia|Military Hospital of Tunis, Tunis, Tunisia|Acibadem Adana Hospital, Adana, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Leeds Teaching Hospitals NHS Trust - St James's University Hospital, Leeds, United Kingdom|Barts Health NHS Trust - The Royal London Hospital, London, United Kingdom|Whittington Hospital, London, United Kingdom|University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04064060"
18,"NCT04057937","A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis",,"Recruiting","No Results Available","Palmoplantaris Pustulosis","Drug: Apremilast|Drug: Placebo","Proportion of subjects who achieve a PPPASI- 50 at Week 16|Proportion of subjects who achieve a PPPASI.|Proportion of subjects who achieve a PPPASI- 75.|Area under the curve (AUC) of PPPASI total score|Percent change from baseline of PPPASI total score|AUC of Palmo-Plantar Pustulosis (PPSI) total score|Percent change from baseline of PPSI total score|Change from baseline of Physician' s Global Assessment (PGA) score|Proportion of subjects who achieve a PGA score of cleared (0) or minimal (1)|Proportion of subjects who achieve a PGA score of cleared (0) or minimal (1) and have at least a 2-grade improvement|Subject's VAS assessment for PPP symptoms|Adverse Events (AEs)","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PPP-001|U1111-1236-1239","September 18, 2019","November 21, 2020","March 1, 2021","August 15, 2019",,"November 11, 2019","Tokyo Teishin Hospital, Chiyoda-ku, Japan|Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Ichinomiya Municipal Hospital, Ichinomiya, Japan|Teikyo University Hospital, Itabashi-ku, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Japan|Shimane University Hospital, Izumo, Japan|Kimitsu Chuo Hospital, Kisarazu, Japan|Yamanashi Prefectual Central Hospital, Kofu, Japan|Kizawa Memorial Hospital, Minokamo, Japan|Nagoya City University Hospital, Nagoya, Japan|Kochi Medical School Hospital, Nankoku-shi, Japan|Nippon Life Hospital, Osaka, Japan|Sagamihara National Hospital, Sagamihara, Kanagawa, Japan|Sapporo Skin Clinic, Sapporo-shi, Hokkaido, Japan|Tohoku University Hospital, Sendai, Japan|Seibo Hosptial, Shinjuku-ku, Japan|Tokyo Medical University Hospital, Shinjyuku-ku, Japan|Ehime University Hospital, Toon, Japan|Mie University hospital, Tsu, Japan|Nomura Dermatology Clinic, Yokohoma City, Kanagawa, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan",,"https://ClinicalTrials.gov/show/NCT04057937"
19,"NCT04048876","Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis",,"Recruiting","No Results Available","Non-alcoholic Fatty Liver Disease|Liver Cirrhosis","Drug: CC-90001|Drug: Placebo","Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis|Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis and no worsening of steatohepatitis|Proportion of subjects with an improvement of ≥2 points in the|Proportion of subjects who demonstrate absence of steatohepatitis and no worsening of liver fibrosis|Proportion of subjects who progress to cirrhosis|Proportion of subjects who achieve the relative reductions in liver stiffness|Percentage change from Baseline in liver stiffness|Proportion of subjects who achieve the relative reductions fat fraction|Percentage change from Baseline in fat fraction|Changes from baseline in liver biochemistry|Changes from baseline in metabolic parameters|Dose-related changes in the primary and secondary endpoints|Adverse Event (AE)|Pharmacokinetics - Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-90001-NASH-001|U1111-1235-3234|2018-004431-79","August 14, 2019","November 16, 2021","May 29, 2023","August 7, 2019",,"October 22, 2019","Saint Joseph's Hosptial and Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic Phoenix, Phoenix, Arizona, United States|UC San Diego School of Medicine, La Jolla, California, United States|Cedars-Sinai Comprehensive Transplant Center, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of Colorado, School of Medicine - Hepatology Clinic - Anschutz, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Miami Schiff Center for Liver Diseases, Miami, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Rush University Medical Center - University Cardiovascular Surgeons, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|WestGlen Gastrointestinal Consultants, P.A., Shawnee Mission, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|The Institute for Digestive Health & Liver Disease at Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Montefiore Medical Center, Bronx, New York, United States|Concorde Medical Group, New York, New York, United States|New York Presbyterian Hospital - Weill-Cornell, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|UNC Hospitals GI Medicine Clinic, Chapel Hill, North Carolina, United States|Duke University School of Medicine, Durham, North Carolina, United States|Carolinas HealthCare System Digestive Health, Huntersville, North Carolina, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center - Center for Liver Diseases, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Texas Clinical Research Institute LLC, Arlington, Texas, United States|Liver Institute at Methodist Dallas, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|Baylor College of Medicine - Baylor Heart Clinic, Houston, Texas, United States|Digestive Health Associates of Texas (DHAT), Rockwell, Texas, United States|American Research Corporation, San Antonio, Texas, United States|Utah Cancer Specialists - Cottonwood, Murray, Utah, United States|University of Vermont Medical Center Gastro, Burlington, Vermont, United States|Bon Secours Liver Institute of Hampton Roads, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours Liver Institute of Richmond, Richmond, Virginia, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States|University of Sydney - Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada|University of Alberta, Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada|South Edmonton Gastroenterology, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Toronto Center for Liver Disease - Francis Family Liver Clinic, Toronto, Ontario, Canada|McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada|CHU d'Angers, Angers, France|Assistance Publique - Hopitaux de Paris - Hopital Beaujon, Clichy cedex, France|Hopital de la Croix-Rousse, Lyon, France|Assistance Publique - Hopitaux de Paris - Hopital Universitaire Pitie Salpetriere, Paris CEDEX 13, France|Assistance Publique - Hopitaux de Paris - Hopital Cochin, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier Universitaire de Rennes - Hopital de Pontchaillou, Rennes cedex 09, France|Hopital Hautepierre, Strasbourg, France|Universitaetsklinikum der RWTH Aachen, Aachen, Germany|Charite -Universitätsmedizin Berlin, Berlin, Germany|Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Universitatsklinik Munster, Münster, Germany|Hamamatsu University Hospital, Hamamatsu, Japan|Nara Medical University Hospital, Kashihara, Japan|Shin-Yurigaoka General Hospital, Kawasaki, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Japanese Red Cross Musashino Hospital, Musashino, Japan|Aichi Medical University Hospital, Nagakute, Japan|Ogaki Municipal Hospital, Ogaki, Japan|Osaka University Hospital OUH, Osaka-Fu, Japan|Saga University Hospital, Saga, Japan|Belland General Hospital, Sakai-shi, Japan|Saiseikai Suita Hospital, Suita, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Soon Chun Hyang University Hospital Bucheon, Bucheon, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Korea University Hospital at Guro, Seoul, Korea, Republic of|Boramae Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju-si, Korea, Republic of|Szpital Specjalistyczny w Chorzowie, Chorzow, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny Im Prof. Kornela Gibinskiego, Katowice, Poland|Wojewodzki Specjalistyczny Szpital im. dr Wladyslawa Bieganskiego, Lodz, Poland|ID Clinic, Myslowice, Poland|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Parc Tauli, Sabadell, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|University of Birmingham Institute of Biomedical Research, Birmingham, United Kingdom|Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, United Kingdom|Kings College Hospital, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust - Chelsea and Westminster Hospital (CWH), London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04048876"
20,"NCT04047303","CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma",,"Not yet recruiting","No Results Available","Astrocytoma|Glioblastoma","Drug: CC-90010","Intratumoral concentration of CC-90010 in tumor tissue collected intraoperatively|Pharmacokinetics - AUC24|Pharmacokinetics - AUClast|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - V2/F|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90010-GBM-001|U1111-1235-8082|2019-000241-12","August 2, 2019","December 19, 2021","January 18, 2022","August 6, 2019",,"August 6, 2019","Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04047303"
21,"NCT04036461","A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: CC-99712","Adverse Events (AEs)|Non-Tolerated Dose (NTD) in subjects with relapsed and refractory MM|Maximum Tolerated Dose (MTD) in subjects with relapsed and refractory MM|Dose Limiting Toxicity (DLT) in subjects with relapsed and refractory MM|Overall Response Rate (ORR)|Time to Response|Duration of Response|Progression-free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics- Cmax|Pharmacokinetics- Cmin|Pharmacokinetics- AUC|Pharmacokinetics- tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL|Pharmacokinetics- Vss|Presence and frequency of ADA using a validated bridging immunoassay with electrochemiluminescence detection","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-99712-MM-001|U1111-1231-9404","August 26, 2019","November 13, 2024","November 13, 2024","July 29, 2019",,"November 1, 2019","University of California San Diego Moores Cancer Center, La Jolla, California, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mount Sinai Hospital, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04036461"
22,"NCT04036448","A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea","RevlimidPMS","Not yet recruiting","No Results Available","Myelodysplastic Syndromes|Lymphoma, Mantle-Cell","Drug: REVLIMID®","Adverse events (AEs)|To evaluate the effectiveness of REVLIMID® treatment in patients with IPSS low- or intermediate-1-risk del (5q) MDS|To evaluate the effectiveness of REVLIMID® treatment in patients with rrMCL","Celgene","All","19 Years and older   (Adult, Older Adult)",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-5013-MDS-013|U1111-1235-2858","August 1, 2019","June 1, 2022","June 1, 2022","July 29, 2019",,"July 29, 2019",,,"https://ClinicalTrials.gov/show/NCT04036448"
23,"NCT04031027","A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice","DARWIN","Recruiting","No Results Available","Plaque Psoriasis","Drug: Apremilast","Mean age of the patients treated with apremilast|Gender frequency of the patients treated with apremilast|Mean body weight of the patients treated with apremilast|Mean body mass index of the patients treated with apremilast|Mean blood pressure of the patients treated with apremilast|Mean duration of psoriatic disease of the patients treated with apremilast|Mean Psoriasis area severity index score of the patients treated with apremilast|Mean Body surface area of the patients treated with apremilast|Mean Physician global assessment (PGA) score of the patients treated with apremilast|Frequency of previous antipsoriatic treatments in the patients treated with apremilast|Reasons for discontinuation of previous antipsoriatic treatments in the patients treated with apremilast|Proportion of participants receiving apremilast at enrollment visit|Apremilast treatment duration|Change from baseline in Body Surface Area (BSA)|Change from baseline in the Physician Global Assessment (PGA) Score|Change from baseline in the Dermatology Life Quality Index (DLQI) score|Proportions of patients achieving PGA score 0 or 1|Proportions of patients achieving DLQI score ≤5|Proportions of patients achieving ≥4 points improvement in DLQI score|Adverse Events (AEs)|Treatment Satisfaction Questionnaire for Medication (TSQM) outcome score|Patient Benefit Index for Skin Diseases Score (standard version) (PBI-S) outcome score","Celgene","All","18 Years and older   (Adult, Older Adult)",,"375","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","CC-10004-PSOR-026|U1111-1236-1175","July 22, 2019","July 30, 2020","July 30, 2020","July 24, 2019",,"November 19, 2019","SOD Clinica Dermatologica A.O.U. Riuniti Umberto I Lancisi Salesi, Ancona, AN, Italy|UOC Dermatologia ASST Spedali Civili, Brescia, BS, Italy|Dermatologia Azienda Ospedaliera Papardo, Messina, ME, Italy|UOC Dermatologia Arcispedale Sant'Anna, Cona, Italy|Dermatologia Ospedale Piero Palagi, Firenze, Italy|UOC Dermatologia A.O.U. Policlinico G. Martino, Messina, Italy|UOC Clinica Dermatologica A.O.U. Università della Campania Vanvitelli, Napoli, Italy|Dermatologia A.O.U. Maggiore della Carità, Novara, Italy|UOC Dermatologia e MST A.O.U. Policlinico P. Giaccone, Palermo, Italy|Clinica Dermatologica Policlinico Tor Vergata, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04031027"
24,"NCT03989414","A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)",,"Not yet recruiting","No Results Available","Multiple Myeloma","Drug: CC-92480|Drug: Bortezomib|Drug: Dexamethasone|Drug: Daratumumab|Drug: Carfilzomib","Dose-limiting Toxicities (DLT)|Adverse Events (AEs)|Overall response rate (ORR)|Time-to-response (TTR)|Duration of response (DOR)|Complete Response (CR) rate|Very good partial response (VGPR) rate","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-92480-MM-002|U1111-1233-5619|2018-004767-31","August 1, 2019","August 5, 2022","August 5, 2027","June 18, 2019",,"June 18, 2019",,,"https://ClinicalTrials.gov/show/NCT03989414"
25,"NCT03971825","A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis",,"Recruiting","No Results Available","Healthy Volunteers|Psoriasis","Drug: CC-92252|Other: Placebo","Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - AUC0-t|Pharmacokinetics - AUC0-∞|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2z|Pharmacokinetics - CL/F|Pharmacokinetics - CL|Pharmacokinetics - Vz/F|Pharmacokinetics - Vz|Anti-drug Antibody Immunogenicity Anti-drug antibody|Assessment of Pharmacodynamic biomarkers","Celgene","All","18 Years to 60 Years   (Adult)","Phase 1","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-92252-CP-001|U1111-1229-5867|2018-001050-10","July 24, 2018","January 30, 2021","January 30, 2021","June 3, 2019",,"June 3, 2019","Charite Research Organisation GmBH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03971825"
26,"NCT03958864","A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects",,"Recruiting","No Results Available","Healthy Volunteer","Drug: CC-90001","Pharmacokinetic- AUC0-t|Pharmacokinetic- AUC0-∞|Pharmacokinetic- CL/F|Pharmacokinetic- Vz/F|Pharmacokinetic- Cmax|Pharmacokinetic- Tmax|Pharmacokinetic- t1/2|Adverse Events (AEs)","Celgene","All","18 Years to 64 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-90001-CP-006|U1111-1229-5813","April 4, 2019","June 10, 2019","June 10, 2019","May 22, 2019",,"May 22, 2019","Paraxel International, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT03958864"
27,"NCT03930953","A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: CC-99282|Drug: rituximab","Dose Limiting Toxicity (DLT)|Maximum tolerated dose (MTD)|Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - V/F|Objective response rate (ORR)|Time to response (TTR)|Duration of response (DoR)|Progression free survival|Overall survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-99282-NHL-001|U1111-1224-5399|2018-003235-29","May 20, 2019","June 11, 2023","May 13, 2024","April 29, 2019",,"October 9, 2019","H Lee Moffitt Cancer Center, Tampa, Florida, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, France|Gustave Roussy, Villejuif CEDEX, France|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori ""Fondazione Giovanni Pascale"", Napoli, Italy|Vall d´Hebron University Hospital, Barcelona, Spain|Fundacion Jimenez Daaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03930953"
28,"NCT03930186","A Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy",,"Recruiting","No Results Available","Psoriasis","Drug: Apremilast","Proportion of subjects who achieve sPGA 0 or 1|Proportion of subjects who achieve ScPGA score of 0 or 1 at weeks 16 and 32|Mean percent change from baseline in psoriasis-affected BSA|Pruritus Visual Analog Scale (VAS) mean percent change from baseline|Shiratori's Pruritus Severity Score mean change in severity score from baseline|Proportion of subjects that achieve a ≥ 50% reduction from baseline in NAPSI score (NAPSI-50) at Week 32 among subjects with NAPSI ≥ 1 at baseline|Dermatology Life Quality Index (DLQI) mean change from baseline|Psoriasis Area and Severity Index (PASI) mean percentage change from baseline|Proportion of subjects who achieve ≥ 75% reduction from baseline (PASI-75)|Proportion of subjects who achieve ≥ 50% reduction from baseline (PASI- 50)|Treatment Satisfaction Questionnaire for Medication (TSQM) mean overall score and mean score in sub-domains|Proportion of subjects who achieve PBI ≥ 1|Adverse Events (AEs)","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-10004-PSOR-023|U1111-1230-7468","May 27, 2019","May 8, 2020","September 25, 2020","April 29, 2019",,"October 22, 2019","Motomachi Dermatology Clinic, Asahikawa-shi, Hokkaido, Japan|Nippon Medical School Hospital, Bunkyo-ku, Japan|The University of Tokyo Hospital, Bunkyo-ku, Japan|Chitose Dermatology and Plastic, Reconstructive Surgery Clinic, Chitose, Japan|Kiryu Dermatology Clinic, Fukuoka-shi, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan|Tomoko Matsuda Dermatology Clinic, Fukuoka-shi, Fukuoka, Japan|Hino Dermatology Clinic, Fukutsu, Japan|Saruwatari Dermatology Clinic, Kagoshima, Japan|Noguchi Dermatorogy Clinic, Kamimashiki-gun, Japan|Japan Community Health-care Organization Kyushu Hospital, Kitakyushu-city, Japan|Maruyama Dermatology Clinic, Koto-ku, Tokyo, Japan|Mita Dermatology Clinic, Minato-ku, Japan|Iwate Medical University Uchimaru Medical Center, Morioka, Japan|Yoshioka Dermatology Clinic, Neyagawa, Japan|Takagi Dermatological Clinic, Obihiro, Japan|Nippon Life Hospital, Osaka, Japan|Kume Clinic, Sakai-shi, Osaka, Japan|Hino Clinic, Sakai, Japan|Sapporo Skin Clinic, Sapporo-shi, Hokkaido, Japan|Fukuzumi Dermatology Clinic, Sapporo-shi, Hokkaido, Japan|Kitagou Dermatology Clinic, Sapporo, Japan|Kobayashi Skin Clinic, Sapporo, Japan|Hosui Medical Clinic, Sapporo, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjyuku-ku, Japan|Fujita Health University Hospital, Toyoake, Japan",,"https://ClinicalTrials.gov/show/NCT03930186"
29,"NCT03915769","To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis",,"Recruiting","No Results Available","Colitis, Ulcerative","Drug: Ozanimod|Other: Placebo","Proportion of subjects with clinical response|Proportion of subjects with clinical remission|Proportion of subjects in clinical remission measured at week 12- Rectal Bleeding|Proportion of subjects with endoscopic improvement|Proportion of subjects with mucosal healing|Proportion of subjects with a clinical response|Change in the EuroQol-5 Dimension (EQ-5D) from baseline|Proportion of subjects in clinical remission measured at week 52 - Mayo Score|Proportion of subject with clinical response|Proportion of subjects in remission while off corticosteroids for any length of time|Change in partial Mayo score from Baseline|Adverse Event (AE)|Proportion of subjects in clinical remission measured at week 52- Rectal Bleeding|Proportion of subject with clinical response at week 52","Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-3103|U1111-1230-3228","June 3, 2019","July 23, 2021","October 31, 2023","April 16, 2019",,"October 17, 2019","Kokikai Tokatsu-Tsujinaka Hospital, Abiko, Japan|Mazda Hospital of Mazda Motor Corporation, Aki-gun, Japan|Medical Hospital of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan|Fukuoka University Chikushi Hospital, Chikushino, Japan|Sai Clinic, Fujiidera, Japan|Fukui Prefectural Hospital, Fukui, Japan|Fukui-ken Saiseikai Hospital, Fukui, Japan|Gifu Prefectural General Medical Center, Gifu, Japan|Hakodate Goryokaku Hospital, Hakodate, Japan|Hirosaki University Hospital, Hirosaki, Japan|Hiroshima University Hospital, Hiroshima, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Saitama Medical University Hospital, Iruma-gun, Japan|Tokai University Hospital, Isehara City, Kanagawa, Japan|Kanazawa Medical University Hospital, Kahoku-gun, Japan|Mitoyo General Hospital, Kannonji, Japan|Nara Medical University Hospital, Kashihara, Japan|Kobe University Hospital, Kobe, Japan|Komatsu Municipal Hospital, Komatsu, Japan|Hoshi General Hospital, Koriyama, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Our Lady of the Snow Social Medical Corporation St. Mary's Hospital, Kurume, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Ehime Prefectural Central Hospital, Matsuyama, Japan|Jikei University Hospital, Minato-ku, Japan|Kitasato University Kitasato Institute Hospital, Minato-ku, Japan|Kyorin University Hospital, Mitaka, Japan|Iwate Medical University Hospital, Morioka, Japan|Nagaoka Chuo General Hospital, Nagaoka, Japan|Hyogo College of Medicine Hospital, Nishinomiya, Japan|Ogaki Municipal Hospital, Ogaki, Japan|Okayama Saiseikai Outpatient Center Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaki Citizen Hospital, Osaki-shi, Japan|Shiga University of Medical Science Hospital, Otsu, Japan|Tokitokai Tokito Clinic, Saitama, Japan|Osaka Rosai Hospital, Sakai, Japan|Toho University Medical Center Sakura Hospital, Sakura, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaidô, Japan|JA Sapporo Kosei General Hospital, Sapporo, Japan|Japan Community Health care Organization Hokkaido Hospital, Sapporo, Japan|IMS Meirikai Sendai General Hospital, Sendai, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan|Tokyo Yamate Medical Center, Shinju-ku, Japan|Shizuoka City Shizuoka Hospital, Shizuoka-shi, Japan|National Hospital Organization Shizuoka Medical Center, Sunto-gun, Japan|Kagawa Prefectural Central Hospital, Takamatsu, Japan|Medical Corporation Shoyu-Kai Fujita Gastroenterology Hospital, Takatsuki, Japan|Takatsuki Red Cross Hospital, Takatsuki, Japan|Toyama City Hospital, Toyama, Japan|Mie University hospital, Tsu, Japan|Kanke Gastrointestinal Clinic, Utsunomiya, Japan",,"https://ClinicalTrials.gov/show/NCT03915769"
30,"NCT03906526","A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer",,"Recruiting","No Results Available","Carcinoma, Squamous Cell","Drug: VTX-2337|Drug: Nivolumab","Numbers of CD8+ T cells within the tumor pre-treatment and post-surgery|Number of Patients With adverse events that lead to delay in resection|Evaluation of safety and tolerability of nivolumab, motolimod and the combination of nivolumab with motolimod","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VTX-2337-HN-001|U1111-1223-3488","July 3, 2019","December 31, 2020","January 25, 2021","April 8, 2019",,"September 30, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Sanford Cancer Center, Sioux Falls, South Dakota, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03906526"
31,"NCT03900715","An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion",,"Recruiting","No Results Available","Myelodysplastic Syndromes","Drug: Luspatercept","Hematologic improvement in erythroid response (HI-E) per IWG|Mean hemoglobin increase ≥ 1.5 g/dL|Hematologic improvement in erythroid response (HI-E) per International Working Group (IWG)|Time to HI-E|Duration of HI-E|Red blood cell transfusion independence (RBC-TI)|Adverse Event(s)|Pharmacokinetic- Cmax|Pharmacokinetic- AUC|Pharmacokinetic- Tmax|Antidrug antibodies (ADA)|Progression to Acute myeloid leukemia (AML)|Overall survival","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-MDS-003|U1111-1224-6268","May 20, 2019","November 19, 2021","June 16, 2024","April 3, 2019",,"November 14, 2019","National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Kameda Medical Center, Kamogawa, Japan|Matsuyama Red Cross Hospital, Matsuyama, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|National Hospital Organization - Nagoya Medical Center, Nagoya-shi, Japan|Japanese Red Cross Narita Hospital, Narita-shi, Japan|Ogaki Municipal Hospital, Ogaki, Japan|Okayama City General Medical Center, Okayama, Japan|Kindai University Hospital, Osaka-Sayama, Japan|Osaka City University Hospital, Osaka, Japan|Kitasato University Hospital, Sagamihara, Japan|Tohoku University Hospital, Sendai, Japan|Japan Red Cross Medical Center, Shibuya-ku, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03900715"
32,"NCT03850067","A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer",,"Recruiting","No Results Available","Small Cell Lung Carcinoma","Drug: CC-90011|Drug: Cisplatin|Drug: Carboplatin|Drug: Etoposide|Drug: Nivolumab","Dose‐Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Adverse Events (AEs)|Objective Response Rate (ORR)|Progression-free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- VzF","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90011-SCLC-001|U1111-1228-2067|2018-002799-42","March 12, 2019","September 30, 2021","September 30, 2022","February 21, 2019",,"November 19, 2019","Hospital Le Timone, Marseille Cedex 5, France|CHU Nantes Hopital Nord Laennec, Nantes CEDEX 1, France|Gustave Roussy, Villejuif CEDEX, France|Azienda Ospedaliero Universitaria Ospedali Riuniti ""Umberto I, G.M. Lancisi, G. Salesi"", Ancona, Italy|Polyclinic S. Orsola-Malpighi, Bologna, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03850067"
33,"NCT03828045","A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment","PREVAIL","Recruiting","No Results Available","Arthritis, Psoriatic","Drug: Apremilast","Treatment persistence at 6 months after initiating apremilast treatment|Demographic characteristics|To describe the characteristics of apremilast treatment (i.e., dosage and regimen) in patients with PsA who start treatment according to the routine clinical practice.|To assess the persistence of apremilast treatment after 12 months of treatment start|To assess the disease activity at 6 and 12 months of treatment with apremilast.|Changes on clinical enthesitis and dactilitis|Tender joints count|Swollen joints count|Changes in the plasma concentration of C-reactive protein.|Physician Global Assessment of Disease Activity (PGA).|To assess the presence of erosive changes after 6 and 12 months of treatment with apremilast.|The VITACORA-19 questionnaires|The Psoriatic Arthritis Impact of Disease (PsAID)-9 questionnaires|Assessment of changes on affected joints|Assessment of DAPSA/cDAPSA scores|To assess the relationship between the count of affected joints DAPSA/cDAPSA score after 6 and 12 months of treatment with apremilast.|Adverse events (AEs)|To assess the changes in patient's assessment of disease activity after 6 and 12 months of apremilast treatment.","Celgene","All","18 Years and older   (Adult, Older Adult)",,"17","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSA-015|U1111-1221-8638","February 6, 2019","October 31, 2019","February 28, 2020","February 4, 2019",,"June 28, 2019","Hospital Monte Naranco, Oviedo, Asturias, Spain|Hospital Can Misses., Ibiza, Baleares, Spain|Hospital Son Espases, Palma Mallorca, Baleares, Spain|Hospital Son Llàtzer, Palma Mallorca, Baleares, Spain|Hospital Universitario de Canarias, Tenerife, Canarias, Spain|Hospital Virgen de la Luz, Toledo, Castilla La Mancha, Spain|Hospital Del Mar, Barcelona, Catalunya, Spain|Hospital de Bellvitge, Barcelona, Catalunya, Spain|Hospital Santa Maria Lleida, Lleida, Catalunya, Spain|Hospital Parc Taulí, Sabadell, Catalunya, Spain|Hospital Esperit Sant, Santa Coloma, Catalunya, Spain|Hospital de Donosti, Hospital De Donosti, Euskadi, Spain|Hospital Universitario Araba, Vitoria, Euskadi, Spain|Infanta Cristina Badajoz, Badajoz, Extremadura, Spain|Hospital Virgen del Puerto, Plasencia, Extremadura, Spain|Complexo Hosp Univ de Vigo, Vigo, Galicia, Spain|Hospital Santa Lucía, Cartagena, Murcia, Spain|Complejo Hosp de Navarra, Pamplona, Navarra, Spain|Hospital de Arritxaca, Murcia, Spain|Hospital Joan XXIII, Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT03828045"
34,"NCT03824678","Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects",,"Not yet recruiting","No Results Available","Hepatic Impairment|Healthy Volunteers","Drug: CC-220","Pharmacokinetic- AUC0-t|Pharmacokinetic- AUC0-∞|Pharmacokinetic- Cmax|Pharmacokinetic- Tmax|Pharmacokinetic- t½|Pharmacokinetic- CL/F|Pharmacokinetic- Vz/F|Adverse Event(s)","Celgene","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-220-CP-007|U1111-1224-6064","February 1, 2019","December 31, 2019","April 15, 2020","January 31, 2019",,"January 31, 2019",,,"https://ClinicalTrials.gov/show/NCT03824678"
35,"NCT03803644","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects",,"Recruiting","No Results Available","Healthy Volunteer","Drug: CC-92480","Pharmacokinetics- Cmax Part 1|Pharmacokinetics- Tmax Part 1|Pharmacokinetics- AUC0-∞ Part 1|Pharmacokinetics- AUC0-t Part 1|Pharmacokinetics- AUC0-24 Part 1|Pharmacokinetics- AUC-t½ Part 1|Pharmacokinetics- CL/F Part 1|Pharmacokinetics- Vz/F Part 1|Pharmacokinetics- Cmax Part 2|Pharmacokinetics- Tmax Part 2|Pharmacokinetics- AUC0-∞ Part 2|Pharmacokinetics- AUC0-t Part 2|Pharmacokinetics- AUC0-24 Part 2|Pharmacokinetics- AUC-t½ Part 2|Adverse Event(s)|Effect of CC-92480 on ECG parameters- Part 1","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-92480-CP-001|U1111-1224-6768","December 21, 2018","May 6, 2019","May 13, 2019","January 14, 2019",,"April 2, 2019","Covance-Daytona Beach, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03803644"
36,"NCT03783403","A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers",,"Recruiting","No Results Available","Neoplasms","Drug: CC-95251|Drug: Rituximab|Drug: Cetuximab","Adverse Event(s)|Non-Tolerated Dose (NTD)|Maximum Tolerated Dose (MTD)|Dose-Limiting Toxicity (DLT)|Overall response rate (ORR)|Time to response (TTR)|Duration of response (DOR)|Progression free survival (PFS)|Overall survival (OS)|Pharmacokinetic - Cmax|Pharmacokinetic - Cmin|Pharmacokinetic - AUC|Pharmacokinetic - tmax|Pharmacokinetic - t1/2|Pharmacokinetic - CL|Pharmacokinetic - Vss|Anti-CC-95251 antibody (ADA) assessment","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","230","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-95251-ST-001|U1111-1224-8251","January 24, 2019","January 17, 2023","January 17, 2023","December 21, 2018",,"October 1, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|Moores UCSD Cancer Center, La Jolla, California, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|University of Pittsburgh Medical Center - Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Austin Health - Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03783403"
37,"NCT03783026","A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis","MOSAIC","Recruiting","No Results Available","Psoriatic Arthritis","Drug: CC-10004","Change from baseline in the composite score of BME, synovitis, and tenosynovitis assessed by Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS)|Change from baseline in the composite score of BME, synovitis, and tenosynovitis assessed by PsAMRIS|Change from baseline in the composite score of BME and synovitis assessed by PsAMRIS|Change from baseline in the PsAMRIS total inflammation score|Change from baseline in BME assessed by PsAMRIS|Change from baseline in synovitis assessed by PsAMRIS|Change from baseline in tenosynovitis assessed by PsAMRIS|Change from baseline in periarticular inflammation assessed by PsAMRIS|Change from baseline in the PsAMRIS total damage score|Change from baseline in bone erosion assessed by PsAMRIS|Change from baseline in bone proliferation/enthesophytes assessed by PsAMRIS|Swollen Joint Count (SJC)|Tender Joint Count (TJC)|Change from baseline in the Clinical Disease Activity Index for Psoriatic Arthritis (c-DAPSA) Score|Change from baseline in Spondyloarthritis Research Consortium of Canada (SPARCC), in subjects with preexisting enthesopathy|Change from baseline in the Leeds Enthesitis Index (LEI), in subjects with preexisting enthesopathy|Proportion of subjects with baseline enthesitis whose enthesitis improves to 0|Change from baseline in the LDI, in subjects with preexisting dactylitis|Proportion of subjects with baseline dactylitis whose dactylitis count improves to 0|Change from baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)|Change from baseline in the Evaluator's global assessment of disease activity|Change from baseline in the Subject's global assessment of disease activity|Change from baseline in the Subject's assessment of pain|Change from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)|Change from baseline in the WB-MRI Peripheral Enthesitis Inflammation Index|Change from baseline in the WB-MRI Peripheral Joints Inflammation Index|Change from baseline in the WB-MRI Total Peripheral Inflammation Index|Change from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|Change from baseline in the Psoriatic Arthritis Impact of Disease 12 domains (PsAID-12)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-10004-PSA-014|U1111-1223-9823|2018-002748-10","January 29, 2019","June 1, 2021","June 29, 2021","December 20, 2018",,"October 17, 2019","The Doctors of Saint John's Medical Group, Santa Monica, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|Malcom Randall VA Medical Center, Gainesville, Florida, United States|Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|NYU Langone Medical Center, New York, New York, United States|Austin Regional Clinic, Austin, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Medizinische Universitat Wien, Vienna, Austria|UZ Leuven, Leuven, Belgium|CHU de Liege, Liege, Belgium|University of Calgary - Cumming School of Medicine, Calgary, Alberta, Canada|Alberta Rheumatology, Edmonton, Alberta, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|G.R.M.O. (Groupe de recherche en maladies osseuses) Inc., Québec, Quebec, Canada|Aalborg Universitetshospital, Aalborg, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Copenhagen University Hospital Rigshospitalet, Glostrup Copenhagen, Denmark|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Duesseldorf, Düsseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Azienda Ospedaliero - Universitaria ""Policlinico - Vittorio Emanuele"" - Ospedale Vittorio Emanuele, Catania, Italy|Azienda Ospedaliera Regionale San Carlo, Potenza/Matera, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Udmurt Republic Republican Clinical Diagnostic Center, Izhevsk, Russian Federation|Research Institute of Rheumatology named after V.A.Nasonova, Moscow, Russian Federation|LLC Medical Center Zdorovaya Semiya, Novosibirsk, Russian Federation|North-West State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russian Federation|Regional Clinical Hospital No 1 - Tyumen, Tyumen, Russian Federation|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Virgen de Macarena, Seville, Spain|Kantonsspital Aarau - KSA, Aarau, Switzerland|Hopital Universitaire Genevois - Beau-Sejour Hospital, Geneva, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|NHS Lothian, Western General Hospital, Edinburgh, United Kingdom|The Leeds Teaching Hospitals NHS Trust - Chapel Allerton Hospital, Leeds, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03783026"
38,"NCT03777436","An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis","DISCREET","Recruiting","No Results Available","Psoriasis","Drug: Apremilast|Other: Placebo","Proportion of subjects with a modified sPGA-G score of|Proportion of subjects achieving an overall sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16|Proportion of subjects with at least a 4-point improvement in|Change from baseline in affected BSA at Week 16|Change from baseline in Dermatology Life Quality Index (DLQI) at Week 16|Change from baseline in Genital Psoriasis Symptoms Scale (GPSS)total score and individual item scores at Week 16","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-025|U1111-1224-6850|2018-002608-15","January 28, 2019","February 19, 2021","July 6, 2021","December 17, 2018",,"October 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|First OC Dermatology, Fountain Valley, California, United States|Clinical Science Institute, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|Glick Skin Institute Clinical Research, Margate, Florida, United States|International Dermatology Research, Miami, Florida, United States|Skin Care Physicians of Georgia, Macon, Georgia, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Adult and Pediatric Dermatology, Overland Park, Kansas, United States|ActivMed Practices & Research Inc, Beverly, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|J. Woodson Dermatology and Associates, Henderson, Nevada, United States|Las Vegas Dermatology, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|ActivMed, Portsmouth, New Hampshire, United States|Stony Brook Dermatology Associates, Stony Brook, New York, United States|Dermatology Consulting Services, High Point, North Carolina, United States|Oakview Dermatology, Athens, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States|Clinical Partners, LLC, Johnston, Rhode Island, United States|Austin Institute for Clinical Research, Pflugerville, Texas, United States|Center for Clinical Studies, Webster, Texas, United States|Virginia Clinical Research Inc, Norfolk, Virginia, United States|Bellevue Dermatology Clinic, Bellevue, Washington, United States|Dermatology Center for Skin Health, Morgantown, West Virginia, United States|Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Skincare Studio, St. John's, Newfoundland and Labrador, Canada|Guenther Dermatology Research Centre, London, Ontario, Canada|Lynderm Research, Markham, Ontario, Canada|K. Papp Clinical Research, Waterloo, Ontario, Canada|Dre Angelique Gagne-Henley M.D. Inc., Saint-Jerome, Quebec, Canada|Hopital Saint Andre' CHU de Bordeaux, Bordeaux, France|Hopital Claude Huriez CHRU Lille, Lille cedex, France|CHU de Nice Archet I, Nice, France|Larrey University Hospital, Toulouse, France|ISA - Interdisciplinary Study Association GmbH, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Heinrich-Heine-Universitaet Duesseldorf - Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Hautklinik Universitatsklinikum Erlangen, Erlangen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Lübeck, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Ospedali Riuniti di Ancona, Ancona, Italy|Presidio Ospedaliero della Misericordia, Grosseto, Italy|Azienda Sanitaria Locale 1 - Ospedale Regionale San Salvatore, L'Aquila, Italy|Universita degli Studi di Padova, Padova, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Di Calabria, Italy|Universita degli Studi di Roma La Sapienza - Ospedale A. Fiorini di Terracina, Terracina, Italy|Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy",,"https://ClinicalTrials.gov/show/NCT03777436"
39,"NCT03774875","A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life","EMBRACE","Recruiting","No Results Available","Psoriasis","Drug: Apremilast (CC-10004)|Other: Placebo","Proportion of subjects who achieve a ≥ 4-point reduction in DLQI from baseline|Mean change from baseline in DLQI|Mean change from baseline in Itch NRS score|Mean change from baseline in skin discomfort/pain VAS|Mean percent change in BSA affected by psoriasis|Proportion of subjects who achieve PBI score of ≥ 1|Proportion of subjects who achieve PASI < 3|Mean percent change from baseline in EQ-5D score|Mean change in WPAI domain scores|Treatment-emergent Adverse events|Clinically significant changes in body weight|Clinically significant changes in waist circumference|Clinically significant changes in vital signs|Clinically significant changes in laboratory findings","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-020|U1111-1224-8381|2018-002850-58","March 19, 2019","September 30, 2020","May 31, 2021","December 13, 2018",,"October 15, 2019","CHU de Grenoble, Grenoble, France|Centre Hospitalier Le Mans, Le Mans, France|CHU Hopital Edouard Herriot, Lyon cedex, France|Groupe Hospitalier Sud Hopital Haut Leveque USN, Pessac, France|Centre Hospitalier D'annecy, Pringy, France|CHRU Rennes, Rennes, France|CHU de Rouen Hopital Charles Nicolle, Rouen Cedex, France|Centre Hospitalier Universitaire de Saint Etienne, Saint Priest en Jarez, France|Centre Hospitalier Universitaire de Toulouse, Toulouse Cedex 9, France|Centre Hospitalier de Valence, Valence, France|Unviversitatsklinikum Aachen, Aachen, Germany|LICCA Clinical Research Intitute, Augsburg, Germany|Psoriasis Study Center, Berlin, Germany|Hautzentrum Friedrichshain - Dermatologie, Berlin, Germany|Hautzentrum Weissensee Dr. Kors und Dr. Bugdahl, Berlin, Germany|Praxis Jutta Dues und Maria Manasterski, Berlin, Germany|Derma Centro Bochum, Bochum, Germany|MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany|Hautklinik Universitatsklinikum Erlangen, Erlangen, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main, Frankfurt am Main, Germany|SRH Wald-Klinikum Gera GmbH, Gera, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|University of Heidelberg, Heidelberg, Germany|Friedrich Schiller Universität, Klinik für Dermatologie und Dermatologische Allergologie, Jena, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, Germany|Praxis Dr. Beate Schwarz, Langenau, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Lübeck, Germany|Universitatsklinikum Marburg, Marburg, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munchen, Germany|University of Tubingen, Tübingen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico, Catania, Italy|IRCCS Azienda Ospedaliera-Universitaria San Martino, Genova, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|AOU della II Universita degli Studi di Napoli, Napoli, Italy|Ospedale Santa Maria Della Misericordia Di Perugia, Perugia, Italy|Polyclinic Tor Vergata, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hospital Universitario Fundacion Alcorcon, Alcorcón, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital General de Castello, Castellon de la Plana, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain|Hospital Lucus Agusti, Lugo, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital de Manises, Manises, Spain|Hospital General Universitario Morales Messeguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Complejo Hospitalario Nuestra Senora de Valme, Sevilla, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital St.Gallen, St. Gallen, Switzerland|University of Zurich Hospital, Zurich, Switzerland|Barnet Hospital, Barnet, United Kingdom|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|Brighton General Hospital, Brighton, United Kingdom|West Suffolk Hospital, Bury Saint Edmunds, United Kingdom|Dudley Group NHS Foundation Trust - Russells Hall Hospital, Dudley, United Kingdom|Dumfries and Galloway Royal Infirmary - PPDS, Dumfries, United Kingdom|Ninewells Hospital and Medical School, Dundee, United Kingdom|Royal Devon and Exeter Hospital NHS Trust, Exeter, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|West Middlesex University Hospital, Isleworth, United Kingdom|The Leeds Teaching Hospitals NHS Trust - Chapel Allerton Hospital, Leeds, United Kingdom|Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, United Kingdom|St Cadocs Hospital, Newport, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|East Surrey Hospital, Redhill, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital, Sheffield, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03774875"
40,"NCT03757013","A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France","REALIZE","Recruiting","No Results Available","Psoriasis","Drug: Apremilast","Proportion of patients with Patient Benefit Index score (PBI-S) ≥1 at 6 months after initiation of apremilast.|Proportion of subjects with PBI-S (range 0-4) at 6 months after apremilast initiation|Proportion of patients with PBI-S=4 at 6 months after apremilast initiation|Adherence Rate|Percentage of patients substituting apremilast|Dermatology Life Quality Index (DLQI)|Proportion of patients with DLQI ≤ 5|Proportion of patients achieving DLQI 0/1|Change in DLQI score from M0 to M6 and M12|Proportion of patients with improvement in DLQI ≥ 5 points between M0 and M6, M12|Treatment Satisfaction Questionnaire for Medication (TSQM9)|Proportion of patients with sPGA 0 or 1|Change in sPGA from baseline to M6 and M12|Percentage of BSA (%BSA) involved at M0, M6, M12|Change in % BSA from M0 to M6, M12|Psoriasis Area Severity Index (PASI) at M0, M6, M12|Change in PASI from M0 to M6, M12|Proportion of patients achieving PASI50 at M6, M12|Proportion of patients achieving PASI75 at M6, M12.|Adverse Events (AEs)|Duration of disease|Number of areas of plaque psoriasis|Type of chronic psoriasis involved|The number of lines of previous systemic treatments|Type of systemic therapy previously administered|Duration of previous chronic psoriasis treatment|Number of motivations of the prescription of apremilast|Percentage of motivations of the prescription of apremilast","Celgene","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CC-10004-PSOR-021|U1111-1218-9791","September 25, 2018","March 24, 2020","March 24, 2021","November 28, 2018",,"November 15, 2019","Private Practice, Amiens, Amiens, France|Saint-Joseph Clinic, Angouleme, Angouleme, France|Private Practice, Antibes, Antibes, France|Private Practice 2, Antony, Antony, France|Private Practice, Antony, Antony, France|Private Practice, Arcachon, Arcachon, France|Private Practice, Argenteuil, Argenteuil, France|Private Practice, Aubière, Aubière, France|Private Practice, Auch, Auch, France|Auxerre Hospital, Auxerre, France|Henri Duffaut Hospital, Avignon Cedex 9, France|Private Practice, Bar-Le-Duc, Bar-Le-Duc, France|Private Practice, Bayonne, Bayonne, France|Private Practice, Beaune, Beaune, France|Private Practice, Besançon, Besançon, France|Reims-Bezannes Polyclinic 2, Bezannes, France|Reims-Bezannes Polyclinic 3, Bezannes, France|Reims-Bezannes Polyclinic, Bezannes, France|Private Practice, Biarritz, Biarritz, France|Private Practice, Bordeaux, Bordeaux, France|Private Practice 2, Bordeaux, Bordeaux, France|Doctor Duchenne Hospital 3, Boulogne-sur-Mer, France|Docteur Duchenne Hospital 2, Boulogne-sur-Mer, France|Docteur Duchenne Hospital, Boulogne-sur-Mer, France|Private Practice, Bègles, Bègles, France|Private Practice 2, Caen, Caen, France|Private Practice, Caen, Caen, France|Private Practice 2, Chalons-en-Champagne, Chalons-en -Champagne, France|Private Practice, Chalons-en-Champagne, Chalons-en-Champagne, France|Chalons-en-Champagne Hospital, Chalons-en-Champagne, France|Private Practice, Chamalières, Chamalières, France|Trousseau Hospital, Chambray-Les-Tours Cedex, France|Métropole Savoie Hospital, Chambéry, France|Private Practice, Charleville Mezières, Charleville Mezières, France|Private Practice 2, Chartres, Chartres, France|Private Practice, Chartres, Chartres, France|New Sud Francilien Hospital, Corbeil Essonnes, France|GH de Dax, Dax, Dax, France|Private Practice 2, Dijon, Dijon, France|Private Practice 3, Dijon, Dijon, France|Private Practice, Dijon, Dijon, France|Private Practice, Dole, Dole, France|Victor Jousselin Hospital, Dreux, France|Emile Durkheim Hospital - Saint Jean Health Center, Epinal Cedex, France|Private Practice, Essey-les-Nancy, Essey-les-Nancy, France|Private Practice, Gardanne, Gardanne, France|Golfe de St-Tropez Clinic, Gassin, France|Private Practice 2, Joue les Tours, Joue les Tours, France|Private Practice 3, Joue les Tours, Joue les Tours, France|Private Practice, Joue les Tours, Joue les Tours, France|Private Practice, L'Union, L'Union, France|Private Practice 2, La Teste-de-Buch, La Teste-de-Buch, France|Private Practice, La Teste-de-Buch, La Teste-de-Buch, France|Private Practice, La Valette du Var, La Valette du Var, France|Private Practice, La Varenne Saint Hilaire, La Varenne Saint Hilaire, France|Private Practice, Laval, Laval, France|Private Practice, Le Mans, Le Mans, France|Private Practice, Le-Bourget-du-Lac, Le-Bourget-du-Lac, France|Private Practice, Lille, Lille, France|Private Practice 2, Luce, Luce, France|Private Practice, Luce, Luce, France|Private Practice, Lyon, Lyon, France|Edouard Herriot Hospital, Lyon, France|Private Practice 2, Lyon, Lyon, France|Private Practice 3, Lyon, Lyon, France|Private Practice 4, Lyon, Lyon, France|Mans Hospital 2, Mans, France|Mans Hospital, Mans, France|Private Practice, Martigues, Martigues, France|Annecy Genevois Hospital, Metz Tessy, Metz Tessy, France|Private Practice, Meudon-la-Forêt, Meudon-la-Forêt, France|Private Practice, Montbard, Montbard, France|Private Practice, Muret, Muret, France|Hotel Dieu Hospital, Dermatologic Clinic, Nantes, France|Private Practice, Nantes, Nantes, France|Private Practice, Narbonne, Narbonne, France|Private Practice, Nevers, Nevers, France|Private Practice 2, Nice, Nice, France|Private Practice 3, Nice, Nice, France|Private Practice, Nice, Nice, France|Private Practice, Nogent-Le-Rotrou, Nogent-Le-Rotrou, France|Private Practice, Orléans, Orléans, France|Private Practice, Paris, Paris, France|Private Practice 2, Paris, Paris, France|Private Practice 3, Paris, Paris, France|Private Practice 4, Paris, Paris, France|Private Practice 5, Paris, Paris, France|Private Practice, Pontarlier, Pontarlier, France|Private Practice, Pontoise, Pontoise, France|Private Practice, Quimper, Quimper, France|CHI de Cornouaille - Laennec, Quimper, France|Mathilde II Clinic, Rouen, France|Private Practice, Saint-Etienne, Saint-Etienne, France|Private Practice, Sainte Maxime, Sainte Maxime, France|Amiens Hospital, Salouel, France|Private Practice, Sanary sur Mer, Sanary sur Mer, France|Saint-Etienne Hospital, St Priest en Jarez, France|Private Practice, Strasbourg, Strasbourg, France|BCRM Toulon - HIA Saint-Anne, Toulon Cedex 9, France|Private Practice 2, Toulon, Toulon, France|Private Practice, Toulon, Toulon, France|Private Practice, Toulouse, Toulouse, France|Private Practice 2, Toulouse, Toulouse, France|Private Practice 3, Toulouse, Toulouse, France|St Jean Languedoc Clinic 2, Toulouse, France|St Jean Languedoc Clinic, Toulouse, Toulouse, France|Nord Franche-Comté Hospital, Trevenans, France|Valence Hospital 2, Valence, France|Valence Hospital 3, Valence, France|Valence Hospital 4, Valence, France|Valence Hospital, Valence, France|CHU Nancy Brabois, Vandoeuvre-les-Nancy, Vandoeuvre-les-Nancy, France|Private Practice, Vannes, Vannes, France|Private Practice, Vence, Vence, France|Jacques Lacarin Hospital, Vichy, France",,"https://ClinicalTrials.gov/show/NCT03757013"
41,"NCT03747939","Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.","FOREMOST","Recruiting","No Results Available","Arthritis, Psoriatic","Drug: Apremilast (CC-10004)|Other: Apremilast (CC-10004) Placebo","Proportion of subjects who achieved a clinical state of minimal disease activity defined MDA-Joints)|Proportion of subjects with cDAPSA remission or low activity|Proportion of subjects with SJC ≤ 1|Proportion of subjects with TJC ≤ 1|Proportion of subjects with improvement in the PsAID-12 score|Proportion of subjects with improvement in the PASDAS score|Proportion of subjects with improvement in the Patient Global Assessment of Disease Activity|Proportion of subjects with improvement in the Patient Global Assessment Pain|Type, frequency, severity, and relationship of adverse events (AEs) to investigational product (IP)|Number of subjects who discontinue IP due to any AE|Frequency of clinically significant changes in physical examination, vital signs, and/or laboratory findings","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-013|U1111-1224-0216|2018-002735-26","December 19, 2018","January 28, 2021","August 12, 2021","November 20, 2018",,"October 22, 2019","Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States|Covina Arthritis Clinic, Covina, California, United States|East Bay Rheumatology Medical, San Leandro, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|Center for Rheumatology, Immunology, & Arthritis, Fort Lauderdale, Florida, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States|North Georgia Rheumatology, Lawrenceville, Georgia, United States|Klein and Associates MD, PA - Cumberland, Cumberland, Maryland, United States|Klein and Associates MD, PA - Hagerstown, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Advanced Rheumatology, Lansing, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|St. Paul Rheumatology, PA, Eagan, Minnesota, United States|Arthritis, Rheumatic, and Back Disease Associates, Sewell, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Joint and Muscle Research Institute, Charlotte, North Carolina, United States|Arthritis & Osteoporosis Center of Southwest Ohio, Springboro, Ohio, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Arthritis Group, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|West Texas Clinical Research, Lubbock, Texas, United States|Seattle Rheumatology Associates, Seattle, Washington, United States|KH Hietzing, Vienna, Austria|AKH Wien, Wein, Austria|CHU Brugmann, Brussels, Belgium|Hopital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Jan Palfijn Ziekenhuis, Merksem, Belgium|Manitoba Clinic, Winnipeg, Manitoba, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Dr. Sabeen Anwar Medicine Professional Corporation, Windsor, Ontario, Canada|Institut de Rhumatologie de Montreal, Montreal, Quebec, Canada|Ipros-Chr Orleans, Orleans, France|Hopital Lariboisiere, Paris Cedex 10, France|Assistance Publique- Hopitaux de Paris AP-HP, Paris, France|CH Toulouse Hopital Pierre-Paul Riquet, Toulouse, France|Praxis fur Rheumatologie - Amberg, Amberg, Germany|Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany|Charite - Campus Mitte, Berlin, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, Germany|MVZ Ambulantes Rheumazentrum Erfurt, Erfurt, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main, Frankfurt am Main, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Rhein-Maas Klinikum, Wurselen, Germany|Policlinico di Bari UOC, Bari, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Universita degli studi Messina, Messina, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Humanitas Research Hospital - Humanitas Mirasole S.p.A, Milan, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Medisch Spectrum Twente, Enschede, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Kazan State Medical University, Kazan, Russian Federation|Kursk Regional Clinical Hospital, Kursk, Russian Federation|Research Institute of Rheumatology named after V.A.Nasonova, Moscow, Russian Federation|Moscow Regional Research Institute n.a. Vladimirsky, Moscow, Russian Federation|Research Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|Municipal Budgetary Healthcare Institution City Emergency Hospital, Rostov-on-don, Russian Federation|I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation|Medical Center Sanavita, St. Petersburg, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|Hospital Universitario de Cruces, Baracaldo, Spain|Hospital Galdakao-Usansolo, Galdakao, Spain|Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Merida, Merida, Spain|Eastbourne District General Hospital, Eastbourne, United Kingdom|Western General Hospital, Edinburgh Scotland, United Kingdom|Kings College Hospital, London, United Kingdom|Luton and Dunstable University Hosptial, Luton, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Torbay Hospital, Torquay South Devon, United Kingdom|Royal Cornwall Hospitals Trust, Truro, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03747939"
42,"NCT03745222","A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","RATIONALE001","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Tislelizumab|Drug: Concurrent chemoradiotherapy (cCRT)|Other: Placebo","Progression free survival (PFS)|Overall survival (OS)|Overall survival (OS) at 24 months|Objective response rate (ORR)|Duration of response (DoR)|Proportion of subjects alive and progression-free at 12 months (APF12)|Proportion of subjects alive and progression-free at 18 months (APF18)|Time to distant metastasis (TTDM)|Adverse Events (AEs)|European Organisation for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30)|European Organisation for Research and Treatment of Cancer - Quality of Life C30 questionnaire lung cancer module (EORTC QLQ-LC13)|Proportion of subjects who continue to monotherapy phase","Celgene|BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 3","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BGB-A317-NSCL-001|U1111-1216-4294|2018-001132-22","May 22, 2019","June 26, 2019","June 26, 2019","November 19, 2018",,"August 28, 2019","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cancer Specialists of North Florida - Jacksonville, Jacksonville, Florida, United States|Bond Clinic, P.A., Winter Haven, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Appalachian Regional Healthcare, Inc., Hazard, Kentucky, United States|Norton Healthcare - Norton Cancer Institute, Louisville, Kentucky, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Dayton Physicians, LLC, Kettering, Ohio, United States|Mercy Health Youngstown Hospital, LLC, Youngstown, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Millennium Oncology, Houston, Texas, United States|Medical Oncology Associates, P.S., Spokane, Washington, United States|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Jewish General Hospital, Montreal, Quebec, Canada|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China|Chinese PLA General Hospital / 307 Hospital, Beijing, China|Beijing Cancer Hospital - Beijing Institute for Cancer Research, Beijing, China|Bengbu Medical College - First Affiliated Hospital, Bengbu Shi, China|Jilin Province Cancer Hospital, Changchun Shi, China|First Hospital of Jilin University, Changchun, China|Central South University - Xiangya School of Medicine - Hunan Cancer Hospital, Changsha-shi, China|Central South University - Xiangya School of Medicine - Hunan Cancer Hospital, Changsha, China|Sichuan Cancer Hospital & Institute, Chengdu, China|Sichuan University - West China Hospital, Chengdu, China|Foshan First People's Hospital, Foshan, China|Fujian Medical University - Fujian Provincial Cancer Hospital, Fuzhou Shi, China|Cancer Center of Guangzhou Medical University, Guangzhou, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Zhejiang University School of Medicine - The Second Affiliated Hospital, Hangzhou, China|Zhejiang Medical University - Zhejiang Cancer Hospital, Hangzhou, China|The First Affiliated Hospital of Harbin Medical University, Harbin, China|Yunnan Cancer Hospital, Kunming Shi, China|Guangxi Tumour Institute and Hospital, Nanning, China|Nantong Tumor Hospital, Nantong, China|Shanghai Chest Hospital, Shanghai Shi, China|Fudan University Shanghai Cancer Center, Shanghai, China|Chongqing Cancer Hospital, Shapingbaqu, China|Liaoning Cancer Hospital & Institute, Shenyang Shi, China|The First Hospital of Xinjiang Medical University, Urumqi, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Zhongnan Hospital of Wuhan University, Wuhan, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, China|First Hospital of Xiamen, Xiamen, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China|Zhengzhou University (ZZU) - Henan Cancer Hospital, Zhengzhou, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China|Tampereen yliopistollinen sairaala, Tampere, Finland|Turku University Hospital, Turku, Finland|Centre Francois Baclesse, Caen Cedex 5, France|Clinique Victor Hugo, Le Mans, France|Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain, Saint Herblain, France|Medical Study Company NORD-WEST GmbH Oncology Aurich, Aurich, Germany|Helios Klinikum Emil Von Behring, Berlin, Germany|Florence Nightingale KH der Kaiserwerther Diakonie, Dusseldorf, Germany|Klinikum Esslingen GmbH, Esslingen Am Neckar, Germany|Asklepios Fachkliniken Muenchen Gauting, Gauting, Germany|Oncological practice Goslar, Goslar, Germany|Evangelisches Krankenhaus Hamm, Hamm, Germany|Health Nordhessen Holding AG - Klinikum Kassel - Medical Clinic IV, Kassel, Germany|Kliniken der Stadt Koln gGmbH - Krankenhaus Merheim, Koln, Germany|Klinik Loewenstein gGmbH, Loewenstein, Germany|LMU Klinikum der Universität, München, Germany|St. Antonius-Hospital, Schweiler, Germany|Medizinische Studiengesellschaft Nord-West, Westerstede, Germany|Sotiria Chest Hospital of Athens, Athens, Greece|IASO General, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|Agioi Anargyroi Cancer Hospital, Kifissia, Greece|Metaxa Cancer Hospital of Piraeus, Piraeus, Greece|Interbalkan Medical Center of Thessaloniki, Pylaia, Greece|University General Hospital of Patras, Rio Patras, Greece|Bioclinic Thessaloniki Galinos clinic, Thessaloniki, Greece|EUROMEDICA General Clinic of Thessaloniki, Thessaloniki, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Pulmonary Institute Torokbalint, Torokbalint, Hungary|Beacon Hospital, Dublin, Ireland|St James Hospital, Dublin, Ireland|MidWestern Regional Hospital, Limerick, Ireland|Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico, Catania, Italy|IRCCS AziendaOspedaliera Universitaria San Martino, Genova, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Universita Campus Bio-Medico di Roma, Roma, Italy|Istituto Nazionale Tumori Regina Elena di Roma, Roma, Italy|Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino-shi, Japan|Kansai Medical University Hospital, Hirakata-shi, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Kanazawa-shi, Japan|Matsusaka Municipal Hospital, Matsusaka-shi, Japan|Toranomon Hospital, Minato-ku, Japan|Iwate Medical University Hospital, Morioka, Japan|National Hospital Organization - Nagoya Medical Center, Nagoya-shi, Japan|Nagoya University Hospital, Nagoya-shi, Japan|Niigata Cancer Center Hospital, Niigata-shi, Japan|Osaka City University Hospital, Osaka, Japan|Gunma Prefectural Cancer Center, Ota-ku, Japan|Kitasato University Hospital, Sagamihara, Japan|Sendai Kousei Hospital, Sendai-shi, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama-shi, Japan|Yokohama Municipal Citizen's Hospital, Yokohama-shi, Japan|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon si, Korea, Republic of|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Gelre Hospitals, Zutphen, Netherlands|Waikato Hospital, Hamilton, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Gliwice, Poland|Med Polonia Sp. z o.o. NSZOZ, Poznan, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Centro Hospitalar do Alto Ave, Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|CUF Descobertas Hospital, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|CUF Porto Hospital, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Oncology Institute Professor Doctor Alexandru Trestioreanu, Bucharest, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj-Napoca, Romania|Medisprof SRL, Cluj-Napoca, Romania|Sf. Apostol Andrei Constanta Emergency Clinical County Hospital, Constanta, Romania|Oncology Center Sfantul Nectarie, Craiova, Romania|Life Search SRL, Timisoara, Romania|Oncocenter Clinical Oncology, Timisoara, Romania|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Russian Federation|Omsk Regional Oncology Center, Omsk, Russian Federation|Ryazan State Medical University n.a. I.P. Pavlov, Ryazan, Russian Federation|Mordovia State University, Saransk, Russian Federation|Clinical Hospital of the Russian Academy of Sciences, St. Petersburg, Russian Federation|GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), St. Petersburg, Russian Federation|Research Oncology Institute of Rosmed Technologies n.a. prof. N.N. Petrov, St. Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Hospital Universitario a Coruna, A Coruna, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Insular-Maternal and Child University Hospital Complex, Las Palmas de Gran Canaria, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital General Carlos Haya, Malaga, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Buddhist Dalin Tzu Chi General Hospital, Dalin, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, San Ming Dist., Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, United Kingdom|East Suffolk and North Essex NHS Foundation Trust - Colchester Hospital, Colchester, United Kingdom|University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom|Guys Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Maidstone and Tunbridge Wells NHS Trust - Maidstone Hospital, Maidstone, United Kingdom|Manchester University NHS Foundation Trust - Wythenshawe Hospital - North West Lung Centre, Manchester, United Kingdom|The Hillingdon Hospitals NHS Foundation Trust - Mount Vernon Hospital, Northwood, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital, Sheffield South Yorkshire, United Kingdom|Royal Cornwall Hospitals Trust, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03745222"
43,"NCT03743246","A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)",,"Active, not recruiting","No Results Available","Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin","Drug: JCAR017|Drug: Lymphodepleting|Drug: Fludarabine|Drug: Cyclophosphamide","Recommended Phase 2 Dose (RP2D) of JCAR017|Overall response rate (ORR)- Cohort 1|Minimal residual disease (MRD) negative rate - Cohort 2|Overall response rate (ORR)- Cohort 3|Adverse Events (AEs)|Overall response rate (ORR) in the non-selected dose from Phase 1b|Duration of response (DOR)|Relapse-free survival (RFS)|Event-free survival (EFS)|Overall survival (OS)|MRD response rate|Rate of hematopoietic stem cell transplant (HSCT) after response to JCAR017 infusion|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC","Celgene","All","up to 25 Years   (Child, Adult)","Phase 1|Phase 2","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR017-BCM-004|U1111-1220-3324|2018-001246-34","October 17, 2018","December 11, 2023","December 11, 2023","November 16, 2018",,"February 25, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States|Seattle Children's Hospital, Seattle, Washington, United States|UZ Gent, Gent, Belgium|Institute for Pediatric Hematology - Oncology, Leon Berard Cancer Center, Lyon, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, France|Hopital Robert Debre, Paris, France|Fondazione MBBM, Monza, Italy|Ospedale Bambin Gesu, Roma, Italy|Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands|Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03743246"
44,"NCT03742921","ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma, T-Cell, Peripheral","Drug: Istodax","Adverse Events (AEs)","Celgene","All","Child, Adult, Older Adult",,"130","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ROMI-PTCL-001|U1111-1222-2854","November 30, 2018","April 17, 2023","April 17, 2023","November 15, 2018",,"November 15, 2018",,,"https://ClinicalTrials.gov/show/NCT03742921"
45,"NCT03742882","A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects",,"Not yet recruiting","No Results Available","Hepatic Impairment","Drug: CC-90001","Pharmacokinetic- AUC0-t|Pharmacokinetic- AUC0-∞|Pharmacokinetic- Cmax|Pharmacokinetic- Tmax|Pharmacokinetic- t1/2|Pharmacokinetic- CL/F|Pharmacokinetic- Vz/F|Adverse Events (AEs)","Celgene","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90001-CP-005|U1111-1223-7431","December 15, 2018","December 31, 2019","April 15, 2020","November 15, 2018",,"December 17, 2018",,,"https://ClinicalTrials.gov/show/NCT03742882"
46,"NCT03740516","Expanded Access for CC-10004",,"No longer available","No Results Available","Bechet's Disease","Drug: CC-10004",,"Celgene","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"CC-10004",,,,"November 14, 2018",,"December 19, 2018","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03740516"
47,"NCT03724227","Expanded Access for ACE-011",,"Available","No Results Available","Myelodysplastic Syndrome","Drug: ACE-011",,"Celgene","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"ACE-011",,,,"October 30, 2018",,"October 30, 2018","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03724227"
48,"NCT03723135","Expanded Access for CC-486",,"Available","No Results Available","Myelodysplastic Syndrome (MDS)","Drug: CC-486",,"Celgene","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"CC-486",,,,"October 29, 2018",,"October 24, 2019","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03723135"
49,"NCT03723096","Expanded Access for CC-4047",,"No longer available","No Results Available","Multiple Myeloma","Drug: CC-4047",,"Celgene","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"CC-4047",,,,"October 29, 2018",,"December 20, 2018","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03723096"
50,"NCT03723083","Expanded Access for CC-2001",,"No longer available","No Results Available","Dermatologic|Other","Drug: CC-2001",,"Celgene","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"CC-2001",,,,"October 29, 2018",,"December 20, 2018","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03723083"
51,"NCT03723057","Expanded Access for AG-221",,"No longer available","No Results Available","Acute Myeloid Leukemia","Drug: AG-221",,"Celgene","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"AG-221",,,,"October 29, 2018",,"October 24, 2019","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03723057"
52,"NCT03721172","Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy","ADVANCE","Recruiting","No Results Available","Psoriasis","Drug: Apremilast|Other: Placebo","Proportion of subjects with an sPGA score of clear (0) or almost clear (1) and with at least a 2- point reduction from baseline at Week 16.|Proportion of subjects who improved ≥ 75% in BSA from baseline at Week 16.|Body Surface Area (BSA)changes|Psoriasis Area and Severity Index (PASI)|Proportion of subjects with BSA ≤ 3%|Proportion of subjects with ≥4-point reduction (improvement) from baseline in the whole-body itch NRS score at Week 16 among subjects with baseline whole body itch NRS ≥ 4.|Proportion of subjects with ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at Week 16 among subjects with baseline ScPGA score ≥ 2.|Dermatology Life Quality Index (DLQI)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","574","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-022|U1111-1218-8372","March 11, 2019","March 4, 2020","July 8, 2020","October 26, 2018",,"October 15, 2019","Total Skin & Beauty Dermatology Center, Birmingham, Alabama, United States|Johnson Dermatology Clinic, Fort Smith, Arkansas, United States|Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology, Rogers, Arkansas, United States|Dermatology Research Associates, Los Angeles, California, United States|TCR Medical Corporation, San Diego, California, United States|University of California San Francisco Psoriasis and Skin Treatment Center, San Francisco, California, United States|Clinical Science Institute, Santa Monica, California, United States|University of Colorado Hospital - Dermatology Clinic, Aurora, Colorado, United States|Total Vein and Skin, LLC, Boynton Beach, Florida, United States|Florida Academic Centers Research and Education, Coral Gables, Florida, United States|International Dermatology Research, Miami, Florida, United States|Center for Clinical and Cosmetic Research, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|University of South Florida - Carol and Frank Morsani Center for Advanced Health Care, Tampa, Florida, United States|Atlanta Dermatology, Vein and Research Center, PC, Alpharetta, Georgia, United States|Medical Dermatology Specialists, Inc. - Advanced Medical Research, Atlanta, Georgia, United States|MedaPhase INC, Newnan, Georgia, United States|Gwinnett Clinical Research Center, Inc., Snellville, Georgia, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Clinical Trials Management LLC, Metairie, Louisiana, United States|Derm Associates, Rockville, Maryland, United States|Lawrence Green, MD, LLC, Rockville, Maryland, United States|ActivMed Practices & Research Inc, Beverly, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Minnesota Clinical Study Center, Fridley, Minnesota, United States|Central Dermatology, Saint Louis, Missouri, United States|JDR Dermatology Research, LLC, Las Vegas, Nevada, United States|Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States|Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Wright State Physicians, Fairborn, Ohio, United States|Temple University - Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Clinical Partners, LLC, Johnston, Rhode Island, United States|Clinical Research Center of the Carolinas, Charleston, South Carolina, United States|Austin Institute for Clinical Research, Pflugerville, Texas, United States|Center for Clinical Studies, Webster, Texas, United States|University of Utah MidValley Dermatology, Murray, Utah, United States|Virginia Clinical Research Inc, Norfolk, Virginia, United States|Dermatology Center for Skin Health, Morgantown, West Virginia, United States|Institute for Skin Advancement, Calgary, Alberta, Canada|Stratica Medical, Edmonton, Alberta, Canada|Chih-Ho Hong Medical, Inc., Surrey, British Columbia, Canada|Enverus Medical Research, Surrey, British Columbia, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|SkinWise Dermatology, Winnipeg, Manitoba, Canada|Brunswick Dermatology Centre, Fredericton, New Brunswick, Canada|Karma Clinical Trials, Saint John's, Newfoundland and Labrador, Canada|SimcoDerm Medical and Surgical Dermatology Center, Barrie, Ontario, Canada|Guelph Dermatology Research, Guelph, Ontario, Canada|DermEffects, London, Ontario, Canada|Lynderm Research, Markham, Ontario, Canada|North Bay Dermatology Centre, North Bay, Ontario, Canada|Skin Center for Dermatology, Peterborough, Ontario, Canada|Toronto Research Centre, Toronto, Ontario, Canada|Sameh Hanna Medicine Professional Corporation DBA Dermatology on Bloor, Toronto, Ontario, Canada|K. Papp Clinical Research, Waterloo, Ontario, Canada|Windsor Clinical Research Inc., Windsor, Ontario, Canada|Dr Isabelle Delorme inc, Drummondville, Quebec, Canada|Dre Angelique Gagne-Henley M.D. Inc., Saint-Jerome, Quebec, Canada|Skinsense Medical Research, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT03721172"
53,"NCT03720366","A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients",,"Not yet recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: enasidenib|Drug: Arm 1 probes|Drug: Arm 2 Probes|Drug: Arm 3 probes","Pharmacokinetics - AUC0-30|Pharmacokinetics - Cmax|Pharmacokinetics - AUC0-∞|Pharmacokinetics -t1/2,z|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Complete Response Rate|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90007-CP-004|U1111-1218-1974","October 31, 2018","January 30, 2020","December 30, 2022","October 25, 2018",,"October 30, 2018",,,"https://ClinicalTrials.gov/show/NCT03720366"
54,"NCT03703375","Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, T-Cell","Drug: Azacitidine|Drug: Romidepsin|Drug: Gemcitabine","Progression Free Survival (PFS)|Overall Survival (OS)|Progression Free Survival (PFS) by Independent Review Committee (IRC)|Overall Response Rate (ORR)|Complete Response Rate (CRR)|Duration of Response|Time to Response|PFS2 using local assessment of progressive disease|EORTC QLQ-C30|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OA-CL-LYM-LYSARC-13134C|U1111-1220-8294|2017-003909-17","November 6, 2018","December 31, 2021","December 31, 2021","October 12, 2018",,"August 13, 2019","National Cancer Center Hospital, Chuo-ku, Japan|Kyushu University Hospital, Fukuoka, Japan|Saitama Medical University International Medical Center, Hidaka, Japan|Tokai University Hospital, Isehara City, Kanagawa, Japan|National Cancer Center Hospital East, Kashiwa, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|National Hospital Organization - Nagoya Medical Center, Nagoya-shi, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka-Sayama, Japan|Hokkaido University Hospital, Sapporo, Hokkaidô, Japan|Tohoku University Hospital, Sendai, Japan|University of Tsukuba Hospital, Tsukuba, Japan",,"https://ClinicalTrials.gov/show/NCT03703375"
55,"NCT03701763","Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis",,"Recruiting","No Results Available","Psoriasis","Drug: Apremilast (CC-10004)|Other: Placebo","Proportion of subjects with an sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline|Proportion of subjects who achieve at least a 75% reduction in PASI (PASI-75) from baseline|Proportion of subjects who achieve at least a 50% reduction in PASI (PASI-50) from baseline|Percent change from baseline in total PASI score|Percent change from baseline in affected Body Surface Area (BSA)|Proportion of subjects who achieve CDLQI (0/1)|Change from baseline in CDLQI score|Adverse Events (AEs)|Stool Diary|Columbia-Suicide Severity Rating Scale (C-SSRS)|Tanner Stages|Psoriasis disease flare|Psoriasis Rebound|Height Measurement|Weight Measurement","Celgene","All","6 Years to 17 Years   (Child)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PPSO-003|U1111-1219-3112|2018-002918-12","December 3, 2018","October 20, 2021","October 19, 2022","October 10, 2018",,"October 22, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Johnson Dermatology Clinic, Fort Smith, Arkansas, United States|Zenith Research, Inc., Beverly Hills, California, United States|First OC Dermatology, Fountain Valley, California, United States|Stanford University, Palo Alto, California, United States|Coastal Family Dermatology, San Luis Obispo, California, United States|Mosaic Dermatology, Santa Monica, California, United States|Ronald Reagan UCLA Medical Center, Santa Monica, California, United States|California Dermatology Institute, Thousand Oaks, California, United States|Solutions Through Advanced Research Inc., Jacksonville, Florida, United States|Glick Skin Institute Clinical Research, Margate, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Ciocca Dermatology, Miami, Florida, United States|University of South Florida - Carol and Frank Morsani Center for Advanced Health Care, Tampa, Florida, United States|Skin Care Physicians of Georgia, Macon, Georgia, United States|Dawes Fretzin Dermatology Group Inc, Indianapolis, Indiana, United States|ActivMed Practices & Research Inc, Beverly, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|J. Woodson Dermatology & Associates, Ltd, Henderson, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Montefiore Medical Center, Bronx, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Forest Hills Dermatology Group, Forest Hills, New York, United States|Wright State Physicians, Fairborn, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Arlington Research Center, Arlington, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Modern Research Associates PLLC, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Dermatology and Laser Specialists, San Antonio, Texas, United States|Jordan Valley Dermatology Center, West Jordan, Utah, United States|MercyHealth East, Janesville, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Kirk Barber Research, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|Enverus Medical Research, Surrey, British Columbia, Canada|Skin Care Centre, Vancouver, British Columbia, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|Karma Clinical Trials, Saint John's, Newfoundland and Labrador, Canada|AvantDerm, Toronto, Ontario, Canada|CHU Saint-Justine, Montreal, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Kralovske Vinohrady, Prague 10, Czechia|Centre Hospitalier Victor Dupouy Argenteuil, Argenteuil CEDEX, France|Centre Hospitalier Universitaire Lyon, Bron, France|Cabinet du Docteur Ruer-Mulard Mireille, Martigues, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|Centre Hospitalier Universitaire de Nice - Hopital L'Archet, Nice CEDEX 3, France|Hopital Necker, Paris Cedex 15, France|Centre Hospitalier de Cornouaille - Hopital Laennec, Quimper, France|CHU Saint Etienne Hopital Nord, Saint Etienne, France|Centre Hospitalier Universitaire de Toulouse, Toulouse Cedex 9, France|Centre Hospitalier de Valence, Valence, France|Charite - Campus Mitte, Berlin, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Praxis Dr. med S. Rotterdam, Gelsenkirchen, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Kinderkrankenhaus Wilhelmstift, Dermatologie, Hamburg, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Universitatsklinikum Muenster, Munster, Germany|University of Tubingen, Tübingen, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero Universitaria Di Cagliari, Caglari, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Polyclinic Tor Vergata, Roma, Italy|Istituto Dermopatico Dell'immacolata IRCCS, Roma, Italy|Istituto Dermatologico San Gallicano IRCCS Dermatologia Clinica, Rome, Italy|Radboud university medical center, Nijmegen, Netherlands|Altai State Medical University, Barnaul, Russian Federation|Chelyabinsk Regional Clinical Skin and Venereal Dispensary, Chelyabinsk, Russian Federation|Ural Scientific Research Institute of Dermatovenereology and Immunopathology, Ekaterinburg, Russian Federation|Republican Clinical Dermatology and Venerology Dispensary, Kazan, Russian Federation|Clinical Dispensary of Dermatology and Venereology of Krasnodar Territory of the Ministry of Health, Krasnodar, Russian Federation|State Scientific Center for Dermatovenereology and Cosmetology, Moscow, Russian Federation|Russian Children's Clinical Hospital, Moscow, Russian Federation|Moscow Scientific Practical Center of Dermatology Venerology and Cosmetology, Moscow, Russian Federation|National Medical Research Center for Children's Health, Moscow, Russian Federation|LLC Medical Center Zdorovaya Semiya, Novosibirsk, Russian Federation|Pierre Wolkenshtein Skin Diseases Clinic LLC, Saint Petersburg, Russian Federation|St. Petersburg State Pediatric Medical University, Saint Petersburg, Russian Federation|OOO Kurator, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Bashkiria State Medical University, Ufa, Russian Federation|Yarosavl State Medical Academy, Yaroslavl, Russian Federation|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Puerta del Mar, Cadiz, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Complexo Hospitalario De Pontevedra, Pontevedra, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital Virgen del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03701763"
56,"NCT03694119","Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response",,"Completed","No Results Available","Healthy Volunteer","Drug: Phenelzine|Drug: Tyramine|Drug: Phenelzine placebo|Drug: ozanimod placebo|Drug: ozanimod","Cardiovascular|Pharmacokinetics - Cmin|Pharmacokinetics - Tmax|Pharmacokinetics - AUC0-24|Pharmacokinetics - Ctrough|Adverse Events (AEs)|Cardiovascular Analysis-SBP|Cardiovascular Analysis-DBP|Cardiovascular Analysis-Heart rate|Pharmacokinetics - Cmax","Celgene","All","25 Years to 55 Years   (Adult)","Phase 1","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","RPC01-1913|U1111-1218-6630","July 24, 2018","January 8, 2019","January 8, 2019","October 3, 2018",,"July 19, 2019","PPD Phase 1 Clinic, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03694119"
57,"NCT03682536","Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions","COMMANDS","Recruiting","No Results Available","Myelodysplastic Syndromes","Drug: Luspatercept|Drug: Epoetin alfa","Red Blood Cell Transfusion Independence (RBCTI) for 24 weeks|Hematologic improvement - erythroid response (HI-E) per International Working Group (IWG) within 24 weeks|Mean hemoglobin increase ≥ 1.5 g/dL|Time to Hematologic improvement - erythroid response (HI-E)|Duration of HI-E|Duration of Red blood cell transfusion independence (RBC-TI) ≥ 24 weeks|RBC-TI for ≥ 84 days|Duration of RBC-TI ≥ 84 days|Time to RBC-TI ≥ 84 days|Time to first Red blood cell (RBC) transfusion|RBC transfusion burden on treatment|For subjects with RBC transfusion burden of ≥4 units/8 weeks at baseline:|RBC-TI during Weeks 4-24|RBC-TI for a consecutive 24-week period|The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30)|The Functional Assessment of Cancer Therapy-Anemia Version 4 (FACT-An) questionnaire|Adverse Event (AE)|Pharmacokinetic - AUC|Pharmacokinetic - Cmax|Antidrug antibodies (ADA)|Progression to AML|Time to AML|Overall survival","Celgene|Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-MDS-002|U1111-1218-1810|2017-003190-34","January 2, 2019","April 6, 2021","November 30, 2022","September 24, 2018",,"October 22, 2019","Alta Bates Summit Medical Center, Berkeley, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Florida Cancer Institute, Hudson, Florida, United States|Florida Cancer Specialists North Region Sarah Cannon Research, Saint Petersburg, Florida, United States|SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Western Kentucky Hematology and Oncology Group, Paducah, Kentucky, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|HCA Midwest Health, Kansas City, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|East Carolina University, Greenville, North Carolina, United States|Univ of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Carolina Blood and Cancer Care, Rock Hill, South Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas- MD Anderson, Houston, Texas, United States|Utah Cancer Specialists - South Salt Lake, Salt Lake City, Utah, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Shoalhaven Cancer Care Centre, Nowra, New South Wales, Australia|Newcastle Calvary Mater Hospital, Waratah, New South Wales, Australia|Wollongong Private Hospital, Wollongong, New South Wales, Australia|Icon Cancer Foundation, Auchenflower, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Perth Blood Institute, West Perth, Western Australia, Australia|The Prince of Wales Hospital, Randwick, Australia|Elisabethinen Hospital Linz, Linz, Austria|Medizinische Universitat Wien, Vienna, Austria|ZNA Middelheim, Antwerpen, Belgium|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|Cliniques Universitaires St-Luc, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Gasthuisberg, Leuven, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|Centre Hospitalier Universitaire de Grenoble Hopital Albert Michallon, La Tronche, France|Centre Hospitalier Le Mans, Le Mans, France|CHRU de Lille France, Lille, France|CHU Limoges, Limoges Cedex, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|CHU Nice Hopital de L'Archet 2, Nice Cedex 3, France|Assistance Publique - Hopitaux de Paris - Hopitaux Saint-Louis, Paris, France|CHU Bordeaux, Pessac, France|CHU Purpan, Toulouse, France|CHU de Nancy-Hopital Brabois Adulte, Vandoeuvre les Nancy, France|Stauferklinikum Schwab. Gmund, Baden-Warttemberg, Germany|Medizinisches Versorgungszentrum (MVZ) Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|St. Johannes Krankenhaus Duisburg, Duisburg, Germany|Marien Hospital, Dusseldorf, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|Ärzte f. Innere Medizin Gemeinschaftspraxis f. Hamatologie u. Onkologie, Köln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munchen, Germany|Rems-Murr-Kliniken, Winnenden, Germany|Hamatologisch-onkologische Praxis, Würzburg, Germany|Istituto di Ematologia L. e A. Seragnoli-Azienda Ospedaliero Universitaria Policlinico S. Orsola M, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|A.O. Ospedale Ca Granda - Niguarda, Milano, Italy|Hospital of Di Padova, Padova, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Di Calabria, Italy|La Sapienza, University of Rome, Rome, Italy|Policlinico Agostino Gemelli, Rome, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Kameda General Hospital, Kamogawa, Japan|Matsuyama Red Cross Hospital, Matsuyama, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|National Hospital Organization - Nagoya Medical Center, Nagoya-shi, Japan|Japanese Red Cross Narita Hospital, Narita-shi, Japan|Ogaki Municipal Hospital, Ogaki, Japan|Okayama City General Medical Center, Okayama, Japan|Kindai University Hospital, Osaka-Sayama, Japan|Osaka City University Hospital, Osaka, Japan|Kitasato University Hospital, Sagamihara, Japan|Tohoku University Hospital, Sendai, Japan|Japan Red Cross Medical Center, Shibuya-ku, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan|Hospital of Lithuanian University Health and Sciences, Kaunas, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|VU University Medical Center, Amsterdam, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Radboudumc, Nijmegen, Netherlands|Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Krakow, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 Klinika Hematoonkologii i Transplantacji Szpiku, Lubin, Poland|Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Kliniczny Szpital Wojewodzki nr 1 im. Fryderyka Chopina w Rzeszowie, Rzwszow, Poland|Specjalistyczny Szpital im. dra Alfreda Sokolowskiego, Walbrzych, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Akademicki Szpital Kliniczny Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw, Poland|Hospital José Joaquim Fernandes, Beja, Portugal|Hospital de Braga, Braga, Portugal|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Ipo Instituto Portugues De Oncologia Porto, Porto, Portugal|Centro Hospitalar de Setubal EPE, Setubal, Portugal|Federal State Institute Kirov Research Inst. of Hematology and Blood Transfusion of Rosmedtec, Kirov, Russian Federation|Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation|Moscow Clinical Scientific Center, Moscow, Russian Federation|City Clinical Hospital 52, Moscow, Russian Federation|Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin, Moscow, Russian Federation|City Clinical Hospital 40, Moscow, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St Petersburg, Russian Federation|Tula Regional Oncology Center, Tula, Russian Federation|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital Virgenes de las Nieves, Granada, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|C. H. de Orense, Ourense, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Skanes Universitetssjukhus Lund, Lund, Sweden|Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Inselspital Bern, Bern, Switzerland|Luzerner Kantonsspital, Luzern 16, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Changhua Christian Hospital, Changhua City, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Niaosong District Kaohsiung City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Ankara University Medical Faculty, Ankara, Turkey|Celal Bayar University Medical Faculty, Manisa, Turkey|Karadeniz Technical University Medical Faculty, Trabzon, Turkey|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|Dnipropetrovsk City Multidisciplinary Clinical Hospital No 4, Hematological Center, Dnipro, Ukraine|State Institution National Research Centre for Radiation Medicine of NAMS of Ukraine, Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the UAMS, Lvov, Ukraine|Mykolaiv Regional Clinical Hospital, Mykolaiv, Ukraine|CI of TRC Ternopil University Hospital, Ternopil, Ukraine|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|University of Oxford, Headington, Oxford, United Kingdom|The Leeds Teaching Hospitals NHS Trust - St James's University Hospital, Leeds, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Kings College Hospital, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03682536"
58,"NCT03665610","Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites",,"Completed","No Results Available","Healthy Volunteers","Drug: ozanimod","Adverse events (AEs)|Pharmacodynamics - absolute lymphocyte count (ALC)|Pharmacodynamics - lymphocyte subsets","Celgene","All","18 Years to 55 Years   (Adult)",,"212","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","RPC01-1915|U1111-1219-5905","September 10, 2018","January 10, 2019","January 10, 2019","September 11, 2018",,"February 6, 2019","PPD Phase 1 Clinic, Austin, Texas, United States|ICON Early Phase Services, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03665610"
59,"NCT03651128","Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","KarMMa-3","Recruiting","No Results Available","Multiple Myeloma","Biological: bb2121|Drug: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Bortezomib|Drug: Ixazomib|Drug: Lenalidomide","Progression-free Survival (PFS)|Overall Survival (OS)|Event-free Survival (EFS)|Overall Response Rate (ORR)|Minimal Residual Disease (MRD)|Complete Response (CR) Rate|Duration of Response (DOR)|Time to Response (TTR)|Adverse Events (AEs)|Pharmacokinetics- Cmax|Pharmacokinetics- tmax|Pharmacokinetics- AUC|Pharmacokinetics- t-last|Pharmacokinetics- AUC0-28days|Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)|Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire|Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20)|Time to next antimyeloma treatment|Progression-free survival after next line therapy (PFS2)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BB2121-MM-003|U1111-1217-9988|2018-001023-38","October 12, 2018","June 23, 2025","June 23, 2025","August 29, 2018",,"October 14, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|University of Colorado Anschutz Cancer Pavilion, Aurora, Colorado, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Moffit Cancer Center, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|The University of Kansas Hospital, Westwood, Kansas, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center - William M. Cooper Ambulatory Care Pavilion, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute Center for Blood, Nashville, Tennessee, United States|MD Anderson Cancer center, Houston, Texas, United States|University of Utah Huntsman Cancer Center, Salt Lake City, Utah, United States|Swedish Cancer Institute, Seattle, Washington, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|UZ Leuven, Leuven, Belgium|Tom Baker Cancer center, Calgary, Alberta, Canada|Hospital Saint-Louis - APHP, Paris, France|Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi - Istituto di Ematolog, Bologna, Italy|Tokai University Hospital, Isehara, Kanagawa, Japan|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT03651128"
60,"NCT03647124","Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden","PASS MCL-005","Recruiting","No Results Available","Lymphoma, Mantle-Cell","Drug: Lenalidomide","To quantify and characterize the event of TFR by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.|To quantify and characterize the proportion of early deaths by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting","Celgene","All","18 Years and older   (Adult, Older Adult)",,"560","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CC-5013-MCL-005|U1111-1213-1816|EUPAS23366","October 2, 2018","December 31, 2026","December 31, 2026","August 27, 2018",,"September 12, 2019","Salzburger Landeskliniken - Universitaetsklinikum Salzburg, Salzburger, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria|AKH Wien, Universitaetsklinik fuer Innere Medizin III, Wien, Austria|CHRU de Brest - Hopital Morvan, Brest, France|CHU de Caen, institut d'hematologie de basse Nomandie, Caen Cedex 9, France|Centre Hospitalier de Versailles André Mignot, Le Chesnay, France|Clinique Victor Hugo, Le Mans, France|Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Universitaire Pitie Salpetriere (Hopital Pitie-Salpetriere), Paris, France|Centre Hospitalier de Saint-Quentin, Saint Quentin Picardie, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse Cedex 9, France|Gesundheitszentrum St. Marien Gmbh, Amberg, Germany|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Berufsausuebungsgemeinschaft Kiehl/Stein, Frankfurt/ Oder Brandenburg, Germany|Klinikum Garmisch-Partenkirchen Gmbh - Zentrum Fuer Innere Medizin, Garmisch-Partenkirchen Bavaria, Germany|Praxis fuer Haematolgie, Onkologie und Palliativmedizin, Leipzig, Germany|Private hospital ""Iatriko Psychikou"", Athens, Athens, Greece|General University Hospital of Athens ""LAIKO"", Athens, Athens, Greece|Metaxa Cancer Hospital, Athens, Piraeous, Greece|Theageneio General Hospital, Thessaloniki, Thessaloniki, Greece|HagaZiekenhuis van Den Haag - Juliana Kinderziekenhuis (JKZ) - Leyweg, Den Haag, Netherlands|Hospital universitario de Alava, Alava País Vasco, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario Carlos Haya, Malaga, Spain|Hospital de Orense, Ourense, Spain|Complejo Hospitalario de Navarra, Pamplona Navarra, Spain|Hospital Clínico Universiatrio de Salamanca, Salamanca, Spain|Nuestra Senora de Valme, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03647124"
61,"NCT03644576","Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate",,"Completed","No Results Available","Healthy Volunteers","Drug: ozanimod|Drug: Pseudoephedrine|Drug: ozanimod placebo","Cardiovascular analysis|Pharmacokinetics- Cmax|Pharmacokinetics- Cmin|Pharmacokinetics- Tmax|Pharmacokinetics- AUC0-24|Pharmacokinetics- Ctrough|Adverse events (AEs)|Pharmacokinetics- % total drug related AUC0-24 for each analyte|Pharmacokinetics- % total active drug related AUC0-24 for each active analyte|Cardiovascular analysis for DBP|Cardiovascular analysis for heart rate|Cardiovascular analysis for blood pressure|Cardiovascular analysis for Heart Rate","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","RPC01-1914|U1111-1215-6267","July 11, 2018","September 12, 2018","September 12, 2018","August 23, 2018",,"May 30, 2019","ICON Early Phase Services, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03644576"
62,"NCT03624959","Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A",,"Completed","No Results Available","Healthy Volunteer","Drug: Ozanimod|Drug: Gemfibrozil|Drug: Itraconazole|Drug: Rifampin","Pharmacokinetics- Cmax|Pharmacokinetics- AUC∞|Pharmacokinetics- AUC0-14d|Adverse Events (AEs)|Pharmacokinetics- Tmax|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Pharmacokinetics- λz|Pharmacokinetics- t1/2","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RPC01-1912|U1111-1215-6965","June 20, 2018","August 10, 2018","August 10, 2018","August 10, 2018",,"May 30, 2019","PPD Phase 1 Clinic, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03624959"
63,"NCT03608657","Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE","APPRAISE","Recruiting","No Results Available","Arthritis, Psoriatic","Drug: Apremilast","The rate of achieving Low Disease Activity (LDA)|Tender Joint Count (TJC)|Swollen Joint Count (SJC)|Assessment of Enthesitis (Leeds Enthesitis Index (LEI)|Assessment of Dactylitis (Leeds Dactylitis Index)|Assessment of Body Surface Area (BSA)|Health Assessment Questionnaire Disability Index (HAQ-DI)|Physician global assessment of disease activity (MDGA)|Patient global assessment of disease activity (PtGA)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Patient subjective assessment of Pain using a 100mm VAS|Psoriatic Arthritis (WPAI:PsA)|Medical Outcomes Study Short- Form 36 (SF-36)|Patient-reported adherence with PsA treatment from the last visit.|Proportion of patients in Patient Acceptable Symptom State (PASS)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSA-011|U1111-1214-0693","June 15, 2018","September 30, 2019","September 1, 2020","August 1, 2018",,"March 28, 2019","The Waterside Clinic, Barrie, Canada|The Arthritis and Osteoporosis Centre, Burlington, Canada|Adachi Medicine Professional Corporation, Hamilton, Canada|Credit Valley Rheumatology, Mississauga, Canada|Institut de Recherche en Rhumatologie de Montréal, Montreal, Canada|Applied Medical Informatics Research Inc. (A.M.I.R.), Montreal, Canada|Brent Appleton Clinic New Westminster, New Westminster, Canada|Dr. A. M. Jaroszynska Rheumatology and Osteoporosis Clinic, Oakville, Canada|Drs M&W Teo, Penticton, Canada|Groupe de recherche en maladies osseuses Inc., Quebec, Canada|Centre de Rhumatologie de l'Est du Quebec, Rimouski, Canada|Polmed Research Inc., Saskatoon, Canada|Clinique Jacques Cartier, Sherbrooke, Canada|St. Clare's Mercy Hospital, St John's, Canada|Dr. Juris Lazovskis Incorporated, Sydney, Canada|Toronto Western Hospital, University Health Network, Toronto, Canada|Arthur Karasik Medicine Professional Inc., Toronto, Canada|Dr. Jonathan D. Chan Inc., Vancouver, Canada|Dr. Sabeen Anwar Medicine Professional Corporation, Windsor, Canada",,"https://ClinicalTrials.gov/show/NCT03608657"
64,"NCT03602755","A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain","RETRO","Completed","No Results Available","Multiple Myeloma",,"Description of the first-line treatment regimens|Description of the characteristics of patients with a diagnosis of MM who were not candidates for ASCT in Spain|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate|Duration of response|Patients who receive second-line treatment|Patients who underwent dose adjustment or switched treatment|Patients who discontinued treatment","Celgene","All","18 Years and older   (Adult, Older Adult)",,"706","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NDS-MM-002|U1111-1215-4398","July 19, 2018","January 18, 2019","January 18, 2019","July 27, 2018",,"February 4, 2019","H. Santiago (CHUS), Santiago de Compostela, A Coruña, Spain|H. Txagorritxu, Vitoria, Alava, Spain|H. Cabueñes, Gijón, Asturias, Spain|H. Central de Asturias, Oviedo, Asturias, Spain|H. Son Espases, Palma, Baleares, Spain|ICO Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|H. Althaia, Manresa, Barcelona, Spain|H. Mutua de Terrassa, Terrasa, Barcelona, Spain|H. Jerez, Jerez de la Frontera, Cadiz, Spain|H. Alvaro Cunqueiro, Vigo, Pontevedra, Spain|H. del Mar, Barcelona, Spain|H. Josep Trueta, Girona, Spain|H. Arnau de Villanova, Lleida, Spain|H- Virgen de la Victoria, Malaga, Spain|H. Carlos Haya, Malaga, Spain|H. Ourense (CHOU), Orense, Spain|H. Virgen Macarena, Sevilla, Spain|H. Joan XXIII, Tarragona, Spain|H. Dr. Peset, Valencia, Spain|H. La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03602755"
65,"NCT03601078","An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","KarMMa-2","Recruiting","No Results Available","Multiple Myeloma","Biological: bb2121","Overall response rate (ORR)- Cohort 1|Complete response (CR) rate - Cohort 2a , b and c|Complete response (CR) rate - Cohort 1|Overall response rate (ORR) - Cohort 2a, b and c|Time to response (TTR)|Duration of response (DoR)|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival (OS)|Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - tmax|Pharmacokinetics - AUC|Pharmacokinetics - tlast|Pharmacokinetics - AUC0-28days|Immunogenicity|Minimal Residual Disease (MRD) negative rate|Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)|Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire|Subject-reported outcomes as measured by EORTC-QLQ-MY20|Very good partial response (VGPR) rate - Cohort 2c","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","181","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BB2121-MM-002|U1111-1216-4209|2018-000264-28","December 13, 2018","March 12, 2025","March 12, 2025","July 26, 2018",,"September 26, 2019","Mayo Clinic Arizona, Scottsdale, Arizona, United States|UCSF Medical Center, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Mt Sinai Medical Center - NY, New York, New York, United States|Columbia University Medical Center / New York Presbyterian Hospital, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Swedish Cancer Inst, Seattle, Washington, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CHU de Poitiers, Poitiers, France|Universitatsklinikum Würzburg, Würzburg, Germany|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|King's College HospitalGKT School of Medicine, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03601078"
66,"NCT03575351","A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","TRANSFORM","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Standard of Care|Genetic: JCAR017","Event-free survival (EFS)|Complete response rate (CRR)|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate (ORR)|Duration of response (DOR)|PFS on next line of treatment (PFS-2)|Adverse Events (AEs)|HRQoL parameters assessed by European Organisation for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC-QLQ-C30)|HRQoL parameters assessed by EQ-5D-5L|HRQoL parameters assessed by FACT-Lym ""Additional concerns"" subscale|Reasons for hospital resource utilization|Rate of hematopoietic stem cell transplant (HSCT)|Frequency of hospital resource utilization|Hospital resource utilization (HRU)","Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR017-BCM-003|U1111-1213-1944|2018-000929-32","November 5, 2018","May 20, 2023","May 20, 2023","July 2, 2018",,"October 17, 2019","Virginia G Piper Cancer Center, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States|Loyola University Medical Center Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Hillman Cancer Institute at UPMC, Pittsburgh, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|UZ Gent, Gent, Belgium|CHRU-Hopital Claude Huriez, Lille, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Gustave Roussy, Villejuif CEDEX, France|Robert-Rössle-Klinik im HELIOS Klinikum Berlin-Buch Klinik für Hämatologie, Onkologie u. Tumorimmuno, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Universitat zu Koln, Köln, Germany|Universitatsklinik Muenster, Muenster, Germany|LMU Klinikum der Universitat, München, Germany|La Sapienza, University of Rome, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan|National Cancer Center Hospital, Chuo-ku, Japan|Toranomon Hospital, Minato-ku, Japan|Osaka City University Hospital, Osaka, Japan|Erasmus Medical Center-Daniel den Hoed, Rotterdam, Netherlands|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Universitatsspital Bern, Bern, Switzerland|UCL Cancer Institute, London, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03575351"
67,"NCT03554993","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects",,"Recruiting","No Results Available","Healthy Volunteer","Drug: CC-99677|Other: Placebo","Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC0-∞|Pharmacokinetics - AUC0-t|Pharmacokinetics - t1/2,z|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Effect of CC-99677 on electrocardiogram (ECG) parameters","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CC-99677-CP-001|U1111-1213-8860|2017-004849-24","May 23, 2018","November 30, 2019","November 30, 2019","June 13, 2018",,"August 14, 2019","Quotient Clinical, Ruddington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03554993"
68,"NCT03539419","Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain","APPROPIATE","Recruiting","No Results Available","Psoriasis",,"Percentage of subjects achieving PBI ≥ 1|Describe the persistence of apremilast treatment|Describe changes in the perception of pruritus intensity during apremilast treatment in patients with moderate to severe plaque psoriasis|Describe the changes in the quality of life associated with treatment with apremilast|Describe the percentage of patients with moderate to severe plaque psoriasis who achieve a relevant minimum clinical benefit, defined as PBI ≥ 1|Describe changes in concomitant medication associated with management of moderate to severe plaque psoriasis during apremilast treatment|Describe changes in cutaneous involvement of patients with psoriasis in severe intensity plaques that change to moderate intensity|Adverse Events (AEs)|Clinical and demographic characteristics of plaque psoriasis patients: Body surface affected (BSA).|Clinical and demographic characteristics of plaque psoriasis patients: Physician Global Assessment (PGA).|Clinical and demographic characteristics of plaque psoriasis patients: PGA x BSA","Celgene","All","18 Years and older   (Adult, Older Adult)",,"125","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSOR-017|U1111-1212-0643","June 12, 2018","July 25, 2019","July 25, 2020","May 28, 2018",,"July 25, 2019","Hospital Juan Ramón Jiménez, Huelva, Andalucia, Spain|Complejo Hospitalario de Jaén, Jaen, Andalucía, Spain|Hospital Carlos Haya, Malaga, Andalucía, Spain|Hospital Royo Vilanova, Zaragoza, Aragón, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Nuestra Señora de Sonsoles, Avila, Castilla-León, Spain|Hospital Universitario Río hortega de Valladolid, Valladolid, Castilla-León, Spain|Hospital Germans Tries i Pujol, Badalona, Cataluña, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Sant Pau, Barcelona, Cataluña, Spain|Hospital Valle Hebrón, Barcelona, Cataluña, Spain|Hospital de Bellvitge, Barcelona, Cataluña, Spain|Hospital Mutua de Terrassa, Terrassa, Cataluña, Spain|Hospital General de Alicante, Alicante, Comunidad Valenciana, Spain|Hospital Clínico Valencia, Valencia, Comunidad Valenciana, Spain|Hospital General Valencia, Valencia, Comunidad Valenciana, Spain|Hospital La Fe Valencia, Valencia, Comunidad Valenciana, Spain|Hospital Infanta Cristina Badajoz, Badajoz, Extremadura, Spain|Hospital Universitario de Ourense, Ourense, Galicia, Spain|Hospital Universitario de Pontevedra, Pontevedra, Galicia, Spain|Hospital Dr Negrin, Las Palmas de Gran Canaria, Islas Canarias, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Islas Canarias, Spain|Hospital Santa Lucía, Cartagena, Murcia, Murcia, Spain|Hospital La Princesa, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital de 12 Octubre, Madrid, Spain|Hospital Universitario Puerta del Hierro, Madrid, Spain|Hospital de Móstoles, Madrid, Spain|Hospital Clínico de Zaragoza, Zaragoza, Áragon, Spain|Hospital Miguel Servet, Zaragoza, Áragon, Spain",,"https://ClinicalTrials.gov/show/NCT03539419"
69,"NCT03521180","A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease",,"Recruiting","No Results Available","Celiac Disease",,"Gut-homing, activated, CD8+ αβ T cells and γδ T cells in PBMC|Evaluation of Gliadin reactive T cell measures- PBMC (peripheral blood mononuclear cells) by Flow Cytometry|Gliadin reactive T cell measures- PBMC (peripheral blood mononuclear cells) by ELISPOT","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)",,"15","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NDS-CP-002|U1111-1208-7879","May 11, 2018","February 28, 2019","February 28, 2019","May 10, 2018",,"December 5, 2018","Covance, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03521180"
70,"NCT03486067","Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: CC-93269","Adverse Events (AEs)|Dose Limiting Toxicity (DLT)|Non-Tolerated Dose (NTD)|Maximum Tolerated Dose (MTD)|Overall Response Rate (ORR)|Time to Response|Duration of Response|Progression Free Survival|Overall Survival|Pharmacokinetics - Cmax|Pharmacokinetics - Cmin|Pharmacokinetics - AUC|Pharmacokinetics - tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL|Pharmacokinetics - Vss|Pharmacokinetics - accumulation index of CC-93269|Presence and frequency of anti-drug antibodies (ADA)|Evaluate measures of tumor sensitivity/ resistance to CC-93269","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-93269-MM-001|U1111-1210-6325|2017-003448-19","April 3, 2018","July 26, 2021","June 16, 2022","April 3, 2018",,"July 24, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|UCSF Medical Center, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Swedish Cancer Institute, Seattle, Washington, United States|Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato, Heidelberg, Germany|University of Tubingen, Tübingen, Germany|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Skanes Universitetssjukhus Lund, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT03486067"
71,"NCT03484702","Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma","TRANSCENDWORLD","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: JCAR017","Overall Response Rate (ORR) of JCAR017 in subjects with Non-Hodgkin Lymphoma (NHL; including secondary central nervous system (CNS) involvement)|ORR of JCAR017 in subjects with relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL)|Adverse Events (AEs)|Overall Response Rate (ORR)on the underlying chronic lymphocytic leukemia (CLL) in subjects with Richter´s transformation|Complete response rate (CRR)|Event-free survival (EFS)|Progression-free survival (PFS)|Overall survival (OS)|Duration of response (DOR)|Pharmacokinetics by quantitative polymerase chain reaction (qPCR) - Cmax|Pharmacokinetics by qPCR - Tmax|Pharmacokinetics by qPCR - AUC|Patient-Reported Outcomes - EORTC QLQ-C30|Patient-Reported Outcomes - EQ-5D-5L|Patient-Reported Outcomes - FACT-Lym","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR017-BCM-001|U1111-1209-4055|2017-000106-38","June 5, 2018","May 31, 2020","August 15, 2022","April 2, 2018",,"October 22, 2019","Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Austria|Universitair Ziekenhuis Gent, Gent, Belgium|Helsinki University, Helsinki, Finland|CHRU-Hopital Claude Huriez, Lille, France|Hopital Saint Louis, Paris Cedex 10, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitat zu Koln, Köln, Germany|LMU Klinikum der Universität, München, Germany|Universitatsklinikum Ulm, Ulm, Germany|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|National Cancer Center Hospital, Chuo-ku, Japan|Toranomon Hospital, Minato-ku, Japan|Erasmus Medisch Centrum, Rotterdam, Netherlands|Hospital Vall d'Hebron, Barcelona, Spain|Universitatsspital Bern, Bern, Switzerland|UCL Cancer Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03484702"
72,"NCT03467958","An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease",,"Recruiting","No Results Available","Crohn Disease","Drug: Ozanimod","Proportion of subjects with a CDAI score of < 150|Proportion of subjects with a simple endoscopy score (SES-CD) decrease from baseline of ≥ 50%|Proportion of subjects with average daily abdominal pain score ≤ 1 point, and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than baseline|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score of < 150|Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any ulcerated surface ≥ 10%|Proportion of subjects with CDAI reduction from baseline of ≥ 70 points|Change from baseline in CDAI|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score of < 150 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with CDAI score of < 150 and SES-CD ≤ 4 points and a SES-CD decrease ≥ 2 points|Proportion of subjects with average daily abdominal pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than baseline and SES-CD ≤ 4 points and a SES-CD decrease ≥ 2 points|Proportion of subjects with SES-CD ≤ 4 points and a SES-CD decrease ≥ 2 points|Proportion of subjects with a CDAI score < 150 in subjects off corticosteroids|Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of ≥ 50%|Proportion of subjects with a PCDAI score of ≤ 10 points","Celgene","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","1040","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC01-3204|U1111-1203-8203|2017-004295-55","August 22, 2018","December 30, 2022","October 31, 2024","March 16, 2018",,"October 22, 2019","Holland Center for Family Health, Peoria, Arizona, United States|Elite Clinical Studies, LLC, Phoenix, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States|Sharp Chula Vista Medical Center, Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Valley View Internal Medicine, Garden Grove, California, United States|UCSD Medical Center, La Jolla, California, United States|San Diego Clinical Trials, La Mesa, California, United States|OM Research, Lancaster, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States|Matrix Clinical Research Inc, Los Angeles, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|VA Northern California Health Care System, Mather, California, United States|Facey Medical Foundation (Parent), Mission Hills, California, United States|ABS Health, LLC, Mission Viejo, California, United States|Alliance Clinical Research, Oceanside, California, United States|Palo Alto Center-Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Havana Research Institute LLC, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Sutter Medical Group, Roseville, California, United States|UC Davis Health - Gastroenterology and Hepatology Clinical Trials Unit, Sacramento, California, United States|Medical Associates Research Group, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|New Hope Research Development, West Covina, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Gastro Florida, Clearwater, Florida, United States|Clinical Reseach of West Florida, Clearwater, Florida, United States|South Lake Pain Institute, Clermont, Florida, United States|American Research Institute Inc, Cutler Bay, Florida, United States|Universal Axon Clinical Research, Doral, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|University of Florida Health Endocrinology - Medical Specialties - Medical Plaza, Gainesville, Florida, United States|Qway Research LLC, Hialeah, Florida, United States|Floridian Clinical Research LLC, Hialeah, Florida, United States|Harmony Medical Research Institute, Hialeah, Florida, United States|The Center for Gastrointestinal Disorders, Hollywood, Florida, United States|Vista Health Research, Homestead, Florida, United States|SIH Research, Kissimmee, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|Precision Clinical Research, LLC., Lauderdale Lakes, Florida, United States|Alliance Medical Research LLC, Lighthouse Point, Florida, United States|Center For Advanced Gastroenterology, Maitland, Florida, United States|Galiz Research LLC, Miami Springs, Florida, United States|LMG Research, Miami, Florida, United States|Nova Clinical Research Center LLC, Miami, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Research Associates of South Florida LLC, Miami, Florida, United States|Innovation Research Institute, Inc., Miami, Florida, United States|Life Medical Center & Research, Inc., Miami, Florida, United States|Advanced Research for Health Improvement, Naples, Florida, United States|Bayside Clinical Research, New Port Richey, Florida, United States|NSB Research, New Smyrna Beach, Florida, United States|Omega Research Maitland, LLC, Orlando, Florida, United States|HMD Research LLC, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Theia Clinical Research, LLC, Pinellas Park, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|University of South Florida, Tampa, Florida, United States|Apex Clinical Research, Tampa, Florida, United States|Guardian Angel Health Svcs Inc, Tampa, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Consultative Gastroenterology, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Gastrointestinal Disease Research, Columbus, Georgia, United States|Atlanta Center For Gastroenterology, P.C., Decatur, Georgia, United States|Gastroenterology Associates Of Central Georgia LLC, Macon, Georgia, United States|Grand Teton Research Group, PLLC, Idaho Falls, Idaho, United States|Rush University Medical Center - University Cardiovascular Surgeons, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|DM Clinical Research, Oak Lawn, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|Cotton ONeil Clinical Research Center Digestive Health, Topeka, Kansas, United States|University of Kentucky Health Care, Lexington, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|CroNOLA LLC, Houma, Louisiana, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Clinical Trials of SW Louisiana LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, LLC, Marrero, Louisiana, United States|Nola Research Works, New Orleans, Louisiana, United States|LSU Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - The Center for Vascular Biol, Boston, Massachusetts, United States|Brigham and Women's Hospital - Crohn's and Colitis Center, Chestnut Hill, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Medex Research Institute, Caro, Michigan, United States|Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, United States|Henry Ford Medical Center - New Center One, Novi, Michigan, United States|Revive Research Institute, Southfield, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research, Jackson, Mississippi, United States|Mid America Gastrointestinal Consultants, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Internal Medicine Specialists, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|Advantage Clinical Trials, Bronx, New York, United States|NY Scientific, Brooklyn, New York, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Northwell Health, Great Neck, New York, United States|Drug Trials America, Hartsdale, New York, United States|Weill Cornell Medical College, New York, New York, United States|Concorde Medical Group, New York, New York, United States|Cornell University, New York, New York, United States|TrialSpark, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|DiGiovanna Institute for Medical Education And Research, North Massapequa, New York, United States|Circuit Clinical, Orchard Park, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Carolinas HealthCare System Digestive Health, Charlotte, North Carolina, United States|Internal Medicine Research, Charlotte, North Carolina, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|Carolina Research Center, Greenville, North Carolina, United States|PMG Research of Winston-Salem LLC, Winston-Salem, North Carolina, United States|Great Lakes Medical Research, LLC, Beachwood, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Advance Clinical Research - Dayton Internal Medicine, Dayton, Ohio, United States|Great Lakes Gastroenterology, Mentor, Ohio, United States|Paramount Medical Research & Consulting, LLC, Middleburg Heights, Ohio, United States|Great Lakes Medical Research, LLC, Warren, Ohio, United States|Cancer Care Associates of OK-N PorterAvenue, Norman, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc., Oklahoma City, Oklahoma, United States|Digestive Disease Specialists, Oklahoma City, Oklahoma, United States|Allergy, Asthma and Immunology Center, PC, Tulsa, Oklahoma, United States|Central States Research, LLC, Tulsa, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Penn State University Milton S Hershey Medical Center, State College, Pennsylvania, United States|Gastroenterology Associates of Orangeburg, Orangeburg, South Carolina, United States|Quality Medical Research, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Advanced Gastroenterology, Union City, Tennessee, United States|Avant Research Associates, LLC - Austin, Austin, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Biopharma Informatic Inc. Research Center, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|GI Specialists of Houston, Houston, Texas, United States|Premier Vein and Vascular Center, Houston, Texas, United States|The Coastal Medical Group, Houston, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|Accurate Clinical Research Inc, Pasadena, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Baylor Scott and White Health, Temple, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Gastroenterology Associates, PC, Gainesville, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Summit Clinical Research, LLC, Petersburg, Virginia, United States|The Gastroenterology Group, Reston, Virginia, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Virginia Gastroenterology Institute PC, Suffolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Dermatologist Specialists of Spokane, Spokane, Washington, United States|Aurora Health Care Aurora Research, Grafton, Wisconsin, United States|Franciscan Skemp Healthcare, La Crosse, Wisconsin, United States|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Universidad Nacional De Rosario - Hospital Provincial Del Centenario, Rosario, Argentina|Sanatorio 9 de Julio - CICE 9 de Julio, San Miguel de Tucuman, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital and Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Coastal Digestive Health, Maroorchydore, Queensland, Australia|University of the Sunshine Coast, North Mackay, Queensland, Australia|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Harry Perkins Medical Research Institute, Fiona Stanley Hospital, Murdoch, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Ballarat Base Hospital, Ballarat, Australia|Medical University Innsbruck, Innsbruck, Austria|University Hospital St. Poelten, St Polten, Austria|Medical University Vienna, Vienna, Austria|Grodno City Clinical Hospital #4, Grodno, Belarus|Vitebsk Regional Clinical Specialized Center, Vitebsk, Belarus|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Universitair Ziehenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|CHC - Clinique St-Jospeh, Liege, Belgium|Sart Tilman Hospital Department of Gastroenterology and Hepatology, Seraing, Belgium|Hospital Centre of Walloon Picarde, Tournai, Belgium|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|General Hospital ""Prim.dr. Abdulah Nakas"", Sarajevo, Bosnia and Herzegovina|Hospital Sao Rafael, Salvador, Bahia, Brazil|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda, Goiania, Goiás, Brazil|CDC - Centro Digestivo de Curitiba, Curitiba, Paraná, Brazil|Hospital Nossa Senhora das Gracas, Curitiba, Paraná, Brazil|Hospital de Clinicas de Porto Alegre (HCPA), Porto Algere, Rio Grande Do Sul, Brazil|Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil|Pesquisare Saude, Santo Andre, São Paulo, Brazil|Kaiser Clinica, Sao Jose do Rio Preto, São Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, São Paulo, Brazil|Instituto De Assistencia Medica Ao Servidor Publico Estadual - Iamspe - Hspe/Fmo, Sao Paulo, São Paulo, Brazil|Santa Casa De Votuporanga-Philanthropic hospital, Votuporanga, São Paulo, Brazil|Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo, Passo Fundo, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Universidade Federal do Estado do Rio de Janeiro (UNIRIO) - Hospital Universitario Gaffree e Guinle, Rio de Janeiro, Brazil|Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF), Rio de Janeiro, Brazil|CEMEC - Centro Multidisciplinar De Estudos Clanicos, Santo Andre, Brazil|Faculdade de Medicina do ABC, Vila Sacadura Cabral, Brazil|CEDOES - Diagnostico e Pesquisa, Vitoria, Brazil|Multiprofile Hospital for Active Treatment Medline, Plovdiv, Bulgaria|MHAT Ruse AD, Ruse, Bulgaria|Second MHAT Sofia AD, Sofia, Bulgaria|Excelsior Medical Center, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, Bulgaria|Diagnostic and Consulting Center Alexandrovska, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|Diagnostic-Consultative Center Sveta Anna, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|ACIBADEM City Clinic Medical Center Bregalnitsa, Varna, Bulgaria|University of Calgary Health - The Gastrointestinal Research Group (GIRG), Calgary, Alberta, Canada|West Edmonton Gastroenterology Consultants, Edmonton, Alberta, Canada|Okanagan Clinical Trials Ltd, Kelowna, British Columbia, Canada|Fraser Clinical Trials Inc., New Westminister, British Columbia, Canada|Vancouver Hospital Gastrointestinal Research Unit The Gordon and Leslie Diamond Centre, Vancouver, British Columbia, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Brandon Medical Arts Clinic, Brandon, Manitoba, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|Viable Clinical Research, Bridgewater, Nova Scotia, Canada|IWK Health Center, Halifax, Nova Scotia, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|LHSC Victoria Hospital, London, Ontario, Canada|Dr.Garisa Jagan Mohan Reddy MD, Sudbury, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Kensington Screening Clinic, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|The Ottawa Hospital - General Campus, Ottawa, Quebec, Canada|Peking University First Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital of Central South University, Changsha, China|Daping Hospital Third Military Medical University of People's Liberation Army, Chongqing, China|PLA Army General Hospital, Dongcheng District, China|Guangzhou First People's Hospital, Guangzhou Shi, China|Sun Yat-sen University - The Sixth Affiliated Hospital, Guangzhou Shi, China|Guangdong General Hospital, Guangzhou, China|Nanfang Hospital of Southern Medical University, Guangzhou, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China|Shanghai City theTenth People's Hospital, Shanghai City, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|China Medical University Hospital, Taichung City, China|RenMin Hospital Of Wuhan University Hubei General Hospital, Wuhan Shi, China|Wuhan Union Hospital, Wuhan, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China|Clinical Hospital Center Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Center Split, Split, Croatia|Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|University Hospital Centre Zagreb, Clinic of Internal Diseases, Zagreb, Croatia|Military Hospital Brno, Brno, Czechia|St. Anne's University Hospital Brno, Brno, Czechia|Hepato-Gastroenterologie HK, s. r. o., Hradec Králové, Czechia|Soukroma Gastroenterologicka ambulance a endoskopie, Most, Czechia|PreventaMed, Olomouc, Czechia|Krajská nemocnice Pardubice, Kožní oddelení, Pardubice, Czechia|University Hospital Pilsen, Plzen, Czechia|University Hospital Motol, Prague 5, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|IBD Centrum/ISCARE IVF a.s., Praha 7, Czechia|Bispebjerg Hospital, Copenhagen, Denmark|Holbaek Hospital, Holbaek, Denmark|Nykobing F Hospital, Nykobing F, Denmark|Helsinki University Central Hospital (HUCH), Helsinki, Finland|Turku University Hospital, Turku, Finland|JSC Evex Medical Corporation - Batumi Referral Hospital, Batumi, Georgia|JSC Evex Medical Corporation - Oncology Center, Kutaisi, Georgia|LLC Vivamedi, Tbilisi, Georgia|Tbilisi State Medical University, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|JSC Infectious Disease, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia|LTD Academician N.Kipshidze Central University Clinic, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|LTD MediClub Georgia, Tbilisi, Georgia|David Tatishvili Medical Center, Tbilisi, Georgia|JSC Evex Medical Corporation - Telavi Referral Hospital, Telavi, Georgia|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Gastroenterological Special Practice at Wittenbergplatz, Berlin, Germany|Gastroenterology Am Bayerischen Platz, Berlin, Germany|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|DRK Clinics Berlin, Berlin, Germany|Hospital Waldfriede e.V., Berlin, Germany|Brandenburg City Hospital, Brandenburg an der Havel, Germany|Medical Care Unit Dachau, Dachau, Germany|Klinikum Darmstadt, Darmstadt, Germany|Kliniken Essen-Mitte, Essen, Germany|Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Interdisciplinary Crohn Colitis Center Rhein Main, Frankfurt, Germany|Studiengesellschaft BSF, Halle, Germany|University Hospital Halle (Saale), Halle, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitaetsklinikum Leipzig AoeR, Leipzig, Germany|Practice for Gastroenterology and Internal Medicine, Ludwigshafen am Rhein, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|University Hospital Muenster, Muenster, Germany|Synesis Research Center, Munich, Germany|Robert-Bosch-Hospital, Stuttgart, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Laiko General Hospital of Athens, Athens, Greece|Sotiria Chest Diseases Hospital of Athens, Athens, Greece|Tzanio General Hospital of Piraeus, Athens, Greece|PAGNI University Hospital, Heraklion, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|424th Army General Hospital, Thessaloniki, Greece|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem - Altalanos Orvostudomanyi Kar, Budapest, Hungary|Szent Margit Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|CRU Hungary Kft, Miskolc, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Clinfan Ltd, Szekszárd, Hungary|Csongrad County Dr. Bugyi Istvan Hospital, Szentes, Hungary|Zala Megyei KorhazHaematologia, Zalaegerszeg, Hungary|St Vincent's University Hospital, Dublin 4, Dublin, Ireland|Beaumont Hospital, Dublin 9, Ireland|Institute of Gastroenterology and Hepatology at Ha'Emek Medical Center, Afula, Israel|Bat Yamon Medical Center, Clalit Medical Services, Bat Yam, Israel|Asaf Harofeh Medical Center, Beer Jacob, Israel|Rambam Health Care Campus, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Clalit Health Services, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Galilee Medical Center, Nahariya, Israel|The Nazareth Hospital E.M.M.S., Nazareth, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|University Polyclinic Hospital of Bari, Bari, Italy|Polyclinic S. Orsola-Malpighi, Bologna, Italy|Civil Hospital of Brescia, Brescia, Italy|Poliambulanza Hospital, Brescia, Italy|IRCCS ""Savario De Bellis"", Castellana Grotte, Italy|University Hospital Mater Domini, Catanzaro, Italy|""Ss. Annunziata"" Policlinic of Chieti, Chieti, Italy|University Polyclinic Hospital G. Martino, Messina, Italy|Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Milano, Italy|Humanitas Research Hospital - Humanitas Mirasole S.p.A, Milan, Italy|Azienda Socio Sanitaria Territoriale (ASST) di Monza, Monza, Italy|Hospital of Di Padova, Padova, Italy|United Hospitals Villa Sofia Cervello, Palermo, Italy|Polyclinic San Matteo IRCCS, Pavia, Italy|Polyclinic Tor Vergata, Roma, Italy|Univerisity Polyclinic Foundation Agostino Gemelli, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Integrated University Hospital Santa Maria della Misericordia of Udine, Udine, Italy|A.O. Universitaria Fondazione Macchi, Varese, Italy|Sacred Heart Don Calabria, Verona, Italy|Korea University Medical Center - Korea University Ansan Hospital, Ansan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|St. Vincent's Hospital, Suwon, Korea, Republic of|P. Stradins Clinical University Hospital, Riga, Latvia|Digestive Diseases Center Gastro, Riga, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Vilnius City Clinical Hospital, Vilnius, Lithuania|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapapan, Jalisco, Mexico|Centro Regiomontano de Estudios Clinicos Roma SC., Monterrey, Nuevo León, Mexico|Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Nuevo León, Mexico|SMIQ, Santiago de Queretaro, Querétaro, Mexico|Hospital Christus Muquerza del Parque S.A. de C.V., Chihuahua, Mexico|Centro de Investigacion Clinica Acelerada (CICA) S.C., Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico|""Sfanta Treime"" Clinical Municipal Hospital, Chisinau, Moldova, Republic of|Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery, Chisinau, Moldova, Republic of|""Sf. Arhanghel Mihail"" Municipal Clinical Hospital, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Department of Colorectal Surgery, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Chisinau, Moldova, Republic of|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|UMC Groningen, Groningen, Netherlands|University Hospital Maastricht, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Akershus University Hospital, Lørenskog, Norway|Lovisenberg Diakonale Sykehus, Oslo, Norway|SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego, Bialystok, Poland|Medical Services Center MaxMed, Bochnia, Poland|St. John Paul 2nd Municipal Hospital in Elblag, Elblag, Poland|Private Medical Practice Miroslaw Fic, Jelenia Gora, Poland|BioVirtus Medical Centre, Jozefow, Poland|Nzoz All-Medicus, Katowice, Poland|Kornel Gibinski Independent Public Central Clinical Hospital in Katowice, Katowice, Poland|GLOBE Clinical Research Sp. z o.o. LLC, Klodzko, Poland|PLEJADY Sp. z o.o. (LLC) Medical Centre, Krakow, Poland|LUX MED Centrum Medyczne - Krakow, Krakow, Poland|Landa Specialist Doctor's Offices, Krakow, Poland|Krakow Medical Center LLC, Krakow, Poland|Centrum Opieki Zdrowotnej Orkan Med, Ksawerow, Poland|Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|Salve Medica, Lodz, Poland|LUX MED Centrum Medyczne - Lodz, Lodz, Poland|1 Military Clinical Hospital in Lublin, Lublin, Poland|Non-Public Healthcare Facility Allmedica Clinical Trials, Nowy Targ, Poland|Provincial Specialist Hospital in Olsztyn, Olsztyn, Poland|SOLUMED Medical Center, Poznan, Poland|Endoskopia Sp. z o.o., Sopot, Poland|TWOJA PRZYCHODNIA Medical Centre of Szczecin LLC, Szczecin, Poland|GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe, Torun, Poland|H-T. Medical Center Sp. z o.o. LLC Limited Partnership, Tychy, Poland|Polimedica, Ul. Piotrkowska 177, Poland|Maternal Pediatric and Adolescent Healthcare Centre, Warsaw, Poland|PRIMA LCC Specialist Clinics, Warsaw, Poland|Endoterapia PFG LLC, Endotherapy PFG Outpatient Clinic Branch No 1, Warszawa, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warszawa, Poland|Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice, Wierzchoslawice, Poland|LUX MED Centrum Medyczne - Wroclaw, Wroclaw, Poland|Wroclaw Medical University, Wroclaw, Poland|Clinical Research Center Early-Phase Research Facility, Wroclaw, Poland|LexMedica, Wroclaw, Poland|Ars Medica, Wroclaw, Poland|EMC Medical Institute S.A, Wroclaw, Poland|Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar do Alto Ave, Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE, Viana do Castelo, Portugal|Hyperclinica MedLife Grivita, Bucharest, Romania|Center of Diagnosis and Treatment Provita, Bucharest, Romania|Fundeni Clinical Institute, Bucharest, Romania|Bucharest University Emergency Hospital, Department of Internal Medicine II, Bucharest, Romania|Dr. Carol Davila Central Military Emergency Clinical Hospital, Bucharest, Romania|Craiova County Emergency Clinical Hospital, Craiova, Romania|Colentina Clinical Hospital, Napoca, Romania|Targu Mures County Emergency Clinical Hospital, Targu Mures, Romania|Joint Venture Company Diagnostic Center, Bioterm Ltd., Barnaul, Russian Federation|Territorial Clinical Hospital, Barnaul, Russian Federation|Regional Clinical Hospital #3, Chelyabinsk, Russian Federation|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|Ural State Medical Academy - Medical Association Novaya Bolnitsa, Ekaterinburg, Russian Federation|Irkutsk State Medical Academy of Postgraduate Education, Irkutsk, Russian Federation|Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation|Kaluga Regional Hospital, Kaluga, Russian Federation|S.V. Beliaev Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Moscow Clinical Scientific and Practical Center, Moscow, Russian Federation|City Clinical Hospital n.a. V.M. Buyanov, Moscow, Russian Federation|City Clinical Hospital 24, Moscow, Russian Federation|CJSC Nasledniki, Moscow, Russian Federation|A.N. Ryzhikh State Research Center for Coloproctology, Moscow, Russian Federation|Railway Station Clinical Hospital, Nizhny Novgorod, Russian Federation|Medical Center Sibnovomed LLC, Novosibirsk, Russian Federation|Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russian Federation|Euromed Multi-Specialty Center for Contemporary Medicine LLC, Omsk, Russian Federation|Medical Diagnostic Center LLC, Orenburg, Russian Federation|N.N. Burdenko Penza Regional Clinical Hospital, Penza, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|Evromedservis, Pushkin, Russian Federation|Clinic UZI 4D, LLC, Pyatigorsk, Russian Federation|Pyatigorsk City Hospital 2, Pyatigorsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Medical Center Reavita Med Spb LLC, Saint Petersburg, Russian Federation|City Clinical Hospital No 31 - St. Petersburg, Saint Petersburg, Russian Federation|S.M. Kirov Military Medical Academy, Saint-Petersburg, Russian Federation|Medical University REAVIZ, Samara, Russian Federation|Samara Station Railway Clinical Hospital under OAO Russian Railways, Samara, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Sochi City Hospital No 5, Sochi, Russian Federation|S.M. Kirov Military Medical Academy, St Petersburg, Russian Federation|Oncology Center of Moskovskiy District, St Petersburg, Russian Federation|City Outpatient Care Unit No 38, St. Petersburg, Russian Federation|I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation|State Unitary Enterprise Passengeravtotrans, St. Petersburg, Russian Federation|Clinical and Diagnostic Center with an outpatient department under the Presidential Executive Office, St. Petersburg, Russian Federation|SPb SBIH City Hospital of Saint Martyr Elizaveta, St. Petersburg, Russian Federation|Medical Center ItanoMed, St. Petersburg, Russian Federation|Medical Center Eko-Bezopasnost LLC, St. Petersburg, Russian Federation|SPb SBIH City Hospital # 9, St. Petersburg, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|G.G. Kuvatov Republican Clinical Hospital, Ufa, Russian Federation|City Clinical Hospital #21, Ufa, Russian Federation|Novgorod Regional Clinical Hospital, Veliky Novgorod, Russian Federation|Primorsky Regional Clinical Hospital No.1, Vladivostok, Russian Federation|Medical Center of Far-Eastern Federal University, Vladivostok, Russian Federation|Medical Scientific Manufacturing Association Dvizheniye Clinic, Volgograd, Russian Federation|King Fahad Specialist Hospital, Dammam, Saudi Arabia|King Abdul Aziz University Hospital, Jeddah, Saudi Arabia|King Saud Medical Complex, Riyadh, Saudi Arabia|King Fahad National Guard Hospital, Riyadh, Saudi Arabia|Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine, Belgrade, Serbia|Clinical Hospital Center Zvezdara Clinic of Internal Diseases, Belgrade, Serbia|Military Medical Academy, Clinic of Gastroenterology and Hepatology, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center of Vojvodina, Clinic of Gastroenterology and Hepatology, Novi Sad, Serbia|General Hospital Pancevo, Pancevo, Serbia|General Hospital Djordje Jovanovic Zrenjanin, Zrenjanin, Serbia|Cliniq, s.r.o., Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Ruzinov, Bratislava, Slovakia|Brezno gastroenterology center s.r.o., Brezno, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|Gastromedic s.r.o., Nove Zamky, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|World of the Health Inc. General Hospital Rimavska Sobota, Rimavska Sobota, Slovakia|General Hospital Celje, Celje, Slovenia|General Hospital Novo Mesto, Novo Mesto, Slovenia|Ahmed Kathrada Private Hospital, Gauteng, South Africa|Emmed Research, Pretoria, South Africa|General University Hospital of Alicante, Alicante, Spain|University Hospital Germans Trias i Pujol, Badalona, Spain|Teknon Medical Center, Barcelona, Spain|University Hospital Reina Sofia, Cordoba, Spain|University Hospital of Girona Dr. Josep Trueta, Girona, Spain|University Hospital of the Canary Islands (HUC) La Laguna, La Laguna, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain|University Hospital de La Princesa, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|University Hospital La Paz, Madrid, Spain|University Hospital Puerta de Hierro Majadajonda, Majadahonda, Madrid, Spain|University Hospital Marques de Valdecilla (HUMV), Santander, Spain|University Hospital Virgen Macarena, Sevilla, Spain|University Hospital Virgen del Rocio, Sevilla, Spain|University Clinical Hospital of Valencia, Valencia, Spain|Viladecans Hospital, Viladecans, Spain|University Hospital Miguel Servet, Zaragoza, Spain|Saint Goran Hospital, Stockholm, Sweden|Ersta Hospital, Stockholm, Sweden|Lindenhofspital, Bern, Switzerland|Cantonal Hospital Saint Gallen, St.Gallen, Switzerland|University Hospital Zurich, Zurich, Switzerland|Kaohsiung Medical University Hospital, Kaohsiung, San Ming Dist., Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Bulent Ecevit Universitesi Uygulama ve Arastirma Hastanesi, Kozlu, Taiwan|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|Chang Gung Memorial Hospital- Linkou, Taoyuan City, Taiwan|Taipei Veterans General Hospital, Tapei, Beitou Dist., Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Hacettepe Universitesi, Ankara, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Firat University Medical Faculty, Elazig, Turkey|Bezmialem Foundation University Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Marmara University, Istanbul, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Dnipropetrovsk II Mechnykov Regional Clinical Hospital Surgery Department 2, Dnipropetrovsk, Ukraine|Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Kharkiv City Clinical Hospital 2, Kharkiv, Ukraine|Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine|Medical and Diagnostic Center Acinus, Kropyvnytskyi, Ukraine|Medical Center Medical Clinic Blagomed LLC, Kyiv, Ukraine|Kyiv City Clinical Hospital #18, Kyiv, Ukraine|BIK-KYIV Ukrainian German Gastroenterology Center, Kyiv, Ukraine|Medical Center Consilium Medical, Kyiv, Ukraine|Ok Clinic Medical Center within International Institute of Clinical Trials, LLC, Kyiv, Ukraine|Kyiv Regional Hospital #2, Kyiv, Ukraine|Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Public City Clinical Hospital of Emergency Medical Care, Lviv, Ukraine|Odesa Regional Clinical Hospital Regional Gastroenterology Center Surgery Department, Odesa, Ukraine|Ternopil City Public Emergency Medical Care Hospital, Ternopil, Ukraine|Vinnytsia City Clinical Hospital #1, Vinnytsia, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine|Health Clinic, LLC, Vinnytsya, Ukraine|Zaporizhzhya Regional, Zaporizhzhya, Ukraine|First Private Clinic, Zhytomyr, Ukraine|Bristol Royal Infirmary, Bristol, United Kingdom|Ulster Hospital, Dundonald, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Victoria Hospital Blackpool, Lancashire Blackpool, United Kingdom|Royal London Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom|Torbay Hospital, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03467958"
73,"NCT03464097","A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease",,"Recruiting","No Results Available","Crohn Disease","Drug: Ozanimod|Other: Placebo","Proportion of subjects with a CDAI score of < 150|Proportion of subjects with a Simple Endoscopic Score for Crohn's Disease (SESCD) score decrease from baseline of ≥ 50%|Proportion of subjects with average daily abdominal pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than baseline|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score of < 150|Proportion of subjects with a CDAI score of < 150 at both pre-randomization (Day 1) and Week 52|Proportion of subjects with a CDAI score of < 150 in subjects with a CDAI score < 150 at pre-randomization|Proportion of subjects with a CDAI score < 150 in subjects off corticosteroids|Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any ulcerated surface ≥10%|Histologic improvement based on differences between ozanimod and placebo in histologic disease activity scores (ie, Global Histologic Disease Activity Score [GHAS] changes (Geboes, 2000))|Proportion of subjects with average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points with abdominal pain and stool frequency no worse than baseline and an SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with CDAI score of < 150 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points with abdominal pain and stool frequency no worse than baseline and an SES-CD ≤ 4 points and a SES-CD decrease ≥2 points|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score < 150 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with CDAI score < 150 at Week 12 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with CDAI reduction from baseline of ≥ 70 points|Proportion of subjects with mucosal healing (SES-CD ≤ 4 points and a SES-CD decrease ≥ 2 points) and histologic improvement by GHAS or Robarts Histologic Index (RHI)|Time to relapse and exclusion of other causes of an increase in disease activity unrelated to underlying CD (eg, infections, change in medication)|Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of ≥ 50%|Proportion of adolescent subjects with Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 10 points|Proportion of adolescent subjects with decrease from baseline in PCDAI score ≥15 points|Change from baseline (Induction) in Inflammatory Bowel Disease Questionnaire (IBDQ) scores (adult subjects only)|Change from baseline (Induction) in 36-Item Short Form-36 Survey (SF-36) scores (adult subjects only)|Change from baseline (Induction) in Work Productivity and Activity Impairment questionnaire for Crohn's disease (WPAI-CD) scores (adult subjects only)|Change from baseline (Induction) in EuroQol 5 dimensions questionnaire (EQ-5D) scores|Patient Global Impression of Change (PGIC) scores (adult subjects only)|Differences in CD-related hospitalizations, procedures, and surgery|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points at Week 52 or CDAI score < 150 in subjects who had previously received biologic treatment.|Assessment of circulating lymphocyte concentration|Assessment of gene expression|Assessment of protein biomarker concentration|Assessment of pharmacogenetics","Celgene","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","535","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-3203|U1111-1203-8002|2017-004294-14","June 27, 2018","April 30, 2021","August 31, 2021","March 13, 2018",,"October 22, 2019","Holland Center for Family Health, Peoria, Arizona, United States|Elite Clinical Studies, LLC, Phoenix, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States|Sharp Chula Vista Medical Center, Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Valley View Internal Medicine, Garden Grove, California, United States|UCSD Medical Center, La Jolla, California, United States|San Diego Clinical Trials, La Mesa, California, United States|OM Research, Lancaster, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States|Matrix Clinical Research Inc, Los Angeles, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|VA Northern California Health Care System, Mather, California, United States|Facey Medical Foundation (Parent), Mission Hills, California, United States|ABS Health, LLC, Mission Viejo, California, United States|Alliance Clinical Research, Oceanside, California, United States|Palo Alto Center-Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Havana Research Institute LLC, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Sutter Medical Group, Roseville, California, United States|UC Davis Health - Gastroenterology and Hepatology Clinical Trials Unit, Sacramento, California, United States|Medical Associates Research Group, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|New Hope Research Development, West Covina, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Gastro Florida, Clearwater, Florida, United States|Clinical Reseach of West Florida, Clearwater, Florida, United States|South Lake Pain Institute, Clermont, Florida, United States|American Research Institute Inc, Cutler Bay, Florida, United States|Universal Axon Clinical Research, Doral, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|University of Florida Health Endocrinology - Medical Specialties - Medical Plaza, Gainesville, Florida, United States|Qway Research LLC, Hialeah, Florida, United States|Floridian Clinical Research LLC, Hialeah, Florida, United States|Harmony Medical Research Institute, Hialeah, Florida, United States|The Center for Gastrointestinal Disorders, Hollywood, Florida, United States|Vista Health Research, Homestead, Florida, United States|SIH Research, Kissimmee, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|Precision Clinical Research, LLC., Lauderdale Lakes, Florida, United States|Alliance Medical Research LLC, Lighthouse Point, Florida, United States|Center For Advanced Gastroenterology, Maitland, Florida, United States|Galiz Research LLC, Miami Springs, Florida, United States|LMG Research, Miami, Florida, United States|Nova Clinical Research Center LLC, Miami, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Research Associates of South Florida LLC, Miami, Florida, United States|Innovation Research Institute, Inc., Miami, Florida, United States|Life Medical Center & Research, Inc., Miami, Florida, United States|Advanced Research for Health Improvement, Naples, Florida, United States|Bayside Clinical Research, New Port Richey, Florida, United States|NSB Research, New Smyrna Beach, Florida, United States|Omega Research Maitland, LLC, Orlando, Florida, United States|HMD Research LLC, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Theia Clinical Research, LLC, Pinellas Park, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|University of South Florida, Tampa, Florida, United States|Apex Clinical Research, Tampa, Florida, United States|Guardian Angel Health Svcs Inc, Tampa, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Consultative Gastroenterology, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Gastrointestinal Disease Research, Columbus, Georgia, United States|Atlanta Center For Gastroenterology, P.C., Decatur, Georgia, United States|Gastroenterology Associates Of Central Georgia LLC, Macon, Georgia, United States|Grand Teton Research Group, PLLC, Idaho Falls, Idaho, United States|Rush University Medical Center - University Cardiovascular Surgeons, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|DM Clinical Research, Oak Lawn, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|Cotton ONeil Clinical Research Center Digestive Health, Topeka, Kansas, United States|University of Kentucky Health Care, Lexington, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|CroNOLA LLC, Houma, Louisiana, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Clinical Trials of SW Louisiana LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, LLC, Marrero, Louisiana, United States|Nola Research Works, New Orleans, Louisiana, United States|LSU Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - The Center for Vascular Biol, Boston, Massachusetts, United States|Brigham and Women's Hospital - Crohn's and Colitis Center, Chestnut Hill, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Medex Research Institute, Caro, Michigan, United States|Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, United States|Henry Ford Medical Center - New Center One, Novi, Michigan, United States|Revive Research Institute, Southfield, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research, Jackson, Mississippi, United States|Mid America Gastrointestinal Consultants, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Internal Medicine Specialists, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|Advantage Clinical Trials, Bronx, New York, United States|NY Scientific, Brooklyn, New York, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Northwell Health, Great Neck, New York, United States|Drug Trials America, Hartsdale, New York, United States|Weill Cornell Medical College, New York, New York, United States|Concorde Medical Group, New York, New York, United States|Cornell University, New York, New York, United States|TrialSpark, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|DiGiovanna Institute for Medical Education And Research, North Massapequa, New York, United States|Circuit Clinical, Orchard Park, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Carolinas HealthCare System Digestive Health, Charlotte, North Carolina, United States|Internal Medicine Research, Charlotte, North Carolina, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|Carolina Research Center, Greenville, North Carolina, United States|PMG Research of Winston-Salem LLC, Winston-Salem, North Carolina, United States|Great Lakes Medical Research, LLC, Beachwood, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Advance Clinical Research - Dayton Internal Medicine, Dayton, Ohio, United States|Great Lakes Gastroenterology, Mentor, Ohio, United States|Paramount Medical Research & Consulting, LLC, Middleburg Heights, Ohio, United States|Great Lakes Medical Research, LLC, Warren, Ohio, United States|Cancer Care Associates of OK-N PorterAvenue, Norman, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc., Oklahoma City, Oklahoma, United States|Digestive Disease Specialists, Oklahoma City, Oklahoma, United States|Allergy, Asthma and Immunology Center, PC, Tulsa, Oklahoma, United States|Central States Research, LLC, Tulsa, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Penn State University Milton S Hershey Medical Center, State College, Pennsylvania, United States|Quality Medical Research, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Advanced Gastroenterology, Union City, Tennessee, United States|Avant Research Associates, LLC - Austin, Austin, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Biopharma Informatic Inc. Research Center, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|GI Specialists of Houston, Houston, Texas, United States|Premier Vein and Vascular Center, Houston, Texas, United States|The Coastal Medical Group, Houston, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|Accurate Clinical Research Inc, Pasadena, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Baylor Scott and White Health, Temple, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Gastroenterology Associates, PC, Gainesville, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Summit Clinical Research, LLC, Petersburg, Virginia, United States|The Gastroenterology Group, Reston, Virginia, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Virginia Gastroenterology Institute PC, Suffolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Dermatologist Specialists of Spokane, Spokane, Washington, United States|Aurora Health Care Aurora Research, Grafton, Wisconsin, United States|Franciscan Skemp Healthcare, La Crosse, Wisconsin, United States|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Universidad Nacional De Rosario - Hospital Provincial Del Centenario, Rosario, Argentina|Sanatorio 9 de Julio - CICE 9 de Julio, San Miguel de Tucuman, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital and Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Coastal Digestive Health, Maroorchydore, Queensland, Australia|University of the Sunshine Coast, North Mackay, Queensland, Australia|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Harry Perkins Medical Research Institute, Fiona Stanley Hospital, Murdoch, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Ballarat Base Hospital, Ballarat, Australia|Medical University Innsbruck, Innsbruck, Austria|University Hospital St. Poelten, St Polten, Austria|Medical University Vienna, Vienna, Austria|Grodno City Clinical Hospital #4, Grodno, Belarus|Vitebsk Regional Clinical Specialized Center, Vitebsk, Belarus|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Universitair Ziehenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|CHC - Clinique St-Jospeh, Liege, Belgium|Sart Tilman Hospital Department of Gastroenterology and Hepatology, Seraing, Belgium|Hospital Centre of Walloon Picarde, Tournai, Belgium|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|General Hospital ""Prim.dr. Abdulah Nakas"", Sarajevo, Bosnia and Herzegovina|Hospital Sao Rafael, Salvador, Bahia, Brazil|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda, Goiania, Goiás, Brazil|CDC - Centro Digestivo de Curitiba, Curitiba, Paraná, Brazil|Hospital Nossa Senhora das Gracas, Curitiba, Paraná, Brazil|Hospital de Clinicas de Porto Alegre (HCPA), Porto Algere, Rio Grande Do Sul, Brazil|Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil|Pesquisare Saude, Santo Andre, São Paulo, Brazil|Kaiser Clinica, Sao Jose do Rio Preto, São Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, São Paulo, Brazil|Instituto De Assistencia Medica Ao Servidor Publico Estadual - Iamspe - Hspe/Fmo, Sao Paulo, São Paulo, Brazil|Santa Casa De Votuporanga-Philanthropic hospital, Votuporanga, São Paulo, Brazil|Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo, Passo Fundo, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Universidade Federal do Estado do Rio de Janeiro (UNIRIO) - Hospital Universitario Gaffree e Guinle, Rio de Janeiro, Brazil|Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF), Rio de Janeiro, Brazil|CEMEC - Centro Multidisciplinar De Estudos Clanicos, Santo Andre, Brazil|Faculdade de Medicina do ABC, Vila Sacadura Cabral, Brazil|CEDOES - Diagnostico e Pesquisa, Vitoria, Brazil|Multiprofile Hospital for Active Treatment Medline, Plovdiv, Bulgaria|MHAT Ruse AD, Ruse, Bulgaria|Second MHAT Sofia AD, Sofia, Bulgaria|Excelsior Medical Center, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, Bulgaria|Diagnostic and Consulting Center Alexandrovska, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|Diagnostic-Consultative Center Sveta Anna, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|ACIBADEM City Clinic Medical Center Bregalnitsa, Varna, Bulgaria|University of Calgary Health - The Gastrointestinal Research Group (GIRG), Calgary, Alberta, Canada|West Edmonton Gastroenterology Consultants, Edmonton, Alberta, Canada|Okanagan Clinical Trials Ltd, Kelowna, British Columbia, Canada|Fraser Clinical Trials Inc., New Westminister, British Columbia, Canada|Vancouver Hospital Gastrointestinal Research Unit The Gordon and Leslie Diamond Centre, Vancouver, British Columbia, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Brandon Medical Arts Clinic, Brandon, Manitoba, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|Viable Clinical Research, Bridgewater, Nova Scotia, Canada|IWK Health Center, Halifax, Nova Scotia, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|LHSC Victoria Hospital, London, Ontario, Canada|Dr.Garisa Jagan Mohan Reddy MD, Sudbury, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Kensington Screening Clinic, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|The Ottawa Hospital - General Campus, Ottawa, Quebec, Canada|Peking University First Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital of Central South University, Changsha, China|Daping Hospital Third Military Medical University of People's Liberation Army, Chongqing, China|PLA Army General Hospital, Dongcheng District, China|Guangzhou First People's Hospital, Guangzhou Shi, China|Sun Yat-sen University - The Sixth Affiliated Hospital, Guangzhou Shi, China|Guangdong General Hospital, Guangzhou, China|Nanfang Hospital of Southern Medical University, Guangzhou, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China|Shanghai City theTenth People's Hospital, Shanghai City, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|China Medical University Hospital, Taichung City, China|RenMin Hospital Of Wuhan University Hubei General Hospital, Wuhan Shi, China|Wuhan Union Hospital, Wuhan, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China|Clinical Hospital Center Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Center Split, Split, Croatia|Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|University Hospital Centre Zagreb, Clinic of Internal Diseases, Zagreb, Croatia|Military Hospital Brno, Brno, Czechia|St. Anne's University Hospital Brno, Brno, Czechia|Hepato-Gastroenterologie HK, s. r. o., Hradec Králové, Czechia|Soukroma Gastroenterologicka ambulance a endoskopie, Most, Czechia|PreventaMed, Olomouc, Czechia|Krajská nemocnice Pardubice, Kožní oddelení, Pardubice, Czechia|University Hospital Pilsen, Plzen, Czechia|University Hospital Motol, Prague 5, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|IBD Centrum/ISCARE IVF a.s., Praha 7, Czechia|Bispebjerg Hospital, Copenhagen, Denmark|Holbaek Hospital, Holbaek, Denmark|Nykobing F Hospital, Nykobing F, Denmark|Helsinki University Central Hospital (HUCH), Helsinki, Finland|Turku University Hospital, Turku, Finland|JSC Evex Medical Corporation - Batumi Referral Hospital, Batumi, Georgia|JSC Evex Medical Corporation - Oncology Center, Kutaisi, Georgia|LLC Vivamedi, Tbilisi, Georgia|Tbilisi State Medical University, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|JSC Infectious Disease, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia|LTD Academician N.Kipshidze Central University Clinic, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|LTD MediClub Georgia, Tbilisi, Georgia|David Tatishvili Medical Center, Tbilisi, Georgia|JSC Evex Medical Corporation - Telavi Referral Hospital, Telavi, Georgia|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Gastroenterological Special Practice at Wittenbergplatz, Berlin, Germany|Gastroenterology Am Bayerischen Platz, Berlin, Germany|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|DRK Clinics Berlin, Berlin, Germany|Hospital Waldfriede e.V., Berlin, Germany|Brandenburg City Hospital, Brandenburg an der Havel, Germany|Medical Care Unit Dachau, Dachau, Germany|Klinikum Darmstadt, Darmstadt, Germany|Kliniken Essen-Mitte, Essen, Germany|Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Interdisciplinary Crohn Colitis Center Rhein Main, Frankfurt, Germany|Studiengesellschaft BSF, Halle, Germany|University Hospital Halle (Saale), Halle, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitaetsklinikum Leipzig AoeR, Leipzig, Germany|Practice for Gastroenterology and Internal Medicine, Ludwigshafen am Rhein, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|University Hospital Muenster, Muenster, Germany|Synesis Research Center, Munich, Germany|Robert-Bosch-Hospital, Stuttgart, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Laiko General Hospital of Athens, Athens, Greece|Sotiria Chest Diseases Hospital of Athens, Athens, Greece|Tzanio General Hospital of Piraeus, Athens, Greece|PAGNI University Hospital, Heraklion, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|424th Army General Hospital, Thessaloniki, Greece|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem - Altalanos Orvostudomanyi Kar, Budapest, Hungary|Szent Margit Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|CRU Hungary Kft, Miskolc, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Clinfan Ltd, Szekszárd, Hungary|Csongrad County Dr. Bugyi Istvan Hospital, Szentes, Hungary|Zala Megyei KorhazHaematologia, Zalaegerszeg, Hungary|St Vincent's University Hospital, Dublin 4, Dublin, Ireland|Beaumont Hospital, Dublin 9, Ireland|Institute of Gastroenterology and Hepatology at Ha'Emek Medical Center, Afula, Israel|Bat Yamon Medical Center, Clalit Medical Services, Bat Yam, Israel|Asaf Harofeh Medical Center, Beer Jacob, Israel|Rambam Health Care Campus, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Clalit Health Services, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Galilee Medical Center, Nahariya, Israel|The Nazareth Hospital E.M.M.S., Nazareth, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|University Polyclinic Hospital of Bari, Bari, Italy|Polyclinic S. Orsola-Malpighi, Bologna, Italy|Civil Hospital of Brescia, Brescia, Italy|Poliambulanza Hospital, Brescia, Italy|IRCCS ""Savario De Bellis"", Castellana Grotte, Italy|University Hospital Mater Domini, Catanzaro, Italy|""Ss. Annunziata"" Policlinic of Chieti, Chieti, Italy|University Polyclinic Hospital G. Martino, Messina, Italy|Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Milano, Italy|Humanitas Research Hospital - Humanitas Mirasole S.p.A, Milan, Italy|Azienda Socio Sanitaria Territoriale (ASST) di Monza, Monza, Italy|Hospital of Di Padova, Padova, Italy|United Hospitals Villa Sofia Cervello, Palermo, Italy|Polyclinic San Matteo IRCCS, Pavia, Italy|Polyclinic Tor Vergata, Roma, Italy|Univerisity Polyclinic Foundation Agostino Gemelli, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Integrated University Hospital Santa Maria della Misericordia of Udine, Udine, Italy|A.O. Universitaria Fondazione Macchi, Varese, Italy|Sacred Heart Don Calabria, Verona, Italy|Korea University Medical Center - Korea University Ansan Hospital, Ansan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|St. Vincent's Hospital, Suwon, Korea, Republic of|P. Stradins Clinical University Hospital, Riga, Latvia|Digestive Diseases Center Gastro, Riga, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Vilnius City Clinical Hospital, Vilnius, Lithuania|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapapan, Jalisco, Mexico|Centro Regiomontano de Estudios Clinicos Roma SC., Monterrey, Nuevo León, Mexico|Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Nuevo León, Mexico|SMIQ, Santiago de Queretaro, Querétaro, Mexico|Hospital Christus Muquerza del Parque S.A. de C.V., Chihuahua, Mexico|Centro de Investigacion Clinica Acelerada (CICA) S.C., Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico|""Sfanta Treime"" Clinical Municipal Hospital, Chisinau, Moldova, Republic of|Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery, Chisinau, Moldova, Republic of|""Sf. Arhanghel Mihail"" Municipal Clinical Hospital, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Department of Colorectal Surgery, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Chisinau, Moldova, Republic of|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|UMC Groningen, Groningen, Netherlands|University Hospital Maastricht, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Akershus University Hospital, Lørenskog, Norway|Lovisenberg Diakonale Sykehus, Oslo, Norway|SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego, Bialystok, Poland|Medical Services Center MaxMed, Bochnia, Poland|St. John Paul 2nd Municipal Hospital in Elblag, Elblag, Poland|Private Medical Practice Miroslaw Fic, Jelenia Gora, Poland|BioVirtus Medical Centre, Jozefow, Poland|Nzoz All-Medicus, Katowice, Poland|Kornel Gibinski Independent Public Central Clinical Hospital in Katowice, Katowice, Poland|GLOBE Clinical Research Sp. z o.o. LLC, Klodzko, Poland|PLEJADY Sp. z o.o. (LLC) Medical Centre, Krakow, Poland|LUX MED Centrum Medyczne - Krakow, Krakow, Poland|Landa Specialist Doctor's Offices, Krakow, Poland|Krakow Medical Center LLC, Krakow, Poland|Centrum Opieki Zdrowotnej Orkan Med, Ksawerow, Poland|Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|Salve Medica, Lodz, Poland|LUX MED Centrum Medyczne - Lodz, Lodz, Poland|1 Military Clinical Hospital in Lublin, Lublin, Poland|Non-Public Healthcare Facility Allmedica Clinical Trials, Nowy Targ, Poland|Provincial Specialist Hospital in Olsztyn, Olsztyn, Poland|SOLUMED Medical Center, Poznan, Poland|Endoskopia Sp. z o.o., Sopot, Poland|TWOJA PRZYCHODNIA Medical Centre of Szczecin LLC, Szczecin, Poland|GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe, Torun, Poland|H-T. Medical Center Sp. z o.o. LLC Limited Partnership, Tychy, Poland|Polimedica, Ul. Piotrkowska 177, Poland|Maternal Pediatric and Adolescent Healthcare Centre, Warsaw, Poland|PRIMA LCC Specialist Clinics, Warsaw, Poland|Endoterapia PFG LLC, Endotherapy PFG Outpatient Clinic Branch No 1, Warszawa, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warszawa, Poland|Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice, Wierzchoslawice, Poland|LUX MED Centrum Medyczne - Wroclaw, Wroclaw, Poland|Wroclaw Medical University, Wroclaw, Poland|Clinical Research Center Early-Phase Research Facility, Wroclaw, Poland|LexMedica, Wroclaw, Poland|Ars Medica, Wroclaw, Poland|EMC Medical Institute S.A, Wroclaw, Poland|Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar do Alto Ave, Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE, Viana do Castelo, Portugal|Hyperclinica MedLife Grivita, Bucharest, Romania|Center of Diagnosis and Treatment Provita, Bucharest, Romania|Fundeni Clinical Institute, Bucharest, Romania|Bucharest University Emergency Hospital, Department of Internal Medicine II, Bucharest, Romania|Dr. Carol Davila Central Military Emergency Clinical Hospital, Bucharest, Romania|Craiova County Emergency Clinical Hospital, Craiova, Romania|Colentina Clinical Hospital, Napoca, Romania|Targu Mures County Emergency Clinical Hospital, Targu Mures, Romania|Joint Venture Company Diagnostic Center, Bioterm Ltd., Barnaul, Russian Federation|Territorial Clinical Hospital, Barnaul, Russian Federation|Regional Clinical Hospital #3, Chelyabinsk, Russian Federation|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|Ural State Medical Academy - Medical Association Novaya Bolnitsa, Ekaterinburg, Russian Federation|Irkutsk State Medical Academy of Postgraduate Education, Irkutsk, Russian Federation|Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation|Kaluga Regional Hospital, Kaluga, Russian Federation|S.V. Beliaev Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Moscow Clinical Scientific and Practical Center, Moscow, Russian Federation|City Clinical Hospital n.a. V.M. Buyanov, Moscow, Russian Federation|City Clinical Hospital 24, Moscow, Russian Federation|CJSC Nasledniki, Moscow, Russian Federation|A.N. Ryzhikh State Research Center for Coloproctology, Moscow, Russian Federation|Railway Station Clinical Hospital, Nizhny Novgorod, Russian Federation|Medical Center Sibnovomed LLC, Novosibirsk, Russian Federation|Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russian Federation|Euromed Multi-Specialty Center for Contemporary Medicine LLC, Omsk, Russian Federation|Medical Diagnostic Center LLC, Orenburg, Russian Federation|N.N. Burdenko Penza Regional Clinical Hospital, Penza, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|Evromedservis, Pushkin, Russian Federation|Clinic UZI 4D, LLC, Pyatigorsk, Russian Federation|Pyatigorsk City Hospital 2, Pyatigorsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Medical Center Reavita Med Spb LLC, Saint Petersburg, Russian Federation|City Clinical Hospital No 31 - St. Petersburg, Saint Petersburg, Russian Federation|S.M. Kirov Military Medical Academy, Saint-Petersburg, Russian Federation|Medical University REAVIZ, Samara, Russian Federation|Samara Station Railway Clinical Hospital under OAO Russian Railways, Samara, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Sochi City Hospital No 5, Sochi, Russian Federation|S.M. Kirov Military Medical Academy, St Petersburg, Russian Federation|Oncology Center of Moskovskiy District, St Petersburg, Russian Federation|City Outpatient Care Unit No 38, St. Petersburg, Russian Federation|I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation|State Unitary Enterprise Passengeravtotrans, St. Petersburg, Russian Federation|Clinical and Diagnostic Center with an outpatient department under the Presidential Executive Office, St. Petersburg, Russian Federation|SPb SBIH City Hospital of Saint Martyr Elizaveta, St. Petersburg, Russian Federation|Medical Center ItanoMed, St. Petersburg, Russian Federation|Medical Center Eko-Bezopasnost LLC, St. Petersburg, Russian Federation|SPb SBIH City Hospital # 9, St. Petersburg, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|G.G. Kuvatov Republican Clinical Hospital, Ufa, Russian Federation|City Clinical Hospital #21, Ufa, Russian Federation|Novgorod Regional Clinical Hospital, Veliky Novgorod, Russian Federation|Primorsky Regional Clinical Hospital No.1, Vladivostok, Russian Federation|Medical Center of Far-Eastern Federal University, Vladivostok, Russian Federation|Medical Scientific Manufacturing Association Dvizheniye Clinic, Volgograd, Russian Federation|King Fahad Specialist Hospital, Dammam, Saudi Arabia|King Abdul Aziz University Hospital, Jeddah, Saudi Arabia|King Saud Medical Complex, Riyadh, Saudi Arabia|King Fahad National Guard Hospital, Riyadh, Saudi Arabia|Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine, Belgrade, Serbia|Clinical Hospital Center Zvezdara Clinic of Internal Diseases, Belgrade, Serbia|Military Medical Academy, Clinic of Gastroenterology and Hepatology, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center of Vojvodina, Clinic of Gastroenterology and Hepatology, Novi Sad, Serbia|General Hospital Pancevo, Pancevo, Serbia|General Hospital Djordje Jovanovic Zrenjanin, Zrenjanin, Serbia|Cliniq, s.r.o., Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Ruzinov, Bratislava, Slovakia|Brezno gastroenterology center s.r.o., Brezno, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|Gastromedic s.r.o., Nove Zamky, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|World of the Health Inc. General Hospital Rimavska Sobota, Rimavska Sobota, Slovakia|General Hospital Celje, Celje, Slovenia|General Hospital Novo Mesto, Novo Mesto, Slovenia|Ahmed Kathrada Private Hospital, Gauteng, South Africa|Emmed Research, Pretoria, South Africa|General University Hospital of Alicante, Alicante, Spain|University Hospital Germans Trias i Pujol, Badalona, Spain|Teknon Medical Center, Barcelona, Spain|University Hospital Reina Sofia, Cordoba, Spain|University Hospital of Girona Dr. Josep Trueta, Girona, Spain|University Hospital of the Canary Islands (HUC) La Laguna, La Laguna, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain|University Hospital de La Princesa, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|University Hospital La Paz, Madrid, Spain|University Hospital Puerta de Hierro Majadajonda, Majadahonda, Madrid, Spain|University Hospital Marques de Valdecilla (HUMV), Santander, Spain|University Hospital Virgen Macarena, Sevilla, Spain|University Hospital Virgen del Rocio, Sevilla, Spain|University Clinical Hospital of Valencia, Valencia, Spain|Viladecans Hospital, Viladecans, Spain|University Hospital Miguel Servet, Zaragoza, Spain|Saint Goran Hospital, Stockholm, Sweden|Ersta Hospital, Stockholm, Sweden|Lindenhofspital, Bern, Switzerland|Cantonal Hospital Saint Gallen, St.Gallen, Switzerland|University Hospital Zurich, Zurich, Switzerland|Kaohsiung Medical University Hospital, Kaohsiung, San Ming Dist., Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Bulent Ecevit Universitesi Uygulama ve Arastirma Hastanesi, Kozlu, Taiwan|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|Chang Gung Memorial Hospital- Linkou, Taoyuan City, Taiwan|Taipei Veterans General Hospital, Tapei, Beitou Dist., Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Hacettepe Universitesi, Ankara, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Firat University Medical Faculty, Elazig, Turkey|Bezmialem Foundation University Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Marmara University, Istanbul, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Dnipropetrovsk II Mechnykov Regional Clinical Hospital Surgery Department 2, Dnipropetrovsk, Ukraine|Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Kharkiv City Clinical Hospital 2, Kharkiv, Ukraine|Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine|Medical and Diagnostic Center Acinus, Kropyvnytskyi, Ukraine|Medical Center Medical Clinic Blagomed LLC, Kyiv, Ukraine|Kyiv City Clinical Hospital #18, Kyiv, Ukraine|BIK-KYIV Ukrainian German Gastroenterology Center, Kyiv, Ukraine|Medical Center Consilium Medical, Kyiv, Ukraine|Ok Clinic Medical Center within International Institute of Clinical Trials, LLC, Kyiv, Ukraine|Kyiv Regional Hospital #2, Kyiv, Ukraine|Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Public City Clinical Hospital of Emergency Medical Care, Lviv, Ukraine|Odesa Regional Clinical Hospital Regional Gastroenterology Center Surgery Department, Odesa, Ukraine|Ternopil City Public Emergency Medical Care Hospital, Ternopil, Ukraine|Vinnytsia City Clinical Hospital #1, Vinnytsia, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine|Health Clinic, LLC, Vinnytsya, Ukraine|Zaporizhzhya Regional, Zaporizhzhya, Ukraine|First Private Clinic, Zhytomyr, Ukraine|Bristol Royal Infirmary, Bristol, United Kingdom|Ulster Hospital, Dundonald, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Victoria Hospital Blackpool, Lancashire Blackpool, United Kingdom|Royal London Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom|Torbay Hospital, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03464097"
74,"NCT03440385","Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease",,"Recruiting","No Results Available","Crohn Disease","Drug: Ozanimod|Other: Placebo","Proportion of subjects with a CDAI score < 150|Proportion of subjects with average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points with abdominal pain and stool frequency no worse than baseline|Proportion of subjects with a Simple Endoscopic Score for Crohn's Disease (SES-CD) score decrease from baseline of ≥ 50%|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score < 150|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score < 150 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with CDAI score < 150 at Week 12 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with an average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points and both no worse than baseline AND an SES-CD ≤ 4 points and decrease ≥2 points|Proportion of subjects with an average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points and both no worse than baseline AND an SES-CD decrease from baseline of ≥ 50%|Histologic Improvement based on differences between ozanimod and placebo in histologic disease activity scores (ie, Global Histologic Disease Activity Score changes (Geboes, 2000)|Proportion of subjects with CDAI reduction from baseline of ≥ 70 points|Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any ulcerated surface ≥ 10%|Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of ≥ 50%|Proportion of adolescent subjects with clinical remission, defined as Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 10 points|Proportion of adolescent subjects with clinical response, defined as a decrease in PCDAI ≥ 15 points from baseline|Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) scores (adult subjects only)|Change from baseline in 36-Item Short Form-36 Survey (SF-36) scores (adult subjects only)|Change from baseline in Work Productivity and Activity Impairment questionnaire for Crohn's disease (WPAI-CD) scores (adult subjects only)|Change from baseline in EuroQol 5 dimensions questionnaire (EQ- 5D) scores|Differences in CD-related hospitalizations, procedures, and surgery|Assessment of circulating lymphocyte concentration|Assessment of gene expression|Assessment of protein biomarker concentration|Assessment of pharmacogenetics","Celgene","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-3202|U1111-1203-7949|2017-004293-33","March 7, 2018","March 31, 2020","March 31, 2022","February 21, 2018",,"October 22, 2019","HonorHealth Research Institute, Scottsdale, Arizona, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|UCSD Medical Center, La Jolla, California, United States|OM Research, Lancaster, California, United States|Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States|Matrix Clinical Research Inc, Los Angeles, California, United States|Facey Medical Foundation (Parent), Mission Hills, California, United States|Havana Research Institute LLC, Pasadena, California, United States|Sutter Medical Group, Roseville, California, United States|UC Davis Health - Gastroenterology and Hepatology Clinical Trials Unit, Sacramento, California, United States|University of California at San Francisco, San Francisco, California, United States|New Hope Research Development, West Covina, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Clinical Reseach of West Florida, Clearwater, Florida, United States|South Lake Pain Institute, Clermont, Florida, United States|American Research Institute Inc, Cutler Bay, Florida, United States|Universal Axon Clinical Research, Doral, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|SIH Research, Kissimmee, Florida, United States|Precision Clinical Research, LLC., Lauderdale Lakes, Florida, United States|Alliance Medical Research LLC, Lighthouse Point, Florida, United States|Center For Advanced Gastroenterology, Maitland, Florida, United States|Galiz Research LLC, Miami Springs, Florida, United States|LMG Research, Miami, Florida, United States|Innovation Research Institute, Inc., Miami, Florida, United States|Life Medical Center & Research, Inc., Miami, Florida, United States|Bayside Clinical Research, New Port Richey, Florida, United States|Omega Research Maitland, LLC, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Theia Clinical Research, LLC, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Apex Clinical Research, Tampa, Florida, United States|Guardian Angel Health Svcs Inc, Tampa, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Atlanta Center For Gastroenterology, P.C., Decatur, Georgia, United States|Grand Teton Research Group, PLLC, Idaho Falls, Idaho, United States|University of Chicago, Chicago, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|Cotton ONeil Clinical Research Center Digestive Health, Topeka, Kansas, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Clinical Trials of SW Louisiana LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, LLC, Marrero, Louisiana, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, United States|Henry Ford Medical Center - New Center One, Novi, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Mid America Gastrointestinal Consultants, Kansas City, Missouri, United States|Internal Medicine Specialists, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Drug Trials America, Hartsdale, New York, United States|Weill Cornell Medical College, New York, New York, United States|Concorde Medical Group, New York, New York, United States|TrialSpark, New York, New York, United States|DiGiovanna Institute for Medical Education And Research, North Massapequa, New York, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|PMG Research of Winston-Salem LLC, Winston-Salem, North Carolina, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Advance Clinical Research - Dayton Internal Medicine, Dayton, Ohio, United States|Paramount Medical Research & Consulting, LLC, Middleburg Heights, Ohio, United States|Cancer Care Associates of OK-N PorterAvenue, Norman, Oklahoma, United States|Allergy, Asthma and Immunology Center, PC, Tulsa, Oklahoma, United States|Central States Research, LLC, Tulsa, Oklahoma, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|The Coastal Medical Group, Houston, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|Accurate Clinical Research Inc, Pasadena, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|Baylor Scott and White Health, Temple, Texas, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|The Gastroenterology Group, Reston, Virginia, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Franciscan Skemp Healthcare, La Crosse, Wisconsin, United States|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital and Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia|Coastal Digestive Health, Maroorchydore, Queensland, Australia|University of the Sunshine Coast, North Mackay, Queensland, Australia|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Medical University Innsbruck, Innsbruck, Austria|University Hospital St. Poelten, St Polten, Austria|Medical University Vienna, Vienna, Austria|Hospital Sao Rafael, Salvador, Bahia, Brazil|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda, Goiania, Goiás, Brazil|Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, São Paulo, Brazil|Instituto De Assistencia Medica Ao Servidor Publico Estadual - Iamspe - Hspe/Fmo, Sao Paulo, São Paulo, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Faculdade de Medicina do ABC, Vila Sacadura Cabral, Brazil|CEDOES - Diagnostico e Pesquisa, Vitoria, Brazil|MHAT Ruse AD, Ruse, Bulgaria|Excelsior Medical Center, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, Bulgaria|Diagnostic and Consulting Center Alexandrovska, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|Diagnostic-Consultative Center Sveta Anna, Sofia, Bulgaria|West Edmonton Gastroenterology Consultants, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc., New Westminister, British Columbia, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Brandon Medical Arts Clinic, Brandon, Manitoba, Canada|IWK Health Center, Halifax, Nova Scotia, Canada|Dr.Garisa Jagan Mohan Reddy MD, Sudbury, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Kensington Screening Clinic, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|The Ottawa Hospital - General Campus, Ottawa, Quebec, Canada|Peking University First Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital of Central South University, Changsha, China|Daping Hospital Third Military Medical University of People's Liberation Army, Chongqing, China|PLA Army General Hospital, Dongcheng District, China|Guangzhou First People's Hospital, Guangzhou Shi, China|Sun Yat-sen University - The Sixth Affiliated Hospital, Guangzhou Shi, China|Guangdong General Hospital, Guangzhou, China|Nanfang Hospital of Southern Medical University, Guangzhou, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China|Shanghai City theTenth People's Hospital, Shanghai City, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|China Medical University Hospital, Taichung City, China|RenMin Hospital Of Wuhan University Hubei General Hospital, Wuhan Shi, China|Wuhan Union Hospital, Wuhan, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China|Helsinki University Central Hospital (HUCH), Helsinki, Finland|Turku University Hospital, Turku, Finland|JSC Evex Medical Corporation - Batumi Referral Hospital, Batumi, Georgia|JSC Evex Medical Corporation - Oncology Center, Kutaisi, Georgia|LLC Vivamedi, Tbilisi, Georgia|Tbilisi State Medical University, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|JSC Infectious Disease, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia|LTD Academician N.Kipshidze Central University Clinic, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|LTD MediClub Georgia, Tbilisi, Georgia|David Tatishvili Medical Center, Tbilisi, Georgia|JSC Evex Medical Corporation - Telavi Referral Hospital, Telavi, Georgia|Gastroenterological Special Practice at Wittenbergplatz, Berlin, Germany|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|Hospital Waldfriede e.V., Berlin, Germany|Brandenburg City Hospital, Brandenburg an der Havel, Germany|Medical Care Unit Dachau, Dachau, Germany|Klinikum Darmstadt, Darmstadt, Germany|Kliniken Essen-Mitte, Essen, Germany|Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany|Studiengesellschaft BSF, Halle, Germany|University Hospital Halle (Saale), Halle, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|University Hospital Muenster, Muenster, Germany|Robert-Bosch-Hospital, Stuttgart, Germany|Laiko General Hospital of Athens, Athens, Greece|Sotiria Chest Diseases Hospital of Athens, Athens, Greece|Tzanio General Hospital of Piraeus, Athens, Greece|PAGNI University Hospital, Heraklion, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|424th Army General Hospital, Thessaloniki, Greece|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem - Altalanos Orvostudomanyi Kar, Budapest, Hungary|Szent Margit Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|CRU Hungary Kft, Miskolc, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Clinfan Ltd, Szekszárd, Hungary|Csongrad County Dr. Bugyi Istvan Hospital, Szentes, Hungary|Zala Megyei KorhazHaematologia, Zalaegerszeg, Hungary|Institute of Gastroenterology and Hepatology at Ha'Emek Medical Center, Afula, Israel|Asaf Harofeh Medical Center, Beer Jacob, Israel|Rambam Health Care Campus, Haifa, Israel|Clalit Health Services, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|St. Vincent's Hospital, Suwon, Korea, Republic of|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santariskes Clinics, Vilnius, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Vilnius City Clinical Hospital, Vilnius, Lithuania|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|UMC Groningen, Groningen, Netherlands|University Hospital Maastricht, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|St. John Paul 2nd Municipal Hospital in Elblag, Elblag, Poland|Private Medical Practice Miroslaw Fic, Jelenia Gora, Poland|BioVirtus Medical Centre, Jozefow, Poland|LUX MED Centrum Medyczne - Krakow, Krakow, Poland|Centrum Opieki Zdrowotnej Orkan Med, Ksawerow, Poland|LUX MED Centrum Medyczne - Lodz, Lodz, Poland|Non-Public Healthcare Facility Allmedica Clinical Trials, Nowy Targ, Poland|Endoskopia Sp. z o.o., Sopot, Poland|TWOJA PRZYCHODNIA Medical Centre of Szczecin LLC, Szczecin, Poland|PRIMA LCC Specialist Clinics, Warsaw, Poland|Endoterapia PFG LLC, Endotherapy PFG Outpatient Clinic Branch No 1, Warszawa, Poland|Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice, Wierzchoslawice, Poland|LUX MED Centrum Medyczne - Wroclaw, Wroclaw, Poland|Wroclaw Medical University, Wroclaw, Poland|Clinical Research Center Early-Phase Research Facility, Wroclaw, Poland|LexMedica, Wroclaw, Poland|Ars Medica, Wroclaw, Poland|EMC Medical Institute S.A, Wroclaw, Poland|Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar do Alto Ave, Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE, Viana do Castelo, Portugal|Joint Venture Company Diagnostic Center, Bioterm Ltd., Barnaul, Russian Federation|Territorial Clinical Hospital, Barnaul, Russian Federation|Regional Clinical Hospital #3, Chelyabinsk, Russian Federation|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|Ural State Medical Academy - Medical Association Novaya Bolnitsa, Ekaterinburg, Russian Federation|Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation|Kaluga Regional Hospital, Kaluga, Russian Federation|S.V. Beliaev Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|City Clinical Hospital n.a. V.M. Buyanov, Moscow, Russian Federation|City Clinical Hospital 24, Moscow, Russian Federation|CJSC Nasledniki, Moscow, Russian Federation|A.N. Ryzhikh State Research Center for Coloproctology, Moscow, Russian Federation|Railway Station Clinical Hospital, Nizhny Novgorod, Russian Federation|Medical Center Sibnovomed LLC, Novosibirsk, Russian Federation|Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russian Federation|Euromed Multi-Specialty Center for Contemporary Medicine LLC, Omsk, Russian Federation|Medical Diagnostic Center LLC, Orenburg, Russian Federation|N.N. Burdenko Penza Regional Clinical Hospital, Penza, Russian Federation|City Clinical Hospital No 31 - St. Petersburg, Saint Petersburg, Russian Federation|S.M. Kirov Military Medical Academy, Saint-Petersburg, Russian Federation|Medical University REAVIZ, Samara, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Sochi City Hospital No 5, Sochi, Russian Federation|Oncology Center of Moskovskiy District, St Petersburg, Russian Federation|City Outpatient Care Unit No 38, St. Petersburg, Russian Federation|I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation|State Unitary Enterprise Passengeravtotrans, St. Petersburg, Russian Federation|Medical Center ItanoMed, St. Petersburg, Russian Federation|Medical Center Eko-Bezopasnost LLC, St. Petersburg, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|G.G. Kuvatov Republican Clinical Hospital, Ufa, Russian Federation|Medical Scientific Manufacturing Association Dvizheniye Clinic, Volgograd, Russian Federation|Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine, Belgrade, Serbia|Clinical Hospital Center Zvezdara Clinic of Internal Diseases, Belgrade, Serbia|Military Medical Academy, Clinic of Gastroenterology and Hepatology, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center of Vojvodina, Clinic of Gastroenterology and Hepatology, Novi Sad, Serbia|General Hospital Pancevo, Pancevo, Serbia|General Hospital Djordje Jovanovic Zrenjanin, Zrenjanin, Serbia|Cliniq, s.r.o., Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Ruzinov, Bratislava, Slovakia|Brezno gastroenterology center s.r.o., Brezno, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|Gastromedic s.r.o., Nove Zamky, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|World of the Health Inc. General Hospital Rimavska Sobota, Rimavska Sobota, Slovakia|General Hospital Celje, Celje, Slovenia|General Hospital Novo Mesto, Novo Mesto, Slovenia|Ahmed Kathrada Private Hospital, Gauteng, South Africa|Emmed Research, Pretoria, South Africa|Teknon Medical Center, Barcelona, Spain|University Hospital Reina Sofia, Cordoba, Spain|University Hospital of Girona Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain|Hospital Clinico San Carlos, Madrid, Spain|University Hospital Puerta de Hierro Majadajonda, Majadahonda, Madrid, Spain|University Hospital Marques de Valdecilla (HUMV), Santander, Spain|University Clinical Hospital of Valencia, Valencia, Spain|University Hospital Miguel Servet, Zaragoza, Spain|Saint Goran Hospital, Stockholm, Sweden|Ersta Hospital, Stockholm, Sweden|Kaohsiung Medical University Hospital, Kaohsiung, San Ming Dist., Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|Chang Gung Memorial Hospital- Linkou, Taoyuan City, Taiwan|Taipei Veterans General Hospital, Tapei, Beitou Dist., Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Hacettepe Universitesi, Ankara, Turkey|Firat University Medical Faculty, Elazig, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Dnipropetrovsk II Mechnykov Regional Clinical Hospital Surgery Department 2, Dnipropetrovsk, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Kharkiv City Clinical Hospital 2, Kharkiv, Ukraine|Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine|Medical and Diagnostic Center Acinus, Kropyvnytskyi, Ukraine|Medical Center Medical Clinic Blagomed LLC, Kyiv, Ukraine|Kyiv City Clinical Hospital #18, Kyiv, Ukraine|BIK-KYIV Ukrainian German Gastroenterology Center, Kyiv, Ukraine|Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Odesa Regional Clinical Hospital Regional Gastroenterology Center Surgery Department, Odesa, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine|Health Clinic, LLC, Vinnytsya, Ukraine|Zaporizhzhya Regional, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03440385"
75,"NCT03440372","Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease",,"Recruiting","No Results Available","Crohn Disease","Drug: Ozanimod|Other: Placebo","Proportion of subjects with a CDAI score < 150|Proportion of subjects with average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points with abdominal pain and stool frequency no worse than baseline|Proportion of subjects with a Simple Endoscopic Score for Crohn's Disease (SES-CD) score decrease from baseline of ≥ 50%|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score < 150|Proportion of subjects with CDAI reduction from baseline of ≥ 100 points or CDAI score < 150 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with CDAI score < 150 at Week 12 and SES-CD decrease from baseline of ≥ 50%|Proportion of subjects with an average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points and both no worse than baseline AND an SES-CD ≤ 4 points and decrease ≥2 points at week 12|Proportion of subjects with an average daily abdominal pain score ≤ 1 point, and average daily stool frequency score ≤ 3 points and both no worse than baseline AND an SES-CD decrease from baseline of ≥ 50% at week 12.|Histologic Improvement based on differences between ozanimod and placebo in histologic disease activity scores (ie, Global Histologic Disease Activity Score changes (Geboes, 2000)|Proportion of subjects with CDAI reduction from baseline of ≥ 70 points|Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any ulcerated surface ≥ 10%|Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of ≥ 50%|Proportion of adolescent subjects with clinical remission, defined as Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 10 points at week 12|Proportion of adolescent subjects with clinical response, defined as a decrease in PCDAI ≥ 15 points from baseline|Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) scores (adult subjects only)|Change from baseline in 36-Item Short Form-36 Survey (SF-36) scores (adult subjects only)|Change from baseline in Work Productivity and Activity Impairment questionnaire for Crohn's disease (WPAI-CD) scores (adult subjects only)|Change from baseline in EuroQol 5 dimensions questionnaire (EQ- 5D) scores|Differences in CD-related hospitalizations, procedures, and surgery|Assessment of circulating lymphocyte concentration|Assessment of gene expression|Assessment of protein biomarker concentration|Assessment of pharmacogenetics","Celgene","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-3201|U1111-1203-7225|2017-004292-31","February 27, 2018","February 20, 2020","April 29, 2022","February 21, 2018",,"October 8, 2019","Holland Center for Family Health, Peoria, Arizona, United States|Elite Clinical Studies, LLC, Phoenix, Arizona, United States|Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States|Sharp Chula Vista Medical Center, Chula Vista, California, United States|Valley View Internal Medicine, Garden Grove, California, United States|San Diego Clinical Trials, La Mesa, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|VA Northern California Health Care System, Mather, California, United States|ABS Health, LLC, Mission Viejo, California, United States|Alliance Clinical Research, Oceanside, California, United States|Palo Alto Center-Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Medical Associates Research Group, San Diego, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Gastro Florida, Clearwater, Florida, United States|University of Florida Health Endocrinology - Medical Specialties - Medical Plaza, Gainesville, Florida, United States|Qway Research LLC, Hialeah, Florida, United States|Floridian Clinical Research LLC, Hialeah, Florida, United States|Harmony Medical Research Institute, Hialeah, Florida, United States|The Center for Gastrointestinal Disorders, Hollywood, Florida, United States|Vista Health Research, Homestead, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|Nova Clinical Research Center LLC, Miami, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Research Associates of South Florida LLC, Miami, Florida, United States|Advanced Research for Health Improvement, Naples, Florida, United States|NSB Research, New Smyrna Beach, Florida, United States|HMD Research LLC, Orlando, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Consultative Gastroenterology, Atlanta, Georgia, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Gastrointestinal Disease Research, Columbus, Georgia, United States|Gastroenterology Associates Of Central Georgia LLC, Macon, Georgia, United States|Rush University Medical Center - University Cardiovascular Surgeons, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|University of Kentucky Health Care, Lexington, Kentucky, United States|CroNOLA LLC, Houma, Louisiana, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Nola Research Works, New Orleans, Louisiana, United States|LSU Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - The Center for Vascular Biol, Boston, Massachusetts, United States|Brigham and Women's Hospital - Crohn's and Colitis Center, Chestnut Hill, Massachusetts, United States|Medex Research Institute, Caro, Michigan, United States|Revive Research Institute, Southfield, Michigan, United States|Southern Therapy and Advanced Research, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|Advantage Clinical Trials, Bronx, New York, United States|TrialSpark, Brooklyn, New York, United States|NY Scientific, Brooklyn, New York, United States|Northern Medical Group, Fishkill, New York, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Northwell Health, Great Neck, New York, United States|Cornell University, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Circuit Clinical, Orchard Park, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Carolinas HealthCare System Digestive Health, Charlotte, North Carolina, United States|Internal Medicine Research, Charlotte, North Carolina, United States|Carolina Research Center, Greenville, North Carolina, United States|Great Lakes Medical Research, LLC, Beachwood, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Great Lakes Gastroenterology, Mentor, Ohio, United States|Great Lakes Medical Research, LLC, Warren, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc., Oklahoma City, Oklahoma, United States|Digestive Disease Specialists, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Penn State University Milton S Hershey Medical Center, State College, Pennsylvania, United States|Quality Medical Research, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Advanced Gastroenterology, Union City, Tennessee, United States|Avant Research Associates, LLC - Austin, Austin, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Biopharma Informatic Inc. Research Center, Houston, Texas, United States|GI Specialists of Houston, Houston, Texas, United States|Premier Vein and Vascular Center, Houston, Texas, United States|Ygenics, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Gastroenterology Associates, PC, Gainesville, Virginia, United States|Summit Clinical Research, LLC, Petersburg, Virginia, United States|Virginia Gastroenterology Institute PC, Suffolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Dermatologist Specialists of Spokane, Spokane, Washington, United States|Aurora Health Care Aurora Research, Grafton, Wisconsin, United States|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Cemic Saavedra, Ciudad Autónoma De Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Universidad Nacional De Rosario - Hospital Provincial Del Centenario, Rosario, Argentina|Sanatorio 9 de Julio - CICE 9 de Julio, San Miguel de Tucuman, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Harry Perkins Medical Research Institute, Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Ballarat Base Hospital, Ballarat, Australia|Grodno City Clinical Hospital #4, Grodno, Belarus|Vitebsk Regional Clinical Specialized Center, Vitebsk, Belarus|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Universitair Ziehenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|CHC - Clinique St-Jospeh, Liege, Belgium|Sart Tilman Hospital Department of Gastroenterology and Hepatology, Seraing, Belgium|Hospital Centre of Walloon Picarde, Tournai, Belgium|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|General Hospital ""Prim.dr. Abdulah Nakas"", Sarajevo, Bosnia and Herzegovina|CDC - Centro Digestivo de Curitiba, Curitiba, Paraná, Brazil|Hospital Nossa Senhora das Gracas, Curitiba, Paraná, Brazil|Hospital de Clinicas de Porto Alegre (HCPA), Porto Algere, Rio Grande Do Sul, Brazil|Pesquisare Saude, Santo Andre, São Paulo, Brazil|Kaiser Clinica, Sao Jose do Rio Preto, São Paulo, Brazil|Santa Casa De Votuporanga-Philanthropic hospital, Votuporanga, São Paulo, Brazil|Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo, Passo Fundo, Brazil|Ribeiralo Preto Medical School, University of Salo Paulo, Ribeirao Preto, Brazil|Universidade Federal do Estado do Rio de Janeiro (UNIRIO) - Hospital Universitario Gaffree e Guinle, Rio de Janeiro, Brazil|Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF), Rio de Janeiro, Brazil|CEMEC - Centro Multidisciplinar De Estudos Clanicos, Santo Andre, Brazil|Multiprofile Hospital for Active Treatment Medline, Plovdiv, Bulgaria|Second MHAT Sofia AD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|ACIBADEM City Clinic Medical Center Bregalnitsa, Varna, Bulgaria|University of Calgary Health - The Gastrointestinal Research Group (GIRG), Calgary, Alberta, Canada|Okanagan Clinical Trials Ltd, Kelowna, British Columbia, Canada|Vancouver Hospital Gastrointestinal Research Unit The Gordon and Leslie Diamond Centre, Vancouver, British Columbia, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|Viable Clinical Research, Bridgewater, Nova Scotia, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|LHSC Victoria Hospital, London, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Clinical Hospital Center Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Center Split, Split, Croatia|Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|University Hospital Centre Zagreb, Clinic of Internal Diseases, Zagreb, Croatia|Military Hospital Brno, Brno, Czechia|St. Anne's University Hospital Brno, Brno, Czechia|Hepato-Gastroenterologie HK, s. r. o., Hradec Králové, Czechia|Soukroma Gastroenterologicka ambulance a endoskopie, Most, Czechia|PreventaMed, Olomouc, Czechia|Krajská nemocnice Pardubice, Kožní oddelení, Pardubice, Czechia|University Hospital Pilsen, Plzen, Czechia|University Hospital Motol, Prague 5, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|IBD Centrum/ISCARE IVF a.s., Praha 7, Czechia|Bispebjerg Hospital, Copenhagen, Denmark|Holbaek Hospital, Holbaek, Denmark|Nykobing F Hospital, Nykobing F, Denmark|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Gastroenterology Am Bayerischen Platz, Berlin, Germany|DRK Clinics Berlin, Berlin, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Interdisciplinary Crohn Colitis Center Rhein Main, Frankfurt, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig AoeR, Leipzig, Germany|Practice for Gastroenterology and Internal Medicine, Ludwigshafen am Rhein, Germany|Synesis Research Center, Munich, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|St Vincent's University Hospital, Dublin 4, Dublin, Ireland|Beaumont Hospital, Dublin 9, Ireland|Bat Yamon Medical Center, Clalit Medical Services, Bat Yam, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|The Nazareth Hospital E.M.M.S., Nazareth, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|University Polyclinic Hospital of Bari, Bari, Italy|Polyclinic S. Orsola-Malpighi, Bologna, Italy|Civil Hospital of Brescia, Brescia, Italy|Poliambulanza Hospital, Brescia, Italy|IRCCS ""Savario De Bellis"", Castellana Grotte, Italy|University Hospital Mater Domini, Catanzaro, Italy|""Ss. Annunziata"" Policlinic of Chieti, Chieti, Italy|University Polyclinic Hospital G. Martino, Messina, Italy|Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Milano, Italy|Humanitas Research Hospital - Humanitas Mirasole S.p.A, Milan, Italy|Azienda Socio Sanitaria Territoriale (ASST) di Monza, Monza, Italy|Hospital of Di Padova, Padova, Italy|United Hospitals Villa Sofia Cervello, Palermo, Italy|Polyclinic San Matteo IRCCS, Pavia, Italy|Polyclinic Tor Vergata, Roma, Italy|Univerisity Polyclinic Foundation Agostino Gemelli, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Integrated University Hospital Santa Maria della Misericordia of Udine, Udine, Italy|A.O. Universitaria Fondazione Macchi, Varese, Italy|Sacred Heart Don Calabria, Verona, Italy|Korea University Medical Center - Korea University Ansan Hospital, Ansan, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|P. Stradins Clinical University Hospital, Riga, Latvia|Digestive Diseases Center Gastro, Riga, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, Latvia|Hospital Dalinde - CECRA Clinica Especializada en Colon, Recto y Ano, Delegacion Cuauhtemoc, Distrito Federal, Mexico|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapapan, Jalisco, Mexico|Centro Regiomontano de Estudios Clinicos Roma SC., Monterrey, Nuevo León, Mexico|Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Nuevo León, Mexico|SMIQ, Santiago de Queretaro, Querétaro, Mexico|Hospital Christus Muquerza del Parque S.A. de C.V., Chihuahua, Mexico|Centro de Investigacion Clinica Acelerada (CICA) S.C., Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico|""Sfanta Treime"" Clinical Municipal Hospital, Chisinau, Moldova, Republic of|Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery, Chisinau, Moldova, Republic of|""Sf. Arhanghel Mihail"" Municipal Clinical Hospital, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Department of Colorectal Surgery, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Chisinau, Moldova, Republic of|Akershus University Hospital, Lørenskog, Norway|Lovisenberg Diakonale Sykehus, Oslo, Norway|SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego, Bialystok, Poland|Medical Services Center MaxMed, Bochnia, Poland|Nzoz All-Medicus, Katowice, Poland|Kornel Gibinski Independent Public Central Clinical Hospital in Katowice, Katowice, Poland|GLOBE Clinical Research Sp. z o.o. LLC, Klodzko, Poland|PLEJADY Sp. z o.o. (LLC) Medical Centre, Krakow, Poland|Landa Specialist Doctor's Offices, Krakow, Poland|Krakow Medical Center LLC, Krakow, Poland|Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|Salve Medica, Lodz, Poland|1 Military Clinical Hospital in Lublin, Lublin, Poland|Provincial Specialist Hospital in Olsztyn, Olsztyn, Poland|SOLUMED Medical Center, Poznan, Poland|GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe, Torun, Poland|H-T. Medical Center Sp. z o.o. LLC Limited Partnership, Tychy, Poland|Polimedica, Ul. Piotrkowska 177, Poland|Maternal Pediatric and Adolescent Healthcare Centre, Warsaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warszawa, Poland|Hyperclinica MedLife Grivita, Bucharest, Romania|Center of Diagnosis and Treatment Provita, Bucharest, Romania|Fundeni Clinical Institute, Bucharest, Romania|Bucharest University Emergency Hospital, Department of Internal Medicine II, Bucharest, Romania|Dr. Carol Davila Central Military Emergency Clinical Hospital, Bucharest, Romania|Craiova County Emergency Clinical Hospital, Craiova, Romania|Colentina Clinical Hospital, Napoca, Romania|Targu Mures County Emergency Clinical Hospital, Targu Mures, Romania|Irkutsk State Medical Academy of Postgraduate Education, Irkutsk, Russian Federation|Moscow Clinical Scientific and Practical Center, Moscow, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|Evromedservis, Pushkin, Russian Federation|Clinic UZI 4D, LLC, Pyatigorsk, Russian Federation|Pyatigorsk City Hospital 2, Pyatigorsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Medical Center Reavita Med Spb LLC, Saint Petersburg, Russian Federation|Samara Station Railway Clinical Hospital under OAO Russian Railways, Samara, Russian Federation|S.M. Kirov Military Medical Academy, St Petersburg, Russian Federation|Clinical and Diagnostic Center with an outpatient department under the Presidential Executive Office, St. Petersburg, Russian Federation|SPb SBIH City Hospital of Saint Martyr Elizaveta, St. Petersburg, Russian Federation|SPb SBIH City Hospital # 9, St. Petersburg, Russian Federation|City Clinical Hospital #21, Ufa, Russian Federation|Novgorod Regional Clinical Hospital, Veliky Novgorod, Russian Federation|Primorsky Regional Clinical Hospital No.1, Vladivostok, Russian Federation|Medical Center of Far-Eastern Federal University, Vladivostok, Russian Federation|King Fahad Specialist Hospital, Dammam, Saudi Arabia|King Abdul Aziz University Hospital, Jeddah, Saudi Arabia|King Saud Medical Complex, Riyadh, Saudi Arabia|King Fahad National Guard Hospital, Riyadh, Saudi Arabia|General University Hospital of Alicante, Alicante, Spain|University Hospital Germans Trias i Pujol, Badalona, Spain|University Hospital of the Canary Islands (HUC) La Laguna, La Laguna, Spain|University Hospital de La Princesa, Madrid, Spain|University Hospital La Paz, Madrid, Spain|University Hospital Virgen Macarena, Sevilla, Spain|University Hospital Virgen del Rocio, Sevilla, Spain|Viladecans Hospital, Viladecans, Spain|Lindenhofspital, Bern, Switzerland|Cantonal Hospital Saint Gallen, St.Gallen, Switzerland|University Hospital Zurich, Zurich, Switzerland|Bulent Ecevit Universitesi Uygulama ve Arastirma Hastanesi, Kozlu, Taiwan|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Bezmialem Foundation University Medical Faculty, Istanbul, Turkey|Marmara University, Istanbul, Turkey|Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Kyiv City Clinical Hospital #18, Kyiv, Ukraine|Medical Center Consilium Medical, Kyiv, Ukraine|Ok Clinic Medical Center within International Institute of Clinical Trials, LLC, Kyiv, Ukraine|Kyiv Regional Hospital #2, Kyiv, Ukraine|Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Public City Clinical Hospital of Emergency Medical Care, Lviv, Ukraine|Ternopil City Public Emergency Medical Care Hospital, Ternopil, Ukraine|Vinnytsia City Clinical Hospital #1, Vinnytsia, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine|First Private Clinic, Zhytomyr, Ukraine|Bristol Royal Infirmary, Bristol, United Kingdom|Ulster Hospital, Dundonald, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Victoria Hospital Blackpool, Lancashire Blackpool, United Kingdom|Royal London Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom|Torbay Hospital, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03440372"
76,"NCT03435796","Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells",,"Recruiting","No Results Available","Neoplasms","Genetic: Gene-modified (GM) T cell therapy","Adverse Events (AEs)|Tumor Response Status|Disease Progression|Disease Relapse|Overall Survival|Health-related quality of life (HRQoL)|Height of pediatric subjects treated with GM T cells|Weight of pediatric subjects treated with GM T cells|Sexual maturation of pediatric subjects treated with GM T cells","Celgene","All","Child, Adult, Older Adult","Phase 2|Phase 3","191","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC-LTFU-001|U1111-1206-8250|2017-001465-24","June 19, 2018","November 30, 2032","November 30, 2032","February 16, 2018",,"October 22, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|Mayo Clinic Phoenix, Phoenix, Arizona, United States|Arizona Cancer Center, Scottsdale, Arizona, United States|City of Hope, Duarte, California, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Sutter Hematology and Oncology, Sacramento, California, United States|University of California, San Francisco- California, San Francisco, California, United States|UCLA Medical Centre-Santa Monica, Santa Monica, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Lombardi Cancer Center - Georgetown University Hospital, Washington, District of Columbia, United States|The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida, United States|Baptist Cancer Center, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|IN Univ Simon Cancer Center, Indianapolis, Indiana, United States|Franciscan St. Francis Health - Indiana Blood and Marrow Transplantation (IBMT), Indianapolis, Indiana, United States|Kansas University Medical Center, Westwood, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute Louisville Oncology, Louisville, Kentucky, United States|University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|National Cancer Institute, Bethesda, Maryland, United States|Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Center Wayne State University, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hosp, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology P.C., Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester James P. Wilmot Cancer Center, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute, Eugene, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas- MD Anderson, Houston, Texas, United States|SAM Clinical Research Center, San Antonio, Texas, United States|Baylor Scott and White Health, Temple, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|Intermountain Healthcare - LDS Hospital, Salt Lake City, Utah, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Austria|UZ Gent, Gent, Belgium|University Hospital Leuven, Leuven, Belgium|University of Calgary, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal, Quebec, Canada|Helsinki University Central Hospital (HUCH), Helsinki, Finland|CHRU de Lille France, Lille Cedex, France|Institute for Pediatric Hematology - Oncology, Leon Berard Cancer Center, Lyon, France|Institut Paoli-Calmettes, Marseille Cedex 9, France|Hôpitaux de La Timone, Marseille Cedex 9, France|CHU Hotel Dieu, Nantes Cedex 01, France|Hopital Saint Louis, Paris, France|Hopital Robert Debre, Paris, France|Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, France|CHU La Miletrie, Poitiers Cedex, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse CEDEX 9, France|Gustave Roussy, Villejuif, France|Robert-Rössle-Klinik im HELIOS Klinikum Berlin-Buch Klinik für Hämatologie, Onkologie u. Tumorimmuno, Berlin, Germany|Charite -Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Hematology Oncology and clinical immunology / Heinrich-Heine-University, Dusseldorf, Germany|Medizinische Klinik II ZIM,Hamatologie Onkologie Uniklinik Frankfurt, Frankfurt, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Kinikum der Universitaeat zu Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|LMU Klinikum der Universität, München, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|University Hospital of Ulm, Ulm, Germany|Universitatsklinikum Wurzburg Medizinische Klinik und Poliklinik II, Würzburg, Germany|Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy|Universita La Sapienza, Roma, Italy|Ospedale Pediatrico Bambino Gesu, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Italy|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan|National Cancer Center Hospital, Chuo-ku, Japan|Tokai University Hospital, Isehara City, Kanagawa, Japan|Toranomon Hospital, Minato-ku, Japan|Osaka City University Hospital, Osaka, Japan|Japan Red Cross Medical Center, Shibuya-ku, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|Tokyo Women's Medical University Hospital, Shinjuku City, Japan|Erasmus Medical Center - Daniel den Hoed, Rotterdam, Netherlands|Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands|Oslo Universitetssykehus, Oslo, Norway|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona, Spain|Institut Clinic de Nefrologia i Urologia - Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Karolinska University Hospital Huddinge, Stockholm, Sweden|Universitatsspital Bern, Bern, Switzerland|The Leeds Teaching Hospitals NHS Trust - St James's University Hospital, Leeds, United Kingdom|Kings College Hospital, London, United Kingdom|UCL Cancer Institute, London, United Kingdom|Christie Hospital NHS Trust, Manchester Withington, United Kingdom|Somers Cancer Research Building, Shirley Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03435796"
77,"NCT03435341","Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain",,"Recruiting","No Results Available","Leukemia, Myeloid, Acute",,"The median survival time in adult patients over 60 with AML diagnosis|Overall Survival|To describe the socio-demographic and clinical characteristics of patients|To describe the disease characteristics|To describe the front-line treatment strategies|To assess the HRQOL evolution over time|To evaluate the impact on early mortality|To evaluate the prognostic impact on overall survival|To explore the scales scores to be used as potential predictors tools of treatment tolerability in patients with newly diagnosed AML.","Celgene","All","60 Years and older   (Adult, Older Adult)",,"107","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NDS-AML-001|U1111-1207-6661","February 28, 2018","February 28, 2020","February 28, 2020","February 16, 2018",,"January 31, 2019","Hospital de Jerez, Jerez, Andalucía/Cádiz, Spain|Hospital Virgen de las Nieves, Granada, Andalucía/Granada, Spain|Hospital Carlos Haya, Málaga, Andalucía/Málaga, Spain|Hospital Virgen del Rocio, Sevilla, Andalucía/Sevilla, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Andalucía/Sevilla, Spain|Hospital Univ. Reina Sofia, Córdoba, Andalucía, Spain|Hospital Universitario Virgen Macarena, Sevilla, Andalucía, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Cabueñes, Gijón, Asturias, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Son Espases, Palma de Mallorca, Baleares, Spain|Hospital Univ. de Guadalajara, Guadalajara, Castilla-La Mancha, Spain|Hospital Universitario de Burgos, Burgos, Castilla-León, Spain|Hospital de León, León, Castilla-León, Spain|Complejo Hospitalario de Salamanca, Salamanca, Castilla-León, Spain|Clínico de Valladolid, Valladolid, Castilla-León, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital de Granollers, Granollers, Barcelona, Cataluña, Spain|Hospital Arnau de Vilanova Lleida, Lleida, Cataluña, Spain|Hospital de Althaia (H. Sant Juan de Deu de Manresa), Manresa, Barcelona, Cataluña, Spain|Hospital Infanta leonor, Madrid, Comunidad Madrid, Spain|Hospital General Alicante, Alicante, Comunidad Valenciana, Spain|Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain|Hospital Infanta Cristina, Badajoz, Extremadura, Spain|Complejo Hospitalario Universitario de A Coruña, La Coruña, Galicia, Spain|Complejo Hospitalario Universitario de Orense, Ourense, Galicia, Spain|Hospital Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain|Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Islas Canarias, Spain|Hospital Universitario Canarias, Santa Cruz de Tenerife, Islas Canarias, Spain|Hospital Santa Lucía, Cartagena, Murcia, Murcia, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Navarra, Spain|Hospital de Basurto, Bilbao, Vizcaya, País Vasco, Spain|Hospital Universitario de Donostia, San Sebastián, Guipúzcoa, País Vasco, Spain|Hospital de Txagorritxu, Vitoria, País Vasco, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital de Getafe, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03435341"
78,"NCT03374085","A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: CC-92480|Drug: Dexamethasone","Adverse Events (AEs)|Pharmacokinetics- AUC|Pharmacokinetics- Cmax|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Maximum tolerated dose (MTD)|Overall response rate (ORR)|Time to response (TTR)|Duration of response (DOR)|Progression free survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-92480-MM-001|U1111-1205-3650|2017-001236-19","February 6, 2018","January 1, 2020","March 1, 2020","December 15, 2017",,"March 14, 2019","City of Hope Cancer Center, Duarte, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Emory Clinic, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Rigshospitalet University Hospital, Copenhagen, Denmark|Helsinki University Hospital, Helsinki, Finland|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital 12 de Octobre, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing, London, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03374085"
79,"NCT03363815","A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects",,"Completed","No Results Available","Heathy Volunteer","Drug: CC-90001|Drug: Omeprazole|Drug: Midazolam|Drug: Warfarin|Dietary Supplement: Vitamin K|Drug: Rosuvastatin|Drug: Metformin|Drug: Digoxin|Drug: Nintedanib","Pharmacokinetic- Cmax|Pharmacokinetic- AUC0-t|Adverse Events (AEs)","Celgene","All","18 Years to 64 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90001-CP-004|U1111-1205-5329","December 4, 2017","July 29, 2018","July 29, 2018","December 6, 2017",,"January 25, 2019","Covance Clinical Research Unit, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03363815"
80,"NCT03361748","Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)","KarMMa","Recruiting","No Results Available","Multiple Myeloma","Biological: bb2121","Overall Response Rate (ORR)|Complete Response (CR) Rate|Time to Response|Duration of Response|Progression-free Survival (PFS)|Time to Progression (TTP)|Overall Survival (OS)|Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC|Immunogenicity|Minimal Residual Disease (MRD)|Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)|Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire|Subject-reported outcomes as measured by EORTC-QLQ-MY20","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BB2121-MM-001|U1111-1202-5554|2017-002245-29","December 13, 2017","November 1, 2024","November 1, 2024","December 5, 2017",,"September 11, 2019","University of California - San Francisco, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mt. Sinai Medical Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Universitaire Ziekenhuizen Leuven, Leuven, Flemish Brabant, Belgium|Princess Margaret Cancer Centre, Toronto, Canada|Centre Hospitalier Regional Universitaire de Lille-Hopital Calude Huriez Service des Maladies du Sang, Lille, Hauts-de-France, France|Centre Hospitalier Universitaire de Nantes - Hotel Dieu, Nantes, Pays De La Loire, France|Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato, Heidelberg, Baden-Württemberg, Germany|University of Tübingen, Tübingen, Baden-Württemberg, Germany|Universitatsklinikum Würzburg, Würzburg, Bavaria, Germany|Azienda Ospedaliero Universitaria Di Bologna Policlinico, Bologna, Emilia-Romagna, Italy|Ospedali Riuniti di Bergamo, Bergamo, Italy|Tokai University Hospital, Isehara, Kanagawa, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Japan Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku City, Japan|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Navarre, Spain",,"https://ClinicalTrials.gov/show/NCT03361748"
81,"NCT03342404","A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia","BEYOND","Active, not recruiting","No Results Available","Thalassemia","Drug: Luspatercept|Other: Placebo|Other: Best Supportive Care (BSC)","Proportion of subjects who have an increase from baseline ≥1.0 g/dl in mean of hemoglobin values over a continuous 12-week interval Week 13 to Week 24 in the absence of transfusions|Mean change from baseline in non-transfusion dependent β- thalassemia-patient reported outcome (NTDT-PRO) Tiredness and Weakness (TW) domain score over a continuous 12-week interval from Week 13 to Week 24|Mean change from baseline in hemoglobin values over a continuous 12-week interval from Week 13 to Week 24|Proportion of subjects who have an increase from baseline ≥1.0|Mean change from baseline in mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score over a continuous 12-week interval from Week 13 to Week 24|Mean change from baseline in mean NTDT-PRO total score over a continuous 12-week interval from Week 13 to Week 24|Mean change from baseline in hemoglobin values over a continuous 12-week interval from Week 37 to Week 48 in the absence of transfusions|Mean change from baseline in mean FACIT-F total score over a continuous 12-week interval from Week 37 to Week 48|Mean change from baseline in mean NTDT-PRO TW domain total score over a continuous 12-week interval from Week 37 to Week 48|Mean change from baseline in mean NTDT-PRO total score over a continuous 12-week interval from Week 37 to Week 48|Proportion of subjects with an increase from baseline ≥ 3 in mean FACIT-F score over a continuous 12-week interval from Week 13 to Week 24|Proportion of subjects with an increase from baseline ≥ 3 in mean FACIT-F score over a continuous 12-week interval from Week 37 to Week 48|Mean change from baseline in Medical Outcomes Study 36-Item Short Form (SF-36) at Week 24 and Week 48|Proportion of subjects with improvement of iron overload at Week 24 and Week 48, as measured by Iron Chelator Treatments use|Mean change from baseline in serum ferritin at Week 24 and Week 48|Mean change from baseline in LIC at Week 24 and Week 48|Proportion of subjects who are transfusion-free over 48 weeks|Duration of the mean hemoglobin increase from baseline ≥1.0 g/dL|Mean change from baseline in the 6-minute walk test (6MWT) distance at Week 24 and Week 48|Proportion of subjects who have an increase from baseline ≥1.5 g/dL in mean of hemoglobin values over a continuous 12-week interval from Week 13 to Week 24 in the absence of transfusions|Adverse Events (AEs)|Pharmacokinetic - AUC|Pharmacokinetic - Cmax|Proportion of subjects with improvement of iron overload at Week 24 and Week 48, as measured via Leaver Iron Concentration (LIC) by MRI","Celgene|Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACE-536-B-THAL-002|U1111-1202-7068|2015-003225-33","February 1, 2018","November 20, 2020","January 22, 2021","November 17, 2017",,"November 11, 2019","Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Laiko General Hospital of Athens, Athens, Greece|Aghia Sofia Children's Hospital, Athens, Greece|Universita degli Studi di Cagliari - ASL8, Cagliari, Italy|Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite, Genoa, Italy|Fondazione Ca Granda IRCCS Ospedale Maggiore, Milan, Italy|Seconda Universita Degli Studi Di Napoli, Naples, Italy|AORN A Cardarelli, Napoli, Italy|Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano, Italy|Chronic Care Center, Hazmieh, Lebanon|Siriraj Hospital Mahidol University, Bangkok, Thailand|University College London Hospitals NHS Foundation Trust - University College Hospital, London Bloomsbury, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03342404"
82,"NCT03340662","Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122",,"Completed","No Results Available","Healthy Volunteer","Drug: CC-122|Drug: Itraconazole|Drug: Fluvoxamine|Drug: Rifampin","Pharmacokinetic- Cmax|Pharmacokinetic- AUC 0-∞|Adverse Events (AEs)","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-CP-006|U1111-1203-1818","November 9, 2017","January 27, 2018","January 27, 2018","November 13, 2017",,"January 16, 2019","PPD Phase 1 Clinic, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03340662"
83,"NCT03337022","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis",,"Recruiting","No Results Available","Psoriasis","Drug: CC-90006|Other: Placebo","Adverse Events (AEs)|Pharmacokinetics: Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC 0-t|Pharmacokinetics - AUC 0-∞|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Pharmacokinetics - Rac [AUCτ]|Fraction of subjects with Anti-drug antibody (ADA)","Celgene","All","18 Years to 60 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-90006-CP-002","December 21, 2017","April 26, 2019","August 30, 2019","November 8, 2017",,"May 27, 2019","Anaheim Clinical Trials, LLC, Anaheim, California, United States|TKL Research, Fair Lawn, New Jersey, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Innovaderm Research, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03337022"
84,"NCT03324503","A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis",,"Recruiting","No Results Available","Sarcoidosis, Pulmonary","Drug: Glucocorticoid (prednisone or prednisolone)","Change from baseline in high-resolution computed tomography (HRCT)","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NDS-CP-001|U1111-1201-4544|2017-002001-34","December 8, 2017","November 15, 2019","November 15, 2019","October 27, 2017",,"June 24, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University School of Medicine - Baltimore, Baltimore, Maryland, United States|Pulmonary and Critical Care Medicine-Washington University School of Medicine, Saint Louis, Missouri, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Catharina Ziekenhuis, Eindhoven, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|Onderzoekscentrum longziekten Zutphen, Zutphen, Netherlands|University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom|Richmond Pharmacology, London, United Kingdom|Imperial College London - Hammersmith Hospital Campus, London, United Kingdom|University Hospital of South Manchester NHS Foundation Trust -Wythenshawe Hospital - North West Lung, Manchester, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom|Southmead Hospital, Westbury-on-Trym/ Bristol, United Kingdom|The Royal Wolverhampton Hospitals NHS Trust - Newcross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03324503"
85,"NCT03310619","A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)","PLATFORM","Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Biological: JCAR017|Drug: Durvalumab|Drug: CC-122","Dose-limiting toxicity (DLT) rates|Complete Response Rate|Adverse Events (AEs)|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate (ORR)|Duration of response (DOR)|Event-free survival (EFS)|Pharmacokinetic (PK)- Cmax|Pharmacokinetic (PK)- Tmax|Pharmacokinetic (PK)- AUC|Health-related quality of life (HRQoL)|Quality of Life C30 questionnaire (EORTC-QLQ-C30)|European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L)","Celgene|Juno Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR017-BCM-002|U1111-1201-2046","November 28, 2017","March 4, 2022","March 4, 2022","October 16, 2017",,"October 30, 2018","City of Hope National Medical Center, Duarte, California, United States|Northwestern University School of Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03310619"
86,"NCT03294603","Radiolabeled Study of CC-220 in Healthy Male Subjects",,"Completed","No Results Available","Healthy Volunteer","Drug: CC-220|Radiation: [14C]","Pharmacokinetics -Total [14C]-Radioactivity (RA)|Pharmacokinetics - Cumulative excretion of total [14C]-RA|Pharmacokinetics - Total [14C]-RA whole blood-to-plasma|Pharmacokinetics - metabolite profiling/characterization|Pharmacokinetics -Cmax|Pharmacokinetics -AUC|Pharmacokinetics -Tmax|Pharmacokinetics -t1/2|Adverse Events (AEs)","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-220-CP-006|U1111-1202-3955","September 11, 2017","October 16, 2017","October 16, 2017","September 27, 2017",,"October 25, 2017","Covance Clinical Research Unit, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03294603"
87,"NCT03290443","A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.",,"Recruiting","No Results Available","Hepatic Impairment","Drug: Enasidenib","Pharmacokinetics - Cmax|Pharmacokinetics - AUC0-∞|Pharmacokinetics - AUC0-t|Pharmacokinetics - tmax|Adverse Events (AEs)","Celgene","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90007-CP-003|U1111-1202-3186","September 21, 2017","November 30, 2018","November 30, 2018","September 21, 2017",,"October 30, 2018","DaVita Clinical Research, Lakewood, Colorado, United States|Clinical Pharmacology of Miami, LLC, Miami, Florida, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|New Orleans Center of Clinical Research, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03290443"
88,"NCT03288974","Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea","Pomalyst PMS","Recruiting","No Results Available","Multiple Myeloma","Drug: POMALYST® (Pomalidomide)","Adverse events|Overall response rate","Celgene","All","19 Years and older   (Adult, Older Adult)",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIPMS-POM-KR-001|U1111-1201-1712","December 28, 2017","June 8, 2023","June 8, 2023","September 20, 2017",,"March 13, 2019","Korea University Ansan Hospital, Ansan, Korea, Republic of|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Soonchunhyang University Hospital, Bucheon, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Medical, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, DaeJeon, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, JinJu, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The catholic University of Korea Seoul St. Maty's, Seoul, Korea, Republic of|Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Ewha Womans University Medical, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ajou Unversity Medical Center, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of|Pusan National University Yangsan, Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03288974"
89,"NCT03284879","Post-Marketing Surveillance Study of OTEZLA",,"Recruiting","No Results Available","Psoriasis",,"Adverse Events (AEs)|General Improvement Rating|General health assessment on VAS|Changes in physician general assessment|Percentage of patients with Dermatology Life Quality Index (DLQI)|Change from baseline activity for arthritis","Celgene","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CC-10004-PSOR-018","September 5, 2017","August 31, 2021","August 31, 2021","September 15, 2017",,"November 21, 2018","Tugi dermatology clinic, Kitakyushu, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03284879"
90,"NCT03283202","Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",,"Active, not recruiting","No Results Available","Diffuse B-Cell Lymphoma","Drug: Avadomide (CC-122)|Drug: Rituximab|Drug: Cyclophosphamide 750mg/m2 by IV infusion|Drug: Vincristine|Drug: Prednisone","Maximum Tolerated Dose/Maximum Administered Dose (MTD/MAD) (Phase 1)|Complete Response Rate (CRR); Percentage of participants experiencing positron emission tomography (PET)-negative complete response (CR) (Phase 2)|Overall Response Rate (ORR); Percentage of participants who achieve a PR or CR according to the Lugano criteria.|ORR by Predictive Gene Signature|Progression-free Survival (PFS)|Event-free Survival (EFS)|Overall Survival (OS)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-DLBCL-002|U1111-1201-1994|2016-003778-42","October 4, 2017","July 30, 2019","January 15, 2021","September 14, 2017",,"September 4, 2019","George Washington University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Washington University, Saint Louis, Missouri, United States|UZ Gent, Gent, Belgium|University Hospital Gasthuisberg, Lueven, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03283202"
91,"NCT03257631","A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors",,"Active, not recruiting","No Results Available","Central Nervous System Neoplasms|Medulloblastoma","Drug: Pomalidomide","Objective Response (OR), Long-term Stable Disease (SD) Rate (ORSDR)|Objective Response Rate (ORR)|Long-term stable disease rate|Duration of response|Progression-free survival|Overall Survival|Adverse Events (AEs)","Celgene","All","1 Year to 21 Years   (Child, Adult)","Phase 2","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-BRN-001|U1111-1199-3348|2016-002903-25","August 22, 2017","November 23, 2018","March 18, 2023","August 22, 2017",,"April 1, 2019","Stanford University Cancer Center, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|National Cancer Institute, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Baylor College of Medicine, Houston, Texas, United States|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, France|Institut Curie, Paris, France|Hopital des Enfants, Toulouse, France|CHU Nancy Hematology, Vandoeuvre les Nancy, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif Cedex, France|Istituto G. Gaslini Ospedale Pediatrico IRCCS, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Ospedale Bambin Gesu, Roma, Italy|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|Leeds General Infirmary, Leeds, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|The Royal Marsden Hospital, Sutton-Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03257631"
92,"NCT03220347","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Neoplasms","Drug: CC-90010","Adverse Events (AEs)|Dose Limiting Toxicities (DLTs)|Maximum tolerated dose (MTD)|Clinical benefit rate (CBR)|Objective response rate (ORR)|Duration of Response Rate|Duration of stable disease|Progression-free survival (PFS)|Overall survival|Pharmacokinetic- Cmax|Pharmacokinetic- AUC|Pharmacokinetic- Tmax|Pharmacokinetic- t1/2|Apparent Clearance|Apparent Volume of Distribution","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","115","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90010-ST-001|U1111-1194-8570|2015-004371-79","July 24, 2017","August 23, 2021","August 23, 2023","July 18, 2017",,"October 22, 2019","Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Gustave Roussy - Cancer Campus, Villejuif, France|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03220347"
93,"NCT03194542","A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence",,"Recruiting","No Results Available","Primary Myelofibrosis|Anemia","Drug: Luspatercept","Anemia response as it relates to hemoglobin (Hgb)increase|Anemia response as it relates to increased red blood cell (RBC)- transfusion independence|Time to anemia response|Duration of anemia response|Frequency of RBC transfusions|Frequency of RBC transfusion dependence|Proportion of subjects who achieve ≥ 50% reduction in fatigue symptom as measured by the Myeloproliferative Neoplasm Symptom Assessment Form, Total Symptom Score (MPN-SAF TSS)|The proportion of subjects who achieve ≥ 50% reduction in total symptom score (TSS)|Health-related quality of life (HRQoL)|Functional Assessment of Cancer Therapy - Anemia (FACT-An)|EQ-5D-5L questionnaires|Adverse Events (AEs)|Frequency of Antidrug Antibodies (ADA)|Pharmacokinetic - AUC|Pharmacokinetic - Cmax|Changes in Hemoglobin|Mean hemoglobin increase","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-MF-001|2017-000322-35|U1111-1197-1202","November 15, 2017","June 16, 2021","November 22, 2025","June 21, 2017",,"November 6, 2019","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Stanford Cancer Center, Stanford, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Mid Florida Hematology and Oncology Centers, PA, Orange City, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Mount Sinai Medical Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Centre Hospitalier de Lens, Lens Cedex, France|Hopital Saint Louis, Paris, France|Institut Gustave Roussy, Villejuif, France|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Ospedale di Circolo di Varese, Varese, Italy|Belfast Health and Social Care Trust, Belfast Northern Ireland, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|University of Oxford, Headington, Oxford, United Kingdom|Guys Hospital, London, United Kingdom|Imperial College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03194542"
94,"NCT03161483","A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus",,"Active, not recruiting","No Results Available","Lupus Erythematosus, Systemic","Drug: CC-220|Other: Placebo","Proportion of subjects who achieve SRI (4) response- Week 24|Proportion of subjects with SLEDAI 2K score improvement of ≥ 4 points from Baseline|Proportion of subjects with a ≥ 50% reduction in Cutaneous Lupus Area and Severity Index (CLASI) activity score from baseline, in subjects with Baseline CLASI activity score ≥ 10|Proportion of subjects with no new organ system affected as defined by 1 or more BILAG A or new 2 or more BILAG B items compared to Baseline using BILAG 2004 Index|Percentage of subjects with no worsening (increase of <0.30 points from Baseline) in Physician's Global Assessment (PGA) compared to Baseline|Mean change from Baseline in swollen joint count in subjects with ≥ 2 swollen joints at Baseline|Mean change from Baseline in tender joint count in subjects with ≥ 2 tender joints at Baseline|Mean change from Baseline in PGA score|Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score|Corticosteroid Reduction|Adverse Event(s)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","289","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-220-SLE-002|U1111-1195-7804","July 6, 2017","January 22, 2020","October 27, 2021","May 19, 2017",,"August 29, 2019","Clinical and Translational Research Center of Alabama, PC, Tuscaloosa, Alabama, United States|AZ Arthritis and Rheum Rsch, PLLC, Mesa, Arizona, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|UCLA Division of Rheumatology, Los Angeles, California, United States|Desert Medical Advances, Palm Desert, California, United States|C Michael Neuwelt M D, San Leandro, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Centre For Rheumatology, Immun. And Arthritis, Fort Lauderdale, Florida, United States|University of Florida College of Medicine, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States|Bay Care Medical Group, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Piedmont Hospital - Atlanta, Atlanta, Georgia, United States|Jefrey Lieberman, MD, PC, Decatur, Georgia, United States|North Georgia Rheumatology, Lawrenceville, Georgia, United States|Clinic of Robert Hozman, Skokie, Illinois, United States|University of Maryland - School of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Advanced Rheumatology, Lansing, Michigan, United States|Great Lakes Center of Rheumatology, Lansing, Michigan, United States|Arthritis and Osteoporosis Associates of New Mexico, Las Cruces, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States|NYU Langone Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|DJL Clinical Research, Charlotte, North Carolina, United States|Shanahan Rheumatology and Immunotherapy, Raleigh, North Carolina, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|St. Anthony's Medical Center, Oklahoma City, Oklahoma, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Department of Dermatology, Philadelphia, Pennsylvania, United States|University of Pittsburgh UPMC Lupus Center of Excellence, Pittsburgh, Pennsylvania, United States|Advanced Rheumatology & Arthritis Research Center, PC, Wexford, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Pioneer Research Solutions, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Organización Médica de Investigación, Buenos Aires, Argentina|Hospital General de Agudos Dr. Jose Maria Ramos Mejia, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Buenos Aires, Argentina|Consultora Integral de Salud Centro Médico Privado, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|CER Instituto Mèdico, Quilmes, Argentina|Instituto de Investigaciones Clinicas de Quilmes, Quilmes, Argentina|Centro Medico Privado de Reumatologia, San Miguel de Tucumán, Argentina|Hopital Erasme, Brussels, Belgium|Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg, Leuven, Belgium|CHU de Liege, Liège, Belgium|Centro Internacional de Pesquisas, Goiânia, Goiás, Brazil|Centro de Estudos em Terapias Inovadoras LTDA, Curitiba, Paraná, Brazil|LMK Servicos Medicos S/S, Porto Alegre, Rio Grande Do Sul, Brazil|State University of Campinas UNICAMP, Campinas, São Paulo, Brazil|Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Centro de Imunoterapia de Ipanema (CITIPA), Rio de Janeiro, Brazil|The University of Calgary, Calgary, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|MAC Research Incorporated, Hamilton, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|CHUL du CHU de Quebec, Quebec, Canada|Clinique de Rhumatologie Du Centre Du Quebec, Quebec, Canada|IPS Centro Integral de Reumatologia del Caribe Circaribe S.A.S., Barranquilla, Colombia|Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S. - Cireem S.A.S, Bogota, Colombia|Idearg S.A.S., Bogota, Colombia|Medicity S.A.S., Bucaramanga, Colombia|Servimed S.A.S., Bucaramanga, Colombia|Preventive Care, Chia, Colombia|Reumalab - Centro Integral de Reumatologia, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|CHRU de Lille France, Lille Cedex, France|Assistance Publique - Hopitaux de Paris - Hopital Universitaire Pitie Salpetriere, Paris, France|CHU Hautepierre, Strasbourg, France|Universitatsklinikum Schleswig-Holstein, Kiel, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Qualiclinic kft, Budapest, Hungary|Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet, Budapest, Hungary|Bekes Megyei Kozponti Korhaz, Gyula, Hungary|ASST Spedali Civili P.O. di Brescia, Brescia, Italy|University of Ferrara, Azienda Ospedaliera-Universitaria S.Anna, Ferrara, Italy|Azienda Ospedaliero - Universitaria di Cagliari, Monserrato, Italy|Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Baja California, Mexico|Biológicos Especializados S.A. de C.V., Mexico, Distrito Federal, Mexico|Clinica Integral de Osteoporosis y Artitis Reumatoide CLINOSAR, Mexico, Distrito Federal, Mexico|Centro de Investigación y Tratamiento Reumatológico, Mexico, Distrito Federal, Mexico|Centro Integral en Reumatología, S.A. de C.V., Guadalajara, Jalisco, Mexico|Centro de Alta Especialidad en Reumatología e Investigación del Potosí S.C., San Luis Potosi, San Luis Potosí, Mexico|Unidad de Atencion Medica e Investigacion en Salud, S.C., Merida, Yucatán, Mexico|Hospital Angeles Lindavista, D.f, Df, Mexico|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Samodzielny Publiczny Zespól Opieki Zdrowotnej w Koscianie Szpital im. Teodora Dunina, Koscian, Poland|Centrum Medyczne Plejady, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Reumatologii i Ukladowych Chorob Tkanki Laczne, Lublin, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.o., Wroclaw, Poland|City Clinical Hospital, Kazan, Russian Federation|Kemerovo State Medical Academy, Kemerovo, Russian Federation|Institution of the Russian Academy of Medical Sciences Research Institute of Rheumatology of the Ru, Moscow, Russian Federation|Orenburg State Medical Academy, Orenburg, Russian Federation|Saint Petersburg Research Institute for Emergency Medical Care, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|State Higher Educational Institution, St. Petersburg, Russian Federation|BioMed, LLC., Vladimir, Russian Federation|Voronezh Regional Clinical Hopsital #1, Voronezh State Medical Academy, Voronezh, Russian Federation|Institute of Rheumatology Belgrade, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Institute Niska Banja, Niska Banja, Serbia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital Universitario Araba - Txagorritxu, Vitoria-Gasteiz, Spain",,"https://ClinicalTrials.gov/show/NCT03161483"
95,"NCT03142191","A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis",,"Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis|Fibrosis|Idiopathic Interstitial Pneumonias|Pathologic Processes|Lung Diseases, Interstitial|Lung Diseases|Respiratory Tract Diseases","Drug: CC-90001|Other: Placebo","Percentage point change in % predicted Forced vital capacity (FVC)|Absolute change and rate of decline in FVC|6-minute Walk Test (6MWT) with Borg Scale|Disease Progression|Quality of Life - Saint George's Respiratory|Quality of life- University of California San Diego Shortness of Breath Questionnaire (UCSD- SOBQ)|Adverse Events (AEs)|Borg Scale","Celgene","All","40 Years and older   (Adult, Older Adult)","Phase 2","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-90001-IPF-001|2016-003473-17|U1111-1192-8549","July 26, 2017","June 30, 2021","January 26, 2023","May 5, 2017",,"October 11, 2019","Cedars Sinai Medical Center Rheumatology, Los Angeles, California, United States|University of California Davis Health System, Sacramento, California, United States|Stanford University Pulmonary and Critical Care Clinic, Stanford, California, United States|University of Miami and Sylvester Cancer Center, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|The Lung and Research Center, LLC, Chesterfield, Missouri, United States|Mt. Sinai School of Medicine, New York, New York, United States|Duke University Health System - Duke Pulmonary Transplant Clinic, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Pulmonary & Sleep Center of Oklahoma, Tulsa, Oklahoma, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Utah Health Care, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Mater Medical Centre, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Institute for Respiratory Health Inc, Nedlands, Western Australia, Australia|St Vincent Hospital - Sydney, Darlinghurst, Australia|Clinica de Pneumologia S/S, Goiania, Goiás, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF), Rio de Janeiro, Brazil|Faculdade de Medicina do ABC, Santo Andre, Brazil|Incor - Instituto do Coracao HCFMUSP, Sao Paulo, Brazil|Kelowna & Respiratory Allergy Clinic, Kelowna, British Columbia, Canada|The Lung Centre Respiratory Clinic - Vancouver General Hospital Location, Vancouver, British Columbia, Canada|Dr. Syed Anees Medicine Professional Corporation, Windsor, Ontario, Canada|Centro Especializado en Enfermedades Pulmonares, Bogotá, Colombia|Centro Medico Imbanaco, Cali, Colombia|Helios Klinikum Emil Von Behring, Berlin, Germany|Ruhrlandklinik University Hospital, Essen, Germany|Pneumologische Klinik - Waldhof Elgershausen, Greifenstein, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Waldburg-Zeil Kliniken -Fachkliniken Wangen, Wangen Im Allgaeu, Germany|Democritus University of Thrace, Alexandroupolis, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|University General Hospital Attikon, Haidari, Greece|General Hospital of Heraklion Benizeleio Pananeio, Heraklion, Greece|University of Crete - University General Hospital of Heraklion, Iraklio, Greece|Spitalul Clinic de Pneumoftiziologie Leon Daniello Cluj Napoca, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Timisoara, Timisoara, Romania|Ural research Institute of Phthisiopulmonology, Ekaterinburg, Russian Federation|Ural State Medical Academy - Medical Association Novaya Bolnitsa, Ekaterinburg, Russian Federation|City clinical hospital No 9, Izhevsk, Russian Federation|Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascul, Kemerovo, Russian Federation|TSBIH Territorial Clinical Hospital, Krasnoyarsk, Russian Federation|Russian Academy of Medical Sciences RAMS - Central Scientific Research Institute of Tuberculosis CTR, Moscow, Russian Federation|Federal Medico-Biological Agency FMBA - Federal Research Clinical Center FGUZ Clinical Hospital No., Moscow, Russian Federation|Nizhny Novgorod Research Institute of Hygiene and Occupational Pathology, Nizhny Novgorod, Russian Federation|Republican Hospital, Petrozavodsk, Russian Federation|FSBHI Clincial Research Institute of Phithisioplulmonoloyg, Saint Petersburg, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation|Saratov Regional Clinical Hospital, Saratov, Russian Federation|Vvedenskaya Hospital, St. Petersburg, Russian Federation|Saint-Petersburg State Institution of Healthcare, St. Petersburg, Russian Federation|SAIH of Yaroslavl region Clinical Hospital for Emergency Medical Care n.a. N.V.Solovyev, Yaroslavl, Russian Federation|Buddhist Dalin Tzu Chi General Hospital, Dalin, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung City, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Ege Universitesi Tip Fakultesi Hastanesi Ege University Medical Faculty Hospital, Bornova, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Istanbul Universitesi - Cerrahpasa Tip Fakultesi Cerrahpasa Medical Faculty, Istanbul, Turkey|Izmir Dr.Suat Seren Chest Diseases Hospital, Izmir, Turkey|Communal Institution Dnipropetrovsk City Clinical Hospital #6 of Dnipropetrovsk Regional Council, Dnipro, Ukraine|Regional Phthisiopulmonological Center, Ivano-Frankivsk, Ukraine|Kharkiv City Clinical Hospital #13, Kharkiv, Ukraine|CI of Healthcare RCH - Center of Medical Emergency and Accident Medicine, Kharkiv, Ukraine|State Institution National Scientific Center of Radiation Medicine of NAMS of Ukraine, Kyiv, Ukraine|SI F.H.Yanovskyi National Institute of Phthisiatry and Pulmonology of Academy of Medical Sciences, Kyiv, Ukraine|Birmingham Chest Clinic, Birmingham, United Kingdom|Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital, Cottingham, United Kingdom|Hinchingbrooke Hospital, Huntingdon, United Kingdom|The Leeds Teaching Hospitals NHS Trust - St James's University Hospital, Leeds, United Kingdom|University Hospitals of Leicester NHS Trust - Glenfield Hospital - Institute for Lung Health ILH, Leicester, United Kingdom|Aintree University Hospital, Liverpool (Walton Centre), United Kingdom|University Hospital Llandough, Llandough, United Kingdom|University College London Hospitals, London, United Kingdom|Royal Victoria Infirmary, Newcastle, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|The University of Nottingham - Nottingham Respiratory Research Unit NRRU, Nottingham, United Kingdom|Salford Royal, Salford, United Kingdom|Southampton General Hospital, Southhampton, United Kingdom|Southmead Hospital, Westbury-on-Trym/ Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03142191"
96,"NCT03135509","A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: CC-220","PK - Cmax|PK - AUC0-t|Adverse Events (AEs)","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-220-CP-005|U1111-1195-6929","May 24, 2017","June 28, 2017","June 28, 2017","May 1, 2017",,"July 2, 2017","Quintiles Phase One Services, LLC, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03135509"
97,"NCT03123471","A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp","STYLE","Completed","Has Results","Psoriasis","Drug: Apremilast|Other: Placebo","Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline|Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 16|Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 16|Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch NRS Score by Visit in the Placebo-Controlled Phase|Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch NRS Score by Visit in the Placebo-Controlled Phase|Change From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Extension Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-SPSO-001|U1111-1194-1248","May 16, 2017","August 13, 2018","January 9, 2019","April 21, 2017","September 4, 2019","September 4, 2019","Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology, Rogers, Arkansas, United States|Tien Q. Nguyen MD Inc, Fountain Valley, California, United States|Dermatology Research Associates, Los Angeles, California, United States|San Luis Dermatology and Laser Clinic, San Luis Obispo, California, United States|University of Connecticut, Farmington, Connecticut, United States|Florida Academic Centers Research and Education, Coral Gables, Florida, United States|International Dermatology Research, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Dermatologic Surgery Specialists, P.C., Macon, Georgia, United States|MedaPhase INC, Newnan, Georgia, United States|The Indiana Clinical Trials Center, PC, Plainfield, Indiana, United States|DS Research, Louisville, Kentucky, United States|DS Research, Louisville, Kentucky, United States|Dermatology and Advanced Aesthetics, Lake Charles, Louisiana, United States|Lawrence Green, MD, LLC, Rockville, Maryland, United States|Central Dermatology, Saint Louis, Missouri, United States|Skin Specialists, PC, Omaha, Nebraska, United States|Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Forest Hills Dermatology Group, Forest Hills, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|Sadick Research Group, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Wright State Physicians, Fairborn, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Austin Dermatology Associates, Austin, Texas, United States|Modern Research Associates PLLC, Dallas, Texas, United States|Center for Clinical Studies, Webster, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Clinical Research Inc, Norfolk, Virginia, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Kirk Barber Research, Calgary, Alberta, Canada|Institute for Skin Advancement, Calgary, Alberta, Canada|Chih-Ho Hong Medical, Inc., Surrey, British Columbia, Canada|Enverus Medical Research, Surrey, British Columbia, Canada|Wiseman Dermatology Research Inc., Winnipeg, Manitoba, Canada|Lynderm Research, Markham, Ontario, Canada|North Bay Dermatology Center, North Bay, Ontario, Canada|Skin Center for Dermatology, Peterborough, Ontario, Canada|Centre For Dermatology and Cosmetic Surgery, Richmond Hill, Ontario, Canada|The Toronto Dermatology Centre, Toronto, Ontario, Canada|K. Papp Clinical Research, Waterloo, Ontario, Canada|XLR8 Medical Research, Windsor, Ontario, Canada|Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03123471/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03123471/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03123471"
98,"NCT03106324","A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Revlimid (lenalidomide)","Incidence of cardiovascular events|Incidence of renal impairment in NDMM patients|Incidence of infections in NDMM patients|Incidence of Second primary malignancy (SPM) in TNE NDMM patients treated with any first line regimen","Celgene","All","18 Years and older   (Adult, Older Adult)",,"888","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-5013-MM-034|U1111-1194-5810","March 31, 2017","March 31, 2025","March 31, 2025","April 10, 2017",,"November 18, 2019","Innsbruck University Hospital, Innsbruck, Austria|LKH Hochsteiermark, Leoben, Austria|University hospital St. Pölten, Polten, Austria|CHU Saint-Pierre, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|CHU-Charleroi, Bruxelles, Belgium|CHU-Charleroi, Charleroi, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge, Kortijk, Belgium|CHR Citadelle Liège, Liege, Belgium|Ziekehuis Oost Limburg, Limburg, Belgium|CHU Ambroise Pare, Mons, Belgium|AZ Nikolaas, Sint Niklass, Belgium|CHPLT Verviers, Verviers, Belgium|CHU du Mont-Godinne, Yvoir, Belgium|Aalborg University Hospital, Aalborg, Denmark|Odense Hospital, Odense, Denmark|Hôpital privé d'Antony - Ramsay Générale de Santé, Antony, France|CH Victor Dupouy, Argenteuil, France|Hospital Nord-Comte, Belfort, France|Polyclinique Bordeaux Nord Aquaitaine, Bordeaux, France|Hospital Prive Sevigne, Cesson-Sevigne, France|GHM Institut Daniel Hollard, Grenoble, France|Clinique Victor Hugo, Le Mans, France|CH de Libourne, Libourne, France|CH Mont de Marsan, Mont de Marsan, France|CHU de Nice, Nice, France|CH St Jean, Perpignan, France|Centre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord, Saint-Etienne, France|Hospital Prive de Villeneuve d'Ascq, Villeneuve d'Ascq, France|W8 Praxis für Onkologie, Aachen, Germany|Klinikum St. Marien Amberg, Amberg, Germany|Sozialstiftung Bamberg, Bamberg, Germany|Charité - Universitätsmedizin Berlin - Campus Charité Mitte, Berlin, Germany|Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Kliniken Berlin Köpenick, Berlin, Germany|HELIOS Klinikum Berlin Buch, Berlin, Germany|Gemeinschaftpraxis Pott/Tirier/Hannig, Bottrop, Germany|Medizinische Klinik II, DONAUISAR Klinikum Deggendorf, Akademisches Lehrkrankenhaus der Medizinischen Hochschule Hannover, Deggendorf, Germany|St. Bernward Krankenhaus GmbH, Hildesheim, Germany|Stadt. Krankenhaus Kiel, 2.med Klinik,, Kiel, Germany|Onkologie Koln, Koln, Germany|Dres. Neise & Lollert, Praxis für Hämatologie & Onkologie, Krefeld, Germany|MVZ Mitte - Onkologische Schwerpunktpraxis, Leipzig, Germany|Lübecker Onkologische Schwerpunktpraxis, Lubeck, Germany|Klinikum Magdeburg, Magdeburg, Germany|Internistische Facharztzentrum mit Dialyse, Memmingen, Germany|Onko-Log Mulheim Gbr, Mulheim, Germany|Medizinisches Zentrum für Hämatologie und Onkologie München MVZ GmbH, Munchen, Germany|Stauferklinikum, Mutlangen, Germany|Klinikum Nord, Klinik für Innere Medizin 5, Nurnberg, Germany|Onkologische Praxis Oldenburg, Oldenburg, Germany|Kreiskliniken Reutlingen, Reutlingen, Germany|Das Diak, Schwabisch Hall, Germany|Klinikum Sindelfingen, Med.Klinik I, Sindelfingen, Germany|Onkologicum Stuttgart, Stuttgart, Germany|Ueboroertliche Berugsausuebungsgemeinschaft, Troisdorf, Germany|Kliniken Villingen-Schwenningen, Villingen-Schwenningen, Germany|Lahn-Dill-Kliniken, Wetzlar, Germany|Hämatologie / Internistische Onkologie, Wiesbaden, Germany|Midlands Regional Hospital , Hematology/Oncology, Country Offaly, Ireland|Waterford Regional Hospital, Waterford, Waterford, Ireland|Ospedale di Ivrea, Chivasso, Corso Galileo Ferraris, 3 Chivasso, Italy|Ospedale Alessandria, Via Venezia, 16, 15121 Alessandria AL, Allessandria, Italy|Centro di Riferimento Oncologico di Aviano, Avianno, Italy|UO di Ematologia Osp. Mons Di Miccolis, Barletta, Italy|Istituto di Ematologia ed Ocnologia Medica ""Seràgnoli"" AUO Sant'Orsola - Bologna, Bologna, Italy|UO di Ematologia Osp. Perrino, Brindisi, Italy|Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Italy|""S.C. di Ematologia e Centro Trapianti di Cellule Staminali Emopoietiche, Cagliari, Italy|Dipartimento di Oncologia Medica e Chirurgica AORN S. Anna e S. Sebastiano, Caserta, Italy|AO Garibaldi Catania - Via Palermo 636, Catania, Italy|AO Garibaldi Catania, Catania, Italy|Ospedali a Cosenza, Cosenza, Italy|Ospedale Ivrea , Areas Medica, Ivrea, Italy|Ospedale dell'Angelo, Mestre, Italy|ASST Grande Ospedale Metropolitano Niguarda - Piazza Ospedale Maggiore, 3 -, Milano, Italy|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy|Opsedale di Bolzano, Milan, Italy|Ospedale Maggiore di Novara, Novara, Italy|UO Ematologia e Centro Trapianti di Midollo Osseo dell'Ospedale San Francesco di Nuoro, Nuoro, Italy|IRCCS Policlinico di Pavia, Pavia, Italy|UO di Ematologia Osp. S. Carlo - Potenza, Potenza, Italy|Servizio immunoematologia e medicina trasfusionale-ASP, Ragusa, Italy|S.C. Ematologia, Dip.to Oncologico e Tecnologie Avanzate, Reggio-Emilia, Italy|A.O Bianchi Melacrino Morelli - Presidio Riuniti, Regio Calabria, Italy|Ospedale Sant'Eugenio, Rome, Italy|Policlinico Gemelli Roma, Rome, Italy|UOSD Ematologia Complesso Opsedaliero-Ospedale S. Spirito e Nuovo Regina Margherita, Rome, Italy|Ospedale di Circolo, Fondazione Macchi, Varese, Italy|Ospdeale Policlinico Borgo Roma, Verona, Italy|Ospedale Belcolle Viterbo, Viterbo, Italy|Rode Kruis Hospital, Beverwijk, Netherlands|Nij Smellinghe, Drachten, Netherlands|Catharina Hospital, Hemato-Oncology, Eindhoven, Netherlands|Admiraal de Ruyter Hospital, Goes, Netherlands|Röpcke-Zweers Hospital, Hardenberg, Netherlands|Academic Hospital Maastricht, Maastricht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|VieCuri Medical Center, Venlo, Netherlands|Isala Hospital, Zwolle, Netherlands|Helse Førde HF sentralsjukehuset, Førde, Norway|Akershus universitetssykehus HF, Lørenskog, Norway|Hospital de Jerez, Cadiz, Spain|Hospital Santa Lucía, Cartagena, Spain|Hospital de Jaen, Jaen, Spain|IP HULA, Lugo, Spain|Hospital Universitario Quironsalud Madrid, Madrid, Spain|Hospital Universitario Central Asturias, Oviedo, Spain|Son Espases, Palma de Mallorca, Spain|Complejo Universitario Navarra, Pamplona, Spain|Hospital Manises, Valencia, Spain|Skåne University Hospital, Lund, Lund, Sweden|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|St Georges Hospital, London, United Kingdom|Norfolk and Norwich University Hospital, Norfolk, United Kingdom|Southend Hospital, Southend-on-Sea, United Kingdom|Royal Stoke Hospital, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03106324"
99,"NCT03106051","Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions","LAPIS-PsA","Active, not recruiting","No Results Available","Arthritis, Psoriatic",,"Percentage of patients with an improvement of ≥ 1 points on the Physician's Global Assessment (PGA) scale on visit 3 compared to baseline on the Physician's Global Assessment scale (PGA; scale from 0-4)|Percentage of patients with an improvement of ≥ 1 points on the Patient Global Assessment (PaGA) scale on visits 1 to 7 compared to baseline|Percentage of patients with an improvement of ≥ 1 points on the Physician's Global Assessment (PGA) scale on visits 1, 2, 4, 5, 6, 7 compared to baseline|Efficacy of the treatment with regard to rheumatic changes measured with Tender Joint Count (TJC) on visits 1 to 7 compared to baseline|Efficacy of the treatment with regard to rheumatic changes measured with Swollen Joint Count (SJC) on visits 1 to 7 compared to baseline|Efficacy of the treatment with regard to rheumatic changes measured with Visual Analog Scale (VAS) on visits 1 to 7 compared to baseline- Pain|Psoriatic arthritis Impact of Disease (PsAID) questionnaire on visits 1, 2, 3, 5 and 7 compared to baseline|Hannover Functional Ability Questionnaire (FFbH) on visits 1, 2, 3, 5 and 7 compared to baseline|Patient Preference Questionnaire (PPQ) on visits 3, 5 and 7|Assessment of psoriatic skin changes (Body Surface Area, BSA) on visits 1 to 7|Adverse Events (AEs)|Efficacy of the treatment with regard to rheumatic changes measured with Visual Analog Scale (VAS) on visits 1 to 7 compared to baseline- Enthesitis|Efficacy of the treatment with regard to rheumatic changes measured with Visual Analog Scale (VAS) on visits 1 to 7 compared to baseline- Joints","Celgene","All","18 Years and older   (Adult, Older Adult)",,"526","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSA-008","February 18, 2016","July 31, 2018","July 31, 2020","April 10, 2017",,"September 6, 2019","Rheumatology at Struenseehaus, Hamburg-Altona, Hamburg, Germany|Klinikum Stephansplatz, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03106051"
100,"NCT03098589","Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)",,"Recruiting","No Results Available","Lymphoma","Drug: Revlimid","Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"80","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-Celgene-JP-PMS-004","May 30, 2017","October 2, 2021","October 2, 2021","April 4, 2017",,"September 12, 2019","ASO KK Iizuka Hospital, Iizuka, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03098589"
101,"NCT03097016","A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment",,"Completed","No Results Available","Renal Insufficiency","Drug: CC-122","Pharmacokinetics - Tmax|Pharmacokinetics - Cmax|Pharmacokinetics - AUC0-t|Pharmacokinetics - AUC0-∞|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Pharmacokinetics - CLR|Pharmacokinetics - Ae|Adverse Events (AEs)","Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-CP-005","March 30, 2017","December 23, 2017","December 23, 2017","March 31, 2017",,"April 26, 2018","DaVita Clinical Research, Lakewood, Colorado, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03097016"
102,"NCT03097003","A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium","OTELO","Active, not recruiting","No Results Available","Psoriasis","Drug: Apremilast","Proportion of patients with Patient Benefit Index for skin diseases (standard version) (PBI-S) ≥ 1 at 6 months after apremilast initiation.|Characteristics of the patients treated with apremilast|Proportion of patients with PBI-S = 4 at 6 months after apremilast initiation|PBI-S outcome score after apremilast initiation|Proportion of patients having clear/no psoriasis based on Patient Global Assessment (PtGA) at 6 months after apremilast initiation|Change from baseline in the PtGA after apremilast initiation|Proportion of patients with Dermatology Life Quality Index (DLQI) ≤ 5 at 6 months after apremilast initiation.|Change from baseline in the DLQI score after apremilast initiation|Change from baseline in the psoriasis symptomatology|Change from baseline in the patient-reported treatment satisfaction (TSQM-9)|Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 50 or PASI 75 at 6 months after apremilast initiation|Change from baseline in the disease activity scores in terms of Body Surface Area (BSA)|Change from baseline in the disease activity scores in terms of PASI|Mean duration of apremilast treatment in biologic-naïve patients and in patients having received a previous biological treatment|Rate of discontinuation of apremilast treatment within 6 months after initiation|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"124","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSOR-016|U1111-1194-1580","April 6, 2017","December 31, 2018","December 31, 2018","March 31, 2017",,"November 21, 2018","AZ Sint Jan, Brugge, Belgium|CHU St Pierre, Brussels, Belgium|CHU Brugmann (Victor Horta), Brussels, Belgium|Clin Univ de Bxl Hôpital Erasme, Brussels, Belgium|UZ Brussel, Brussels, Belgium|Cliniques Universitaires St-Luc, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|Private Practice Geel, Geel, Belgium|Private Practice Genk, Genk, Belgium|AZ Sint Lucas, Gent, Belgium|UZ Gent, Gent, Belgium|CHU UCL Mont-Godinne, Godinne, Belgium|Clinique André Renard d'Herstal, Herstal, Belgium|Private Practice Lede, Lede, Belgium|UZ Leuven Sint Rafael, Leuven, Belgium|CHU Sart-Tilman, Liège, Belgium|GHdC - site IMTR, Loverval, Belgium|Dermatologie Maldegem, Malgegem, Belgium|Private Practice Mons, Mons, Belgium|Private Practice Namur, Namur, Belgium|Ste Elisabeth - Namur, Namur, Belgium|CH Bois Abbaye-Hesbaye, Seraing, Belgium",,"https://ClinicalTrials.gov/show/NCT03097003"
103,"NCT03096990","A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium","APOLO","Active, not recruiting","No Results Available","Arthritis, Psoriatic","Drug: apremilast","Proportion of patients showing response assessed by improvement for at least 2 out of 4 measures which compose the Psoriatic Arthritis Response Criteria (PsARC) at 6 months after apremilast initiation with respect to baseline|Characteristics of the patients treated with apremilast|Change from baseline in measures which compose the PsARC (PtGA of disease activity, PGA of disease activity, 68-joint count for pain/tenderness, and 66-joint count for swelling)|Change from Baseline in Psoriatic Arthritis Impact Of Disease 12 [PsAID12] score|Change from Baseline in Health Assessment Questionnaire Disability Index [HAQ-DI] score|Change from Baseline in disease activity Numerical Rating Scale (NRS)|Change from Baseline in pain/itch Visual Analogue Scale [VAS]|Change from Baseline in body surface area (BSA)|Change from Baseline in Leeds Enthesitis Index (LEI)|Change from Baseline in Dactylitis score|Mean duration of treatment with apremilast in biologic-naïve patients and in patients having received a previous biological treatment.|Rate and reasons for discontinuation of apremilast treatment within 6 months after initiation|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSA-010|U1111-1194-0305","April 21, 2017","December 31, 2018","December 31, 2018","March 31, 2017",,"November 16, 2018","ASZ Aalst, Aalst, Belgium|Onze Lieve Vrouw Aalst, Aalst, Belgium|AZ Sint-Jan, Brugge, Belgium|CHU St Pierre (César de Paepe), Bruxelles, Belgium|Clinicque Saint-Jean Botanique, Bruxelles, Belgium|CHU Brugmann, Bruxelles, Belgium|Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium|Cliniques Universiatires Saint-Luc, Bruxelles, Belgium|Private Practice, Céroux-Mousty, Belgium|UZ Antwerpen, Edegem, Belgium|Reumacentrum Genk, Genk, Belgium|Reumaclinic, Genk, Belgium|UZ Gent, Gent, Belgium|GHdC Site Saint-Joseph, Gilly, Belgium|CHU UCL Mont-Godinne, Godinne, Belgium|Reuma Instituut, Hasselt, Belgium|AZ Zeno campus Knokke-Heist, Knokke-Heist, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Sart-Tilman, Liège, Belgium|Reumatologie Medizorg, Merksem, Belgium|ZNA Jan Palfijn, Merksem, Belgium|Private Practice, Uccle, Belgium",,"https://ClinicalTrials.gov/show/NCT03096990"
104,"NCT03003520","A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","Has Results","Lymphoma, Large B-Cell, Diffuse","Drug: Durvalumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Lenalidomide","Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy|Percentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)|Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density|Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage|Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells|Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data|Participants With Treatment Emergent Adverse Events (TEAE) (Database Cutoff Date: 02-Aug-2018)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-DLBCL-001|2015-005173-20","February 28, 2017","August 2, 2018","March 13, 2023","December 28, 2016","September 16, 2019","September 16, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Mid Ohio Oncology Hematology Inc, Columbus, Ohio, United States|Swedish Cancer Institute, Seattle, Washington, United States|Innsbruck Medical University Department of Internal Medicine, Innsbruck, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Medical University of Vienna Internalmedicine 1, Hematology, Vienna, Austria|Hanusch Krankenhaus, Wien, Austria|Aarhus Sygehus, Arhus C, Denmark|Rigshospitalet, Kobenhavns Universitet - Centre for Clinical Intervention Research - The Copenhagen, Copenhagen, Denmark|Odense Universitetshospital, Odense C, Denmark|(North Estonia Medical Centre) - Onkoloogia-ja Hematoloogiakliinik, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|University Hospital Birmingham, Birmingham, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03003520/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03003520/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03003520"
105,"NCT03001804","Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients",,"Recruiting","No Results Available","Multiple Myeloma",,"Number of patients receiving full dose of dexamethasone after 6 months|Number of patients with Deep Venous Thrombosis (VTE) prophylaxis|Over all response rate (ORR)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"56","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-5013-MM-037","July 31, 2017","December 30, 2021","December 31, 2021","December 23, 2016",,"January 30, 2019","Landeskrankenhaus Kirchdorf, Kirchdorf, Austria|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria|Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria|Krankenhaus der Barmherzigen Schwestern Ried Innere Medizin 1, Ried, Austria|Landeskrankenhaus Steyr - Innere Medizin, Steyr, Austria|Klinische Abteilung für Hämatologie und Hämostaseologie, Vienna, Austria|St. Josef Krankenhaus, Vienna, Austria|Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie, Vienna, Austria|Salzkammergut-Klinikum Vöcklabruck Abteilung Innere Medizin, Vöcklabruck, Austria|LKH Wiener Neustadt, Innere Medizin, Wr. Neustadt, Austria",,"https://ClinicalTrials.gov/show/NCT03001804"
106,"NCT03000452","A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","FUSION-MM-005","Completed","Has Results","Multiple Myeloma","Drug: DARATUMUMAB|Drug: DURVALUMAB","Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria|Time-to-Response (TTR)|Duration of Response (DOR)|Progression Free Survival|Overall Survival|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of Durvalumab|Area Under the Plasma Concentration-time Curve From Time 0 to Extrapolated to Infinity (AUC-inf) of Durvalumab|Maximum Observed Concentration (Cmax) Of Durvalumab|Time to Reach Maximum Concentration (Tmax) of Durvalumab|Terminal Half-Life (T1/2) of of Durvalumab|Apparent Total Clearance (CL/F) of of Durvalumab|Apparent Volume of Distribution (Vz/F) of Durvalumab|Participants With Treatment-Emergent Adverse Events (TEAEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-MM-005","March 14, 2017","September 18, 2017","December 4, 2017","December 22, 2016","October 16, 2018","October 16, 2018","City of Hope Cancer Center, Duarte, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Kansas Hospital, Westwood, Kansas, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hosp, Morristown, New Jersey, United States|OHSU, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|Universitaetsklinik Innsbruck, Innsbruck, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Medizinische Universitat Wien, Vienna, Austria|Alexandra General Hospital of Athens, Athens, Greece|UMCU Utrecht, Utrecht, Netherlands|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Dr. Pesset, Valencia, Spain|Falu lasarett, Falun SE, Sweden|Helsingborg hospital, Helsingborg, Sweden|Lund University Hosptial, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03000452/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03000452/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03000452"
107,"NCT02994381","A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults",,"Completed","No Results Available","Healthy Volunteers","Drug: RPC1063","Percentage of elimination of [14C]-RPC1063|Pharmacokinetic- amount of drug excreted|Pharmacokinetic- Cmax|Pharmacokinetic- Tmax|Pharmacokinetic- AUC0-last|Pharmacokinetic- AUC0-inf|Pharmacokinetic- λz|Pharmacokinetic- t1/2|Pharmacokinetic- CL/F|Pharmacokinetic- Vz/F|Pharmacokinetic- CLr|Adverse Events (AEs)","Celgene","Male","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC01-1909","October 2016","November 2016","November 2016","December 15, 2016",,"January 27, 2017","Quotient Clinical, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02994381"
108,"NCT02974322","A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease",,"Withdrawn","No Results Available","Crohn Disease","Drug: GED-0301|Drug: Placebo","Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and Crohn's Disease Activity Index (CDAI) (Rest of World)|Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and CDAI|Endoscopic improvement by the Simple Endoscopic Score for Crohn's Disease (SES-CD)|Clinical response defined by CDAI|Clinical remission defined by PCDAI|Adverse Events (AEs)|Pharmacokinetics (PK)- plasma concentration of GED-0301","Celgene","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GED-0301-CD-003","December 1, 2017","November 17, 2018","December 24, 2018","November 28, 2016",,"November 14, 2017","Dcr-Pi Pc, Litchfield Park, Arizona, United States|Arizona Digestive Health, Mesa, Arizona, United States|Arizona Digestive Health, Phoenix, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Arizona Digestive Health, Sun City, Arizona, United States|Gastroenterology Associates PA, Little Rock, Arkansas, United States|Valley View Internal Medicine, Garden Grove, California, United States|High Desert Gastroenterology, Inc., Lancaster, California, United States|University of Southern California Medical Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|Medical Associates Research Group Inc., San Diego, California, United States|University of California at San Francisco (PARENT), San Francisco, California, United States|HCP Clinical Research LLC, Torrance, California, United States|Ventura Clinical Trials, Ventura, California, United States|University Of Colorado, Aurora, Colorado, United States|Innovative Clinical Research, Lafayette, Colorado, United States|Connecticut Gastroenterology Institute, Bristol, Connecticut, United States|Medical Research Center of Connecticut LLC, Hamden, Connecticut, United States|Connecticut GI PC Research Division, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|Galiz Research LLC, Miami Springs, Florida, United States|University of Miami, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Cordova Research Institute, Miami, Florida, United States|Sanitas Research, Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|GCRM, Orlando, Florida, United States|Center For Digestive Health, Orlando, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|East Coast Institute for Research LLC, Saint Augustine, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Cleveland Clinic Florida Weston, Weston, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Atlanta Gastroenterology Specialists PC, Suwanee, Georgia, United States|Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|Health Science Research Center, LLC, Pratt, Kansas, United States|Heartland Research Associates LLC, Wichita, Kansas, United States|Via Christi Research a division of Via Christi Hospitals Wichita Inc, Wichita, Kansas, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Clinical Trials of SW Louisiana LLC, Lake Charles, Louisiana, United States|Louisiana Research Center LLC, Shreveport, Louisiana, United States|University of Maryland Medical Group, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Charm City Research Group, Towson, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Clinic Inc. - PARENT ACCOUNT, Burlington, Massachusetts, United States|UMass Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Medex Research Institute, Caro, Michigan, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Gastroenterology Associates of Western Michigan PLC, Wyoming, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Mercy Research, Washington, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States|NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States|Montefiore Medical Center PRIME, Lake Success, New York, United States|The Feinstein Institute for Medical Research PRIME, Manhasset, New York, United States|Winthrop University Hospital, Mineola, New York, United States|New York University School of Medicine, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolina Center for Liver Disease, Charlotte, North Carolina, United States|Gaffney Health Services, Charlotte, North Carolina, United States|PhysiqueMed Clinical Trials, Greensboro, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Clinical Trials of America, LLC, Mount Airy, North Carolina, United States|Trial Management Associates LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Ohio Clinical Research Partners LLC, Akron, Ohio, United States|Clinical Inquest Center Ltd, Beavercreek, Ohio, United States|Dr. Deepak Sarwal, MD, Centerville, Ohio, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, United States|Consultants for Clinical Research Inc., Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Springfield Health Care Center, Springfield, Ohio, United States|Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Main Line Gastroenterology, Havertown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|Penn State University Milton S Hershey Medical Center, State College, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Carolinas Healthcare System, Charleston, South Carolina, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Clinical Research Institute LLC, Arlington, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Houston Endoscopy and Research Center, Houston, Texas, United States|Digestive Health Center, Pasadena, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|University of Utah Division of Gastroenterology, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Charlottesville Medical Research Center, Charlottesville, Virginia, United States|Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Hunter Holmes Mcguire Ctr, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States|The Vancouver Clinic, Vancouver, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Dean Clinic Oregon, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Centre For Digestive Diseases, Five Dock, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Ballarat Base Hospital, Ballarat, Australia|Monash Medical Centre Clayton, Bentleigh East, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Klinikum Klagenfurt am Wörtersee, Klagenfurt, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Krankenanstalt Rudolfstiftung Wien, Wein, Austria|Hopital Universitaire des Enfants, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|CHU Sart Tilman, Liege, Belgium|Alberta Childrens Hospital, Calgary, Alberta, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Barrie GI Associates, Barrie, Ontario, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Centre de sante et de services sociaux Champlain Charles Le Moyne, Greenfield Park, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Clinical Hospital Centre Osijek, Osijek, Croatia|Hepato-Gastroenterologie HK, s. r. o., Hradec Králové, Czechia|PreventaMed, Olomouc, Czechia|CCBR Prague CZ, Praha 3, Czechia|Thomayerova nemocnice, Praha 4, Czechia|Aarhus Universitetshospital, Aahus C, Denmark|Alborg Universitets Hospital, Alborg, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Koge Sygehus, Koge, Denmark|Odense Universitetshospital, Odense C, Denmark|Regionshospitalet Silkeborg, Silkeborg, Denmark|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Tampereen yliopistollinen sairaala, Tampere, Finland|CHU Amiens Hopital Sud, Amiens Cedex, France|CHU Besancon Hopital Jean Minjoz, Besancon Cedex, France|Hopital Claude Huriez CHRU Lille, Lille cedex, France|Hopital Nord CHU Marseille, Marseille cedex 20, France|CHU Nice Hopital de lArchet 2, Nice Cedex 3, France|Hopital Saint Louis, Paris Cedex 10, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|CHU Reims Hopital Robert Debre, Reims, France|CHU de Rouen Hopital Charles Nicolle, Rouen, France|CHU de Toulouse Hopital Rangueil, Toulouse Cedex 09, France|Hopital de Brabois Adultes, Vandoeuvre les Nancy, France|Charite - Campus Virchow-Klinikum, Berlin, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|St. Josef-Hospital, Bochum, Germany|Staedisches Klinikum Brandenburg, Brandenburg an der Havel, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Universitaetsklinikum EssenZentrum fuer Innere Medizin, Essen, Germany|Kliniken Essen-Mitte, Essen, Germany|Katholische Kliniken Ruhrhalbinsel GmbH, Essen, Germany|Crohn Colitis Centrum Rhein Main, Frankfurt, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, Germany|EUGASTRO GmbH, Leipzig, Germany|Gastroenterologische Praxis Minden, Minden, Germany|Universitatsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|HELIOS Klinikum Wuppertal, Wuppertal, Germany|General Hospital of Athens Evangelismos, Athens, Greece|Athens Medical Center, Athens, Greece|University General Hospital of Patras, Rio Patras, Greece|Obudai Egeszsegugyi Centrum Kft., Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Szent Margit Korhaz, Budapest, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szent-Gyorgyi Albert TE AOK Borgyogy, Szeged, Hungary|Rabin Medical Center, Petah Tikva, Israel|Kaplan Medical Center, Rechovot, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Di Padova, Padova, Italy|Azienda Ospedaliera Vincenzo Cervello, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Universita Campus Bio-Medico di Roma, Roma, Italy|Complesso Integrato Columbus, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi dAragona, Salerno, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Hanyang Univerisy Guri Hospital, Guri-si, Korea, Republic of|CHA Bundang Medical Center CHA University, Seongnam-si,, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju-Si, Korea, Republic of|Digestive Diseases Center Gastro, Riga, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, Latvia|Amphia Ziekenhuis, Breda, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego, Bialystok, Poland|Clinsante S.C. Osrodek Badan Klinicznych, Bydgoszcz, Poland|Centrum Medyczne A-Z Clinic, Kraków, Poland|Centrum Medyczne AMED, Lodz, Poland|Nzoz Vivamed, Warsaw, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Hospital de Braga, Braga, Portugal|Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|Hospital Da Luz, Lisboa, Portugal|Centro Hospitalar de Sao Joao, EPE, Porto, Portugal|Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE, Viana do Castelo, Portugal|CMI Dr. Tirnaveanu Amelita, Oradea, Romania|Centrul de Gastroenterologie Dr. Goldis, Timisoara, Romania|Medical Center Stolitsa-Medikl, Moscow, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|FSBI Scientific Research Institute of Physyology and Basic Medicine under the SB of RAMS, Novosibirsk, Russian Federation|SPb SBIH City Hospital # 26, Saint-Petersburg, Russian Federation|NonState Healthcare Institution Central Clinical Hospital, Samara station JSC Russian Railways, Samara, Russian Federation|Clinical Center Bezanijska Kosa, Belgrade, Serbia|GASTRO I., s.r.o., Presov, Slovakia|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Danderyds Sjukhus AB, Stockholm, Sweden|Inselspital - Universitaetsspital Bern, Bern, Switzerland|Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner, Bern, Switzerland|Hopitaux Universitaires de Geneve-HUG, Geneva, Switzerland|UniversitatSspital Zurich, Zuerich, Switzerland|Ankara University Medical Faculty, Ankara, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Firat University Medical Faculty, Elazig, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Acibadem Fulya Hospital, Istanbul, Turkey|Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Izmir, Izmir, Turkey|Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey|Inonu Uni. Med. Fac., Malatya, Turkey|Mersin University Medical Faculty, Mersin, Turkey|CI of PH Kharkiv CCH #2, Kharkiv, Ukraine|Treatment-Diagnostic Center of Private Enterprise of PMF Atsynus, Kirovohrad, Ukraine|Kyiv City Clinical Hospital #1, Kyiv, Ukraine|CI Odesa Regional Clinical Hospital, Odessa, Ukraine|CI of SRC Sumy RCH Dept of Rheumatology Sumy SU MI, Sumy, Ukraine|Ternopil City Communal Emergency Medical Care Hospital, Ternopil, Ukraine|SRI of Invalid Rehabilitation EST Complex of Vinnytsia M.I.Pyrogov NMU MOHU, Vinnytsia, Ukraine|SI Branch CH of Zaporizhzhia Station-2 of SE Prydniprovska Railway Dept of Surgery Zaporizhzhia SMU, Zaporizhia, Ukraine|CI Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporozhje, Ukraine|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Royal London Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Nottingham University Hospitals Queens Medical Centre, Nottingham, United Kingdom|Borders General Hospital, Roxburghshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02974322"
109,"NCT02973191","A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia","ORBIT","Withdrawn","No Results Available","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Drug: JCAR015","Overall Response Rate (ORR)|Minimal residual disease (MRD)|Adverse Events (AEs)|Duration of Minimal residual disease (MRD) response|Relapse-free survival (RFS)|Event-free survival (EFS)|Overall survival (OS)|Percent Minimal residual disease (MRD) negative|Depth of Minimal residual disease (MRD) response|Duration of remission (DOR)|Pharmacokinetics - Cmax|Pharmacokinetics- Tmax|Pharmacokinetics - AUC","Celgene|Juno","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR015-ALL-001","December 20, 2016","June 25, 2019","January 24, 2021","November 25, 2016",,"April 10, 2017","Universitair Ziekenhuis Gent, Gent, Belgium|University de Lille, Lille, France|Hopital Saint Louis, Paris, France|Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden, Dresden, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|University of Munich Grosshadern, Grosshadern Campus, Germany|University of Cologne, Köln, Germany|University of Leipzig, Leipzig, Germany|Universitaetsklinikum Ulm, Ulm, Germany|USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Istituto Clinico Humanitas - Istituti di Ricovero E Cura A Carattere Scientifico (IRCSS), Milan, Italy|Universita La Sapienza, Roma, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|ICO-Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Chuv Bh-04, Lausanne, Switzerland|Bristol Royal Infirmary, University of Bristol Foundation Trust, Bristol, United Kingdom|UCL Cancer Institute, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02973191"
110,"NCT02957474","A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: GED-0301|Drug: Omeprazole","Pharmacokinetics ‐ Cmax|Pharmacokinetics ‐AUC0-∞|Adverse Event (AE)","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GED-0301-CP-001","November 2016","December 2016","December 2016","November 7, 2016",,"January 12, 2017","Richmond Pharmacology, Ltd., Croydon, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02957474"
111,"NCT02954081","APremilast After FumaRic Acid Ester Treatment","APART","Recruiting","No Results Available","Psoriasis","Drug: Phase I: Fumaric acid esters. Phase II: Apremilast","Mean absolute value of the overall TSQM score at week 24 of apremilast (APR) therapy (phase II).","Celgene","All","18 Years and older   (Adult, Older Adult)",,"1600","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","CC-10004-PSOR-024","January 31, 2017","December 31, 2019","December 31, 2020","November 3, 2016",,"November 21, 2018","Site, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02954081"
112,"NCT02946333","A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain","QoLMMBuS","Recruiting","No Results Available","Multiple Myeloma",,"Health-related quality of life (HRQoL)|EuroQoL 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)|Quality of Life Questionnaire (QLQ-C30)|Quality of Life Questionnaire — Multiple Myeloma Module 20 (QLQ-MY20)|Health care cost for Multiple Myeloma (MM) patients|Time to progression (TTP)|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate|Response duration|Treatment-free interval [TFI]","Celgene","All","18 Years and older   (Adult, Older Adult)",,"450","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-MIE-2016-01","November 25, 2016","October 10, 2020","October 30, 2025","October 27, 2016",,"April 17, 2019","Hospital Punta de Europa, Algeciras, Andalusia, Spain|Hospital de Antequera, Antequera, Andalusia, Spain|Hospital Reina Sofía, Córdoba, Andalusia, Spain|Hospital Huercal Olvera, Huercal Olvera, Andalusia, Spain|Hospital General Jaén, Jaén, Andalusia, Spain|Hospital Jerez de la Frontera, Jerez de la Frontera, Andalusia, Spain|Hospital de Motril, Motril, Andalusia, Spain|Clinico Univ. Virgen de la Victoria, Málaga, Andalusia, Spain|Hospital Carlos Haya, Málaga, Andalusia, Spain|Hospital de Costa del Sol, Málaga, Andalusia, Spain|Hospital Valle de los Pedroches Pozoblanco, Pozoblanco, Andalusia, Spain|Hospital Puerto Real, Puerto Real, Andalusia, Spain|Hospital de Macarena, Sevilla, Andalusia, Spain|Hospital Miguel Servet, Zaragoza, Aragón, Spain|Hospital ICO Durán y Reynals, Hospitalet de Llobregat, Barcelona, Spain|ICO Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Canarias, Spain|Hospital de Guadalajara, Guadalajara, Castilla La Mancha, Spain|Hospital Universitario de Burgos, Burgos, Castilla Y León, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Castilla Y León, Spain|Hospital Clínico de Valladolid, Valladolid, Castilla Y León, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Cataluña, Spain|Hospital Vall Hebrón, Barcelona, Cataluña, Spain|Hospital General de Granollers, Granollers, Cataluña, Spain|Hospital Arnau Vilanova de Lleida, Lleida, Cataluña, Spain|Fundació Althaia, Manresa, Cataluña, Spain|Parc Taulí, Sabadell, Cataluña, Spain|Mutua Terrassa, Terrassa, Cataluña, Spain|Hospital Universitario de Getafe, Getafe, Comunidad De Madrid, Spain|Hospital de la Princesa, Madrid, Comunidad De Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Comunidad De Madrid, Spain|Hospital Clínico San Carlos, Madrid, Comunidad De Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Comunidad De Madrid, Spain|Hospital 12 de Octubre, Madrid, Comunidad De Madrid, Spain|Hospital General Castellón, Castellón de la Plana, Comunidad Valenciana, Spain|Hospital Arnau Vilanova Valencia, Valencia, Comunidad Valenciana, Spain|Hospital Doctor Peset, Valencia, Comunidad Valenciana, Spain|Hospital La Fe Valencia, Valencia, Comunidad Valenciana, Spain|Hospital La Ribera, Valencia, Comunidad Valenciana, Spain|Hospital Punta de Europa, Algeciras, Cádiz, Spain|Complejo Hospitalario Llerena-Zafra, Llerena, Extremadura, Spain|Hospital de Mérida, Mérida, Extremadura, Spain|Complexo Hospitalario Universitario de A Coruña, A Coruña, Galicia, Spain|Hospital Lucus Augustí, Lugo, Galicia, Spain|Complexo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain|Complexo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain|Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain|Hospital Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain|Hospital Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain|Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Islas Canarias, Spain|Hospital Universitario Canarias, Santa Cruz de Tenerife, Islas Canaria, Spain|Hospital Quirón, Pozuelo de Alarcón, Madrid, Spain|Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain|Complejo Hospitalario Navarra, Pamplona, Navarra, Spain|Hospital de Basurto, Bilbao, País Vasco, Spain|Hospital de Galadakao, Usansolo, País Vasco, Spain|Hospital de Txagorritxu, Vitoria-Gasteiz, País Vasco, Spain|Hospital de La Ribera, Alzira, Valencia, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital La Paz, Madrid, Spain|Complejo Hospitalario de Navarra, Navarra, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain|Complejo Hospitalario de Ávila, Ávila, Spain",,"https://ClinicalTrials.gov/show/NCT02946333"
113,"NCT02935790","Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab",,"Completed","No Results Available","Malignant Melanoma","Drug: ACY-241|Drug: nivolumab|Drug: ipilimumab","Number of Dose Limiting Toxicities defining the MTD|Percentage of Patients with ORR based on RECIST 1.1 change from baseline by CT or MRI measurements|Percentage of Patients with ORR based on irRC change from baseline by CT or MRI measurements|Maximum observed concentration (Cmax) of ACY-241 administered in combination with ipilimumab and nivolumab|trough concentrations of ACY-241 administered in combination with ipilimumab and nivolumab","Celgene|Syneos Health|ApoCell, Inc.|Celerion|NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-ST-204","September 30, 2016","April 7, 2017","April 7, 2017","October 18, 2016",,"August 24, 2017","NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02935790"
114,"NCT02934269","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: Placebo|Drug: CC-90006","Adverse Events (AEs)|Pharmacokinetics- Cmax|Pharmacokinetics- Tmax|Pharmacokinetics- AUC0-∞|Pharmacokinetics- AUC0-t|Pharmacokinetics- T1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Pharmacokinetics- Anti-drug antibody","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-90006-CP-001","November 21, 2016","August 15, 2017","August 15, 2017","October 14, 2016",,"February 8, 2018","PPD Phase 1 Unit, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02934269"
115,"NCT02922543","A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use",,"Active, not recruiting","No Results Available","Multiple Myeloma",,"Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"361","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-Celgene-JP-PMS-001b","February 18, 2011","December 31, 2019","December 31, 2019","October 4, 2016",,"June 5, 2019","Shinko Hospital, Kobe, Hyogo, Japan",,"https://ClinicalTrials.gov/show/NCT02922543"
116,"NCT02921828","A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg",,"Active, not recruiting","No Results Available","Multiple Myeloma",,"Adverse event (AE)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"1149","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-Celgene-JP-PMS-002","May 21, 2015","May 20, 2025","May 20, 2025","October 3, 2016",,"June 4, 2019","Shinko Hospital, Kobe, Hyogo, Japan",,"https://ClinicalTrials.gov/show/NCT02921828"
117,"NCT02921815","A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment",,"Active, not recruiting","No Results Available","Myelodysplastic Syndromes|Leukemia, Myeloid, Acute",,"Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"84","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-Celgene-JP-PMS-001c","March 3, 2011","December 31, 2019","December 31, 2019","October 3, 2016",,"June 5, 2019","Shinko Hospital, Kobe, Hyogo, Japan",,"https://ClinicalTrials.gov/show/NCT02921815"
118,"NCT02921802","A Study of Special Use Results Surveillance of Revlimid 5mg Capsules",,"Active, not recruiting","No Results Available","Multiple Myeloma|Myelodysplastic Syndromes",,"Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"4626","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-Celgene-JP-PMS-001a","July 20, 2010","June 19, 2020","June 19, 2020","October 3, 2016",,"June 5, 2019","Shinko Hospital, Kobe, Hyogo, Japan",,"https://ClinicalTrials.gov/show/NCT02921802"
119,"NCT02903069","Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer",,"Active, not recruiting","No Results Available","Glioblastoma|Malignant Glioma","Drug: MRZ|Drug: TMZ|Radiation: RT|Device: Optune","Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)|To assess adverse events during the adjuvant treatment|To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients|Assess adverse events during concomitant and adjuvant treatment|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT|MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)|MRZ pharmacokinetics - Elimination Half-Life (t1/2)|MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)|MRZ pharmacokinetics - Clearance (CL)|MRZ pharmacokinetics - Volume of Distribution (Vd)|TMZ serum concentration|Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + Optune|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + Optune","Celgene|Triphase","All","18 Years and older   (Adult, Older Adult)","Phase 1","73","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRZ-112","February 10, 2016","January 31, 2020","January 31, 2020","September 16, 2016",,"October 17, 2019","University of California San Diego Medical Center, La Jolla, California, United States|UC Irvine, Orange, California, United States|John Wayne Cancer Center Outpatient Clinic, Santa Monica, California, United States|Northwestern Center For Clinical Research, Chicago, Illinois, United States|Duke Cancer Center, Durham, North Carolina, United States|Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|University of Zurich Hospital, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02903069"
120,"NCT02902900","An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice","MIROIR","Recruiting","No Results Available","Multiple Myeloma",,"Progression Free Survival (PFS)|Overall Response Rate (ORR)|Duration of Response (DOR)|Overall Survival (OS)|Time to Progression (TTP)|Time to Treatment Failure (TTF)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"3000","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CC-4047-MM-018","September 25, 2015","September 30, 2019","September 30, 2020","September 16, 2016",,"November 15, 2018","Centre Hospitalier General, Albi Cedex, France|Groupe Hospitalier Sud, Amiens Cedex 1, France|Hotel Dieu, Angers Cedex 9, France|Ch D'Arras, Arras Cedex, France|Centre Hospitalier Intercommunal Robert Ballanger, Aulnay Sous Bois, France|Centre Hospitalier H. Duffaut, Avignon Cedex 9, France|Centre Hospitalier Jeanne d'Arc, Bar Le Duc Cedex, France|Chic Cote Basque Bayonne, Bayonne Cedex, France|Hopital Nord Franche-Comte - Site de Belfort, Belfort Cedex, France|Hopital Jean Minjoz, Besancon Cedex, France|Centre Hospitalier General, Blois Cedex, France|Hôpital Avicenne, Bobigny Cedex, France|Institut Bergonie, Bordeaux Cedex, France|Polyclin Bordeaux Nord Aquitaine, Bordeaux Cedex, France|Ch Docteur Duchenne, Boulogne Sur Mer, France|Ch de Fleyriat, Bourg En Bresse Cedex, France|Ch Pierre Oudot, Bourgoin Jallieu Cedex, France|Hôpital d'Instruction des Armées, Brest Armees Cedex 9, France|Hopital Augustin Morvan, Brest Cedex, France|Ch de Brive La Gaillarde, Brive La Gaillarde, France|Hopital Cote de Nacre, Caen Cedex 9, France|Hopital Pierre Nouveau, Cannes Cedex, France|Clinique Du Parc, Castelnau Le Lez, France|Hopital Prive Sevigne, Cesson Sevigne Cedex, France|Médipôle de Savoie, Challes Les Eaux, France|Ch William Morey, Chalon Sur Saone Cedex, France|Ch de Chambery, Chambery, France|Centre Hospitalier, Cholet, France|Hopital Antoine Beclere, Clamart Cedex, France|Pole Sante Republique, Clermont Ferrand Cedex 2, France|Chu Estaing, Clermont Ferrand, France|Ch Sud Francilien, Corbeil Essonnes Cedex, France|Centre Hospitalier de Creil, Creil Cedex, France|Gh Henri Mondor Albert Chenevier, Creteil Cedex, France|Ch de Dax, Dax Cedex, France|Hopital Francois Mitterrand, Dijon, France|Ch Dracenie, Draguignan, France|Ch de Dunkerque, Dunkerque Cedex 1, France|Centre Hospitalier Emile Durkheim, Epinal Cedex, France|Clinique Pasteur, Evreux, France|Chi de Frejus Saint Raphael, Frejus Cedex, France|Chi Des Alpes Du Sud, Gap Cedex, France|Institut Daniel Hollard, Grenoble, France|Hopital Charles Foix, Ivry Sur Seine, France|Polyclinique de Blois, La Chaussee St Victor, France|Ch Dptal Les Oudairies, La Roche Sur Yon Cedex 9, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Hopital Albert Michallon, La Tronche, France|Ch Andre Mignot, Le Chesnay Cedex, France|Hopital Louis Pasteur, Le Coudray Cedex, France|Clinique Victor Hugo, Le Mans Cedex 2, France|Ch Du Mans, Le Mans Cedex 9, France|Ch Du Docteur Schaffner, Lens Cedex, France|Hopital Robert Boulin, Libourne Cedex, France|Hopital Saint Vincent, Lille Cedex, France|Hopital Claude Huriez, Lille Cedex, France|Hopital Dupuytren, Limoges Cedex 1, France|Ch Bretagne Sud Site Lorient, Lorient Cedex, France|Centre Hospitalier General, Lourdes Cedex, France|Hopital Edouard Herriot, Lyon Cedex 3, France|Hopital de La Conception, Marseille Cedex 05, France|Institut J Paoli-Calmettes, Marseille Cedex 09, France|Hôpital Saint Joseph, Marseille Cedex 8, France|Centre Hospitalier de Martigues, Martigues, France|Ch de Meaux, Meaux Cedex, France|Hopital Marc Jacquet, Melun, France|Hopital Belle Isle, Metz Cedex 01, France|HOPITAL Metz Mercy, Metz Cedex 03, France|Hopital Jacques Monod, Montivilliers, France|Hopital Saint Eloi, Montpellier Cedex 5, France|Clinique Beau Soleil, Montpellier, France|Ch Des Pays de Morlaix, Morlaix Cedex, France|Ch Mulhouse, Mulhouse Cedex 1, France|Hopital Hotel Dieu Et Hme, Nantes Cedex 1, France|Centre Catherine de Sienne, Nantes Cedex 2, France|Ch Pierre Beregovoy, Nevers Cedex, France|Hopital de L'Archet, Nice Cedex 3, France|Centre Antoine Lacassagne, Nice, France|Hopital Caremeau, Nimes Cedex 9, France|Hopital Saint Louis, Paris Cedex 10, France|Hôpital Saint Antoine, Paris Cedex 12, France|Gh Pitie Salpetriere, Paris Cedex 13, France|Gh Cochin St Vincent de Paul, Paris Cedex 14, France|Hopital Necker Enfants Malades, Paris Cedex 15, France|Ch de Perigueux, Perigueux Cedex, France|Polyclinique Francheville, Perigueux, France|Hopital Saint Jean, Perpignan Cedex, France|Ch Lyon Sud, Pierre Benite Cedex, France|Hopital La Miletrie, Poitiers Cedex, France|Ch Rene Dubos, Pontoise, France|CH Annecy Genevois, Pringy, France|Chi de Cornouaille, Quimper Cedex, France|Ch de Rambouillet, Rambouillet Cedex, France|Chu Reims, Reims Cedex, France|Hopital Robert Debre, Reims Cedex, France|Chu Rennes - Hopital Sud, Rennes Cedex 2, France|Hopital Pontchaillou, Rennes Cedex 9, France|Ch de Roanne, Roanne, France|Hopitaux Drome Nord, Romans Sur Isere Cedex, France|Hopital Victor Provo, Roubaix Cedex 1, France|Centre Henri Becquerel, Rouen Cedex, France|Centre Hospitalier General, Saint Germain En Laye, France|Centre Rene Gauducheau, Saint Herblain Cedex, France|Centre Hospitalier, Saint Malo, France|Chg de Saint Quentin, Saint Quentin Cedex, France|C.H. Jacques Boutard, Saint Yrieix La Perche, France|Centre Hospitalier, Sens Cedex, France|Hopital Yves Le Foll, St Brieuc Cedex 1, France|Centre Rene Huguenin, St Cloud, France|Institut de Cancérologie de la Loire, St Priest En Jarez Cedex, France|Hôpital Nord, St Priest En Jarez, France|Hopital Hautepierre, Strasbourg Cedex 2, France|Hopital Hautepierre, Strasbourg Cedex, France|Hopital Foch, Suresnes, France|C.H.I Les Hopitaux Du Leman, Thonon Les Bains, France|Hopital Sainte Musse, Toulon, France|Hopital Rangueil, Toulouse Cedex 9, France|IUCT Oncopole, Toulouse Cedex 9, France|Hopital Bretonneau, Tours, France|Hopital Des Hauts Clos, Troyes Cedex, France|Centre Hospitalier de Valence, Valence Cedex 9, France|Ch de Valenciennes, Valenciennes Cedex, France|Hopitaux de Brabois, Vandoeuvre Les Nancy Cedex, France|Ch Bretagne Atlantique de Vannes, Vannes Cedex, France|Chi de La Haute Saone de Vesoul, Vesoul Cedex, France|Institut Gustave Roussy, Villejuif Cedex, France",,"https://ClinicalTrials.gov/show/NCT02902900"
121,"NCT02891551","An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands","OCEAN","Completed","No Results Available","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute",,"Adverse Events (AEs)|Fact-Anemia Quality of life questionnaire|Percentage of patients with a Haematological Response in daily clinical practice using the International Work Group Criteria in Myelodysplastic Syndrome Assessed by the Investigator|Percentage of patients with a Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by the investigator in daily clinical practice|Time to treatment Failure daily clinical practice|Overall Survival in daily clinical practice","Celgene","All","18 Years and older   (Adult, Older Adult)",,"209","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIPMS-VZ-NL-001","May 1, 2012","June 30, 2016","December 30, 2018","September 7, 2016",,"July 24, 2019",,,"https://ClinicalTrials.gov/show/NCT02891551"
122,"NCT02875223","A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Neoplasms","Drug: CC-90011","Dose‐Limiting Toxicity (DLT)|Adverse Events (AEs)|Clinical Benefit Rate (CBR)|Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics ‐ Cmax|Pharmacokinetics ‐ AUC|Pharmacokinetics ‐Tmax|Pharmacokinetics ‐t1/2|Pharmacokinetics ‐CL/F|Pharmacokinetics ‐Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","115","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90011-ST-001","August 31, 2016","June 30, 2021","June 7, 2023","August 23, 2016",,"October 22, 2019","Centre Georges Francois Leclerc, Dijon, France|Institut Paoli Calmettes, Marseille Cedex 9, France|Gustave Roussy, Villejuif Cedex, France|Bologna University, Bologna, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Hospital Universitario Vall D hebron, Barcelona, Spain|Fundacion Jimenez Daaz, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Royal Marsden Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02875223"
123,"NCT02875184","A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands","REWARD","Recruiting","No Results Available","Arthritis, Psoriatic",,"Percentage of patients with a Health Assessment Questionnaire - Disability Index (HAQ-DI) score of ≤ 0.5 or with a decrease of ≥ 0.3 of the HAQ-DI score compared with baseline|Change from Baseline in Psoriatic Arthritis Impact of Disease (PsAID) at various time point|Change from Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) at various time points|Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at month 6|Change from Baseline in Dermatology Life Quality Index (DLQI) at month 6|Change from Baseline in Short Form 36 (SF36) at 12 months|Change from Baseline in EuroQol-5 dimensions (EQ5D) at 12 months|Change from Baseline in visual analogue scales (VAS) at various time point","Celgene","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSA-009","March 6, 2017","March 1, 2020","March 1, 2020","August 23, 2016",,"November 21, 2018","Viecuri Medisch Centrum, Venlo, Limburg, Netherlands|Reumazorg ZWN, Roosendaal, Noord-Brabant, Netherlands|Amphia, Breda, North-Brabant, Netherlands|Elkerliek ziekenhuis, Helmond, North-Brabant, Netherlands|Erasmus MC, Rotterdam, South-Holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, South-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT02875184"
124,"NCT02859324","A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)",,"Active, not recruiting","No Results Available","Carcinoma, Hepatocellular","Drug: CC-122|Drug: Nivolumab","Dose Limiting Toxicity (DLT)|Adverse Events (AEs)|Overall Response Rate (ORR) - Phase 2|Disease control rate (DCR)|Duration of response (DoR)|Progression free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Pharmacokinetic - Cmax|Pharmacokinetic - AUC|Pharmacokinetic - Tmax|Pharmacokinetic - t1/2|Pharmacokinetic - CL/F|Pharmacokinetic - Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-HCC-002|2016-000112-15","September 20, 2016","April 9, 2020","April 9, 2020","August 9, 2016",,"November 6, 2019","UCLA Division of Hematology Oncology, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|NYU Langone Medical Center, New York, New York, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Institut Paoli Calmettes, Marseille Cedex 9, France|Centre Eugene Marquis, Rennes, France|Institut Universitaire du Cancer IUCT - Oncopole, Toulouse Cedex, France|Institut Gustave Roussy Hematologie, Villejuif CEDEX, France|IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center, Milan, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02859324"
125,"NCT02849444","A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance","MIR50","Active, not recruiting","No Results Available","Multiple Myeloma","Other: Anti-myeloma treatment at physician discretion","Creatinine levels to determinates Renal function response|Age of participants at baseline to determinates Renal function response|Weight of participants at baseline to determinates Renal function response|Gender of participants at baseline to determinates Renal function response|Race of participants at Baseline|Clinical Outcome of participants with Multiple Myeloma (MM) clinical description|Renal response rate assessment in clinical practice.|Time dependent Renal response rate assessment in clinical practice.|Type of Anti-myeloma therapeutic regimens.|Multiple Myeloma (MM) response to anti-myeloma treatment|MM response to Time to Progression|MM response to Time to first response|MM response to Progression Free Survival|Adverse events (AEs)|Cost of visit to hospital/primary health care associated with anti-myeloma therapy|Number of participants with relapsed kidney function","Celgene","All","18 Years and older   (Adult, Older Adult)",,"326","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-MIE-2012-01","September 23, 2012","October 31, 2019","March 1, 2020","July 29, 2016",,"February 1, 2019","Hospital Universitario Ciudad de Jaen, Jaen, Andalucia, Spain|Hospital Torrecárdenas, Almería, Andalucía, Spain|Hospital Universitario Puerta del Mar, Cádiz, Andalucía, Spain|Hospital Virgen de la Nieves, Granada, Andalucía, Spain|Hospital general de jeréz, Jerez de la Frontera, Andalucía, Spain|Hospital Virgen de la macarena, Sevilla, Andalucía, Spain|Hospital Miguel Servet, Zaragoza, Aragón, Spain|Hospital de Cabueñes, Gijón, Asturias, Spain|Hospital de Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, Spain|Hospital General de Ciudad Real, Ciudad Real, Castilla La Mancha, Spain|Hospital de Basurto, Bilbao, Castilla Y León, Spain|Hospital de Burgos, Burgos, Castilla Y León, Spain|Hospital de León, León, Castilla Y León, Spain|Rio Hortega de Valladolid, Valladolid, Castilla Y León, Spain|Hospital La Ribera, Alzira, Cataluña, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Vall d´Hebron, Barcelona, Cataluña, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Cataluña, Spain|Hospital Duran reynls, Barcelona, Cataluña, Spain|Hospital Universitario Josep Trueta de Girona, Girona, Cataluña, Spain|Hospital Arnau de Vilanova de Lleida, Lleida, Cataluña, Spain|Hospital Sant Joan de manresa, Manresa, Cataluña, Spain|Hospital de Sabadell ( Parc Taulí), Sabadell, Cataluña, Spain|Hospital Mutua terrassa, Terrassa, Cataluña, Spain|Hospital Clínico Universitario Valencia, Valencia, Comunidad Valenciana, Spain|Hospital La fe, Valencia, Comunidad Valenciana, Spain|Complejo Hospitalario Universitario Santiago, Santiago de Compostela, Galicia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain|Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain|Hospital san pedro, Logroño, La Rioja, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Santa Lucía, Cartagena, Murcia, Spain|Hospital Virgen de Arrixaca, El Palmar, Murcia, Murcia, Spain|Hospital General de Alicante, Alicante, Valencia, Spain|Hospital Gregorio marañon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Complejo Universitario de San Carlos, Madrid, Spain|Hospital Universitario La paz, Madrid, Spain|Hospital Dr peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02849444"
126,"NCT02848001","A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes",,"Recruiting","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes","Drug: CC-90009","Dose- limiting toxicity (DLT)|Non-tolerated dose (NTD)|Maximum tolerated dose (MTD)|Pharmacokinetics-Cmax|Pharmacokinetics - AUC24|Pharmacokinetics - tmax|Pharmacokinetics - t 1/2|Pharmacokinetics - CL|Pharmacokinetics - Vss|Preliminary efficacy of CC-90009|Preliminary efficacy of CC-90009 - AML|Preliminary efficacy of CC-90009 - MDS","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90009-AML-001|2017-001535-39","November 14, 2016","March 12, 2021","March 12, 2021","July 28, 2016",,"August 21, 2019","Yale Cancer Center, New Haven, Connecticut, United States|Northwestern Memorial, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|Institut Paoli Calmettes, Marseille Cedex 9, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif, France|Spedali Civili Di Brescia, Brescia, Italy|A.O. Ospedale Ca Granda - Niguarda, Milano, Italy|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Rikshospitalet HF, Oslo, Norway|H Clinic I Provincial, Barcelona, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hosptial La Fe, Valencia, Spain|The Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02848001"
127,"NCT02842229","A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms",,"Completed","No Results Available","Myelodysplastic Syndromes|Leukemia Myeloid Acute|Multiple Myeloma|Leukemia, Lymphocytic, Chronic, B-Cell",,"Assessment of the tolerability of the treatment administered|The score of number of drugs on the Geriatric Assessment in Haematology (GAH) scale|The time of gait velocity on the Geriatric Assessment in Haematology (GAH) scale|The score of activities of daily living on th Geriatric Assessment in Haematology (GAH) scale|The score of subjective health status on the Geriatric Assessment in Haematology (GAH) scale|The score of nutrition on the Geriatric Assessment in Haematology (GAH) scale|The score of mental State on the Geriatric Assessment in Haematology (GAH) scale|The score of comorbidity on the Geriatric Assessment in Haematology (GAH) scale|Therapeutic approach according to clinical judgment|Discontinuation of the planned treatment due to toxicity|Modification of the planned treatment regimen due to toxicity|Percentage of patients with toxicity|Number of participants visit to hospital as a result of toxicity","Celgene","All","65 Years and older   (Older Adult)",,"117","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CEL-GAH-2016-01","July 20, 2016","February 2, 2017","February 2, 2017","July 22, 2016",,"July 26, 2017","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Durán I Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Parc Taulí, Sabadell, Barcelona, Spain|C. H. Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, San Cristóbal de la Laguna, Tenerife, Spain|Hospital Ntra. Sra. La Candelaria, Santa Cruz de Tenerife, Tenerife, Spain|Hospital La Ribera, Alzira, Valencia, Spain|Hospital Vall d' Hebrón, Barcelona, Spain|C.H. Universitario A Coruña, La Coruña, Spain|Hospital U. Gregorio Marañón, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital de Segovia, Segovia, Spain|Hospital La Fe, Valencia, Spain|Hospital Txagorritxu, Vitoria, Álava, Spain",,"https://ClinicalTrials.gov/show/NCT02842229"
128,"NCT02807454","A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma","FUSIONMM-003","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Daratumumab|Drug: Durvalumab|Drug: Pomalidomide|Drug: Dexamethasone","Overall Response Rate (ORR)|Adverse Events (AEs)|Time to response (TTR)|Duration of Response (DOR)|Progression-free Survival (PFS)|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-MM-003","July 7, 2016","April 5, 2020","April 5, 2020","June 21, 2016",,"August 20, 2019","City of Hope National Medical Center, Duarte, California, United States|UCLA Division of Hematology Oncology, Los Angeles, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Emory University Hospital, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Dana-Farber Partners Cancer Care, Inc., Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Swedish Medical Center, Seattle, Washington, United States|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Universitaire Ziekenhuizen Leuven Univeristy Hospitals Leuven, Leuven, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|MUHC Glen Site, Montreal, Quebec, Canada|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|University Hospital Tubingen, Tubingen, Germany|Universitatsklinikum Wuerzburg, Wuerzburg, Germany|Policlinico S. Orsola - Malpighi, Bologna, Italy|A.O.U. Maggiore della Carità, Novara, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|A.O. Universitaria Ospedale S.Chiara Dip.Oncologia, Div. Ematologia, Pisa, Italy|Hospital Durán i Reynals - Instituto Catalàn de Oncologìa ICO, Barcelona, Spain|Hospital de Cabuenes, Gijon, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Skanes Universitetssjukhus Malmo, Lund, Sweden|Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|St. Bartholomew's and The Royal London Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom|Royal Marsden Hospital, Sutton (Surrey), United Kingdom|The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02807454"
129,"NCT02802735","Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects",,"Completed","No Results Available","Pharmacokinetics","Drug: Apremilast|Drug: Placebo","Pharmacokinetics - Cmax|Pharmacokinetics - AUCt|Pharmacokinetics - AUC∞|Pharmacokinetics - AUCτ|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Adverse Events (AEs)","Celgene","Male","18 Years to 45 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-CP-033","June 22, 2016","August 5, 2016","August 5, 2016","June 16, 2016",,"November 22, 2018","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02802735"
130,"NCT02797015","Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS",,"Completed","No Results Available","Multiple Sclerosis","Drug: RPC1063","Maximum plasma concentration (Cmax)|Area under the plasma concentration-time curve (AUC)|Adverse Events|EDSS (Expanded Disability Status Scale)|Pharmacodynamic response measured in change from baseline in Absolute Lymphocyte Count","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RPC01-1001","June 23, 2016","October 20, 2017","October 20, 2017","June 13, 2016",,"March 27, 2018","Breastlink Medical Group, Inc., Long Beach, California, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, United States|Hope Neurology MS Center, Knoxville, Tennessee, United States|Central Texas Neurology Consultants PA, Round Rock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02797015"
131,"NCT02786511","Longterm Follow-up of Subjects Treated With bb2121",,"Enrolling by invitation","No Results Available","Multiple Myeloma","Drug: Safety and efficacy assessments","Overall survival|Monitoring for all Adverse Events, including Serious Adverse Events, related to the drug product|Monitoring for all Serious Adverse Events including any new malignancy or new diagnosis of a neurologic, rheumatologic, or hematologic disorder that is clinically significant|Monitoring for Multiple Myeloma-specific response according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma|Progression Free Survival|Monitoring for Vector Copy Number (VCN)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","LTF-305","April 28, 2016","April 28, 2035","April 28, 2035","June 1, 2016",,"October 30, 2019","Stanford Cancer Center, Palo Alto, California, United States|National Cancer Institute, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02786511"
132,"NCT02777554","An Open Label Study to Evaluate the Pharmacokinetic Exposure of Apremilast in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: Apremilast","Pharmacokinetic - Cmax|Pharmacokinetic - Tmax|Pharmacokinetic - AUC0-24|Pharmacokinetic - AUC0-∞|Pharmacokinetic - AUC0-t|Pharmacokinetic - t1/2|Pharmacokinetic - CL/F|Pharmacokinetic - Vz/F|Pharmacokinetic - Ctrough|Pharmacokinetic - Tz|Pharmacokinetic - Cmin|Pharmacokinetic - Cavg|Pharmacokinetic - tlag|Pharmacokinetic - Ratio of accumulation (RA)|Adverse Events (AEs)","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-10004-CP-035","August 17, 2016","November 22, 2016","November 22, 2016","May 19, 2016",,"November 22, 2018","Covance-Daytona Beach, Daytona Beach, Florida, United States|Covance Clinical Research Unit Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02777554"
133,"NCT02775903","An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)",,"Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes","Drug: Azacitidine|Drug: Durvalumab","Overall Response Rate (ORR)- MDS(Myelodysplastic syndromes)|Overall Response Rate (ORR) - AML(Acute myeloid leukemia)|Time to response - MDS|Relapse-free survival - MDS|Cytogenetic response - MDS|Progression-free survival (PFS) - MDS|Duration of hematologic response- MDS|Time to AML transformation- MDS|Transformation to AML- MDS|Time to response - AML|Relapse-free survival- AML|Complete cytogenetic response (CyCR)- AML|Hematologic Improvement Rate - AML|Duration of response - AML|Adverse Events (AEs) - MDS + AML|Overall survival - MDS + AML|One-year survival|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-MDS-001","June 3, 2016","October 31, 2018","September 30, 2020","May 18, 2016",,"August 20, 2019","Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas- MD Anderson, Houston, Texas, United States|Medizinische Universitat Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|Elisabethinen Hospital Linz, Linz, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|AKH Wien, Wein, Austria|Hanusch Krankenhaus der Stadt Wien, Wien, Austria|Cliniques Universitaires St-Luc, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|UH Gent, Gent, Belgium|UH Gasthuisberg, Leuven, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|University of Alberta, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM - Notre Dame, Montreal, Quebec, Canada|Centre Hospitalier Universitaire d' Angers, Angers, France|Hopital Avicenne, Bobigny Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Universitaire de Grenoble Hopital Albert Michallon, La Tronche, France|Centre Leon Berard, Lyon, France|CHRU de Nantes - Hotel Dieu, Nantes, France|Hopital Saint Louis, Paris, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|IUCT Oncopole, Toulouse, France|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Marien Hospital, Dusseldorf, Germany|Universitatsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule HannoverZentrum Innere Medizin, Hannover, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinikum der LMU Campus Grosshadern, Munchen, Germany|Klinikum rechts der Isar der TU Munchen, Munchen, Germany|Universitatsklinikum Ulm, Ulm, Germany|AO Spedali Civili di Brescia, Brecia, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Ospedale Niguarda Milano, Milano, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Roma, Italy|Policlinico Agostino Gemelli - Istituto di Ematologia, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|VU University Medical Center, Amsterdam, Netherlands|Oddzial Hematologii Onkologicznej Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologicz, Brzozow, Poland|Katedra i Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 Klinika Hematoonkologii i Transplantacji Szpiku, Lubin, Poland|Oddzial Hematologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSW, Olsztyn, Poland|Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisbon, Portugal|Ipo Instituto Portugues De Oncologia Porto, Porto, Portugal|Hospital de Sao Joao, Porto, Portugal|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Complejo Hospitalario San Pedro de Alcantara, Caceres, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|University Hospital Birmingham, Birmingham, United Kingdom|St James University Hospital, Leeds, United Kingdom|University College London Hospital, London Bloomsbury, United Kingdom|St Bartholomews Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02775903"
134,"NCT02773030","A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)",,"Recruiting","No Results Available","Multiple Myeloma","Drug: CC-220|Drug: Dexamethasone|Drug: Daratumumab|Drug: Bortezomib (BTZ)|Drug: Carfilzomib","Maximum tolerated doses (MTDs) of CC-220 as monotherapy and in combination with other treatment|Establish Recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy and in combination with other treatment|Overall response rate (ORR) of CC-220 in combination with DEX in Part 2|Adverse Events (AEs)|Overall response rate (ORR)|Time to Response (TTR)|Duration of Response (DOR)|Pharmacokinetics ‐AUC 0-τ|Pharmacokinetics ‐Cmax|Pharmacokinetics ‐Tmax|Pharmacokinetics ‐t1/2|Pharmacokinetics ‐CLss/F|Pharmacokinetics ‐Vss/F|Progression-free Survival (PFS)|Overall Survival (OS) in Part 2","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-220-MM-001|U1111-1182-9200|2016-000860-40","October 14, 2016","April 16, 2021","February 14, 2026","May 16, 2016",,"October 22, 2019","Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Robert H Lurie Comprehensive Cancer Center NW Univ, Chicago, Illinois, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Winthrop Hospital, Mineola, New York, United States|New York University School of Medicine, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital Weil Cornell Medical College, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Prisma Health Cancer Institute, Greenville, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|McGill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|CHRU Hopital Claude Huriez, Lile Cedax, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|CHU La Miletrie, Poitiers Cedex, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma - Centro di Ematologia, Rome, Italy|Osp. S.Giovanni Battista Le Molinette, Torino, Italy|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Nagoya City University Hospital, Nagoya, Japan|Tohoku University Hospital, Sendai, Japan|VU University Medical Center, Amsterdam, Netherlands|Maastricht University Medical Center, Maastrich, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Vall d'Hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Dr. Pesset, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|University College London, London, United Kingdom|Genesis Care, Oxford, United Kingdom|The Institut of Cancer Research, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02773030"
135,"NCT02741544","Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])",,"Active, not recruiting","No Results Available","Multiple Myeloma",,"Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"578","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIS-Celgene-JP-PMS-003|U1111-1181-9845","March 3, 2016","August 21, 2021","August 21, 2021","April 18, 2016",,"February 5, 2019","Shinko Hospital, Kobe, Hyogo, Japan",,"https://ClinicalTrials.gov/show/NCT02741544"
136,"NCT02740218","A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice","APPRECIATE","Recruiting","No Results Available","Psoriasis","Other: Patient questionnaire","The Patient Benefit Index (PBI) outcome score|Treatment Satisfaction Questionnaire for Medication (TSQM) outcome score|Percentage of patients achieving PASI75|Percentages of patients achieving PASI50|Mean change in Dermatology Life Quality Index (DLQI)|Percentages of patients achieving ≥5 point improvement in DLQI|Percentages of patients achieving PASI50 plus ≥5 point improvement in DLQI|Mean change in Body Surface Area (BSA)|Mean change in PGA|Percentage of patients achieving PGA 0/1 (clear/almost clear)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"555","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CC-10004-PSOR-013","June 24, 2016","October 31, 2019","October 31, 2019","April 15, 2016",,"March 8, 2019","Medizinische Universität Graz, Graz, Austria|Praxis Dr. Wolfgang Fuchs, Großwarasdorf, Austria|Praxis Dr. Schicher, Klagenfurt, Austria|Praxis Dr. Wilhelm, Landeck, Austria|Kepler Universitätsklinikum, Linz, Austria|Praxis Dr. Dunst-Huemer, Linz, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria|Krankenanstalt Rudolfstiftung, Wien, Austria|Medizinische Universität Wien, Wien, Austria|Praxis Dr. Göttfried, Wien, Austria|Praxis Dr. Holub-Hoberger, Wien, Austria|Krankenhaus Hietzing, Wien, Austria|Praxis Dr. Nordberg, Wien, Austria|Praxis Dr. Menzinger, Wien, Austria|Praxis Dr. Sator, Wien, Austria|Praxis Dr. Perl-Convalexius, Wien, Austria|Praxis Dr. Harst, Aachen, Germany|Praxis Dr. Wagner-Schiffler, Aachen, Germany|Praxis Dr. Dietz, Ampfing, Germany|Praxis Dr. Bell, Andernach, Germany|Licca Clinical Research Institute, Augsburg, Germany|Gefäß- und Hautzentrum Blaustein, Blaustein, Germany|St. Josef und St. Elisabeth Hospital gGmbH, Bochum, Germany|Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany|Praxis Dr. Jordan, Brühl, Germany|Elbe Klinikum Buxtehude, Buxtehude, Germany|Praxis Dr. Schneider, Dachau, Germany|Praxis Dr. Thelen, Delmenhorst, Germany|Klinikum Dortmund, Dortmund, Germany|Praxis Dr. Scheibner, Dresden, Germany|Praxis Dr. Korge, Düren, Germany|Praxis für Dermatologie und Venerologie, Allergologie, Eltville, Germany|Praxis Dr. Schurhammer-Fuhrmann, Endingen, Germany|Uniklinikum Erlangen, Erlangen, Germany|Praxis Dr. Huerkamp, Euskirchen, Germany|Praxis Dr. Swirski, Euskirchen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Praxis Dr. Kämmerer, Freiberg, Germany|Praxis Dr. Kurzen, Freising, Germany|GP Dr. Rotterdam & Kollegen, Gelsenkirchen, Germany|Praxis Dr. med W. Klövekorn, Dr. med. A. Tepe, Dr. med. O. Wilde, Gilching, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Praxis Dr. Schmidt, Kusel, Germany|Praxis Birgit Zimmermann, Malchow, Germany|Praxis Dr. Piontek, Mechernich, Germany|Dermatologische Praxis Dr. med. Schwinn, Memmingen, Germany|Praxis Büchler, Memmingen, Germany|Praxis Dr. Antal, Mühldorf Am Inn, Germany|Praxis Dr. Cords, Mühlheim-Kärlich, Germany|Praxis Dr. Liebich, München, Germany|Technische Universität München, München, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Praxis Dr. Prell, Rosenheim, Germany|Praxis Dr. Blank, Rostock, Germany|Praxis Dr. Hoene, Rostock, Germany|Praxis Dr. Schenkelberger, Saint Ingbert, Germany|Company for Medical Study & Service, Selters / Westerwald, Germany|Praxis Dr. Neisius, Stolberg, Germany|Praxis Dr. Steinborn, Straubing, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Gemeinschaftspraxis Dr. Christian Fischer, Florian Kreuziger, Vilshofen, Germany|Praxis Dr. Dehmel, Wasserburg am Inn, Germany|Praxis Dr. Schmeel, Wesseling, Germany|Praxis Dr. Buttgereit, Wildau, Germany|Praxis Dr. Süß, Wittlich, Germany|Bon Secours Hospital, Co. Kerry, Ireland|Mater Misericordiae University Hospital, Dublin 7, Ireland|University Hospital Galway, Galway, Ireland|Hospital Fundacion Alcorcon, Madrid, Alcorcon, Madrid, Spain|Vithas Xanit Iinternational Hospital, Benalmádena, Spain|Hospital Universitario San Cecilio (PTS), Granada, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hudkliniken Mälarsjukhuset, Eskilstuna, Sweden|Hudkliniken SU/ Sahlgrenska, Göteborg, Sweden|Hudmottagningen Karlskoga Lasarett, Karlskoga, Sweden|Hudmottagningen Lindesbergs Lasarett, Lindesberg, Sweden|Capio Citykliniken Lund, Lund, Sweden|Diagnostiskt Centrum Hud Malmö, Malmö, Sweden|SUS Malmö Hudkliniken, Malmö, Sweden|Hudkliniken Vrinnevisjukhuset Norrköping, Norrköping, Sweden|Diagnostiskt Centrum Hud Stockholm, Stockholm, Sweden|Cutisgruppen/Stockholm Hud, Stockholm, Sweden|Hudkliniken SÖS, Stockholm, Sweden|Hudcentrum Hagastaden, Stockholm, Sweden|Karolinska Psoriasis Center, Stockholm, Sweden|Hudkliniken Danderyds Sjukhus, Stockholm, Sweden|Hudmottagningen Trelleborg, Trelleborg, Sweden|Hudmottagningen Västervik, Västervik, Sweden|Dermatologie Aesche, Basel, Switzerland|Somamedica, Basel, Switzerland|Ospedale Bellinzona e Valli EOC, Bellinzona, Switzerland|Insel Gruppe AG, Bern, Switzerland|Clinique dermatologie du Seujet, Genève, Switzerland|Hautarzt Oberaargau AG, Herzogenbuchsee, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Studio medico Dr. Pelloni, Lugano, Switzerland|Practice Dr. Niklaus, Martigny, Switzerland|Pallas Klinik Olten, Olten, Switzerland|Haut und Laserzentrum Dr. Zuder, St. Gallen, Switzerland|Praxis Dr. med. Christian Schuster, St. Gallen, Switzerland|Haut und Allergiezentrum Brunnehof, Uster, Switzerland|Dr. Tomi Haut- und Laserzentrum, Weinfelden, Switzerland|Hautpraxis Dermateam, Winterthur, Switzerland|Praxisgemeinschaft Bünz AG, Wohlen, Switzerland|Zug Hautarzt, Zug, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Bradford Teaching Hospitals NHS, Bradford, United Kingdom|West Suffolk NHS Foundation, Bury St Edmunds, United Kingdom|East Kent & Canterbury Hospital, Canterbury, United Kingdom|NHS Dumfries and Galloway, Dumfries, United Kingdom|Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom|West Middlesex University Hospital, Isleworth, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom|Chelsea & Westminster NHS Foundation Trust, London, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|University of Manchester, Salford, United Kingdom|Warwick Hospital, Warwick, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02740218"
137,"NCT02733042","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","FUSION NHL 001","Active, not recruiting","No Results Available","Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell","Drug: Durvalumab|Drug: Lenalidomide|Drug: Rituximab|Drug: Ibrutinib|Drug: Bendamustine","Adverse Events (AEs)- Phase|Dose Limiting Toxicity (DLT) - Phase 1|Non-Tolerated Dose (NTD)- Phase 1|Maximum Tolerated Dose (MTD)- Phase 1|Overall Response Rate (ORR)- Phase 2|Overall Response Rate- Phase 1|Adverse Events (AEs) - Phase 2|Overall Response Rate-Phase1/2|Duration of response (DoR)- Phase1/2|Progression free survival (PFS) - Phase 1/2|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Pharmacodynamics - Phase 1/2|Time to First Response(TTR)- Phase1/2","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","106","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-NHL-001","May 11, 2016","March 6, 2019","July 8, 2022","April 11, 2016",,"October 22, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Shands Cancer Center University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, Rochester, New York, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier, Dijon Cedex, France|Institut Paoli Calmettes, Marseille Cedex 9, France|CHU Montpellier, Montpellier Cedex 5, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, France|CHRU Rennes, Rennes, France|Centre Henri Becquerel, Rouen Cedex, France|Universitatsklinikum Essen, Essen, Germany|UKG Universitatsklinikum Gottingen, Göttingen, Germany|Universitatsklinikum des Saarlandes, Homburg-Saar, Germany|Universitatsklinik Koln, Köln, Germany|Medizinische Klinik III Klinikum der Universität München-Großhadern, München, Germany|University of Bologna, Bologna, Italy|Spedali Civili Di Brescia, Brescia, Italy|IEO- Istituto Europeo di Oncologia, Milano, Italy|A.O. Ospedale Ca Granda - Niguarda, Milano, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|I.R.C.C.S. Policlinico San Matteo, Pavia, Italy|IRCCS Humanitas Clinical Institute, Rozzano (milano), Italy|National Cancer Center Hospital, Chuo-ku, Japan|Tokai University Hospital, Isehara City, Kanagawa, Japan|Aichi Cancer Center, Nagoya, Japan|VU Academic Medical Center, Amsterdam, Amsterdam, Netherlands|UMC Groningen, Groningen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|St James University Hospital, Leeds, United Kingdom|UCL Cancer Institute, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02733042"
138,"NCT02692339","Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma","PrObe-L","Recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone","Number of Adverse events of special interest during Len/Dex therapy|Incidence (number) of thromboembolism|Duration of Len/Dex treatment over the course of the study|Number of patients with good and poor compliance to lenalidomide and dexamethasone|Type and frequency of prophylaxis treatment for prevention of thromboembolism","Celgene","All","18 Years and older   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-5013-MM-028","February 25, 2016","September 29, 2023","September 29, 2023","February 26, 2016",,"June 5, 2019","Hospital Garcia Orta, E.P.E., Almada, Portugal|Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal|Hospital Central de Faro, Faro, Portugal|Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, Portugal|Centro Hospitalar Lisboa Central, EPE - Hospital de Sto. Ant. Capuchos, Lisboa, Portugal|Fundação Champalimaud, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE - Hospital Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar de São João, EPE - Hospital de São João, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Hospital de São Teotónio, E.P.E., Viseu, Portugal",,"https://ClinicalTrials.gov/show/NCT02692339"
139,"NCT02685826","A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Durvalumab|Drug: Lenalidomide|Drug: Dexamethasone","Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28)|Participants With Treatment Emergent Adverse Events (TEAE)|Overall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria|Response Improvement Rate (RIR) for Cohort C: Percentage of Participants Achieving a Response Improved From Cycle 1 Day 1 as Assessed by the Investigators Using the International Myeloma Working Group (IMWG) Uniform Response Criteria|Time to Response (for Cohorts A and B)|Kaplan-Meier Estimates for Duration of Response (for Cohort A and B)|Durvalumab (DURVA) Serum Pharmacokinetic (PK) Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Maximum Observed Concentration (Cmax)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Time to Maximum Observed Concentration (Tmax)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Terminal Elimination Half-life (t1/2)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Clearance (CL)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Volume of Distribution (Vz)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Maximum Observed Concentration (Cmax)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Time to Maximum Observed Concentration (Tmax)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Terminal Elimination Half-life (t1/2)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Clearance (CL/F)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Volume of Distribution (Vz/F)|Lenalidomide Plasma PK Parameters in Cycle 1 Day 15: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Maximum Observed Concentration (Cmax)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Time to Maximum Observed Concentration (Tmax)|Participants Who Developed Anti-drug Antibody Against Durvalumab|Participants Who Had Either Disease Progression or Death|Participants Who Died Up To Data Cut-off Date (15 December 2017)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-MM-002|2015-004831-11","April 25, 2016","December 15, 2017","September 6, 2022","February 19, 2016","February 11, 2019","February 11, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Medical College of Cornell University, New York, New York, United States|Carolinas Healthcare System, Charleston, South Carolina, United States|Swedish Medical Center, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Helsinki UniversityCentral Hospital, Helsinki, Finland|Universitatsklinikum Essen, Essen, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|University of Tubingen, Tübingen, Germany|Policlinico S. Orsola, Bologna, Italy|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova, Reggio Emilia, Italy|Policlinico Agostino Gemelli, Rome, Italy|Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette, Torino, Italy|VU Medical Center, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Hopsital Germans Trias I Pujol, Badalona, Spain|Hospital 12 de Octobre, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02685826/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02685826/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02685826"
140,"NCT02685683","Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease",,"Terminated","No Results Available","Crohn's Disease","Drug: GED-0301","Change from baseline of Smad7 (Mothers Against Decapentaplegic homolog 7) expression in the intestinal mucosa|Change from baseline in messenger ribonucleic acid (mRNA) expression of inflammatory cytokines|The proportion of subjects achieving clinical remission, defined as a Crohn's Disease Activity Index (CDAI) score < 150, at Weeks 4, 8, and 12|Change from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12 and 52|Number of Adverse Events","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GED-0301-CD-005","April 4, 2016","September 25, 2017","November 9, 2017","February 19, 2016",,"August 14, 2018","Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Tor Vergata, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT02685683"
141,"NCT02677922","A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)",,"Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: AG-120|Drug: Azacitidine|Drug: AG-221","Dose limiting toxicities (DLTs)-Phase 1B|Adverse Events (AEs) in Ph 1b|Pharmacokinetics- Cmax|Pharmacokinetics- Tmax|Pharmacokinetics- AUC|Overall response rate (ORR) Ph 2|Overall Response Rate - Phase 1b (Ph 1b)|Event-Free Survival - Phase 2 (Ph 2)|Adverse Events (AEs) - Ph 2|Complete remission rate - Ph 2|Hematologic improvement rate - Ph 2|Duration of Response - Ph 2|Overall Survival - Ph 2|One-year survival- Ph 2|Pharmacokinetics- Cmax - Ph 2|Pharmacokinetics- Tmax - Ph 2|Pharmacokinetics- AUC - Ph 2|EORTC QLQ-C30 - European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire - Ph 2|EQ-5D-5L Health Questionnaire - Ph 2|Overall Response Rate - Phase 1b (Ph 2)|Time to Response - Phase 2","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG-221-AML-005","June 3, 2016","November 20, 2019","September 21, 2020","February 9, 2016",,"May 24, 2019","City of Hope, Duarte, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Parkville Cancer Clinical Trials Unit, Melbourne, Australia|The Alfred Hospital, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institut Paoli Calmettes, Marseille Cedex 9, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Hopital Saint Louis, Paris Cedex 10, France|Hospital haut leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Universitaire du Cancer Oncopole, Toulouse, France|CHRU Hopital Bretonneau, Tours cedex, France|Institut Gustave Roussy, Villejuif CEDEX, France|Medizinische Klinik III Klinikum der Universität München-Großhadern, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Heinrich Heine Universitat Dusseldorf, Düsseldorf, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Zentrum Innere Medizin Klinik fur Hamatologie, Hannover, Germany|Universitatsklinikum Ulm, Ulm, Germany|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria S. Martino di Genova, Genova, Italy|Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy|Hospital of Di Padova, Padova, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord AORMN, Pesaro, Italy|Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Italy|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|VU University Medical Center, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Porto, Portugal|H Clinic I Provincial, Barcelona, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital General de la Palma, Breña Alta, Spain|Hospital San Pedro de Alcantara, Caceres, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|M. D. Anderson, Madrid, Spain|Hospital General Carlos Haya, Malaga, Spain|Hospital Universitario La Fe, Valencia, Spain|UniversitatsSpital Basel, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois CHUV BH-04, Lausanne, Switzerland|Universitatsspital Zurich, Zurich, Switzerland|Queen Elizabeth Hospital UHB NHS Foundation Trust, Birmingham, United Kingdom|John Radcliffe Hospital, Headington, United Kingdom|Leeds Teaching Hospitals Trust, Leeds, United Kingdom|Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom|King's College Hospital, London, United Kingdom|Royal Marsden Hospital, Sutton (Surrey), United Kingdom",,"https://ClinicalTrials.gov/show/NCT02677922"
142,"NCT02670746","A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer","TRUST","Terminated","No Results Available","Pancreatic Neoplasms",,"Overall survival|Adverse Event (AE)|Change from baseline in the EORTC-QLQ-CIPN-20 (European Organization for Research and Treatment of Cancer Quality of Life Instrument In Patients With Chemotherapy Induced Peripheral Neuropathy )|Change from baseline in the EORTC-QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Instrument)|Change from baseline in the EuroQuality of Life : EQ5D-3L|Evaluate the incidence of neuropathy - grade 1-5|Evaluate reversibility of neuropathy to Gr ≤1|Evaluate the resources utilized for treatment of pancreatic adenocarcinoma with the combination nab-paclitaxel/gemcitabine in routine clinical practice","Celgene","All","18 Years and older   (Adult, Older Adult)",,"44","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ABI-007-PANC-008","October 1, 2015","November 28, 2017","November 28, 2017","February 2, 2016",,"September 16, 2019","Ziekenhuis de Tjongerschans, Heerenveen, Friesland, Netherlands|Antonius Ziekenhuis Sneek, Sneek, Friesland, Netherlands|Rijnstate Ziekenhuis, Arnhem, Gelderland, Netherlands|Amphia ziekenhuis, Breda, Gelderland, Netherlands|Gelderse Vallei, Ede, North Brabant, Netherlands|Elkerliek Ziekenhuis, Helmond, North Brabant, Netherlands|Spaarne Gasthuis, Haarlem, North Holland, Netherlands|Tergooi, Hilversum, North Holland, Netherlands|BovenIJ Ziekenhuis, Amsterdam, North- Holland, Netherlands|Academic Medical Centre, Amsterdam, North- Holland, Netherlands|Maxima Medisch Centrum, Veldhoven, North-Brabant, Netherlands|Isala, Zwolle, Overijssel, Netherlands|HagaZiekenhuis, The Hague, South- Holland, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, South-Holland, Netherlands|LUMC, Leiden, South-Holland, Netherlands|Zorgsaam Zeeuws -Vlaanderen, Terneuzen, Zeeland, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02670746"
143,"NCT02658929","Study of bb2121 in Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Biological: bb2121","Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)|Disease-specific response criteria including: overall response rate (ORR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM.","Celgene|bluebird bio","All","18 Years and older   (Adult, Older Adult)","Phase 1","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRB-401","December 22, 2015","November 30, 2023","November 30, 2023","January 20, 2016",,"August 21, 2019","Stanford Cancer Center, Stanford, California, United States|National Cancer Institute, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mt. Sinai Medical Center Division of Hematology/Oncology, New York, New York, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02658929"
144,"NCT02652494","Observational Study of Apremilast in Patients With Psoriasis in The Netherlands","APRIL","Recruiting","No Results Available","Psoriasis",,"Percentage of patients with Dermatology Life Quality Index (DLQI) ≤ 5 points|Percentage of patients with Dermatology Life Quality Index (DLQI) improvement in DLQI ≥ 5 points|Changes in treatment satisfaction questionnaire for medication (TSQM) at 6 and 12 months treatment|Changes in generic quality of life at 6 and 12 months treatment Short Form 36 (SF-36v2) health survey|Changes in generic quality of life at 6 and 12 months treatment using EuroQol-5 dimensions (EQ-5D)|Change in itch at 6 and 12 months treatment using the itch Visual Analog Scale (VAS)|Changes in psoriasis area and severity index (PASI) at 6 and 12 months treatment|Changes in body surface area (BSA)at 6 and 12 months treatment|Changes in static physician global assessment (sPGA) at 6 and 12 months treatment|Baseline characteristics of patients initiating apremilast treatment|Reasons for discontinuation of apremilast","Celgene","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PSOR-014","February 22, 2016","December 31, 2018","December 31, 2018","January 12, 2016",,"November 21, 2018","Antonius Ziekenhuis Sneek, Sneek, Friesland, Netherlands|Zorggroep Twente, Hengelo, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Zuyderland MC, Sittard, Limburg, Netherlands|TweeSteden Ziekenhuis, Tilburg, North Brabant, Netherlands|Bravis Ziekenhuis, Bergen op Zoom, North-Brabant, Netherlands|Amphia, Breda, North-Brabant, Netherlands|Maxima MC, Veldhoven, North-Brabant, Netherlands|Centrum Oosterwal, Alkmaar, North-Holland, Netherlands|Spaarne Gasthuis, Hoofddorp, North-Holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, South Holland, Netherlands|Meander MC, Amsersfoort, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02652494"
145,"NCT02641392","A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease",,"Terminated","Has Results","Crohn's Disease","Drug: GED-0301|Other: Placebo","Number of Participants With Treatment Emergent Adverse Events From Week 0 to Week 208","Celgene","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GED-0301-CD-004","July 25, 2016","January 4, 2018","January 4, 2018","December 29, 2015","January 29, 2019","January 29, 2019","Medical Associates Research Group Inc., San Diego, California, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Health Science Research Center, LLC, Pratt, Kansas, United States|Via Christi Research a division of Via Christi Hospitals Wichita Inc, Wichita, Kansas, United States|Gastroenterology Associates LLC, Baton Rouge, Louisiana, United States|Metropolitan Gastroenterology, Chevy Chase, Maryland, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Gastroenterology Associates of Western Michigan PLC, Wyoming, Michigan, United States|Ehrhardt Clinical Research LLC, Belton, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Trial Management Associates LLC, Wilmington, North Carolina, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Texas Clinical Research Institute LLC, Arlington, Texas, United States|Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States|Texas Digestive Disease Consultants - Southlake, Flower Mound, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Sagact Pllc, San Antonio, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States|The Vancouver Clinic, Vancouver, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Centre For Digestive Diseases, Five Dock, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Monash Medical Centre Clayton, Bentleigh East, Australia|LKH Universitaetsklinikum Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|KH der Barmherzigen Bruder Linz, Linz, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|KH der Barmherzigen Brüder St.Veit an der Glan, St Veit An Der Glan, Austria|Krankenanstalt Rudolfstiftung Wien, Wein, Austria|AKH Medizinische Universitat Wien, Wein, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|MHAT Kaspela EOOD, Plovdiv, Bulgaria|MHAT Ruse AD, Ruse, Bulgaria|Second MHAT Sofia AD, Sofia, Bulgaria|City Clinic UMHAC EOOD, Sofia, Bulgaria|UMHAT Sv Ivan Rilski EAD, Sofia, Bulgaria|UMHAT Tsaritsa Yoanna - ISUL EAD, Sofia, Bulgaria|MHAT Doverie AD, Sofia, Bulgaria|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|South Edmonton Gastroenterology, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|GI Research Institute, Vancouver, British Columbia, Canada|PerCuro Clinical Research, Victoria, British Columbia, Canada|Brandon Medical Arts Clinic, Brandon, Manitoba, Canada|McMaster University Health Sciences Center, Hamilton, Ontario, Canada|London Health Science Center U. Hospital, London, Ontario, Canada|LHSC Victoria Hospital, London, Ontario, Canada|Montfort Hospital, Ottawa, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Medicine Professional Corporation, Waterloo, Ontario, Canada|Centre de sante et de services sociaux Champlain Charles Le Moyne, Greenfield Park, Quebec, Canada|McGill University Health Centre Glen Site Royal Victoria Hospital, Montreal, Quebec, Canada|Clinical Hospital Centre Osijek, Osijek, Croatia|Fakultni nemocnice u sv Anny v Brne, Brno, Czechia|Hepato-Gastroenterologie HK, Hradec Kralove, Czechia|PreventaMed, Olomouc, Czechia|CCBR Prague CZ, Praha 3, Czechia|Aarhus Universitetshospital, Aahus C, Denmark|Alborg Universitets Hospital, Alborg, Denmark|Nordsjaellands Hospital Frederikssund, Frederikssund, Denmark|Herlev Hospital, Herlev, Denmark|Koge Sygehus, Koge, Denmark|Regionshospitalet Silkeborg, Silkeborg, Denmark|CHU Amiens Hopital Sud, Amiens Cedex, France|CHU Besancon Hopital Jean Minjoz, Besancon Cedex, France|CHU Tours Hopital Trousseau, Chambray les Tours, France|CHU Clermont Ferrand, Clermont-Ferrand, France|Hopital Beaujon, Clichy cedex, France|CHU Nantes Hotel Dieu, Nantes Cedex 1, France|CHU Nice Hopital de lArchet 2, Nice Cedex 3, France|Groupe Hospitalier Sud Hopital Haut Leveque USN, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|CHU Reims Hopital Robert Debre, Reims, France|CHU Rennes Hopital Pontchaillou, Rennes cedex 09, France|CHU Saint Etienne Hopital Nord, Saint Etienne, France|CHU Strasbourg Hopital Hautepierre, Strasbourg Cedex, France|CHU de Toulouse Hopital Rangueil, Toulouse Cedex 09, France|Hopital de Brabois Adultes, Vandoeuvre les Nancy, France|Charite Universitaetsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Krankenhaus Waldfriede e V, Berlin, Germany|Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH, Bochum, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Essen, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Universitaetsklinikum Halle Saale, Halle, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Praxis fuer Gastroenterologie Dr Ehehal Dr Helmstaedter, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, Germany|University Leipzig, Leipzig, Germany|EUGASTRO GmbH, Leipzig, Germany|Medizinisches Zentrum Klinikum Lueneburg, Lueneburg, Germany|Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Germany|Gastro Campus Research, Muenster, Germany|Klinikum der Universitaet Muenchen, München, Germany|Staedtisches Klinikum Braunschweig gGmbH Standort Salzdahlumer, Niedersachsen, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|General Hospital of Athens Evangelismos, Athens, Greece|Athens Medical Center, Athens, Greece|University General Hospital of Patras, Rio Patras, Greece|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfured, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem AOK, Budapest, Hungary|Endomedix Diagnosztikai Kozpont, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Szent Pantaleon Korhaz Rendelointezet Dunaujvaros, Dunaujvaros, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Clinfan Szolgaltato Kft, Szekszard, Hungary|HaEmek Medical Center, Afula, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel|The Baruch Padeh MC, Poriya, Tiberias, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Policlinico G Martino, Messina, Italy|Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Vincenzo Cervello, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Universita Campus Bio Medico di Roma, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|IRCCS Policlinico San Donato, San Donato Milanese, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|CHA Bundang Medical Center CHA University, Seongnam-si,, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Digestive Diseases Center Gastro, Riga, Latvia|Pauls Stradins Clinical University Hospital, Riga, Latvia|VU Medisch Centrum, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Radboudumc, Nijmegen, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Akershus universitetssykehus HF, Lørenskog, Norway|Oslo Universitetssykehus Rikshospitalet, Oslo, Norway|Niepubliczny Zaklad Opieki Zdrowotnej POLIMEDICA, Kielce, Poland|Indywidualna Praktyka Lekarska Maciej Zymla, Knurow, Poland|SPZOZ Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej - Centralny Szpital Weteranow, Lodz, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Endoskopia Sp. z o.o., Sopot, Poland|Hospital de Braga, Braga, Portugal|Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|S.C MedLife S.A, Bucuresti, Romania|CMI Dr. Tirnaveanu Amelita, Oradea, Romania|Centrul de Gastroenterologie Dr. Goldis, Timisoara, Romania|TSBIH Territorial Clinical Hospital, Krasnoyarsk, Russian Federation|SBHI of NN region RCH of NN n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|FSBI Scientific Research Institute of Physyology and Basic Medicine under the SB of RAMS, Novosibirsk, Russian Federation|Evromedservis, Pushkin, Russian Federation|SEIHPE Rostov State Medical University of MoH of RF, Rostov-on-Don, Russian Federation|SPb SBIH City Hospital # 26, Saint-Petersburg, Russian Federation|NonState Healthcare Institution Central Clinical Hospital, Samara station JSC Russian Railways, Samara, Russian Federation|Clinical Center Zvezdara, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia|Alian s.r.o., Bardejov, Slovakia|Gastroeneterologicka ambulancia MUDr. Peter Hegyi s.r.o., Malacky, Slovakia|Fakultna nemocnica Nitra, Nitra, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|Hospital del Mar, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Danderyds Sjukhus AB, Stockholm, Sweden|Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner, Bern, Switzerland|Ankara University Medical Faculty, Ankara, Turkey|Yeditepe University Medical School Hospital, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey|Acibadem Fulya Hospital, Istanbul, Turkey|Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey|RCI Chernivtsi Regional Clinical Hospital Dept of Surgery Bukovinian SMU, Chernivtsi, Ukraine|CI of PH Kharkiv CCH #2, Kharkiv, Ukraine|Treatment-Diagnostic Center of Private Enterprise of PMF Atsynus, Kirovohrad, Ukraine|Ukrainian-German Antiulcer Gastroenterological Center BYK-Kyiv LLC, Kyiv, Ukraine|Kyiv City Clinical Hospital #1, Kyiv, Ukraine|SI Republican Clinical Hospital of the MOHU Dept of Gastroenterology O.O.Bogomolets NMU, Kyiv, Ukraine|CI Odesa Regional Clinical Hospital, Odessa, Ukraine|Ternopil City Communal Emergency Medical Care Hospital, Ternopil, Ukraine|CI Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporozhje, Ukraine|Royal Devon and Exeter Hospital Wonford, Exeter, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Royal London Hospital, London, United Kingdom|St Marys Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Nottingham University Hospitals Queens Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02641392/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02641392/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02641392"
146,"NCT02641353","Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and a Study to Assess Effect of Food on the Pharmacokinetic (PK) of the Oral Suspension",,"Completed","No Results Available","Healthy Volunteers","Drug: Apremilast|Drug: Apremilast Oral Suspension","Cmax|Area under the plasma concentration curve time 0 to a definite time (AUC0-t)|Area Under the Curve from 0 to infinity|Percent AUC extrapolated|Fraction|Time Delay Lag|Time to reach the observed maximum (peak) concentration (Tmax)|Terminal half life (T1/2)|Apparent total plasma or serum clearance of CC-10004 after oral administration|Apparent volume of distribution during terminal phase after oral administration (Vz/F)|Adverse Events","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-10004-CP-032","January 5, 2016","February 27, 2016","February 27, 2016","December 29, 2015",,"November 22, 2018","Covance Clinical Research Unit Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02641353"
147,"NCT02641002","A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)",,"Terminated","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes","Drug: CC-90002","Dose-limiting Toxicity (DLT)|Non-tolerated Dose (NTD)|Maximum tolerated dose (MTD)|Preliminary Efficacy of CC-90002|Pharmacokinetics-Cmax|Pharmacokinetics-AUC|Pharmacokinetics-Tmax|Pharmacokinetics-T 1/2|Pharmacokinetics- CL|Pharmacokinetics- Vss|Anti-Drug Antibodies (ADAs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90002-AML-001","March 1, 2016","July 18, 2018","July 18, 2018","December 29, 2015",,"October 18, 2018","Mayo Clinic Phoenix, Phoenix, Arizona, United States|UCLA Division of Hematology Oncology, Los Angeles, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02641002"
148,"NCT02635061","Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer",,"Recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: ACY-241|Drug: Nivolumab","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|recommended Phase 2 dose (RP2D) of ACY 241 in combination with nivolumab|preliminary antitumor activity of ACY 241 in combination with nivolumab|Maximum Plasma Concentration [Cmax] of ACY 241 in combination with nivolumab on biomarkers in peripheral blood and tumor tissue","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-ST-203","August 25, 2016","November 30, 2019","December 31, 2019","December 18, 2015",,"August 15, 2019","University of Southern California, Los Angeles, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02635061"
149,"NCT02631070","A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","MEDALIST","Active, not recruiting","No Results Available","Myelodysplastic Syndromes","Drug: Luspatercept|Other: Placebo","Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 weeks|Red Blood Cell Transfusion Independence (RBC-TI) ≥ 12 weeks|Reduction in red blood cell (RBC) units transfused over 16 weeks|Proportion of subjects achieving Modified hematologic improvement - erythroid (mHI-E) per International Working Group (IWG) over any consecutive 56 days|Mean hemoglobin increase ≥ 1.0 g/dL|Duration of Red Blood Cell Transfusion Independence (RBC-TI)|Change in EORTC QLQ-C30 score|Hematologic improvement - neutrophils (HI-N) per International Working Group (IWG)|Mean decrease in serum ferritin|Mean decrease in iron chelation therapy (ICT) use|Time to red blood cell transfusion independence (RBC-TI)|Number of subjects progressing to acute myeloid leukemia (AML)|Progression to acute myeloid leukemia (AML)|Overall survival (OS)|Adverse Events (AEs)|Anti-drug antibodies (ADA)|Pharmacokinetics - AUC|Pharmacokinetics ‐ Cmax|Hematologic improvement- platelets (HI-P) per International Working Group (IWG)|A population PK model and Exposure-Response relationship","Celgene|Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACE-536-MDS-001","February 9, 2016","November 21, 2017","November 5, 2020","December 15, 2015",,"July 9, 2019","Stanford Cancer Center, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Ochsner Medical Institutions, New Orleans, Louisiana, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Montefiore Medical Center Albert Einstein Cancer Center, Bronx, New York, United States|Columbia-Presbyterian Medical Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|AZ Sint-Jan AV Brugge, Brugge, Belgium|UZ Brussels, Brussel, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHU d'Angers, Angers, France|CHU Hotel, Grenoble Cedex 09, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institut Paoli Calmettes, Marseille cedex, France|CHU de Nice Archet I, Nice, France|Hopital Saint Louis, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Centre hospitalier Lyon Sud Hematologie, Pierre-Bénite cedex, France|Hopital civil, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Hopital Bretonneau, Tours, France|Universitatsklinikum Bonn, Bonn, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Marien Hospital, Dusseldorf, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Sanitaria Locale Lecce, Lecce, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio, Calabria, Italy|Fondazione Policlinico Universitario A Gemelli, Roma, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Hospital Universitario Cruces, Barakaldo, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Seville, Spain|Hospital Universitario La Fe, Valencia, Spain|Sahlgrenska Universitetssjukhus, Göteborg, Sweden|Skanes Universitetssjukhus Lund, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|John Radcliffe Hospital, Headington, United Kingdom|St James University Hospital, Leeds, United Kingdom|Guys Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02631070"
150,"NCT02626793","A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions",,"Completed","No Results Available","Psoriasis",,"Change from baseline in the Dermatology Life Quality Index (DLQI) ≤ 5 or improvement in DLQI by ≥ 5 points at Visit 2 from baseline|Change from Baseline in the Dermatology Life Quality Index (DLQI) ≤ 5 or improvement in DLQI by ≥ 5 points at all other visits from baseline.|Change in the Physician Global Assessment (PGA) Score|Percent Change in Percent of Affected Body Surface Area (BSA)|Percent Change in the Psoriasis Area Severity Index (PASI) Score|Change in the Patient's Global Assessment (PaGA)|Patient Preference Questionnaire (PPQ)|Patient Satisfaction (Systemic Therapy Adherence Questionnaire, STAQ)|Change in Pain (Visual Analogue Scale; VAS)|Adverse Events (AEs)|Change in Itch (Pruritus) (Visual Analogue Scale; VAS)|Change in Scalp Involvement -Physician's Global Assessment (PGA)|Change in Scalp Involvement - Patient's Global Assessment (PaGA)|Change in Nail Involvement - Target Nail Psoriasis Severity Index (NAPSI)|Change in Nail Involvement Fingernail - Patient's Global Assessment (PaGA)|Change in Palmoplantar involvement - Palmoplantar physician's global assessment (PGA)|Change in Palmoplantar involvement - Palmoplantar patient's global assessment (PaGA)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"391","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-10004-PPSO-002","August 3, 2015","June 8, 2017","June 14, 2018","December 10, 2015",,"August 12, 2019","Gertraud Krähn-Senftleben, Blaubeuren, Baden-Württemberg, Germany|Ralf-Uwe Peter, Blaustein, Baden-Württemberg, Germany|Regina Renner, Esslingen am Neckar, Baden-Württemberg, Germany|Universitätsklinikum Heidelberg - Hautklinik, Heidelberg, Baden-Württemberg, Germany|Ina Reitenbach-Blindt, Karlsruhe, Baden-Württemberg, Germany|Kaiserstraße 231-233, Karlsruhe, Baden-Württemberg, Germany|Naomi Gerhardus, Karlsruhe, Baden-Württemberg, Germany|Johannes Glutsch, Karlsruhe, Baden-Württemberg, Germany|Beate Schwarz, Langenau, Baden-Württemberg, Germany|Astrid Schmieder, Mannheim, Baden-Württemberg, Germany|Katharina Wroblewska, Spaichingen, Baden-Württemberg, Germany|Michael Sticherling, Erlangen, Bayern, Germany|Hjalmar Kurzen, Freising, Bayern, Germany|Claus Jung, Germering, Bayern, Germany|Clarissa Allmacher, Hersbruck, Bayern, Germany|Ildiko Sugar-Bunk, Krumbach, Bayern, Germany|Sabine Anders, München, Bayern, Germany|Hortensia Pfannenstiel, München, Bayern, Germany|Technische Universität München - Kilian Eyerich, München, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Andreas Eggert, Würzburg, Bayern, Germany|Lars Freitag, Falkensee, Brandenburg, Germany|Förster-Funke-Allee 104, Kleinmachnow, Brandenburg, Germany|Silke Thies, Schwedt, Brandenburg, Germany|Christoph Hartl, Eltville, Hessen, Germany|Universitätsklinikum Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt am Main, Hessen, Germany|Pia Freyschmidt-Paul, Schwalmstadt, Hessen, Germany|Andreas Timmel, Bergen, Mecklenburg-Vorpommern, Germany|Raimund Paech, Neubrandenburg, Mecklenburg-Vorpommern, Germany|Jutta Ramaker-Brunke, Braunschweig, Niedersachsen, Germany|Andreas Kleinheinz, Buxtehude, Niedersachsen, Germany|Marco Averbeck, Cloppenburg, Niedersachsen, Germany|Florian Schenck, Hannover, Niedersachsen, Germany|Ulrike Stein, Hannover, Niedersachsen, Germany|Holger Petering, Hildesheim, Niedersachsen, Germany|Silke Reinecke, Holzminden, Niedersachsen, Germany|Reinhard Knöll, Lüneburg, Niedersachsen, Germany|Christian Kock, Vechta, Niedersachsen, Germany|Gesundheitszentrum Winsen, Winsen, Niedersachsen, Germany|Theaterplatz 9, Aachen, Nordrhein-Westfalen, Germany|Isaak Effendy, Bielefeld, Nordrhein-Westfalen, Germany|Volker Riesopp, Duisburg, Nordrhein-Westfalen, Germany|Bernhard Korge, Düren, Nordrhein-Westfalen, Germany|Herderstr.71 b, Düsseldorf, Nordrhein-Westfalen, Germany|Dechant-Deckers-Straße 5-7, Eschweiler, Nordrhein-Westfalen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Christina Huerkamp, Euskirchen, Nordrhein-Westfalen, Germany|Sebastian Rotterdam, Gelsenkirchen-Feldmark, Nordrhein-Westfalen, Germany|Jörg Brinkmann, Gladbeck, Nordrhein-Westfalen, Germany|Hautartzpraxis, Kleve, Nordrhein-Westfalen, Germany|Rudolf Stadler, Minden, Nordrhein-Westfalen, Germany|Rolf Ostendorf, Mönchengladbach, Nordrhein-Westfalen, Germany|Athanasios Tsianakas, Münster, Nordrhein-Westfalen, Germany|Stefanie Montag, Rheinbach, Nordrhein-Westfalen, Germany|Hautarztpraxis, Steinfeldstr. 5, Stolberg (Rheinland), Nordrhein-Westfalen, Germany|Oliver Mainusch, Velbert, Nordrhein-Westfalen, Germany|Kurt-Kräcker-Str. 47, Wesel, Nordrhein-Westfalen, Germany|Ulrich Blaese, Bendorf, Rheinland Pfalz, Germany|Magnus Bell, Andernach, Rheinland-Pfalz, Germany|Schloss Straße 17, Koblenz, Rheinland-Pfalz, Germany|Petra Staubach-Renz, Mainz, Rheinland-Pfalz, Germany|Dirk Maaßen, Maxdorf, Rheinland-Pfalz, Germany|Marktstr. 20, Neuwied, Rheinland-Pfalz, Germany|Praxis für Haut- und Geschlechtskrankheiten - Allergologie - Am Johannisborn, Prüm, Rheinland-Pfalz, Germany|Ralph von Kiedrowski, Selters, Rheinland-Pfalz, Germany|Mohammad Asefi, Simmern, Rheinland-Pfalz, Germany|Puschkinstr. 110, Eilenburg, Sachsen-Anhalt, Germany|Franckestr. 1, Magdeburg, Sachsen-Anhalt, Germany|Jens Ulrich, Quedlinburg, Sachsen-Anhalt, Germany|Gabriela Fiedler, Weißenfels, Sachsen-Anhalt, Germany|Karolin Schneider, Chemnitz, Sachsen, Germany|Beatrice Gerlach, Dresden, Sachsen, Germany|Liane John, Dresden, Sachsen, Germany|Mary-Krebs-Straße 1, Dresden, Sachsen, Germany|Stefan Beissert, Dresden, Sachsen, Germany|Bernhard-Göring-Str. 162, Leipzig, Sachsen, Germany|Riebeckstraße 65, Leipzig, Sachsen, Germany|Schweizergartenstr. 2a, Wurzen, Sachsen, Germany|Harald Brüning, Kiel, Schleswig-Holstein, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Schleswig-Holstein, Germany|Christian Meewes, Neumünster, Schleswig-Holstein, Germany|Jens Thieme, Artern, Thüringen, Germany|Mario Pawlak, Heiligenstadt, Thüringen, Germany|Raoul Hasert, Berlin, Germany|Klaus Spickermann, Berlin, Germany|Jens Olaf Mielcke, Berlin, Germany|Albert-Einstein-Str. 2, Berlin, Germany|Hautarztpraxis Zahn, Berlin, Germany|Maria Manasterski, Berlin, Germany|Martin Miehe, Berlin, Germany|Uwe Schwichtenberg, Bremen, Germany|Matthias Augustin, Hamburg, Germany|Kristian Reich, Hamburg, Germany|Christian Mensing, Hamburg, Germany|Johannes-R.-Becher-Straße 24, Königs Wusterhausen, Germany|Florian Kreuziger, Vilshofen, Germany",,"https://ClinicalTrials.gov/show/NCT02626793"
151,"NCT02626689","To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care",,"Completed","No Results Available","Beta-Thalassemia","Other: Quality of Life (QOL) questionnaires|Other: Healthcare Resource Utilization","Change in the Physical component score (PSC) over the study period versus the country specific population norms using the 36-item Short Form (SF-36) Quality of Life instrument|Change in the Mental component score (MCS) over the study period versus the country specific population norms using the 36-item Short Form (SF-36) Quality of Life instrument|Change in the total scores over the study period using the The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire|Change in the total scores over the study period using the Tran-QOL questionnaire|Change in the total scores over the study period using the Patient Reported Outcome (PRO) questionnaire in non-transfusion dependent (NTD) subjects|Changes in the annual Healthcare Resource Care (HRC) involving the number of office visits|Number of minutes spent in sedentary, lightly active, fairly active, or very active lifestyles|Changes in the annual Healthcare Resource Care (HRC) involving the number of prescriptions dispensed|Changes in the annual Healthcare Resource Care (HRC) involving the number of procedures undergone|Changes in the annual Healthcare Resource Care (HRC) involving the number of lab assessments completed|Changes in the annual Healthcare Resource Care (HRC) involving the number of days that a patient is hospitalized|Changes in the annual Healthcare Resource Care (HRC) involving the number of emergency room visits|Percentage of time spent in sedentary, lightly active, fairly active, or very active lifestyles","Celgene","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACE-536-B-THAL-003","March 1, 2016","January 3, 2017","January 3, 2017","December 10, 2015",,"April 7, 2017","Aghia Sofia Children's Hosptial, Athens, Goudi, Greece|Fondazione IRCCS Ca Granda Ospedale Maggiore, Milano, Italy|American University of Beirut Medical Center, Beirut, Lebanon|Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Bangkoknoi, Thailand|Cukurova University Medical Faculty Balcali Hospital, Cukurova, Turkey",,"https://ClinicalTrials.gov/show/NCT02626689"
152,"NCT02620800","Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer","FABLOx","Completed","No Results Available","Metastatic Pancreas Adenocarcinoma","Drug: 5FU|Drug: nab-paclitaxel|Drug: bevacizumab|Drug: calcium leucovorin|Drug: oxaliplatin","Dose limiting toxicities (Phase 1)|1 year survival rate (Phase II portion)|Number of subjects experiencing Adverse Events (AEs) by severity and overall tabulations by cohort and overall including treatment emergent and Serious AEs|Summary for the number of subjects experiencing Adverse Events (AEs) by severity and overall in tabulations by cohort and overall including treatment emergent AEs and Serious AEs|Objective Response Rate using Response Evaluation Criteria In Solid Tumours (Recist) v1.1 presented by frequency and percentages|Progression free survival (PFS)|Overall Survival (OS)|Percentage of subjects with symptom improvement|Percentage of subjects with symptom improvement between subjects who experienced at least partial response and those without partial response|Percentage of subjects who experienced symptom improvement by a score of ≥ 2","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-PANC-009","January 18, 2016","October 29, 2018","October 29, 2018","December 3, 2015",,"October 22, 2019","Northwestern University, Chicago, Illinois, United States|Tufts - New England Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Center Wayne State University, Detroit, Michigan, United States|Cornell University Weill Medical College, New York, New York, United States|Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina, United States|Virginia Mason Cancer Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02620800"
153,"NCT02616640","A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Durvalumab|Drug: Pomalidomide|Drug: Dexamethasone","Dose-limiting Toxicities (DLTs)|Adverse Events (AEs)|Overall response rate (ORR)|Time to response (TTR)|Duration of response (DOR)|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-MM-001","January 11, 2016","January 10, 2017","February 6, 2020","November 30, 2015",,"May 9, 2019","University of Arkansas, Little Rock, Arkansas, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Partners Cancer Care, Inc., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mt. Sinai School of Medicine, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State Medical Center, Columbus, Ohio, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|CHU Nantes Hotel Dieu, Nantes, France|CHU Bordeaux, Pessac, France|CHU La Miletrie, Poitiers Cedex, France|Institut universitaire du cancer de Toulouse (IUCT) - Oncopole, Toulouse CEDEX 9, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum EssenZentrum fuer Innere Medizin, Essen, Germany|University of Heidelberg, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Istituto Nazionale Dei Tumori, Milano, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori ""Fondazione Giovanni Pascale"", Napoli, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|ICO-Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02616640"
154,"NCT02604433","An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia","BELIEVE","Active, not recruiting","No Results Available","Erythrocyte Transfusion|Beta-Thalassemia","Drug: Luspatercept|Other: Placebo","Proportion of subjects with hematological improvement from Week 13 to Week 24 compared to 12-week prior to randomization|Proportion of subjects with hematological improvement from Week 37 to Week 48 compared to the 12-week interval prior to randomization|Proportion of subjects with a ≥50% reduction in red blood cell (RBC) transfusion burden from week 37 to Week 48|Proportion of subjects with a ≥50% reduction in red blood cell (RBC) transfusion burden from week 13 to Week 24|Mean change from baseline in transfusion burden (RBC units) from Week 13 to Week 24|Mean change from baseline in liver iron concentration (LIC, mg/g dw) by magnetic resonance imaging (MRI)|Mean change from baseline in mean daily dose of iron chelation therapy (ICT)|Mean change from baseline in serum ferritin|Mean change from baseline in total hip and lumbar spine bone mineral density (BMD)by Dual energy x-ray absorptiometry (DXA)|Mean change from baseline in myocardial iron by magnetic resonance imaging (MRI)|TranQOL Quality of Life tool administered within 4 weeks prior to Dose 1 Day 1, and weeks 12, 24, 36 and 48, then every 12 weeks during long term period|SF-36 Quality of Life tool administered within 4 weeks prior to Dose 1 Day 1, and weeks 12, 24, 36 and 48, then every 12 weeks during long term treatment period|The effect of luspatercept on healthcare resource utilization (hospitalizations) versus placebo|The effect of luspatercept on healthcare resource utilization (prior concomitant therapies and surgeries) versus placebo|The effect of luspatercept on healthcare resource utilization (RBC transfusion utilization) versus placebo|Proportion of subjects who are transfusion independent for ≥8 weeks during treatment|Duration of reduction in transfusion burden|Duration of transfusion independence|Time to erythroid response|Post-baseline transfusion events frequency versus placebo|Pharmacokinetic - AUC|Pharmacokinetic - Cmax|Adverse Events (AEs)","Celgene|Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","336","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACE-536-B-THAL-001","May 2, 2016","November 24, 2017","June 7, 2025","November 13, 2015",,"June 5, 2019","Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Haematological Diseases - Sofia, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|University Health Network, Toronto, Ontario, Canada|Hopital Henri Mondor, Creteil, France|GH de Institut Catholique St. VincentHématologie, Lille, France|Hôpitaux de La Timone, Marseille Cedex 9, France|Hospital of Necker, Paris, France|Laiko General Hospital, Ampelokipi - Athens, Greece|Childrens' Hospital of Athens Aghoa Sofia, Athens, Greece|General Hospital Georgios Gennimatas of Athens, Athens, Greece|University General Hospital of Patras, Rio Patras, Greece|Hippokration Hospital, Thessaloniki, Greece|Soroka University Medical Centre, Beer Sheva, Israel|Rambam Health Corporation, Haifa, Israel|HaEmek Medical Center, Haïfa (Afula), Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Rabin Medical Center, Petah Tikva, Israel|Presidio Ospedaliero Antonio Perrino, Brindisi, Italy|Universita degli Studi di Cagliari - ASL8, Cagliari, Italy|Azienda Ospedaliera Universitaria Di Ferrara Arcispedale Sanna, Ferrara, Italy|Ospedale Galliera, Genoa, Italy|Fondazione Ca Granda IRCCS Ospedale Maggiore, Milan, Italy|Seconda Universita Degli Studi Di Napoli, Naples, Italy|AORN A Cardarelli, Napoli, Italy|Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy|Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy|Chronic Care Center, Beirut, Lebanon|Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia|Hospital Pulau Pinang c/o Penang Medical College, Georgetown, Malaysia|Changhua Christian Hospital, Changhua City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Chulalongkorn University, Bangkok, Thailand|Siriraj Hospital Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Chiang Mai University, Chiang Mai, Thailand|University Hospital Farhat Hached, Sousse, Tunisia|Bone Marrow Transplant Center, Tunis, Tunisia|Aziza Othmana Hospital, Tunis, Tunisia|Military Hospital of Tunis, Tunis, Tunisia|Acibadem Adana Hospital, Adana, Turkey|Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey|Hacettepe Universitesi, Ankara, Turkey|Antalya Egitim Arastirma, Antalya, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Mersin University Medical Faculty, Mersin, Turkey|St James University Hospital, Leeds, United Kingdom|University College Hospital Trust, London Bloomsbury, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Whittington Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02604433"
155,"NCT02601300","An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis",,"Completed","Has Results","Colitis, Ulcerative","Drug: GED-0301","Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8|Percentage of Participants Who Achieved a Modified Mayo Score of ≤ 2, With Rectal Bleeding Subscore (RBS) of 0 and Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore ≤ 1 at Week 8|Percentage of Participants Who Achieved a Mayo Endoscopic Subscore of ≤ 1 at Week 8|Percentage of Participants Who Achieved a Mayo Endoscopic Subscore of ≤ 1 by Individual Segment at Week 8|Percentage of Participants Who Achieved a Clinical Response in the Modified Mayo Score at Week 8|Percentage of Participants Who Achieved a Mayo Endoscopic Response at Week 8|Percentage of Participants Who Achieved a Clinical Remission in the Total Mayo Score (TMS) at Week 8|Percentage of Participants Who Achieved a Clinical Response in the Total Mayo Score at Week 8|The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GED-0301-UC-002","December 14, 2015","September 6, 2016","August 8, 2017","November 10, 2015","September 12, 2018","October 17, 2018","Macks Research Group, Newport Beach, California, United States|Medical Associates Research Associates, San Diego, California, United States|Florida Research Network, LLC, Gainesville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Concorde Medical Group, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Gastroenterology Center of The Midsouth PC, Germantown, Tennessee, United States|Nashville Gastrointestinal Specialists, Nashville, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Dean Medical Center, Madison, Wisconsin, United States|Multiprofile Hospotal for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD, Lom, Bulgaria|Multiprofile Hospital for Active Treatment Doverie AD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveti Panteleimon - Sofia AD, Sofia, Bulgaria|GI Research Institute, Vancouver, British Columbia, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Pandy Kalman Megyei Korhaz, Siófok, Hungary|Centrum Medyczne sw. Lukasza, Czestochowa, Poland|Endoskopia Sp. z o.o., Sopot, Poland|Centrum Zdrowia Matki, Dziecka i Mlodziezy, Warsaw, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|IBD Centrum s.r.o., Bratislava, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|GASTRO I., s.r.o., Presov, Slovakia",,"https://ClinicalTrials.gov/show/NCT02601300"
156,"NCT02596893","Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease",,"Terminated","Has Results","Crohn Disease","Drug: GED-0301|Drug: Placebo","The Percentage of Participants Who Achieved a Clinical Remission at Week 12|Percentage of Participants Who Achieved Clinical Remission at Week 52|Percentage of Participants With Endoscopic Response-50 Centrally Read at Week 52|The Percentage of Participants Who Achieved a Clinical Response at Week 12|The Percentage of Participants Who Achieved a Clinical Response at Week 4|The Percentage of Participants Who Achieved a Clinical Remission at Week 4|The Percentage of Participants Who Achieved a Corticosteroid-Free Clinical Remission at Week 52|Percentage of Participants Who Achieved a Sustained Clinical Remission at Both Week 12 and 52|Percentage of Participants With Endoscopic Response-25 Centrally Read at Week 12|Percentage of Participants With Endoscopic Remission Centrally Read at Week 52|The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE) From Week 0 to Week 52|The Number of Participants Who Discontinued IP Due to an Treatment Emergent Adverse Events","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","701","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GED-0301-CD-002","December 8, 2015","January 5, 2018","January 5, 2018","November 4, 2015","January 23, 2019","August 28, 2019","ADDC Research LLC, Huntsville, Alabama, United States|Arizona Digestive Health, Mesa, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Colon & Digestive Health Specialists, Scottsdale, Arizona, United States|Arizona Digestive Health, Sun City, Arizona, United States|Gastroenterology Associates PA, Little Rock, Arkansas, United States|HCP Clinical Research LLC, Anaheim, California, United States|T. Joseph Raoof MD Inc, Encino, California, United States|Valley View Internal Medicine, Garden Grove, California, United States|OM Research, Lancaster, California, United States|University of Southern California Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|Medical Associates Research Group Inc., San Diego, California, United States|Clinical Applications Laboratories Inc, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Ventura Clinical Trials, Ventura, California, United States|University Of Colorado, Aurora, Colorado, United States|Innovative Clinical Research, Lafayette, Colorado, United States|Connecticut Gastroenterology Institute, Bristol, Connecticut, United States|Medical Research Center of Connecticut LLC, Hamden, Connecticut, United States|Connecticut GI PC Research Division, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Florida Medical Research - Southeastern Integrated Medical, Gainesville, Florida, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|Galiz Research LLC, Miami Springs, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Cordova Research Institute, Miami, Florida, United States|My Community Research Center inc, Miami, Florida, United States|Sanitas Research, Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|GCRM, Orlando, Florida, United States|Center For Digestive Health, Orlando, Florida, United States|BRCR Medical Center Inc., Plantation, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|East Coast Institute for Research LLC, Saint Augustine, Florida, United States|Cleveland Clinic Florida Weston, Weston, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Atlanta Gastroenterology Specialists PC, Suwanee, Georgia, United States|Grand Teton Research Group PLLC, Idaho Falls, Idaho, United States|Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Highland Park, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|Health Science Research Center, LLC, Pratt, Kansas, United States|Heartland Research Associates LLC, Wichita, Kansas, United States|Via Christi Research a division of Via Christi Hospitals Wichita Inc, Wichita, Kansas, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Gastroenterology Associates LLC, Baton Rouge, Louisiana, United States|Clinical Trials of SW Louisiana LLC, Lake Charles, Louisiana, United States|Louisiana Research Center LLC, Shreveport, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Metropolitan Gastroenterology, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Commonwealth Clinical Studies PLLC, Brockton, Massachusetts, United States|UMass Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Medex Research Institute, Caro, Michigan, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Henry Ford Medical Center - New Center One, Novi, Michigan, United States|Gastroenterology Associates of Western Michigan PLC, Wyoming, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Ehrhardt Clinical Research LLC, Belton, Missouri, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Mercy Clinic East Communities d/b/a Mercy Health Research, Washington, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|Southwest Gastroenterology Associates PC, Albuquerque, New Mexico, United States|Sing Chan Private Practice, Flushing, New York, United States|NYU Langone Nassau Gastroenterology Associates, Great Neck, New York, United States|Montefiore Medical Center PRIME, Lake Success, New York, United States|The Feinstein Institute for Medical Research PRIME, Manhasset, New York, United States|Winthrop University Hospital, Mineola, New York, United States|North Shore Long Island Jewish Health System, New Hyde Park, New York, United States|Concord Medical Group PRIME, New York, New York, United States|New York University School of Medicine, New York, New York, United States|New York - Presbyterian/Weill Cornell Medical Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolina Center for Liver Disease, Charlotte, North Carolina, United States|Gaffney Health Services, Charlotte, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|PhysiqueMed Clinical Trials, Greensboro, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Clinical Trials of America, LLC, Mount Airy, North Carolina, United States|Trial Management Associates LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem LLC, Winston-Salem, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Ohio Clinical Research Partners LLC, Akron, Ohio, United States|Dr. Deepak Sarwal, MD, Centerville, Ohio, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, United States|Consultants for Clinical Research Inc., Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Clinical Inquest Center Ltd, Huber Heights, Ohio, United States|Springfield Health Care Center, Springfield, Ohio, United States|Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Main Line Gastroenterology, Havertown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|Penn State University Milton S Hershey Medical Center, State College, Pennsylvania, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Clinical Research Institute LLC, Arlington, Texas, United States|Texas Digestive Disease Consultants - Dallas, Arlington, Texas, United States|Texas Digestive Disease Consultants Dallas, Dallas, Texas, United States|Texas Digestive Disease Consultants - Southlake, Flower Mound, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Houston Endoscopy and Research Center, Houston, Texas, United States|Sagact Pllc, San Antonio, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States|Scott & White Medical Center, Temple, Texas, United States|Digestive Health Specialist of Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Vermont, Colchester, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Charlottesville Medical Research Center, Charlottesville, Virginia, United States|Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States|Emeritas Research Group, Leesburg, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Hunter Holmes Mcguire Ctr, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States|The Vancouver Clinic, Vancouver, Washington, United States|Dean Clinic Oregon, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Bankstown-Lidcombe Hospital, Bankstown, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Centre For Digestive Diseases, Five Dock, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Ballarat Base Hospital, Ballarat, Australia|Monash Medical Centre Clayton, Bentleigh East, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Austin Hospital, Heidelberg, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Nepean Hospital, Kingswood, NSW, Australia|LKH Universitaetsklinikum Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|Klinikum Klagenfurt am Wörtersee, Klagenfurt, Austria|KH der Barmherzigen Bruder Linz, Linz, Austria|a.o.Krankenhaus d.Barmherz.Schwestern Ried, Ried I Innkreis, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Ordination Dr. Thomas Haas Darmpraxis Salzburg, Salzburg, Austria|KH der Barmherzigen Brüder St.Veit an der Glan, St Veit An Der Glan, Austria|Krankenanstalt Rudolfstiftung Wien, Wein, Austria|AKH Medizinische Universitat Wien, Wein, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|Centre Hospitalier de Mouscron, Mouscron, Belgium|MHAT Sv Nikolay Chudotvorets EOOD, Lom, Bulgaria|MHAT Kaspela EOOD, Plovdiv, Bulgaria|MHAT Ruse AD, Ruse, Bulgaria|Second MHAT Sofia AD, Sofia, Bulgaria|City Clinic UMHAC EOOD, Sofia, Bulgaria|UMHAT Sv Ivan Rilski EAD, Sofia, Bulgaria|UMHAT Tsaritsa Yoanna - ISUL EAD, Sofia, Bulgaria|Fourth MHAT Sofia EAD, Sofia, Bulgaria|MHAT Doverie AD, Sofia, Bulgaria|University of Calgary, Calgary, Alberta, Canada|GI Research Institute, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|South Edmonton Gastroenterology, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|GI Research Institute, Vancouver, British Columbia, Canada|PerCuro Clinical Research, Victoria, British Columbia, Canada|Brandon Medical Arts Clinic, Brandon, Manitoba, Canada|Barrie GI Associates, Barrie, Ontario, Canada|McMaster University Health Sciences Center, Hamilton, Ontario, Canada|London Health Science Center U. Hospital, London, Ontario, Canada|LHSC Victoria Hospital, London, Ontario, Canada|Montfort Hospital, Ottawa, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Medicine Professional Corporation, Waterloo, Ontario, Canada|Tarabain Osman MD, Windsor, Ontario, Canada|Centre de sante et de services sociaux Champlain Charles Le Moyne, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada|CHUM Hôpital Saint-Luc, Montreal, Quebec, Canada|McGill University Health Centre Glen Site Royal Victoria Hospital, Montreal, Quebec, Canada|CHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada|Recherche Medicale St Jerome Inc, St Jerome, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Recherche Clinique Sigma Inc, Quebec, Canada|Clinical Hospital Centre Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|Clinical Hospital Merkur, Zagreb, Croatia|Clinical Hospital Sveti Duh, Zagreb, Croatia|Fakultni nemocnice u sv Anny v Brne, Brno, Czechia|Hepato-Gastroenterologie HK, Hradec Kralove, Czechia|Soukroma Gastroenterologicka ambulance a endoskopie, Most, Czechia|PreventaMed, Olomouc, Czechia|CCBR Czech as, Pardubice, Czechia|CCBR Prague CZ, Praha 3, Czechia|IBD Centrum ISCARE IVF as, Praha 7, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La, Usti nad Labem, Czechia|Nemocnice Znojmo, Znojmo, Czechia|Aarhus Universitetshospital, Aahus C, Denmark|Nordsjaellands Hospital Frederikssund, Frederikssund, Denmark|Herlev Hospital, Herlev, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Koge Sygehus, Koge, Denmark|Regionshospitalet Silkeborg, Silkeborg, Denmark|Alborg University Hospital, Ålborg, Denmark|West Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Tampereen yliopistollinen sairaala, Tampere, Finland|Turunmaan sairaala, Turku, Finland|CHU Amiens Hopital Sud, Amiens Cedex, France|CHU Besancon Hopital Jean Minjoz, Besancon Cedex, France|CHU Tours Hopital Trousseau, Chambray les Tours, France|CHU Clermont Ferrand, Clermont-Ferrand, France|Hopital Beaujon, Clichy cedex, France|CHU Dijon - Hopital Bocage Central, Dijon, France|CHU de Grenoble Hopital Nord, Grenoble cedex 9, France|Groupement Hospitalier Sud Hopital Bicetre, Le Kremlin Bicetre cedex, France|Hopital Claude Huriez CHRU Lille, Lille cedex, France|Hopital Nord, Marseille cedex 20, France|CHU Nantes Hotel Dieu, Nantes Cedex 1, France|CHU Nice Hopital de lArchet 2, Nice Cedex 3, France|Hopital Saint Antoine, Paris, France|Hopital Saint Louis, Paris, France|Groupe Hospitalier Sud Hopital Haut Leveque USN, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|CHU Reims Hopital Robert Debre, Reims, France|CHU Rennes Hopital Pontchaillou, Rennes cedex 09, France|CHU de Rouen Hopital Charles Nicolle, Rouen Cedex, France|CHU Saint Etienne Hopital Nord, Saint Etienne, France|CHU Strasbourg Hopital Hautepierre, Strasbourg Cedex, France|CHU de Toulouse Hopital Rangueil, Toulouse Cedex 09, France|Hopital de Brabois Adultes, Vandoeuvre les Nancy, France|Charite Universitaetsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany|Charite Campus Virchow Klinikum, Berlin, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Krankenhaus Waldfriede e V, Berlin, Germany|Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH, Bochum, Germany|Staedisches Klinikum Brandenburg, Brandenburg an der Havel, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Zentrum fuer HIV und Hepatogastroenterologie GmbH, Duesseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Essen, Germany|Katholische Kliniken Ruhrhalbinsel GmbH, Essen, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Crohn Colitis Centrum Rhein Main, Frankfurt, Germany|Universitaetsklinikum FreiburgInnere Med.1, Haematologie, Freiburg, Germany|Universitaetsklinikum Halle Saale, Halle, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Praxis fuer Gastroenterologie Dr Ehehal Dr Helmstaedter, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, Germany|University Leipzig, Leipzig, Germany|Internistische Gemeinschaftspraxis f. Verdauungs- und Stoffwechselerkrankungen, Leipzig, Germany|EUGASTRO GmbH, Leipzig, Germany|Medizinisches Zentrum Klinikum Lueneburg, Lueneburg, Germany|Universitaetsklinikum Magdeburg A oeR, Magdeburg, Germany|Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Germany|Gastroenterologische Praxis Minden, Minden, Germany|Isar Klinik GmbH, Muenchen, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Gastro Campus Research, Muenster, Germany|Klinikum der Universitaet Muenchen, München, Germany|Staedtisches Klinikum Braunschweig gGmbH Standort Salzdahlumer, Niedersachsen, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|General Hospital of Athens Evangelismos, Athens, Greece|Athens Medical Center, Athens, Greece|General Hospital of Nikaea Piraeus Ag. Panteleimon, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|General Hospital of Heraklion Benizeleio Pananeio, Heraklion, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Patras, Rio Patras, Greece|Anticancer Hospital of Thessaloniki THEAGENIO, Thessaloniki, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfured, Hungary|Clinexpert Egeszsegugyi Szolg es Ker Kft, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem AOK, Budapest, Hungary|Semmelweis Egyetem AOK, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Pannonia Maganorvosi Centrum, Budapest, Hungary|Endomedix Diagnosztikai Kozpont, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Szent Pantaleon Korhaz Rendelointezet Dunaujvaros, Dunaujvaros, Hungary|Markhot Ferenc Oktato Korhaz es Rendelointezet, Eger, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Mohacsi Korhaz, Mohacs, Hungary|SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Mazso-Pharma Kutatas-fejlesztesi Kft, Szeged, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Clinfan Szolgaltato Kft, Szekszard, Hungary|HaEmek Medical Center, Afula, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Policlinico G Martino, Messina, Italy|Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico, Milano, Italy|Seconda Universita Degli Studi Di Napoli, Naples, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Hospital of Di Padova, Padova, Italy|Azienda Ospedaliera Vincenzo Cervello, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Universita Campus Bio-Medico di Roma, Roma, Italy|Ospedale Sandro Pertini, Roma, Italy|Complesso Integrato Columbus, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi dAragona, Salerno, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Hanyang Univerisy Guri Hospital, Guri-si, Korea, Republic of|CHA Bundang Medical Center CHA University, Seongnam-si,, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Vicent's Hospital, Suwon-si, Korea, Republic of|Digestive Diseases Center Gastro, Riga, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, Latvia|Pauls Stradins Clinical University Hospital, Riga, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan, Malaysia|Hospital Ampang, Ampang, Selangor, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia|Hospital Universiti Sains Malaysia, Kelantan, Malaysia|VU Medisch Centrum, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Medisch Centrum Haaglanden,Antoniushoeve, Leidschendam, Netherlands|Radboudumc, Nijmegen, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Waikato Hospital, Hamilton, New Zealand|Sykehuset Ostfold Fredrikstad, Fredrikstad, Norway|Akershus universitetssykehus HF, Lørenskog, Norway|Oslo Universitetssykehus HF Ulleval, Oslo, Norway|Oslo Universitetssykehus Rikshospitalet, Oslo, Norway|Stavanger Unviversitetssjukehus Helse Stavanger HF, Stavanger, Norway|SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego, Bialystok, Poland|Clinsante S.C. Osrodek Badan Klinicznych, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Niepubliczny Zaklad Opieki Zdrowotnej POLIMEDICA, Kielce, Poland|Indywidualna Praktyka Lekarska Maciej Zymla, Knurow, Poland|Centrum Medyczne Plejady, Krakow, Poland|LUX MED Sp. z o.o., Krakow, Poland|SPZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|SPZOZ Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej - Centralny Szpital Weteranow, Lodz, Poland|Centrum Medyczne AMED, Lodz, Poland|GASTROMED Sp.zo.o., Lublin, Poland|Ai Centrum Medyczne Sp. Z O.O. Sp.K., Poznan, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Endoskopia Sp. z o.o., Sopot, Poland|Nzoz Vivamed, Warsaw, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Hospital de Braga, Braga, Portugal|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal|Hospital Da Luz, Lisboa, Portugal|Centro Hospitalar de Sao Joao, EPE, Porto, Portugal|Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE, Viana do Castelo, Portugal|S.C MedLife S.A, Bucuresti, Romania|Tvm Med Serv Srl, Cluj Napoca, Romania|Spitalul Clinic Judetean de Urgente Sf. Spiridon, Iasi, Romania|CMI Dr. Tirnaveanu Amelita, Oradea, Romania|Centrul de Gastroenterologie Dr. Goldis, Timisoara, Romania|Irkutsk State Medical Academy of Continuing Education, Irkutsk, Russian Federation|TSBIH Territorial Clinical Hospital, Krasnoyarsk, Russian Federation|Medical Center Stolitsa-Medikl, Moscow, Russian Federation|SBHI of NN region RCH of NN n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|RSHI State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|FSBI Scientific Research Institute of Physyology and Basic Medicine under the SB of RAMS, Novosibirsk, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, Russian Federation|SBEI of HPE Omsk State Medical Academy Ministry of healthcare of RF, Omsk, Russian Federation|SBIH of Perm territory City Clinical Hospital 2 na Fedor Khristoforovich Gral, Perm, Russian Federation|Evromedservis, Pushkin, Russian Federation|SEIHPE Rostov State Medical University of MoH of RF, Rostov-on-Don, Russian Federation|City Mariinskaya Hospital, Saint-Petersburg, Russian Federation|SPb SBIH City Hospital # 26, Saint-Petersburg, Russian Federation|Private Educational Institution of Higher Education Medical university REAVIZ, Samara, Russian Federation|NonState Healthcare Institution Central Clinical Hospital, Samara station JSC Russian Railways, Samara, Russian Federation|SHI Regional Clinical Hospital, Saratov, Russian Federation|SBI of Healthcare of Leningrad region Clinical Interregional Hospital of Tosno, Tosno, Russian Federation|SBHI of Yaroslavl Region Clinical Hospital 8, Yaroslavl, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Zvezdara, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Zemun, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia|Alian s.r.o., Bardejov, Slovakia|Univerzitna nemocnica Bratislava Nemocnica Ruzinov, Bratislava, Slovakia|Gastroentero-Hepatologicke centrum THALION, Bratislava, Slovakia|Nemocnica A.Lena Humenne n o, Humenne, Slovakia|B & B MED, s.r.o., Kosice, Slovakia|KARDIO 1 s.r.o., Lucenec, Slovakia|Gastroeneterologicka ambulancia MUDr. Peter Hegyi s.r.o., Malacky, Slovakia|Fakultna nemocnica Nitra, Nitra, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|Nemocnica s poliklinikou sv Barbory Roznava a s, Roznava, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Zilina, Slovakia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Sodersjukhuset, Stockholm, Sweden|Danderyds Sjukhus AB, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Universitaetsspital Basel, Basel, Switzerland|Inselspital - Universitaetsspital Bern, Bern, Switzerland|Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner, Bern, Switzerland|Kantonsspital St.Gallen, St. Gallen, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|Ankara University Medical Faculty, Ankara, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Firat University Medical Faculty, Elazig, Turkey|Gaziantep University Medical Faculty Sahinbey Educational Research Hospital, Gaziantep, Turkey|Yeditepe University Medical School Hospital, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey|Acibadem Fulya Hospital, Istanbul, Turkey|Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Inonu Uni. Med. Fac., Malatya, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Kocaeli Derince Training and Research Hospital, Umuttepe Kocaeli, Turkey|RCI Chernivtsi Regional Clinical Hospital Dept of Surgery Bukovinian SMU, Chernivtsi, Ukraine|CI of PH Kharkiv CCH #2, Kharkiv, Ukraine|GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine|Treatment-Diagnostic Center of Private Enterprise of PMF Atsynus, Kirovohrad, Ukraine|Ukrainian-German Antiulcer Gastroenterological Center BYK-Kyiv LLC, Kyiv, Ukraine|Kyiv City Clinical Hospital #1, Kyiv, Ukraine|SI Republican Clinical Hospital of the MOHU Dept of Gastroenterology O.O.Bogomolets NMU, Kyiv, Ukraine|Lviv Regional Clinical Hospital D Halytskyi Lviv NMU, Lviv, Ukraine|Lviv Municipal City Clinical Hospital #5 Dept of Therapy D.Halytsky Lviv NMU, Lviv, Ukraine|CI Odesa Regional Clinical Hospital, Odessa, Ukraine|Communal Institution City Policlinic #20 Cabinet of Gastroenterology, Odessa, Ukraine|M.V. Sklifosovskyi Poltava RCH Outpatient UMSA HSEIU Ukrainian Medical Stomatological Academy, Poltava, Ukraine|CI of SRC Sumy RCH Dept of Rheumatology Sumy SU MI, Sumy, Ukraine|Ternopil City Communal Emergency Medical Care Hospital, Ternopil, Ukraine|M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU, Vinnytsia, Ukraine|SRI of Invalid Rehabilitation EST Complex of Vinnytsia M.I.Pyrogov NMU MOHU, Vinnytsia, Ukraine|SI Branch CH of Zaporizhzhia Station-2 of SE Prydniprovska Railway Dept of Surgery Zaporizhzhia SMU, Zaporizhia, Ukraine|CI Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporozhje, Ukraine|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Royal Devon and Exeter Hospital Wonford, Exeter, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Royal London Hospital, London, United Kingdom|St Marys Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|University Hospital of South Manchester NHS Foundation Trust -Wythenshawe Hospital - North West Lung, Manchester, United Kingdom|Nottingham University Hospitals Queens Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Borders General Hospital, Roxburghshire, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom|Southampton General Hospital, Southhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02596893/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02596893/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02596893"
157,"NCT02577406","An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","IDHENTIFY","Recruiting","No Results Available","Leukemia, Myeloid|Isocitrate Dehydrogenase","Drug: AG-221|Other: BSC|Drug: Azacitidine|Drug: Low-dose cytarabine (LDAC)|Drug: Intermediate-dose cytarabine (IDAC)","Overall survival|Overall response rate|Event-free survival|Duration of response|Time to response|Treatment mortality at 30 and 60 days|One-year survival|Overall remission rate|Complete remission rate|Hematologic improvement rate|Rate of Hematopoietic stem cell transplantation (HSCT)|Time to treatment failure|Adverse Events (AEs)|European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30)|EuroQoL Group EQ-5D-5L Health Questionnaire","Celgene","All","60 Years and older   (Adult, Older Adult)","Phase 3","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG-221-AML-004","December 30, 2015","March 31, 2020","July 28, 2022","October 16, 2015",,"May 24, 2019","University of Southern California Norris Cancer Center, Los Angeles, California, United States|UCLA School of Medicine Hematology Oncology, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Shands Cancer Center University of Florida, Gainesville, Florida, United States|University of Miami Sylvester Cancer Research Center, Miami, Florida, United States|University of Florida Health Cancer Center at Orlando Health, Orlando, Florida, United States|Northwestern University Medical Center Division of Hematology Oncology, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center Albert Einstein Cancer Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Strong Health System, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|West Virginia University CTRU, Morgantown, West Virginia, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre - East Melbourne, East Melbourne, Australia|Royal Brisbane Hospital, Herston, Australia|The Alfred Hospital, Melbourne, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Medical University of Graz, Graz, Austria|Elisabethinen Hospital Linz, Linz, Austria|Klinik fur Innere Medizin III, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Gent, Gent, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Santa Casa de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Hospital Amaral Carvalho, Jau, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|HEMORIO - Unidade de Pesquisa Clínica, Rio de Janeiro, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|University of Alberta, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|The First Hospital of China Medical University, Beijing, China|Peking University Third Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|The Third Xiangya hospital of central south university, Changsha, China|West China Hospital, Chengdu, Sichuan, China|Fujian Medical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, China|Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|Changhai Hospital, Shanghai, China|Institution of Hematology & Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Henan Cancer Hospital, Zhengzhou, China|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Aalborg Universitetshospital, Aalborg, Denmark|Aarhus Sygehus, Arhus C, Denmark|Copenhagen University Hospital Rigshosptalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|CHU d'Angers, Angers, France|Hopital Aviecenne, BOBIGNY Cedex, France|CHU Hotel, Grenoble Cedex 09, France|CHRU Claude Huriez, Lille, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|CHRU Nantes, Nantes, France|Hopital Saint Louis, Paris, France|Hospital haut leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|Hopital Purpan, Toulouse Cedex, France|Centre Hospitalier de Versailles, Versailles, France|Institut Gustave Roussy, Villejuif CEDEX, France|Unviversitatsklinikum Aachen, Aachen, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitatsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule HannoverZentrum Innere Medizin, Hannover, Germany|SLK Kliniken Heilbronn GmbH - Klinikum am Gesundbrunnen, Heilbronn, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|LMU Klinikum der Universitat, München, Germany|TU München - Klinikum rechts der Isar, München, Germany|Robert Bosch Krankenhaus, Stuttgart, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|University Hospital of Ulm, Ulm, Germany|Policlinico S. Orsola - Malpighi, Bologna, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Hematology Dept Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Cardarelli, Naples, Italy|Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano, Italy|Hospital of Di Padova, Padova, Italy|Casa di Cura La Maddalena, Palermo, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Ospedale di Circolo di Varese, Varese, Italy|Hwasun Chonnam National University Hospital, Hwasun-gun, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation|City Clinical Hospital 52, Moscow, Russian Federation|City Clinical Hospital 40, Moscow, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, Saint-Petersburg, Russian Federation|Hospital Universitario La Fe, Avda, Campanar 21, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|China Medical University Hospital, Taichung, Northern Dist., Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji hospital, Ankara, Turkey|Gazi Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Gaziantep University, Gaziantep, Turkey|University Hospital of Wales - Cardiff, Cardiff, United Kingdom|Queens Centre for Oncology & Haematology, Hull, United Kingdom|St Bart's London, London, United Kingdom|Kings College Hospital, London, United Kingdom|Christie Hospital NHS Trust, Manchester Withington, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|John Radcliffe Hospital The Oxford Radcliffe Hospital Clinical Haematology, Oxford, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield South Yorkshire, United Kingdom|Royal Marsden Hospital, Sutton (Surrey), United Kingdom|Spire Little Aston Hospital, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02577406"
158,"NCT02576717","A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis","Drug: RPC1063","Safety and tolerability of RPC1063 in patients with RMS as assessed by evaluation of adverse events","Celgene","All","18 Years to 55 Years   (Adult)","Phase 3","2495","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC01-3001","October 16, 2015","June 30, 2020","June 30, 2020","October 15, 2015",,"October 17, 2019","Xenosciences Inc, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Neuro Pain Medical Center, Fresno, California, United States|Collaborative Neuroscience Network Inc, Long Beach, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, United States|Denver Neurological Clinic, Denver, Colorado, United States|Neurology Associates PA, Maitland, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Consultants In Neurology, Northbrook, Illinois, United States|Associates In Neurology, Lexington, Kentucky, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Neuro Medical Care Associates PLLC, Johnson City, New York, United States|The Neurological Institute PA, Charlotte, North Carolina, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, United States|MDH Research, LLC, Westerville, Ohio, United States|Hope Neurology MS Center, Knoxville, Tennessee, United States|Bhupesh Dihenia MD PA, Lubbock, Texas, United States|Central Texas Neurology Consultants PA, Round Rock, Texas, United States|EvergreenHealth, Kirkland, Washington, United States|The Polyclinic, Seattle, Washington, United States|Gomel Regional Clinical Hospital, Gomel, Belarus|Grodno Clinical Regional Hospital, Grodno, Belarus|Minsk Municipal Clinical Hospital 5, Minsk, Belarus|Republican Scientific and Practical Centre of Neurology and Neurosurgery, Minsk, Belarus|Minsk City Clinical Hospital 9, Minsk, Belarus|Vitebsk Regional Diagnostic Centre, Vitebsk, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|AZ Sint-Jan AV Brugge, Brugge, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, Belgium|Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|Military Medical Academy HBAT, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment National Cardiology Hospital EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|Clinical Hospital Centre Osijek, Osijek, Croatia|Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Center Zagreb, Zagreb, Croatia|Clinical Hospital Sveti duh, Zagreb, Croatia|East Tallinn Central Hospital, Tallinn, Estonia|West Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Sarajishvili Institute of Neurology, Tbilisi, Georgia|Aversi Clinic LTD, Tbilisi, Georgia|LTD MediClubGeorgia, Tbilisi, Georgia|Curatio JSC, Tbilisi, Georgia|Khechinashvili University Hospital, Tbilisi, Georgia|Universitatsklinikum Leipzig, Leipzig, Germany|St. Josefs-Krankenhaus Potsdam-Sanssouci GmbH, Potsdam, Germany|NeuroPoint Akademie, Ulm, Germany|Evangelismos General Hospital of Athens, Athens, Greece|Navy Hospital of Athens, Athens, Greece|401 Military Hospital of Athens, Athens, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece|Uzsoki Utcai Korhaz, Budapest, Hungary|Jahn Ferenc DelPesti Korhaz es Rendelointezet, Budapest, Hungary|Valeomed Egészségügyi és Szolgáltató Kft, Esztergom, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|SzabolcsSzatmarBereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Italy|Fondazione Istituto San Raffaele G Giglio di Cefalu, Cefalu, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy|Presidio Ospedaliero di Montichiari, Montichiari, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Latvian Maritime Medicine Centre, Riga, Latvia|Pauls Stradins Clinical University Hospital, Riga, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|IMSP Institutul de Medicina Urgenta, Chisinau, Moldova, Republic of|Institutul de Neurologie si Neurochirurgie, Chisinau, Moldova, Republic of|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Niepubliczny Zaklad Opieki Zdrowotnej - KENDRON, Bialystok, Poland|B&B Robert Bonek, Pawel Bochniak, Spolka Cywilna, Bydgoszcz, Poland|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, Poland|Copernicus Podmiot Leczniczy Sp. z o.o., Gdansk, Poland|Akson Clinical Research Maciejowski Bielecki Sp. Jawna, Jaroslaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC, Katowice, Poland|M.A.- Lek A.M.Maciejowscy Spolka Cywilna, Katowice, Poland|Novo-Med Zielinski i wsp. Sp.J., Katowice, Poland|NEURO- CARE Site Management Organization Gabriela Klodowska-Duda, Katowice, Poland|RESMEDICA Spolka z o.o., Kielce, Poland|Niepubliczny Zespol Leczniczo-Rehabilitacyjny Centrum Kompleksowej Rehabilitacji, Konstancin Jeziorna, Poland|Krakowska Akademia Neurologii Sp. z. o.o., Krakow, Poland|NZOZ NEUROMED M. I M. Nastaj Spolka Partnerska, Lublin, Poland|Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny, Lublin, Poland|Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego, Lublin, Poland|Centrum Neurologii Krzysztof Selmaj, Lódzkie, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Mazowieckie, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, Poland|Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak, Pomorskie, Poland|Szpital Kliniczny im HSwiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|EUROMEDIS Sp. z.o.o., Szczecin, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Centrum Medyczne doktorA, Warszawa, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospital de Braga, Braga, Portugal|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Campus Neurologico Senior, Torres Vedras, Portugal|Clinical Hospital of Psychiatry and Neurology Brasov, Brasov, Romania|Fundeni Clinical Institute, Bucharest, Romania|Colentina Clinical Hospital, Bucharest, Romania|Health Club Medical Center S.R.L., Campulung, Romania|Cluj Clinical County Hospital, Cluj Napoca, Romania|Rehabilitation Clinical Hospital, Cluj-Napoca, Romania|Cai Ferate Clinical Hospital, Constanta, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, Romania|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|Bryansk Regional Hospital 1, Bryansk, Russian Federation|Chelyabinsk City Clinical Hospital 3, Chelyabinsk, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Republican Clinical Hospital for Rehabilitation Treatment, Kazan, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Russian Federation|Kirov State Medical Academy, Krov, Russian Federation|Kursk Regional Clinical Hospital, Kursk, Russian Federation|Central Clinical Hospital 2 na NA Semashko OAO RZhD, Moscow, Russian Federation|City Clinical Hospital 24, Moscow, Russian Federation|City Clinical Hospital 1 na NIPirogov, Moscow, Russian Federation|Research Center of Neurology of RAMS, Moscow, Russian Federation|Nizhniy Novgorod City Hospital 33, Nizhny Novgorod, Russian Federation|City Clinical Hospital 3 Nizhniy Novgorod Geriatrics Centre, Nizhny Novgorod, Russian Federation|Siberian Regional Medical Center, Novosibirsk, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|City neurology center Sibneuromed LLC, Novosibirsk, Russian Federation|Perm State Medical Academy, Perm, Russian Federation|Pyatigorsk City Hospital 2, Pyatigorsk, Russian Federation|Rostov Regional Clinical Hospital, Rostov on Don, Russian Federation|S.M. Kirov Military Medical Academy, Saint-Petersburg, Russian Federation|Samara Regional Clinical Hospital named after MI Kalinin, Samara, Russian Federation|City Clinical Hospital 4, Saransk, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|First St Petersburg State Medical University na IP Pavlov, St. Petersburg, Russian Federation|St. Petersburg Hospital #31, St. Petersburg, Russian Federation|Institute of Human Brain RAN, St. Petersburg, Russian Federation|City Clinical Hospital 40, St. Petersburg, Russian Federation|Siberian State Medical University, Tomsk, Russian Federation|Neftyanik Medical and Sanitary Unit, Tyumen, Russian Federation|Kuvatov Republican Clinical Hospital, Ufa, Russian Federation|Yaroslavl Clinical Hospital 8, Yaroslavl, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Hospital Centre Zemun, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|University Hospital Bratislava - Hospital ak. L. Derera, II Neurology Clinic, Bratislava, Slovakia|General Hospital with Outpatient Clinic Lucenec n.o., Department of Neurology, Lucenec, Slovakia|University Hospital Trnava, Trnava, Slovakia|Dr. CC Coetzee Inc., Umhlanga, South Africa|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Organizacion Sanitaria Integrada Bilbao Basurto, Bilbao, Spain|Hospital de Santa Caterina - Parc Hospitalari Martí i Julià, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Hospital Universitario de Donostia, San Sebastian, Spain|Hospital Moises Broggi, Sant Joan Despí, Spain|Hospital Universitario Virgen Macarena, Sevillla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|MI Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, Ukraine|Hospital 4 of Chernihiv City Council, Chernihiv, Ukraine|Municipal Treatment and Preventive Institution Chernihiv Regional Clinical Hospital, Chernihiv, Ukraine|Municipal Institution Chernivtsi Regional Psychiatric Hospital, Chernivtsi, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, Ukraine|Regional Clinical Hospital., Ivano Frankivsk, Ukraine|Ivano-Frankivsk city clinical hospital #1, Ivano-Frankivsk, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, Ukraine|Regional Clinical Hospital Center for Emergency Medical Care and Disaster Medicine, Kharkiv, Ukraine|Public Healthcare Institution Kharkiv City Clinical Hospital #7 Neurology Department #1, Kharkiv, Ukraine|Municipal Institution Kherson City Clinical Hospital, Kherson, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kyiv, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Kyiv City Clinical Hospital 4, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Municipal City Clinical Hospital 5, Lviv, Ukraine|Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU, Odesa, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|Odessa Regional Clinical Hospital, Department of General Surgery, Odesa, Ukraine|M.V. Sklifosovskyi Poltava RCH Outpatient UMSA HSEIU Ukrainian Medical Stomatological Academy, Poltava, Ukraine|Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod, Ukraine|Municipal Institution Vinnytsia Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsia, Ukraine|Zaporizhia City Multispecialty Clinical Hospital #9, Department of Neurology, Zaporizhia, Ukraine|Municipal Institution City Clinical Hospital 2, Zaporizhia, Ukraine|Municipal Institution Zaporizhzhia, Zaporizhzhia, Ukraine|Municipal Institution City Clinical Hospital 6, Zaporizhzhya, Ukraine|Regional Clinical Hospital na OFHerbachevskyi of Zhytomyr Regional Council, Zhytomyr, Ukraine|Royal Sussex County Hospital, Neurology Research, East Sussex, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Kings College Hospital, London, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02576717"
159,"NCT02576678","A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: Apremilast","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Maximum Observed Plasma Concentration (Cmax) of Apremilast|Time to Maximum Plasma Concentration (Tmax) of Apremilast|Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose of Apremilast (AUC0-12)|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration of Apremilast (AUC0-t)|Apparent Total Plasma Clearance When Dosed Orally (CL/F) for Apremilast|Apparent Total Volume of Distribution When Dosed Orally, Based on Study-State (Vss/F) or in the Terminal Phase (Vz/F)|Terminal Phase Elimination Half-Life|Taste and Acceptability of Apremilast Tablets Using the Faces Likert Scale","Celgene","All","6 Years to 17 Years   (Child)","Phase 2","42","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-10004-PPSO-001","October 13, 2015","September 4, 2017","July 29, 2019","October 15, 2015","September 27, 2018","August 27, 2019","Rady Children's Hospital, San Diego, California, United States|Emory Clinic, Atlanta, Georgia, United States|Northwestern University Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Dundee Dermatology, West Dundee, Illinois, United States|Mount Sinai, St. Luke's, New York, New York, United States|Texas Dermatology and Laser Specialists, San Antonio, Texas, United States|Stollery Children's Hospital, Edmonton, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|CHU Saint-Justine, Montreal, Quebec, Canada|Rheinische Friedrich-Wilhelms-Universitaet Bonn - Universitaetsklinikum Bonn, Bonn, Germany|Universitatsklinikum Essen, Essen, Germany|Universitatsklinikum Klinikum Frankfurt Main, Frankfurt, Germany|Kinderkrankenhaus Wilhelmstift, Dermatologie, Hamburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitatsklinikum Münster Klinik fur Hautkrankheiten-Allgemeine Dermatologie und Venerologie, Munster, Germany|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Sant Joan de Deu, Esplugues de Llobregat, Spain|Hospital La Paz, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02576678/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02576678/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02576678"
160,"NCT02556905","A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea",,"Completed","No Results Available","Multiple Myeloma","Drug: REVLIMID®|Drug: Dexamethasone","Adverse events (AEs)|Overall response rate","Celgene","All","18 Years and older   (Adult, Older Adult)",,"624","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIPMS-RV-KR-001","March 9, 2011","November 30, 2016","November 30, 2016","September 22, 2015",,"December 4, 2017","Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon, Bucheon, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Dong-a University Medical Center, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Hwasun Chonnam National University Hospital, Hwasun-gun, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Boramae Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02556905"
161,"NCT02555839","Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone","Number of Adverse Events|Response Rate|Progression Free Survival|Duration of Response","Celgene","All","18 Years and older   (Adult, Older Adult)",,"70","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CC-4047-MM-017","March 1, 2015","September 30, 2019","September 30, 2019","September 22, 2015",,"November 14, 2018","LKH Feldkirch, Intern E, Hämatologie, Feldkirch, Austria|Medical University Graz, Graz, Austria|KH der Elisabethinen Linz , 1. Interne Hämato-Onkologie, Linz, Austria|SCRI-CCCIT gemeinnützige GmbH & Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH, Salzburg, Austria|LKH Steyr, Innere Medizin II, Steyr, Austria|AKH, Innere Medizin I, Klin. Abt. f. Hämatologie, Vienna, Austria|AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie, Vienna, Austria|St. Josef Krankenhaus Wien,1. Abteilung für Innere Medizin Zentrum für Onkologie, Vienna, Austria|Hanusch Krankenhaus Wien 3. Medizinische Abteilung Hämatolog, Vienna, Austria|Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02555839"
162,"NCT02555813","Treatment of Pancreatic Cancer With Abraxane",,"Active, not recruiting","No Results Available","Metastatic Pancreatic Cancer","Drug: Abraxane|Drug: Gemcitabine","Number of participants with adverse events|Best Overall Response","Celgene","All","18 Years and older   (Adult, Older Adult)",,"315","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ABI-007-PANC-006","May 8, 2015","December 31, 2019","December 31, 2020","September 22, 2015",,"January 29, 2019","BHB Eisenstadt, Eisenstadt, Austria|LKH Feldkirch, Feldkirch, Austria|Medical University Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|KH Elisabethinen Klagenfurt, Klagenfurt, Austria|LKH Klagenfurt, Klagenfurt, Austria|KH Krems, Krems, Austria|LKH Leoben, Leoben, Austria|KH Barmherzige Schwestern Linz, Linz, Austria|LKH Salzburg, Salzburg, Austria|LKH St. Pölten, St. Pölten, Austria|LKH Steyr, Steyr, Austria|Medical University Vienna, Vienna, Austria|KH St. Josephs, Vienna, Austria|KH Hanusch, Vienna, Austria|KH SMZ Ost, Vienna, Austria|LKH Vöcklabruck, Vöcklabruck, Austria|Klinikum Wels, Wels, Austria|LKH Wr. Neustadt, Wr. Neustadt, Austria|KH Zams, Zams, Austria",,"https://ClinicalTrials.gov/show/NCT02555813"
163,"NCT02555696","Abraxane in Treatment of Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer","Drug: nab-paclitaxel","Adverse Events|Overall Response","Celgene","All","18 Years and older   (Adult, Older Adult)",,"203","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NIPMS-Celgene-AUT-002","May 31, 2012","February 28, 2016","December 31, 2016","September 21, 2015",,"February 23, 2017","LKH Feldkirch, Feldkirch, Austria|Medical University Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|LKH Leoben, Leoben, Austria|KH Barmherzige Schwestern Linz, Linz, Austria|LKH Salzburg, Salzburg, Austria|LKH St. Pölten, St. Pölten, Austria|LKH Steyr, Steyr, Austria|Medical University Vienna, Vienna, Austria|KH SMZ Ost, Vienna, Austria|LKH Vöcklabruck, Vöcklabruck, Austria|Klinikum Wels, Wels, Austria|LKH Wr. Neustadt, Wr. Neustadt, Austria",,"https://ClinicalTrials.gov/show/NCT02555696"
164,"NCT02551185","ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Solid Tumors","Drug: ACY-241","Dose limiting toxicities (DLTs)|Recommended phase 2 dose and schedule of ACY 241 in combination with paclitaxel on a weekly schedule.|Maximum tolerated dose (MTD), if present.|Safety profile of ACY 241 administered in combination with paclitaxel.|Preliminary antitumor activity of ACY 241 administered in combination with paclitaxel in the patient population.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-ST-201","December 22, 2015","November 30, 2019","December 31, 2019","September 16, 2015",,"June 12, 2019","Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Remove - Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|CTRC at The UT Health Science Center at San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02551185"
165,"NCT02546986","Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer",,"Active, not recruiting","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: CC-486|Drug: Pembrolizumab|Drug: Placebo","Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on Food and Drug Administration (FDA) Methodology|Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on European Medicines Agency Methodology|Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for a Minimum Duration of 18 Weeks Compared to Baseline|Kaplan Meier Estimate of Overall Survival|Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response|Number of Participants With Treatment Emergent Adverse Events|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of CC-486|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of CC-486|Maximum Observed Plasma Concentration (Cmax) of CC-486|Time to Maximum Plasma Concentration (Tmax) of CC-486|Terminal Phase of Half-life (T1/2) of CC-486|Apparent Total Plasma Clearance (CL/F) of CC-486|Apparent Volume of Distribution (Vd/F) of CC-486","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-486-NSCL-001","October 9, 2015","April 13, 2017","December 31, 2019","September 11, 2015","May 14, 2018","April 24, 2019","Palo Verde Hematology Oncology, Glendale, Arizona, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Cancer and Blood Center, LLC, Athens, Georgia, United States|Research Medical Center, Kansas City, Missouri, United States|Washington Univ School of Medicine, Saint Louis, Missouri, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|Vanderbilt Univ Medical Center, Nashville, Tennessee, United States|Centre Leon Berard, Lyon, France|CHU Amiens Picardie- Hôpital Nord, Marseille, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Institut Gustave Roussy IGR Centre de Lutte Contre le Canc, Villejuif, France|Evangelische Lungenklinik Berlin, Berlin, Germany|Klinikum Esslingen GmbH, Esslingen Am Neckar, Germany|Universitatsklinikum Koln, Koeln, Germany|Klinik Lowenstein gGmbH, Löwenstein, Germany|IASO General, Athens, Greece|Centro Di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|A.O.U. Maggiore della Carità, Novara, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Hospital De Cruces, Baracaldo, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Daaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain","""Study Protocol: CC-486-NSCL-001_original protocol_Redacted.15May2015"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02546986/Prot_000.pdf|""Study Protocol: CC-486-NSCL-001.ProtocolAM1.14December 2015"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02546986/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02546986/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02546986"
166,"NCT02538965","A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia",,"Completed","Has Results","Leukemia, Myeloid","Drug: Lenalidomide","Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International Working Group (IWG) Criteria|Number of Participants Who Achieved a Bone Marrow Confirmed CR/CRi Lasting 3 Months (Durable Response Rate)|Duration of Response|Number of Participants Who Achieved a Best Response of Morphologic Complete Remission, Morphologic Complete Remission Incomplete or Partial Remission|Number of Participants With a Morphologic CR, CRi, PR or Treatment Failure at Cycles 1, 2 and 3|Number of Participants Who Received a Haematopoietic Stem Cell Transplant (HSCT)|Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE)|Percentage of Participants With of Graft Versus Host Disease (GVHD)|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Lenalidomide (AUC-t)|Area Under the Plasma Concentration Time Curve From 0 Extrapolated to Infinity (AUC-inf, AUC0∞) Of Lenalidomide|Maximum Observed Concentration (Cmax) of Lenalidomide|Time to Reach Maximum Concentration (Tmax) of Lenalidomide|Terminal Half-Life (t1/2) of Lenalidomide|Apparent Total Clearance (CL/F) of Lenalidomide|Apparent Volume of Distribution (Vz/F) of Lenalidomide|Correlation of Peripheral White Blood Cell Count, Absolute Blast Count and Cytogenetics With Response to Lenalidomide","Celgene","All","1 Year to 18 Years   (Child, Adult)","Phase 2","17","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-AML-002","November 19, 2015","July 22, 2017","January 11, 2019","September 2, 2015","September 20, 2018","March 4, 2019","Children's Hospital, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Salter Packard Children's Hospital at Stanford, Palo Alto, California, United States|Loma Linda University, San Bernardino, California, United States|UCSF Children's Hospital, San Francisco, California, United States|Colorado Children's Hospital, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I Dupont Hospital For Children, Wilmington, Delaware, United States|Children's Hospital National Medical Center, Washington, District of Columbia, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Advocate Chilldren's Hospital, Oak Lawn, Illinois, United States|Riley Hospital For Children at IU Health, Indianapolis, Indiana, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Children's Specialty Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hosp, Morristown, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Inst, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Carolinas Healthcare System, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Cancer Center, Houston, Texas, United States|Methodist Hospital, San Antonio, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Alberta Childrens Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|IWK Health Center, Halifax, Nova Scotia, Canada|Childrens Hospital of Eastern Ontario, Ottawa, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|Hospital For Sick Children, Torento, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02538965/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02538965/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02538965"
167,"NCT02531126","Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",,"Recruiting","No Results Available","Ulcerative Colitis","Drug: RPC1063","Evaluate the long-term safety of RPC1063 for the treatment of all patients with moderate to severe UC.|Evaluate the long-term efficacy of RPC1063 for the treatment of adult patients with moderate to severe UC.","Celgene","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","890","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC01-3102|2015-001600-64|U1111-1218-0284","December 2, 2015","February 28, 2022","February 28, 2022","August 24, 2015",,"October 22, 2019","Adobe Clinical Research LLC, Tucson, Arizona, United States|Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States|Anaheim Clinical Trials, Anaheim, California, United States|Aurora Care Clinic, Costa Mesa, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|OM Research, Lancaster, California, United States|Facey Medical Foundation (Parent), Mission Hills, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|University of California at San Francisco (PARENT), San Francisco, California, United States|West Central Gastroenterology d/b/a Gastro Florida, Clearwater, Florida, United States|Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|City Medical Group, Miami, Florida, United States|Regenerate Clinical Trials, Miami, Florida, United States|NSB Research, New Smyrna Beach, Florida, United States|Harmony Clinical Research, North Miami Beach, Florida, United States|Center For Digestive Health, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Theia Clinical Research, LLC, Pinellas Park, Florida, United States|Florida Medical Clinic, P.A., Zephyrhills, Florida, United States|Atlanta Gastroenterology Associates LLC, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Grand Teton Research Group, PLLC, Idaho Falls, Idaho, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Woodholme Gastroenterology, Baltimore, Maryland, United States|Johns Hopkins Clinical Research Network, Baltimore, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Charm City Research Group, Towson, Maryland, United States|Boston Medical Center Boston Univ School of Medicine, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|Clinical Research Professionals, LLC - De Paul Medical Dr, Bridgeton, Missouri, United States|Clinical Research Professionals, LLC - Olde Cabin Rd, Saint Louis, Missouri, United States|Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States|Centex Studies-Webster, Brooklyn, New York, United States|Long Island Clinical Research Associates, Great Neck, New York, United States|Concord Medical Group PRIME, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Mount Sinai - PRIME, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Carolinas HealthCare System Digestive Health, Charlotte, North Carolina, United States|East Carolina Gastroenterology, PA, Jacksonville, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Clinical Inquest Center Ltd, Beavercreek, Ohio, United States|Consultants for Clinical Research Inc., Cincinnati, Ohio, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, United States|Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Consultants in Gastroenterology, PA, Columbia, South Carolina, United States|Gastroenterology Associates of Orangeburg, Orangeburg, South Carolina, United States|Gastro One, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Digestive Disease Consultants Dallas, Dallas, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Houston Endoscopy and Research Center, Houston, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Gastroenterology, LTD, Virginia Beach, Virginia, United States|University of Washington School of Medicine, Seattle, Washington, United States|Hospital Italiano, Buenos Aires, Argentina|Instituto Medico CER, Quilmes, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Medical University Vienna, Vienna, Austria|Gomel Regional Clinical Hospital, Gomel, Belarus|City Clinical Hospital No 10, Minsk, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Imeldaziekenhuis, Bonheiden, Belgium|AZ Maria Middelares, Gent, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHC - Clinique St-Jospeh, Liege, Belgium|Medical Centre ""Asklepii"", OOD, Dupnitsa, Bulgaria|MC Rusemed ltd., Ruse, Bulgaria|NMTH ""Tsar Boris III"", Sofia, Bulgaria|MHAT ""Lyulin"", EAD, Sofia, Bulgaria|""City Clinic UMHAC"" EOOD, Sofia, Bulgaria|MHAT 'Tokuda Hospital Sofia', EAD, Sofia, Bulgaria|UMHAT ""Sv. Ivan Rilski"", EAD, Sofia, Bulgaria|UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria|Fourth MHAT - Sofia EAD, Sofia, Bulgaria|Medical Center ""Nov Rehabilitatsionen Tsentar"", EOOD, Stara Zagora, Bulgaria|MHAT 'Sv. Marina', EAD, Varna, Bulgaria|MC Medica Plus, Veliko Tarnovo, Bulgaria|Vancouver General Hospital, Vancouver, British Columbia, Canada|Viable Clinical Research - Lindsay, Lindsay, Ontario, Canada|LHSC - University Hospital, London, Ontario, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Quebec, Canada|Clinical Hospital Centre Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Vojenska nemocnice Brno, Brno, Czechia|Hepato-Gastroenterologie HK, s.r.o., Hradec Kralove, Czechia|GASTRO JeKa s.r.o., Klatovy, Czechia|Gregar s.r.o., Olomouc, Czechia|PreventaMed, Olomouc, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|IBD Centrum/ISCARE IVF a.s., Praha 7, Czechia|Nemocnice Slany, Slany, Czechia|LTD Research Institute of Clinical Medicine, Tbilisi, Georgia|LLC Vivamedi, Tbilisi, Georgia|LTD Academician N.Kipshidze Central University Clinic, Tbilisi, Georgia|LTD Coloproctological Center, Tbilisi, Georgia|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Campus Virchow-Klinikum, Berlin, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Medizinisches Versorgungszentrum Dachau, Dachau, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Germany|Crohn Colitis Centrum Rhein Main, Frankfurt, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|EUGASTRO GmbH, Leipzig, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|General Hospital of Athens Evangelismos, Athens, Greece|Laiko General Hospital of Athens, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|424th Army General Hospital, Thessaloniki, Greece|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfured, Hungary|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Pannonia Maganorvosi Centrum, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Vasutegeszsegugyi Kft. - Debreceni Egeszsegugyi Kozpont, Letavertes, Hungary|Mohacsi Korhaz, Mohacs, Hungary|Clinfan Szolgaltato Kft, Szekszard, Hungary|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco), Milano, Italy|A.O.U. Policlinico di Modena, Modena, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Complesso Integrato Columbus, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Hanyang Univerisy Guri Hospital, Guri-si, Korea, Republic of|CHA Bundang Medical Center CHA University, Seongnam-si,, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju-si, Korea, Republic of|P. Stradins Clinical University Hospital, Riga, Latvia|""Sfanta Treime"" Clinical Municipal Hospital, Chisinau, Moldova, Republic of|Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery, Chisinau, Moldova, Republic of|""Sf. Arhanghel Mihail"" Municipal Clinical Hospital, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Chisinau, Moldova, Republic of|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen (UMCG), Groningen, Netherlands|Zuyderland Medisch Centrum - Sittard-Geleen, Sittard-Geleen, Netherlands|ETZ Elisabeth, Tilburg, Netherlands|Dunedin Public Hospital, Dunedin, New Zealand|Clinsante S.C. Osrodek Badan Klinicznych, Bydgoszcz, Poland|Specjalistyczna Przychodnia Lekarska Medicus, Chorzow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Inter-Med, Czestochowa, Poland|GLOBE Clinical Research Sp. z o.o. LLC, Klodzko, Poland|PLEJADY Sp. z o.o. (LLC) Medical Centre, Krakow, Poland|Healthcare Center Orkan Med Stec Michalska Spolka Jawna, Ksawerow, Poland|Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Trialmed Llc, Piotrkow Trybunalski, Poland|Specjalistyczna Praktyka Lekarska dr med. Marek Horynski, Sopot, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe, Torun, Poland|MDM Healthcare Centre, Warsaw, Poland|Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice, Wierzchoslawice, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Bacau County Emergency Hospital, Department of Gastroenterology, Bacau, Romania|Hyperclinica MedLife Grivita, Bucharest, Romania|Bucharest University Emergency Hospital, Department of Internal Medicine II, Bucharest, Romania|TVM MED SERV SRL, Medical Center for Gastroenterology, Hepatology and Digestive Endoscopy, Cluj-Napoca, Romania|Craiova County Emergency Clinical Hospital, Craiova, Romania|""Pius Brinzeu"" County Emergency Clinical Hospital, Department of Gastroenterology and Hepatology, Timisoara, Romania|Multidisciplinary Medical Clinic ""Anthurium"", Barnaul, Russian Federation|Irkutsk State Medical Academy of Continuing Education, Irkutsk, Russian Federation|SBEI HPE ""Kazan State Medical University"" of the MoH of the RF, Kazan, Russian Federation|SBIH of Nizhniy Novgorod region "" Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko"", Nizhniy Novgorod, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|FSBI ""Scientific Research Institute of Physyology and Basic Medicine"" under the SB of RAMS, Novosibirsk, Russian Federation|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|SBEI HPE Rostov State Medical University of the MoH of the RF, Rostov-on-Don, Russian Federation|City Clinical Hospital No 31 - St. Petersburg, Saint Petersburg, Russian Federation|Union Clinic, Saint-Peterburg, Russian Federation|FSMEI HPE ""Military Medical Academy n.a. S.M.Kirov""of Ministry of Defense of Russia, Saint-Petersburg, Russian Federation|SPb SBIH City Hospital # 26, Saint-Petersburg, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation|Private Educational Institution of Higher Education ""Medical University ""REAVIZ"", Samara, Russian Federation|LLC Medical Company Hepatologist, Samara, Russian Federation|FFSBI ""The Nikiforov Russian Center of Emergency and Radiation Medicine"", St. Petersburg, Russian Federation|SPb SBIH Alexandrovskaya City Hospital, St.Petersburg, Russian Federation|SBEI HPE ""Stavropol State Medical Academy"" MoH of RF, Stavropol, Russian Federation|Clinical Hospital Center Zvezdara Clinic of Internal Diseases, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Clinical Hospital Center Zemun Department of Gastroenterology, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|General Hospital Djordje Jovanovic Zrenjanin, Zrenjanin, Serbia|Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia|Alian s.r.o., Bardejov, Slovakia|PIGEAS s.r.o., Martin, Slovakia|Gastromedic s.r.o., Nove Zamky, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|Dr MJ Prins Practice, Cape Town, South Africa|Endocare Research, Cape Town, South Africa|Emmed Research, Pretoria, South Africa|University Hospital of the Canary Islands (HUC) La Laguna, La Laguna, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain|RCI Chernivtsi Regional Clinical Hospital Dept of Gastroenterology Bukovinsky SMU, Chernivtsi, Ukraine|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipropetrovsk, Ukraine|Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk, Ukraine|Central City Clinical Hospital Dept of Theraphy No. 2 SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|CI of PH Kharkiv CCH #2, Kharkiv, Ukraine|GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine|Ok Clinic Medical Center within International Institute of Clinical Trials, LLC, Kyiv, Ukraine|Kyiv Regional Hospital #2, Kyiv, Ukraine|SI Republican Clinical Hospital of the MOHU Dept of Gastroenterology O.O.Bogomolets NMU, Kyiv, Ukraine|Kyiv CCH #8 Dept of Gastroenterology P.L. Shupyk NMA of PGE, Kyiv, Ukraine|Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU, Kyiv, Ukraine|Lviv Regional Clinical Hospital D Halytskyi Lviv NMU, Lviv, Ukraine|Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU, Lviv, Ukraine|CI Sumy City Clinical Hospital #1 Dept of Therapy Sumy SU, Sumy, Ukraine|Sumy Regional Clinical Hospital, Sumy, Ukraine|Vinnytsia Regional Clinical Hospital for Invalids of the Great Patriotic War, Vinnytsia, Ukraine|M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU, Vinnytsia, Ukraine|Vinnytsia M.I. Pyrohov National Medical University, Vinnytsia, Ukraine|City Clinical Hospital of Emergency and Urgent Care of Zaporizhzhya, Zaporizhia, Ukraine|CI City Hospital #1, Zaporizhia, Ukraine|CI Zapor City Multifunctional CH#9 City Center of Gastroenterology SI Zapor MA of PGE of MOHU, Zaporizhzhia, Ukraine|Zaporizhia Regional Clinical Hospital, Zaporizhzhia, Ukraine|Central District Hospital under Zhytomyr District Council, Zhytomyr, Ukraine|Royal Devon and Exeter Hospital (Wonford), Exeter, United Kingdom|Whipps Cross University Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02531126"
168,"NCT02531113","Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease",,"Active, not recruiting","No Results Available","Crohn's Disease","Drug: RPC1063","Change in Simple Endoscopic Score for Crohn's Disease from baseline|Change in the Crohn's Disease Activity Index (CDAI) score from baseline|Proportion of patients with clinical remission based on CDAI at Week 12|Proportion of patients with clinical response based on CDAI at Week 12|Proportion of patients with clinical remission based on Patient-Reported Outcome (PRO2) definitions|Proportion of patients with clinical response based on PRO2|Proportion of patients with endoscopic remission based on SES-CD definitions|Proportion of patients with endoscopic response based on SES-CD definitions|Change in intestinal mucosa histopathologic features and disease activity|Changes in biomarkers|Improvement in perianal and enterocutaneous fistulas|Proportion of patients in endoscopic remission based on SES-CD definitions|Proportion of patients in endoscopic response based on SES-CD definitions|Proportion of patients in clinical remission based on CDAI definitions|Proportion of patients in clinical remission based on PRO2 definitions|Proportion of patients in clinical response based on PRO2 definitions|Proportion of patients in clinical remission based on CDAI and PRO2 definitions who are off corticosteroids of those on corticosteroids at baseline|Proportion of patients in clinical remission based on CDAI|Proportion of patients in clinical response based on CDAI|Change in intestinal mucosa histopathologic features, histologic disease activity, and biomarkers|Change in fecal calprotectin and serum C-reactive protein (CRP) levels|Improvement in perianal and enterocutaneous fistulas in those patients with fistulas at baseline|Plasma concentration of RPC1063 and active metabolites at scheduled assessments during the treatment period|Absolute lymphocyte count (ALC) derived from hematology laboratory results|Peripheral immune cell phenotype determined by Flow cytometry|Number of treatment emergent adverse events during induction and extension|Proportion of patients in clinical response based on CDAI definitions","Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","69","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPC01-2201","October 9, 2015","October 12, 2019","December 11, 2019","August 24, 2015",,"September 19, 2019","Adobe Clinical Research LLC, Tucson, Arizona, United States|Florida Center for Gastroenterology, Largo, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Atlanta Gastroenterology Specialists PC, Suwanee, Georgia, United States|DM Clinical Research, Oak Lawn, Illinois, United States|Gastroenterology Associates LLC, Baton Rouge, Louisiana, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Ehrhardt Clinical Research LLC, Belton, Missouri, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, United States|Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States|Gastroenterology Associates of Orangeburg, Orangeburg, South Carolina, United States|Gastro One, Germantown, Tennessee, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|LHSC Victoria Hospital, London, Ontario, Canada|Szent Margit Korhaz, Budapest, Hungary|Tolna Megyei Balassa Janos Korhaz, Szekszárd, Hungary|Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|GASTROMED Sp.zo.o., Lublin, Poland|Centrum Zdrowia Matki, Dziecka i Mlodziezy, Warsaw, Poland|Centralny Szpital Kliniczny MSWIA, Warsaw, Poland|Nzoz Vivamed, Warsaw, Poland|Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk, Ukraine|Kharkiv City Clinical Hospital 2, Kharkiv, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU, Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Vinnytsia Regional Clinical, Vinnytsia, Ukraine|CI City Hospital #1, Zaporizhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02531113"
169,"NCT02528838","An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.","REVIEW","Completed","No Results Available","Multiple Myeloma",,"Adverse Event (AE)|Quality of Life|Lenalidomide usage patterns|Lenalodomide dose modifications|Reasons for discontinuation of lenalidomide|Clinical outcome","Celgene","All","18 Years and older   (Adult, Older Adult)",,"238","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIPMS-Celgene-NETH-001","May 1, 2011","June 30, 2016","January 15, 2018","August 19, 2015",,"February 8, 2019",,,"https://ClinicalTrials.gov/show/NCT02528838"
170,"NCT02521714","Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension",,"Completed","No Results Available","Healthy Volunteers","Drug: Lenalidomide","Pharmacokinetics - AUCt|Pharmacokinetics - AUC∞|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - T1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Adverse Events (AEs)","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-5013-CP-013","August 14, 2015","September 23, 2015","September 23, 2015","August 13, 2015",,"November 8, 2019","Covance-Daytona Beach, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02521714"
171,"NCT02510937","Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis",,"Completed","No Results Available","Pulmonary Fibrosis","Drug: CC-90001","Adverse Events (AEs)|Dose interruptions, reductions, and discontinuation|Complete PEs|Clinical laboratory assessments|Vital sign measurements|12-lead ECGs|Urine pregnancy tests|Concomitant medications and procedures|CC-90001 plasma concentrations|Population-based PK","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90001-CP-003","August 5, 2015","February 6, 2017","February 6, 2017","July 29, 2015",,"April 4, 2017","Tampa General Hospital, Tampa, Florida, United States|LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Prince Charles Hospital, Chermside, Australia|St. Vincent's Hospital- Sydney, Darlinghurst, Australia",,"https://ClinicalTrials.gov/show/NCT02510937"
172,"NCT02509039","A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)",,"Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: CC-122","Dose Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Adverse Events (AEs)|Pharmacokinetics -AUC|Pharmacokinetics - Cmax|Pharmacokinetics - t1/2|Pharmacokinetics - Tmax|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Antitumor activity","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-ST-002","September 2, 2015","March 30, 2017","December 31, 2020","July 27, 2015",,"October 29, 2019","Aichi Cancer Center Hospital, Nagoya-shi, Aichi, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02509039"
173,"NCT02502188","Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis",,"Terminated","No Results Available","Parapsoriasis|Healthy Volunteers","Drug: CC-90005|Drug: Placebo","Adverse Events (AEs)|Pharmacokinetics- Cmax|Pharmacokinetics- Tmax|Pharmacokinetics- AUC∞|Pharmacokinetics- AUCt|Pharmacokinetics- AUC24|Pharmacokinetics- AUCτ|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Pharmacokinetics- RAc|Quality of Life Analysis|Body Surface Area Involvement|Psoriasis Area and Severity Index Scores|Static Physicians Global Assessment score|Effect of CC-90005 on ECG parameters","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-90005-CP-001","July 17, 2015","November 2, 2015","November 2, 2015","July 20, 2015",,"November 18, 2019","PPD Development, LP, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02502188"
174,"NCT02494258","A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.",,"Recruiting","No Results Available","Hematologic Neoplasm|Neoplasms","Drug: CC-486","Adverse Events (AEs)|Overall Survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-GEN-001","October 22, 2015","November 30, 2020","December 31, 2020","July 10, 2015",,"November 22, 2018","University of Florida College of Med, Gainesville, Florida, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02494258"
175,"NCT02450877","A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.",,"Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: Azacitidine|Other: Control Arm","Adverse Events (AEs)|Dose-limiting toxicities (DLTs)|Progression-free rate at Day 84 post randomization|Pharmacokinetics ‐ Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUCt|Pharmacokinetics - AUC∞|Pharmacokinetics - λz|Pharmacokinetics - t½|Pharmacokinetics - CL|Pharmacokinetics - Vz|Changes in DNA methylation (assessments of BM samples using Nano-HELP assay)|Leukemia-free survival (LFS)|Minimal residual disease pre-, and 3 and 6 months post-HSCT|Overall survival|Proportion treated with HSCT|Molecular response|Treatment-related mortality/morbidity|Toxicity after HSCT","Celgene","All","3 Months to 21 Years   (Child, Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-AML-004","August 12, 2015","October 10, 2018","October 10, 2019","May 21, 2015",,"January 10, 2019","Rigshospitalet, Copenhagen, Denmark|Charite Berlin, Berlin, Germany|Universitatsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main, Frankfurt am Main, Germany|Universitatsklinik, Freiburg, Germany|Medical School of Hannover, Hannover, Germany|VU University Medical Center, Amsterdam, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02450877"
176,"NCT02447666","Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)",,"Completed","No Results Available","Myelodysplastic Syndrome|Leukemia, Myelomonocytic, Juvenile","Drug: Azacitidine","Myelodysplastic Syndrome (MDS) response rate at end of third 28-day cycle|Juvenile Myelomonocytic Leukemia (JMML) response rate at end of 3 Months|Cytogenetic response for MDS|Cytogenetic response for JMML subjects|Molecular Response for JMML subjects|Duration of Response (CR, PR or marrow CR) for MDS patients|Duration of Response (Clinical CR or Clinical PR) for JMML patients|Time to Response (TTR) for MDS patients|TTR of Clinical CR or Clinical PR for JMML patients|Time to Progression (TTP)|Leukemia free survival (LFS)|Overall survival (OS)|Deoxyribonucleic acid methylation status in (BM)|Percentage of subjects undergoing HSCT|Time to first HSCT|Adverse Events (AEs)|Pharmacokinetic parameters of azacitidine; Cmax|Pharmacokinetic parameters of azacitidine; Tmax|Pharmacokinetic parameters of azacitidine; AUCt|Pharmacokinetic parameters of azacitidine; area under the plasma concentration-time curve from time zero to infinity (AUC ∞)|Pharmacokinetic parameters of azacitidine; Terminal Rate λz|Pharmacokinetic parameters of azacitidine; terminal phase half-life|Pharmacokinetic parameters of azacitidine; total clearance (CL)|Pharmacokinetic parameters of azacitidine; volume of distribution (Vz)","Celgene","All","1 Month to 18 Years   (Child, Adult)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-JMML-001","September 15, 2015","February 28, 2018","May 24, 2019","May 19, 2015",,"July 11, 2019","St. Anna Kinderkrebsforschung, CHILDREN'S CANCER RESEARCH INSTITUTE, Vienna, Austria|Hopital Universitaire des Enfants, Brussels, Belgium|University Hospital Ghent, Ghent, Belgium|University Hospital Motol, Prague 5, Czechia|Rigshospitalet, Copenhagen, Denmark|Centre Hospitalier Universitaire Lyon, Lyon, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, France|Hopital Robert Debre, Paris, France|Klinikum Augsburg, Augsburg, Germany|Charite Berlin, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Hematology, Oncology and clinical immunology / Heinrich-Heine-University, Dusseldorf, Germany|Universitatsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main, Frankfurt am Main, Germany|Universitatsklinik, Freiburg, Germany|University of Hamburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum, Jena, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, Germany|Klinikum der Universitaet Muenchen, Munchen, Germany|Universitatsklinik Munster, Münster, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany|Universitatsklinikum, Tübingen, Germany|Our Lady's Hospital for Sick Children, Dublin 12, Ireland|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|IRCCS Gaslini Hospital, Genova Quarto, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|General Hospital, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Bambin Gesu, Roma, Italy|Regina Margherita Children's Hospital, Torino, Italy|Erasmus University Medical Center, Rotterdam, Netherlands|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, Spain|Queen Silvia Childrens Hospital, Gothenburg, Sweden|Karolinska University Hospital, Stockholm, Sweden|Universitäts-Kinderklinik, Zurich, Switzerland|Royal Manchester Children's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02447666"
177,"NCT02443168","Radiolabeled Study of AG-221 in Healthy Male Subjects.",,"Completed","No Results Available","Healthy Volunteers","Drug: AG-221|Radiation: 14C AG-221","Pharmacokinetics - Total [14C] Whole blood and plasma|Pharmacokinetics - Total [14C] urine and feces|Pharmacokinetics - Total [14C] Cumulative excretion|Pharmacokinetics - Total [14C] radioactivity|Pharmacokinetics - Total [14C] metabolites|Pharmacokinetics: Metabolite profiling and characterization in select biological matrices (Part 1)|Pharmacokinetics - Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics -T1/2|Adverse Events (AEs)","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AG-221-CP-002","May 14, 2015","July 21, 2015","July 21, 2015","May 13, 2015",,"October 30, 2018",,,"https://ClinicalTrials.gov/show/NCT02443168"
178,"NCT02435992","Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis",,"Recruiting","No Results Available","Ulcerative Colitis","Drug: RPC1063|Drug: Placebo","Clinical remission assessed by Mayo component sub-scores","Celgene","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","900","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-3101","June 17, 2015","June 29, 2020","March 28, 2021","May 6, 2015",,"October 22, 2019","Arizona Digestive Health, Sun City, Arizona, United States|Adobe Clinical Research LLC, Tucson, Arizona, United States|Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States|Anaheim Clinical Trials, Anaheim, California, United States|Aurora Care Clinic, Costa Mesa, California, United States|Valley View Internal Medicine, Garden Grove, California, United States|Davita Clinical Trials, LLC, Huntington Beach, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|OM Research, Lancaster, California, United States|University of Southern California - Keck School of Medicine, Los Angeles, California, United States|Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Facey Medical Foundation (Parent), Mission Hills, California, United States|Alliance Clinical Research, LLC, Oceanside, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|University of California at San Francisco (PARENT), San Francisco, California, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|Gastro Florida, Clearwater, Florida, United States|Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States|Advanced Pharma Research, Inc, Delray Beach, Florida, United States|Universal Axon Clinical Research, Doral, Florida, United States|Dolphin Medical Research, Doral, Florida, United States|South Florida Clinical Trials, Hialeah, Florida, United States|Florida Center for Gastroenterology, Largo, Florida, United States|City Medical Group, Miami, Florida, United States|Advanced Clincial Research, Miami, Florida, United States|Advanced Clinical Research of Miami, Miami, Florida, United States|Regenerate Clinical Trials, Miami, Florida, United States|Advanced Research for Health Improvement, Naples, Florida, United States|Advanced Research Institute, Inc., New Port Richey, Florida, United States|NSB Research, New Smyrna Beach, Florida, United States|Harmony Clinical Research, North Miami Beach, Florida, United States|Med-Care Research, North Miami Beach, Florida, United States|Center For Digestive Health, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|DBC Research, Corp, Pembroke Pines, Florida, United States|Theia Clinical Research, LLC, Pinellas Park, Florida, United States|Florida Medical Clinic, P.A., Zephyrhills, Florida, United States|Atlanta Gastroenterology Associates LLC, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Grand Teton Research Group, PLLC, Idaho Falls, Idaho, United States|Northwestern University Feinberg Sch of Medicine Division of Gastroenterology, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|DM Clinical Research, Oak Lawn, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Digestive Health, Topeka, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|University of Maryland Medical Group, Baltimore, Maryland, United States|Woodholme Gastroenterology, Baltimore, Maryland, United States|Johns Hopkins Clinical Research Network, Baltimore, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Charm City Research Group, Towson, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Community Clinical Research Network, Marlborough, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Center For Digestive Health, Troy, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|Clinical Research Professionals, LLC - De Paul Medical Dr, Bridgeton, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Clinical Research Professionals LLC - The Pines Court, Saint Louis, Missouri, United States|Clinical Research Professionals, LLC - Olde Cabin Rd, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States|Montefiore Medical Center, Bronx, New York, United States|NY Scientific, Brooklyn, New York, United States|Long Island Clinical Research Associates, Great Neck, New York, United States|Icahn School of Medicine Mount Sinai Beth Isreal, New York, New York, United States|Concord Medical Group PRIME, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai - PRIME, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas HealthCare System Digestive Health, Charlotte, North Carolina, United States|East Carolina Gastroenterology, PA, Jacksonville, North Carolina, United States|Kinston Medical Specialists, PA, Kinston, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States|Clinical Inquest Center Ltd, Springfield, Ohio, United States|Clinical Inquest Center Ltd, Springfield, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Consultants in Gastroenterology, PA, Columbia, South Carolina, United States|Gastroenterology Associates of Orangeburg, Orangeburg, South Carolina, United States|Gastro One, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Brooke-Army Medical Center, Fort Sam Houston, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Houston Endoscopy and Research Center, Houston, Texas, United States|Gastroenterology Research of San Antonio, LLC, San Antonio, Texas, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Spring Gastroenterology, Spring, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States|Gastroenterology, LTD, Virginia Beach, Virginia, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Hospital Italiano, Buenos Aires, Argentina|Instituto DAMIC Fundacion Rusculleda, Cordoba, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|Instituto Medico CER, Quilmes, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Centre For Digestive Diseases, Five Dock, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Mater Hospital Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Monash Medical Centre Clayton, Bentleigh East, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Medical University Vienna, Vienna, Austria|Gomel Regional Clinical Hospital, Gomel, Belarus|City Clinical Hospital No 10, Minsk, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Imeldaziekenhuis, Bonheiden, Belgium|AZ Maria Middelares, Gent, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHC - Clinique St-Jospeh, Liege, Belgium|Medical Centre ""Asklepii"", OOD, Dupnitsa, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|UMHAT ""Kaspela"", EOOD, Plovdiv, Bulgaria|MC Rusemed ltd., Ruse, Bulgaria|NMTH ""Tsar Boris III"", Sofia, Bulgaria|MHAT ""Lyulin"", EAD, Sofia, Bulgaria|City Clinic UMHAC EOOD, Sofia, Bulgaria|MHAT 'Tokuda Hospital Sofia', EAD, Sofia, Bulgaria|UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria|Fourth MHAT - Sofia EAD, Sofia, Bulgaria|UMHAT 'Sveta Anna' AD, Sofia, Bulgaria|UMHAT ""SofiaMed"", OOD, Sofia, Bulgaria|Medical Center ""Nov Rehabilitatsionen Tsentar"", EOOD, Stara Zagora, Bulgaria|MHAT 'Sv. Marina', EAD, Varna, Bulgaria|MC Medica Plus, Veliko Tarnovo, Bulgaria|Vancouver General Hospital, Vancouver, British Columbia, Canada|Brandon Medical Arts Clinic, Brandon, Manitoba, Canada|Viable Clinical Research - Lindsay, Lindsay, Ontario, Canada|LHSC - University Hospital, London, Ontario, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|Centre integre de sante et de services sociaux de la Monteregie-Centre - Hopital Charles-Le Moyne, Greenfield Park, Quebec, Canada|The Ottawa Hospital - General Campus, Ottawa, Quebec, Canada|CHUS - Hôpital Fleurimont, Sherbrooke, Quebec, Canada|Clinical Hospital Center Osijek, Osijek, Croatia|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital ""Sveti Duh"", Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Dubrava, Clinic of Internal Medicine, Department of Gastroenterology, Zagreb, Croatia|Vojenska nemocnice Brno, Brno, Czechia|Hepato-Gastroenterologie HK, s.r.o., Hradec Kralove, Czechia|GASTRO JeKa s.r.o., Klatovy, Czechia|Gregar s.r.o., Olomouc, Czechia|PreventaMed, Olomouc, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|Thomayerova nemocnice, Praha 4, Czechia|IBD Centrum/ISCARE IVF a.s., Praha 7, Czechia|Nemocnice Slany, Slany, Czechia|LTD Research Institute of Clinical Medicine, Tbilisi, Georgia|LLC Vivamedi, Tbilisi, Georgia|LTD Academician N.Kipshidze Central University Clinic, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|LTD Coloproctological Center, Tbilisi, Georgia|Charite - Universitaetsmedizin Berlin Charité - Campus Benjamin Franklin, Berlin, Germany|Charite - Campus Virchow-Klinikum, Berlin, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Medical Care Unit Dachau, Dachau, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Germany|Crohn Colitis Centrum Rhein Main, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik Hamburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Koeln, Koeln, Germany|EUGASTRO GmbH, Leipzig, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Universitatsklinikum Ulm, Ulm, Germany|Laiko General Hospital of Athens, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|University General Hospital of Larissa, Larissa Thessaly, Greece|General Hospital of Thessaloniki Hippokration, Thessaloniki, Greece|424th Army General Hospital, Thessaloniki, Greece|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfured, Hungary|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Obudai Egeszsegugyi Centrum Kft., Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Pannonia Maganorvosi Centrum, Budapest, Hungary|Szent Margit Korhaz, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Vasutegeszsegugyi Kft. - Debreceni Egeszsegugyi Kozpont, Letavertes, Hungary|Mohacsi Korhaz, Mohacs, Hungary|SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale Sacco, Milano, Italy|A.O.U. Policlinico di Modena, Modena, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Complesso Integrato Columbus, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Hanyang Univerisy Guri Hospital, Guri-si, Korea, Republic of|CHA Bundang Medical Center CHA University, Seongnam-si,, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Vicent's Hospital, Suwon, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju-Si, Korea, Republic of|Pauls Stradins Clinical University Hospital, Riga, Latvia|""Sfanta Treime"" Clinical Municipal Hospital, Chisinau, Moldova, Republic of|Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery, Chisinau, Moldova, Republic of|""Sf. Arhanghel Mihail"" Municipal Clinical Hospital, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Chisinau, Moldova, Republic of|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen (UMCG), Groningen, Netherlands|Maastricht University Medical Center, Maastrich, Netherlands|Zuyderland Medisch Centrum - Sittard-Geleen, Sittard-Geleen, Netherlands|ETZ Elisabeth, Tilburg, Netherlands|Christchurch Hospital NZ, Christchurch, New Zealand|Dunedin Public Hospital, Dunedin, New Zealand|Clinsante S.C. Osrodek Badan Klinicznych, Bydgoszcz, Poland|Specjalistyczna Przychodnia Lekarska Medicus, Chorzow, Poland|GLOBE Clinical Research Sp. z o.o. LLC, Klodzko, Poland|PLEJADY Sp. z o.o. (LLC) Medical Centre, Krakow, Poland|Centrum Medyczne A-Z Clinic, Kraków, Poland|Healthcare Center Orkan Med Stec Michalska Spolka Jawna, Ksawerow, Poland|Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Trialmed Llc, Piotrkow Trybunalski, Poland|SOLUMED Centrum Medyczne, Poznan, Poland|Specjalistyczna Praktyka Lekarska dr med. Marek Horynski, Sopot, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe, Torun, Poland|MDM Healthcare Centre, Warsaw, Poland|Nzoz Vivamed, Warsaw, Poland|Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice, Wierzchoslawice, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Bacau County Emergency Hospital, Department of Gastroenterology, Bacau, Romania|Hyperclinica MedLife Grivita, Bucharest, Romania|Bucharest University Emergency Hospital, Department of Internal Medicine II, Bucharest, Romania|TVM MED SERV SRL, Medical Center for Gastroenterology, Hepatology and Digestive Endoscopy, Cluj-Napoca, Romania|Sf. Apostol Andrei Constanta Emergency Clinical County Hospital, Constanta, Romania|Craiova County Emergency Clinical Hospital, Craiova, Romania|""Pius Brinzeu"" County Emergency Clinical Hospital, Department of Gastroenterology and Hepatology, Timisoara, Romania|Multidisciplinary Medical Clinic ""Anthurium"", Barnaul, Russian Federation|Road Clinical Hospital on Station Irkutsk-Passazhirskiy of OJSC Russian Railways, Irkutsk, Russian Federation|SBEI HPE ""Kazan State Medical University"" of the MoH of the RF, Kazan, Russian Federation|FSBIH ""Central Clinical Hospital of Russian Academy of Sciences"", Moscow, Russian Federation|SBIH of Nizhniy Novgorod region "" Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko"", Nizhniy Novgorod, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|FSBI ""Scientific Research Institute of Physyology and Basic Medicine"" under the SB of RAMS, Novosibirsk, Russian Federation|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|SBEI HPE Rostov State Medical University of the MoH of the RF, Rostov-on-Don, Russian Federation|SBIH City Clinical Hospital #31, Saint Petersburg, Russian Federation|Union Clinic, Saint-Peterburg, Russian Federation|FSMEI HPE ""Military Medical Academy n.a. S.M.Kirov""of Ministry of Defense of Russia, Saint-Petersburg, Russian Federation|SPb SBIH City Hospital # 26, Saint-Petersburg, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation|Private Educational Institution of Higher Education ""Medical University ""REAVIZ"", Samara, Russian Federation|LLC Medical Company Hepatologist, Samara, Russian Federation|FFSBI ""The Nikiforov Russian Center of Emergency and Radiation Medicine"", St. Petersburg, Russian Federation|SPb SBIH Alexandrovskaya City Hospital, St.Petersburg, Russian Federation|SBEI HPE ""Stavropol State Medical Academy"" MoH of RF, Stavropol, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine, Belgrade, Serbia|Clinical Center of Serbia, Clinic of Gastroenterology and Hepatology, Department of Gastroenterology, Belgrade, Serbia|Clinical Hospital Center Zvezdara Clinic of Internal Diseases, Belgrade, Serbia|Military Medical Academy, Clinic of Gastroenterology and Hepatology, Belgrade, Serbia|Clinical Hospital Center Zemun Department of Gastroenterology, Belgrade, Serbia|Clinical Center Kragujevac, Clinic of Internal Medicine, Center for Gastroenterohepatology, Kragujevac, Serbia|Clinical Center Nis, Clinic of Gastroenterology and Hepatology, Nis, Serbia|General Hospital Djordje Jovanovic Zrenjanin, Zrenjanin, Serbia|Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia|Alian s.r.o., Bardejov, Slovakia|PRO SANUS, a.s., Poliklinika ProCare Central, Bratislava, Slovakia|IBDcentrum s.r.o., Bratislava, Slovakia|Slovak Research Center-team member, Sukromna gastroenterologicka ambulancia, Ilava, Slovakia|Gastroped s.r.o., Kosice, Slovakia|Gastroeneterologicka ambulancia MUDr. Peter Hegyi, s.r.o., Malacky, Slovakia|PIGEAS s.r.o., Martin, Slovakia|Nemocnica s poliklinikou S. Kukuru Michalovce, a.s., Michalovce, Slovakia|Gastromedic s.r.o., Nove Zamky, Slovakia|EndoCorp s.r.o., Trnava, Slovakia|Dr MJ Prins Practice, Cape Town, South Africa|Tiervlei Trial Centre, Cape Town, South Africa|Endocare Research, Cape Town, South Africa|Dr JP Wright Practice, Cape Town, South Africa|Dr YS Nanabhay Practice, Johannesburg, South Africa|Emmed Research, Pretoria, South Africa|University Hospital Germans Trias i Pujol, Badalona, Spain|University Hospital of the Canary Islands (HUC) La Laguna, La Laguna, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain|University Hospital Virgen del Rocio, Sevilla, Spain|RCI Chernivtsi Regional Clinical Hospital Dept of Gastroenterology Bukovinsky SMU, Chernivtsi, Ukraine|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipropetrovsk, Ukraine|Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases, Dnipropetrovsk, Ukraine|Ivano-Frankivsk City Clinical Hospital #1 Dep of Surgery SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|Central City Clinical Hospital Dept of Theraphy No. 2 SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|CI of PH Kharkiv CCH #2, Kharkiv, Ukraine|GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine|Kyiv City Clinical Hospital #1, Kyiv, Ukraine|SI Republican Clinical Hospital of the MOHU Dept of Gastroenterology O.O.Bogomolets NMU, Kyiv, Ukraine|CI of Kyiv RC Regional Clinical Hospital #2, Kyiv, Ukraine|Kyiv CCH #8 Dept of Gastroenterology P.L. Shupyk NMA of PGE, Kyiv, Ukraine|Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU, Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU, Lviv, Ukraine|CI Sumy City Clinical Hospital #1 Dept of Therapy Sumy SU, Sumy, Ukraine|Sumy Regional Clinical Hospital, Sumy, Ukraine|CI of TRC Ternopil University Hospital, Ternopil, Ukraine|A. Novak Transcarpathian Regional Clinical Hospital, Uzhgorod, Ukraine|MCIC MC LLC Health Clinic, Vinnytsia, Ukraine|Vinnytsia Regional Clinical Hospital for Invalids of the Great Patriotic War, Vinnytsia, Ukraine|M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU, Vinnytsia, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine|Vinnytsia M.I. Pyrohov National Medical University, Vinnytsia, Ukraine|City Clinical Hospital of Emergency and Urgent Care of Zaporizhzhya, Zaporizhia, Ukraine|Zaporizhia City Multispecialty Clinical Hospital #9, Department of Neurology, Zaporizhia, Ukraine|CI City Hospital #1, Zaporizhia, Ukraine|CI Zapor City Multifunctional CH#9 City Center of Gastroenterology SI Zapor MA of PGE of MOHU, Zaporizhzhia, Ukraine|Zaporizhia Regional Clinical Hospital, Zaporizhzhia, Ukraine|Central District Hospital under Zhytomyr District Council, Zhytomyr, Ukraine|University Hospital Coventry, Coventry, United Kingdom|Royal Devon and Exeter Hospital (Wonford), Exeter, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Whipps Cross University Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02435992"
179,"NCT02425826","A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.","UNVEIL","Completed","Has Results","Parapsoriasis","Drug: Apremilast|Drug: Placebo|Drug: Placebo-Apremilast","Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16|Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16|Percentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline|Percentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline|Mean Change From Baseline in Pruritus Visual Analog Scale (VAS)|Percentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16.|Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 16|Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 52|Mean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16|Percentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16.|Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 16|Mean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52|Percentage of Participants With Scalp Psoriasis Who Were Initially Randomized to Apremilast and Maintained the Scalp Physician's Global Assessment (ScPGA) Response From Week 16 to Week 52.|Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the Apremilast-Exposure Phase","Celgene","All","Child, Adult, Older Adult","Phase 4","221","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-012","April 20, 2015","February 12, 2016","November 22, 2016","April 24, 2015","June 6, 2017","December 12, 2018","UAB at Birmingham - The Kirklin Clinic, Birmingham, Alabama, United States|Center For Dermatology, Fremont, California, United States|Dermatology Research Associates, Los Angeles, California, United States|Blue Harbor Dermatology, Newport Beach, California, United States|Center for Dermatology and Laser Surgery, Sacramento, California, United States|East Bay Rheumatology Medical, San Leandro, California, United States|Tien Q. Nguyen MD Inc, Tustin, California, United States|UConn Health Center, Farmington, Connecticut, United States|Dermatology Associates, Panama City, Florida, United States|USF Health Faculty Office Building-FOB, Tampa, Florida, United States|Forward Clinical Trials Inc, Tampa, Florida, United States|Dermatologic Surgery Specialists, P.C., Macon, Georgia, United States|Shideler Clinical Research Center, Carmel, Indiana, United States|Dermatology Specialists, PSC, Louisville, Kentucky, United States|DermResearch, PLLC, Louisville, Kentucky, United States|Lawrence Green, MD, LLC, Rockville, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Las Vegas Skin and Cancer Clinics, Las Vegas, Nevada, United States|Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States|Garden City Dermatology, Garden City, New York, United States|Sadick Research Group, New York, New York, United States|Dermatology Associates of Rochester PC, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Dermatology and Laser Center of Charleston, Charleston, South Carolina, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Dermatology Consultants, Inc., Lynchburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02425826"
180,"NCT02417285","A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin","Drug: Obinutuzumab|Drug: CC-122","Adverse Events (AEs)|Tumor Response|Response Duration|Progression-free Survival (PFS)|Pharmacokinetics - Cmax|Pharmacokinetics AUC|Pharmacokinetics Tmax|Pharmacokinetics T1/2|Pharmacokinetics - CL/F|Pharmacokinetics ‐ Vz/f","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-NHL-001","May 22, 2015","December 31, 2020","December 31, 2020","April 15, 2015",,"April 5, 2019","Institut Bergonie, Borddeaux Cedex, France|Institut Paoli Calmettes, Marseille cedex, France|Centre hospitalier Lyon Sud Hematologie, Pierre-Bénite cedex, France|Institut Gustave Roussy, Villejuif Cedex, France|Institute of Hematology and Medical Oncology L. and A. Seragnoli, Bologna, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Academisch Medisch Centrum, Amsterdam, Netherlands|Erasmus Medical Center-Daniel den Hoed, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02417285"
181,"NCT02406742","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","ENHANCE","Active, not recruiting","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell","Drug: CC-122|Drug: Ibrutinib|Drug: Obinutuzumab","Adverse Events (AEs)|Dose-Limiting Toxicity (DLT)|Not Tolerated Dose (NTD)|Maximum Tolerated Dose (MTD)|Overall Response (OR)|CC-122 pharmacokinetic parameters/plasma concentrations when administered alone or in combination with ibrutinib or obinutuzumab|Ibrutinib plasma concentrations when given alone and administered in combination with CC-122|Minimal Residual Disease (MRD)|Duration of response (DoR)|Progression-free survival (PFS)|Pharmacokinetics ‐ Cmax - CC-122|Pharmacokinetics - AUC - CC-122|Pharmacokinetics ‐ T1/2 - CC-122|Progression-f Pharmacokinetics ‐ Vz/f - CC-122|Pharmacokinetics - CL/F - CC-122|Pharmacokinetics ‐ Cmax - Ibrutinib|Pharmacokinetics - AUC - Ibrutinib|Pharmacokinetics ‐ T1/2 - Ibrutinib|Progression-f Pharmacokinetics ‐ Vz/f - Ibrutinib|Pharmacokinetics - CL/F - Ibrutinib|Plasma concentration for CC-122|Plasma concentration for Ibrutinib","Celgene","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1|Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-CLL-001","July 27, 2015","June 9, 2020","June 9, 2020","April 2, 2015",,"December 11, 2018","University of California San Diego, La Jolla, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States|Ohio State University Medical CenterJames Cancer Hospital, Columbus, Ohio, United States|The West Clinic, Memphis, Tennessee, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University Hospital Innsbruck, Innsbruck, Austria|University Hospital of Salzburg St Johanns Spital, Salzburg, Austria|Allgemeines Krankenhaus Wien, Wien, Austria|Universitaetsklinikum EssenInnere Klinik und Poliklinik, Essen, Germany|University of Schleswig-Holstein, Kiel, Germany|Universitat zu Koln, Köln, Germany|Universitatsklinikum Würzburg, Würzburg, Germany|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Ospedale Niguarda Milano, Milano, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Hospital Universitario Vall D hebron, Barcelona, Spain|Fundacion Jimenez Daaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02406742"
182,"NCT02403869","Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy","DD-CMM","Active, not recruiting","No Results Available","Breast Neoplasms",,"Definitive deterioration at 6 months|Definitive deterioration at 3 months|Definitive deterioration at 9 months|Definitive deterioration at 12 months|Time to Definitive deterioration (TTDD)|Overall survival|TTDD as a prognostic factor|Quality of life|Quality of life every 3 months|Chemotherapy-induced peripheral neuropathy|Chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20|Definitive deterioration","Celgene","All","18 Years and older   (Adult, Older Adult)",,"148","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-CMM-2013-01","March 12, 2014","February 28, 2019","June 30, 2019","March 31, 2015",,"February 6, 2019","Hospital Juan Ramón Jiménez, Huelva, Andalucía, Spain|Hospital Virgen de Valme, Sevilla, Andalucía, Spain|Hospital Virgen del Rocío, Sevilla, Andalucía, Spain|Hospital Miguel Servet, Zaragoza, Aragón, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Universitario Son Espases, Palma Mallorca, Baleares, Spain|Hospital Universitario Canarias, La Laguna, Santa Cruz De Tenerife, Canarias, Spain|Hospital Virgen de la Salud. Toledo, Toledo, Castilla La Mancha, Spain|Hospital Universitario Burgos, Burgos, Castilla Y León, Spain|Complejo Hospitalario de León, León, Castilla Y León, Spain|Hospital Bierzo, León, Castilla Y León, Spain|Hospital Universitario Salamanca, Salamanca, Castilla Y León, Spain|Centro Médico Teknon, Barcelona, Cataluña, Spain|Hospital Clinic Barcelona, Barcelona, Cataluña, Spain|Hospital Universitario San Joan de Reus, Reus, Tarragona, Cataluña, Spain|Corporación Sanitaria Parc Taulí- Sabadell, Sabadell, Cataluña, Spain|Hospital Universitario Elche, Elche, Comunidad Valenciana, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain|H. Infanta Cristina de Badajoz, Badajoz, Extremadura, Spain|H. San Pedro de Alcántara, Cáceres, Extremadura, Spain|Complejo Hospitalario de Ourense, Ourense, Galicia, Spain|Complejo Hospitalario de Pontevedra-Montecelo, Pontevedra, Galicia, Spain|Complejo Hospitalario Universitario de Santiago Compostela, Santiago de Compostela, Galicia, Spain|Complejo Hospitalario de Vigo, Vigo, Galicia, Spain|Hospital Universitario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Infanta Sofía, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02403869"
183,"NCT02400242","Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: ACY-241|Drug: Pomalidomide|Drug: Dexamethasone","Maximum tolerated dose of ACY-241 as monotherapy as assessed by dose limiting toxicities|Maximum tolerated dose of ACY-241 in combination with pomalidomide and low dose dexamethasone as assessed by dose limiting toxicities|Frequency and severity of AEs as measured by safety and tolerability|Single- and multiple-dose peak-plasma concentration|Single- and multiple-dose area under the plasma concentration versus time curve|Change in acetylation of histone and tubulin as a measure of pharmacodynamics|Change in fetal hemoglobin expression as a measure of pharmacodynamics|ACY-241 metabolite concentration in blood samples|Exposure response analyses of potential biomarkers of response.|Frequency and severity of AEs as measured by safety and tolerability in combination|Quantification of M-protein as a measure of anti-tumor activity","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","85","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-MM-200","May 7, 2015","December 30, 2019","December 30, 2019","March 27, 2015",,"October 17, 2019","University of Arizona, Tucson, Arizona, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Miami Medical Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|CTRC at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato, Heidelberg, Germany|Alexandra Hospital, University of Athens, Athens, Greece|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT02400242"
184,"NCT02394210","Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma","EPA-MMBR","Active, not recruiting","No Results Available","Multiple Myeloma",,"Time to progression (TTP)|Race of participants at Baseline|Age of participants at Baseline|Gender of participants at Baseline|Stage of Multiple Myeloma (MM) before study entry based on the international staging system (ISS)|Time from first pathologic diagnosis|The number of Comorbidities|Concomitant treatments related to MM|ECOG performance status|Define the abnormal finding in complete blood count at base line|Define the abnormal findings within the Biochemistry panel|The time from biological progression until clinical relapse|Overall Response rate|Event-free survival (EFS)|Progression-free survival (PFS)|Overall survival (OS)|EORTC QLQ-C30 Questionnaire|QLQ-MY24 Questionnaire|Cost associated with participants visit to hospital/primary health care associated with anti-myeloma therapy|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"415","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-MIE-2012-02","May 14, 2013","January 31, 2021","January 31, 2021","March 20, 2015",,"February 5, 2019","Hospital Miguel Servet, Zaragoza, Aragón, Spain|Hospital Royo Villanova, Zaragoza, Aragón, Spain|Hospital de Cabueñes, Gijón, Asturias, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Universitario de Canarias, La Laguna. Santa Cruz De Tenerife, Canarias, Spain|Hospital de Gran Canaria, Dr. Negrín, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Ntra. Sra. de la Candelaria, Santa Cruz de Tenerife, Canarias, Spain|Hospital Universitario de Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Nuestra Señora de Sonsoles Avila, Avila, Castilla Y León, Spain|Hospital de Burgos, Burgos, Castilla Y León, Spain|Hospital de León, León, Castilla Y León, Spain|Hospital de Segovia, Segovia, Castilla Y León, Spain|Clínico Universitario de Valladolid, Valladolid, Castilla Y León, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Vall d´Hebron, Barcelona, Cataluña, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Cataluña, Spain|Hospital Universitario Josep Trueta de Girona, Girona, Cataluña, Spain|Hospital Arnau de Vilanova de Lleida, Lleida, Cataluña, Spain|Hospital de Sabadell ( Parc Taulí), Sabadell, Cataluña, Spain|Hospital General de Castellon, Catellón, Comunidad Valenciana, Spain|Hospital Clínico Universitario Valencia, Valencia, Comunidad Valenciana, Spain|Hospital Arnau de Vilanova (Valencia), Valencia, Comunidad Valenciana, Spain|Hospital de Manises, Valencia, Comunidad Valenciana, Spain|Complejo Hospitalario de Cáceres (S. Pedro de Alcántara), Cáceres, Extremadura, Spain|Hospital de Llerena, Llerena, Badajoz, Extremadura, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain|Complexo Hospitalario de Ourense, Ourense, Galicia, Spain|Hospital Montecelo, Pontevedra, Galicia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain|Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Quirón, Pozuelo de Alarcón, Madrid, Spain|Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain|Hospital Santa Lucía, Cartagena, Murcia, Spain|Hospital Virgen de Arrixaca, El Palmar, Murcia, Murcia, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital de Donostia, Donostia-San Sebastián, Pais Vasco, Spain|Hospital Txagorritxu, Vitoria, País Vasco, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Complejo Universitario de San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02394210"
185,"NCT02387879","A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR",,"Active, not recruiting","No Results Available","Multiple Myeloma",,"Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-5013-PASS-TR","December 25, 2013","December 31, 2021","December 31, 2022","March 13, 2015",,"September 26, 2019","Baskent University Adana Application and Research Hospital, Adana, Turkey|Cukurova University Medical Faculty, Adana, Turkey|Gulhane Military Medical Academy, Ankara, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Ankara Numune Training and Research Hospital, Ankara, Turkey|Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital, Ankara, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Ankara Bayindir Hospital, Ankara, Turkey|Baskent University Ankara Hospital, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Antalya Medstar Hospital, Antalya, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Ali Osman Sonmez Oncology Hospital, Bursa, Turkey|Uludag University Medical Faculty, Bursa, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Osmangazi University Medical Faculty, Eskisehir, Turkey|Gaziantep University Medical Faculty, Gaziantep, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Bakırkoy Dr.Sadi Konuk Training and Research Hospital, Istanbul, Turkey|Medipol University Medical Faculty, Istanbul, Turkey|Kartal Training and Research Hospital, Istanbul, Turkey|Marmara University Pendik Training and Research, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Medical Faculty, Izmir, Turkey|Izmir Medical Park Hospital, Izmir, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Necmettin Erbakan University Meram Medical Faculty, Konya, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Celal Bayar University Medical Faculty, Manisa, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Ondokuz Mayis University Medical Faculty, Samsun, Turkey|Namik Kemal University Medical Faculty, Tekirdag, Turkey|Karadeniz Technical University Medical Faculty, Trabzon, Turkey",,"https://ClinicalTrials.gov/show/NCT02387879"
186,"NCT02387866","PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects",,"Completed","No Results Available","Healthy","Drug: AG-221","Pharmacokinetics -AUC 0-t|Pharmacokinetics - AUC ∞|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics -T1/2|Pharmacokinetics -CL/F|Pharmacokinetics -Vz/f|Adverse Events (AEs)","Celgene","Male","20 Years to 50 Years   (Adult)","Phase 1","62","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AG-221-CP-001","March 2, 2015","May 21, 2015","July 27, 2015","March 13, 2015",,"October 30, 2018","Parexel International, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02387866"
187,"NCT02374099","Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant",,"Terminated","Has Results","Breast Neoplasms","Drug: CC-486|Drug: Fulvestrant","Kaplan-Meier Estimate of Progression Free Survival (PFS)|Percentage of Participants Who Achieved a Confirmed Complete Response (CR) or Partial Response (PR) to Treatment (Objective Response Rate) Based On the Investigator Assessment|Percentage of Participants Who Achieved a Confirmed CR, PR or Stable Disease (SD) for ≥ 24 Weeks (Clinical Benefit Rate) by Investigator Assessment|Kaplan Meier Estimate of Overall Survival|Kaplan Meier Estimate of Duration of Response (DoR)|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-BRSTM-001","March 13, 2015","December 13, 2016","November 21, 2017","February 27, 2015","December 14, 2018","December 14, 2018","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Virginia G Piper Cancer Center, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University of Kansas Hospital, Westwood, Kansas, United States|Henry Ford Health System, Detroit, Michigan, United States|Clinical Research Alliance, New York, New York, United States|Medical Oncology Associates, Spokane, Washington, United States|Grand Hopital de Charleroi, Charleroi, Belgium|AZ Groeninge, Kortrijk, Belgium|Clinique Sainte Elisabeth - Service d'Oncologie, Namur, Belgium|GasthuisZusters Antwerpen, Wilrijk, Belgium|Centre Regional de lutte contre le cancer Paul Papin, Angers, France|Institut Bergonie, Borddeaux Cedex, France|Hopital Pitie Salpetriere, Paris, France|Centre Rene Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Saint Herblain, France|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany|Hamatologisch Onkologische Praxis Eppendorf, Hamburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|TU München - Klinikum rechts der Isar, München, Germany|Policlinico S. Orsola - Malpighi, Bologna, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|IEO- Istituto Europeo di Oncologia, Milano, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Universitario A Gemelli, Roma, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall D Hebron, Barcelona, Spain|Complejo Universitario La Coruna, La Coruna, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario Virgen de La Victoria, Malaga, Spain|Hospital Virgen del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02374099"
188,"NCT02367196","A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers",,"Active, not recruiting","No Results Available","Hematologic Neoplasms","Drug: CC-90002|Drug: Rituximab","Dose‐Limiting Toxicity (DLT)|Non-Tolerated Dose (NTD) - Part A|Maximum Tolerated Dose (MTD) - Part A|Non-Tolerated Dose (NTD) - Part B|Maximum Tolerated Dose (MTD) - Part B|Antitumor efficacy|Pharmacokinetics ‐ Cmax|Pharmacokinetics - AUC|Pharmacokinetics - tmax|Pharmacokinetics ‐ T1/2|Pharmacokinetics - CL|Pharmacokinetics - Vmax|Anti-Drug Antibodies (ADAs)|Overall Survival - Part B|Progression-free survival- Part B","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90002-ST-001|2015-000101-39","March 12, 2015","February 6, 2020","February 6, 2020","February 20, 2015",,"October 22, 2019","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of California San Francisco, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Medical College of WI Froedtert Multi-Disciplinary Cancer Clinic, Milwaukee, Wisconsin, United States|University of Cologne, Cologne, Germany|Universitaetsklinikum Muenster, Muenster, Germany|University Hospital of Ulm, Ulm, Germany|ASST Spedali Civili P.O. di Brescia, Brescia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Milano, Italy|Polyclinic San Matteo IRCCS, Pavia, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Vall d'Hebron, Barcelona, Spain|Duran i Reynals Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clinico Virgen de la Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital de la Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02367196"
189,"NCT02367183","A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease",,"Completed","No Results Available","Crohn Disease","Drug: GED-0301|Drug: Placebo","Change in SES-CD Score|Proportion of subjects achieving a clinical remission, defined as a CDAI score < 150 at Induction Week 4|Adverse Event (AE)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GED-0301-CD-001","April 8, 2015","September 6, 2016","December 14, 2017","February 20, 2015",,"January 10, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States|Macks Research Group, Newport Beach, California, United States|Medical Associates Research Group, San Diego, California, United States|University of California, San Francisco Medical Center, San Francisco, California, United States|Florida Research Network, LLC, Gainesville, Florida, United States|University of Florida Shands Endoscopy Center University of Florida at Gainesville, Gainesville, Florida, United States|Borland - Groover Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Gastroenterology Specialists, Suwanee, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|Metropolitan Gastroenterology, Chevy Chase, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States|Concorde Medical Group, New York, New York, United States|Cornell University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Cumberland Research Associates, Fayetteville, North Carolina, United States|The Management Associates, Wilmington, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Nashville Gastrointestinal Specialists, Nashville, Tennessee, United States|Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States|Digestive Disease Consultants, Grapevine, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Digestive Disease Consultants - Southlake, Irving, Texas, United States|University of Utah Division of Gastroenterology, Salt Lake City, Utah, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Centre For Digestive Diseases, Five Dock, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Concord Repatriation General Hospital, Concord, Australia|GI Research Institute, Vancouver, British Columbia, Canada|PerCuro Clinical Research, Victoria, British Columbia, Canada|London Health Science Center U. Hospital, London, Ontario, Canada|McMaster University Medical Centre, West Hamilton, Ontario, Canada|Szent Imre Korhaz, Budapest, Hungary|Szegedi Tudomanyegyetem, Szeged, Hungary|Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|IBD Centrum s.r.o., Bratislava, Slovakia|KM Management, spol. s r.o., Nitra, Slovakia|GASTRO I., s.r.o., Presov, Slovakia",,"https://ClinicalTrials.gov/show/NCT02367183"
190,"NCT02348528","Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year",,"Completed","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone","Adverse Events (AEs)|Progression Free Survival (PFS|Time to Progression (TTP)|Overall Survival (OS)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-024","September 11, 2012","September 29, 2016","September 29, 2016","January 28, 2015",,"November 11, 2019","Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|The 301 Hospital-Chinese PLA General Hospital, Beijing, China|Xiangya Hospital of Central South University, Changsha, China|Guangdong General Hospital, Guangzhou, China|Nanfang Hospital of Southern medicine university in Guangzhou, Guangzhou, China|1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, China|1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, China|Shanghai Changzheng Hospital, Shanghai, China|Shanghai 6th Hospital, Shanghai, China|The 1st Hospital of Soochow University, Suzhou, China",,"https://ClinicalTrials.gov/show/NCT02348528"
191,"NCT02343536","A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Drug: Oral Azacitidine|Drug: Rituximab|Drug: cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Maximum Tolerated Dose (MTD)|Maximal Administered Dose (MAD)|Adverse Event (AE)|Pharmacokinetics- Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics CL/F|Pharmacokinetics - Vz/F|Overall response rate (ORR)|Complete response (CR) rate|Progression free survival (PFS)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-DLBCL-001","April 29, 2015","February 1, 2020","February 1, 2020","January 22, 2015",,"February 15, 2019","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02343536"
192,"NCT02342847","Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer","aLIVE","Completed","No Results Available","Pancreatic Neoplasms","Other: N/A (non-interventional study)","Patients with mild improvement in Quality of life questionnaire - Current standard version 3.0 (EORTC QLQ-C30) scoring|Patients with mild impairment of EORTC QLQ-C30 scoring|Patients with moderate improvement in EORTC QLQ-C30 scoring|Patients with moderate impairment of EORTC QLQ-C30 scoring|Patients with high improvement in EORTC QLQ-C3 scoring|Patients with high impairment of EORTC QLQ-C30 scoring|Impairment of mild EORTC QLQ-C30 score|Deterioration of Moderate EORTC QLQ-C30 Score|Deterioration of severe EORTC QLQ-C30|Definite deterioration of moderate EORTC QLQ-C30 Score|Mild/moderate/severe decline in EORTC QLQ-C30|Patients with mild/moderate/high improvement in EORTC QLQ-C30|Deterioration of severe QLQ-C30|Change from baseline of the EuroQoL Five Dimensions Questionnaire (EQ-5D).|Change from baseline of the Karnofsky index|Feasibility of using the EORTC QLQ-C30 and EQ-5D questionnaires|Average variation of Karnofsky index versus EORTC QLQ-C30 score|Percentage of improved Karnofsky index|Average variation of Karnofsky index versus EQ-5D score|Percentage of worse Karnofsky index|Mean of improvement of Karnofsky index|Mean of deterioration of Karnofsky index|Weight variation|Number of patients who use Painkillers during treatment observation period (maximum 6 months)|Number of patients who use analgesics during treatment observation period (maximum 6 months).|Duration of treatment|Average dose of treatment (minimum, maximum)|Delayed/Reduced dose treatment|Rate response based on the treatment given.|Response to treatment determined by (Response Evaluation Criteria in Solid Tumors )RECIST v.1.1.|Overall survival determined by RECIST v.1.1.|Progression-free survival determined by RECIST v.1.1|Hematologic toxicity|Radiological examinations|Laboratory assessments|Physical examinations","Celgene","All","18 Years and older   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-CPM-2014-01","December 10, 2014","November 9, 2016","November 16, 2018","January 21, 2015",,"January 25, 2019","Hospital Universitario Burgos, Burgos, Castilla Y León, Spain|Complejo Asistencial León, León, Castilla Y León, Spain|Hospital del Bierzo, León, Castilla Y León, Spain|Hospital Universitario Salamanca, Salamanca, Castilla Y León, Spain|Germans Trias i Pujol, Badalona, Cataluña, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Vall d´Hebron, Barcelona, Cataluña, Spain|Hospital Universitario Josep Trueta de Girona, Girona, Cataluña, Spain|Hospital Duran I Reynals (ICO Bellvitge), Hospitalet de Llobregat, Cataluña, Spain|Hospital San Joan Reus, Reus, Cataluña, Spain|Hospital de Sabadell ( Parc Taulí), Sabadell, Cataluña, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02342847"
193,"NCT02341781","Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment","MCL-004","Completed","No Results Available","Lymphoma, Mantle-Cell",,"Overall Response Rate (ORR)|Duration of response (DoR)|Adverse Events","Celgene","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CC-5013-MCL-004","April 2015","September 2016","September 2016","January 19, 2015",,"January 26, 2017","Mayo Clinic Scottsdale, Phoenix, Arizona, United States|Innovative Clinical Research Institute, Whittier, California, United States|University of Miami and Sylvester Comprehensive Cancer, Miami, Florida, United States|University of Michigan Comprehensive Cancer Center Division of Hematology Oncology, Ann Arbor, Michigan, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Universitatsmedizin der Johannes Gutenberg- Universitat, Mainz, Rhineland-Palatinate, Germany|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|Derriford Hospital Plymouth Oncology Center Clinical, Plymouth, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02341781"
194,"NCT02330562","Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab",,"Active, not recruiting","No Results Available","Malignant Glioma|Glioblastoma","Drug: MRZ|Drug: BEV","Part 1 (Phase 1): Maximum Tolerated Dose (MTD) / Maximum Administered Dose (MAD)|Part 1 (Phase 1): Recommended Phase 2 Dose (RP2D)|Part 2 (Phase 2): MRZ single agent tumor activity|Part 3 (Phase 2): activity of MRZ + BEV with intra-patient dose escalation|Part 4 (Phase 1): Maximum Tolerated Dose (MTD) of enterally administered MRZ|Part 1 (Phase 1): Tumor activity|Parts 1, 2, 3 & 4 (Phase 1 and Phase 2): Assess safety and tolerance|Part 1 & 4 (Phase 1): MRZ pharmacokinetics|PParts 1 & 4 (Phase 1): Proteasome Activity in Packed Whole Blood (PWB) and peripheral blood mononuclear cells (PBMCs)|Parts 1, 2 & 3 (Phase 1 and Phase 2): Neurological Coordination Assessment|Parts 1, 2 & 3 (Phase 1 and Phase 2): Quality of Life Assessment","Celgene|Triphase","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","121","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRZ-108","April 15, 2015","December 10, 2019","December 10, 2019","January 5, 2015",,"October 1, 2019","University of Californai, Irvine, Orange, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Weill Cornell Medical College, New York, New York, United States|Duke Univ Medical Center, Durham, North Carolina, United States|Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02330562"
195,"NCT02323906","Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer",,"Terminated","No Results Available","Carcinoma, Hepatocellular","Drug: CC-122|Drug: Sorafenib","Adverse Event|Dose-Limiting Toxicity (DLT)|Overall Response Rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Progression-free survival|Overall survival|Time to progression (TTP)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-HCC-001","January 16, 2015","December 21, 2016","December 21, 2016","December 24, 2014",,"March 20, 2017","University of California San Francisco, San Francisco, California, United States|University of Florida College of Med, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Greenville Hospital System, Greenville, South Carolina, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02323906"
196,"NCT02313012","Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors",,"Terminated","No Results Available","Neoplasm Metastasis","Drug: CC-90003","Summary of the adverse events (type, severity, and incidence) related to CC-|Dose Limiting Toxicities of CC-90003|Maximum Tolerated Dose (MTD) of CC-90003|Pharmacokinetics (PK) observed maximum concentration (Cmax)|PK-Area under the plasma concentration time curve (AUC)|PK-Time to maximal plasma concentration (Tmax)|PK- terminal half-life; t1/2|PK-Apparent total body clearance (CL/F)|PK- Apparent Total Volume of Distribution (Vz/F)|Accumulation index of CC-90003|Response Rate based on RECIST 1.1|Duration of Response|Disease Control|Progression Free Survival|Overall Survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90003-ST-001","January 5, 2015","May 3, 2016","May 3, 2016","December 9, 2014",,"November 18, 2019","Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California, United States|Smilow Cancer Center, New Haven, Connecticut, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Peter MacCallum Cancer Centre, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT02313012"
197,"NCT02309177","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",,"Completed","No Results Available","Breast Neoplasms|Pancreatic Neoplasms","Drug: nab-Paclitaxel|Drug: Nivolumab|Drug: Gemcitabine|Drug: Carboplatin","Evaluate Dose Limiting Toxicity (DLT) of each combination regimen|Evaluate the safety of the nab-paclitaxel/nivolumab combination regimens|Grade 3 or 4 TEAE|Treatment Emergent Adverse Events|Progression-free survival|Overall Survival|Disease Control Rate|Overall Response Rate|Duration of Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-ST-001","January 12, 2015","September 12, 2018","September 12, 2018","December 5, 2014",,"May 31, 2019","UC Davis Cancer Center, Sacramento, California, United States|University of California Los Angeles, Santa Monica, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida, United States|Northwestern University-NMDTI, Chicago, Illinois, United States|Dana-Farber / Harvard Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Regional Care Cancer Centers NJ, Morristown, New Jersey, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Ohio State Medical Center, Columbus, Ohio, United States|University of Pennslyvania, Philadelphia, Pennsylvania, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02309177"
198,"NCT02307513","A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease",,"Active, not recruiting","Has Results","Behçet's Syndrome","Drug: Apremilast|Drug: Placebo","Area Under the Curve (AUC) for the Number of Oral Ulcers (Counts) From Baseline Through Week 12 (AUC Week 0-12)|Change From Baseline in Oral Ulcer Pain as Measured by Visual Analogue Scale (VAS) Score at Week 12|Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12|Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12|Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12|Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12|Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks|Time to Oral Ulcer Resolution (Complete Response)|Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12|Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12|Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12|Percentage of Participants With no Oral Ulcers Following a Complete Response|Time to Recurrence of Oral Ulcers Following Loss of CR Who Had a CR Prior to Week 12|Number of Oral Ulcers Following Loss of Complete Response Through Week 12|Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12|Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo- Controlled Period|Number of Participants With TEAEs During the Apremilast-Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-BCT-002|2013-004800-20","December 16, 2014","September 25, 2017","March 3, 2021","December 4, 2014","September 11, 2019","October 29, 2019","Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States|University of California Davis Medical Center, Sacramento, California, United States|Millennium Research, Ormond Beach, Florida, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Advanced Rheumatology, Lansing, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York Methodist Hospital, Brooklyn, New York, United States|NYU Langone Medical Center, New York, New York, United States|University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States|Hopital de La Conception, Marseille Cedex 05, France|Pitié-Salpêtriere Hospital Paris, Paris, France|Hopital Cochin, Paris, France|Hospital Saint Louis, Paris, France|Charite Universitaetsmedizin Berlin, Berlin, Germany|Stadtisches Klinikum Dessau, Dessau, Germany|Asklepios Rheumazentrum Hamburg, Hamburg, Germany|Navy Hospital of Athens, Athens, Greece|Athens General Hospital 'G Gennimatas', Athens, Greece|Laiko General Hospital of Athens, Athens, Greece|Ippokratio General Hospital of Thessaloniki, Thessaloniki, Greece|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Regionale San Carlo, Potenza/Matera, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Medical Hospital of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Japan|St. Luke's International Hospital, Chuo-ku, Japan|Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan|Japanese Red Cross Society Himeji Hospital, Himeji-shi, Japan|Saitama Medical University Hospital, Iruma-gun, Saitama, Japan|Teikyo University Hospital, Itabashi-ku, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Japan|St Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|University of Occupational and Environmentall Health, Kitakyushu, Japan|Kagawa University Hospital, Miki-cho, Japan|Kitasato University Hospital, Sagamihara, Japan|Saga Medical School Hospital, Saga, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaidô, Japan|Hokkaido University Hospital, Sapporo, Hokkaidô, Japan|Shimonoseki City Hospital, Shimonoseki, Japan|Tokyo Medical University Hospital, Shinjyuku-ku, Japan|Tomishiro Central Hospital, Tomigusuku-shi, Japan|Ehime University Hospital, Toon, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Chungnam National University Hospital, Daejeon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon si, Korea, Republic of|Hotel Dieu de France, Beirut, Lebanon|Ain Wazein Hospital, El Chouf, Lebanon|American University of Beirut Medical Center, El Chouf, Lebanon|Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey|Eskisehir Osmangazi University, Eskisehir, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Marmara University Hospital, Istanbul, Turkey|Selcuk University Medical Faculty, Konya, Turkey","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02307513/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02307513/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02307513"
199,"NCT02301143","Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)","LAPACT","Completed","Has Results","Pancreatic Neoplasms","Drug: nab-Paclitaxel|Drug: Gemcitabine|Drug: Chemoradiation|Drug: Capecitabine|Procedure: Surgery","Kaplan-Meier Estimates for Time to Treatment Failure (TTF)|Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1|Overall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.1|Kaplan-Meier Estimate of Progression-Free Survival (PFS)|Kaplan-Meier Estimates for Overall Survival (OS)|Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Global Health Status and 5 Functioning Scales|Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Symptom Scales and Single Symptom Items|Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Six Summary Scales|Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Satisfaction With Health Care Scale|Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): 10 Individual Item Scores|Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-PANC-007","April 21, 2015","November 21, 2017","April 26, 2018","November 25, 2014","January 8, 2019","March 20, 2019","Mayo Clinic - Arizona, Scottsdale, Arizona, United States|UC Davis Cancer Center, Sacramento, California, United States|Scripps Clinic Torrey Pines, San Diego, California, United States|Smilow Cancer Hospital At Yale-New Haven, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Piedmont Cancer Institute PC, Atlanta, Georgia, United States|Cancer Treatment Centers of America - Southeastern Regional Medical Center, Newnan, Georgia, United States|ME Center for Cancer Medicine, Scarborough, Maine, United States|Tufts - New England Medical Center, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Saint Joseph Mercy Ann Arbor Hospital, Ann Arbor, Michigan, United States|Karmanos Cancer Center Wayne State University, Detroit, Michigan, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Regional Cancer Care Associates LLC, Morristown, New Jersey, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|State University of New York Upstate Medical Center, Syracuse, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Mark H Zangmeister Center, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|CHUM Hôpital Saint-Luc, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Centre Regional de lutte contre le cancer Paul Papin, Angers, France|CHRU Besancon, Besançon, France|Centre Hospitalier Belfort Montbeliard, Besançon, France|Hopital Beaujon, Clichy cedex, France|Hopital Saint Antoine, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Ospedale Sacro Cuore di Gesu FatebeneFratelli, Benevento, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Hospital Universitario a Coruna, A Coruna, Spain|ICO-Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Miguel Servet, Zaragoza, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02301143/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02301143/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02301143"
200,"NCT02294058","Phase 3 Study of RPC1063 in Relapsing MS",,"Completed","No Results Available","Multiple Sclerosis","Drug: RPC1063|Drug: Beta interferon","Annualized relapse rate","Celgene","All","18 Years to 55 Years   (Adult)","Phase 3","1346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-301|2014-002320-27","December 3, 2014","December 22, 2016","December 22, 2016","November 19, 2014",,"May 8, 2017","Xenosciences Inc, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Northwest Neuro Specialists PLLC, Tucson, Arizona, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Collaborative Neuroscience Network Inc, Long Beach, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, United States|Denver Neurological Clinic, Denver, Colorado, United States|Neurology Associates PA, Maitland, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Infinity Clinical Research LLC, Pompano Beach, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|West Georgia Sleep Disorder Center and Neurology Associates, Douglasville, Georgia, United States|Consultants In Neurology, Northbrook, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Research Foundation, Lenexa, Kansas, United States|Associates In Neurology, Lexington, Kentucky, United States|Norton Healthcare, Louisville, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Neurology Specialists of Monmouth County PA, West Long Branch, New Jersey, United States|Neuro Medical Care Associates PLLC, Johnson City, New York, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, United States|Neurological Research Institute Inc, Columbus, Ohio, United States|Providence Multiple Sclerosis Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hope Neurology MS Center, Knoxville, Tennessee, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Bhupesh Dihenia MD PA, Lubbock, Texas, United States|EvergreenHealth, Kirkland, Washington, United States|The Polyclinic, Seattle, Washington, United States|Neurology of Neurosurgery Associates of Tacoma, Tacoma, Washington, United States|Center for Neurological Disorders, Milwaukee, Wisconsin, United States|Grodno Clinical Regional Hospital, Grodno, Belarus|Minsk Municipal Clinical Hospital 5, Minsk, Belarus|Republican Scientific and Practical Centre of Neurology and Neurosurgery, Minsk, Belarus|Minsk City Clinical Hospital 9, Minsk, Belarus|Vitebsk Regional Diagnostic Centre, Vitebsk, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina|Military Medical Academy HBAT, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment National Cardiology Hospital EAD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|Clinique Neuro Outaouais, Gatineau, Quebec, Canada|Clinical Hospital Osijek, Osijek, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinical Hospital Center Zagreb, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia|Clinical Hospital Sveti duh, Zagreb, Croatia|University Hospital Brno, Brno, Czechia|Fakultni nemocnice u sv Anny v Brne, Brno, Czechia|Private Neurological Practice Radomir Talab MD, Hradec Kralove, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|Nemocnice Jihlava prispevkova organizace, Jihlava, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia|Krajska zdravotni as Nemocnice Teplice oz, Teplice, Czechia|East Tallinn Central Hospital, Tallinn, Estonia|West Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Aversi Clinic LTD, Tbilisi, Georgia|Khechinashvili University Hospital, Tbilisi, Georgia|LTD MediClubGeorgia, Tbilisi, Georgia|Sarajishvili Institute of Neurology, Tbilisi, Georgia|Curatio JSC, Tbilisi, Georgia|Ltd DEKA, Tbilisi, Georgia|Praxis Dr. Wilfried Luer, Berlin, Germany|St. Joseph Krankenhaus Berlin, Berlin, Germany|Asklepios Fachklinikum Teupitz, Brandenburg, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Heinrich Heine Universitat Dusseldorf, Düsseldorf, Germany|DataMed GmbH, Köln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen am Rhein, Germany|Klinikum der Philipps Universitat Marburg, Marburg, Germany|St. Josefs-Krankenhaus Potsdam-Sanssouci GmbH, Potsdam, Germany|Krankenhaus der Barmherzigen Brueder, Trier, Germany|NeuroPoint Akademie, Ulm, Germany|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Latvian Maritime Medicine Centre, Riga, Latvia|Riga East Clinical University Hospital clinic Gailezers, Riga, Latvia|Pauls Stradins Clinical University Hospital, Riga, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|IMSP Institutul de Medicina Urgenta, Chisinau, Moldova, Republic of|Municipal Clinical Hospital Sf Arhanghel Mihail, Chisinau, Moldova, Republic of|Institutul de Neurologie si Neurochirurgie, Chisinau, Moldova, Republic of|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|B&B Robert Bonek, Pawel Bochniak, Spolka Cywilna, Bydgoszcz, Poland|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, Poland|Copernicus Podmiot Leczniczy Sp. z o.o., Gdansk, Poland|Akson Clinical Research Maciejowski Bielecki Sp. Jawna, Jaroslaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC, Katowice, Poland|M.A.- Lek A.M.Maciejowscy Spolka Cywilna, Katowice, Poland|Novo-Med Zielinski i wsp. Sp.J., Katowice, Poland|NEURO- CARE Site Management Organization Gabriela Klodowska-Duda, Katowice, Poland|RESMEDICA Spolka z o.o., Kielce, Poland|Niepubliczny Zespol Leczniczo-Rehabilitacyjny Centrum Kompleksowej Rehabilitacji, Konstancin Jeziorna, Poland|NZOZ NEUROMED M. I M. Nastaj Spolka Partnerska, Lublin, Poland|Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego, Lublin, Poland|Centrum Neurologii Krzysztof Selmaj, Lódzkie, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Mazowieckie, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, Poland|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON, Podlaskie, Poland|Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak, Pomorskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Centrum Medyczne doktorA, Warszawa, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospital de Braga, Braga, Portugal|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Campus Neurologico Senior, Torres Vedras, Portugal|Fundeni Clinical Institute, Bucharest, Romania|Colentina Clinical Hospital, Bucharest, Romania|Cluj Clinical County Hospital, Cluj Napoca, Romania|Cai Ferate Clinical Hospital, Constanta, Romania|Sibiu Emergency County Clinical Hospital, Sibiu, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, Romania|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|Regional Clinical Hospital, Barnaul, Russian Federation|Belgorod Regional Clinical Hospital, Belgorod, Russian Federation|Bryansk Regional Hospital 1, Bryansk, Russian Federation|Chelyabinsk City Clinical Hospital 3, Chelyabinsk, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Regional Clinical Hospital, Khanty-mansiysk, Russian Federation|Kirov City Clinical Hospital 1, Kirov, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Russian Federation|Kursk Regional Clinical Hospital, Kursk, Russian Federation|Central Clinical Hospital 2 na NA Semashko OAO RZhD, Moscow, Russian Federation|City Clinical Hospital 24, Moscow, Russian Federation|City Clinical Hospital 1 na NIPirogov, Moscow, Russian Federation|Research Center of Neurology of RAMS, Moscow, Russian Federation|City Clinical Hospital 11, Moscow, Russian Federation|Nizhniy Novgorod City Hospital 33, Nizhny Novgorod, Russian Federation|City Clinical Hospital 3 Nizhniy Novgorod Geriatrics Centre, Nizhny Novgorod, Russian Federation|Siberian Regional Medical Center, Novosibirsk, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Penza Regional Clinical Hospital na NN Burdenko, Penza, Russian Federation|Perm State Medical Academy, Perm, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|Pyatigorsk City Hospital 2, Pyatigorsk, Russian Federation|Rostov Regional Clinical Hospital, Rostov on Don, Russian Federation|Samara Regional Clinical Hospital named after MI Kalinin, Samara, Russian Federation|Smolensk State Medical Academy, Smolensk, Russian Federation|City Hospital 31, St. Petersburg, Russian Federation|City Hospital Nikolaevskaya Bolnitsa, St. Petersburg, Russian Federation|St. Petersburg Multi Field City Hospital 2, St. Petersburg, Russian Federation|First St Petersburg State Medical University na IP Pavlov, St. Petersburg, Russian Federation|Institute of Human Brain RAN, St. Petersburg, Russian Federation|City Clinical Hospital 40, St. Petersburg, Russian Federation|Siberian State Medical University, Tomsk, Russian Federation|Regional State Budget Institution of Healthcare Tver Regional Clinical Hospital, Tver, Russian Federation|Neftyanik Medical and Sanitary Unit, Tyumen, Russian Federation|Kuvatov Republican Clinical Hospital, Ufa, Russian Federation|Yaroslavl Clinical Hospital 8, Yaroslavl, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Hospital Centre Zemun, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Hospital Moises Broggi, Sant Joan Despí, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, Sweden|MI Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, Ukraine|Hospital 4 of Chernihiv City Council, Chernihiv, Ukraine|Municipal Treatment and Preventive Institution Chernihiv Regional Clinical Hospital, Chernihiv, Ukraine|Municipal Institution Chernivtsi Regional Psychiatric Hospital, Chernivtsi, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, Ukraine|Ivano Frankivsk City Clinical Hospital 1, Ivano Frankivsk, Ukraine|Regional Clinical Hospital., Ivano Frankivsk, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, Ukraine|Regional Clinical Hospital Center for Emergency Medical Care and Disaster Medicine, Kharkiv, Ukraine|Municipal Institution of Health Care Kharkiv Clinical City Hospital 7, Kharkiv, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kyiv, Ukraine|Kyiv City Clinical Hospital 4, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Municipal City Clinical Hospital 5, Lviv, Ukraine|Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU, Odesa, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|Regional Clinical Hospital na NV Sklifosovskyi, Poltava, Ukraine|Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod, Ukraine|Municipal Institution Vinnytsia Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsia, Ukraine|Municipal Institution City Clinical Hospital 2, Zaporizhya, Ukraine|Municipal Institution 6th City Clinical Hospital of Zaporizhzhia City Council, Zaporizhzhia, Ukraine|Municipal Institution Zaporizhzhia, Zaporizhzhia, Ukraine|Regional Clinical Hospital na OFHerbachevskyi of Zhytomyr Regional Council, Zhytomyr, Ukraine|University Hospital of Wales, Cardiff, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Kings College Hospital, London, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02294058"
201,"NCT02289456","Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2","AboundPS2","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: nab-Paclitaxel|Drug: Carboplatin","Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).|Percentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)|Dose Intensity of Nab-Paclitaxel During the Entire Study|Dose Intensity of Carboplatin During the Entire Study|Percentage of Participants With Dose Reductions During the Entire Study|Kaplan Meier Estimate of Progression-Free Survival (PFS)|Percentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)|Kaplan Meier Estimate of Overall Survival (OS)|Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines|Time to Response|Kaplan Meier Estimate of Duration of Response|Number of Participants With TEAEs During the Induction and Monotherapy Periods","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-NSCL-004","April 28, 2015","February 22, 2017","February 22, 2017","November 13, 2014","April 24, 2018","December 7, 2018","University Cancer Institute, Boynton Beach, Florida, United States|Ochsner Clinic Nephrology, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|University of RochesterJames P. Wilmont Cancer Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02289456/SAP_000.pdf|""Study Protocol: ABI-007-NSCL-004ProtocolAm1RedactedFinal.12Jan 2015"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02289456/Prot_001.pdf|""Study Protocol: ABI-007-NSCL-004.OriginalProtocolRedacted11Aug2014"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02289456/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT02289456"
202,"NCT02289417","Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis","UC","Completed","Has Results","Ulcerative Colitis","Drug: Apremilast|Drug: Placebo","Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12|Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12|Percentage of Participants Who Achieved an Endoscopic Remission at Week 12|Percentage of Participants Who Achieved an Endoscopic Response at Week 12|Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12|Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12|Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12|Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8|Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8|The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE)|The Number of Participants Who Discontinued Apremilast Due toTreatment Emergent Adverse Events","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-UC-001|2014-002981-64","December 10, 2014","September 25, 2017","June 3, 2019","November 13, 2014","October 29, 2018","August 20, 2019","Digestive Health Specialists of The Southeast, Dothan, Alabama, United States|Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Sunrise Medical Research, Inc., Lauderdale Lakes, Florida, United States|Pharmax Research Clinic, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|UMass Medical Center, Worcester, Massachusetts, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Center For Digestive Health, Troy, Michigan, United States|Gastrointestinal Associates PA, Jackson, Mississippi, United States|NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Quality Medical Research, Nashville, Tennessee, United States|Digestive Health Specialist of Tyler, Pasadena, Texas, United States|San Antonio Gastroenterology, San Antonio, Texas, United States|Gastroenterology Consultants of San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington Medical Center, Seattle, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Monash Medical Centre Clayton Campus, Clayton, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Multiprofile Hospital for Active Treatment Kaspela, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|City Clinic Cardiology Center Multiprofile Hospital for Active Treatment EOOD, Sofia, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|University of Manitoba, Winnipeg, Manitoba, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|Fakultni nemocnice u sv Anny v Brne, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Hepato-Gastroenterologie HK, s. r. o., Hradec Králové, Czechia|Nemocnice Slany, Slany, Czechia|Amiens University Hospital, Amiens, France|Hopital Beaujon, Clichy, France|CHRU Nantes, Nantes, France|CHU de Nice Archet I, Nice, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Centre Hospitalier Universitaire de Saint Etienne, Saint Priest en Jarez, France|CHRU Nancy, Vandoeuvre les Nancy, France|DRK Kliniken Berlin Westend, Berlin, Germany|Crohn-Colitis-Centre Rhein-Main, Frankfurt, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Gastroenterologische Praxis Minden, Minden, Germany|Universitatsklinikum Ulm, Ulm, Germany|Pannónia Klinika Magánorvosi Kft., Budapest, Hungary|ENDOMEDIX Kft., Budapest, Hungary|Vasútegészségügyi Nonprofit Kiemelten Közhasznú Kft. Debreceni Egészségügyi Központja, Debrecen, Hungary|Karolina Korhaz Rendelointezet, Mosonmagyaróvár, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Tolna Megyei Balassa Janos Korhaz, Szekszárd, Hungary|Javorszky Odon Korhaz, Vác, Hungary|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center, Milan, Italy|Azienda Sanitaria Locale Salerno, Nocera Inferiore, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Complesso Integrato Columbus, Roma, Italy|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato hospital, Hamilton, New Zealand|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Bydgoszcz, Poland|Centrum Medyczne sw. Lukasza, Czestochowa, Poland|Economicus - NZOZ ALL-MEDICUS, Katowice, Poland|Endoskopia Sp. z o.o., Sopot, Poland|Sonomed Sp. z o.o., Szczecin, Poland|Torunskie Centrum Gastrologiczne Gastromed, Torun, Poland|Centrum Zdrowia Matki, Dziecka i Mlodziezy, Warsaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warszawa, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Ars Medica, Wroclaw, Poland|Kazan State Medical University, Kazan, Russian Federation|Medical Center Stolitsa-Medikl, Moscow, Russian Federation|SEIHPE Rostov State Medical University of MoH of RF, Rostov on Don, Russian Federation|Saratov Regional Clinical Hospital, Saratov, Russian Federation|Russian Medical Military Academy na SMKirov, St Petersburg, Russian Federation|Regional Municipal Institution Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Kharkiv City Clinical Hospital 2, Kharkiv, Ukraine|Private Enterprise Private Manufactire Company Acinus, Kirovograd, Ukraine|Kremenchuk City Hospital # 1 n.a O.T.Bohaievskyi, Kremenchuk, Ukraine|Municipal City Clinical Emergency Hospital, Lviv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|Central City Clinical Hospital, Uzhgorod, Ukraine|Vinnytsia Regional Clinical Hospital n a M I Pyrohov, Vinnytsia, Ukraine|Municipal Institution Zaporizhzhia, Zaporizhzhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02289417/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02289417/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02289417"
203,"NCT02285062","Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","ROBUST","Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: lenalidomide|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: prednisone|Drug: vincristine","Progression Free Survival|Overall Survival|Complete Response Rate|Duration of Complete Response|Time to Next Lymphoma Treatment|Objective Response Rate|Health Related Quality of Life|Event Free Survival","Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","570","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-DLC-002|2013-004054-21","January 21, 2015","March 15, 2019","August 3, 2022","November 6, 2014",,"October 8, 2019","Highlands Oncology Group, Fayetteville, Arkansas, United States|John Muir Health, Concord, California, United States|California Cancer Associates for Research and Excellence cCARE, Encinitas, California, United States|Moores UCSD Cancer Center MC-0987, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of Californai, Irvine, Orange, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Memorial Hospital, Colorado Springs, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Memorial Healthcare System, Hollywood, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Cancer Treatment Centers of America - Southeastern Regional Medical Center, Newnan, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|McFarland Clinic, Ames, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States|Cancer Center of Acadiana, Lafayette, Louisiana, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Willis Knighton Medical Center, Shreveport, Louisiana, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|Associates of Oncology/Hematology, P.C., Rockville, Maryland, United States|Saint Joseph Medical Center, Westminster, Maryland, United States|St. Joseph Mercy Hosp, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Louis Cancer Care LLP, Bridgeton, Missouri, United States|Saint Louis Univ Hospital - Saint Louis, Saint Louis, Missouri, United States|Regional Cancer Care Associates/Cherry Hill Division, LLC., Cherry Hill, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Carol G Simon Cancer Center, Morristown, New Jersey, United States|Regional Cancer Care Associates - Somerset Division, Somerville, New Jersey, United States|Queens Medical Associates PC, Fresh Meadows, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Firsthealth of The Carolinas, Pinehurst, North Carolina, United States|St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Bon Secours Saint Francis Health System, Greenville, South Carolina, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Parkland Health and Hospital Systems, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|VCU Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, United States|Swedish Medical Center, Issaquah, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Cancer Institute Ballard Campus, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia|Shoalhaven Cancer Care Centre, Nowra, New South Wales, Australia|Bendigo Hosp, Bendigo, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Geelong Hospital, Geelong, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Frankston Hospital, Frankston, Australia|Austin Hospital, Heidelberg, Australia|Royal Melbourne Hospital, Parkville, Australia|Wellington Hospital, Wellington, Australia|Westmead Hospital, Westmead, Australia|Wollongong Hospital, Wollongong, Australia|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat, Roeselare, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Regionaal Ziekenhuis Jan Yperman VZW, West-Vlaanderen, Belgium|GZA St. Augustinus, Wilrijk, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Fraser Health Authority, Surrey, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke CHUS, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Beijing Cancer Hospital, Beijing, PR, China|Peking University People's Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|West China Medical School West China Hospital Sichuan University, Chengdu, China|Xinqiao Hospital, Third Military Medical University, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Nanfang Hospital of Southern medicine university in Guangzhou, Guangzhou, China|First Affiliated Hospital, Hangzhou, China|Harbin Medical University Tumor Hospital, Harbin, Heilongjiang, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|First Affiliated Hospital of Soochow University, Suzhu, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Centre Hospitalier de la cote basque, Bayonne, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Departemental de Vendee, La Roche -Sur-Yon - Cedex 9, France|CHU Hopital Saint Eloi, Montepellier Cedex 5, France|Hotel Dieu, Nantes, France|Hopital Necker, Paris Cedex 15, France|Hopital Saint Louis, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier D'annecy, Pringy, France|CHRU Rennes, Rennes, France|Centre Hospitalier de Saint Brieuc Hopital Yves le Foll, ST-Brieuc cedex 1, France|Centre Hospitalier Universitaire de Toulouse, Toulose, France|CHU de Nancy-Hopital Brabois Adulte, Vandoeuvre les Nancy, France|Institut Gustave Roussy, Villejuif CEDEX, France|Cork University Hospital, Wilton, Cork, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|St James's Hospital, Dublin 8, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|University College Hospital Galway, Galway, Ireland|The Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Assuta Medical Centers, Tel Aviv, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliero Universitaria Ospedali, Ancona, Italy|Centro di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliera Poloclinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|Spedali Civili Di Brescia, Brescia, Italy|Ospedale Ferrarotto, Catania, Italy|Azienda Sanitaria Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale Civile di Ivrea, Ivrea, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|Azienda Ospedaliera Niguarda Ca Granda, Milano, Italy|Azienda Ospedaliero Universitaria Di Modena Policlinico, Modena, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|A.O.U. Maggiore della Carità, Novara, Italy|AOU San Luigi Gonzaga, Orbassano (TO), Italy|Hospital of Di Padova, Padova, Italy|Presidio Ospedaliero Andrea Tortora, Pagani, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Civile Spirito Santo, Pescara, Italy|Azienda Sanitaria Locale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Policlinico Umberto I, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Presidio Ospedaliero Di Treviso Ca' Foncello, Treviso, Italy|Azienda Ospedaliera Cardinale G Panico, Tricase, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Azienda ULSS 6 Vicenza, Vicenza, Italy|Akita University Hospital, Akita-shi, Japan|National Cancer Center Hospital, Chuo-ku, Japan|Kyushu University Hospital, Fukuoka, Japan|Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital, Fukuyama, Japan|Tokai University School of Medicine, Isehara City, Kanagawa, Japan|National Cancer Center Hospital East, Kashiwa, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-City, Japan|National Hospital Organization Kyushu Cancer Center, Minami-Ku, Fukuoka, Japan|Toranomon Hospital, Minato-ku, Japan|Aichi Cancer Center, Nagoya, Japan|Kochi Medical School Hospital, Nankoku-shi, Japan|Sendai Medical Center, Sendai-city, Japan|Ehime University Hospital, Toon, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Marys Hospital College of Medicine The Catholic University of Korea, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis Molengracht, Breda, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Jeroen Bosch Ziekenhuis, s-Hertogenbosch, Netherlands|Vlietland Ziekenhuis, Schiedam, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Auckland City Hospital, Auckland, New Zealand|Canterbury Health Laboratories, Christchurch, New Zealand|Palmerston North Hospital, Palmerston, New Zealand|Szpital Morski im. PCK, Gdynia, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Samodz.Pub.Zaklad Opieki Zdrow-ej Min-wa Spraw Wewnetrznych w Poznaniu im Prof.Ludwika Bierkowskiego, Poznan, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Hospital Distrital Da Figueira Da Foz, Figueira da Foz, Portugal|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Champalimaud Cancer Center, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Hospital Garcia de Orta, Pragal, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Tatarstan Republican Oncology Center, Kazan, Russian Federation|Russian Cancer Research Center n.a. Blokhin, Chemotherapy Department, Moscow, Russian Federation|Research Oncology Institute of Rosmed Technologies n.a. prof. N.N. Petrov, St. Petersburg, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Complejo Hospitalario Nuestra Senora de Valme, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Kantonsspital Aarau AG, Aarau, Switzerland|Ente Ospedaliero Cantonale, Bellinzona, Switzerland|Hopitaux Universitaire de Geneve, Geneva, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|Chang Gung Memorial Hospital - Chiayi, Puzi City Chiayi County, Taiwan|China Medical University Hospital, Taichung City, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Cukurova Universitesi Tip Fakultesi Balcali Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi Hastanesi, Edirne, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey|Koc Universitesi Tip Fakultesi Amerikan Hastanesi, Istanbul, Turkey|Dokuz Eylul University Izmir, Izmir, Turkey|Erciyes University Kayseri, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT02285062"
204,"NCT02281084","Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes",,"Active, not recruiting","No Results Available","Myelodysplastic Syndromes","Drug: CC-486 (ORAL AZACITIDINE)","Overall Response Rate|Overall survival|Time to onset of responses|Duration of responses|Progression free survival|Stabilization of progression disease|Time to achieving stable disease|Duration of stable disease|Progression to AML|Time to AML progression|Adverse Events|Pharmacokinetic - Cmax|Pharmacokinetic - AUCt|Pharmacokinetic - AUCinf|Pharmacokinetic - Tmax|Pharmacokinetic - t1/2|Pharmacokinetic - CL/F|Pharmacokinetic - Vz/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-MDS-006","July 6, 2015","June 19, 2019","December 18, 2020","November 3, 2014",,"September 5, 2019","Yale University, New Haven, Connecticut, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Chicago Medicine, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Institute at UPMC, Pittsburgh, Pennsylvania, United States|University of Texas- MD Anderson, Houston, Texas, United States|Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Royal Perth Hospital, Perth, Australia|Universitair Ziekenhuis Brussel, Brussel, Belgium|Hopital Erasme, Bruxelles, Belgium|Centre Hospitalier Universitaire de Liege, Liège, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|Institut Paoli Calmettes, Marseille Cedex 9, France|Hopital Saint-Louis, Paris, France|CHU Purpan, Toulouse, France|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Marien Hospital, Dusseldorf, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitatsklinikum Halle Saale, Halle, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Medizinische Klinik III Klinikum der Universität München-Großhadern, München, Germany|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland|Institut Calatà d'Oncologia, L'Hospitalet, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Virgenes de las Nieves, Granada, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|CEIC Hospital Universitario La Fe, Valencia, Spain|United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|King's College HospitalSchool of Medicine, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|University College London, London, United Kingdom|Northwick Park Hospital, Middlesex, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02281084"
205,"NCT02279654","Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)","PASS MDS del5q","Active, not recruiting","No Results Available","Myelodysplastic Syndrome","Drug: Lenalidomide","Ascertain the Disease Progression to AML (through calculation of product limit estimators and incidence rates) for those with transfusion dependent Low to Intermediate 1 risk MDS del 5 q and have been treated with Revlimid|Overall Survival for patients with transfusion-dependent low to intermediate 1 risk MDS and isolated del (5q) and who have been treated with Lenalidomide|Adverse Events|Evaluate risk factors associated with progression of AML|Clinical practice","Celgene","All","18 Years and older   (Adult, Older Adult)",,"380","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-5013-MDS-010","December 17, 2014","March 31, 2022","March 31, 2023","October 31, 2014",,"April 19, 2019","AZ Klina, Brasschaat, Belgium|AZ Sint Jan, Brugge, Belgium|CHU Saint-Pierre - Site César De Paeppe, Bruxelles, Belgium|GHdCharleroi, Charleroi, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|CHR Citadelle, Liège, Belgium|CHU Vésale, Montigny- le- tilleul, Belgium|Clinique Saint-Pierre Ottignie, Ottignies, Belgium|Aalborg Sygehus, Dept of Hematology, Aalborg, Denmark|Århus University Hospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Rokslide Hospital, Roskilde, Denmark|Hopital de L'archet I, Nice, Alpes-Maritimes, France|Institut Paoli Calmettes, Marseille, Bouches-du-Rhône, France|Groupe Hospitalo-Universitaire Caremeau, Nimes Cedex 09, Gard, France|CHU Haut-Lévêque, Pessac, Gironde, France|CHU Hôtel Dieu, Nantes cedex 01, Loire-Atlantique, France|C.H de la Côte Basque, Bayonne, Pyrénées-Atlantiques, France|Hopital Avicenne - Aphp Hôpitaux Universitaires Paris-Seine-, Bobigny, Seine-Saint-Denis, France|CHU Hôtel Dieu, Angers, France|Centre Hospitalier D'Avignon - Hopital Henri Duffaut, Avignon, France|CHU Morvan, Brest, France|CHRU - Hôpital Côte de Nacre, Caen, France|CH Chalon/Saone William Morey, Chalon Sur Saone, France|CHU Estaing Service d'Hematolo, Clermont-Ferrand, France|CHU Grenoble, La Tronche, France|CH Le Mans, Le Mans, France|CHRU De Lille - Hôpital Claude - Rue Michel Polonovski, Lille, France|Centre Hospitalier Universitaire De Limoges - Hopital Dupuyt, Limoges, France|CHU Hôtel Dieu - Place A Ricordeau, Nantes, France|Hospital Cochin, Paris, France|Hôpital St Louis, Paris, France|CH de Perpignan, Perpignan, France|Centre Hospitalier Lyon-SUD [U, Pierre- Bénite, France|Hopital de Hautepierre CHRU de Strasbourg, Strasbourg, France|Hopital Purpan-Place du Dr. Baylac, Toulouse, France|CHU Bretonneau, Tours, France|CHU Nancy Brabois Adultes - 58 Allee dy morvan, Vandoeuvre les Nancy, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Hämatologie und Onkologie, Klinikum Chemnitz gGmbH International Patient Center, Chemnitz, Germany|Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany|Universitätsklinik Carl-Gustav, Dresden, Germany|HELIOS St. Johannes Klinik, Duisburg, Germany|Uniklinikum Düsseldorf, Klinik für Hämatologie, Onkologie und Klinische Immunologie, Düsseldorf, Germany|Marien Hospital Düsseldorf, Düsseldorf, Germany|St Antonius Hospital (SAH), Eschweiler, Germany|Kreiskrankenhaus St. Elisabeth - Von Werth-Str., Grevenbroich, Germany|Praxis, Onkologische Schwerpunktpraxis Dres. Verpoort, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|InVO Institut fur Versorgungsforschung, Koblenz, Germany|Gemeinschaftspraxis fur Hamatologie und Onkologie, Onkologisches zentrum Lebach, Lebach, Germany|Abteilung Hämatologie, Internistische Onkologie, Universitatklinikum Leipzig, Leipzig, Germany|III. Medizinische Klinik, Hämatologie und internistische Onkologie , Univesitatsmedizin Mannheim, Mannheim, Germany|Gesellschaft für Medizinische, Mönchengladbach, Germany|MLL Münchner Leukämielabor GmbH, München, Germany|III. Medizinische Klinik, Klinikum rechts der Isar der Technischen Universität München, München, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Innere Medizin II - Onkologie, Hämatologie, Univesitatklinikum Tubingen, Tübingen, Germany|Klinik für Innere Medizin III, Ulm, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany|Rems-Murr-Klinikum Winnenden, Winnenden, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|ZENTRUM FÜR INNERE MEDIZIN, Universitatklinikum Wurzburg, Würzburg, Germany|University Hospital of Alexandroupolis, Alexandroupolis, Greece|General Hospital of Athens - LAIKO, Athens, Greece|University General Hospital, Athens, Greece|Georgios Gennimatos General Hospital, Athens, Greece|University Hospital Of Herakli, Herakleion - Crete, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Larissa, Larissa, Greece|University General Hospital of Patras, Patras, Greece|G. Papanikolaou General Hospital, Thessaloniki, Greece|Irccs Crob, Rionero in Vulture, Potenza, Italy|Ospedale di Castelfranco Venet, Castelfranco Veneto, Treviso, Italy|AOU Ospedali Riuniti Umberto I G.M. Lancisi G. Salesi, Ancona, Italy|U.O Ematologia con Trapianto, Bari, Italy|Azienda Ospedaliera Papa Giovanni XX111 Piazza OMS, Bergamo, Italy|Policlinico S.Orsola Malpighi, AOU di Bologna, Bologna, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Ospedale Oncologico Businco, A - Via Jenner, Cagliari, Italy|Policlinico di Catania, Catania, Italy|AOU Careggi, Firenze, Italy|Ospedale Nuovo di Legnano, ASST Ovest Milanese - Medicina Interna - Legnano, Legnano, Italy|U.O .C di Oncoematologia, Mirano, Italy|AOU Maggiore della Carità, Novara, Italy|Ospedale S. Luigi Gonzaga, Orbassano, Italy|Azienda ospedaliero-universita, Parma, Italy|Azienda Ospedaliera di Perugia, Perugia, Italy|Ospedale Civile Santo Spirito, Pescara, Italy|Arcispedale S.Maria Nuova, Reggio Emilia, Italy|U.O Ematologia Azienda Ospedaliera, Regio Calabria, Italy|Univesita La Sapienza, Roma, Italy|AOU Policlinico Tor Vergata, Università Roma Tor Vergata, Roma, Italy|Presidio Ospedaliero ""A. Torto, Salerno, Italy|Azienda Ospedaliera Universitaria di Sassari, Sassari, Italy|A.O. Citta' della Salute e del, Torino, Italy|Policlinico ""G.B. Rossi"" Verona, Veneto, Italy|Centre Hospitalier Emile Mayri, Differdange, Luxembourg|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Umc St Radboud, Nijmegen, Netherlands|Haukeland Sykehus, Bergen, Norway|Helse Forde HF Central Hospital, Forde, Norway|Hospital Universitario de Gran Canaria Servicio de Hematología y, Las Palmas de Gran Canaria, Canarias, Spain|H.U.Marq.Valdecilla, Hospital Universitario Marqués de Valdecilla. Hematología, Santander, Cantabria, Spain|Hospital costa del sol, Marbella, Málaga, Spain|H.U. Ribera de Alzira, Alzira, Spain|Hospital de Cruces, Barakaldo, Spain|Hospital del Mar,Hematologia Hemotheropia, Barcelona, Spain|H. Clinic de Barcelona, Barcelona, Spain|Pauc Tauli, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Instit Catalia D'Oncologia, Barcelona, Spain|San Pedro De Alcantara, Caceres, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Josep Trueta (ICO Girona), Girona, Spain|Hospital Virgen de Las Nieves, Grenada, Spain|Department of Hematology, Hospital Duran i Reynals, LLobregat, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hopsital Clinico San Carlos, Madrid, Spain|Hospital Universitario fundacion Jiminez Diaz, Madrid, Spain|Hospital Universitario 12 de Octobre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|H Universitario Puera de Hierro, Madrid, Spain|Hospital Son Espaces, Mallorca, Spain|Hospital Universitario central de Asturias, Oviedo, Spain|Univesity Hospital de Salamanca, Salamenca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hopsital Nuestra Senora de Valme, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospiral Universitario de la Fe, Valencia, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Sahlgrenska University Hospital, Göteborg, Sweden|Länssjukhuset Kalmar, Kalmar, Sweden|Lund University Hospital - Lasarettsgatan 23, Lund, Sweden|Karolinska University Hopsital, Stockholm, Sweden|Universitetssjukhuset, Örebro, Örebro, Sweden|Maidstone Hospital, Maidstone, Kent, United Kingdom|Aberdeen Royal Infirmary - Foresterhill Road, Aberdeen, United Kingdom|Bath United Hospital - Coombe Park, Bath, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Pilgrim Hospital, Boston, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Monkton, Wishaw and Hairmyres Hospitals, East Kilbride, United Kingdom|Broomfield Hospital - Mid-Essex Hospitals NHS Trust, Essex, United Kingdom|Basildon and Thurrock Hospitals, Essex, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|Lincoln county Hospital, Lincoln, United Kingdom|Aintree Hospital - Longmoor Lane, Liverpool, United Kingdom|University Hospital South Manc, Manchester, United Kingdom|Royal Oldham Hospital, Oldham, United Kingdom|Radcliffe Hospitals and University - Headley Way, Headington, Oxford, United Kingdom|Wexham Park Hospital, Slough, United Kingdom|Great Western Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02279654"
206,"NCT02269943","Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma",,"Completed","Has Results","Nasopharyngeal Neoplasms","Drug: CC-486","Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent Radiology Assessment (IRA)|Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on an Independent Radiology Assessment According to RECIST 1.1 Criteria|Kaplan Meier Estimate of Overall Survival|Percentage of Participants With Stable Disease for ≥ 16 Weeks From the Date of the First Treatment, or CR or PR According to RECIST 1.1 Criteria and Based on an Independent Radiology Assessment|Number of Participants With Treatment Emergent Adverse Events|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of CC-486 (AUC-t)|Area Under the Plasma Concentration -Time Curve From 0 Extrapolated to Infinity (AUC-inf, AUC0-∞) Of CC-486|Maximum Observed Concentration (Cmax) Of CC-486|Time to Reach Maximum Concentration (Tmax) Of CC-486|Terminal Half-Life (t1/2) of CC-486|Apparent Total Clearance (CL/F) Of CC-486|Apparent Volume of Distribution (Vz/F) Of CC-486","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-NPC-001|2014-001745-25","February 13, 2015","April 20, 2017","April 20, 2017","October 21, 2014","June 1, 2018","December 12, 2018","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University, Montreal, Quebec, Canada|Institut Hospitalier Franco-Britannique, Levallois-Perret, France|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif Cedex, France|University General Hospital of Heraklion, Heraklion, Greece|Thermi Clinic, Thessaloniki, Greece|Istituto Nazionale Dei Tumori, Milano, Italy|National Cancer Center, Singapore, Singapore|Singapore Oncology Consultants, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Instituto Catalan de Oncologia-Hospital Duran, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Hopital Abderrahman Mami de Pneumo-Phtisiologie de l'Ariana, Ariana, Tunisia|Institut Salah Azaiez, Bab Saadoun, Tunisia|Hospital Habib Bourguiba, Sfax, Tunisia","""Study Protocol: CC-486-NPC-001_original protocol_Redacted.11July2014"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02269943/Prot_000.pdf|""Study Protocol: CC-486-NPC-001.01.protocolAM1_RedactedOctober2014"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02269943/Prot_001.pdf|""Study Protocol: CC-486-NPC-001_protocolAM2_Redacted.03April2015"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02269943/Prot_002.pdf|""Study Protocol: CC-486-NPC-001_protocolAM3_Redacted.23September2016"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02269943/Prot_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02269943/SAP_004.pdf","https://ClinicalTrials.gov/show/NCT02269943"
207,"NCT02267707","Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia",,"Terminated","No Results Available","Pancreatic Neoplasms|Cholestasis","Drug: nab-paclitaxel|Drug: Gemcitabine","Maximum Tolerated Dose|Pharmacokinetics - Cmax|Pharmacokinetics - AUC|Pharmacokinetics - T1/2|Pharmacokinetics - Vss|Pharmacokinetics - CL|Tumor response|Progression-free survival|Overall survival|Adverse Events|Gemcitabine PK profile","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-PANC-004","May 27, 2015","February 10, 2016","February 10, 2016","October 17, 2014",,"November 1, 2019","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Charite -Universitätsmedizin Berlin, Berlin, Germany|St. Josef-Hospital, Bochum, Germany|University Hospital of Ulm, Ulm, Germany|Universitatsklinikum Wurzburg, Wuerzburg, Germany",,"https://ClinicalTrials.gov/show/NCT02267707"
208,"NCT02250326","Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer","abound2L+","Active, not recruiting","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: nab-paclitaxel IV|Drug: CC-486|Drug: Duravalumab","Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator|Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to RECIST V 1.1 Criteria|Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST V 1.1 Criteria|Kaplan Meier Estimate of Overall Survival (OS)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Entire Treatment Period|Percentage of Participants Who Discontinued Study Treatment|Dose Intensity Per Week of Nab-Paclitaxel|Dose Intensity Per Week of CC-486|Dose Intensity Per Week of Durvalumab|Percentage of Participants With Study Drug Dose Reductions","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-NSCL-006|2014-001105-41","January 7, 2015","July 17, 2017","October 31, 2019","September 26, 2014","August 10, 2018","October 29, 2019","University of California San Francisco, San Francisco, California, United States|Hospital of Central Connecticut Gynecologic Oncology, New Britain, Connecticut, United States|University Cancer and Blood Center, LLC, Athens, Georgia, United States|Washington University, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|Millennium Oncology, Houston, Texas, United States|Ottawa Hospital Riverside Campus, Ottawa, Ontario, Canada|Royal Victoria Hospital McGill Department of Oncology(RVH), Montreal, Quebec, Canada|Hopital Calmette, Lille, France|Centre Rene Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Saint Herblain, France|Hopital Paul Brousse, Villejuif, France|Universitatsklinikum Essen, Essen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Klinik Loewenstein gGmbH, Loewenstein, Germany|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital General Carlos Haya, Malaga, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Liverpool Heart and Chest Hospital, Bebington, Wirral, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|University Hospital of South Manchester NHS Foundation Trust -Wythenshawe Hospital - North West Lung, Manchester, United Kingdom|Newcastle Hospital, Newcastle Upon Tyne, United Kingdom|Churchhill Hospital, Oxford, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/SAP_000.pdf|""Study Protocol: ABI_007-NSCL_Protocol_AM5_Redacted_09December 2016"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/Prot_001.pdf|""Study Protocol: ABI-007-NSCL-006_Protocol_AM4_Redacted.31May2016"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/Prot_002.pdf|""Study Protocol: ABI_007-NSCL_Protocol_AM3_Redacted_14 April 2016"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/Prot_003.pdf|""Study Protocol: ABI_007-NSCL_Protocol_AM2_Redacted_18July2014"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/Prot_004.pdf|""Study Protocol: ABI_007-NSCL_Protocol_AM1_Redacted_24 June 2014"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/Prot_005.pdf|""Study Protocol: ABI_007-NSCL_Protocol_Original_Redacted_29May2014"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02250326/Prot_006.pdf","https://ClinicalTrials.gov/show/NCT02250326"
209,"NCT02236988","Study to Evaluate Pharmacokinetics of Apremilast in Heatlhy Male Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: Apremilast","Pharmacokinetics (PK): Cmax|PK: AUC0-t|PK: Area Under the Curve - Infinity AUC0-∞|PK: Terminal Half Life|PK: T max|PK: CL/F|Number and incidence of Adverse Events (AE)","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Other","CC-10004-CP-027","January 7, 2014","September 11, 2014","September 11, 2014","September 11, 2014",,"November 22, 2018","Covance Clinical Research Unit Inc., Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02236988"
210,"NCT02234999","Radiolabeled Study of CC-122 in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: CC-122","Total [14C]-radioactivity in biological matrices-Pharmacokinetics (PK)|Cumulative excretion of total [14C]-radioactivity in urine and feces (PK)|Total [14C]-radioactivity whole blood-to-plasma ratios: PK|Metabolite profiling/characterization in select biological matrices-PK|Peak (maximum) plasma concentration (Cmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate PK|Area under the plasma concentration-time curve (AUC) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate|Time to maximum plasma concentration (Tmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate|Terminal elimination half-life (t1/2) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate|The incidence, type, severity of adverse events (AE)","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Other","CC-122-CP-003","September 23, 2014","October 8, 2014","October 8, 2014","September 9, 2014",,"November 11, 2019","Covance Clinical Research Unit Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02234999"
211,"NCT02223052","Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies",,"Active, not recruiting","No Results Available","Hematological Neoplasms|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndromes|Neoplasms|Melanoma|Breast Cancer|Metastatic Breast Cancer|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Renal Cell Carcinoma|Glioblastoma Multiforme|Osteosarcoma|Sarcoma|Thyroid Cancer|Genitourinary","Drug: CC-486|Drug: Vidaza","Pharmacokinetics Cmax - Stage I (Bioequivalence)|Pharmacokinetics Tmax - Stage I (Bioequivalence)|Pharmacokinetics AUC-t - Stage I (Bioequivalence)|Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)|Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)|Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)|Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)|Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)|Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-CAGEN-001","October 27, 2014","December 9, 2018","December 9, 2018","August 22, 2014",,"November 22, 2018","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of Iowa, Iowa City, Iowa, United States|Henry Ford Health System, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States|The Methodist Hospital Research Institute l, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02223052"
212,"NCT02192489","A Phase 2 Study With CC-220 in Skin Sarcoidosis",,"Withdrawn","No Results Available","Sarcoidosis","Drug: CC-220 0.3 mg Daily|Drug: CC-220 0.6mg Daily|Drug: Placebo","Number of participants with adverse events (AEs)|Improvement in modified Sarcoidosis Activity and Severity Index|Improvement in lesion induration|Improvement in sarcoidosis disease markers|Pharmacokinetics- Maximum Plasma Concentration (Cmax) of CC-220 After Single and Multiple Doses|Pharmacokinetics - Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point After Single and Multiple Doses (AUC 0-t)|Pharmacokinetics - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity After Single and Multiple Doses (AUC0-inf)|Pharmacokinetics - Terminal Phase Half-life (t1/2) After Single and Multiple Doses|Pharmacokinetics - Apparent Volume of Distribution (Vz/f) After Single and Multiple Doses|Pharmacokinetics - Apparent Total Clearance of CC-220 (CL/F) After Single and Multiple Doses|Pharmacokinetics - Time to Maximum Plasma Concentration (Tmax) After Single and Multiple Doses","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-220-SAR-001|2014-001065-27","November 1, 2014","June 30, 2017","June 30, 2017","July 16, 2014",,"November 11, 2019",,,"https://ClinicalTrials.gov/show/NCT02192489"
213,"NCT02189343","Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: ACY-1215 in combination with pomalidomide and dexamethasone","Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule|Safety|Anti-Tumor Activity|Pharmacokinetics|Pharmacodynamics","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ACE-MM-104","September 15, 2014","April 18, 2018","April 30, 2018","July 14, 2014",,"November 21, 2019","UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States|CTRC at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02189343"
214,"NCT02185040","A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: CC-220|Drug: Placebo","Type, Frequency , Severity and Relationship of Adverse Events to CC-220 Part 1|Type, Frequency , severity and relationship of Adverse Events to CC-220 ATEP|Pharmacokinetics - Cmax (Part 1)|Pharmacokinetics - Cmin (Part 1)|Pharmacokinetics - AUC -t (Part 1)|Pharmacokinetics - AUC - τ (Part 1)|Pharmacokinetics - AUC - infinity (Part 1)|Pharmacokinetics - Terminal Half Life (T1/2 Part 1)|Pharmacokinetics - Volume of Distribution (Vz/f Part 1)|Pharmacokinetics - Apparent total body clearance (CL/F Part 1)|Pharmacokinetics - Tmax (Part 1)|Hybrid SELENA SLEDAI ATEP|Swollen and Tender Joint Count Score ATEP|CLASI Activity score ATEP|PGA ATEP|BILAG 2004 ATEP|Pericardial/Pleuritic Pain Scale ATEP|Fatigue VAS ATEP|CLASI Damage ATEP|SLICC/ACR SLE Damage Index ATEP","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-220-SLE-001","September 16, 2014","September 25, 2018","September 25, 2018","July 9, 2014",,"August 20, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Arthritis and Rheumatology Research, PLLC, Paradise Valley, Arizona, United States|University of Arizona, Tucson, Arizona, United States|MetroHealth Medical Systems, Beachwood, California, United States|University of California San Francisco Fresno Campus, Fresno, California, United States|Dermatology Research Associates, Los Angeles, California, United States|C Michael Neuwelt M D, San Leandro, California, United States|Dermatology Institute and Skin Care Center, Santa Monica, California, United States|Los Angeles Biomedical Research Institute at Harbor - UCLA, Torrance, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Advanced Medical Research, Atlanta, Georgia, United States|Arthritis Research and Treatment Center, Stockbridge, Georgia, United States|Northwestern University Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northshore University Health System, Skokie, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|North Shore Long Island Jewish Health System, Lake Success, New York, United States|Feinstein Institute For Medical Research, Manhasset, New York, United States|NYU Langone Medical Center, New York, New York, United States|Columbia Presbyterian Medical Center, New York, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|DJL Clinical Research, Charlotte, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Low Country Rheumatology PA, Charleston, South Carolina, United States|Austin Regional Clinic, Austin, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Seattle Arthritis Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02185040"
215,"NCT02168205","Food Effect and CYP1A2 Induction Study in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: Pomalidomide|Other: Caffeine|Other: Tobacco","Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC|Pharmacokinetics - T1/2|Pharmacokinetics - Vz/f|Pharmacokinetics - CL/F|Adverse events","Celgene","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-4047-CP-011","May 30, 2014","September 19, 2014","September 19, 2014","June 20, 2014",,"November 15, 2018","Covance Clinical Research Unit, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02168205"
216,"NCT02164955","A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: IMNOVID","Determine incidence of risks as outlined in the Risk Management Plan|Pregnancy Prevention Programme Effectiveness","Celgene","All","18 Years and older   (Adult, Older Adult)",,"775","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-4047-MM-015","June 26, 2014","August 31, 2022","August 31, 2022","June 17, 2014",,"July 17, 2019","Cliniques Universitaires Saint Luc, Bruxelles, Avenue Hippocrate 10, Belgium|Ziekenhuis Netwerk Antwerpen- Campus Middelheim, Antwerpen, Lindendreef 1, Belgium|Az Nikolaas, Sint-Niklaas, Lodewijk De Meesterstraat 5, Belgium|Centre Hospitalier Peltzer-La Tourelle, Verviers, Rue Du Parc 29, Belgium|Centre hospitalier de Jolimont, La Louviere, Rue Ferrer 159, Belgium|Les Cliniques Du Sud Luxembourg- Clinique Saint-Joseph, Arlon, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|CHC, Liege, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|Odense Hospital, Odense, Kloevervanget 10, Denmark|Aarhus Universitetshospital, Midtjylland, Noerrebrogade 44, Denmark|Vejle Hospital, Dep of hema Kabbeltoft, Kabbeltoft 25, Vejle, Denmark|Gemeinschaftspraxis Fur Hamatologie Und Onkologie, Koln-Kalk, Buchforststr 14, Germany|Charite der Humboldt-Universität, Berlin, Chariteplatz 1, Germany|Klinikum Enroll von Bergmann, Potsdam, Charlotteustr 72, Germany|Klinikum Traunstein, Traunstein, Cuno-Niggl-Strate 3, Germany|Studienzentrum Haematologie/Onkologie/Diabetologie, Aschaffenburg, Elisenstr.26, Germany|Universitaetsklinikum Essen, Westdeutsches Tumorzentrum, Essen, Hufelandstraße 55, Germany|Diakonie-Klinikum Schwabisch Hall, Schwabisch Hall, Innere Medizin III, Germany|UBAG MVZ Mitte/ MVZ Delitzsch GmbH, Delitzsch, Ludwig- Jahn- Str. 4, Germany|Klinikum Grosshadern-Klinikum Der Ludwig-Maximilian Universitaet Muenchen, Muenchen, Marchioninistr. 15, Germany|Stadtisches Klinikum Karlsruhe, Karlsruhe, Medizinische Klinik III, Germany|Schwerpunktpraxis und Tagesklinik fur Hamatologie und Onkologie, Kronach, Niederbronner Stabe 2, Germany|Klinikum Lippe-Lemgo, Minden, Rintelner Strae 85, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Schwanebecker Chaussee 50, Germany|Malteser Krankenhaus St. Franziskus Hospital, Flensburg, Waldstr. 17, Germany|Dr. Reiner Weinberg, Md, Office Of, Aachen, Weberstr. 8, Germany|Evangelisches Krankenhaus Hamm GgmbH, Hamm, Werler Str. 110, Germany|Carl-Thiem-Klinikum Cottbus, Cottbus, Germany|Klinikum Frankfurt Höchst, Klinik für Innere Medizin 3, Frankfurt, Germany|GP Dres. Verpoort, Hamburg, Germany|Praxis Dr Schwarzer, Leipzig, Germany|Klinik für Hämatologie, Onkologie und Palliativmedizin Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany|Gemeinschaftspraxis für, Hämato-Onkologie am St. Josef, Krankenhaus Moers, Moers, Germany|Zentrum für Innere Medizin, Mutlangen, Germany|Studienzentrum Onkologie Ravensburg, Ravensburg, Germany|Laboratorio Analisi Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy|AOUC Azienda Ospedaliero-Universitaria Careggi, Firenze, Florence, Italy|Reparto Di Ematologia Dell'Azienda, Brescia, Lombardy, Italy|Azienda Ospedaliera Di Rilievo Nazionale (AORN) 'Antonio Cardarelli', Napoli, Naples, Italy|Institute of Hematology- Sapienza University -Rome, Italy, Roma, Rome, Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Veneto, Italy|Azienda Ospedaliera Univarsitaria Consorziale Policlinico di Bari, Bari, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy|AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna, Bologna, Italy|Centro Trapianti Midollo Osseo Ospedale Bnaghi, Cagliari, Italy|A.O.U. Vittorio Emanuele di Catania-Ospedale Ferrarotto, Catania, Italy|Azienda Ospedaliera Universitaria ""San Martino"", Genova, Italy|Ematologia, Policlinico di Milano, Milano, Italy|Ospedale San Raffaele Srl, Milan, Italy|Casa di Cura La Maddalena, Palermo, Italy|AOUP, Santa Chiara Hospital, Pisa, Italy|A.O. Bianchi Melacrino Morelli, Reggio Calabria, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Policlinico S.Eugenio, Roma, Italy|A.O.U.S. Giovanni e Ruggi d'Aragona UOC UTIC, Salerno, Italy|AOU Ospedali Riuniti Umbertio I, Torrette Di Ancona, Italy|U.O Ematologia Az. ULSS9 di Treviso, Treviso, Italy|Unita di Oncologia Polmonare A.o. San, Turin, Italy|Universita Degli Studi Policlinico, Udine, Italy|HF Alesund Hospital, Alesund, Norway|Helse Bergen HF Haukeland University Hospital, Bergen, Norway|Vestre Viken/Baerums sjukhus, Drammen, Norway|Fredrikstad Hospital, Fredrikstad, Norway|Hospital Costa Del Sol, Marbella, Autovia A-7, Km 187, Spain|University Hospital Reina Sofia, Cordoba, Avda Menendez Pidal S/n, Spain|Nuestra Senora de Valme, Sevilla, Avda. Bellavista, S/N, Spain|Hospital Puerta del Mar, Cadiz, Avenida Ana De Viya, 21, Spain|Hospital Universitario Central de Asturias, Oviedo, Avenida De Roma S/n, Spain|General de Jane, Jaen, Avenida Ejercito Espanol 10, Spain|General San Pedro de Alcantara, Caceres, Avenida Pablo Naranjo Porras, Spain|Hospital Clinico Universitario De Valladolid, Valladolid, Avenida Ramon Y Cajal 3, Spain|Hospital Universitario de La Princesa, Madrid, C/ Diego De León 62, 3a Planta, Spain|Hospital Xeral de Lugo, Lugo, C/ Doctor Severo Ochoa S/N, Spain|Hospital Son Dureta, Palma De Mallorca, Calle Andrea Doria 55, Spain|Hospital General Universitario Santa Lucia, Cartagena (murcia), Calle Mezquita, Spain|Hospital Arnau De Vilanova De Valencia, Valencia, Calle San Clemente, 12, Spain|Hospital General Universitario de Elche, Elche, CAMI DE L´almassera 11, Spain|Hospital de Cabuenes, Gijon, Camino De Los Prados, Spain|Hospital Universitario Nuestra Senora De Candelaria, Tenerife, Carretera Del Rosario, 145, Spain|Hospital Fundacion Son Llatzer, Palma de Mallorca, Ctra. Manacor, Km. 4, Spain|Hospital universitario de Alava, Alava, Jose Achotegui, Spain|IC0 Duran y Reynalds, Barcelona, L´Hospitalet De Llobregat, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Passeig De La Vall D'Hebron 119-129, Spain|Ctra. Orihuela - Almoradi, Orihuela (alicante), S/N San Bartolome, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Servicio De Oncologia, Spain|Sunderby Hospital, Lulea, Sweden|University Hospital UMEA, Umea, Sweden|Pinderfields Hospital-Mid Yorkshire Nhs Trust, Wakefield, Aberford Road, United Kingdom|Doncaster Royal Infirmary - Doncaster And Bassetlaw Hospitals Nhs Foundation Trust, Doncaster, Armthorpe Road, United Kingdom|Northhampton Gerneral Hospital, Northampton, Cliftonville, United Kingdom|County Durham and Darlington NHS foundation Trust, County Durham, Darlington Memorial Hospital, United Kingdom|Broomfield Hospital, Broomfield,Chelmsford, Essex, United Kingdom|Aberdeen Royal Infirmary - Nhs Grampian, Aberdeen, Foresterhill Road, United Kingdom|The Newcastle Upon Tyne Hospitals Nhs Foundation, Newcastle Upon Tyne, Freeman Hospital, United Kingdom|Lincoln County Hospital - United Lincolnshire Hospitals Nhs Trust, Lincoln, Greetwell Road, United Kingdom|Maidstone Hospital - Maidstone And Tunbridge Wells Nhs Trust-Kent Oncology Centre, Maidstone, Kent, United Kingdom|Blackpool Victoria Hospital - Blackpool, Fylde And Wyre Hospitals Nhs Foundation Trust, Blackpool, Lancashire, United Kingdom|Huddersfield Royal Infirmary - Calderdale And Huddersfield Nhs Foundation Trust, Huddersfield, Lindley, United Kingdom|Worthing Hospital - Western Sussex Hospitals Nhs Trust, Worthing, Lyndhurst Road, United Kingdom|Monklands Hospital Trust: Nhs Lanarkshire - Acute Services Division, Airdrie, Monkscourt Avenue, United Kingdom|Southmead Hospital - North Bristol Nhs Trust Recruiting, Bristol, Southmead Road, United Kingdom|City Hospitals Sunderland NHS Trust Recruiting, Sunderland, Sunderland Royal Hospital, United Kingdom|Colchester General Hospital - Colchester Hospital University Nhs Foundation Trust, Colchester, Turner Road, United Kingdom|University Hospital of Wales, Cardiff, Vale Of Glamorgan, United Kingdom|Northwick Park Hospital - North West London Hospitals Nhs Trust, Harrow, Watford Road, United Kingdom|Singleton Hospital - Abertawe Bro Morgannwg University Nhs Trust, Swansea, West Glamorgan, United Kingdom|Worcestershire Acute Hospitals NHS Trust - Worcestershire Royal Hospital, Worcester, Worcestershire, United Kingdom|St Helier Hospital - Epsom and St Helier University Hospitals NHS Trust, Carshalton, Wrythe Lane, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Royal United Hospital, Bath - Royal United Hospital Bath NHS Trust, Bath, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|The Royal Liverpool and Broadgreen -University Hospitals NHS, Liverpool, United Kingdom|Specialist Cancer Pharmacist-Oxford Cancer Centre & Cancer Research UK-Churchill Hospital-Oxford University Hospitals NHS Trust, Oxford, United Kingdom|Royal Berkshire hospital, Reading, United Kingdom|Wexham Park Hospital, Slough, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Northumbria Healthcare NHS Foundation Trust North Tyneside Hospital, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02164955"
217,"NCT02164071","Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies","GAH","Completed","No Results Available","Myelodysplastic Syndromes|Leukemia Myeloid Acute|Multiple Myeloma|Leuklemia, Lymphocytic, Chronic","Other: Geriatric Assessment of Health Status Scale administration","Geriatric Health Assessment (GHA) Questionnaire","Celgene","All","65 Years and older   (Older Adult)",,"363","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-GAH-2011-01","April 11, 2012","December 3, 2013","July 4, 2015","June 16, 2014",,"November 18, 2019","Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu, Espluges De Llobregat, Barcelona, Spain|Hospital Duran I Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Parc Tauli, Sabadell, Barcelona, Spain|Hospital de Donostia, San Sebastian, Guipuzcoa, Spain|Hospital U. Puerta de Hierro, Majadahonda, Madrid, Spain|C.H. Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, Tenerife, Spain|Hospital Ntra. Sra. La Candelaria, Santa Cruz de Tenerife, Tenerife, Spain|Hospital La Ribera, Alzira, Valencia, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Virgen de las Nieves, Granada, Spain|C.H. Universitario A Coruna, La Coruna, Spain|Arnau de Vilanova, Lerida, Spain|Hospital U. Gregorio Maranon, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02164071"
218,"NCT02155634","Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma",,"Withdrawn","No Results Available","Multiple Myeloma|Neoplasms|Plasma Cells|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases|Therapeutic Uses","Drug: Lenalidomide","Progression free survival (PFS)|Response Rate|Time to progression (TTP)|Overall survival (OS)|Safety","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-027","July 2014","April 2017","March 2021","June 4, 2014",,"April 10, 2018",,,"https://ClinicalTrials.gov/show/NCT02155634"
219,"NCT02151149","Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly","ABOUND 70+","Completed","Has Results","Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Large Cell|Lung Neoplasm","Drug: nab-paclitaxel|Drug: Carboplatin","Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values|Number of Participants With Treatment Emergent Adverse Events During the Treatment Period|Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn|Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study|Dose Intensity Per Week of Carboplatin During the Entire Study|Percentage of Participants With Dose Reductions During the Entire Study|Percentage of Participants With a Dose Delay During the Entire Study|Kaplan Meier Estimate of Progression-Free Survival (PFS)|Kaplan Meier Estimate of Overall Survival (OS)|Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria","Celgene","All","70 Years and older   (Older Adult)","Phase 4","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-NSCL-005","June 9, 2014","July 14, 2017","July 14, 2017","May 30, 2014","September 24, 2018","September 24, 2018","Arizona Clinical Research Center, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|Global Cancer Research Institute (GCRI), Inc., Gilroy, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|University of California Los Angeles, Santa Monica, California, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|St Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Baptist Cancer Inst, Jacksonville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Oncology Specialists, S.C., Niles, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Western Kentucky Hematology and Oncology Group, Paducah, Kentucky, United States|West Jeffersion Medical Center, Marrero, Louisiana, United States|Ochsner Medical Institutions, New Orleans, Louisiana, United States|Medstar Health Research Institute, Baltimore, Maryland, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Carol G Simon Cancer Center, Morristown, New Jersey, United States|Somerset Hematology-Oncology Associates, Somerville, New Jersey, United States|Regional Cancer Care Associates LLC- Sparta division, Sparta, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|SUNY Upstate Medical University Medicine Oncology, Syracuse, New York, United States|Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Forsyth Memorial Hospital, Inc., Winston-Salem, North Carolina, United States|St Elizabeth Hospital, Youngstown, Ohio, United States|Cancer Centres of Southwest Okahoma Research, Lawton, Oklahoma, United States|Good Samaritan Hospital Corvalis, Corvallis, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Medical College, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UTMB Galveston, Galveston, Texas, United States|Texas Oncology, PA - Longview, Longview, Texas, United States|Virginia Mason Cancer Center, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States","""Statistical Analysis Plan: ABI-007-NSCL-005_SAP_AM!_Redacted.17March 2016"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/SAP_000.pdf|""Study Protocol: ABI-007-NSCL-005_PA1_Redacted.09April2014"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_001.pdf|""Statistical Analysis Plan: ABI-007-NSCL-005.OriginalSAP.Redacted24 June2016"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/SAP_002.pdf|""Study Protocol: ABI-007-NSCL-005_PA2_Redacted.05 December 2014"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_003.pdf|""Study Protocol: ABI-007-NSCL-005_PA3_Redacted.17 March 2016"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_004.pdf|""Study Protocol: ABI-007-NSCL-005_Original_Redacted.06 March2014"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_005.pdf","https://ClinicalTrials.gov/show/NCT02151149"
220,"NCT02137629","Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea",,"Completed","No Results Available","Myelodysplastic Syndrome","Drug: Vidaza®","Number of patients with Adverse Events (AE)|Overall Response Rate","Celgene","All","18 Years and older   (Adult, Older Adult)",,"511","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIPMS-Celgene-KOR-001","December 27, 2010","May 19, 2016","May 19, 2016","May 14, 2014",,"November 18, 2019","Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon, Bucheon, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Dong-a University Medical Center, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Dongnam Inst. of Radiological & Medical Science, Busan, Korea, Republic of|Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Daegu Fatima Hospita, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Eulji University Hospital - Daejeon, Daejeon, Korea, Republic of|Dongguk University Ilsan Hospital, Goyang, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Goyang, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Dongguk University Gyeongju Hospital, Gyeongju, Korea, Republic of|Hwasun Chonnam National University Hospital, Hwasun-gun, Korea, Republic of|Wonkwang University Hospital, Iksan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gacheon University Gil Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Inje University Seoul Paik Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Boramae Medical Center, Seoul, Korea, Republic of|Chung-ang University Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vicent's Hospital, Suwon, Korea, Republic of|Ajou University Medical Center, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02137629"
221,"NCT02124850","A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab",,"Terminated","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Motolimod|Drug: Cetuximab|Drug: Nivolumab","The change in immune biomarkers including FcγR genotype, NK activation, tumor infiltration and serum cytokines, mDC, T cell activation, and tumor-antigen specific cytotoxic T lymphocyte induction.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VRXP-A106","October 28, 2014","August 11, 2016","October 31, 2016","April 28, 2014",,"October 25, 2019","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02124850"
222,"NCT02112175","Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM","ARUMM","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide","Overall Survival (OS)|Safety; Adverse Events (AE) [type, frequency, and severity of AEs, and relationship of AEs to investigational product (IP) SAEs, laboratory abnormalities, hospitalizations, and SPMs","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-026","April 30, 2014","October 12, 2020","October 12, 2020","April 11, 2014",,"November 13, 2019","Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour, Baudour, Belgium|AZ-VUB, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Universitair Ziehenhuis Antwerpen, Edegem, Belgium|Centre Hospitalier de Jolimont-Lobbes, La Louvière-(Haine St-Paul), Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|CH Argenteuil Victor DupouyHematologie, Argenteuil, France|Centre Hospitalier de la cote basque, Bayonne, France|Hopital Jean Minjoz Hematologie, Besancon, France|Centre Hospitalier de Blois, Blois Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital de Fleyriat, Bourg en Bresse cedex, France|Hopital A. MorvanHematologie, Brest cedex, France|CHU de la cote de Nacre, Caen, France|CHRU - Hotel Dieu, Clemont-Ferrand Cedex, France|Chu Estaing, Clermont Ferrand, France|Centre Hospitalier Sud Francilien - Site Gilles de Corbeil, Corbeil Essonnes, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier, Dunkerque, France|CHD Vendee, La Roche Sur Yon, France|CH Hematologie, Le Chesnay Cedex, France|Kremlin Bicetre, Le Kremlin bicetre CDX, France|Centre Hospitalier Medecine interne, Le Mans cedex, France|Centre Jean BernardOnco-Hematologie, Le Mans, France|CHRU Hopital Claude Huriez, Lile Cedax, France|CH - Hôpital Dupuytren, Limoges Cedex 1, France|Centre Hospitalier Regional Metz-Thionville Hopital de Mercy, Metz Cedex 03, France|CHU de Nimes, Nimes Cedex 9, France|CH La Source Onco-Hèmatologie, Orleans, France|Hopital Saint Louis, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|CH Perpignan - Hopital Saint-Jean, Perpignan, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Centre Hospitalier de la Region d'Annecy, Pringy, France|CHRU Hopital sud Medecine Interne, Rennes cedex 02, France|Centre Hospitalier Yves Le Foll, St-Brieuc cedex 1, France|Hopital civil, Strasbourg, France|CHRU Hôpital de Hautepierre, Strasbourg, France|Institut Universitaire du Cancer IUCT - Oncopole, Toulouse Cedex, France|CHRU Hopital BretonneauOnco-hematologie, Tours cedex, France|CHRU Hôpitaux de Brabois, Vandoeuvre, France|Laiko General Hospital of Athens, Athens, Greece|Alexandra General Hospital of Athens, Athens, Greece|University of Patras, Patras, Greece|Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki, Greece|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Spedali Civili Brescia, Brescia, Italy|Ospedale Ferrarotto, Catania, Italy|Clinica Ematologica, A.O.U. San Martino di Genova, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce, Lecce, Italy|Unità Operativa di Oncoematologia, Ospedale di Matera, Matera, Italy|U.O. di Ematologia e Trapianto di Midollo Osseo, Milano, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Ospedale Civile di Piacenza, Piacenza, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Umberto I, Roma, Italy|Ospedale Sant'Eugenio, Rome, Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Dipartimento Medicina ed Oncologia Sperimentale - Divisione Universitaria di Ematologia Azienda Ospe, Torino, Italy|Ospedale Umberto I, Torrette Di Ancona, Italy|A.O. Universitaria Fondazione Macchi, Varese, Italy|Hospital Sant Pau, Barcelona, Spain|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital virgen de la Arrixaca, El Palmar (murcia), Spain|Hospital Virgenes de las Nieves, Granada, Spain|Hospital La Princesa, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Central de Asturias, Oviedo, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario de Santiago, Santiago de Compostela, Spain",,"https://ClinicalTrials.gov/show/NCT02112175"
223,"NCT02098473","Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis",,"Completed","No Results Available","Eosinophilic Esophagitis","Drug: RPC4046|Drug: Placebo","Mean Eosinophil Count","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC02-201","August 31, 2014","February 17, 2016","January 30, 2017","March 28, 2014",,"May 9, 2017","Mayo Clinic - Arizona, Scottsdale, Arizona, United States|Desert Sun Clinical Research, LLC, Tucson, Arizona, United States|Alliance Clinical Research, Oceanside, California, United States|Precision Research Institute, LLC, San Diego, California, United States|University of Colorado School of Medicine, Aurora, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Grand Teton Research Group, Idaho Falls, Idaho, United States|Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Gastroenterology and Hepatology Service Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Metropolitan Gastroenterology Group Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|Minnesota Gastroenterology, Plymouth, Minnesota, United States|GI Associates and Endoscopy Center-GI Clinical Research Department, Flowood, Mississippi, United States|Darthmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Great Lakes Gastroenterology Research, Mentor, Ohio, United States|University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Utah Division of Gastroenterology, Salt Lake City, Utah, United States|Gastrointestinal Research Group, University of Calgary Health, Calgary, Alberta, Canada|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Swiss EoE Clinic, Olten, Switzerland",,"https://ClinicalTrials.gov/show/NCT02098473"
224,"NCT02087943","Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis",,"Completed","Has Results","Dermatitis, Atopic Dermatitis","Drug: Apremilast|Drug: Placebo","Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12.|Percentage of Participants Who Achieved a Score of 0 (Cleared) or 1 (Almost Cleared) and at Least a 2-point Reduction From Baseline in a Static Physician's Global Assessment of Acute Signs (sPGA-A) at Week 12.|Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI 50) at Week 12|The Percentage Change From Baseline in the Average Weekly Pruritus Numerical Rating Scale (NRS) Score at Week 4|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Period|Number of Participants With TEAEs During the Apremilast Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","191","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-AD-001","June 2014","October 2015","February 2016","March 14, 2014","December 12, 2016","April 26, 2017","Arizona Research Center, Phoenix, Arizona, United States|Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, United States|Dermatology Research Associates, Los Angeles, California, United States|Renstar Medical Research, Ocala, Florida, United States|Emory Clinic, Atlanta, Georgia, United States|Advanced Medical Research, Atlanta, Georgia, United States|Northwestern University Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Dermatology Specialists, PSC, Louisville, Kentucky, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|NYU Department of Dermatology, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|PMG Research of Winston-Salem LLC, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Virginia Clinical Research Inc, Norfolk, Virginia, United States|Chih-Ho Hong Medical, Inc., Surrey, British Columbia, Canada|Eastern Canada Cutaneous Research Associates Ltd, Halifax, Nova Scotia, Canada|Ultranova Skincare, Barrie, Ontario, Canada|K. Papp Clinical Research, Waterloo, Ontario, Canada|Innovaderm Research, Montreal, Quebec, Canada|Centre Dermatologique du Quebec Metropolitain, Ste-Foy, Quebec, Canada|Kokubu Abashiri Dermatology Clinic, Abashiri-shi, Hokkaido, Japan|Asanuma Dermatology Clinic, Chitose-shi, Hokkaido, Japan|Fukuoka University Hospital Dermatology, Fukuoka-shi, Fukuoka, Japan|Hatamoto Dermatology Clinic, Fukuoka-shi, Fukuoka, Japan|Tashiro Clinic, Iizuka-shi, Fukuoka, Japan|Kokubu Dermatology, Kitami-shi, Hokkaido, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-City, Japan|Kyoto University Hospital, Kyoto, Japan|Sapporo Skin Clinic, Sapporo-shi, Hokkaido, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02087943"
225,"NCT02085798","Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)",,"Active, not recruiting","No Results Available","Myelodysplastic Syndrome|Leukemia, Myelomonocytic, Chronic","Other: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion","Event Free Survival|Health Assesment/performance Status|Response to active treatment|Patient evolution based on time-dependent response parameters|Adverse Events|Patient Description","Celgene","All","18 Years and older   (Adult, Older Adult)",,"503","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIPMS-CELGENE-SP-006","December 17, 2012","March 30, 2019","July 24, 2019","March 13, 2014",,"February 6, 2019","Hospital Universitario Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario La Ribera, Alzira, Alicante, Spain|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Complejo Hospitalrio La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain|Hospital Punta de Europa, Algeciras, Cádiz, Spain|Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario Getafe, Getafe, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital de Antequera, Hospital De Antequera, Málaga, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital Nuestra Señora del Prado, Talavera de la Reina, Toledo, Spain|Complejo Hospitalario Torrecárdenas, Almeria, Spain|Parc de Salut Mar- Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Duran Reynals, Barcelona, Spain|Hospital Universitario Puerta del Mar, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitari de Girona Josep Trueta, Girona, Spain|Hospital Can Misses, Ibiza, Spain|Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain|CHU-Insular, Las Palmas de Gran Canaria, Spain|Hospital de León, León, Spain|Hospital Lucus Augusti, Lugo, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Fundación Jimenez Díaz, Madrid, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Complejo Universitario Hospitalario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Complejo Hospitalrio Universitario de Pontevedra, Pontevedra, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|Hospital de Valme, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Santa Bárbara, Soria, Spain|Hospital Clínico Universitario Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Río Hortega, Valladolid, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02085798"
226,"NCT02049528","Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study",,"Completed","No Results Available","Clinical Pharmacology, Healthy Male Volunteer Study","Drug: CC-122","Pharmacokinetics - AUC|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - T1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/f|Safety and tolerability","Celgene","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-122-CP-001","January 16, 2014","February 2, 2014","February 8, 2014","January 30, 2014",,"November 11, 2019","Covance Clinical Development Services, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02049528"
227,"NCT02047734","Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (Radiance Study)",,"Completed","No Results Available","Relapsing Multiple Sclerosis","Drug: Ozanimod 0.5 mg|Drug: Ozanimod 1 mg|Drug: Ozanimod placebo|Drug: Interferon β-1a|Drug: IFN β-1a placebo","Annualized relapse rate (ARR) at the end of Month 24|The number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months|The number of GdE brain MRI lesions at Month 24|Time to onset of disability progression as defined by a sustained worsening in EDSS of 1.0 points or more, confirmed after 3 months and after 6 months|Proportion of patients who are GdE lesion-free at Month 24|Proportion of patients who are new or enlarging T2 lesion-free at Month 24|The percent change in normalized brain volume (atrophy) on brain MRI scans from baseline to|Change in MSFC score from Baseline to Month 24 (including the Low-Contrast Letter Acuity|Change in MSQOL-54 score from Baseline to Month 24","Celgene","All","18 Years to 55 Years   (Adult)","Phase 3","1320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-201-PartB|2012-002714-40","December 3, 2013","March 27, 2017","April 13, 2017","January 28, 2014",,"June 24, 2019","Receptos Study Site 115, Phoenix, Arizona, United States|Xenoscience, Phoenix, Arizona, United States|Receptos Study Site 118, Phoenix, Arizona, United States|Saint Josephs Hosptial and Medical Center, Phoenix, Arizona, United States|Territory Neurology and Research Institute, Tucson, Arizona, United States|Receptos Study Site 119, Tucson, Arizona, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Receptos Study Site 110, Berkeley, California, United States|Receptos Study Site 122, Long Beach, California, United States|Receptos Study Site 112, Sacramento, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, United States|Receptos Study Site 120, San Francisco, California, United States|Denver Neurological Research LLC, Denver, Colorado, United States|Receptos Study Site 127, Denver, Colorado, United States|Neurology Associates PA, Maitland, Florida, United States|Receptos Study Site 114, Maitland, Florida, United States|Receptos Study Site 124, Pompano Beach, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Receptos Study Site 123, Port Charlotte, Florida, United States|Infinity Clinical Research LLC, Sunrise, Florida, United States|West Georgia Sleep Disorder Center and Neurology Associates, Douglasville, Georgia, United States|Consultants In Neurology, Northbrook, Illinois, United States|Receptos Study Site 113, Northbrook, Illinois, United States|Receptos Study Site 121, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Receptos Study Site 101, Charlotte, North Carolina, United States|The Neurological Institute PA, Charlotte, North Carolina, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, United States|Receptos Study Site 107, Akron, Ohio, United States|Receptos Study Site 104, Cleveland, Ohio, United States|Receptos Study Site 109, Philadelphia, Pennsylvania, United States|Receptos Study Site 102, Seattle, Washington, United States|The Polyclinic, Seattle, Washington, United States|Receptos Study Site 125, Tacoma, Washington, United States|Gomel Regional Clinical Hospital, Gomel, Belarus|Receptos Study Site 904, Gomel, Belarus|Grodno Clinical Regional Hospital, Grodno, Belarus|Receptos Study Site 907, Grodno, Belarus|Minsk Municipal Clinical Hospital 5, Minsk, Belarus|Receptos Study Site 902, Minsk, Belarus|Receptos Study Site 901, Minsk, Belarus|Republican Scientific and Practical Centre of Neurology and Neurosurgery, Minsk, Belarus|Minsk City Clinical Hospital 9, Minsk, Belarus|Receptos Study Site 903, Minsk, Belarus|Receptos Study Site 905, Vitebsk, Belarus|Vitebsk Regional Diagnostic Centre, Vitebsk, Belarus|Receptos Study Site 906, Vitebsk, Belarus|AZ Sint-Jan AV Brugge, Brugge, Belgium|Receptos Study Site 256, Brugge, Belgium|Receptos Study Site 255, Brussels, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, Belgium|Receptos Study Site 252, Montegnée, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Receptos Study Site 254, Ottignies, Belgium|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|Receptos Study Site 911, Sarajevo, Bosnia and Herzegovina|Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD, Sofia, Bulgaria|Receptos Study Site 453, Sofia, Bulgaria|Receptos Study Site 454, Sofia, Bulgaria|Receptos Study Site 452, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia, Sofia, Bulgaria|Receptos Study Site 456, Sofia, Bulgaria|Receptos Study Site 457, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia, Bulgaria|Receptos Study Site 451, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|Receptos Study Site 455, Sofia, Bulgaria|University of Alberta MS Clinic, Edmonton, Alberta, Canada|Receptos Study Site 154, Edmonton, Alberta, Canada|Clinical Hospital Center Osijek, Osijek, Croatia|Receptos Study Site 923, Osijek, Croatia|Receptos Study Site 921, Zagreb, Croatia|Receptos Study Site 922, Zagreb, Croatia|Receptos Study Site 924, Zagreb, Croatia|Clinical Hospital Center ""Sestre milosrdnice"", Clinic of Internal Diseases, Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Sveti duh, Zagreb, Croatia|Receptos Study Site 301, Tbilisi, Georgia|LTD MediClubGeorgia, Tbilisi, Georgia|Receptos Study Site 302, Tbilisi, Georgia|Khechinashvili University Hospital, Tbilisi, Georgia|Receptos Study Site 303, Tbilisi, Georgia|Sarajishvili Institute of Neurology, Tbilisi, Georgia|Evaggelismos General Hospital, Athens, Greece|Receptos Study Site 552, Athens, Greece|Receptos Study Site 554, Athens, Greece|Navy Hospital of Athens, Athens, Greece|Receptos Study Site 553, Athens, Greece|401 Military Hospital of Athens, Athens, Greece|Receptos Study Site 551, Athens, Greece|AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece|Receptos Study Site 557, Thessaloniki, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece|Receptos Study Site 555, Thessaloniki, Greece|Receptos Study Site 352, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Jahn Ferenc DelPesti Korhaz es Rendelointezet, Budapest, Hungary|Receptos Study Site 356, Budapest, Hungary|Receptos Study Site 354, Esztergom, Hungary|Vaszary Kolos Korhaz, Esztergom, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Receptos Study Site 358, Kistarcsa, Hungary|SzabolcsSzatmarBereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Receptos Study Site 351, Nyíregyháza, Hungary|Receptos Study Site 355, Szekesfehervar, Hungary|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Italy|Receptos Study Site 654, Catania, Italy|Fondazione Istituto San Raffaele G Giglio di Cefalu, Cefalu, Italy|Receptos Study Site 653, Cefalù, Italy|Receptos Study Site 655, Milano, Italy|Receptos Study Site 652, Milano, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy|Presidio Ospedaliero di Montichiari, Montichiari, Italy|Receptos Study Site 659, Montichiari, Italy|Receptos Study Site 656, Napoli, Italy|Receptos Study Site 658, Pavia, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Receptos Study Site 651, Roma, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Receptos Study Site 657, Siena, Italy|IMSP Institutul de Medicina Urgenta, Chisinau, Moldova, Republic of|Receptos Study Site 932, Chisinau, Moldova, Republic of|Institutul de Neurologie si Neurochirurgie, Chisinau, Moldova, Republic of|Receptos Study Site 931, Chisinau, Moldova, Republic of|Receptos Study Site 933, Chisinau, Moldova, Republic of|Receptos Study Site 401, Bialystok, Poland|Receptos Study Site 423, Bydgoszcz, Poland|Specjalistyczna Praktyka Lekarska Lek Med Robert Bonek, Bydgoszcz, Poland|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, Poland|Receptos Study Site 406, Czeladz, Poland|Receptos Study Site 405, Gdansk, Poland|Receptos Study Site 425, Gdansk, Poland|Copernicus PL Sp. z. o.o., Gdansk, Poland|NEUROMEDIC Janusz Zbrojkiewicz, Katowice, Poland|MA LEK AM Maciejowscy SC Centrum Terapii SM, Katowice, Poland|Receptos Study Site 427, Katowice, Poland|NovoMed Zielinski i Wspolnicy Spolka Jawna, Katowice, Poland|Receptos Study Site 426, Katowice, Poland|NEUROCARE Site Management Organization Gabriela KlodowskaDuda, Katowice, Poland|Receptos Study Site 407, Katowice, Poland|Receptos Study Site 417, Katowice, Poland|Receptos Study Site 424, Kielce, Poland|RESMEDICA Spolka z o.o., Kielce, Poland|Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny, Konstancin Jeziorna, Poland|Receptos Study Site 404, Konstancin-Jeziorna, Poland|Krakowska Akademia Neurologii Sp. z. o.o., Krakow, Poland|Receptos Study Site 414, Krakow, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, Poland|Receptos Study Site 411, Lodz, Poland|Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny, Lublin, Poland|Receptos Study Site 412, Lublin, Poland|Receptos Study Site 420, Lublin, Poland|Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego, Lublin, Poland|Receptos Study Site 402, Olsztyn, Poland|Receptos Study Site 415, Olsztyn, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, Poland|Receptos Study Site 421, Plewiska, Poland|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON, Podlaskie, Poland|Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak, Pomorskie, Poland|Receptos Study Site 408, Poznan, Poland|Szpital Kliniczny im HSwiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, Poland|Receptos Study Site 418, Poznan, Poland|EUROMEDIS Sp. z.o.o., Szczecin, Poland|Receptos Study Site 419, Szczecin, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, Poland|Receptos Study Site 410, Warszawa, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Receptos Study Site 428, Warszawa, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|Receptos Study Site 422, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Receptos Study Site 403, Warszawa, Poland|Receptos Study Site 413, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Clinical Hospital of Psychiatry and Neurology Brasov, Brasov, Romania|Receptos Study Site 503, Brasov, Romania|Health Club Medical Center S.R.L., Campulung, Romania|Receptos Study Site 502, Campulung, Romania|Receptos Study Site 501, Cluj-Napoca, Romania|Rehabilitation Clinical Hospital, Cluj-Napoca, Romania|Receptos Study Site 505, Sibiu, Romania|Sibiu Emergency County Clinical Hospital, Sibiu, Romania|Receptos Study Site 506, Timisoara, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, Romania|Chelyabinsk City Clinical Hospital 3, Chelyabinsk, Russian Federation|Receptos Study Site 701, Chelyabinsk, Russian Federation|Receptos Study Site 704, Kazan, Russian Federation|Republican Clinical Hospital for Rehabilitation Treatment, Kazan, Russian Federation|Receptos Study Site 713, Kazan, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Central Clinical Hospital 2 na NA Semashko OAO RZhD, Moscow, Russian Federation|Receptos Study Site 712, Moscow, Russian Federation|City Clinical Hospital 1 na NIPirogov, Moscow, Russian Federation|Receptos Study Site 709, Moscow, Russian Federation|City neurology center Sibneuromed LLC, Novosibirsk, Russian Federation|Receptos Study Site 703, Novosibirsk, Russian Federation|Perm State Medical Academy, Perm, Russian Federation|Receptos Study Site 710, Perm, Russian Federation|Receptos Study Site 716, Samara, Russian Federation|Samara Regional Clinical Hospital named after MI Kalinin, Samara, Russian Federation|City Clinical Hospital 4, Saransk, Russian Federation|Receptos Study Site 715, Saransk, Russian Federation|Receptos Study Site 714, Saratov, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Receptos Study Site 707, Smolensk, Russian Federation|Smolensk State Medical Academy, Smolensk, Russian Federation|Receptos Study Site 708, St. Petersburg, Russian Federation|Russian Medical Military Academy na SMKirov, St. Petersburg, Russian Federation|Receptos Study Site 717, Tyumen, Russian Federation|Neftyanik Medical and Sanitary Unit, Tyumen, Russian Federation|Receptos Study Site 711, Yaroslavl, Russian Federation|Yaroslavl Clinical Hospital 8, Yaroslavl, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Receptos Study Site 602, Belgrade, Serbia|Receptos Study Site 603, Belgrade, Serbia|Receptos Study Site 604, Belgrade, Serbia|Clinical Hospital Centre Zemun, Belgrade, Serbia|Receptos Study Site 601, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Receptos Study Site 605, Kragujevac, Serbia|University Hospital Bratislava - Hospital ak. L. Derera, II Neurology Clinic, Bratislava, Slovakia|Receptos Study Site 946, Bratislava, Slovakia|Receptos Study Site 942, Lucenec, Slovakia|Receptos Study Site 945, Trnava, Slovakia|Receptos Study Site 956, KwaZulu-Natal, South Africa|Neurology Practice, Pretoria, South Africa|Receptos Study Site 953, Pretoria, South Africa|Receptos Study Site 755, Sevilla, Andalucía, Spain|Receptos Study Site 763, Santa Cruz de Tenerife, Canarias, Spain|Receptos Study Site 756, Barcelona, Cataluña, Spain|Receptos Study Site 760, Girona, Cataluña, Spain|Receptos Study Site 762, Alicante, Comunidad Valenciana, Spain|Receptos Study Site 752, Valencia, Comunidad Valenciana, Spain|Receptos Study Site 761, Bilbao, País Vasco, Spain|Receptos Study Site 759, San Sebastián, País Vasco, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Receptos Study Site 758, Barcelona, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Organizacion Sanitaria Integrada Bilbao Basurto, Bilbao, Spain|Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Receptos Study Site 757, Madrid, Spain|Receptos Study Site 751, Madrid, Spain|Receptos Study Site 754, Majadahonda (Madrid), Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital Universitario Vírgen Macarena, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Municipal Medical & Preventive Institution Chernigiv Regional Clinical Hospital, Chernigiv, Ukraine|Receptos Study Site 805, Chernihiv, Ukraine|Municipal Institution Chernivtsi Regional Psychiatric Hospital, Chernivtsi, Ukraine|Receptos Study Site 813, Chernivtsi, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, Ukraine|Receptos Study Site 802, Dnipropetrovsk, Ukraine|State Institution Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine, Dnipropetrovsk, Ukraine|Receptos Study Site 815, Dnipropetrovsk, Ukraine|Regional Clinical Hospital, Ivano Frankivsk, Ukraine|Receptos Study Site 801, Ivano-Frankivsk, Ukraine|Receptos Study Site 814, Kharkiv, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, Ukraine|Municipal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Receptos Study Site 811, Kherson, Ukraine|Receptos Study Site 818, Kyiv, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Receptos Study Site 803, Kyiv, Ukraine|Kyiv City Clinical Hospital 4, Kyiv, Ukraine|Municipal Institution Lutsk City Clinical Hospital, Lutsk, Ukraine|Receptos Study Site 816, Lutsk, Ukraine|Receptos Study Site 817, Lutsk, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Receptos Study Site 812, Lviv, Ukraine|Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU, Odesa, Ukraine|Receptos Study Site 810, Odesa, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|Receptos Study Site 804, Odesa, Ukraine|Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsya, Ukraine|Receptos Study Site 809, Vinnytsya, Ukraine|Municipal Institution City Clinical Hospital 6, Zaporizhzhya, Ukraine|Receptos Study Site 806, Zaporizhzhya, Ukraine|Royal Sussex County Hospital, Brighton East Sussex, United Kingdom|Receptos Study Site 965, Brighton, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Receptos Study Site 963, Inverness, United Kingdom|Kings College Hospital, London, United Kingdom|Receptos Study Site 961, London, United Kingdom|National Hospital for Neurology and Neurosurgery, London, United Kingdom|Receptos Study Site 967, London, United Kingdom|Receptos Study Site 966, Romford, United Kingdom|Receptos Study Site 964, Sheffield, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02047734"
228,"NCT02045017","Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide and Dexamethasone","Evaluate efficacy of the combination of pomalidomide and low-dose dexamethasone in subjects with RRMM and impaired renal function|Assessment of renal response according to the criteria defined by Dimopoulos and Ludwig (Dimopoulos, 2009; Dimopoulos, 2010 b,c; Ludwig, 2010).|Time to Myeloma response|Time to renal response|Duration of response|Progression-free survival|Time to progression|Overall Survival|Adverse events (AEs) assessment (type, frequency, seriousness, severity, relationship to pomalidomide and/or dexamethasone and outcomes) including second primary malignancy (SPM).","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-013|2013-001903-36","February 28, 2014","January 27, 2017","June 30, 2021","January 24, 2014",,"October 30, 2019","Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Austria|Medizinische Universitat Wien, Wien, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|Hopital Dypuytren-CHU de Limoges, Limoges cedex, France|Hopital Saint Louis, Paris, France|CHU de Poitiers, Poitiers, France|Medizinische Klinik und Poliklinik V Hamatologie, Onkologie und Rheumatologie, Neuenheimer Feld 410, Germany|University Hospital Tubingen, Tubingen, Germany|Alexandra Hospital, University of Athens, Athens, Greece|Azienda Ospedaliero Universitaria Ospedali, Ancona, Italy|S.C. Oncologia Medica, Lecco, Italy|Ospedale Maggiore Policlinico Mangiagalli Regina Elena, Milano, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Daniel den Hoed Kliniek Medical Oncology, Erasmus MC, Rotterdam, Netherlands|Hospital de La Princesa, Madrid, Spain|CEIC Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Queen Elizabeth Hospital UHB NHS Foundation Trust, Birmingham, United Kingdom|Ninewells Hospital and Medical School, Dundee, United Kingdom|Oxford Radcliffe Hospital ICRF Medical Oncology Unit, Headington, United Kingdom|St Thomas' HospitalGuy's Hospital Dept. of Haematology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02045017"
229,"NCT02031419","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: CC-122|Drug: CC-223|Drug: Rituximab|Drug: CC-292","Safety|Efficacy|Pharmacokinetics - CC-223 and CC-292 interaction","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","174","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-DLBCL-001","December 18, 2013","December 15, 2019","November 30, 2020","January 9, 2014",,"August 20, 2019","Sansum Clinic, Santa Barbara, California, United States|Stanford Cancer Center, Stanford, California, United States|Rocky Mountain Cancer Centers, LLP [Boulder-COBO], Boulder, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northwestern University, Division of Hematology Oncology, Dept. of Medicine, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Osteoporosis Clinical Center and Research Program, Madison, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Centre Leon Berard, Lyon, France|Institut Gustave Roussy, Villejuif CEDEX, France|Istituto Nazionale Dei Tumori, Milano, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Italy",,"https://ClinicalTrials.gov/show/NCT02031419"
230,"NCT02027428","Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer",,"Completed","Has Results","Squamous Cell Carcinoma, Non-Small-Cell Lung","Drug: Abraxane (Induction)|Drug: Carboplatin (Induction)|Drug: Abraxane (Maintenance)|Other: Best Supportive Care (Maintenance)","Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance|Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance|Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study|Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study|Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study|Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction|Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study|Time to Confirmed Response During Induction and Over the Entire Study|Kaplan-Meier Estimate for Duration of Response Over the Entire Study|Participants With Treatment-Emergent Adverse Events (TEAEs) in the Induction Part|Participants With Treatment-Emergent Adverse Events (TEAEs) Over the Entire Study","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","427","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-NSCL-003|2014-003804-66","February 11, 2014","September 15, 2017","August 1, 2019","January 6, 2014","December 7, 2018","August 27, 2019","Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States|Palo Verde Hematology Oncology, Ltd., Glendale, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|City of Hope Cancer Center, Duarte, California, United States|Cancer Care Associates of Fresno Medical Group Inc, Fresno, California, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Clinical Trials and Research Associates, Montebello, California, United States|VA Palo Alto Health Care System, Palo Alto, California, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Watson Clinic, LLP Center for Cancer Care and Research, Lakeland, Florida, United States|University of Miami Miller School of Medicine Jackson Memorial Hospital, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Memorial Cancer Institute West, Pembroke Pines, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Cancer and Blood Center, LLC, Athens, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|Kansas University Medical Center, Westwood, Kansas, United States|Cancer Center of Kansas (MAT), Wichita, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Norton Healthcare, Louisville, Kentucky, United States|University of Louisville, J.G. Brown Cancer Center, Louisville, Kentucky, United States|Norton Cancer Institute Louisville Oncology, Louisville, Kentucky, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Eastern Maine Medical Center, Brewer, Maine, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Meritus Medical Center, Hagerstown, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Western Michigan Cancer Center, Kalamazoo, Michigan, United States|St Joseph Oncology, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, United States|New York Oncology Hematology P.C., Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Montefiore Medical Center Albert Einstein Cancer Center, Bronx, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|NYU Langone Medical Center, Lake Success, New York, United States|Beth Israel Medical Centers, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Moses H. Cone Regional Cancer Center, Greensboro, North Carolina, United States|Hematology and Oncology Associates, Inc., Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Mark H. Zangmeister Center, Columbus, Ohio, United States|Tri-County Hematology and Oncology Associates, Massillon, Ohio, United States|Toledo Community Oncology Program, Toledo, Ohio, United States|Mercy Clinic Oklahoma Communities, Inc., Oklahoma City, Oklahoma, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Erie Regional Cancer Center, Erie, Pennsylvania, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States|Allegheny Singer Research Institute, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center - Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Greenville Hospital System, Greenville, South Carolina, United States|Chattanooga Oncology Hematology Care, Chattanooga, Tennessee, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|TX Onc, PA- Beaumont, Beaumont, Texas, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|UT Health Oncology, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|TX Onc Tyler Cancer Center, Tyler, Texas, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|St Mary's Medical Center, Huntington, West Virginia, United States|West Virginia University, Berkeley Medical Center, Cancer and Infusion Center, Martinsburg, West Virginia, United States|West Virginia University, Berkeley Medical Center, Cancer and Infusion Center, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Antonius Hospital, Eschweiler, Germany|Asklepios Fachkliniken Muenchen Gauting, Gauting, Germany|Diakoniekrankenhaus Halle, Halle (Saale), Germany|Universitatsklinikum Halle Saale, Halle, Germany|Thorax Klinik, Heidelberg, Germany|Universitat Des Saarlandes, Homburg, Germany|Kliniken der Stadt Koln gGmbH - Krankenhaus Merheim, Koln, Germany|Klinik Loewenstein gGmbH, Loewenstein, Germany|Lungenklinik Lostau gGmbH, Lostau, Germany|Universitatsklinikum Ulm, Ulm, Germany|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Istituto Nazionale Per La Ricerca Sul Cancro, Genova, Italy|Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Istituto Nazionale Tumori Regina Elena di Roma, Roma, Italy|Ospedale San Vincenzo Taormina, Taormina, Italy|Intituto Catalán de Oncología de Girona, Girona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Spain|Churchhill Hospital, Oxford, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02027428/SAP_000.pdf|""Study Protocol: ABI-007-NSCL-003_protocol_AM1_Redacted 28 October 2014"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02027428/Prot_001.pdf|""Study Protocol: ABI-007-NSCL-003_protocol_AM2_Redacted.27May2015"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02027428/Prot_002.pdf|""Study Protocol: ABI-007-NSCL-003_protocol_AM3_Redacted.13March2017"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02027428/Prot_003.pdf|""Study Protocol: ABI-007-NSCL-003.OriginalProtocolRedacted.27September2013"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02027428/Prot_004.pdf","https://ClinicalTrials.gov/show/NCT02027428"
231,"NCT02021500","A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.",,"Completed","No Results Available","Pancreatic Cancer","Drug: ABI-007","Overall Survival|Disease progression","Celgene","All","Child, Adult, Older Adult",,"40","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","ABI-007-PANC-CA046C","January 2, 2014","April 16, 2015","April 16, 2015","December 27, 2013",,"November 1, 2019","TGen Clinical Research Services, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Florida Cancer Specialists, Englewood, Florida, United States|Florida Cancer Specialist, Tavares, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Arena Oncology Associates, Lake Success, New York, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|South Texas Oncology and Hematology (STOH), San Antonio, Texas, United States|Fairfax-Northern Virginia Haematology-Oncology, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Froedtert and Medical College ID Clinic, Milwaukee, Wisconsin, United States|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|HOCA - the Wesley Clinic for Heamatology and Oncology, Auchenflower, Queensland, Australia|Mater Medical Center, South Brisbane, Australia|Landesklinikum St. Pölten, St. Pölten, Austria|Medizinische Universität Wien, Vienna, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Centre Hospsitalier Universitaire de Montreal - Notre Dame, Montreal, Quebec, Canada|Hôpital Beaujon, Clichy, France|Hôpital Saint Antoine, Paris, France|Kliniken Essen-Mitte, Essen, Germany|LMU Klinikum der Universität München, Munchen, Germany|Ospedale San Raffaele S.r.l., Milano, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotundo, Italy|Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Municipal institution Multifield City Clinical Hospital #4 of Dnipropetrovsk Regional Council, Dnipropetrovsk, Ukraine",,"https://ClinicalTrials.gov/show/NCT02021500"
232,"NCT02017015","Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer","PANC-001","Completed","Has Results","Pancreatic Neoplasms","Drug: nab-paclitaxel|Drug: Gemcitabine","Overall Response Rate (ORR) Based on Independent Radiological Review (IRR)|Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)|Duration of Response (DoR) Based on IRR According to RECIST Guidelines|Kaplan-Meier Estimate of Overall Survival (OS)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-PANC-001","December 24, 2013","June 1, 2015","August 3, 2016","December 20, 2013","November 22, 2016","September 26, 2017","Beijing Cancer Hospital, Beijing, PR, China|307 Hospital of Chinese PLA, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Tumor Hospital, Harbin, Heilongjiang, China|Jiangsu Province Hospital The First Hospital affiliated with Nanjing Medical University, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai First People's Hospital, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Xijing Hospital, Xi'an, China|Henan Cancer Hospital, Zhengzhou, China",,"https://ClinicalTrials.gov/show/NCT02017015"
233,"NCT01999582","A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis",,"Completed","No Results Available","Anemia|Kidney Failure, Chronic","Biological: Sotatercept","Pharmacokinetics (Cmax)|Pharmacokinetics (Tmax)|Pharmacokinetics (AUC 28d)|Pharmacokinetics (t1/2,z)|Adverse Event|Efficacy|Bone Turnover","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-011-REN-002|2012-003788-23","November 2013","August 2016","August 2016","December 3, 2013",,"February 16, 2017","Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour, Baudour, Belgium|Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg, Leuven, Belgium|CHR de la CITADELLE, Liege, Belgium|KfH Nierenzentrum Coburg, Coburg, Germany|Gemeinschaftspraxis und Dialysezentrum Karlstrass, Düsseldorf, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.v., München, Germany|KfH Nierenzentrum Rosenheim, Rosenheim, Germany|Nephrocare Faro, Faro, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Nephrocare Portimao, Portimão, Portugal|Complejo Hospitalario de Torrecardenas, Almeria, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Galdakao-Usansolo, Galdakao, Spain|Servicio de Nefrologia Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital de Torrevieja, Torrevieja (Alicante), Spain|Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|St Georges Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01999582"
234,"NCT01997840","ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone","Phase 1b: MTD and dosing schedule of ACY-1215 administered in combination with pomalidomide and low-dose dexamethasone in patients with MM|Phase 2: Overall response rate of ACY-1215 in combination with pomalidomide and dexamethasone in patients with relapsed-and-refractory multiple myeloma|Phase 1b & 2: Safety assessed by type, frequency and severity of AEs and relationship of AEs to study drug|Phase 1b and 2: Efficacy assessed by time to response, duration of response, time to progression, progression free survival, and objective response as assessed by a central adjudication committee|Phase 1b: Plasma levels of ACY-1215 and plasma levels of pomalidomide|Phase 1b: Exposure response of treatment including biomarkers relating to intracellular protein acetylation, protein levels, mRNA and microRA expression profiles.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","101","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-MM-102","March 1, 2014","January 27, 2021","January 27, 2021","November 28, 2013",,"May 24, 2019","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Univesity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York Medical College, Hawthorne, New York, United States|Mt. Sinai Medical Center Division of Hematology/Oncology, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Arthur G. James Cancer Hospital, Columbus, Ohio, United States|University of Pittsburgh Medical Center - Cancer Pavilion, Pittsburgh, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Alexandra Hospital, University of Athens, Athens, Greece|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT01997840"
235,"NCT01996865","Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.","MAGNIFY","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Lenalidomide|Drug: Rituximab","Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL)|Adverse Events|Complete response rate|Overall response rate|Duration of response|Duration of complete response|Time to the next anti-lymphoma treatment|Time to treatment failure|Time to histological transformation","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NHL-008","April 2, 2014","April 8, 2023","July 8, 2024","November 27, 2013",,"August 22, 2019","Arizona Oncology, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Sutter East Bay Hospitals, Berkeley, California, United States|John Muir Health, Concord, California, United States|Sutter Hematology and Oncology, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers, LLP [Boulder-COBO], Boulder, Colorado, United States|VA Eastern Colorado, Denver, Colorado, United States|Colorado Cancer Research Program, Denver, Colorado, United States|VVH Cancer Center Valley View Hospital, Glenwood Springs, Colorado, United States|Praxair Cancer Center Danbury, Danbury, Connecticut, United States|Whittingham Cancer Center, Norwalk, Connecticut, United States|Hematology Oncology Associates, PC, Stamford, Connecticut, United States|Yale University School of Medicine, Trumbull, Connecticut, United States|Hematology and Oncology, Waterbury, Connecticut, United States|Cancer Specialists, LLC dba Cancer Specialists of North Florida, Fleming Island, Florida, United States|Florida Cancer Affiliates, New Port Richey, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Cancer Treatment Centers of America - Southeastern Regional Medical Center, Newnan, Georgia, United States|Alexian Brothers Hospital Network, Elk Grove Village, Illinois, United States|United States Department of Veterans Affairs - VA Great Lakes Health Care System - Edward Hines Jr, Hines, Illinois, United States|AMITA Health Cancer Institute & Outpatient Center, Hinsdale, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Oncology Specialists, PC, Park Ridge, Illinois, United States|American Health Network of Indiana, LLC, New Albany, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|CentralCare Cancer Center, Great Bend, Kansas, United States|Baptist Healthcare System, Inc., Louisville, Kentucky, United States|Maine General Medical Center, Waterville, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Associates of Oncology/Hematology, P.C., Rockville, Maryland, United States|Trinity Health -Michigan, d/b/a Saint Joseph Mercy Health System, Ann Arbor, Michigan, United States|Sparrow Hospital and Health System, Lansing, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Central Care Cancer Center, Bolivar, Missouri, United States|University of Missouri Health Care, Columbia, Missouri, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group Overlook Oncology Center, Berkeley Heights, New Jersey, United States|Veterans Affairs New Jersey Health Care System, East Orange, New Jersey, United States|Drs. Forte, Schleider, and Attas, P.A., Englewood, New Jersey, United States|Regional Cancer Care Associates LLC, Mount Holly, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|C.R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|Mid Ohio Oncology Hematology Inc, Columbus, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute, Eugene, Oregon, United States|Hematology Oncology Associates, P.C., Medford, Oregon, United States|Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Arlington Cancer Center, Arlington, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Michael Debakey VA Medical Center, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|Texas Health Physicians Group, Plano, Texas, United States|Texas Oncology Round Rock Cancer Center - Round Rock, Round Rock, Texas, United States|Cancer Care Network of South Texas - SAT & BC, San Antonio, Texas, United States|Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States|Central Texas Veterans Health Care System, Temple, Texas, United States|Tyler Hematology and Oncology, Tyler, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|Texas Oncology, P.A. - Deke Slayton Cancer Center, Webster, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Rutland Regional Medical Center, Rutland, Vermont, United States|Oncology and Hematology Associates of Southwest Virginia, Inc. - Market Street, Christiansburg, Virginia, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|PeaceHealth St. Joseph Medical Center, Bellingham, Washington, United States|Northwest Medical Specialties PLLC, Gig Harbor, Washington, United States|Vista Oncology, Inc., Olympia, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|West Virginia University, Berkeley Medical Center, Cancer and Infusion Center, Morgantown, West Virginia, United States|Aurora Health Care Aurora Research, Milwaukee, Wisconsin, United States|DN Greenwald Center, Mukwonago, Wisconsin, United States|Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Onkologische Schwerpunktpraxis Kurfurstendamm, Berlin, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Centrum fur Hamatologie und Onkologie Bethanien, Frankfurt, Germany|Praxis Internistischer Onkologie und Hamatologie Frechen, Frechen, Germany|Onkologischisches Ambulanzzentrum Hannover, Hannover, Germany|Gemeinschaftspraxis fur Hamatologie und Onkologie, Kassel, Germany|Gemeinschaftspraxis fur Hamatologie und Onkologie, Köln, Germany|OnkoNet Marburg GmbH, Marburg, Germany|Hamato-Onkologische Uberortliche Gemeinschaftspraxis Pasing und Furstenfeldbruck, Munchen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Klinikum Ernst von Bergmann gGmbH, Potsdam, Germany|Klinikum Ernst von Bergmann gGmbH, Potsdam, Germany|Hamatologie und Onkologie, Ravensberg, Germany|Hamatologisch-onkologische Schwerpunktpraxis, Würzburg, Germany|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01996865"
236,"NCT01986894","A Phase 1 QT Study in Healthy Male Subjects","QT/QTc","Completed","No Results Available","Clinical Pharmacology, Healthy Volunteer Study","Drug: Placebo|Drug: Pomalidomide|Drug: Moxifloxacin","Time matched, baseline corrected change from placebo of QTcF|Categorical analyses on ECG intervals and changes in ECG morphology|Time matched, baseline corrected changes from placebo of other ECG intervals (RR, PR, QRS) and categorical analyses on ECG intervals and changes in ECG morphology|Safety|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUCinf|Pharmacokinetics - AUCt|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F","Celgene","Male","18 Years to 50 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","CC-4047-CP-010","October 18, 2013","December 2, 2013","December 2, 2013","November 19, 2013",,"November 11, 2019","PPD Phase I Clinic, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01986894"
237,"NCT01975610","Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: CC-292|Drug: Placebo","American College of Rheumatology Criteria for a 20% improvement (ACR 20)|Number of participants with adverse events|American College of Rheumatology Criteria for a 50% improvement (ACR 50)|American College of Rheumatology Criteria for a 70% improvement (ACR 70)","Celgene","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-292-RA-001","October 2013","January 2016","February 2016","November 4, 2013",,"July 31, 2017","Achieve Clinical Research LLC, Birmingham, Alabama, United States|Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States|Generations Medical Research, Hot Springs, Arkansas, United States|UCLA, Los Angeles, California, United States|Joao Nascimento, MD, Bridgeport, Connecticut, United States|Southeastern Integrated Medical, Gainesville, Florida, United States|Family Arthritis Center, Jupiter, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Integral Rheumatology and Immunology specialists, Plantation, Florida, United States|Columbia Medical Practice, Columbia, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Arthritis and Osteoporosis Associates, Freehold, New Jersey, United States|Albuquerque Clinic, Albuquerque, New Mexico, United States|NYU Langone Medical Center, New York, New York, United States|DJL Clinical Research, Charlotte, North Carolina, United States|Lynn Health Science Instiute, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|PMG Research of Charlotte LLC, Rock Hill, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|DM Clinical Research, Houston, Texas, United States|Mountain State Clinical Research, Clarksburg, West Virginia, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Gundersen Clinic Ltd, Onalaska, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01975610"
238,"NCT01964430","Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)","apact","Active, not recruiting","No Results Available","Pancreatic Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Neoplasms|Endocrine Gland Neoplasms|Pancreatic Diseases|Digestive System Diseases|Endocrine System Diseases|Gemcitabine|Antimetabolites, Antineoplastic","Drug: nab-Paclitaxel 125 mg/m2|Drug: gemcitabine 1000 mg/m2","Disease Free Survival (DFS)|Overall Survival|Number of Participants with Adverse Events","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","866","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-PANC-003|2013-003398-91","March 28, 2014","December 31, 2018","September 15, 2022","October 17, 2013",,"August 14, 2019","Mayo Clinic - Arizona, Scottsdale, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|UC Davis Cancer Center, Sacramento, California, United States|University of California, San Francisco Cutaneous Oncology and Melanoma Center, San Francisco, California, United States|University of California Los Angeles, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, LLP [Denver-Midtown], Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Florida Cancer Institute Cancer Spec, Fort Myers, Florida, United States|Gainesville Heme Oncology Associates, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami and Sylvester Cancer Center, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Georgia Cancer Specialist, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel-Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Center Wayne State University, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|MSKCC Basking Ridge, Basking Ridge, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, Commack, New York, United States|Memorial Sloan Kettering Cancer Center West Harrison, Harrison, New York, United States|NYU Langone Medical Center, Lake Success, New York, United States|Memorial Sloan-Kettering Cancer Center - NYC, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Cancer Center, James P. Wilmot Cancer Center, Rochester, New York, United States|MSKCC at Mercy Medical Center Mercy RockvilleCenter, Rockville Center, New York, United States|MSKCC at Phelps Memorial Hospital Center. Phelps Sleepy Hollow, Sleepy Hollow, New York, United States|State University of New York Upstate Medical Center, Syracuse, New York, United States|Wake Forest Univ. Health Sciences Outpatient Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|University of Cincinnati Medical CenterDivsion of Hematology OncologyThe Barrett Center, Cincinnati, Ohio, United States|Case Western Reserve Center, Cleveland, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Cleveland Clinic Foundation IRB, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Chattanooga Oncology Hematology Care, Chattanooga, Tennessee, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance - Seattle, Seattle, Washington, United States|Virginia Mason Cancer Center, Seattle, Washington, United States|University of Wisconsin - Madison Cancer Center, Madison, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|ICON Cancer Center, Milton, Queensland, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Monash Medical Centre Moorabbin Campus, Bentleigh East, Australia|Saint Vincent's Hospital, Darlinghurst, Australia|Austin Hospital, Heidelberg, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Cabrini Hospital, Malvern, Australia|Prince of Wales Hospital, Randwick, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Medical University of Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|Hospital of Elisabethinen Linz, Linz, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Hospital Wiener Neustadt, Wiener Neustadt, Austria|Medizinische Universitat Wien, Wien, Austria|Kaiser-Franz-Josef Spital, Wien, Austria|Hopital Erasme, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de L'Universite de Montreal St-Luc, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Krajska nemocnice Liberec, a.s., Liberec, Czechia|Krajska nemocnice T. Bati a.s., Zlin, Czechia|Hæmatologisk afd. B Aalborg Sygehus Syd, Aalborg, Denmark|Herlev Hospital, Herlev, Denmark|Onk.Dep., Odense Universitets hospital, Odense C, Denmark|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Tampereen yliopistollinen sairaala, Tampere, Finland|Turku University Hospital, Turku, Finland|Center Hospitalier Universitaire d' Angers, Angers cedex 09, France|Hopital Henri Mondor, Creteil, France|CHRU de Lille France, Lille, France|Hopital Edouard Herriot - Hepato-gastroenterologie, Lyon Cedex 3, France|Hopital prive Jean Mermoz, Lyon, France|Hopital Europeen Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Pitie Salpetriere, Paris, France|CHU La Miletrie, Poitiers Cedex, France|Pole Des Specialites Medicales, Hopital Purpan, Toulose, France|Klinikum Weiden, Bayern, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Kliniken Essen-Mitte, Essen, Germany|Universitatsklinkum Frankfurt, Frankfurt, Germany|Praxis Internistischer Onkologie und Hamatologie Frechen, Frechen, Germany|Praxis für Innere Medizin, Dr.Oettle Helmut, Friedrichshafen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Praxis Internistischer Onkologie und Hamatologie Koln, Köln, Germany|Universitatsklinik Magdeburg, Magdeburg, Germany|Klinikum der Johannes Gutenberg Uniervsitaet ,Haematologie, Mainz, Germany|Klinikum der Universitat Munchen-Grosshadern, München, Germany|Klinikum Neuperlach, München, Germany|University of Tubingen, Tübingen, Germany|Universitatsklinikum Würzburg, Würzburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital the Chinese University of Hong Kong, Sha Tin, Hong Kong|Fovarosi Szent Istvan es Szent Laszlo Korhaz es Rendelointezet, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szent-Gyorgyi Albert TE AOK Borgyogy, Szeged, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|Cork University Hospital, Cork, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|Ospedali Riuniti Umberto I GM Lancisi, Ancona, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Azienda Ospedaliera Niguarda Ca Granda, Milano, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Academisch Medisch Centrum Amsterdam, Amsterdam, Netherlands|Catharina Hospital, Eindhoven, Netherlands|Isala Klinieken, Zwolle, Netherlands|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Hospital Da Luz, Lisboa, Portugal|Hospital de Sao Joao, Porto, Portugal|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Clinic Barcelona Hospital Universitari, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Ramon y Cajal Univeresity Hospital, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Centro Integral, Madrid, Spain|Hospital General Carlos Haya, Malaga, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario De Santiago De Compostela, Santiago De Compostela, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Addenbrookes Hospital, Cambridge, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Weston Park Hospital, Sheffield South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01964430"
239,"NCT01962103","Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors",,"Completed","Has Results","Neuroblastoma|Rhabdomyosarcoma|Ewing's Sarcoma|Ewing's Tumor|Sarcoma, Ewing's|Sarcomas, Epitheliod|Sarcoma, Soft Tissue|Sarcoma, Spindle Cell|Melanoma|Malignant Melanoma|Clinical Oncology|Oncology, Medical|Pediatrics, Osteosarcoma|Osteogenic Sarcoma|Osteosarcoma Tumor|Sarcoma, Osteogenic|Tumors|Cancer|Neoplasia|Neoplasm|Histiocytoma|Fibrosarcoma|Dermatofibrosarcoma","Drug: nab-paclitaxel","Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)|Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Phase 2: Overall Response Rate (ORR)|Phase 1: ORR|Phase 1: Maximum Observed Concentration of Paclitaxel in Blood Plasma (Cmax)|Phase 1: Cmax - Dose-Normalized|Phase 1: Area Under the Plasma Concentration-Time Curve (AUC)|Phase 1: AUC - Dose-Normalized|Phase 1: Clearance (CL)|Phase 1: CL - Body Surface Area (BSA)-Normalized|Phase 1: Volume of Distribution (Vss)|Phase 1: Vss - BSA-Normalized|Phase 1 and 2 Population PK: Volume of Distribution of the Central Compartment (V1)|Phase 1 and 2 Population PK: Maximum Elimination Rate From the Central Compartment (VMEL)|Phase 1 and 2 Population PK: Concentration in the Central Compartment at 50% of VMEL (KMEL)|Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the First Peripheral Compartment (Q2)|Phase 1 and 2 Population PK: Intercompartmental CL Between the Central Compartment and the Second Peripheral Compartment (Q3)|Phase 1 and 2 Population PK: Volume of Distribution of the First Peripheral Compartment (V2)|Phase 1 and 2 Population PK: Volume of Distribution of the Second Peripheral Compartment (V3)|Phase 2: Duration of Response (DOR)|Phase 2: Disease Control Rate (DCR)|Phase 2: Progression-Free Survival (PFS)|Phase 2: Kaplan-Meier Estimate of Overall Survival Rate at 1 Year|Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","Celgene","All","6 Months to 24 Years   (Child, Adult)","Phase 1|Phase 2","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-PST-001","December 4, 2013","December 5, 2017","November 6, 2018","October 14, 2013","December 27, 2018","November 5, 2019","Phoenix Childrens Hospital, Phoenix, Arizona, United States|Columbia University Medical Center, New York, New York, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Institute for Pediatric Hematology - Oncology, Leon Berard Cancer Center, Lyon, France|Hopital d'Enfants, CHU Nancy, Nancy, France|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif, France|Azienda Ospedaliera Universitaria Meyer, Firenze, Italy|Children's Hospital Largo, Genova, Italy|Istituto Nazionale Tumori, Milan, Italy|Clinica di Oncoematologia, Padova, Italy|Policlinico Agostino Gemelli, Rome, Italy|l'Azienda Ospedaliera Regina Margherita - Sant Anna, Torino, Italy|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Spanish National Cancer Research Centre, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Unidad de Oncologia Pediatrica, Hospital Universitario la Fe, Valencia, Spain|Universitäts-Kinderklinik, Zurich, Switzerland|Royal Marsden Hospital, Sutton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01962103/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01962103/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01962103"
240,"NCT01947309","Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)",,"Terminated","No Results Available","Multiple Myeloma","Drug: Revlimid (lenalidomide)","Progression Free Survival (PFS)|Response Rates|Overall Survival (OS)|Time to Response (TTR) and Duration of Response (DOR)|Duration of Treatment with Revlimid|Safety Profile of Revlimid","Celgene","All","18 Years and older   (Adult, Older Adult)",,"176","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIPMS-RV-CN-001","November 2013","July 2016","September 2016","September 20, 2013",,"January 12, 2017","Peking Chao-Yang Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|People's Liberation Army Hospital 307, Beijing, China|Beijing Hospital, Beijing, China|The Fisrt Hospital Of Jilin University, Changchun, China|Xiangya Hospital Central-South University, Changsha, China|Xinqiao Hospital, 3rd Military Medical University, Chongqing, China|NanFang Hospital of China Southern Medical University, Guangzhou, China|The First Affliated Hospital of Anhui Medical University, Hefei, China|Qilu Hospital of Shandong University, Jinan, China|The Affiliated Hospital of Mecical College Qingdao University, Qingdao, China|Shanghai Changzhen Hospital, Shanghai, China|The Second Affiliated Hospital Of China Medical University, Shenyang, China|The First Affiliated Hospital of Suzhou University, Suzhou, China|People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China|Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China|Tongji Medical College Huazhong University of Science & Technology, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT01947309"
241,"NCT01946477","Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting","POM MM 014","Recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Daratumumab","Overall response rate (ORR)|Overall survival (OS)|Progression-free survival (PFS)|Duration of Response (DoR)|Time to Response (TTR)|Time to progression (TTP)|Adverse Events","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","188","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-014","May 29, 2014","December 31, 2024","December 31, 2024","September 19, 2013",,"May 22, 2019","University of Arizona Cancer Center, Tucson, Arizona, United States|Marin Oncology Associates, Greenbrae, California, United States|University of California at Los Angeles, Los Angeles, California, United States|Bay Area Cancer Research Group, LLC, Pleasant Hill, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Stamford Hospital, Stamford, Connecticut, United States|Cancer Specialist of North Florida, Jacksonville, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Memorial West Cancer Institute, Pembroke Pines, Florida, United States|Florida Cancer Specialists North Region Sarah Cannon Research, Saint Petersburg, Florida, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Cotton O'Neil Clinical Research, Hematology and Oncology, Topeka, Kansas, United States|Norton Cancer Institute Louisville Oncology, Louisville, Kentucky, United States|Carroll Regional Cancer Center, Westminster, Maryland, United States|Saint John Hospital and Medical Center, Gross Pointe, Michigan, United States|St. Luke's Hospital, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Veterans Affairs New Jersey Health Care System, East Orange, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|CR Wood Cancer Center, Glens Falls, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Mayfield Heights, Ohio, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Tennessee Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|Texas Health Physicians Group, Plano, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States|Foothills Hospital, Calgary, Alberta, Canada|Fraser Valley Centre, Surrey, British Columbia, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Vitalite Health Network, Moncton, New Brunswick, Canada|Health Sciences Center, St John's, Newfoundland and Labrador, Canada|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kameda Medical Center, Kamogawa, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Nagoya City University Hospital, Nagoya, Japan|Okayama Medical Center, Okayama, Japan|Shibukawa Medical Center, Shibukawa-shi, Gunma-ken, Japan|Toyohashi Municipal Hospital, Toyohashi, Japan|Fundacion de Investigacion, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01946477"
242,"NCT01938001","Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)","AUGMENT","Active, not recruiting","Has Results","Lymphoma, Non-Hodgkin","Drug: Rituximab|Drug: Lenalidomide|Drug: Placebo","Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)|Durable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC|Kaplan-Meier Estimate of Overall Survival (OS)|Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC|Percentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC|Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC|Kaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRC|Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC|Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","358","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-NHL-007","November 1, 2013","June 22, 2018","December 28, 2021","September 10, 2013","August 13, 2019","August 13, 2019","Mitchell Cancer Center, University of South Alabama, Mobile, Alabama, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Southwest Cancer Care Medical Group, Escondido, California, United States|Marin Oncology Associates, Greenbrae, California, United States|Wilshire Oncology Medical Group, Inc, La Verne, California, United States|North County Hematology Oncology (NCHO) - TRM, LLC., Oceanside, California, United States|Hematology-Oncology Medical Group of Orange County, Inc., Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Wellness Hematology Oncology, West Hills, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Florida Cancer Specialists North Region Sarah Cannon Research, Saint Petersburg, Florida, United States|Illinois Cancer Care, P.C., Peoria, Illinois, United States|LRG Healthcare Oncology Clinic, Laconia, Indiana, United States|Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Louisville, J.G. Brown Cancer Center, Louisville, Kentucky, United States|Providence Cancer Institute, Southfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at the St. Cloud Hospital, Saint Cloud, Minnesota, United States|NH Oncology - Hematology, PA, Hooksett, New Hampshire, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care Sarah Cannon Research, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|St Francis Hospital, Greenville, South Carolina, United States|Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute, Spartanburg, South Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|CHU Mont -Godinne, Yvoir, Belgium|Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Associacao Educudora Sao Carlos AESC Hospital Giovanni Battista HGB Hospital Mae de Deus Center, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú, Jau/SP, São Paulo, Brazil|MS INCA HC I Hospital do Cancer I, Rio De Janeiro, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia, São Paulo, Brazil|Fundação Antonio Prudente - AC Camargo Câncer center, São Paulo, Brazil|Beijing Cancer Hospital, Beijing, PR, China|Peking University People's Hospital, Beijing, China|307 Hospital of PLA, Beijing, China|Peking Union Medical College Hospital, Beijing, China|The Third Xiangya hospital of central south university, Changsha, China|West China Hospital of Sichuan University, Chengdu, China|Fujian Medical University Union Hospital, Fuzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, China|Jiangsu Province Hospital The First Hospital affiliated with Nanjing Medical University, Nanjing, China|Cancer Hospital, Fudan University, Shanghai, China|Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Xijing Hospital, Xi'an, China|Interni hematoonkologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, IV.interni hematologicka klinika, Hradec Kralove, Czechia|Fakultni Nemocnice Ostrava, Klinika hematoonkologie,, Ostrava, Czechia|Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|CHU d'Angers, Angers, France|Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Hopital Saint-Louis, Paris, France|CH Perpignan - Hopital Saint-Jean, Perpignan, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de Valence, Valence, France|Charite - Universitaetsmedizin Berlin Charité - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitaetsmedizin Berlin Campus Virchow Klinikum, Berlin, Germany|Krankenhaus Nordwest, Frankfurt, Germany|Onkologische Schwerpunktpraxis Leer - Emden, Leer, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Germany|Klinkum der Stadt Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Soroka University Medical Center, Beer Sheva, Israel|Hadassah University Hospital, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Centro di Riferimento Oncologico - IRCCS, Aviano (PN), Italy|U.O.C. Ematologia, Barletta, Italy|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi - Nesima, Catania, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|IRCCS- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione ""G. Pascale"", Napoli, Italy|Az. Osp. Vincenzo Cervello, Palermo, Italy|Casa di Cura La Maddalena, Palermo, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|Ospedale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Italy|National Cancer Center Hospital, Chuo-ku, Japan|Chugoku Central Hospital, Hiroshima, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Kobe City Medical Center General Hospital, Kobe-city, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Toranomon Hospital, Minato-ku, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Nagoya Medical Center,Division of Hematology/Oncology, Nagoya, Japan|National University Corporation Tohoku University, Tohoku University Hospital, Sendai-shi, Japan|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Instytut Hematologii i Transfuzjologii w Warszawie, Warszawa, Poland|Centrum Onkologii, Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Hospital Auxilio Muto Centro de Cancer, San Juan, Puerto Rico|Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation|Russian Academy of Medical Sciences Institution, Moscow, Russian Federation|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, St.Petersburg, Russian Federation|The Ministry of Health and Social Development of the Tula region state institution Health Tula regio, Tula, Russian Federation|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Cukurova University Medical Faculty Balcali Hospital, Adana, Turkey|Hacettepe Universitesi, Ankara, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Gaziantep University, Gaziantep, Turkey|Marmara University, Istanbul, Turkey|Dokuz Eylul University Izmir, Izmir, Turkey|19 Mayis Medical Faculty - Samsun, Samsun, Turkey|Kocaeli Derince Training and Research Hospital, Umuttepe Kocaeli, Turkey|Eastbourne District General Hospital, Eastbourne, United Kingdom|Royal Liverpool University Hospital, Prescot Street, Liverpool, United Kingdom|Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom|Southend University Hospital NHS Foundation Trust, Prittlewell Chase, Westcliff on Sea, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01938001/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01938001/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01938001"
243,"NCT01937442","Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide Celgene™","Pharmacokinetic parameters for plasma thalidomide: Tmax Cmax AUC t1/2 CL/F V/F","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-2001-CP-001|2012-005529-62","November 7, 2013","September 23, 2015","September 23, 2015","September 9, 2013",,"November 11, 2019","Hopital Augustin Morvan, Brest Cedex, France|CHU Grenoble, Grenoble Cedex 09, France|CHRU-Hopital Claude Huriez, Lille, France|CHRU Hopital Bretonneau, Tours cedex, France|CHRU Hopital Brabois, Vandoeuvre Cedex, France|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01937442"
244,"NCT01925768","Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis",,"Completed","Has Results","Psoriatic Arthritis","Drug: Apremilast 30 mg|Drug: Placebo","Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24|Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) at Week 24|Change From Baseline in the 28-Joint Disease Activity Score Using C-reactive Protein as the Acute-Phase Reactant (DAS28 [CRP]) at Week 24|Change From Baseline in the Medical Outcomes Short Form Health Survey (SF-36) V2 Physical Function Domain Score at Week 24|Change From Baseline in the 36-item SF-36 Physical Component Summary Score at Week 24|Change From Baseline in the Duration of Morning Stiffness at Week 24|Percentage of Participants With Improved Change in Severity of Morning Stiffness at Week 24|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16|Change From Baseline in the Disease Activity Score DAS28 (CRP) at Week 16|Change From Baseline in 36-item Short Form Health Survey (SF-36) V 2 Physical Functioning Domain at Week 16|Mean Change From Baseline in the Duration of Morning Stiffness at Week 16|Percentage of Participants Whose Severity of Morning Stiffness at Week 16 Improved From Baseline|Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, 6, 8, 12 and 20|Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 52 and 104|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 52 and 104|Change From Baseline in the Disease Activity Score (DAS28) at Week 52 and 104|Change From Baseline in 36-item SF-36 (V2.0) Physical Functioning Domain Score at Weeks 52 and 104|Change From Baseline in the Duration of Morning Stiffness at Weeks 52 and 104|Percentage of Participants Whose Severity of Morning Stiffness at Week 52 and 104 Improved From Baseline|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the 24 Week Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-006","September 4, 2013","February 25, 2015","November 17, 2016","August 20, 2013","June 13, 2016","November 14, 2019","Achieve Clinical Research LLC, Birmingham, Alabama, United States|Desert Medical Advances, Palm Desert, California, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|Health Point Medical Group, Brandon, Florida, United States|Palmetto Medical Research, Hialeah, Florida, United States|Jeffrey Alper MD Research, Naples, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|University of South Florida, Tampa, Florida, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|Rockford Orthopedic Associates, LLC, Rockford, Illinois, United States|Advanced Rheumatology, Lansing, Michigan, United States|Research West Incorporated, Kalispell, Montana, United States|Heartland Clinical Research, Inc., Omaha, Nebraska, United States|Physicians East, Greenville, North Carolina, United States|Piedmont Medical Research Associates Inc, Winston-Salem, North Carolina, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|Houston Medical Research, Houston, Texas, United States|Arthritis and Osteoporosis Associates LLP, Lubbock, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Mountain State Clinical Research, Clarksburg, West Virginia, United States|Colin Bayliss Research and Teaching Unit, Victoria Park, Western Australia, Australia|Eastern Health Clinical School, Box Hill, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Menzies Centre for Population Health Research, Hobart,, Australia|Optimus Clinical Research Pty. Ltd, Kogarah, Australia|Coastal Joint Care, Maroochydore, Australia|Westmead Cancer Care Center, Westmead, NSW, Australia|Manna Research, Vancouver, British Columbia, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|Karma Clinical Trials, Saint John's, Newfoundland and Labrador, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|MAC Research Incorporated, Hamilton, Ontario, Canada|Arthur Karasik Private Practice, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Jude Rodrigues Private Practice, Windsor, Ontario, Canada|CHUL du CHU de Quebec, Quebec, Canada|Revmatologicky ustav, Praha 2, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV - MEDICAL, s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Qualiclinic kft, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|MAV Korhaz es Rendelointezet Szolnok, Szolnok, Hungary|Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet, Veszprém, Hungary|Waikato hospital, Hamilton, New Zealand|Middlemore Clinical Trials, Manukau, New Zealand|Timaru Hospital, Timaru, New Zealand|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|SC Covamed SRL, Sfantu Gheorghe, Covasna, Romania|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|Hospital Universitario a Coruna, A Coruña, Spain|Hospital Universitari de Bellvitge, Barcelona, Hospitalet De Llobregat, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Basurto-Osakidetza, Bilbao, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Carlos Haya, Málaga, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain",,"https://ClinicalTrials.gov/show/NCT01925768"
245,"NCT01915498","Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation",,"Active, not recruiting","No Results Available","Hematologic Neoplasms","Drug: AG-221","Adverse Events (AEs)|Maximum Tolerated Dose|Clinical Activity of AG-221 for subjects with relapsed or refractory acute myelogenous leukemia (AML) with Isocitrate dehydrogenase protein 2 (IDH2) mutation|Dose Limiting Toxicities|Pharmacokinetic Cmax|Pharmacokinetic Tmax|Clinical Activity pf AG-221 in subjects with hematologic malignancies|Pharmacokinetic AUC|Pharmacokinetic Elimination half-life|Pharmacodynamics Analyses Plasma|Pharmacodynamics Analyses Urine|Pharmacodynamics Analyses Bone Marrow (2-HG)|Clinical Activity of AG-221 in subjects with Relapse/Refractory AML with an IDH2 mutation","Celgene|Agios Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","357","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG-221-C-001","August 27, 2013","July 25, 2019","December 31, 2020","August 5, 2013",,"October 22, 2019","City of Hope, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Miami Sylvester Cancer Center, Miami, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Cornell University Weill Medical College, New York, New York, United States|Memorial Sloan-Kettering Cancer Center - NYC, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Gahanna, Ohio, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Institut Bergonie Department Oncologie, Bordeaux, France|Hospital Saint Louis, Paris, France|Hospital haut leveque, Pessac, France|CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT01915498"
246,"NCT01896323","CC-223 and Ketoconazole Drug-Drug Interaction Study",,"Completed","No Results Available","Healthy Volunteers","Drug: CC-223|Drug: Ketoconazole","Pharmacokinetics|Adverse Events","Celgene","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CC-223-CP-003","July 1, 2013","August 1, 2013","August 1, 2013","July 11, 2013",,"November 11, 2019",,,"https://ClinicalTrials.gov/show/NCT01896323"
247,"NCT01881230","Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","tnAcity","Completed","Has Results","Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer","Drug: nab-Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine","Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.|Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.|Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy|Kaplan-Meier Estimates of Overall Survival|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)|Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs","Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","191","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-MBC-001|2013-000113-20","September 26, 2013","October 28, 2016","October 28, 2016","June 19, 2013","March 8, 2018","February 21, 2019","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Arizona Cancer Research Alliance, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Pacific Cancer Medical Center Inc, Anaheim, California, United States|California Cancer Associates for Research and Excellence cCARE, Escondido, California, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Wilshire Oncology Medical Group, Inc, La Verne, California, United States|Translational Research Management, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Redwood Regional Medical Group, INC, Santa Rosa, California, United States|Center for Hematology-Oncology, Boca Raton, Florida, United States|Memorial Breast Cancer Center, Hollywood, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Joliet Oncology-Hematology Associates, Ltd, Joliet, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|University of South Alabama Mitchell Cancer Institute, Lafayette, Louisiana, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Midwest Physicians Group, Kansas City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|New Hampshire Oncology Hematology, Hooksett, New Hampshire, United States|Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Hematology Oncology Associates of CNY, East Syracuse, New York, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|Clinical Research Alliance, New York, New York, United States|Alamance Regional Medical Cancer Center, Burlington, North Carolina, United States|University of Cincinnatti, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Mark H Zangmeister Center, Columbus, Ohio, United States|Toledo Community Oncology Program, Toledo, Ohio, United States|Cancer Centers of Southwest Oklahoma, Lawton, Oklahoma, United States|North Bend Medical Center, Coos Bay, Oregon, United States|Northwest Cancer Specialists, P.C. - Hoyt, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Texas Oncology, PA, Dallas, Texas, United States|Texas Oncology, PA- Dallas, Dallas, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|UT Physicians General Medicine, Houston, Texas, United States|Cancer Care Centers of South Texas - Loop, San Antonio, Texas, United States|Texas Oncology P.A.- Tyler, Tyler, Texas, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Delta Hematologyoncology Associates, Portsmouth, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Medical Oncology Associates, Spokane, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Columbia St Marys Cancer Center, Milwaukee, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Frankston Hospital Oncology Research, Frankston, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Universitaetsklinik Innsbruck, Innsbruck, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Medizinische Universitat Wien, Vienna, Austria|Centro de Oncologia Da Bahia, Salvador, Bahia, Brazil|Liga Paranaense de Combate Ao Cancer, Curitiba, Paraná, Brazil|Instituto Nacional de Cancer - INCA, Rio De Janerio, Rio De Janeiro, Brazil|Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú, Jau/SP, São Paulo, Brazil|ONCOCLINIC Clinica de Oncologia LTDA, Fortaleza, Brazil|Instituto Ribeiraopretano de Combate Ao Cancer, Ribeirao Preto, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP, Ribeirao Preto, Brazil|Hospital Bruno Born, Rio Grande Do Sul, Brazil|Hospital de Base Da Faculdade de Medicina de, Sao Jose Do Rio Preto, Brazil|Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira, Sao Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|Instituto Brasileiro de Controle Do Cancer IBCC, São Paulo, Brazil|Ottawa General Hospital, Ottawa, Ontario, Canada|CHUM - Notre Dame, Montreal, Quebec, Canada|Hospital du Saint Scarement Sacrement Laboratory, Quebec City, Quebec, Canada|CSSS de Rimouski Neigette, Rimouski, Quebec, Canada|Alan Blair Cancer Centre at Pasqua Hosptial, Regina, Saskatchewan, Canada|Centre Jean Perrin, Clermont-Ferrand, France|Sankt Gertrauden-Krankenhaus, Berlin, Germany|Facharztpraxis fur Gynakologie und Geburtshilfe, Bonn, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Praxis fur interdisziplinare Onkologie & Hamatologie, Freiburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Frauenarzte am Bahnhofsplatz, Hildesheim, Germany|Schwerpunktpraxis fur Gynakologische Onkologie, Köln, Germany|LMU Klinikum der Universitat, München, Germany|Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany|Universitatsklinikum Ulm, Ulm, Germany|University of Athens Medical school - Regional General Hospital, Athens, Greece|IASO General, Athens, Greece|Metropolitan Hospital, Faliro, Greece|University General Hospital of Heraklion, Heraklion, Greece|University General Hospital of Patras, Rio Patras, Greece|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant' Anna, Ferrara, Italy|IRCCS AziendaOspedaliera Universitaria San Martino, Genova, Italy|Presidio Ospedaliero della Misericordia, Grosseto, Italy|Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte, Messina, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Istituto Oncologico Veneto, Padova, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Universitario A Gemelli, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy|Hospital Espirito Santo, Evora, Portugal|Hospital Da Luz, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Clinic Barcelona Hospital Universitari, Barcelona, Spain|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Onkologikoa - Kutxaren Institutu Onkologikoa, San Sebastian, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Royal United Hospital, Bath, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The East and North Hertfordshire NHS Trust, Middlesex, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01881230"
248,"NCT01836029","Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",,"Completed","Has Results","Carcinoma, Squamous Cell of Head and Neck","Drug: VTX-2337|Drug: Carboplatin|Drug: Cisplatin|Drug: 5-fluorouracil|Drug: Placebo","Comparison of Progression Free Survival (PFS) Between Treatment Groups Using irRECIST and Evaluated by Independent Radiology.|Comparison of Adverse Events (AEs) Between the Two Treatment Groups.|Comparison of Overall Survival (OS) Between the 2 Treatment Groups.|Comparison of the Objective Response Rate Between the Two Treatment Groups p","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VRXP-A202","October 14, 2013","April 13, 2016","September 19, 2016","April 19, 2013","October 29, 2019","October 29, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|California Cancer Associates for Research and Excellence (CCARE), Escondido, California, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|University of California Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|VA Eastern Colorado Healthcare System, Denver, Colorado, United States|Helen F. Graham Cancer Center, Newark, Delaware, United States|MD Anderson Cancer Center, Orlando, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Robert W. Veith, MD, LLC, Metairie, Louisiana, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Saint Louis Cancer Care, LLP, Bridgeton, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Oncology and Hematology Specialists, P.A., Denville, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Monter Cancer Center, Lake Success, New York, United States|The Bellevue Hospital, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Saint Charles Medical Center, Bend, Oregon, United States|Providence Cancer Center, Portland, Oregon, United States|Saint Lukes Cancer Centre, Easton, Pennsylvania, United States|Pennsylvania State Hershey Cancer Institute, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Virginia Cancer Specialists, PD, Fairfax, Virginia, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Advanced Healthcare, Inc., Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01836029"
249,"NCT01835587","Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).",,"Completed","Has Results","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes","Drug: CC-486","The Number of Participants With Dose Limiting Toxicities (DLT)|Number of Participants With Treatment Emergent Adverse Events (TEAE)|Percentage of Participants With Graft Versus Host Disease During the Entire Course of the Study|Kaplan Meier Estimate of Time to Discontinuation From Treatment|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of CC-486 (AUC-t)|Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated to Infinity (AUC-inf; AUC0-∞) Of CC-486|Maximum Observed Concentration (Cmax) Of CC-486|Time to Reach Maximum Concentration (Tmax) of CC-486|Terminal Half-Life (T1/2) of CC-486|Apparent Total Clearance (CL/F) of CC-486|Apparent Volume of Distribution (Vz/F) of CC-486|Percentage of Participants With Disease Relapse or Progression|Time to Disease Recurrence/Progression|Overall Survival|Kaplan Meier Estimate of Relapse-Free Survival (RFS)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-AML-002","October 25, 2013","November 13, 2016","May 26, 2017","April 19, 2013","November 20, 2018","November 20, 2018","Memorial Sloan-Kettering Cancer Center., New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Queen Elizabeth Hospital UHB NHS Foundation Trust, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01835587"
250,"NCT01835561","Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males",,"Completed","No Results Available","Clinical Pharmacology, Healthy Volunteer Study","Drug: Pomalidomide","C max|T max|Area Under the Curve Time Zero to time(AUC0-t)|Area Under the Curve (AUCinf) ; from time 0 to infinity|t ½: Terminal Half Life|CL/F: apparent clearance|Vz/F: apparent volume of distribution|Number of participants with adverse events (AEs).","Celgene","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-4047-CP-009","March 1, 2013","August 16, 2014","August 21, 2014","April 19, 2013",,"November 11, 2019","Orlando Clinical Research Center, Orlando, Florida, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01835561"
251,"NCT01757535","Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission","QUAZAR AML-001","Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: 300 mg Oral Azacitidine|Drug: Placebo","Overall Survival (OS)|Relapse free survival (RFS)|Complete Remission (CR)/Complete Remission with incomplete blood count recovery (CRi)|Safety and Tolerability|Healthcare Resource Utilization|Patient-reported outcomes utilizing the FACIT-Fatigue Scale and the EQ-5D","Celgene","All","55 Years and older   (Adult, Older Adult)","Phase 3","472","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-486-AML-001|2012-003457-28","April 24, 2013","July 15, 2019","December 31, 2021","December 31, 2012",,"October 24, 2019","Arizona Oncology Associates, P.C., Phoenix, Arizona, United States|Providence St Joseph Medical Center Cancer Center, Burbank, California, United States|City of Hope, Duarte, California, United States|University of California San Francisco Fresno Campus, Fresno, California, United States|University of Southern California Norris Cancer Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|UC Irvine, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|The Hospital of Central Connecticut, Southington, Connecticut, United States|George Washington University Cancer Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Florida Health Cancer Center at Orlando Health, Orlando, Florida, United States|Northwestern University Medical Center Division of Hematology Oncology, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Cancer Care and Hematology Specialists of Chicagoland, P.C. - Niles, IL, Niles, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Kansas University Medical Center, Westwood, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Norton Cancer Institute Louisville Oncology, Louisville, Kentucky, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City VA Medical Center University of Kansas Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Greenville Hospital System, Greenville, South Carolina, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Brooke-Army Medical Center, Fort Sam Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas - Loop, San Antonio, Texas, United States|Methodist Hospital, San Antonio, Texas, United States|VA Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Inst, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Mater Private Medical Centre Haematology and Oncology Clinics of Australasia Research Centre, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Dept Of Oncology, Bedford Park, South Australia, Australia|Austin Hospital, Heidelberg, Australia|Royal Hobart Hospital, Hobart, Australia|Liverpool Hospital, Liverpool, Australia|The Alfred Hospital, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Royal North Shore Hospital, St Leonards, Australia|Wollongong Hospital, Wollongong, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medical University of Graz, Graz, Austria|University Hospital of Salzburg, Salzburg, Austria|KH Hietzing, Vienna, Austria|Medical University of Vienna, Vienna, Austria|Hanusch Krankenhaus, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Center Hospitalier Universitaire Ambroise Pare, Mons, Belgium|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil|Saint Petersburg Medical State Institution Municipal n.a. I.P. Pavlov, Saint Petersburg, Brazil|Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira, Sao Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|University of Alberta, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Regional Health Authority B-Saint John Regional Hospital, Saint John, New Brunswick, Canada|Health Sciences Center, St John's, Newfoundland and Labrador, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University, Dept. Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|Helsinki University Central Hospital, Helsinki, Finland|University HospitaClinik of internal medicin, Tampere, Finland|Turku University Hospital, Turku, Finland|Hopital Sud, CHU d'Amiens, Amiens, France|CH Argenteuil Victor Dupouy, Argenteuil, France|Hopital Avicenne, Bobigny Cedex, France|Centre hospitalier de Boulognes - Duchenne, Boulognes Sur Mer, France|Hopital dinstruction des armees Percy, Clamart Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier de Versailles Hopital Andre Mignot, Le Chesnay Cedex, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|CHU Limoges, Limoges Cedex, France|CHU Hopital Edouard Herriot, Lyon cedex, France|Hopital Saint Louis, Paris Cedex 10, France|Hospital of Necker, Paris, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Pontoise Rene Dubos, Pontoise, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France|Institut Gustave Roussy, Villejuif Cedex, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|University Duesseldorf, Düsseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Staedtische Kliniken Frankfurt am Main Hochst, Frankfurt am Main, Germany|Wilhelm-Anton-Hospital Goch gGmbH Hämatologie und Internistische Onkologie, Goch, Germany|Medizinische Hochschule Hannover, Hannover, Germany|SLK Kliniken Heilbronn GmbH - Klinikum am Gesundbrunnen, Heilbronn, Germany|Universitatsklinikum Jena, Jena, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitaetsklinikum Mannheim, Mannheim, Germany|Staedtisches Klinikum Muenchen Schwabing, Muenchen, Germany|TU München - Klinikum rechts der Isar, München, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|St. Antonius-Hospital, Schweiler, Germany|University of Ulm, Ulm, Germany|Tallaght Adelaide and Meath Hospital, Dublin, Ireland|University College Hospital Galway, Galway, Ireland|Soroka University Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Az. Osp. SS.Antonio e Biagio - SC Ematologia, Alessandria, Italy|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Bingaghi, Cagliari, Italy|Istituti Ospitalieri di Cremona, Cremona, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|IRCCS AziendaOspedaliera Universitaria San Martino, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce, Lecce, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Milano, Italy|Fondazione Ca Granda IRCCS Ospedale Maggiore, Milan, Italy|Ospedale S. Gerardo di Monza, Monza, Italy|Azienda ospedeliera della 2 Universita di Napoli, Naples, Italy|Ospedale Cardarelli, Naples, Italy|AOU San Luigi Gonzaga, Orbassano (TO), Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|Casa di Cura La Maddalena, Divisione di Ematologia, Palermo, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord AORMN, Pesaro, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Universita degli Studi di Roma La Sapienza - Azienda Policlinico Umberto I, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera S. Andrea - Università La Sapienza, Roma, Italy|University Hospital Tor Vergata, Rome, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|A.O. Universitaria Fondazione Macchi, Varese, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Klaipeda seaman hospital, Klaipeda, Lithuania|Hospital Angeles Lomas - Consultorio 830, Huixquilucan de Degollado, Mexico|Instituto Nacional de Cancerología, Mexico, Mexico|Hospital Universitario Eleuterio Gomez, Monterrey, Mexico|Szpital Uniwersytecki nr 2 im dr. Jana Biziela, Bydgoszcz, Poland|Institute of Internal Diseases University of Medicine, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Centro Hospital e Universitario de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Hospital de Sao Joao, Porto, Portugal|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Complejo Universitario La Coruna, La Coruna, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Gregorio Maranon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Taipei Veterans General Hospital, Beitou District, Taipei City, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Niaosong District Kaohsiung City, Taiwan|China Medical University Hospital, Taichung, Northern Dist., Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Hacettepe Universitesi, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji hospital, Ankara, Turkey|Marmara School of Medicine, Istanbul, Turkey|Ondokuz Mayis University Medical Faculty, Samsun, Turkey|United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom|Royal Sussex County Hospital, Brighton East Sussex, United Kingdom|Kent and Canterbury Hospital, Canterbury Kent, United Kingdom|University College London Hospitals, London, United Kingdom|Kings College Hospital, London, United Kingdom|Imperial College Hammersmith Hospital, London, United Kingdom|Maidstone Hospital, Maidstone Kent, United Kingdom|Christie NHS Trust Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, Essex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01757535"
252,"NCT01752075","A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan",,"Completed","No Results Available","Multiple Myeloma","Drug: Revlimid","Adverse Events|Efficacy","Celgene","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","T-CC-5013-MM-009","January 1, 2011","July 12, 2013","July 19, 2013","December 19, 2012",,"November 18, 2019","NTUH, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01752075"
253,"NCT01736683","Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)",,"Completed","Has Results","Anemia|Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Low to Intermediate-1 MDS|Myelodysplastic Syndromes (MDS)|Chronic Myelomonocytic Leukemia (CMML)","Drug: Sotatercept","Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate)|Time to Erythroid Hematological Improvement (HI-E) Response|Duration of Erythroid Hematological Improvement (HI-E)|Time to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression|Time to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression|Kaplan-Meier Estimates for Progression-free Survival|Kaplan-Meier Estimates for Overall Survival (OS)|Pharmacokinetic Parameters of Sotatercept: Serum Concentration at Various Study Timepoints|Participants With Treatment-Emergent Adverse Events (TEAE)|Dose Limiting Toxicities (DLTs)|Number of Participants Who Achieved Red Blood Cell (RBC)-Transfusion Independence During the Erythroid Hematological Improvement (HI-E) Interval","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-011-MDS-001|2012-002601-22","November 28, 2012","April 30, 2018","April 30, 2018","November 29, 2012","June 13, 2019","June 25, 2019","Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Johns Hopkins, Baltimore, Maryland, United States|Dana-Farber / Harvard Cancer Institute, Boston, Massachusetts, United States|Monter Cancer Center, North Shore LIJ Health Systems, Lake Success, New York, United States|Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York, United States|The Cleveland Clinic Foundation Hematology and Medical Oncology Rm 35, Cleveland, Ohio, United States|Sarah Cannon Research Inst, Nashville, Tennessee, United States|Texas Oncology Round Rock Cancer Center - Round Rock, Round Rock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States|Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France|Institute Paoli-Calmettes Service Haematology, Bp 156,, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|CHRU Nantes, Nantes, France|Hopital Cochin Hematologie, Paris Cedex 14, France|Centre Henri Becquerel, Rouen, France|CHU Purpan, Toulouse, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01736683/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01736683/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01736683"
254,"NCT01734928","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","OPTIMISMM","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Bortezomib|Drug: Dexamethasone","Progression Free Survival|Overall Survival|Adverse Event|Overall Response Rate|Duration of Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","559","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-007","January 7, 2013","May 1, 2022","May 1, 2022","November 28, 2012",,"April 17, 2019","Southern Cancer Center, Mobile, Alabama, United States|Arizona Oncology, Tucson, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|University of California San Francisco Fresno Campus, Fresno, California, United States|Marin Oncology Associates, Greenbrae, California, United States|Moore UCSD Cancer Center, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|George Washington Medical Center, Washington, District of Columbia, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|University Cancer Institute, Boynton Beach, Florida, United States|Broward Oncology Associates PA, Fort Lauderdale, Florida, United States|Broward Oncology Assoc., Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States|Northwest Georgia Oncology Centers, PCWilliam S. Gibbons Center Research Institute, Marietta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Western Kentucky Hematology and Oncology Group, PSC, Paducah, Kentucky, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Cancer Care of Maine, Bangor, Maine, United States|St. Agnes - Medical Center, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Medstar Health Research Institute, Hyattsville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Detroit Clinical Research Center, Lansing, Michigan, United States|Beaumont Cancer Center, Royal Oak, Michigan, United States|Essentia Health Duluth CCOP, Duluth, Minnesota, United States|Metro MN CCOP, Saint Louis Park, Minnesota, United States|Columbia Comprehensive, Jefferson City, Missouri, United States|Kansas City VA Medical Center University of Kansas Medical Center, Kansas City, Missouri, United States|St John's Mercy Medical Center, Saint Louis, Missouri, United States|St. John's Clinic Cancerand Hematology - Springfield, Springfield, Missouri, United States|Billings Clinic, Billings, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|CarePoint Health Research Institute, Jersey City, New Jersey, United States|Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, United States|Somerset Hematology-Oncology Associates, Somerville, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|Stony Brook University, Stony Brook, New York, United States|New York Medical College, Valhalla, New York, United States|Eastern Institute of Medical Sciences, Greenville, North Carolina, United States|Boice-Willis Clinic P.A., Rocky Mount, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|Mid Ohio Oncology Hematology Inc, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute, Spartanburg, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Prairie Lakes Health Care System, Watertown, South Dakota, United States|University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Swedish Cancer Inst, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|West Virginia University CTRU, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hospital St. Polten, St. Pölten, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital-Center for Hematology and Oncology, Vienna, Austria|RSM Durham Regional Cancer Center - Lakeridge Health Oshawa, Oshawa, Ontario, Canada|CSSS Champlain Charles LeMoyne, Greenfield Park, Quebec, Canada|Centre De Sante Et De Services Sociaux De Rimouski-Neigette, Rimouski, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke-Hospital Fleurimont, Sherbrooke, Quebec, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Canada|Aarhus University Hospital, Aarhus, Denmark|Copenhagen University Hospital Rigshosptalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Hyvinkaa Hospital, Hyvinkaa, Finland|Centre Hospitalier de la cote basque, Bayonne, France|Centre Hospitalier William Morey, Chalon sur Saone, France|CHU Hotel, Grenoble Cedex 09, France|GH Institut Catholique St Vincent, Lille, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|CHRU Hotel Dieu, Nantes, France|Groupement Hospitalier Universitaire Est - Hopital Saint-Antoine, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|CHU La Miletrie, Poitiers Cedex, France|CHRU Rennes, Rennes, France|Institut Claudius Regaud, Toulouse Cedex, France|CHRU Hopital Bretonneau, Tours cedex, France|ChariteUniversitatsmedizinCampus Benjamin Franklin, Berlin, Germany|Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum EssenInnere Klinik und Poliklinik, Essen, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|University of Heidelberg, Heidelberg, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|General Hospital of Athens Evangelismos, Athens, Greece|University of Athens Medical school - Regional General Hospital, Athens, Greece|University General Hospital of Larissa, Mezourlo, Greece|George Papanikolaou General Hospital of Thessaloniki, Thessloniki, Greece|St James Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|University College Hospital Galway, Galway, Ireland|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel|USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Policlinico S. Orsola - Malpighi, Bologna, Italy|Ospedale Ferrarotto, Catania, Italy|University of Modena, Modena, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Unita Sanitaria Locale (Ausl) Pescara - Presidio Ospedaliero Di Pescara, Pescara, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|La Sapienza, University of Rome, Rome, Italy|A.O.U.S. Giovanni e Ruggi d'Aragona UOC UTIC, Salerno, Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliera San Giovanni Battista, Torino, Italy|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Kameda Medical Center, Kamogawa, Japan|Okayama Medical Center, Okayama, Japan|Japan Red Cross Medical Center, Shibuya-ku, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Japan|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Oslo universitetssykehus, Rikshospitalet, Oslo, Norway|St Olavs Hospital, Trondheim, Norway|Szpital Specjalistyczny w Brzozowie, Brzozow, Poland|Szpital Uniwersytecki nr 2 im dr. Jana Biziela, Bydgoszcz, Poland|Zespol Szpitali Miejskich, Chorzow, Poland|Klinika Hematologii Akademii Medycznej w Gdansku, Gdansk, Poland|Oddzial Kliniczny Kliniki Hematologii, Krakow, Poland|Kopernik Memorial Hospital, Lodz, Poland|Klinika Hematoonkologii i Transplantacji Szpiku, Lublin, Poland|Oddzial Hematologii i Chorob Rozrostowych Ukladu Krwiotworczego, Poznan, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|Hospital de Braga, Braga, Portugal|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Fundacao Champalimaud, Lisbon, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Hospital de Santo Antonio- Porto, Porto, Portugal|Ad-Vance Medical Research, LLC, Ponce, Puerto Rico|City Clinical Hospital 52, Moscow, Russian Federation|Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin, Moscow, Russian Federation|State Budgetary Healthcare Institution of Nizhniy Novgorod Region, Nizhny Novgorod, Russian Federation|Russian Research Institute of Hematology and Transfusiology of the Federal Biomedical Agency, Saint Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital de Basurto-Osakidetza, Bilbao, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Complejo Hospitalario De Orense, Orense, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario Nuestra Senora de Valme, Sevilla, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Falu lasarett, Falun, Sweden|Sahlgrenska University Hospital, Gothenburg, Sweden|Sunderby Sjukhus, Luleå, Sweden|Karolinska University, Stockholm, Sweden|Sundsvalls sjukhus- Medicinkliniken, Sundsvall, Sweden|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Gazi Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Ankara Universitesi Tip Fakultesi, Ankara, Turkey|Medstar Antalya Hospital, Antalya, Turkey|Eskisehir Osmangazi University, Eskisehir, Turkey|Gaziantep University, Gaziantep, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Istanbul University Faculty of Medicine, Istanbul, Turkey|Ege University Medical School, Izmir, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey|The Royal Bournemouth Hospital, Bournemouth, United Kingdom|Kent and Canterbury Hospital, Canterbury Kent, United Kingdom|Western General Hospital, Edinburgh Scotland, United Kingdom|University College London Hospitals, London, United Kingdom|Kings College Hospital, London, United Kingdom|University of Oxford, Oxford, United Kingdom|Derriford Hospital Plymouth Oncology Centre Clinical Trials Unit, Plymouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|University Hospital of North Staffordshire Nhs Trust - City General Hospital, Stoke-On-Trent, United Kingdom|Singleton Hospital, Swansea, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom|Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01734928"
255,"NCT01733875","2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: CC-220 0.03 mg|Drug: CC-220 0.1 mg|Drug: CC-220 0.3 mg|Drug: CC-220 1 mg|Drug: CC-220 2 mg|Drug: Placebo|Drug: CC-220","Adverse Events|Concentrations of CC-220 and its R-enantiomer in plasma (Part 2 only)|Concentrations of CC-220 and its R-enantiomer in plasma (Part 1 only)|PK-Cmax|PK-Tmax|PK-AUC 0-∞|PK-AUC 0-t|PK-t1/2,z|PK-CL/F|PK-Vz/F|PK-Ae48|PK-fe48|PK-CLr","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-220-CP-001","November 1, 2012","October 9, 2013","October 9, 2013","November 27, 2012",,"November 11, 2019","Covance Clinical Research Unit, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01733875"
256,"NCT01732861","Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma",,"Completed","No Results Available","Leukemia Lymphocytic Chronic B-Cell","Drug: CC-292|Drug: Lenalidomide","Adverse Events|Percentage of Participants Who Have Received Some Form of Response|PK-Cmax|PK-Tmax|PK-λz|PK-t1/2|PK-AUC (0-t)|PK-AUC0-∞","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-292-CLL-001|2012-003766-41","December 28, 2012","January 23, 2019","January 23, 2019","November 26, 2012",,"May 23, 2019","Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|The West Clinic, Memphis, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Universitatsklinik fur Innere Medizin, Innsbruck, Austria|AKh Linz, Linz, Austria|Universitatsklinik der PMU, Salzburg, Austria|Allgemeines Krankenhaus Wien, Wien, Austria|Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT01732861"
257,"NCT01724177","A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma",,"Completed","Has Results","Adult T-Cell Leukemia-Lymphoma","Drug: Lenalidomide","Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)|Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC|Kaplan-Meier Estimate of Time to Progression (TTP)|Number of Participants With Treatment Emergent Adverse Events|Kaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC|Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response (CRu), Partial Response or Stable Disease (SD) as Assessed by the ESEC|Kaplan-Meier Estimate for Overall Survival","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-ATLL-002","November 12, 2012","November 20, 2014","March 21, 2017","November 9, 2012","January 5, 2016","May 28, 2018","Nagoya City University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Ehime University Hospital, Toon, Ehime, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Sasebo City General Hospital, Sasebo, Nagasaki, Japan|Heart Life Hospital, Nakagami, Okinawa, Japan|Shimane University Hospital, Izumo, Shimane, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Imamura Bunin Hospital, Kagoshima, Japan|Kagoshima University Medical and Dental Hospital, Kagoshima, Japan|National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Oita Prefectual Hospital, Oita, Japan|National Cancer Center Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01724177"
258,"NCT01712828","Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males",,"Completed","No Results Available","Healthy","Drug: Lenalidomide|Drug: Quinidine|Drug: Temsirolimus|Drug: Diphenhydramine","Lenalidomide PK-AUC (0-24)|Lenalidomide PK-(Cmax)|Lenalidomide PK-(Tmax)|Lenalidomide PK-AUC(0-t)|Lenalidomide PK-AUC(0-∞)|Lenalidomide PK-(T1/2)|Temsirolimus and Sirolimus PK-AUC (0-24)|Temsirolimus and Sirolimus PK-(Cmax)|Temsirolimus and Sirolimus PK-(Tmax)|Temsirolimus and Sirolimus PK-(AUC 0-t)|Number of participants with adverse events","Celgene|Covance","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-5013-CP-011","October 1, 2012","January 1, 2013","January 1, 2013","October 24, 2012",,"November 8, 2019","Covance Clinical Research Unit Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01712828"
259,"NCT01712789","Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma","STRATUS","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone","Adverse Events|PK-Cmax|PK-AUC|PK-Cmin|Overall response rate|Time to response|Duration of response|Progression-free survival|Time to progression|Overall survival|POM population pharmacokinetics and exposure-response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","682","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-010|2012-001888-78","November 6, 2012","December 11, 2019","December 11, 2019","October 24, 2012",,"May 9, 2019","Medical University of Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|Wilhelminenspital Vienna, Vienna, Austria|Medical University of Vienna, Vienna, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|VUB Vrije Universiteit Brussel, Brussel, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|CHU Mont -Godinne, Yvoir, Belgium|Aarhus University Hospital, Aarhus, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Tartu University Hospital Clinic, Tartu, Estonia|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Turku University Hospital, Turku, Finland|Centre Hospitalier de la cote basque, Bayonne, France|Hopital Henri Mondor, Créteil, France|Hopital A. Michallon, La Tronche, France|CHRU Claude Huriez, Lille, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|CHU Hotel Dieu, Nantes, France|Hopital Saint Antoine, Paris, France|Service Hemato-Immunologie Hopital St Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|CHU de Reims, Reims cedex, France|Hematologie - CHU Purpan, Toulouse, France|CHRU Hopital Bretonneau, Tours cedex, France|CHU Nancy Hematology, Vandoeuvre les Nancy, France|Charite, Campus Benjamin Franklin Universitatsmedizin Berlin, Berlin, Germany|Klinikum Chemnitz, Chemnitz, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie, Dusseldorf, Germany|Universitatsklinikum Essen-, Essen, Germany|Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, Germany|Abt Haematologie - Onkologie / Allg. Krankenhaus Altona, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitatsklinikum Jena, Jena, Germany|University of Schleswig Holstein, Kiel, Germany|Klinikum der Universitat zu Koln, Köln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Universitatsklinik MuensterMedizinische Klinik A, Muenster, Germany|TU München - Klinikum rechts der Isar, München, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|University Hospital of Ulm, Ulm, Germany|Universitatsklinikum Wurzburg, Würzburg, Germany|University of Athens, Athens, Greece|Cork University HospitalHaematology Consultant, Wilton, Cork, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Ospedali Riuniti di Ancona, Ancona, Italy|A.O. Policlinico - Università di Bari, Bari, Italy|University of Bologna, Bologna, Italy|Ospedale Ferrarotto, Catania, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Milano, Italy|Universita degli Studi di Padova, Padova, Italy|Casa di Cura La Maddalena, Palermo, Italy|Ospedale Civile di Piacenza, Piacenza, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Universita degli Studi di Roma La Sapienza - Azienda Policlinico Umberto I, Roma, Italy|Ospedale Sant'Eugenio, Rome, Italy|Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette, Torino, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Ospedale San Bortolo, Vicenza, Italy|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Haga Hospital, Den Haag, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Oslo University Hospital, Rikshospitalet HF, Oslo, Norway|St. Olavs Hospital Trondheim, Trondheim, Norway|Akademia Medyczna w Gdansku Katedra i Klinika Hematologii i Transplantologii, Gdansk, Poland|Szpitala Uniwersyteckiego w. Krakowie, Kraków, Poland|Instytut Hematologii i Transfuzjologii w Warszawie, Warszawa, Poland|Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Hospital Geral de Santo António - Serviço de Hematologia Clínica, Porto, Portugal|University Hospital Bratislava - Hospital Ss Cyril and Methodius, Bratislava, Slovakia|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Canarias, La Laguna (Tenerife), Spain|Hospital de La Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital Morales Meseguer, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital de Donosti, San Sebastián (Guipuzcoa), Spain|Hospital Clinico Universitario De Santiago De Compostela, Santiago De Compostela, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Universitetssjukhuset i Lund, Lund, Sweden|Karolinska University HospitalSolna, Stockholm, Sweden|Universitatsspital Bern, Bern, Switzerland|Hopitaux Universitaires de Geneve-HUG, Genèva, Switzerland|University Hospital Zurich, Zurich, Switzerland|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Ege University Medical School, Izmir, Turkey|Belfast City Hospital Haematology Department, Belfast Northern Ireland, United Kingdom|Kent and Canterbury Hospital, Canterbury/Kent, United Kingdom|Leeds Teaching Hospitals Trust, Leeds, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Newcastle Hospital Foundation Trust, Newcastle upon Tyne, United Kingdom|Royal Marsden Hospital, Sutton (Surrey), United Kingdom|Southmead Hospital, Westbury-on-Trym/ Bristol, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01712789"
260,"NCT01707407","A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects","DDI","Completed","No Results Available","Pharmacology, Clinical|Healthy","Drug: Pomalidomide|Drug: Ketoconazole|Drug: Fluvoxamine|Drug: Carbamazepine","PK-Cmax|PK-Tmax|PK-AUC|PK-(T1/2)|PK-CL/F|PK-Vz/F|Adverse Events","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-4047-CP-008","September 1, 2012","November 1, 2012","November 1, 2012","October 16, 2012",,"November 11, 2019","Covance Research Unit, Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01707407"
261,"NCT01698801","A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide|Drug: dexamethasone","Overall Response Rate|Time to Response|Duration of Response|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants With Adverse Events","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-025","October 1, 2012","November 26, 2013","June 26, 2018","October 3, 2012","December 3, 2014","November 8, 2018","Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|Kameda Medical Center, Kamogawa, Chiba, Japan|Japanese Red Cross Narita Hospital, Narita, Chiba, Japan|Ehime University Hospital, Touon, Ehime, Japan|Nishigunma National Hospital, Shibukawa, Gunma, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Iwate Medical University, Morioka, Iwate, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, Japan|Kinki University Hospital, Faculty of Medicine, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto, Shizuoka, Japan|National Disaster Medical Center, Tachikawa, Tokyo, Japan|Kagoshima Medical Center, Kagoshima, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama Medical Center, Okayama, Japan|Osaka Red Cross Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan|Japanese Red Cross Medical Center, Tokyo, Japan|Keio University Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01698801"
262,"NCT01692184","Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292",,"Completed","No Results Available","Healthy","Drug: 50 mg AVL-292|Drug: 100 mg AVL-292|Drug: 200 mg AVL-292|Drug: 350 mg AVL-292|Drug: Placebo capsules","Adverse Events|PK-(Cmax)|PK-(AUC)|Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","AVL-292-004","August 1, 2012","October 8, 2012","October 8, 2012","September 25, 2012",,"November 4, 2019","Covance Clinical Research Unit, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01692184"
263,"NCT01690299","Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis",,"Completed","Has Results","Psoriasis|Psoriatic Arthritis","Drug: Apremilast|Drug: Etanercept|Drug: Placebo tablet|Drug: Placebo injection","Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline|Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16|Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16|Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16|Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16|Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16|Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-exposure Period|Psoriasis Flare/Rebound","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-010|2012-000859-14","October 1, 2012","July 3, 2014","April 4, 2016","September 21, 2012","August 4, 2015","June 8, 2017","Arizona Research Center, Phoenix, Arizona, United States|Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, United States|University of California Irvine-Department of Dermatology, Irvine, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Horizons Clinical Research, Denver, Colorado, United States|George Washington University, Washington, D.C., District of Columbia, United States|Florida Center for Dermatology, PA, Jacksonville, Florida, United States|Florida Academic Dermatology Center, Miami, Florida, United States|International Dermatology Research, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Atlanta Dermatology, Vein and Research Center, PC, Alpharetta, Georgia, United States|NorthShore University HealthSystem, Skokie, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Dermatology and Advanced Aesthetics, Lake Charles, Louisiana, United States|Lawrence Green, MD, LLC, Rockville, Maryland, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Robert Wood Johnson Medical School, Somerset, New Jersey, United States|Forest Hills Dermatology Group, Forest Hills, New York, United States|NYU Department of Dermatology, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Tennesse Clinical Research Center, Nashville, Tennessee, United States|Teckton Research, Austin, Texas, United States|The Education and Research Foundation, Lynchburg, Virginia, United States|Virginia Clinical Research Inc, Norfolk, Virginia, United States|Dermatology Associates of Seattle, Seattle, Washington, United States|The Skin Centre, Benowa, Queensland, Australia|Sinclair Dermatology, East Melbourne, Victoria, Australia|Fremantle Dermatology, Fremantle, Western Australia, Australia|Gairdner Hospital, Victoria Park, Australia|Rheumatology unit Ward 5C Queen Elizabeth Hospital, Woodville, Australia|Veracity Clinical Research, Woolloongabba, Australia|Cliniques Universitaires St-Luc, Brussels, Belgium|University Hospital Ghent, Ghent, Belgium|University Hospital of Liege CHU Liege, Liege, Belgium|Eastern Canada Cutaneous Research Associates Ltd, Halifax, Nova Scotia, Canada|Skin Center for Dermatology, Peterborough, Ontario, Canada|K. Papp Clinical Research Inc., Waterloo, Ontario, Canada|Siena Medical Research, Montreal, Quebec, Canada|Q & T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Dorothea, Kožní a korektivne dermatologické pracovište, Chomutov, Czechia|Dermamedica, Nachod, Czechia|Východoceské dermatologické centrum Homea s.r.o., Pardubice, Czechia|Krajská nemocnice Pardubice, Kožní oddelení, Pardubice, Czechia|Dermatovenerologicka ambulance, Svitavy, Czechia|Koznia zilni ambulance, Ústí nad Labem, Czechia|South Estonian Hospital Ltd, Meegomäe Village, Võru county, Estonia|Dermatology Clinic of Tartu University Hospital, Tartu, Estonia|Psoriasis Study Center, Berlin, Germany|Dermatologische Praxis, Berlin, Germany|Klinische Forschung Berlin - Buch GmbH, Berlin, Germany|University Hospital Carl Gustav Carus, Dresden, Germany|Hautklinik Universitatsklinikum Erlangen, Erlangen, Germany|University Hospital Frankfurt, Frankfurt, Germany|SCIderm GmbH, Hamburg, Germany|Institute for Health Services Research in Dermatology and Nursing - IVDP, University Medical Center, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|UniversitatsKlinikum Leipzig A.o.R., Leipzig, Germany|Comprehensive Center of Inflammatory Medicine (CCIM) University Medical Center Schleswig-Holstein, Lübeck, Germany|Gemeinschaftspraxis Mahlow, Mahlow, Germany|University Hospital Munster, Münster, Germany|Praxis fr Dermatologie und Venerologie, Wuppertal, Germany|Tolna Megyei Balassa Janos Korhaz, Szekszárd, Hungary|Allergo-Derm Bakos Kft., Szolnok, Hungary|LTD M & M centrs, Adazi, Latvia|Arija's Ancane's Family Doctor Private Practice, Baldone, Latvia|Riga 1st Hospital Skin and Sexually Transmitted Diseases Clinical Centre, Riga, Latvia|Adoria Ltd, Riga, Latvia|Family Doctor's Indra's Kenina's Practice, Riga, Latvia|Health Center of Talsi Ltd, Talsi, Latvia|Academic Medical Center, Amsterdam, Netherlands|Radboud University Medical Centre, Nijmegen, Netherlands|University Hospital of Wales, Cardiff, United Kingdom|Leeds Teaching Hospitals Trust, Leeds, United Kingdom|Whipps Cross University Hospital, London, United Kingdom|St Helier Hospital, London, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01690299"
264,"NCT01688011","Connect® MDS/AML Disease Registry",,"Recruiting","No Results Available","Myelodysplastic Syndromes|Acute Myeloid Leukemia",,"Patient Demographics|Diagnostic and Treatment Patterns|Safety and Effectiveness|Patient Reported Outcome|Correlative Studies","Celgene","All","18 Years and older   (Adult, Older Adult)",,"2100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Connect® MDS/AML Registry","December 12, 2013","December 12, 2022","December 12, 2030","September 19, 2012",,"October 25, 2019","ONCOLOGY SPECIALTIES, PC - Clearview Cancer Institute, Huntsville, Alabama, United States|DCH Health System (Lewis and Faye Manderson Cancer Center), Tuscaloosa, Alabama, United States|Arizona Oncology, Phoenix, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Clopton Clinic of Jonesboro, Inc., Jonesboro, Arkansas, United States|NEABC- Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|CARTI, Little Rock, Arkansas, United States|Alta Bates Summit Comprehensive Cancer, Berkeley, California, United States|Sutter East Bay Hospitals (dba Jordan Research and Education Institute - REDI), Berkeley, California, United States|John Muir Clinical Research Center, Concord, California, United States|Robert A. Moss, M.D.,F AC.P, Inc, Fountain Valley, California, United States|VA Central California Health Care System, Fresno, California, United States|Marin Cancer Care, Greenbrae, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Pacific Cancer Care, Monterey, California, United States|HealthCare Alliance (UHA), Pleasanton, California, United States|Mercy Cancer Center, Sacramento, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|St. Joseph's Regional Cancer Center, Stockton, California, United States|Ashwin Kashyap MD, INC., Thousand Oaks, California, United States|Saint Joseph Hospital, Cancer Centers of Colorado, Denver, Colorado, United States|Regional Cancer Care Associates, Manchester, Connecticut, United States|Bennett Cancer Center Stamford Hospital, Stamford, Connecticut, United States|Delaware Clinical and Laboratory Physicians, Christiana, Delaware, United States|MedStar Health Research Institute (Washington), Washington, District of Columbia, United States|University Cancer Institute, Boynton Beach, Florida, United States|Halifax Health Center for Oncology, Daytona Beach, Florida, United States|Broward Oncology Associates, Fort Lauderdale, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Southeast FL Hematology Oncology Grp, Fort Lauderdale, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|21st Century Oncology, Orange Park, Florida, United States|Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States|Memorial Healthcare System, Pembroke Pines, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Cancer Care Centers of Brevard, Rockledge, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Space Coast Medical Associates, Titusville, Florida, United States|Indian River Memorial Hospital Scully Welsh Cancer Center, Vero Beach, Florida, United States|Bond Clinic, Winter Haven, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Piedmont Cancer Institute, P.C. (was Peachtree Hematology-Oncology Consultants), Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Georgia Regents University Cancer Center, Augusta, Georgia, United States|Southeast Georgia Health System, Brunswick, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Hektoen Inst for Medical Resrch on behalf of itself and John H Stroger Hosp, Chicago, Illinois, United States|RUSH University Cancer Center, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|DuPage Medical Group - Oncology (University of Rodchester), Hinsdale, Illinois, United States|Joliet Oncology Hematology Associates Ltd, Joliet, Illinois, United States|Oncology Specialists, SC, Niles, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|St. Vincent Anderson Regional Hospital Research, Anderson, Indiana, United States|IU health Bloomington Hospital, Bloomington, Indiana, United States|Horizon Oncology Research, Inc, Lafayette, Indiana, United States|Floyd Memorial Cancer Center of Indiana, New Albany, Indiana, United States|Oncology Hematology Associates of Southwest Indiana, Newburgh, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Good Samaritan Hospital - Wabash Valley Clinical Research Center, Vincennes, Indiana, United States|McFarland Clinic, P.C, Ames, Iowa, United States|Siouxland Hematology-Oncology Associates, Sioux City, Iowa, United States|Covenant Clinic, Waterloo, Iowa, United States|Cotton O'Neil Clinical Research/ Stormont Vail Health, Topeka, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Baptist Health Systems, Inc., DBA Baptist, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center (Baton Rouge), Baton Rouge, Louisiana, United States|Our Lady of the Lake Physician Group-Medical Oncology, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center at St. Tammany, Covington, Louisiana, United States|Maine Research Associates/Central Maine Medicine, Lewiston, Maine, United States|Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology, Columbia, Maryland, United States|Western Maryland Health System, Cumberland, Maryland, United States|UM St. Joseph's Medical Center, Towson, Maryland, United States|Carroll Regional Cancer Center, Westminster, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Boone Hospital Center, Columbia, Michigan, United States|Oakwood Healthcare Inc., Dearborn, Michigan, United States|John D. Dingell VA Medical Center /Cynthia Marbury, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Ascension St. John Hospital_Hematology (was St. Johns Hospital and Hematology-Oncology Associates East PC ), Grosse Pointe Woods, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Michigan State University/Breslin Cancer Center, Lansing, Michigan, United States|St. John Providence Hospital System, Southfield, Michigan, United States|Togus Va Medical Center, Augusta, Minnesota, United States|Essentia Health Oncology Clinical Trials, Duluth, Minnesota, United States|Southdale Cancer Clinic, Edina, Minnesota, United States|Metro MN CCOP/Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Metro MN CCOP/Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States|MCDA - Central Care Center, Bolivar, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Harry S Truman Memorial Veterans' Hospital, Columbia, Missouri, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Mercy Cancer Center - Joplin, Joplin, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Heartland Regional Medical Center (Heartland Health), Saint Joseph, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Cancer - St. Louis, Saint Louis, Missouri, United States|Mercy Research - Springfield, Springfield, Missouri, United States|Billings Clinic, Billings, Montana, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Montana Cancer Institute Foundation, Missoula, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|VA Medical Center Manchester, Manchester, New Hampshire, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|John Theurer Cancer Center (Hackensack U Med Center), Hackensack, New Jersey, United States|Hematology-Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|St Joseph Healthcare System, Paterson, New Jersey, United States|Somerset Medical Center 110 Rehill Avenue, Somerville, New Jersey, United States|Sparta Cancer Center, Sparta, New Jersey, United States|Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States|New York Cancer and Blood Specialists, Bronx, New York, United States|Maimonides Cancer Center, Brooklyn, New York, United States|Bassett Heathcare Network, Cooperstown, New York, United States|Hematology Oncology Associates of Central NY, East Syracuse, New York, United States|C.R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States|Huntington Medical Group, Huntington Station, New York, United States|Weill Cornell Medical College, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|University of Rochester ~ Wilmot Cancer Institute, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|New York Medical College, Valhalla, New York, United States|Ccs Oncology, Williamsville, New York, United States|Leo W Jenkins Cancer Center, Greenville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|TriHealth, Good Samaritan Hospital, Cincinnati, Ohio, United States|University Hospitals, Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center, Columbus, Ohio, United States|Dayton Physicians, Kettering, Ohio, United States|University of Toledo Medical Center (Utmc), Toledo, Ohio, United States|INTEGRIS Cancer Institute Southwest Medical Center, Oklahoma City, Oklahoma, United States|INTEGRIS Cancer Institute of Oklahoma Proton Campus, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialist and Research Institute, Tulsa, Oklahoma, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Providence Cancer Center, Portland, Oregon, United States|Salem Health, Salem, Oregon, United States|Consultants in Medical Oncology and Hematology, Drexel Hill, Pennsylvania, United States|Hematology and Oncology Assoc of NEPA, Dunmore, Pennsylvania, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Allegheny Singer Research Institute (was West Penn Hospital), Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Cancer Care Associates of York, York, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Prairie Lakes Health Systen, Inc, Watertown, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|University of Tennessee Medical Center Cancer Intitute, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Hendrick Cancer Center, Abilene, Texas, United States|BSL Health System (Harrington Cancer Center), Amarillo, Texas, United States|Texas Oncology, Amarillo Cancer Center, Amarillo, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Christus Spohn Cancer Center, Corpus Christi, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|HOLD - Texas Oncology, Dallas, Dallas, Texas, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States|UTMB Galveston, Galveston, Texas, United States|Oncology and Hematology of South Texas, PA, Laredo, Texas, United States|Southwest Cancer Treatment & Research Center, Lubbock, Texas, United States|Texas Oncology, McAllen (plus 2 satelite sites), McAllen, Texas, United States|Texas Oncology, Midland, Midland, Texas, United States|Scott & White Healthcare, Round Rock, Texas, United States|Baylor Research Institute dba Scott & White Memorial Hospital, Temple, Texas, United States|Blood and cancer Center of East Texas, Tyler, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|Foley Cancer Center/RRMC, Rutland, Vermont, United States|VA Medical Center - White River Junction, White River Junction, Vermont, United States|Lynchburg Hematology Oncology Clinic, Lynchburg, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|PeaceHealth St Joseph Cancer Center, Bellingham, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Kadlec Regional Medical Center (KRMC), Kennewick, Washington, United States|Vista Oncology Inc. PS, Olympia, Washington, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Bellin Memorial Hospital/ Bellin Cancer Team, Green Bay, Wisconsin, United States|Gundersen Lutheran Inc, La Crosse, Wisconsin, United States|Froedtert & Medical College of Wisconsin CLCC, Milwaukee, Wisconsin, United States|Columbia St. Mary'S, Milwaukee, Wisconsin, United States|Wheaton Franciscan Cancer Care - All Saints, Racine, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Memorial Hospital of Laramie County dba Cheyenne Regional Medical Center, Cheyenne, Wyoming, United States|Puerto Rico Hematology Oncology Group, Bayamon, Puerto Rico|VA Caribbean Healthcare System CRADA, San Juan, Puerto Rico|Fundacion de lnvestigaci6n, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01688011"
265,"NCT01666444","VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",,"Completed","Has Results","Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo","Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs)","Celgene|Gynecologic Oncology Group","Female","18 Years and older   (Adult, Older Adult)","Phase 2","297","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GOG-3003","October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01666444"
266,"NCT01647516","Efficacy and Safety Study of RPC1063 in Ulcerative Colitis",,"Active, not recruiting","No Results Available","Ulcerative Colitis","Drug: RPC1063|Drug: placebo","Remission","Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-202","December 12, 2012","October 8, 2014","August 31, 2019","July 23, 2012",,"July 16, 2019","Anaheim Clinical Trials, Anaheim, California, United States|Alliance Clinical Research, Oceanside, California, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|UMHAT Sv Ivan Rilski EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria|Military Medical Academy, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sofiamed, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|Evaggelismos General Hospital, Athens, Greece|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Pannonia Maganorvosi Centrum, Budapest, Hungary|Vasútegészségügyi Nonprofit Kiemelten Közhasznú Kft. Debreceni Egészségügyi Központja, Debrecen, Hungary|Barzilai Medical Center, Ashkelon, Israel|Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Yeungnam University Medical Center, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Wonju Christian Hospital, Wonju, Korea, Republic of|Academisch Medisch Centrum, Amsterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Hutt Valley District Health Board, Lower Hutt, New Zealand|Niepubliczny Zaklad Opieki Zdrowotnej INTERMED, Czestochowa, Poland|Elblaski Szpital Specjalistyczny z Przychodnia, Elblag, Poland|Economicus - NZOZ ALL-MEDICUS, Katowice, Poland|Centrum Opieki Zdrowotnej Orkan Med, Ksawerow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej CENTRUM MEDYCZNE Szpital Swietej Rodziny, Lodz, Poland|Instytut Medycyny Wsi, Lublin, Poland|MEDICOR Centrum Medyczne, Rzeszow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warsaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Triclinium, Warszawa, Poland|Regional Clinical Hospital, Krasnoyarsk, Russian Federation|Nizhegorodskaya Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|SBEI of HPE Omsk State Medical Academy Ministry of healthcare of RF, Omsk, Russian Federation|SEIHPE Rostov State Medical University of MoH of RF, Rostov on Don, Russian Federation|Russian Medical Military Academy na SMKirov, Saint Petersburg, Russian Federation|City Hospital 26, Saint Petersburg, Russian Federation|Medical Company Hepatolog, Samara, Russian Federation|Slovak Research Center, Ilava, Slovakia|Specializovana Nemocnica Svorada Zobor, Nitra, Slovakia|GASTRO I., s.r.o., Presov, Slovakia|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk City Clinical Hospital #1 Dep of Surgery SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|Institute of Therapy n.a. L.T. Maloy of NAMS of Ukraine, Kharkiv, Ukraine|Kyiv CCH #8 Dept of Gastroenterology P.L. Shupyk NMA of PGE, Kyiv, Ukraine|Order of the Red Star MMMCC MMCH Clinic of Gastroenterology, Kyiv, Ukraine|CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv, Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU, Lviv, Ukraine|Vinnytsia Regional Clinical, Vinnytsia, Ukraine|Medical Clinical Research Center ""Health Clinic"", Vinnytsya, Ukraine|Zaporizhzhya city multidisciplinary clinical hospital #9, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01647516"
267,"NCT01634191","Pharmacokinetics of Apremilast (CC-10004) in Healthy Elderly Subjects",,"Completed","No Results Available","Healthy Volunteer","Drug: Apremilast","AUC0-24|Cmax|Tmax|AUC0-t|AUC0-∞|t1/2|Number or participants with adverse events","Celgene","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-10004-CP-024","February 1, 2012","March 1, 2012","April 1, 2012","July 6, 2012",,"November 11, 2019","PRA International, Lenexa, Kansas, United States|Clinical Development Services, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01634191"
268,"NCT01634178","Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteer","Drug: Apremilast","AUC0-24|Cmax|Tmax|AUC0-t|AUC0-∞|t1/2|Number of participants with Adverse Events","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-10004-CP-022","February 1, 2012","March 1, 2012","March 1, 2012","July 6, 2012",,"November 11, 2019","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01634178"
269,"NCT01632826","Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma","PEXIUS","Approved for marketing","No Results Available","Multiple Myeloma","Drug: Pomalidomide",,"Celgene","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"CC-4047-MM-009",,,,"July 3, 2012",,"November 11, 2019","Celgene Study Site, Duarte, California, United States|Celgene Study Site, Greenbrae, California, United States|Celgene Study Site, Los Angeles, California, United States|Celgene Study Site, Denver, Colorado, United States|Celgene Study Site, West Palm Beach, Florida, United States|Celgene Study Site, Marietta, Georgia, United States|Celgene Study Site, Peoria, Illinois, United States|Celgene Study Site, Indianapolis, Indiana, United States|Celgene Study Site, Iowa City, Iowa, United States|Celgene Study Site, Baltimore, Maryland, United States|Celgene Study Site, Hyannis, Massachusetts, United States|Celgene Study Site, Saint Louis, Missouri, United States|Celgene Study Site, Omaha, Nebraska, United States|Celgene Study Site, Hackensack, New Jersey, United States|Celgene Study Site, New York, New York, United States|Celgene Study Site, New York, New York, United States|Celgene Study Site, Philadelphia, Pennsylvania, United States|Celgene Study Site, Sellersville, Pennsylvania, United States|Celgene Study Site, Greenville, South Carolina, United States|Celgene Study Site, Sioux Falls, South Dakota, United States|Celgene Study Site, Dallas, Texas, United States|Celgene Study Site, Houston, Texas, United States|Celgene Study Site, Salt Lake City, Utah, United States|Celgene Study Site, Morgantown, West Virginia, United States|Celgene Study Site, Milwaukee, Wisconsin, United States|Celgene Study Site, Calgary, Alberta, Canada|Celgene Study Site, Edmonton, Alberta, Canada|Celgene Study Site, Vancouver, British Columbia, Canada|Celgene Study Site, Victoria, British Columbia, Canada|Celgene Study Site, Winnipeg, Manitoba, Canada|Celgene Study Site, St. John's, Newfoundland and Labrador, Canada|Celgene Study Site, Halifax, Nova Scotia, Canada|Celgene Study Site, Hamilton, Ontario, Canada|Celgene Study Site, London, Ontario, Canada|Celgene Study Site, Ottawa, Ontario, Canada|Celgene Study Site, Toronto, Ontario, Canada|Celgene Study Site, Windsor, Ontario, Canada|Celgene Study Site, Montreal, Quebec, Canada|Celgene Study Site, Montreal, Quebec, Canada|Celgene Study Site, Montreal, Quebec, Canada|Celgene Study Site, Quebec City, Quebec, Canada|Celgene Study Site, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT01632826"
270,"NCT01628393","Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study)",,"Completed","No Results Available","Relapsing Multiple Sclerosis","Drug: RPC1063|Drug: placebo","Total number of new GdE lesions, assessed on brain MRIs","Celgene","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPC01-201-PartA|2012-002714-40","September 18, 2012","April 15, 2014","May 3, 2016","June 26, 2012",,"June 6, 2019","Alta Bates Summit Medical Center, Berkeley, California, United States|Neuro Pain Medical Center, Fresno, California, United States|University of California Davis Medical Center, Sacramento, California, United States|The Neurological Institute PA, Charlotte, North Carolina, United States|Neurology and Neuroscience Associates Inc., Akron, Ohio, United States|The Polyclinic, Seattle, Washington, United States|Cliniques Universitaires St-Luc, Brussels, Belgium|Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia, Bulgaria|Sarajishvili Institute of Neurology, Tbilisi, Georgia|LTD MediClubGeorgia, Tbilisi, Georgia|Khechinashvili University Hospital, Tbilisi, Georgia|Evaggelismos General Hospital, Athens, Greece|401 Military Hospital of Athens, Athens, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece|Vaszary Kolos Korhaz, Esztergom, Hungary|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Cantania, Italy|Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi, Czeladz, Poland|Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego, Grudziadz, Poland|Novo-Med Zielinski i wsp. Sp.J., Katowice, Poland|NEURO- CARE Site Management Organization Gabriela Klodowska-Duda, Katowice, Poland|NEURO MEDIC Janusz Zbrojkiewicz, Katowice, Poland|RESMEDICA Spolka z o.o., Kielce, Poland|Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny, Konstancin Jeziorna, Poland|Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny, Lublin, Poland|Centrum Neurologii Krzysztof Selmaj, Lódzkie, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, Poland|Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, Plewiska, Poland|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON, Podlaskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy, Poznan, Poland|EUROMEDIS Sp. z.o.o., Szczecin, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski, Warminsko-mazurskie, Poland|Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warsaw, Poland|Centralny Szpital Kliniczny MSWIA, Warsaw, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Health Club Medical Center S.R.L., Campulung, Romania|Rehabilitation Clinical Hospital, Cluj-Napoca, Romania|Colentina Clinical Hospital, Napoca, Romania|Timisoara Emergency County Clinical Hospital, Timisoara, Romania|Republican Clinical Hospital for Rehabilitation Treatment, Kazan, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|City Clinical Hospital 4, Saransk, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Hospital Centre Zemun, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Hospital Donostia, San Sebastian, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Municipal Medical & Preventive Institution Chernigiv Regional Clinical Hospital, Chernigiv, Ukraine|Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov, Dnipropetrovsk, Ukraine|Regional Clinical Hospital, Ivano Frankivsk, Ukraine|State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya, Kharkiv, Ukraine|Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko, Vinnytsya, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01628393/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01628393/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01628393"
271,"NCT01611467","A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects","AME/FE","Completed","No Results Available","Safety and Pharmacokinetics in Healthy Volunteer Subjects","Drug: CC-223","Total radioactivity|Cumulative excretion of radioactivity|Total radioactivity ratios|Metabolite concentration|Cmax|Tmax|AUC|t1/2|Adverse Events","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-223-CP-002","June 1, 2012","July 1, 2012","July 1, 2012","June 5, 2012",,"November 11, 2019","Covance Research Unit, Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01611467"
272,"NCT01599325","Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome",,"Completed","Has Results","Myelodysplastic Syndrome (MDS)","Drug: Azacitidine","Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.|Percentage of Participants With a Hematologic Response Using IWG Criteria for MDS and Assessed by the Investigator|Percentage of Participants Achieving a Hematologic Improvement (HI) Based on 2000 IWG Response Criteria for MDS and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.|The Number of Units of Platelet Transfusions by Cycle|The Number of Platelet Transfusions by Cycle|The Number of Units of Red Blood Cell (RBC) Transfusions by Cycle|The Number of RBC Transfusions by Cycle|The Number of Infections (Post-baseline Average) Requiring Intravenous (IV) Antibiotics, Anti-fungals, or Antivirals by Cycle|Kaplan Meier Estimates for Overall Survival (OS)|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Parent Phase|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine|Maximum Observed Plasma Concentration (Cmax) of Azacitidine|Time to Maximum Plasma Concentration (Tmax) of Azacitidine|Terminal Phase of Half-life (T1/2) of Azacitidine|Apparent Total Plasma Clearance (CL/F) of Azacitidine|Apparent Volume of Distribution (Vd/F) of Azacitidine|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Extension Phase","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-MDS-002","July 24, 2012","January 29, 2015","March 13, 2018","May 16, 2012","February 29, 2016","March 19, 2019","Peking University People's Hospital, Beijing, China|The 301 Hospital- Chinese PLA General Hospital, Beijing, China|The Third Hospital of Peking University, Beijing, China|West China Hospital of Sichuan University, Chengdu, China|Guangdong General Hospital, Guangzhou, China|1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Shanghai 6th Hospital, Shanghai, China|The 1st Hospital of Soochow University, Suzhou, China|Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China|Wuhan Union Hospital, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT01599325"
273,"NCT01593410","Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone","Overall Response Rate|Adverse Events|Progression Free Survival (PFS)|Overall Survival|Response duration|Maximum observed concentration in plasma|Area under the plasma concentration-time curve|Time to maximum concentration|Terminal half-life|Apparent total body clearance|Apparent volume of distribution","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","194","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-021","August 1, 2010","January 3, 2013","January 3, 2013","May 8, 2012",,"September 20, 2017","307 Hospital of Chinese PLA, Beijing, China|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|Xiangya Hospital of Central- South University, Changsha, China|Guangdong General Hospital, Guangzhou, China|Nanfang Hospital of Southern Medical University, Guangzhou, China|The First Hospital Affiliated of College Medicine, Zhejiang University, Hangzhou, China|The First Hospital Affiliated of College Medicine, Zhejiang University, Hangzhou, China|Shanghai Changzheng Hospital, Shanghai, China|Shanghai 6th People's Hospital, Shanghai, China|Changhai Hospital, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China",,"https://ClinicalTrials.gov/show/NCT01593410"
274,"NCT01583374","Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis","POSTURE","Completed","Has Results","Ankylosing Spondyloarthritis","Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo","Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","490","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CC-10004-AS-001|2011-001555-37","May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","November 7, 2019","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01583374"
275,"NCT01583283","Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: ACY-1215|Drug: lenalidomide|Drug: Dexamethasone","To determine DLT of ACY-1215 administered in combination with lenalidomide and dexamethasone in patient with relapsed/refractory MM|To determine MTD of ACY-1215 administered in combination with lenalidomide and dexamethasone in patient with relapsed/refractory MM|Objective Response Rate of ACY-1215|Duration of Response|Adverse Events (AEs)|Disease Control Rate|Progression-free Survival|Evaluate the pharmacodynamics of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory MM|Pharmacokinetic- Cmax|Pharmacokinetic- Cmin|Pharmacokinetic- Tmax|Pharmacokinetic- AUC|Pharmacokinetic- t1/2","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-MM-101","July 12, 2012","December 31, 2019","December 31, 2019","April 24, 2012",,"April 23, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01583283"
276,"NCT01575925","Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)","POM Renal","Active, not recruiting","No Results Available","Multiple Myeloma|Renal Impairment","Drug: 4 mg Oral POM + 40 mg Oral DEX|Drug: 2 mg Oral POM + 40 mg Oral DEX","PK-Area under the plasma concentration time curve (AUC)|PK-Time to maximum plasma concentration (Cmax)|PK-Apparent total body clearance (CL/F)|PK-Renal clearance (CLr)|PK-Apparent volume of distribution (V/F)|PK-Effective terminal half-life (T1/2)|Number of participants with adverse events (AEs)|Number of participants alive|Time to response|Duration of response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-008","June 1, 2012","June 11, 2021","June 11, 2021","April 12, 2012",,"January 21, 2019","Colorado Blood Cancer Institute, Denver, Colorado, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Ingalls Cancer Research Center, Harvey, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|L'Hotel Dieu de Quebec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01575925"
277,"NCT01571648","A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: Oral azacitidine","Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events|PK- Maximum concentration in plasma (Cmax)|PK- Time to maximum plasma concentration (Tmax)|PK-Elimination rate constant (Kel)|PK-Terminal half-life (T1/2,z)|PK-Area under the plasma concentration-time curve (AUC)|PK-Apparent total body clearance (CL/F)|PK-Apparent volume of distribution (Vz/f)|Safety (type, frequency, severity, number of participants with adverse events)|Efficacy (Hematologic response and hematologic improvement)","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-MDS-005","April 1, 2012","January 1, 2013","January 1, 2013","April 5, 2012",,"November 11, 2019","Celgene Trial Site, Fukuoka, Japan|Celgene Trial Site, Hiroshima, Japan|Celgene Trial Site, Nagoya, Japan|Celgene Trial Site, Osaka, Japan|Celgene Trial Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01571648"
278,"NCT01571635","Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.",,"Active, not recruiting","No Results Available","Beta Thalassemia Major|Beta Thalassemia Intermedia","Drug: Sotatercept 0.1mg/kg|Drug: Sotatercept 0.3mg/kg|Drug: Sotatercept 0.5mg/kg|Drug: Sotatercept 0.75mg/kg|Drug: Sotatercept 1.0mg/kg|Drug: Sotatercept 1.5mg/kg|Drug: SOTATERCEPT (ACE-011)","Potential Recommended Dose (PRD)|Actual Recommended Dose (RD)|Reduction of Transfusion Burden|Number of Participants with Adverse Events|PK-Observed Maximum Concentration (Cmax)|PK-Time to Maximum Concentration (Tmax)|PK-Area Under the Concentration-Time Curve (AUC)|PK-Concentration of Anti-Sotatercept Antibody in Serum|Hgb Level Increase|RBC Transfusion Burden|PK-Serum Concentration of Sotatercept","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-011-B-THAL-001|2011-005659-15","October 10, 2012","July 2, 2015","July 30, 2020","April 5, 2012",,"March 26, 2019","Hopital Henri Mondor, Créteil, France|Groupe Hospitalier Henri Mondor, Créteil, France|Hospital of Necker, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Laiko General Hospital, Ampelokipi - Athens, Greece|Universita degli Studi di Cagliari - ASL8, Cagliari, Italy|Universita Degli Studi Di Cagliari, Cagliari, Italy|Ospedale Galliera, Genoa, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione IRCCS Ospedale Maggiore, Milano, Italy|UCL Cancer Institute, London, United Kingdom|UCL Cancer Institue, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01571635"
279,"NCT01568294","Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: pomalidomide","Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events|Maximum observed plasma concentration (Cmax)|Time to maximum observed plasma concentration (tmax)|Area under the plasma concentration-time curve (AUC0-t)|Apparent total plasma clearance (CL/F)|Apparent total volume of distribution (Vz/F)|Estimate of the terminal elimination half-life in plasma (t1/2)|Safety (the number of participants with adverse events, incidence, severity, causality)|Progression-free survival|Myeloma response|Time to Response|Duration of Response","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-004","April 1, 2012","July 8, 2015","July 8, 2015","April 2, 2012",,"November 11, 2019","Nagoya City University Hospital, Nagoya, Aichi, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan|National Cancer Center Hospital, Tyuuou, Tokyo, Japan|Kyusyu University Hospital, Fukuoka, Japan|Kameda General Hospital, Kamogawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama Medical Center, Okayama, Japan",,"https://ClinicalTrials.gov/show/NCT01568294"
280,"NCT01566695","The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)",,"Active, not recruiting","No Results Available","Myelodysplastic Syndrome","Drug: Oral Azacitidine|Drug: Placebo","Red blood cell (RBC) transfusion independence|Hematological improvement-platelet response (HI-P)|Duration of RBC transfusion independence|Time to RBC transfusion independence|Progression to acute myeloid leukemia (AML)|Time to AML progression|Hematological improvement-erythroid response (HI-E)|Platelet-transfusion independence|Duration of platelet transfusion independence|Time to platelet transfusion independence|Hematologic response|Clinically significant bleeding events|Adverse Events (AEs)|Health-related quality-of-life|Healthcare resource utilization (HRU)|Number of patients alive","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZA-MDS-003|2012-002471-34","April 26, 2013","January 25, 2019","December 30, 2021","March 29, 2012",,"October 1, 2019","Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|Tower Hematology/Oncology Medical Group and Tower Cancer Research Found, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|California Cancer Associates for Research and Excellence cCARE, Escondido, California, United States|Marin Oncology Associates, Greenbrae, California, United States|UCSD-Thornton Hospital, La Jolla, California, United States|University of Southern California Norris Cancer Center, Los Angeles, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Florida Health Cancer Center at Orlando Health, Orlando, Florida, United States|Phoebe Cancer Center of Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Robert H Lurie Comprehensive Cancer Center NW Univ, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, J.G. Brown Cancer Center, Louisville, Kentucky, United States|Hematology and Oncology Specialists, LLC, Metairie, Louisiana, United States|Johns Hopkins Medicine, Baltimore, Maryland, United States|UMASS Memorial Hospital, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Jackson Oncology Associates PLLC, Jackson, Mississippi, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Kansas City VA Medical Center University of Kansas Medical Center, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Eastern Institute of Medical Sciences, Greenville, North Carolina, United States|University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|Michael Debakey VA Medical Center, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|VA Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Royal Prince Alfred Hospital, Sydney Cancer Centre, Camperdown, Australia|The Northern Hospital, Epping, VIC, Australia|St Vincent's Hospital Melbourne, Fitzroy, Australia|St George Hospital, Kogarah, Australia|Cabrini Hospital, Malvern, Australia|Haematoloy and Oncology Clinics of Australia, Milton, Brisbane, Australia|Calvary Mater New Castle, Waratah, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|UZ Leuven, Leuven, Belgium|Universidade Federal do Ceara, Fortaleza, Ceará, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|MS INCA HC I Hospital do Cancer I, Rio De Janeiro, Brazil|Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira, Sao Paulo, Brazil|University of Alberta Hospital Adult Hematology Research, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Victoria Hospital, Barrie, Barrie, Ontario, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|McGill University, Dept. Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|University Hospital Hradec Kralove, Hradec Králové, Czechia|University Hospital Olomouc, Olomouc, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|Aarhus University Hospital, Aarhus, Denmark|Onk.Dep., Odense Universitets hospital, Odense C, Denmark|Roskilde Hospital, Roskilde, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Turku University Hospital, Turku, Finland|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institute Paoli-Calmettes Service Haematology, Marseille Cedex 9, France|CHU Nantes Hotel Dieu, Nantes, France|Hospital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|CHRU Hôpital de Pontchaillou, Rennes Cedex, France|Centre Henri Becquerel, Rouen Cedex, France|Hopital Civil de Strasbourg, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Hopital Bretonneau, Tours, France|Gemeinschaftspraxis Haematologie-Onkologie, Dresden, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Marien Hospital, Duesseldorf, Germany|Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie, Dusseldorf, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Schleswig-Holstein, Keil, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|TU München - Klinikum rechts der Isar, München, Germany|University Hospital Tubingen, Tubingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Democritus University of Thrace, Alexandroupolis, Greece|Evangelismos General Hospital of Athens, Athens, Greece|Laiko General Hospital, Athens, Greece|Attikon General University Hospital of Athens, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|University of Patras, Patras, Greece|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Az. Osp. SS.Antonio e Biagio - SC Ematologia, Alessandria, Italy|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|U.O. Ematologia. Ospedale Oncologico di Riferimento Regionale Armando Businco, Cagliari, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|AUSL LE1 - Vito Fazzii Hospital Medical Oncology Department, Lecce, Italy|Opsedale Maggiore Policlinico and University, Milano, Italy|IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center, Milan, Italy|A.O.U. Maggiore della Carità, Novara, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale S. Chiara, Pisa, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|IRCCS Centro di Riferimento Oncologico di Basilicata, Rionero in Vulture, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Universitario ""A. Gemelli"", Roma, Italy|AO Santa Maria, Terni, Italy|Azienda Ospedaliera San Giovanni Battista, Torino, Italy|Ospedale Umberto I, Torrette Di Ancona, Italy|Policlinico Univeristario di Udine, Udine, Italy|Ospedale dell Angelo di Mestre, Venezia - Mestre, Italy|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Marys Hospital College of Medicine The Catholic University of Korea, Seoul, Korea, Republic of|Hospital Angeles Lomas - Consultorio 830, Huixquilucan de Degollado, Mexico|Hospital Universitario ""Dr. Jose E. Gonzalez"", Monterrey, Mexico|AVIX Investigacion Clinica, Monterrey, Mexico|Instituto Nacional de Cancerologia, Tlalpan, Mexico|VU University Medical Center, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|UMC St Radboud, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Helse Forde HF Central hospital, Førde, Norway|Oslo University Hospital, Rikshospitalet HF, Oslo, Norway|Szpital Uniwersytecki nr 2 im dr. Jana Biziela, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Specjalistyczny Szpital Miejski im. M. Kopernika w Toruniu, Torun, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Wroclaw, Poland|ULSBA (Unidade Local de Saúde do Baixo Alentejo, EPE) - Hospital de Beja, Beja, Portugal|Hospital Universitario de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Porto, Portugal|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall D Hebron, Barcelona, Spain|Complejo Hospitalario Universitario de Granada, Granada, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Seville, Spain|Hospital Txagorritxu - Hospital Universitario de Álava, Vitoria-Gasteiz, Álava, Spain|SU/Sahlgrenska, Section of Haematology and Coagulation, Goeteborg, Sweden|University Hospital in Lund, Lund, Sweden|Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Baskent University Medical Faculty Adana Practice and Research Center, Adana, Turkey|Antalya Egitim Arastirma, Antalya, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey|Istanbul University Faculty of Medicine, Istanbul, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|University Hospital of Wales - Cardiff, Cardiff, United Kingdom|Northwick Park Hospital, Harrow Middlesex, United Kingdom|Queens Centre for Oncology & Haematology, Hull, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool University Hospital, Prescot Street, Liverpool, United Kingdom|Barts and The London NHS Trust, London, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Nottingham City Hospital - Dept of Haematology, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01566695"
281,"NCT01561963","A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast",,"Completed","No Results Available","Healthy","Drug: Apremilast|Drug: Rifampin","Pharmacokinetic measures: area under the plasma concentration-time curve|Pharmacokinetic measures: area under the maximum observed plasma concentration","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CC-10004-CP-025","February 1, 2012","April 1, 2012","April 1, 2012","March 23, 2012",,"November 11, 2019","Quintiles, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01561963"
282,"NCT01559129","Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease",,"Terminated","Has Results","Scleroderma, Systemic|Sclerosis, Systemic|Systemic Scleroderma|Systemic Sclerosis|Interstitial Lung Disease","Drug: Pomalidomide (CC-4047)|Drug: Placebo","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52|Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52/Early Termination|Change From Baseline in University of California, Los Angeles, Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) Total Score at Week 52/Early Termination|Change From Baseline in Percent Predicted Forced Vital Capacity Over Time|Change From Baseline in Modified Rodnan Skin Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Total Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Reflux Subscale Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Distension/Bloating Subscale Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Fecal Soilage Subscale Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Diarrhea Subscale Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Social Functioning Subscale Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Emotional Well Being Subscale Score Over Time|Change From Baseline in UCLA SCTC GIT 2.0 Constipation Subscale Score Over Time|Change From Baseline in Dyspnea Functional Impairment at Week 12|Change From Baseline in Dyspnea Functional Impairment at Week 24|Change From Baseline in Dyspnea Functional Impairment at Week 52/Early Termination|Change From Baseline in Dyspnea Functional Impairment at Week 64|Change From Baseline in Dyspnea Functional Impairment at Week 76|Change From Baseline in Dyspnea Functional Impairment at Week 156/Early Termination|Change From Baseline in Dyspnea Magnitude of Task at Week 12|Change From Baseline in Dyspnea Magnitude of Task at Week 24|Change From Baseline in Dyspnea Magnitude of Task at Week 52/Early Termination|Change From Baseline in Dyspnea Magnitude of Task at Week 64|Change From Baseline in Dyspnea Magnitude of Task at Week 76|Change From Baseline in Dyspnea Magnitude of Task at Week 156/Early Termination|Change From Baseline in Dyspnea Magnitude of Effort at Week 12|Change From Baseline in Dyspnea Magnitude of Effort at Week 24|Change From Baseline in Dyspnea Magnitude of Effort at Week 52/Early Termination|Change From Baseline in Dyspnea Magnitude of Effort at Week 64|Change From Baseline in Dyspnea Magnitude of Effort at Week 76|Change From Baseline in Dyspnea Magnitude of Effort at Week 156/Early Termination|Oxygen Saturation Over Time|Pharmacokinetic Parameters of Pomalidomide in Plasma","Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CC-4047-SSC-001|2010-023047-15","August 9, 2012","November 3, 2016","November 3, 2016","March 21, 2012","October 18, 2019","October 18, 2019","UCLA Division of Rheumatology, Los Angeles, California, United States|Advances in Medicine, Rancho Mirage, California, United States|Delaware Medical Care Associates, LLC, Newark, Delaware, United States|Georgetown University School of Medicine, Washington, District of Columbia, United States|USF Health Faculty Office Building-FOB, Tampa, Florida, United States|Arthritis Research and Treatment Center, Stockbridge, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Louisiana State University, Shreveport, Louisiana, United States|Boston University of Medicine BUMC, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|UMDNJ-Robert Wood Johnson Medical School Clinical Research Center, New Brunswick, New Jersey, United States|North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Toledo College of Medicine, Toledo, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Monash Medical Centre, Clayton, Victoria, Australia|The Prince Charles Hospital, Chermside, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|CHRU de Lille FR, Lille, France|Hopital Saint Louis, Paris, France|Groupe Hospitalier Saint Vincent de Paul, Paris, France|Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|University of Erlangen-Nuremberg, Erlangen, Germany|Klinikum der J.W. Gothe-Universitat Frankfurt, Frankfurt, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|University Hospital of Ulm, Ulm, Germany|Azienda Ospedaliera Universitaria S. Martino di Genova, Genova, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Centrum Miriada Prywatny Gabinet Specjalistyczny Profesora Dra Stanislawa Sierakowskiego, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|SPSK Nr 7 Slaskiego Uniwersytetu Medycznego, Oddzial Chorob Wewnetrznych i Reumatologii, Katowice, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 im. prof.Tadeusza Sokolowskiego Pomorskiego UM w Szczec, Szczecin, Poland|Instytut Reumatologii, Klinika i Poliklinika Ukladowych Chorób Tkanki Lacznej, Warszawa, Poland|Akademicki Szpital Kliniczny Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw, Poland|Institution of the Russian Academy of Medical Sciences Research Institute of Rheumatology of the Ru, Moscow, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|St. Petersburg State Healthcare Institution ""Clinical Rheumatology Hospital # 25"", St. Petersburg, Russian Federation|Hospital Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|University Hospital Basel, Basel, Switzerland|Chapel Allerton Hospital, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital - Interstitial Lung Disease Unit, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01559129"
283,"NCT01545947","Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer","Drug: CC-223, erlotinib|Drug: CC-223, oral azacitidine","Adverse events|MTD|PK-Cmax|PK-AUC|PK-Tmax|PK-T1/2|PK-CL/F|PK-Vz/F|mTORC1 and mTORC2 pathway biomarkers|CC-223 metabolite, M1|Tumor Response Rate|Number of participants surviving without tumor progression","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-223-NSCL-001|2011-005290-23","May 1, 2012","December 11, 2014","December 11, 2014","March 7, 2012",,"November 11, 2019","Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|NYU School of Medicine, New York, New York, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital Virgen del Rocio Servicio de Hematologia, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01545947"
284,"NCT01522547","Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease","SCD-001","Completed","No Results Available","Anemia, Sickle Cell","Drug: pomalidomide","Maximum Tolerated Dose (MTD)|Adverse Events|Absolute fetal hemoglobin change|% total hemoglobin|Rate of total hemoglobin change|Inflammation markers and cytokines","Celgene","All","18 Years to 60 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-SCD-001","August 1, 2007","October 1, 2012","December 1, 2013","January 31, 2012",,"November 8, 2019","Karmanos Cancer Institute, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01522547"
285,"NCT01519011","Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine",,"Completed","No Results Available","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute","Drug: oral azacitidine","PK-(AUC)|PK-(T½)|PK-(Cmax)|PK-(Tmax)|To evaluate the effect of gastric acid pH modulation, through a proton pump inhibitor, on the PK of oral azacitidine|Adverse Events|Hematological response/improvement|Transfusion independence|Platelet transfusion independence","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-MDS-004|T-AZA-006","February 7, 2012","December 31, 2012","May 12, 2015","January 26, 2012",,"November 11, 2019","Moores UCSD Cancer Center MC-0987, La Jolla, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|University of Cincinnati Physician's Inc., Cincinnati, Ohio, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01519011"
286,"NCT01497093","Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Bortezomib|Drug: Dexamethasone","Maximum Tolerated Dose|Adverse events|Overall Survival|Response Rate|Duration of response|Time to response","Celgene|Multiple Myeloma Research Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-005","February 15, 2012","April 2, 2015","July 23, 2019","December 22, 2011",,"October 22, 2019","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01497093"
287,"NCT01478685","A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors",,"Completed","No Results Available","Urinary Bladder Neoplasms|Carcinoma, Transitional Cell|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Pancreatic Ductal|Tumor Virus Infections","Drug: CC-486|Drug: Carboplatin|Drug: ABI-007","Number of participants with adverse events|Cmax|AUC|Tmax|T1/2|CL/F|Vz/F|DNA Methylation|DNMT1 protein levels|Tumor Response Rate|Progression Free Survival|Duration of Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","169","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-ST-001","November 29, 2011","November 17, 2015","November 17, 2015","November 23, 2011",,"November 11, 2019","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|University of California, San Francisco, San Francisco, California, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Greenville Hospital, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Centre Georges Francois Leclerc, Dijon, France|Institut Curie, Paris, France|The Netherlands Cancer Instiute Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01478685"
288,"NCT01476787","Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","RELEVANCE","Active, not recruiting","No Results Available","Follicular Lymphoma","Drug: Rituximab|Drug: Lenalidomide|Drug: Rituximab-CHOP|Drug: Rituximab-CVP|Drug: Rituximab-Bendamustine","Complete Response Rate (CR/CRu) at 120 weeks|Progression free survival (PFS)Follicular lymphoma|Number of participants with adverse events|Time to Treatment Failure (TTF)Follicular Lymphoma|Number of Participants who Survive without an Event(s)|Time to Next Anti-Lymphoma Treatment (TTNLT) for Follicular Lymphoma|Time to Next Chemotherapy Treatment (TTNCT) for Follicular Lymphoma|Number of participants alive or dead|Overall response by International Working Group (IWG) 1999 criteria|Health related quality of life as measured by the EORTC QLQ-C30 for Follicular Lymphoma patients|Event-Free Survival (EFS)|Overall Survival (OS)","Celgene|The Lymphoma Academic Research Organisation","All","18 Years and older   (Adult, Older Adult)","Phase 3","255","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-FOL-GELARC-0683C|2011-002792-42","December 29, 2011","June 1, 2024","June 1, 2024","November 22, 2011",,"October 1, 2019","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Providence St Joseph Medical Center Cancer Center, Burbank, California, United States|Compassionate Cancer Care Medical Group, Corona, California, United States|Lalita Pandit, MD Inc., Fountain Valley, California, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|Santa Monica Hematology Oncology, Los Angeles, California, United States|Memorial Hospital, Colorado Springs, Colorado, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|University Cancer Institute, Boynton Beach, Florida, United States|Florida Cancer Specialists, Englewood, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Saint Joseph Medical Center, Westminster, Maryland, United States|Mass General Hospital, Boston, Massachusetts, United States|Newland Medical Associates, PC, Southfield, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Cancer Center at Hackensack University Medical Center, Cherry Hill, New Jersey, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology Oncology Associates of NJ, Morristown, New Jersey, United States|Somerset Hematology-Oncology Associates, Somerset, New Jersey, United States|The Cancer Center at Hackensack University Medical Center, Sparta, New Jersey, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|National Cancer Center Hospital, Chuo-ku, Japan|Kyushu University Hospital, Higashi-ku, Fukuoka, Japan|Chugoku Central Hospital, Hiroshima, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Tokai University School of Medicine, Isehara City, Kanagawa, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Toranomon Hospital, Minato-ku, Japan|Kurashiki Central Hospital, Okayama, Japan|Sendai Medical Center, Sendai-city, Japan|Juntendo University Shizuoka Hospital, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01476787"
289,"NCT01474330","A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects",,"Completed","No Results Available","Healthy","Drug: Pomalidomide|Drug: Placebo","Number of participants with adverse events|area under the plasma concentration-time curve|time to maximum observed plasma concentration|maximum observed plasma concentration|terminal elimination half-life|apparent total plasma clearance|apparent total volume of distribution, and accumulation ratio","Celgene","Male","18 Years to 55 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CC-4047-CP-006","August 1, 2011","October 1, 2011","October 1, 2011","November 18, 2011",,"November 11, 2019","PPD Phase I Clinic, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01474330"
290,"NCT01466725","A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus",,"Terminated","No Results Available","Discoid Lupus","Drug: CC-930|Drug: Placebo","Number of subjects with adverse events|To describe the pharmacokinetics of CC-930 in subjects with recalcitrant DLE.","Celgene","All","18 Years to 64 Years   (Adult)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CC-930-DLE-002","November 1, 2011","July 30, 2012","July 30, 2012","November 8, 2011",,"November 19, 2019","UAB Dermatology, Birmingham, Alabama, United States|The Regents of the University of California, Irvine, California, United States|Medical Faculty Associates, Washington, District of Columbia, United States|Advanced Pharma, CR, LLC, Miami, Florida, United States|University of Miami - Department of Dermatology, Miami, Florida, United States|Rush Medical Center, Chicago, Illinois, United States|North Shore University Health System, Skokie, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|John Hopkins University, Baltimore, Maryland, United States|Boston Cancer Center, Boston, Massachusetts, United States|University of Minnesota-Department of Dermatology, Minneapolis, Minnesota, United States|University of Rochester Medical Center, Rochester, New York, United States|Ohio State Univ Medical Center, Division of Dermatology, Columbus, Ohio, United States|Rhode Island Hospital University Dermatology, Inc., Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Dermatology and Research, Dallas, Texas, United States|University of Texas Dermatology, Houston, Texas, United States|Sun Research Institute, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01466725"
291,"NCT01456039","A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)",,"Completed","Has Results","Lymphoma, T-cell, Peripheral","Drug: Romidepsin","Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 as Determined by the Efficacy and Safety Evaluation Committee (ESEC)|Percentage of PTCL Participants With an Overall Best Response in Accordance With a Modified International Workshop Response Criteria (IWC) 1999 in Phase 2|Participants With Treatment-Emergent Adverse Events (TEAEs) Associated With Romidepsin|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Romidepsin in Phase 1|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Romidepsin in Phase 1|Maximum Plasma Concentration (Cmax) of Romidepsin in Phase 1|Time to Maximum Plasma Concentration of Romidepsin (Tmax) in Phase 1|Terminal Phase Half-life of Romidepsin (t½) in Phase 1|Apparent Total Clearance of Romidepsin (CL/F) of Romidepsin in Phase 1|Apparent Volume of Distribution (Vz/F) of Romidepsin in Phase 1|AUC0-t, at Steady State (ss) of Romidepsin in Phase 1 at Cycle 1, Day 15|Cmax, ss of Romidepsin in Phase 1 at Cycle 1, Day 15|Tmax,ss of Romidepsin in Phase 1 at Cycle 1, Day 15|Terminal Phase Half-life of Romidepsin (t½) in Phase 1 at Cycle 1, Day 15|AUC0-t, Accumulation Ratio of Romidepsin in Phase 1, Cycle 1|Cmax Accumulation Ratio of Romidepsin in Phase 1, Cycle 1|The Percentage of Participants With Abnormal Q-wave and T Wave Intervals|Percentage of PTCL Participants With the Best Response in Accordance With the Modified 2007 International Workshop Response Criteria as Assessed by IER|Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 1999 IWC as Assessed by IER|Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 2007 IWC as Assessed by IER|Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 1999 IWC as Assessed by the IER.|Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 2007 IWC as Assessed by the IER.|Kaplan Meier Estimate of Time to Progression (TTP) in PTCL Participants Based on the 1999 IWC as Assessed by IER|Kaplan Meier (K-M) Estimate of Time to Progression (TTP) in PTCL Participants Based on the Modified 2007 IWC as Assessed by IER","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROMI-TCL-001","December 1, 2011","July 28, 2015","December 14, 2018","October 20, 2011","August 19, 2016","February 11, 2019","Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Ehime University Hospital, To-on, Ehime, Japan|Chugoku Central Hospital, Fukuyamashi, Hiroshima, Japan|Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Tokai University School of Medicine, Isehara, Kanagawa, Japan|Kochi Medical School Hospital, Nankoku, Kochi, Japan|Kinki University Hospital, Sayama, Osaka, Japan|National Cancer Center Hospital, Chuo, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto, Japan|University hospital, Kyoto prefectural University of Medicine, Kyoto, Japan|Tohoku University Hospital, Miyagi, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01456039"
292,"NCT01421524","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma|Lymphoma, Large B-Cell, Diffuse|Pleiotropic Pathway Modifier|Glioblastoma|Lymphoma|Primary Central Nervous System Lymphoma","Drug: CC-122","Dose‐Limiting Toxicity (DLT)|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Non-tolerated dose (NTD)|Maximum Tolerated Dose (MTD)|Response Rate|Tissue concentration of CC-122|6-month progression free survival (PFS) rate for GBM chort","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-ST-001|U1111-1203-5132","September 12, 2011","August 1, 2020","August 1, 2020","August 23, 2011",,"October 8, 2019","City of Hope Cancer Center, Duarte, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Rutgers Cancer Institute of New Jersey University, New Brunswick, New Jersey, United States|Mount Sinai Hospital, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|MUSC Rheumatology and Immunology Dept., Charleston, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Texas Oncology, PA - Dallas 75246, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|CU CHU Clemenceau, Caen Cedex, France|Paoli CalmettesHematology, Marseille le Cedex, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Institut universitaire du cancer de Toulouse (IUCT) - Oncopole, Toulouse CEDEX 9, France|Institut Gustave Roussy, Villejuif Cedex, France|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|U.O.C. Ospedale Bellaria, Bologna, Italy|Istituto Nazionale Tumori, Milan, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Istituto Nazionale Tumori Regina Elena, Struttura Complessa Ematologia ed Unita di Cellule Staminali, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital del Mar, Barcelona, Spain|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario Clinico de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01421524"
293,"NCT01358734","A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia",,"Completed","Has Results","Acute Myeloid Leukemia|Acute Myelogenous Leukemia","Drug: Azacitidine|Drug: Lenalidomide|Other: Best Supportive Care (BSC)","Kaplan Meier Estimates for One Year Survival|Overall Survival|Percentage of Participants With a Complete Response or Morphologic Incomplete Response.|Duration of Remission (DoR)|Cytogenetic Complete Remission Rate (CRc)|Percentage of Participants With an Overall Response Rate (CR +CRi+ PR)|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Relapse-Free Survival (RFS)|Percentage of Participants With 30-Day Treatment-Related Mortality|Number of Participants With Treatment Emergent Adverse Events (TEAE)|Number of Participants With a Second Primary Malignancy","Celgene","All","65 Years and older   (Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-AML-001","April 27, 2012","May 19, 2015","May 15, 2018","May 24, 2011","July 4, 2016","June 25, 2019","(210) University of Arizona Cancer Center, Tucson, Arizona, United States|(180) University of California, San Diego, La Jolla, California, United States|(240) Cedars-Sinai Medical Center, Los Angeles, California, United States|(215) Hematology Oncology Medical Group, Orange, California, United States|(130) UC Davis Medical Center, Sacramento, California, United States|(200) Coastal Integrative Cancer Care, San Luis Obispo, California, United States|(125) University of Stanford, Stanford, California, United States|(115) University of Colorado Anschultz Cancer Center, Aurora, Colorado, United States|(145) Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|(140) Rush University Medical Center, Chicago, Illinois, United States|(185) The University of Kansas Cancer Center, Westwood, Kansas, United States|(175) University Lousiville, Louisville, Kentucky, United States|(195) Tulane University Hospital Tulane Cancer Center, New Orleans, Louisiana, United States|(235) University of Minnesota, Minneapolis, Minnesota, United States|(100) Washington University School of Medicine, Saint Louis, Missouri, United States|(150) Billings Clinic, Billings, Montana, United States|(165) Mount Sinai Medical Center New York, New York, New York, United States|(160) The Western Pennsylvania Hospital- Cancer Institute, Pittsburgh, Pennsylvania, United States|(205) Greenville Hospital System, Greenville, South Carolina, United States|(120) Avera Cancer Institute, Sioux Falls, South Dakota, United States|(230) Tennessee Oncology, PLLC, Nashville, Tennessee, United States|(105) University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States|(155) Cancer Care Centers of South Texas, San Antonio, Texas, United States|(135) University of Wisconsin, Madison, Wisconsin, United States|(402) Tom Baker Cancer Centre, Calgary, Alberta, Canada|(405) University of Alberta Hospital, Edmonton, Alberta, Canada|(401) Cancer Care Manitoba, Winnipeg, Manitoba, Canada|(403) Queen Elizabeth II Health Sciences Centre - VG Site, Halifax, Nova Scotia, Canada|(404) The Ottawa Hospital, Ottawa, Ontario, Canada|(400) Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01358734"
294,"NCT01353625","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",,"Active, not recruiting","No Results Available","Glioblastoma Multiforme|Squamous Cell Carcinoma of Head and Neck|Prostate Cancer|Ewing's Osteosarcoma|Chronic Lymphocytic Leukemia|Neoplasm Metastasis","Drug: CC-115","Dose-Limiting Toxicity|Non-Tolerated Dose|Maximum Tolerated Dose|Maximum Observed Concentration in Plasma of CC-115|Area Under the Concentration-Time Curve for CC-115|Time to Maximum Concentration of CC-115|Terminal Half-Life for CC-115|Apparent Total Body Clearance of CC-115|Apparent Volume of Distribution of CC-115|Accumulation Index of CC-115|Pharmacodynamics|Anti-Tumor Efficacy","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","118","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-115-ST-001","April 25, 2011","November 30, 2019","November 30, 2019","May 13, 2011",,"May 2, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Institut Gustave Roussy, Villejuif Cedex, France|Uniklinik Koln, Koeln, Germany|Universitatsklinikum Wurzburg, Würzburg, Germany|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital de Donosti, San Sebastián (Guipuzcoa), Spain|Hospital Virgen del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01353625"
295,"NCT01351935","Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",,"Completed","No Results Available","B Cell Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia","Drug: AVL-292","Safety, tolerability,and dose limiting toxicities will be determined using AEs,PE,ophthalmologic examinations,clinical laboratory tests,vital signs, ECGs and echocardiograms/MUGA scans.|Establish recommended Phase 2 dose, after completing dose escalation in Part 1 and evaluating accumulated safety,PK,and PD data from the dose escalation phase (Part1)|Evaluate the Pharmacokinetic parameters of AVL-292|Evaluate the Pharmacodynamics of AVL-292 by measurement of free Btk|Characterize preliminary anti-tumor efficacy of AVL-292 in relapsed and/or refractory B-NHL, CLL and WM","Celgene|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 1","113","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVL-292-003","July 18, 2011","June 26, 2015","June 26, 2015","May 11, 2011",,"November 8, 2019","Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States|University of Arizona SPORE, Tucson, Arizona, United States|University of California San Diego, La Jolla, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mount Sinai School of Medicine and Mount Sinai Graduate School of Biological Sciences, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|US Oncology, The Woodlands, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01351935"
296,"NCT01347944","MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry","MORE","Completed","No Results Available","Myelodysplastic Syndrome","Drug: lenalidomide","Number of subjects achieving red blood cell (RBC) transfusion independence|Number of subjects achieving an erythroid response|Number of subjects achieving a cytogenetic response|Number of participants with adverse events|Duration of RBC transfusion independence|Duration of cytogenetic response|Time to RBC transfusion independence|Progression to acute myeloid leukemia (AML)|Number of participants alive","Celgene","All","18 Years and older   (Adult, Older Adult)",,"149","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","NIPMS- Celgene-MDS-ITA-002","January 1, 2011","June 30, 2013","June 30, 2013","May 5, 2011",,"November 18, 2019","Dipartimento Onco - Ematologico Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo, Alessandria, Italy|Unità Operativa Clinica di Ematologia Azianda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Dipartimento di Oncologia Medica Ospedale Cardinale G. Massaia, Asti, Italy|Ematologia Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, Italy|Dipartimento di Ematologia Ospedale dell'U.L.S.S. n.1 Belluno, Belluno, Italy|Ematologia A.O. Ospedale Riuniti di Bergamo, Bergamo, Italy|Dip. Medicina Interna Ospedale degli Infermi di Biella, Biella, Italy|Dipartimento di Ematologia Spedale Civili di Brescia, Brescia, Italy|Dipartimento Trapianto di Midollo Allogenico Spedale Civili di Brescia, Brescia, Italy|Dipartimento di Ematologia Ospedale R. Binaghi, Cagliari, Italy|Dip. Di Oncoematologia A.O. S.Anna e S. Sebastiano, Caserta, Italy|Dip. Di Ematologia A.O. Istituti Ospedalieri, Cremona, Italy|Dip. Di Ematologia Az. Ospedaliero-Universitaria Careggi, Firenze, Italy|Dip. Di Ematologia A.O. Universitaria S. Martino, Genova, Italy|Dip. Di Medicina Interna A.O. Universitaria S. Martino, Genova, Italy|Struttura di Ematologia, Dip. di Oncoematologia IRCCS Casa Sollievo della Sofferenza, Giovanni Rotondo, Italy|Dip. Di Ematologia Azienda Ospedaliera V. Fazzi, Lecce, Italy|Centro Trapianti di Midollo Ospedale Maggiore Policlinico, Milano, Italy|Dip. Di Ematologia Policlinico, Az. Ospedaliero- Universitaria, Modena, Italy|Dip. Di Ematologia Azienda Ospedaliera S. Gerardo, Monza, Italy|Dip. Di Oncoematologia A.O. Universitaria Federico II, Napoli, Italy|Dip. Di Ematologia Presidio Ospedaliero Umberto I, Nocera Inferiore, Italy|Dip. Di Ematologia Ospedale S. Francesco, Nuoro, Italy|Dip. Di Ematologia Azienda Ospedaliera, Padova, Italy|Dip. di Ematologia Azienda Ospedaliera, Parma, Italy|Dip. Di Ematologia Azienda Ospedaliera - Osp. S. Maria della Misericordia, Perugia, Italy|Dip. Di Ematologia Azienda Ospedaliera s. Salvatore, Pesaro, Italy|Dip. Di Ematologia Az. Ospedaliera Regionale S. Carlo, Potenza, Italy|Servizio di Ematologia - Dip. di Oncologia Az. Ospedaliera di Reggio Emilia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Dip. Di Ematologia Ospedale S. Maria delle Croci, Revenna, Italy|U. O. Ematologia Az. Ospedaliero-Universitaria Policlinico Tor Vergata, Roma, Italy|U.O.C Ematologia Ospedale S. Eugenio, Piazzale dell'Umanesimo, Roma, Italy|Dip. di Ematologia Policlinico Umberto I, Roma, Italy|U.O.C. Ematologia Policlinico Universitario Gemelli, Roma, Italy|Dip. di Oncoematologia Ospedale Civile Giannettasio, Rossano, Italy|Dip. di Oncoematologia Az. ULSS 18, Rovigo, Italy|Dip. di Ematologia Policlinico Universitario di Sassari, Sassari, Italy|Divisione di Ematologia e Trapianti Spedali Riuniti, Sienna, Italy|Dip. di Ematologia 1 A.O. Universitaria S.Giovanni Battista, Torino, Italy|Dip. di Ematologia 2 A.O. Universitaria S.Giovanni Battista, Torino, Italy|Dip. di Ematologia e Terapie Cellulari Ospedale Mauriziano Umberto I, Torino, Italy|Unità Operativa Trasfusionale ed Immunologia Centro di riferimento per le malattie rare e centro regionale per le malattie del sangue Ospedale S. Giacomo Apostolo, Treviso, Italy|Ospedale Dell'Angelo USL12 - Venezia (Mestre), Venezia, Italy|Dip. Funzionale di Terapie Cellulari e Ematologia Azienda Sanitaria ULSS 6 - Osp. di Vicenza, Vicenza, Italy|Dip. Di Ematologia Ospedale di Belcolle, Viterbo, Italy",,"https://ClinicalTrials.gov/show/NCT01347944"
297,"NCT01324947","Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: pomalidomide","Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment|Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria Based on Investigator Assessment|Number of Participants With Adverse Events and Type of Adverse Events|Kaplan Meier Estimates for Progression Free Survival (PFS) by Investigator Based on IMWG|Kaplan-Meier Estimate for Time to Progression (TTP) Based on Investigator Assessment Using IMWG Criteria|Kaplan-Meier Estimate Duration of Response Based on Investigator Assessment Using IMWG Criteria|Kaplan-Meier Estimate for Overall Survival|Time to Response Based on IMWG and Assessed by the Investigator","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","74","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-003/C|2010-023343-16","March 1, 2011","July 31, 2014","July 31, 2014","March 29, 2011","July 30, 2015","November 19, 2019","Royal Adelaide Hospital - SA Pathology Haematology, Adelaide, Australia|Princess Alexandra Hospital - Haematology, Brisbane, Australia|Royal Prince Alfred Hospital - Institute of Haematology, Camperdown, Australia|Peter McCallum Cancer Institute - Directorate of Cancer Medicine, East Melbourne, Australia|Frankston Hospital-Peninsula Health - Oncology Day Unit, Frankston, Australia|The Alfred Hospital - Malignant Haematology & Stem Cell Transplantation, Melbourne, Australia|Calvary Mater Newcastle - Haematology, Waratah, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital - Haematology, Wollongong, Australia|UZ Gent - Hematology, Gent, Belgium|University Hospital Leuven - Hematology, Leuven, Belgium|Cliniques Universitaires ULC de Mont-Godinne - Hematology, Yvoir, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Charles University Hospital - Internal Medicine, Prague, Czechia|Aalborg Sygemus - Haematology, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital - Hematology, Vejle, Denmark|CHU Angers - Service des maladies du sang, Angers, France|Centre Hospitalier de la côte basque - Hematologie, Bayonne, France|Centre Hospitalier Départemental Vendée - Onco-hematologie, La Roche, France|CHRU de Lille - Service des maladies du sang, Lille, France|Institut Paoli Calmette - Hematology 1, Marseille, France|CHU Hôtel-Dieu - Hematologie, Nantes, France|Hôpital Saint Louis - Immuno-hematologie, Paris, France|CHU Saint Antoine - Service des maladies du sang, Paris, France|CHRU - Hôpital du Haut Lévêque - Centre François Magendie Service des maladies du sang, Pessac, France|Centre Hospitalier Lyon sud - Hematologie, Pierre-Benite, France|CHRU Hôpital Purpan - Hematologie, Toulouse, France|Hôpital Bretonneau - Hématologie & Thérapie cellulaire, Tours, France|CHU Nancy - Hematologie, Vandoeuvre-les-Nancy, France|Universitatsklinikum Carl Gustav Carus-Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitätsklinikum Essen, Klinik für Hämatologie Westdeutsches Tumorzentrum, Essen, Germany|Askepios Klinik Altona-Abteilung Hamatologie und Internistische Onkologie, Hamburg, Germany|Universitätsklinikum Heidelberg - Medizinische Klinik und Poliklinik V, Heidelberg, Germany|Universitätsklinikum Jena - Klinik fur Innere Medizin II-Hamatologie/Onkologie, Jena, Germany|Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik II, Leipzig, Germany|Universitätsklinikum Münster - Medizinische Klinik und Poliklinik A, Münster, Germany|Universitätsklinikum Tübingen - Medizinische Klinik und Poliklinik - Abteilung II, Tübingen, Germany|Universitätsklinikum Ulm - Klinik fur Innere Medizin III, Ulm, Germany|Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik II, Würzburg, Germany|University of Athens - Alexandra Hospital, Athens, Greece|Università degli Studi di Bologna - Policlinico S. Orsola - Hematology, Bologna, Italy|AO Universitaria San Martino - hematooncology, Genova, Italy|Fondazione ""G. Pascale"" - Hematology, Napoli, Italy|Ospedale San Luigi AO Luigi Gonzaga - Hematology, Orbassano, Italy|Universita degli Studi di Padova - Clinical & Experimental Medicine, Padova, Italy|Ospedale Guglielmo da Saliceto - hematooncology, Piacenza, Italy|Unità di Ematologia Arcispedale S. Maria Nuova - Haematology, Reggio Emilia, Italy|Policlinico Umberto I, Università ""La Sapienza"" di Roma - Hematology, Roma, Italy|A.O.U. San Giovanni Battista - Hematology, Torino, Italy|VUMC - Hematology, Amsterdam, Netherlands|Erasmus Medical Center - Hematology, Rotterdam, Netherlands|University Medical Center - Hematology, Utrecht, Netherlands|Hematological Research Center under the Russian Academy of Medical Sciences - Hematology & BMT, Moscow, Russian Federation|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin - Hematology, Moscow, Russian Federation|Russian Research Institute of Hematology and Blood Transfusion - Hematology, St. Petersburg, Russian Federation|State Higher Educational Institution St. Petersburg State Medical University - Onco-hematology, St. Petersburg, Russian Federation|Hospital Germans Trias i Pujol - Hematology, Badalona, Spain|Hospital Clinic i Provincial de Barcelona - Hematology, Barcelona, Spain|Hospital de Donostia - Hematology, Guipúzcoa, Spain|Hospital de La Princesa - Hematology, Madrid, Spain|Hospital 12 de Octubre - Hematology, Madrid, Spain|Hospital de Salamanca - Hematology, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla - Hematology, Santander, Spain|Hospital La Fe - Hematology, Valencia, Spain|Sahlgrenska Hospital, University of Goteborg - Hematology, Goteborg, Sweden|Karolinska University Hospital Huddinge - Center of hematology, Stockholm, Sweden|Karolinska University Hospital-medicine, Stockholm, Sweden|Karolinska University Hospital Solna- medicine, Stockholm, Sweden|Overlakare Medocomcentrum - Hematology, Uppsala, Sweden|Inselspital, Institut für Medizinische Onkologie, Bern, Switzerland|Hôpitaux Universitaire de Genève - Oncologie, Genève, Switzerland|Klinik und Poliklinik für Onkologie - UniversitätsSpital Zürich, Zürich, Switzerland|Royal Bournemouth Hospital - Haematology, Bournemouth, United Kingdom|St James's University Hospital - Haematology, Leeds, United Kingdom|St Bartholomew's Hospital - Medical Oncology, London, United Kingdom|King's College Hospital - Haematology Clinical Trials, London, United Kingdom|Freeman Hospital - Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital - Centre for Clinical Haematology, Nottingham, United Kingdom|Derriford Hospital - Haematology, Plymouth, United Kingdom|Royal hallamshire Hospital - Haematology, Sheffield, United Kingdom|Royal Marsden NHS Foundation Trust - Haematology, Surrey, United Kingdom|Royal Wolverhampton Hospitals Trust - Research and Development, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01324947"
298,"NCT01323751","Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma","ACY-1215","Completed","No Results Available","Multiple Myeloma","Drug: ACY-1215","Phase 1 (a & b): To determine the maximum tolerated dose of ACY-1215 as monotherapy or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.|Phase 2a: To determine the objective response rate to ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.|Characterize the safety of ACY-1215 alone or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma|Determine the single- and multiple-dose PK of ACY-1215 alone and in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma|Evaluate the pharmacodynamics of ACY-1215 alone or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.","Celgene|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACY-100","July 2011","December 2016","December 3, 2016","March 28, 2011",,"April 6, 2017","Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mt. Sinai Medical Center, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin - Clinical Cancer Center, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01323751"
299,"NCT01311687","A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study","NIMBUS","Completed","Has Results","Multiple Myeloma","Drug: pomalidomide|Drug: Dexamethasone","Progression-free Survival (PFS) - Primary Analysis|Progression-free Survival (PFS) With a Later Cut-off Date|Number of Participants With Adverse Events (AEs)|Overall Survival - Primary Analysis|Overall Survival With a Later Cut-off Date|Overall Survival Based on the Final Dataset|Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria|Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria|Time to Progression|Time to Response|Duration of Response|Time to the First Hemoglobin Improvement|Time to Improvement in Bone Pain|Time to Improvement in Renal Function|Time to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status|Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain|Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Fatigue Domain|Change From Baseline in the EORTC QLQ-C30 Pain Domain|Change From Baseline in the European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms|Change From Baseline in the EORTC QLQ-MY20 Side Effects Domain|Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Utility Index Score|Time to First Worsening of Quality of Life (QOL) Domains","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-003|2010-019820-30","March 11, 2011","March 1, 2013","August 29, 2017","March 9, 2011","April 30, 2014","October 24, 2018","Mayo Clinic, Rochester, Minnesota, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Princess Alexandra Hospital, Brisbane, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Alfred hospital, Melbourne, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Calvary Mater Hospital, Waratah, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital, Wollongong, Australia|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU UCL Mont-Godinne-Dinant asbl, Yvoir, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|James Cancer Hospital, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Maisonneuve Rosemont, Montreal, Quebec, Canada|Royal Victoria Hospital McGill Department of Oncology(RVH), Montreal, Quebec, Canada|Sir Mortimer B. Davis - Jewish Genl, Montreal, Quebec, Canada|Charles University General Hospital, Praha 2, Czechia|Hæmatologisk afd. B Aalborg Sygehus Syd, Aalborg, Denmark|Aarhus University Hospital, Arhus C, Denmark|Odense Universitetshospital, Odense C, Denmark|Vejle Hospital, Vejle, Denmark|CHU d'Angers, Angers Cedex 01, France|Centre Hospitalier de la cote basque, Bayonne, France|Centre Hospitalier Departemental, La Roche sur Yon, France|CHRU de Lille FR, Lille, France|Institut Paoli-Calmettes, Marseille Cedex 9, France|CHRU Nantes, Nantes Cedex 1, France|Hopital Saint-Louis, Paris, Cedex 10, France|CHU Hôpital St-Antoine, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Hopital Bretonneau, Tours, France|Hopital Purpan, Tulouse Cedex 9, France|CHU Nancy, Vandoeuvre, France|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinikum Essen, Essen, Germany|Askepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitatsklinikum Jena, Jena, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|University of Tubingen, Tübingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Universitatsklinikum Wurzburg, Wuerzburg, Germany|Alexandra General Hospital of Athens, Athens, Greece|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Clinica Ematologica- A.O.U. San Martino, Genova, Italy|Oncoematologia, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|Universita degli Studi di Padova, Padova, Italy|Hospital Clinic, Placenza, Italy|Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova, Reggio Emilia, Italy|Univerita La Sapienza Dipartimento di Biotecnologie Cellulari ed Ematologia, Rome, Italy|Azienda Ospedaliera San Giovanni Battista, Torino, Italy|VU University Medical Center, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|State Institution Hematological Research, Centre of Russian Academy of Medical Science, Moscow, Russian Federation|State Institution Moscow Regional Research Clinical Institute, Moscow, Russian Federation|State Educational Institution, Saint Petersburg State Medical University, Saint Petersburg, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Donostia, San Sebastián (Guipuzcoa), Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital de la Fe, Valencia, Spain|Department of Hematology Hematology Centre, Göteborg, Sweden|University Hospital in Lund, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Overlakare Medocomcentrum, hematologi, Uppsala, Sweden|Medizinische Universitatsklinik, Berne, Switzerland|Hopitaux Universitaires de Geneve-HUG, Geneva, Switzerland|UniversitatSspital Zurich, Zürich, Switzerland|Royal Bournemouth Hospital, Bournemouth, United Kingdom|St James's University Hospital, Leeds, United Kingdom|St.Bartholomew's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Hallamshire HospitalSheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom|The Royal Marsden Hospital, Sutton-Surrey, United Kingdom|The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01311687"
300,"NCT01307423","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)","PALACE4","Completed","Has Results","Psoriatic Arthritis","Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16|Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 16|Percentage of Participants With an ACR 20 Response at Week 24|Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 24|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16|Change From Baseline in Patient's Assessment of Pain at Week 16|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16|Change From Baseline in Dactylitis Severity Score at Week 16|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16|Change From Baseline in the Disease Activity Score (DAS28) After 16 Weeks of Treatment|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24|Change From Baseline in Participants Assessment of Pain at Week 24|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24|Change From Baseline in Dactylitis Severity Score at Week 24|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24|Change From Baseline in Disease Activity Score (DAS 28) at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24|Percentage of Participants With ≥ 20% Improvement in Maastricht Ankylosing Spondylitis Entheses Score at Week 16|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16|Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16|Percentage of Participants With MASES Improvement ≥ 20% at Week 24|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24|Percentage of Participants With Good or Moderate EULAR Response at Week 24|Percentage of Participants With a ACR 50 Response at Week 16|Percentage of Participants With a ACR 70 Response at Week 16|Percentage of Participants With a ACR 50 Response at Week 24|Percentage of Participants With a ACR 70 Response at Week 24|Percentage of Participants With Pre-existing Enthesopathy Whose Maastricht Ankylosing Spondylitis Entheses Score Improves to 0 at Week 16|Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves to 0 at Week 16|Percentage of Participants Achieving a MASES Score of Zero at Week 24|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24|Percentage of Participants With a ACR 20 Response at Week 52|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52|Change From Baseline in the SF-36v2 Physical Functioning Scale Score at Week 52|Percentage of Participants With a Modified PsARC Response at Week 52|Change From Baseline in the Participants Assessment of Pain Using the Visual Analog Scale at Week 52|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52|Change From Baseline in the Dactylitis Severity Score at Week 52|Change From Baseline in the CDAI Score at Week 52|Change From Baseline in the DAS28 at Week 52|Change From Baseline in the FACIT-Fatigue Scale Score at Week 52|Percentage of Participants With MASES Improvement ≥ 20% at Week 52|Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline by ≥ 1 at Week 52|Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52|Percentage of Participants With an ACR 50 Response at Week 52|Percentage of Participants With an ACR 70 Response at Week 52|Percentage of Participants With Pre-existing Enthesopathy Whose MASES Improves From Baseline to 0 at Week 52|Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline to 0 at Week 52|Number of Participants With Treatment Emergent Adverse Events During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","529","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-005|2010-020324-22","December 9, 2010","February 21, 2013","August 16, 2017","March 2, 2011","August 15, 2014","September 14, 2018","Arizona Research Center, Phoenix, Arizona, United States|Desert Medical Advances, Palm Desert, California, United States|In Vivo Clinical Research, Doral, Florida, United States|Centre For Rheumatology, Immun. And Arthritis, Fort Lauderdale, Florida, United States|North Florida Dermatology, Jacksonville, Florida, United States|Florida Center for Dermatology, PA, Saint Augustine, Florida, United States|Tampa Medical Group Pa, Tampa, Florida, United States|Atlanta Dermatology, Vein and Research Center, PC, Alpharetta, Georgia, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Sonora Clinical Research, LLC, Boise, Idaho, United States|Rockford Orthopedic Associates, LLC, Rockford, Illinois, United States|The Arthritis Center, Springfield, Illinois, United States|Indiana. University, Indianapolis, Indiana, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Justus Fiechtner MD PC, Lansing, Michigan, United States|Heartland Clinical Research, Inc., Omaha, Nebraska, United States|Physicians East, Greenville, North Carolina, United States|Unifour Medical Research Associatets LLC, Hickory, North Carolina, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|Center for Clinical Studies, Houston, Texas, United States|Houston Medical Research, Houston, Texas, United States|Luckster Enterprises, San Antonio, Texas, United States|Center for Clinical Studies, Webster, Texas, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|PharmaSeek, Middleton, Wisconsin, United States|Monash Medical Centre, Clayton, Victoria, Australia|Eastern Health Clinical School, Box Hill, Australia|Repatriation General Hospital, Daws Park, Australia|Menzies Centre for Population Health Research, Hobart, Australia|Optimus Clinical Research Pty. Ltd, Kogarah, Australia|The Queen Elizabeth Hospital, Woodville, Australia|UZ Leuven, Leuven, Belgium|CHU de Liege, Liège, Belgium|Multiprofile Hospital for Active Treatment Trimontsium, Plovdiv, Bulgaria|17 Diagnostic and Consulting Centre Sofia EOOD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sv. Ivan Rilski, Sofia, Bulgaria|Diagnostic-Consultative Center Sveta Anna, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Arthritis Research Centre of Canada, Vancouver, British Columbia, Canada|PerCuro Clinical Research, Victoria, British Columbia, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|St. Clare's Health Care Corporation of St. John's, St John's, Newfoundland and Labrador, Canada|Ultranova Skincare, Barrie, Ontario, Canada|William Bensen's Private Practice, Hamilton, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Wilderman Medical Clinic, Thornhill, Ontario, Canada|Probity Medical Research Inc, Waterloo, Ontario, Canada|Darryl Toth's Private Practice, Windsor, Ontario, Canada|Centre de Rhumatologie St-Louis, Sainte Foy, Quebec, Canada|Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada|Affidea Praha s.r.o, Praha 11, Czechia|Revmatologicky ustav, Praha 2, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|PV - MEDICAL, s.r.o., Zlin, Czechia|East Tallinn Central Hospital, Tallinn, Estonia|North Estonia Regional Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Hotel Dieu, Nantes Cedex 01, France|Groupe Hospitalier Archet I et II, Nice, France|Hopital Lariboisiere, Paris Cedex 10, France|Fondation Hôpital Saint-Joseph, Paris, France|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Honvéd Kórház - Állami Egészségügyi Központ, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Principal SMO Kft., Mako, Hungary|MAV Korhaz es Rendelointezet Szolnok, Szolnok, Hungary|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale Luigi Sacco, Milano, Italy|AOU della II Universita degli Studi di Napoli, Napoli, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Ospedale Civile Maggiore Borgo Trento, Verona, Italy|Chungnam National University Hospital, DaeJeon, Korea, Republic of|Inha University Hosiptal, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Siauliai Hospital, Siauliai, Lithuania|Waikato hospital, Hamilton, New Zealand|North Shore Hospital, Takapuna, New Zealand|Timaru Hospital, Timaru, New Zealand|Bytomskie Centrum Medyczne Silesiana Sp. z o.o., Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Centrum Medyczne Silesiana Sp. z o.o., Bytom, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Synexus SCM Sp. z o.o., Katowice, Poland|Niepubliczny Zaklad Opieki Zdrowotnej REUMED, Lublin, Poland|Prywatna Praktyka Lekarska, Poznan, Poland|REUMATIKA-Centrum Reumatologii Niepubliczny Zaklad Opieki Zdrowotnej, Warszawa, Poland|Synexus SCM Sp. z o.o. Oddz. Warszawa, Warszawa, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|C.M.I. Dr. Ciornohuz Adriana, Iasi, Romania|Veterans of Wars Regional Clinical Hospital, Kemerovo, Russian Federation|Kemerovo State Medical Academy of Roszdrav, Kemerovo, Russian Federation|Research Medical Complex Vashe Zdorovie, Kezch, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Russian Federation|City Clinical Hospital #5, Nizhniy Novgorod, Russian Federation|Research Institute of Clinical Immunology, Novosibirsk, Russian Federation|Research Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Voronezh Regional Clinical Hopsital #1, Voronezh State Medical Academy, Voronezh, Russian Federation|Taipei Veterans General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Barnsley Hospital, Barnsley South Yorkshire, United Kingdom|Haywood Hospital, Burslem, United Kingdom|Cannock Chase Hospital, Cannock, United Kingdom|Poole Hospital, Poole, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01307423"
301,"NCT01300208","To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus",,"Completed","No Results Available","Cutaneous Lupus Erythematosus","Drug: CC-11050|Other: Placebo","Laboratory values from chemistry, hematology, urinalysis, inflammation/immunology panel that reveal clinically significant abnormalities and that may constitute a safety concern|Pharmacokinetics (PK)|To assess the clinical response rate of CC-11050 in subjects with discoid lupus erythematosus or sub acute lupus erythematosus using the Cutaneous Lupus Area and Severity Index Activity Score following 12-weeks of treatment|Pharmacokinetics","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-11050-CLE-002","October 1, 2010","January 1, 2013","March 1, 2013","February 21, 2011",,"November 11, 2019","Northwest Arkansas Clinical Trials Center, PLLC, Rogers, Arkansas, United States|Dermatology Research Associates, Los Angeles, California, United States|Medderm Associates, San Diego, California, United States|Emory Univ. School of Medicine, Atlanta, Georgia, United States|Peachtree Dermatology Associates Research Center, Atlanta, Georgia, United States|Central Medaphase Inc, Newnan, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|DermResearch, PLLC, Louisville, Kentucky, United States|Dermatology & Advanced Aesthetics, Lake Charles, Louisiana, United States|Central Dermatology, P.C., Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Penn State Hershey Dermatology, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Clinical Partners, LLC, Johnston, Rhode Island, United States|UT Southwestern Medical Center Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01300208"
302,"NCT01289210","VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas",,"Terminated","Has Results","Low Grade B Cell Lymphoma","Drug: VTX-2337 plus radiotherapy","Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation.|Assess the Safety and Feasibility of the Combination Regimen.","Celgene|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","2","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VRXP-A104","July 2011","November 2011","October 2012","February 3, 2011","October 6, 2014","September 25, 2019","Stanford Cancer Center, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01289210"
303,"NCT01285310","Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis",,"Terminated","Has Results","Rheumatoid Arthritis","Drug: Apremilast 30 mg|Drug: Apremilast 20 mg|Drug: Placebo","Percentage of Participants With an American College of Rheumatology 20% Improvement (ACR 20) Response at Week 16|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16|Percentage of Participants With an American College of Rheumatology 20% Improvement (ACR 20) Response at Week 24|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 24|Change From Baseline in the Medical Outcome Study Short Form 36-item (SF-36) Physical Functioning Domain at Week 16|Change From Baseline in the Clinical Disease Activity Index (CDAI) at Week 16|Percentage of Participants Who Achieve Low Disease Activity or Remission Based on the Clinical Disease Activity Index (CDAI) ≤ 10 at Week 16|Change From Baseline in Disease Activity Score 28 (DAS28) (Using C-Reactive Protein) (CRP) at Week 16|Percentage Change From Baseline in the Tender Joint Count at Week 16|Percentage Change From Baseline in the Swollen Joint Count at Week 16|Percentage Change From Baseline in the Subject Assessment of Pain at Week 16|Percentage Change From Baseline in the Subject Global Assessment of Disease Activity at Week 16|Percentage Change From Baseline in the Physician Global Assessment of Disease Activity at Week 16|Percentage Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 16|Percentage Change From Baseline in the High Sensitivity C-Reactive Protein (CRP) at Week 16|Percentage Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 16|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16|Percentage of Participants Who Achieve an Improvement of ≥ 0.22 Units From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16|Percentage of Participants Who Achieve an Improvement of at Least 4 Units From Baseline in the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-Fatigue) at Week 16|Percentage of Participants Who Achieve the European League Against Rheumatism (EULAR) Response Criteria Using CRP at Week 16|Percentage of Participants With an American College of Rheumatology 50% Improvement (ACR 50) Response at Week 16|Percentage of Participants With an American College of Rheumatology 70% Improvement (ACR 70) Response at Week 16|Percentage of Participants With an American College of Rheumatology 50% Improvement (ACR 50) Response at Week 24|Percentage of Participants With an American College of Rheumatology 70% Improvement (ACR 70) Response at Week 24|Change From Baseline in the Medical Outcome Study Short Form 36-item (SF-36) Physical Functioning Domain at Week 24|Change From Baseline in the Clinical Disease Activity Index (CDAI) at Week 24|Percentage of Participants Who Achieve Low Disease Activity or Remission Based on the Clinical Disease Activity Index (CDAI) ≤ 10 at Week 24|Change From Baseline in Disease Activity Score 28 (DAS28) Using CRP at Week 24|Percentage Change From Baseline in the Tender Joint Count at Week 24|Percentage Change From Baseline in the Swollen Joint Count at Week 24|Percentage Change From Baseline in the Subject Assessment of Pain at Week 24|Percentage Change From Baseline in the Subject Global Assessment of Disease Activity at Week 24|Percentage Change From Baseline in the Physician Global Assessment of Disease Activity at Week 24|Percentage Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24|Percentage Change From Baseline in the High Sensitivity C-Reactive Protein (CRP) at Week 24|Percentage Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24|Percentage of Participants Who Achieve an Improvement of ≥ 0.22 Units From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24|Percentage of Participants Who Achieve an Improvement of at Least 4 Units From Baseline in the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-Fatigue) at Week 24|Percentage of Participants Who Achieve the European League Against Rheumatism (EULAR) Response Criteria Using CRP at Week 24|Percentage of Participants With an American College of Rheumatology 20% Improvement (ACR 20) Response at Week 52|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52|Change From Baseline in the Medical Outcome Study Short Form 36-item (SF-36) Physical Functioning Domain at Week 52|Change From Baseline in the Clinical Disease Activity Index (CDAI) at Week 52|Percentage of Participants Who Achieve Low Disease Activity or Remission Based on the Clinical Disease Activity Index (CDAI) ≤ 10 at Week 52|Change From Baseline in the Disease Activity Score 28 (DAS 28) Using CRP at Week 52|Percentage Change From Baseline in the Tender Joint Count at Week 52|Percentage Change From Baseline in the Swollen Joint Count at Week 52|Percentage Change From Baseline in the Subject Assessment of Pain at Week 52|Percentage Change From Baseline in the Subject Global Assessment of Disease Activity at Week 52|Percentage Change From Baseline in the Physician Global Assessment of Disease Activity at Week 52|Percentage Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 52|Percentage Change From Baseline in the High Sensitivity C-Reactive Protein (CRP) at Week 52|Percentage Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 52|Change From Baseline in the FACIT-Fatigue Scale Score at Week 52|Percentage of Participants Who Achieve an Improvement of ≥ 0.22 Units From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 52|Percentage of Participants With an American College of Rheumatology 50% Improvement (ACR 50) Response at Week 52|Percentage of Participants With an American College of Rheumatology 70% Improvement (ACR 70) Response at Week 52|Percentage of Participants Who Achieve an Improvement of at Least 4 Units From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 52|Percentage of Participants Who Achieve the European League Against Rheumatism (EULAR) Response Criteria Using CRP at Week 52|Percentage of Participants With an American College of Rheumatology 20% Improvement (ACR 20) Response at Year 2|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Year 2|Change From Baseline in the Medical Outcome Study Short Form 36-item (SF-36) Physical Functioning Domain at Year 2|Change From Baseline in the Clinical Disease Activity Index (CDAI) at Year 2|Percentage of Participants Who Achieve Low Disease Activity or Remission Based on the Clinical Disease Activity Index (CDAI) ≤ 10 at Year 2|Change From Baseline in Disease Activity Score 28 (DAS28) (Using C-Reactive Protein) (CRP) at Year 2|Percentage Change From Baseline in the Individual American College of Rheumatology Components at Year 2|Change From Baseline in the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-Fatigue) at Year 2|Percentage of Participants Who Achieve an Improvement of ≥ 0.22 Units From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Year 2|Percentage of Participants With an American College of Rheumatology 50% Improvement (ACR 50) Response at Year 2|Percentage of Participants With an American College of Rheumatology 70% Improvement (ACR 70) Response at Year 2|Percentage of Participants Who Achieve an Improvement of at Least 4 Units From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Year 2|Percentage of Participants Who Achieve the European League Against Rheumatism (EULAR) Response Criteria Using CRP at Year 2","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","237","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-RA-002|2010-019926-15","December 9, 2010","February 21, 2012","September 10, 2012","January 28, 2011","August 15, 2014","October 19, 2017","ArthroCare, Arthritis Care Research, Gilbert, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|TriWest Research Associates, La Mesa, California, United States|Desert Medical Advances, Palm Desert, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Med Investigations/Sierra, Roseville, California, United States|Inland Rheumatology Clinical Trials, Inc., Upland, California, United States|Denver Arthritis Clinic, Denver, Colorado, United States|In Vivo Clinical Research, Doral, Florida, United States|San Marcus Research Clinic, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Jeffrey Alper, MD Research, Naples, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Tampa Medical Group, PA, Tampa, Florida, United States|Alastair Kennedy, MD, Vero Beach, Florida, United States|LaPorte County Institute for Clinical Research, Inc., Michigan City, Indiana, United States|Associated Internal Medicine Specialists, PC, Battle Creek, Michigan, United States|Saint Paul Rheumatology, Eagan, Minnesota, United States|Physician's East, Greenville, North Carolina, United States|David R. Mandel, M.D., Inc., Mayfield, Ohio, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Austin Regional Clinic, Austin, Texas, United States|Metroplex Research Center, Dallas, Texas, United States|Modern Research Associates, Dallas, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Stone Oak Rheumatology, San Antonio, Texas, United States|Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Arthritis Northwest, Rheumatology, Spokane, Washington, United States|Revmatologie s.r.o., Brno, Czechia|L.K.N. Arthrocentrum s.r.o., Hlucin, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|Revmatologicky ustav, Praha, Czechia|Revmatologicka ambulance, Praha, Czechia|Fakultni Thomayerova nemocnice s poliklinikou, Praha, Czechia|PV - MEDICAL, s.r.o., Zlin, Czechia|NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik, Bialystok, Poland|NZOZ Centrum Osteoporozy i Chorob Kostno-Stawowych, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Centrum Kliniczno-Badawcze, Elblag, Poland|Centrum Leczenia Chorob Cywilizacyjnych, Gdynia, Poland|Centrum Leczenia Chorob Cywilizacyjnych, Katowice, Poland|Malopolskie Centrum Medyczne (408), Krakow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej REUMED, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|Centrum Leczenia Chorob Cywilizacyjnych, Warszawa, Poland|Hospital Universitario a Coruña, A Coruña, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Sierrallana, Torrelavega, Spain",,"https://ClinicalTrials.gov/show/NCT01285310"
304,"NCT01284348","To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer",,"Terminated","No Results Available","Anemia|Carcinoma, Non-Small-Cell Lung|Carcinoma, Small-Cell Lung|Bladder Cancer|Cancer of Head and Neck|Uterine Cervical Cancer","Drug: Sotatercept 15 mg|Drug: Sotatercept 30 mg","Hematopoietic response|Adverse Events|Disease progression|Progression free survival (PFS)|Overall survival (OS)|Overall response rate (ORR)|Serum concentration of ACE-011|Maximum ACE-011 concentration|Quality of Life|Time to reach the maximum ACE-011 concentration|Area under the concentration versus time curve|Terminal Elimination Half-life|Apparent Serum Clearance (CL/F)|Apparent Volume of distribution (Vz)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","ACE-011-NSCL-001","January 2011","April 2013","April 2013","January 27, 2011",,"November 17, 2017","Arizona Oncology Associates, P.C.,, Phoenix, Arizona, United States|Pacific Cancer Medical Inc., Anaheim, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Compassionate Cancer Care Medical Group, Inc, Fountain Valley, California, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|Loma Linda University Cancer Institute, Loma Linda, California, United States|University of California Los Angeles, Los Angeles, California, United States|North Valley Hematology Oncology Medical Group, Mission Hills, California, United States|Medical Oncology Care Associates, Orange, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Central Coast Medical Oncology Group, Santa Maria, California, United States|Stockton Hematology Oncology Medical Group, Inc, Stockton, California, United States|Saint Mary Regional Cancer Center, Grand Junction, Colorado, United States|Hematology Oncology Associates, PC, Stamford, Connecticut, United States|Ocala Oncology Center Pl, Ocala, Florida, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Iowa Blood & Cancer Care, Cedar Rapids, Iowa, United States|Purchase Cancer Group, Paducah, Kentucky, United States|Lahey Clinic, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Minnesota Oncology Associates, PC, Minneapolis, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada (TORI), Henderson, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Monter Cancer Center, North Shore LIJ Health Systems, Lake Success, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Piedmont Hematology Oncology Associates, PLLC, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|University of Cincinnati Physician's Inc., Cincinnati, Ohio, United States|Saint Charles Medical Center, Bend, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Allison Cancer Center, Midland, Texas, United States|Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, Virginia, United States|Northwestern Medical Specialists, PLLC, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01284348"
305,"NCT01232283","Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.","ESTEEM 2","Completed","Has Results","Plaque Psoriasis","Drug: Apremilast|Drug: Placebo|Other: Topical or Phototherapy Therapy","Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline|Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction From Baseline|Percent Change From Baseline in the Affected Body Surface Area (BSA) at Week 16|Percent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16|Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline|Change From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16|Change From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16|Percentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline|Time to Loss of Effect (Loss of 50% Improvement in PASI Score Obtained at Week 32 Compared to Baseline) During the Randomized Treatment Withdrawal Phase|Number of Participants With Treatment Emergent Adverse Events (TEAEs) in the Placebo Controlled Phase|Number of Participants With Psoriasis Flare or Rebound in the Placebo Controlled Phase|Number of Participants With TEAEs During the Apremilast-Exposure Period Through Week 260|Number of Participants With Psoriasis Flare or Rebound in the Apremilast-Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","413","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-009","November 22, 2010","March 15, 2012","November 30, 2016","November 2, 2010","November 5, 2014","January 4, 2018","Arizona Skin and Laser Therapy Inst., Ltd., Phoenix, Arizona, United States|Burke Pharmaceutical Research, Hot Springs, Arkansas, United States|Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, United States|Dermatology Research Associates, Los Angeles, California, United States|Clinical Science Institute, Santa Monica, California, United States|Florida Academic Dermatology Center, Miami, Florida, United States|Advanced Medical Research, Atlanta, Georgia, United States|MedaPhase Inc., Newnan, Georgia, United States|Northwestern University Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Clinical Partners, LLC, Johnston, Rhode Island, United States|Radiant Research, Inc., Anderson, South Carolina, United States|Austin Dermatology Associates, Austin, Texas, United States|Modern Research Associates PLLC, Dallas, Texas, United States|Center for Clinical Studies, Houston, Texas, United States|Center for Clinical Studies, Webster, Texas, United States|Virginia Medical Research, Norfolk, Virginia, United States|Medizinische Universitat Wien, Universitatsklinik fur Dermatologie. Abteilung fur Immundermatologie, Vienna, Austria|Northwest Dermatology and Laser Centre, Calgary, Alberta, Canada|Stratica Medical, Edmonton, Alberta, Canada|NewLab Clinical Research, St. John's, Newfoundland and Labrador, Canada|Skin Center for Dermatology, Peterborough, Ontario, Canada|Windsor Clinical Research Inc., Winsor, Ontario, Canada|Q & T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ, Quebec, Canada|Bispebjerg Hospital, Copenhagen, Denmark|Centre d'lnvestigation Clinique, Hopital Jean Minjoz, Besancon, France|Hospital haut leveque, Pessac, France|Larrey University Hospital, Toulouse, France|Dr. med. Beatrice Gerlach, Dresden, Germany|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany|Universitäts-Hautklinik Kiel, Kiel, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Hautarztpraxis Mahlow, Mahlow, Germany|Universita degli Studi di Napoli Federico II, Napoli, Italy|Istituto Dermatologico San Gallicano IRCCS Dermatologia Clinica, Rome, Italy|A.O.U. Integrata di Verona Universitá degli Studi di Verona Sezione di Dermatologia e Venerologia, Verona, Italy|Hospital Universitario Fundacion Alcorcon, Alcorcón, Spain|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital Abente y Lago, La Coruna, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hopitaux Universitaires de Geneve-HUG, Geneva, Switzerland|University of Zurich Hospital, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01232283"
306,"NCT01212770","PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","PALACE 3","Completed","Has Results","Psoriatic Arthritis","Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16|Percentage of Participants With an ACR 20 Response at Week 24|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16|Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 16|Change From Baseline in Patient's Assessment of Pain at Week 16|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16|Change From Baseline in Dactylitis Severity Score at Week 16|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16|Change From Baseline in the Disease Activity Score (DAS28) at Week 16|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24|Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 24|Change From Baseline in Patient's Assessment of Pain at Week 24|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24|Change From Baseline in Dactylitis Severity Score at Week 24|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24|Change From Baseline in the Disease Activity Score (DAS28) at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24|Percentage of Participants With MASES Improvement ≥ 20% at Week 16|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16|Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16|Percentage of Participants With MASES Improvement ≥ 20% at Week 24|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24|Percentage of Participants With Good or Moderate EULAR Response at Week 24|Percentage of Participants With a ACR 50 Response at Week 16|Percentage of Participants With an ACR 70 Response at Week 16|Percentage of Participants With an ACR 50 Response at Week 24|Percentage of Participants With a ACR 70 Response at Week 24|Percentage of Participants Achieving a MASES Score of Zero at Week 16|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16|Percentage of Participants Achieving a MASES Score of Zero at Week 24|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24|Percentage of Participants With an ACR 20 Response at Week 52|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52|Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52|Percentage of Participants With a Modified PsARC Response at Week 52|Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI75) at Week 52|Change From Baseline in the Patient Assessment of Pain at Week 52|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52|Change From Baseline in the Dactylitis Severity Score at Week 52|Change From Baseline in the CDAI Score at Week 52|Change From Baseline in the DAS28 at Week 52|Change From Baseline in the FACIT-Fatigue Scale Score at Week 52|Percentage of Participants With MASES Improvement ≥ 20% at Week 52|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52|Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52|Percentage of Participants With an ACR 50 Response at Week 52|Percentage of Participants With an ACR 70 Response at Week 52|Percentage of Participants Achieving a MASES Score of Zero at Week 52|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","505","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-004","September 30, 2010","August 21, 2012","February 9, 2017","October 1, 2010","May 20, 2014","November 15, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Elite Clinical Studies, LLC, Phoenix, Arizona, United States|Catalina Pointe Clinical Research Incorporated, Tucson, Arizona, United States|Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, United States|Dermatology Research Associates, Los Angeles, California, United States|Desert Medical Advances, Palm Desert, California, United States|Joao Nascimento, MD, Bridgeport, Connecticut, United States|In Vivo Clinical Research, Doral, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Rheumatology Associates of Long Island, Orlando, Florida, United States|Advent Clinical Research, Pinellas Park, Florida, United States|Rockford Orthopedic Associates, LLC, Rockford, Illinois, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|DermResearch, PLLC, Louisville, Kentucky, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|STAT Research, Inc., Dayton, Ohio, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Austin Dermatology Associates, Austin, Texas, United States|Austin Regional Clinic, Austin, Texas, United States|Center for Clinical Studies, Houston, Texas, United States|Houston Medical Research, Houston, Texas, United States|Texas Research Center, Sugar Land, Texas, United States|Royal Prince Alfred Hospital, Camperdown, Australia|Skin Cancer Foundation, Carlton, Australia|Coff's Clinical Trials, Coffs Harbour, Australia|Heidelberg Repatriation Hospital, Heidelberg, Australia|Menzies Centre for Population Health Research, Hobart, Australia|Optimus Clinical Research Pty. Ltd, Kogarah, Australia|Coastal Joint Care, Maroochydore, Australia|The Queen Elizabeth Hospital, Woodville, Australia|Arthritis Research Centre of Canada, Vancouver, British Columbia, Canada|PerCuro Clinical Research, Victoria, British Columbia, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|Arthritis Centre, Winnipeg, Manitoba, Canada|Alpha Clinical Research, LLC, St John's, Newfoundland and Labrador, Canada|Niagara Peninsula Arthritis Centre Inc., St Catharines, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Helsingin Reumakeskus Oy, Helsinki, Finland|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Finnish Medical Research Co, Pori, Finland|Centre Hospitalier Sud Francilien - Site Gilles de Corbeil, Corbeil Essonnes, France|Hôtel-Dieu, Nantes, France|Groupe Hospitalier Archet I et II, Nice, France|Hopital Larrey Universite Paul Sabatier, Toulouse, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Klinische Forschung Berlin - Buch GmbH, Berlin, Germany|Klinikum der Friedrich-Schiller-Universität Jena, Jena, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Hallym University Sacred Heart Hospital, Anyang, Kyunggi, Korea, Republic of|Chungnam National University Hospital, DaeJeon, Korea, Republic of|Inha University Hosiptal, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Hospital of Lithuanian University Health and Sciences, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|Panevezys Hospital, Panevezys, Lithuania|Siauliai Hospital, Siauliai, Lithuania|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|Centrum Medyczne Silesiana Sp. z o.o., Bytom, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|REUMATIKA-Centrum Reumatologii Niepubliczny Zaklad Opieki Zdrowotnej, Warszawa, Poland|Baia Mare, Emergency County Hospital ""Dr. Constantin Opris"", Baia Mare, Romania|SC Duo Medical SRL, Bucharest, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|C.M.I. Dr. Ciornohuz Adriana, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kezch, Russian Federation|Research Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|City Hospital 26, St. Petersburg, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Poprad,Spisska Sobota, Slovakia|REUMEX s.r.o., Rimavska Sobota, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Basurto-Osakidetza, Bilbao, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Infanta Sofia, San Sebastian de los Reyes, Spain|HFR Fribourg - Hôpital Cantonal, Fribourg, Switzerland|Chuv Bh-04, Lausanne, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Haywood Hospital, Burslem, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01212770"
307,"NCT01212757","PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","PALACE2","Completed","Has Results","Psoriatic Arthritis","Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16|Percentage of Participants With an ACR 20 Response at Week 24|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16|Change From Baseline in Patient's Assessment of Pain at Week 16|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16|Change From Baseline in Dactylitis Severity Score at Week 16|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16|Change From Baseline in the Disease Activity Score (DAS28) at Week 16|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24|Change From Baseline in Patient's Assessment of Pain at Week 24|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24|Change From Baseline in Dactylitis Severity Score at Week 24|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24|Change From Baseline in the Disease Activity Score (DAS28) at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24|Percentage of Participants With MASES Improvement ≥ 20% at Week 16|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16|Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16|Percentage of Participants With MASES Improvement ≥ 20% at Week 24|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24|Percentage of Participants With Good or Moderate EULAR Response at Week 24|Percentage of Participants With a ACR 50 Response at Week 16|Percentage of Participants With an ACR 70 Response at Week 16|Percentage of Participants With an ACR 50 Response at Week 24|Percentage of Participants With a ACR 70 Response at Week 24|Percentage of Participants Achieving a MASES Score of Zero at Week 16|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16|Percentage of Participants Achieving a MASES Score of Zero at Week 24|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24|Percentage of Participants With a ACR 20 Response at Week 52|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52|Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52|Percentage of Participants With a Modified PsARC Response at Week 52|Change From Baseline in the Patient Assessment of Pain at Week 52|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52|Change From Baseline in the Dactylitis Severity Score at Week 52|Change From Baseline in the CDAI Score at Week 52|Change From Baseline in the DAS28 at Week 52|Change From Baseline in the FACIT-Fatigue Scale Score at Week 52|Percentage of Participants With MASES Improvement ≥ 20% at Week 52|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52|Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52|Percentage of Participants With an ACR 50 Response at Week 52|Percentage of Participants With an ACR 70 Response at Week 52|Percentage of Participants Achieving a MASES Score of Zero at Week 52|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52|Number of Participants With Treatment Emergent Adverse Events During the Placebo-Controlled Phase|Number of Participants With TEAEs During the Apremilast-Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","488","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-003|2010-018386-32","September 27, 2010","July 26, 2012","January 25, 2017","October 1, 2010","May 19, 2014","July 13, 2018","Clinical and Translational Research Center of Alabama, PC, Tuscaloosa, Alabama, United States|Denver Arthritis Clinic, Denver, Colorado, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Centre For Rheumatology, Immun. And Arthritis, Fort Lauderdale, Florida, United States|DMI Research, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Michael Bukhalo MD SC, Arlington Hts, Illinois, United States|Associated Internal Medical Specialist, PC, Battle Creek, Michigan, United States|Advanced Rheumatology, Lansing, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Research West Incorporated, Kalispell, Montana, United States|University of Rochester Medical Center, Rochester, New York, United States|Vital Research, Greensboro, North Carolina, United States|Unifour Medical Research Associatets LLC, Hickory, North Carolina, United States|Rheumatic Disease Associates, Willow Grove, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|Arthritis Care and Diagnostic Center, Dallas, Texas, United States|Luckster Enterprises, San Antonio, Texas, United States|Seattle Rheumatology Associates, Seattle, Washington, United States|Tacoma Center for Arthritis Research, PS, Tacoma, Washington, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|CHU Brugmann, Bruxelles, Belgium|UZ Gent, Ghent, Belgium|UZ Leuven, Leuven, Belgium|University Hospital of Liege CHU Liege, Liège, Belgium|Diagnostic and Consulting Centre 7, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria|17 Diagnostic and Consulting Centre Sofia EOOD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sv. Ivan Rilski, Sofia, Bulgaria|Diagnostic-Consultative Center Sveta Anna, Sofia, Bulgaria|Diagnostic and Consulting Centre 4, Varna, Bulgaria|Rheumatology Research Associates, Edmonton, Alberta, Canada|PerCuro Clinical Research, Victoria, British Columbia, Canada|Anna Jaroszynska Private Practice, Burlington, Ontario, Canada|William Bensen's Private Practice, Hamilton, Ontario, Canada|North Bay Dermatology Center, North Bay, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Wilderman Medical Clinic, Thornhill, Ontario, Canada|Darryl Toth's Private Practice, Windsor, Ontario, Canada|Revmatologie s.r.o., Brno, Czechia|MEDIPONT PLUS s.r.o.., Ceske Budejovice, Czechia|L.K.N. Arthrocentrum s.r.o., Hlucin, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|Affidea Praha s.r.o, Praha 11, Czechia|Revmatologicky ustav, Praha 2, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV - MEDICAL, s.r.o., Zlin, Czechia|Parnu Hospital, Pärnu, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|North Estonia Regional Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Universitaire Dupuytren, Limoges, France|Hopital Lariboisiere, Paris, France|Fondation Hôpital Saint-Joseph, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Klinikum der Johann-Wolfgang Goethe-Universität, Frankfurt, Germany|Praxis Karin Rockwitz, Goslar, Germany|Synexus Clinical Research GmbH, Leipzig, Germany|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Principal SMO Kft., Makó, Hungary|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale Luigi Sacco, Milano, Italy|Seconda Universita degli Studi di Napoli, Napoli, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Universita di Pisa, Pisa, Italy|Ospedale Civile Maggiore Borgo Trento, Verona, Italy|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Niepubliczny Zaklad Opieki Zdrowotnej REUMED, Lublin, Poland|Instytut Reumatologii im. prof. dr hab. med. Eleonory Reicher, Warsaw, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|City Clinical Hospital #5, Nizhniy Novgorod, Russian Federation|St.Petersburg State Medical Academy n. a. I.I.Mechnikov, St. Petersburg, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|Nelson Mandela School Of Medicine, Durban, South Africa|Greenacres Hospital, Port Elizabeth, South Africa|Jacaranda Hospital, Pretoria, South Africa|Hospital Universitario de Canarias, La Laguna, Spain|Hospital General Carlos Haya, Málaga, Spain|Hospital Sierrallana, Torrelavega, Spain|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Cathay General Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Cannock Chase Hospital, Cannock, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Poole Hospital, Poole, United Kingdom|Great Western Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01212757"
308,"NCT01203943","A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)",,"Terminated","No Results Available","Idiopathic Pulmonary Fibrosis|Pulmonary Fibrosis|Fibrosis|Interstitial Lung Disease|Lung Diseases, Interstitial","Drug: CC-930|Other: Placebo","Safety|Long-term safety|Disease progression/death rates|Pharmacokinetics-Cmax|Pharmacokinetics-Cmin|Pharmacokinetics-AUC|Pharmacokinetics-Tmax|Pharmacokinetics - t 1/2|Pharmacokinetics-Vz/f|Pharmacokinetics-CL/F","Celgene","All","50 Years and older   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-930-IPF-001","January 1, 2011","January 31, 2012","August 24, 2012","September 17, 2010",,"November 19, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|UC Davis Medical Center, Division of Pulmonary and Critical Care Medicine, Sacramento, California, United States|Stanford University, Pulmonary & Critical Care Clinic, Stanford, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Geisenger Center for Clinical Studies, Danville, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas, Galveston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Vermont Lung Center, Colchester, Vermont, United States|University of Calgary, Peter Lougheed Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital/University of British Columbia, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Victoria Hospital, London, Ontario, Canada|Notre-Dame Hospital du CHUM, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01203943"
309,"NCT01197560","Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Lenalidomide|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Rituximab|Drug: Etoposide","Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC)|Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase|Number of Participants With Treatment Emergent Events (TEAEs) in the Overall Treatment Phase by Initial Treatment Assignment|Stage 2: Overall Response Rate (ORR)|Stage 2: Duration of Response (DoR)|Stage 2: Overall Survival (OS)|Stage 2: Duration of Complete Response|Stage 2: Overall Response Rate for With a Duration of Response Lasting ≥ 16 Weeks|Stage 2: Time to Progression|Stage 2: Health Related Quality of Life Questionnaires","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-DLC-001","September 2, 2010","July 4, 2013","April 5, 2018","September 9, 2010","August 20, 2014","April 17, 2019","Providence St Joseph Medical Center/Cancer Center, Burbank, California, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Houston, Houston, Texas, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Brisbaine and Womens Hospital, Herston, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Innsbruck University Hospital, Innsbruck, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|University Hospital Hradec Kralove, Hradec Kralove 5, Czechia|Charles University, Praha, Czechia|ICH CHU Brest- C.H.U. MORAVAN, Brest Cedex 2, France|CHU de Grenoble-Hopital Albert Michallon, Grenoble, France|Chd -Vendee, La Roche Sur Yon, France|Centre Hospitalier Lyon Sud, Lyon, France|Institute Paoli-Calmette, Marsielle, France|Hotel Dieu, Nantes Cedex 1, France|Hôpital Saint Jean, Perpignan, France|CHRU-Hopital du Haut -Leveque, Pessac, France|CHU de Rennes Hopital de Pontchaillou, Rennes, France|University Hospital OF Toulouse Purpan, Toulouse, France|Hopital de Brabois Adultes, Vandoeuvre-les Nancy cedex, France|Istituto di Ematologica Istituto di Ematologica "" L.e. A. Seragnoli' Azienda Ospedaliera Universitaria Policlinico, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Clinica Ematologica, A.O.U. San Martino di Genova, Genova, Italy|IEO istituto Europeo di Oncologia, Miano, Italy|Universita Federico II di Napoli Nuovo Policlinico, Napoli, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Irccs/Crob, Rionero In Vulture (PZ), Italy|Policlinico Tor Vergata (Universta Tor Vergata), Roma, Italy|Azienda Ospedaliera di Perugai Ospedale S. Maria della Miseri, Terni, Italy|Hospital Universitari Vll D' Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Costa Del Sol, Marbella, Spain|CH de Orense, Ourense, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hosptial Clinico Universitario de Salamanca, Salamanca, Spain|Onkologiska kliniken, Umea, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Royal Bournemouth Hospital Haematology, Bournemouth, United Kingdom|Royal Devon and Exeter Hospital Haematology Department, Exeter, United Kingdom|St. James Institute of Oncology, Leeds, United Kingdom|Royal Mardsen Hospital - Fulham (Satellite Site), London, United Kingdom|The Christie Foundation Trust, I'st Floor, Haemotology Oncology Outpatients, Lymphoma Team, Manchester, United Kingdom|Derrford Hospital, Plymouth, United Kingdom|Southhampton University Hospital NHS Trust, Southhampton, United Kingdom|Royal Mardsen NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01197560"
310,"NCT01194219","Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis","ESTEEM 1","Completed","Has Results","Plaque Psoriasis","Drug: Apremilast|Drug: Placebo|Drug: Topical treatments or phototherapy","Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline|Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With At Least 2 Points Reduction From Baseline|Percent Change From Baseline in Percent of Affected Body Surface Area (BSA) at Week 16|Percent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16|Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline|Change From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16|Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16|Change From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16|Percentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline|Kaplan Meier Estimate of Time to Loss of PASI-75 Response (Loss of Effect) at Week 32 During the Re-Randomized Treatment Withdrawal Phase|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase|Number of Participants With TEAEs During the Apremilast-Exposure Period Through Week 260|Number of Participants With a Psoriasis Flare or Rebound During the Placebo-Controlled Phase|Number of Participants With a Psoriasis Flare or Rebound During the During the Apremilast-exposure Period Through Week 260","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","844","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-008","September 9, 2010","February 23, 2012","November 22, 2016","September 2, 2010","November 5, 2014","December 26, 2017",,,"https://ClinicalTrials.gov/show/NCT01194219"
311,"NCT01190644","Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors",,"Terminated","No Results Available","Solid Tumors","Drug: ACE 011","Red Blood Cell Mass|Plasma Volume|Absolute Reticulocyte Increase|Changes in Hemoglobin|Number of patients with adverse events","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ACE-011-ST-001","June 1, 2010","September 18, 2012","September 18, 2012","August 27, 2010",,"November 6, 2019","Saint Agnes Healthcare, Baltimore, Maryland, United States|Weinberg Cancer Institution at Franklin Square, Baltimore, Maryland, United States|Pennsylvania Oncology, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01190644"
312,"NCT01186939","An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: Azacitidine","Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA PH GL 2003 CL001 E","April 1, 2007","September 1, 2009","September 1, 2009","August 23, 2010","September 21, 2010","November 14, 2019","East Melbourne, Victoria, Australia|Herston, Australia|Perth, Australia|Woolloongabba, Australia|Plovdiv, Bulgaria|Aulnay Sous Bois Cedex, France|Berlin, Germany|Dusseldorf, Germany|Essen, Germany|Kiel, Germany|Heraklio, Crete, Greece|Haidari, Greece|Budapest, Hungary|Bologna, Italy|Firenze, Italy|Genova, Italy|Rome, Italy|Nijmegen, Netherlands|Lodz, Poland|Avda Campanar, Spain|Leon, Spain|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01186939"
313,"NCT01178281","Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence","RESUME","Completed","Has Results","Primary Myelofibrosis|MPN-associated Myelofibrosis","Drug: Pomalidomide 0.5 mg|Drug: Placebo|Drug: Pomalidomide","Percentage of Participants Who Achieved RBC-Transfusion Independence|China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days|Overall Survival|Duration of RBC-Transfusion Independence|Time to RBC-Transfusion Independence|Number of Participants With Treatment-emergent Adverse Events (TEAE)|Healthcare Resource Utilization|Change From Baseline in EuroQoL-5D (EQ-5D) Health Index Score|Change From Baseline in EuroQoL-5D (EQ-5D) Visual Analog Scale|Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CC-4047-MF-002|2010-018965-42","September 8, 2010","January 1, 2013","May 15, 2018","August 10, 2010","March 14, 2014","July 17, 2019","Mayo Clinic, Scottsdale, Arizona, United States|UCLA School of Medicine, Los Angeles, California, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai School of Medicine Brookdale University Hospital, Brooklyn, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Ruttenberg Treatment Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Medicine Taussig Cancer Institute, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Avera Hematology and Transplant, Sioux Falls, South Dakota, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States|Gosford Hospital, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Frankston Hospital, Frankston, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Medizinische Universitatklinik Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|Medizinische Universitat Wien, Vienna, Austria|Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Universitaire Ziekenhuis Leuven Gathuisberg, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de L'Universite de Montreal, Montreal,, Canada|Peking University People's Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Jiangsu Province Hospital, Jiangsu, China|Shanghai Ruijin Hospital, Shanghai, China|West China Hospital, Sichuan University, Sichuan, China|Blood Disease Hospital Chinese Academy of Medical Sciences, Tianjin, China|Hopital Albert Michallon, La Tronche, France|Hopital Saint Vincent de Paul, Lille, France|CHU Dupuytren, Limoges, France|Hopital Saint-Louis, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|Hopitaux Universitaires de Strasbourg, CHU Haute-Pierre, Strasbourg, France|Hopital Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Universitatsklinikum Aachen, Aachen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Universitatsklinikum Ulm, Ulm, Germany|Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria Federico II di Napoli, Napoli, Italy|Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy|IRCCS Fondazione Policlinico San Matteo, Universita di Pavia, Centro per lo Studio della Mielofibrosi, Pavia, Italy|IRCCS Fondazione Policlinico San Matteo, Universita di Pavia, Ematologia, Pavia, Italy|Ospedale di Circolo e Fondazione Macchi Varese, Varese, Italy|Juntendo University Hospital, Bunkyou-ku, Japan|Kyushu University Hospital, Fukuoka City, Japan|Tokai University Hospital, Isehara City, Japan|Kyoto University Hospital, Kyoto City, Japan|Nagasaki University Hospital, Nagasaki City, Japan|Tokyo Medical University Hospital, Shinjuku, Japan|VU University Medical Center, Amsterdam, Netherlands|Erasmus Medish Centrum, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Wojewodzki Szpital Specjalistyczny im. F.Chopina, Rzeszow, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 PAM, Szczecin, Poland|Centralny Szpital Kliniczny MSWiA, Warsaw, Poland|Russian Scientific Haematology Centre, Moscow, Russian Federation|Federal State Institution Russian Scientific-research Institute of Hematology and Transfusiology of Federal Medical-Biological Agency of Russia, Saint-Petersburg, Russian Federation|State Pavlov Medical University, Saint-Petersburg, Russian Federation|Federal State Institution ""Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies named after V.A. Almazov"", Saint-Petersburg, Russian Federation|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Clinico de Valencia, Valencia, Spain|Skane University Hospital, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Belfast City Hospital, Belfast, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|John Radcliffe Hospital NHS Trust, Headington, United Kingdom|St. Thomas Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01178281"
314,"NCT01177397","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma|Diffuse Large B-Cell Lymphoma|Glioblastoma Multiforme|Hepatocellular Carcinoma|Non-Small Cell Lung Cancer|Neuroendocrine Tumors of Non-Pancreatic Origin|Hormone Receptor-Positive Breast Cancer","Drug: CC-223","Safety|Pharmacokinetics|Pharmacodynamics|Efficacy","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","173","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-223-ST-001","July 20, 2010","November 15, 2016","December 9, 2016","August 9, 2010",,"November 14, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Mayo Clinic Cancer Clinical Studies Unit, Rochester, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Cancer Institute - Bellevue Hospital, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Institut Claudius Regaud, Toulouse Cedex, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif, France|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Sarah Cannon Research Institute UK, London, United Kingdom|UCL Cancer Institute, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01177397"
315,"NCT01172938","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","PALACE-1","Completed","Has Results","Psoriatic Arthritis","Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16|Percentage of Participants With an ACR 20 Response at Week 24|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24|Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16|Change From Baseline in Patient's Assessment of Pain at Week 16|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16|Change From Baseline in Dactylitis Severity Score at Week 16|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16|Change From Baseline in the Disease Activity Score (DAS28) at Week 16|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16|Change From Baseline in SF-36 Physical Function at Week 24|Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24|Change From Baseline in Patient's Assessment of Pain at Week 24|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24|Change From Baseline in Dactylitis Severity Score at Week 24|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24|Change From Baseline in the Disease Activity Score (DAS28) at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24|Percentage of Participants With MASES Improvement ≥ 20% at Week 16|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16|Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16|Percentage of Participants With MASES Improvement ≥ 20% at Week 24|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24|Percentage of Participants With Good or Moderate EULAR Response at Week 24|Percentage of Participants With a ACR 50 Response at Week 16|Percentage of Participants With an ACR 70 Response at Week 16|Percentage of Participants With an ACR 50 Response at Week 24|Percentage of Participants With a ACR 70 Response at Week 24|Percentage of Participants Achieving a MASES Score of Zero at Week 16|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16|Percentage of Participants Achieving a MASES Score of Zero at Week 24|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24|Percentage of Participants With a ACR 20 Response at Week 52|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52|Change From Baseline in the SF-36 Physical Functioning Domain at Week 52|Percentage of Participants With a Modified PsARC Response at Week 52|Change From Baseline in the Patient Assessment of Pain at Week 52|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52|Change From Baseline in the Dactylitis Severity Score at Week 52|Change From Baseline in the CDAI Score at Week 52|Change From Baseline in the DAS28 at Week 52|Change From Baseline in the FACIT-Fatigue Scale Score at Week 52|Percentage of Participants With MASES Improvement ≥ 20% at Week 52|Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52|Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52|Percentage of Participants With an ACR 50 Response at Week 52|Percentage of Participants With an ACR 70 Response at Week 52|Percentage of Participants Achieving a MASES Score of Zero at Week 52|Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52|Number of Participants With Adverse Events During the Placebo-Controlled Period|Number of Participants With Adverse Events During the Apremilast-Exposure Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-002","June 2, 2010","April 27, 2012","October 27, 2016","July 30, 2010","May 20, 2014","March 12, 2018","Achieve Clinical Research LLC, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|UCSD-Thornton Hospital, La Jolla, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States|North Florida Dermatology, Jacksonville, Florida, United States|Tampa Medical Group Pa, Tampa, Florida, United States|Sonora Clinical Research, LLC, Boise, Idaho, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|The Arthritis Center, Springfield, Illinois, United States|St. Francis Hospital and Health Centers, Michigan City, Indiana, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Justus Fiechtner MD PC, Lansing, Michigan, United States|Physicians East, Greenville, North Carolina, United States|Carolina Bone and Joint, Monroe, North Carolina, United States|Piedmont Medical Research Associates Inc, Winston-Salem, North Carolina, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|Dermatology Treatment and Research Center, Dallas, Texas, United States|Accurate Clinical Research Inc, Houston, Texas, United States|Arthritis and Osteoporosis Associates LLP, Lubbock, Texas, United States|Center for Clinical Studies, Webster, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Rheumatology Associates, Seattle, Washington, United States|Arthritis Northwest Rheumatology, Spokane, Washington, United States|Monash Medical Centre, Clayton, Victoria, Australia|Eastern Health Clinical School, Box Hill, Australia|Repatriation General Hospital, Daws Park, Australia|St Vincent's Hospital Melbourne, Fitzroy, Australia|Emeritus Research, Malvern, Australia|Ordination Wien Dr. Hanusch, Vienna, Austria|Medizinische Universitat Wien, Vienna, Austria|Kaiser-Franz-Josef Spital, Wien, Austria|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|St. Clare's Health Care Corporation of St. John's, St John's, Newfoundland and Labrador, Canada|Ultranova Skincare, Barrie, Ontario, Canada|MAC Research Incorporated, Hamilton, Ontario, Canada|K-W Musculoskeletal Research Inc., Kitchener, Ontario, Canada|Saint Josephs Healthcare System, London, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Probity Medical Research Inc, Waterloo, Ontario, Canada|Jude Rodrigues Private Practice, Windsor, Ontario, Canada|Hospital Maisonneuve - Rosemont, Montreal, Quebec, Canada|Institut de Rhumatologie de Montreal, Montreal, Quebec, Canada|Centre de Rhumatologie St-Louis, Sainte Foy, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke-Hospital Fleurimont, Sherbrooke, Quebec, Canada|Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada|Ipros - Chr Orleans, Orleans, France|Hopital Purpan, Toulouse Cedex, France|Klinikum Duisburg, Wedau Kliniken, Duisburg, Germany|Friedrich-Alexander-Universiät Erlangen Nürnberg, Erlangen, Germany|Allgemeines Krankenhaus Eilbeck, Hamburg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Praxis Prof. Herbert Kellner, München, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Honvéd Kórház - Állami Egészségügyi Központ, Budapest, Hungary|MAV Korhaz es Rendelointezet Szolnok, Szolnok, Hungary|Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet, Veszprém, Hungary|P3 Research, Crofton Downs, New Zealand|Waikato hospital, Hamilton, New Zealand|Middlemore Clinical Trials, New Zealand, New Zealand|Queen Elizabeth Hospital for Rheumatic Disease, Rotorua, New Zealand|North Shore Hospital, Takapuna, New Zealand|Timaru Hospital, Timaru, New Zealand|Szpital Uniwersytecki im. Dr A.Jurasza, Bydgoszcz, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Synexus SCM Sp. z o.o., Katowice, Poland|Wojewodzki Zespol Reumatologiczny, Sopot, Poland|Synexus SCM Sp. z o.o. Oddz. Warszawa, Warszawa, Poland|Kemerovo State Medical Academy, Kemerovo, Russian Federation|Ryazan I.P. Pavlov State Medical University, Ryazan, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Voronezh Regional Clinical Hopsital #1, Voronezh State Medical Academy, Voronezh, Russian Federation|Panorama Medical Centre, Cape Town, South Africa|Groote Schuur Hospital, Cape Town, South Africa|Chelmsford Medical Centre 2, Durban, South Africa|Clinresco Centres Pty Ltd, Johannesburg, South Africa|The Park, Pinelands, South Africa|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Barnsley Hospital, Barnsley South Yorkshire, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|West Suffolk Hospital, Edmunds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01172938"
316,"NCT01169298","A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma",,"Completed","No Results Available","Adult T-cell Leukemia-Lymphoma|Peripheral T-cell Lymphoma","Drug: Lenalidomide","The safety of lenalidomide evaluated based on the severity of adverse events and their causality|Response|PK-Time to Maximum Plasma Concentration (Tmax)|PK-Apparent Total Body Clearance (CL/F)|PK-Apparent Volume of Distribution (Vz/F)|PK-Terminal half-life (T1/2)|PK-Area under the Plasma concentration time curve (AUC)|Accumulation ratio (Cmax)|Accumulation ratio (AUCτ)|PK-Maximum Concentration in Plasma (Cmax)","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-ATLL-001","July 1, 2010","December 1, 2013","December 20, 2013","July 26, 2010",,"November 8, 2019","National Kyusyu Cancer Center, Fukuoka, Japan|Imamura Bun-in Hospital, Kagoshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|Nagoya Daini Red Cross Hospital, Nagoya, Japan|National Cancer Center Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01169298"
317,"NCT01146574","A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.",,"Completed","No Results Available","Anemia","Biological: Sotatercept|Biological: Placebo","PK-Observed maximum Concentration (Cmax)|PK-Time to maximum concentration (Tmax)|PK-Area under the concentration-time curve over the 28 day dosing interval (AUC 28d)|PK-Terminal half-life (T1/2,z)|Number of participants with Adverse Events|Proportion of subjects with Hb > 12g/dL|Proportion of subjects with rise in Hb > 2 g/dL during a 4 week period|Frequency of clinically significant changes in laboratory parameters from baseline|Blood pressure changes from baseline|Proportion of subjects that are able to achieve an absolute Hb concentration of > 10 g/dL|Time to reach target Hb concentration (> 10 g/dL) and target increase in Hb (≥ 1g/dL)|Proportion of subjects rescued and length of time to rescue therapy|Changes in Follicle Stimulating Hormone (FSH) and Sex Steroid Concentrations","Celgene|Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACE-011-REN-001","June 30, 2010","March 7, 2016","March 7, 2016","June 17, 2010",,"March 8, 2017","North American Research Institute, Azusa, California, United States|West Glendale Dialysis, Glendale, California, United States|California Institute of Renal Research, La Mesa, California, United States|Academic Medical Center, Los Angeles, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Nephrology Specialist Medical Group, Orange, California, United States|Pines Clinical Research Inc., Pembroke Pines, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Fresenius Medical Care North America MI, Kalamazoo, Michigan, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|Nephrology and Hypertension Associates, LTD, Tupelo, Mississippi, United States|St. Louis University Medical Center, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Kidney Specialists of Southen Nevada, Las Vegas, Nevada, United States|Brookview Hill Research Associates, LLC, Winston-Salem, North Carolina, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States|Nephrology Associates, PC, Nashville, Tennessee, United States|Corva Kidney Center Webster, Houston, Texas, United States|Beechnut Dialysis Center, Houston, Texas, United States|Miracle Medical Clinic, Houston, Texas, United States|Gessner Dialysis Center, Houston, Texas, United States|Tyler Nephrology Associates, PC, Tyler, Texas, United States|University of Virginia at University Ave., Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01146574"
318,"NCT01099267","Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003",,"Completed","Has Results","Myelodysplastic Syndrome",,"Participants Survival Status as of the Time of the Extension Study Follow-up|Kaplan Meier Estimate for Overall Survival|Participants Status Regarding Progression to Acute Myeloid Leukemia (AML) as of the Time of the Extension Study Follow-up|Kaplan Meier Estimate for Progression to Acute Myeloid Leukemia (AML)|Cause of Death for Participants Who Died","Celgene","All","18 Years and older   (Adult, Older Adult)",,"54","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","CC-5013-MDS-009|CC-5013-MDS-003E","March 1, 2010","October 1, 2010","October 1, 2010","April 6, 2010","November 18, 2011","November 19, 2019","Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Stanford University Cancer Center, Stanford, California, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|John Hopkins University Hospital, Baltimore, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|St. Johannes Hospital, Duisburg, Germany",,"https://ClinicalTrials.gov/show/NCT01099267"
319,"NCT01081028","Connect® MM- The Multiple Myeloma Disease Registry",,"Active, not recruiting","No Results Available","Multiple Myeloma",,"Identify and summarize patterns in therapeutic regimens|Identify and summarize patterns in therapeutic regimens and patient outcomes|Summarize Effectiveness of Treatment Regimens|Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes","Celgene","All","18 Years and older   (Adult, Older Adult)",,"3011","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Connect ® MM","September 1, 2009","December 31, 2024","December 31, 2024","March 5, 2010",,"September 2, 2019","The Cancer Center of Huntsville, Huntsville, Alabama, United States|DCH Health System, Tuscaloosa, Alabama, United States|US Oncology - Arizona Oncology Associates - Rudasill, Tucson, Arizona, United States|St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Clopton Clinic Hematology/Oncology, Jonesboro, Arkansas, United States|Little Rock Hematology Oncology Associates, PA, Little Rock, Arkansas, United States|Pacific Cancer Medical Center, Inc, Anaheim, California, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Southbay Oncology Hematology Partners, Campbell, California, United States|Compassionate Cancer Care Medical Group (Corona), Corona, California, United States|Southwest Cancer Care, Escondido, California, United States|Compassionate Cancer Care Medical Group (Fountain Valley), Fountain Valley, California, United States|Virginia K. Crosson Cancer Center, Fullerton, California, United States|TORI - Antelope Valley Cancer Center, Lancaster, California, United States|Monterey Bay Oncology, Monterey, California, United States|TORI - North Valley Hematology/Oncology, Northridge, California, United States|Hematology Oncology Associates, Oakland, California, United States|Comprehensive Cancer Center, Palm Springs, California, United States|Bay Area Cancer Research Group, LLC, Pleasant Hill, California, United States|New Hope Cancer & Research Institute, Pomona, California, United States|Campassionate Cancer Care Medical Group (Riverside), Riverside, California, United States|Capitol Hematology Oncology Medical Group - Sutter Roseville, Roseville, California, United States|TORI - Central Coast Medical Oncology, Santa Maria, California, United States|Redwood Regional Medical Group, Inc., Santa Rosa, California, United States|Stockton Hematology Oncology Medical Group, Inc., Stockton, California, United States|Institute for Myeloma and Bone Cancer Research, West Hollywood, California, United States|US Oncology- Rocky Mountain Cancer Center-Aurora, Aurora, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Boulder, Boulder, Colorado, United States|US Oncology- Rocky Mountain Cancer Center at the Pavillion, Colorado Springs, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Colorado Springs, Colorado Springs, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Rose, Denver, Colorado, United States|TORI - St. Mary's Advanced Medical Pavilion, Grand Junction, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Lakewood, Lakewood, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Littleton, Littleton, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Sky Ridge, Lone Tree, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Longmont, Longmont, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Parker, Parker, Colorado, United States|US Oncology - Rocky Mountain Cancer Center-Thornton, Thornton, Colorado, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Medical Oncology and Blood Disorders, LLP, Manchester, Connecticut, United States|Hospital of Central Connecticut, New Britain, Connecticut, United States|Hematology Oncology, PC, Stamford, Connecticut, United States|Delaware Clinical & Laboratory Physicians, PA, Newark, Delaware, United States|Hematology Oncology Associates, Boynton Beach, Florida, United States|University Cancer Institute, Boynton Beach, Florida, United States|Collaborative Research Group, Boynton Beach, Florida, United States|Flora Research Associates, Coral Springs, Florida, United States|Archbold Cancer Center, Deerfield Beach, Florida, United States|Flora Research Associates, Deerfield Beach, Florida, United States|Broward Oncology Associates, PA, Fort Lauderdale, Florida, United States|Florida Cancer Specialists & Research Institute, Gainesville, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|US Oncology - Florida Cancer Institute - New Hope-Hudson, Hudson, Florida, United States|Integrated Community Oncology Network, LLC, Jacksonville, Florida, United States|Watson Clinic, Lakeland, Florida, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|Pasco Hernando Oncology Associates (Kumar), New Port Richey, Florida, United States|US Oncology - Florida Cancer Institute - New Hope-New Port Richey, New Port Richey, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Cancer Care Centers of Brevard, Rockledge, Florida, United States|Florida Hospital Waterman-Lake County Oncology & Hematology, The Villages, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Peachtree Hematology-Oncology Consultants, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Cancer Care & Hematology Specialists of Chicagoland, PC, Arlington Heights, Illinois, United States|John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Univeristy of Chicago Medical Center, Section of Hematology/Oncology, Chicago, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|Northshore University Health System, Evanston, Illinois, United States|Ingalls Cancer Research Center, Harvey, Illinois, United States|Joliet Oncology, Joliet, Illinois, United States|Medical Arts Associates, Ltd, Moline, Illinois, United States|Oncology Specialists, S.C., Niles, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Orchard Research, Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana Blood and Marrow Transplant, LLC, Beech Grove, Indiana, United States|St. Francis Cancer Research, Beech Grove, Indiana, United States|Center for Cancer Care @ Goshen Health Systems, Goshen, Indiana, United States|Indiana University Cancer Center Clinical Research Office, Indianapolis, Indiana, United States|Cancer Research-Munster, Munster, Indiana, United States|Cancer Care Center Inc., New Albany, Indiana, United States|Oncology Hematology Associates of SW IN, Newburgh, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States|Iowa Blood and Cancer Care of PCI, Cedar Rapids, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Cedar Valley Medical Specialists, Waterloo, Iowa, United States|Covenant Clinic, Waterloo, Iowa, United States|Cancer Center of Kansas, PA, Wichita, Kansas, United States|Baptist Hospital East, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Alliance Hematology Oncology, PA, Westminster, Maryland, United States|Capecod Hospital/Davenport Mugar Cancer Center, Hyannis, Massachusetts, United States|Fallon Clinic, Worcester, Massachusetts, United States|Michigan State University/Bay Regional Medical Center, Bay City, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Michigan State University/McLaren Regional Medical Center, Flint, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Michigan State University/Breslin Cancer Center, Lansing, Michigan, United States|Michigan State University/Lapeer Regional Medical Center, Lapeer, Michigan, United States|Michigan State University/Mount Clemens Regional Medical Center, Mount Clemens, Michigan, United States|Newland Medical Associates, Novi, Michigan, United States|Michigan State University/Memorial Cancer Center, Owosso, Michigan, United States|Newland Medical Associates, Southfield, Michigan, United States|Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Park Nicollet Institute - Louisiana Ave., Saint Louis Park, Minnesota, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|St. Louis Cancer Care, LLP, Chesterfield, Missouri, United States|Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|St. Joseph Oncology, Saint Joseph, Missouri, United States|University Hematology Oncology, Inc., Saint Louis, Missouri, United States|Washington University in St. Louis, Division of Oncology, Section of Bone Marrow Transplantation & Leukemia, Saint Louis, Missouri, United States|Hematology Oncology Consultants, Inc, Saint Louis, Missouri, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|Montana Cancer Institute Foundation, Missoula, Montana, United States|Nebraska Hematology Oncology, PC, Lincoln, Nebraska, United States|Southeast Nebraska Hematology & Oncology Consultants, PC, Lincoln, Nebraska, United States|TORI - Comprehensive Cancer Centers of NV, Henderson, Nevada, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|VA Sierra Nevada Healthcare System, Reno, Nevada, United States|Essex Oncology of North Jersey, PA, Belleville, New Jersey, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Drs. Forte, Schleider, Attas & Condemi, PA, Englewood, New Jersey, United States|Hematology-Oncology Associates of Northern NJ dba Carol G. Simon, Morristown, New Jersey, United States|Steeplechase Cancer Center, Somerville, New Jersey, United States|US Oncology - New York Oncology Hematology, PC-Albany, Albany, New York, United States|US Oncology - Albany Medical Cancer Center, Albany, New York, United States|US Oncology - Amsterdam Community Cancer Program, Amsterdam, New York, United States|Bronx River Medical Associates, Bronx, New York, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Jonah Cancer Care Center & ECMC, Buffalo, New York, United States|US Oncology - Cavell Cancer Treatment Program, Hudson, New York, United States|Broome Oncology, Johnson City, New York, United States|Arena Oncology Associates, PC, Lake Success, New York, United States|US Oncology - New York Oncology Hematology, PC-Latham, Latham, New York, United States|US Oncology - New York Oncology Hematology, PC-Rexford, Rexford, New York, United States|SUNY Upstate Medical University - Adult Program, Syracuse, New York, United States|US Oncology - Troy Cancer Treatment Program, Troy, New York, United States|US Oncology - Cancer Centers of North Carolina - Cary, Cary, North Carolina, United States|DUMC Division of Cellular Therapy/ABMT, Durham, North Carolina, United States|Carolina Oncology Specialists, PA, Hickory, North Carolina, United States|Emerywood Hematology/Oncology, High Point, North Carolina, United States|US Oncology - Cancer Centers of North Carolina - Falls, Raleigh, North Carolina, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Med Center One, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Summa Health System - Cancer Research Office, Akron, Ohio, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Cleveland VA Medical Center, Cleveland, Ohio, United States|Mid Ohio Oncology/Hematology, Inc, Columbus, Ohio, United States|Hematology Oncology Center, Inc, Elyria, Ohio, United States|Lawrence M. Stallings MD LTD dba Trilogy Cancer Care, Wooster, Ohio, United States|US Oncology - Willamette Valley Cancer Institute - Eugene, Eugene, Oregon, United States|US Oncology - Willamette Valley Cancer Institute - Springfield, Springfield, Oregon, United States|Oncology Hematology of Lehigh Valley, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Consultants in Medical Oncology and Hematology, PC, Drexel Hill, Pennsylvania, United States|Andrews and Patel Associates, Harrisburg, Pennsylvania, United States|US Oncology - Medical Oncology Associates (Nahar), Kingston, Pennsylvania, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|UPCI Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Berks Hematology Oncology Associates, Reading, Pennsylvania, United States|Hematology & Oncology Associates of Rhode Island, Cranston, Rhode Island, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Butternut, Greenville, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - West Faris, Greenville, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Eastside, Greenville, South Carolina, United States|SC Cancer Specialists, PA, Hilton Head Island, South Carolina, United States|US Oncology - Cancer Center of the Carolinas - Seneca, Seneca, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Sanford Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Family Cancer Center, PLLC, Collierville, Tennessee, United States|SCRI, Nashville, Tennessee, United States|US Oncology - Texas Cancer Center - Abilene (South), Abilene, Texas, United States|US Oncology - Texas Oncology, PA - Amarillo, Amarillo, Texas, United States|US Oncology - Texas Oncology - Arlington South, Arlington, Texas, United States|US Oncology - Texas Oncology - Midtown, Austin, Texas, United States|US Oncology - Texas Oncology Cancer Center, Austin, Texas, United States|US Oncology - South Austin Cancer Center, Austin, Texas, United States|US Oncology - Texas Oncology North Austin, Austin, Texas, United States|Austin Cancer Centers, Austin, Texas, United States|US Oncology - Southwest Regional Cancer Center - North, Austin, Texas, United States|US Oncology - Texas Oncology, PA - Bedford, Bedford, Texas, United States|St. Joseph Regional Cancer Center, Bryan, Texas, United States|US Oncology - Texas Oncology Cedar Park, Cedar Park, Texas, United States|Scott & White Clinic, College Station, Texas, United States|South Texas Institute of Cancer, Corpus Christi, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|US Oncology - Texas Cancer Center at Medical City, Dallas, Texas, United States|US Oncology -Texas Oncology, PA - Dallas, Dallas, Texas, United States|US Oncology - El Paso Cancer Treatment Ctr, El Paso, Texas, United States|US Oncology - Texas Oncology, PA - Forth Worth, Fort Worth, Texas, United States|US Oncology - Southwest Forth Worth Cancer Center, Fort Worth, Texas, United States|US Oncology - Texas Oncology, PA - Garland, Garland, Texas, United States|US Oncology - Texas Oncology - Grapevine, Grapevine, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital Research Institute-AOCT, Houston, Texas, United States|Southlake Oncology dba Las Colinas Hematology Oncology, Irving, Texas, United States|US Oncology - San Antonio Tumor & Blood Clinic - Kerrville, Kerrville, Texas, United States|US Oncology - Texas Oncology - Kyle, Kyle, Texas, United States|US Oncology - Longview Cancer Center, Longview, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|US Oncology - Allison Cancer Center, Midland, Texas, United States|US Oncology - Texas Oncology - Odessa, Odessa, Texas, United States|US Oncology - North Texas Regional Cancer Center, Plano, Texas, United States|US Oncology - Texas Oncology Plano West Cancer Center, Plano, Texas, United States|US Oncology - Texas Oncology Seton Williamson, Round Rock, Texas, United States|US Oncology - Texas Oncology - Round Rock Cancer Center, Round Rock, Texas, United States|US Oncology - Cancer Care Centers of South Texas, San Antonio, Texas, United States|US Oncology - HOAST - Medical Dr., San Antonio, Texas, United States|US Oncology - San Antonio Tumor & Blood Clinic - M. Oak, San Antonio, Texas, United States|US Oncology - Texas Oncology - San Marcos, San Marcos, Texas, United States|Scott & White Healthcare Department of Research, Temple, Texas, United States|ETMC dba Blood and Cancer Center - East Texas, Tyler, Texas, United States|ETMC dba Tyler Hematology Oncology, Tyler, Texas, United States|US Oncology - Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|US Oncology - Texoma Cancer Center, Wichita Falls, Texas, United States|Central Utah Clinic, American Fork, Utah, United States|Northern Utah Associates, Ogden, Utah, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|US Oncology - Arlington Fairfax Hematology Oncology, Arlington, Virginia, United States|US Oncology - Fairfax-Northern VA Hem-Onc PC, Fairfax, Virginia, United States|US Oncology - Fairfax Northern Virginia Hematology-Oncology, PC-Gainesville, Gainesville, Virginia, United States|US Oncology - Fairfax-Northern Virgina Hem-Onc, PC-Leesburg, Leesburg, Virginia, United States|US Oncology - Shenandoah Oncology - Winchester, Winchester, Virginia, United States|US Oncology - Fairfax-Northern Virginia Hem-Onc, PC-Woodbridge, Woodbridge, Virginia, United States|Peace Health Medical Group, Bellingham, Washington, United States|US Oncology - Puget Sound Cancer Center-Edmonds, Edmonds, Washington, United States|Providence Everett Medical Center, Everett, Washington, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|US Oncology - Puget Sound Cancer Center-Seattle, Seattle, Washington, United States|US Oncology - Cancer Care Northwest - Sherman, Spokane, Washington, United States|Medical Oncology Associates PS, Spokane, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|US Oncology - Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|West Virginia University - Clinical Trials Research Unit, Morgantown, West Virginia, United States|Fox Valley Hematology & Oncology, Appleton, Wisconsin, United States|St. Vincent Hospital/Green Bay Oncology, Green Bay, Wisconsin, United States|CMS Water Tower Medical Commons Medical Oncology #100, Milwaukee, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Auxilio Cancer Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01081028"
320,"NCT01081015","Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry",,"Completed","No Results Available","Chronic Lymphocytic Leukemia",,"Identify and summarize patterns in therapeutic regimens and patient outcomes|Summarize Effectiveness of Treatment Regimens|Health Related Quality of Life Measures Related to Therapeutic Regimens","Celgene","All","18 Years and older   (Adult, Older Adult)",,"1494","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Connect™ CLL","March 19, 2010","December 31, 2017","December 31, 2017","March 5, 2010",,"September 26, 2018","New Hope Cancer & Research Institute, Pomona, California, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|University Cancer Institute, Boynton Beach, Florida, United States|Thomas Niederman, MD, Boynton Beach, Florida, United States|Pasco Hernando Oncology Associates (Kumar), New Port Richey, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Peachtree Hematology-Oncology Consultants, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|US Oncology - Dublin Hematology & Oncology, Dublin, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Arlington, Arlington Heights, Illinois, United States|John H. Stroger, Jr., Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Ingalls Cancer Research Center, Harvey, Illinois, United States|Elmhurst Memorial Hospital, Lombard, Illinois, United States|Oncology Specialists, S.C., Niles, Illinois, United States|US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Niles, Niles, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Orchard Research, Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Winfield, Winfield, Illinois, United States|St. Francis Cancer Research, Beech Grove, Indiana, United States|Center for Cancer Care @ Goshen Health Systems, Goshen, Indiana, United States|Indiana University Cancer Center Clinical Research Office, Indianapolis, Indiana, United States|Cancer Care Partners, LLC, Mishawaka, Indiana, United States|Cancer Care Center, Inc., New Albany, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States|Iowa Blood and Cancer Care of PCI, Cedar Rapids, Iowa, United States|Covenant Clinic, Waterloo, Iowa, United States|Cancer Center of Kansas, PA, Wichita, Kansas, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Western Maryland Health System, Inc., Cumberland, Maryland, United States|Alliance Hematology Oncology, PA, Westminster, Maryland, United States|Capecod Hospital / Davenport Mugar Cancer Center, Hyannis, Massachusetts, United States|Fallon Clinic, Worcester, Massachusetts, United States|Michigan State University / McLaren Regional Medical Center, Flint, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Park Nicollet Institute Metro - MN CCOP, Saint Louis Park, Minnesota, United States|Park Nicollet Institute - Louisiana Ave., Saint Louis Park, Minnesota, United States|US Oncology - University of Tennessee Cancer Institute - Southaven, Southaven, Mississippi, United States|US Oncology - Missouri Cancer Associates, Columbia, Missouri, United States|Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|St. Joseph Oncology, Inc., Saint Joseph, Missouri, United States|Hematology Oncology Consultants, Inc., Saint Louis, Missouri, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|Montana Cancer Institute Foundation, Missoula, Montana, United States|Nebraska Hematology Oncology, PC, Lincoln, Nebraska, United States|Southeast Nebraska Hematology & Oncology Consultants, PC, Lincoln, Nebraska, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|VA Sierra Nevada Healthcare System, Reno, Nevada, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Drs. Forte, Schleider, Attas & Condemi, PA, Englewood, New Jersey, United States|Charles Farber, MD, Morristown, New Jersey, United States|Hematology Oncology of Northern New Jersey, Morristown, New Jersey, United States|Steeplechase Cancer Center, Somerville, New Jersey, United States|Samuel S Stratton VAMC, Albany, New York, United States|Hematology Oncology Associates of Western Suffolk, Bay Shore, New York, United States|Eduardo Saponara, MD, Bronxville, New York, United States|Bronx River Medical Associates, Bronx, New York, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Jonah Cancer Care Center & ECMC, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|SUNY Upstate Medical University - Adult Program, Syracuse, New York, United States|US Oncology - Cancer Centers of North Carolina - Cary, Cary, North Carolina, United States|US Oncology - Cancer Centers of North Carolina - Macon, Raleigh, North Carolina, United States|US Oncology - Cancer Centers of North Carolina - Falls, Raleigh, North Carolina, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Summa Health System - Cancer Research Office, Akron, Ohio, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Mid Ohio Oncology / Hematology, Inc., Columbus, Ohio, United States|Hematology Oncology Center, Inc., Elyria, Ohio, United States|US Oncology - Willamette Valley Cancer Institute - Eugene, Eugene, Oregon, United States|US Oncology - Northwest Cancer Specialists, PC - Portland - Hoyt, Portland, Oregon, United States|US Oncology - Northwest Cancer Specialists, PC - Portland - Barnes, Portland, Oregon, United States|US Oncology - Northwest Cancer Specialists, PC - Portland - Broadway, Portland, Oregon, United States|US Oncology - Willamette Valley Cancer Institute - Springfield, Springfield, Oregon, United States|US Oncology - Northwest Cancer Specialists, PC - Tualatin, Tualatin, Oregon, United States|Oncology Hematology of Lehigh Valley, Bethlehem, Pennsylvania, United States|Consultants in Medical Oncology and Hematology, PC, Drexel Hill, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Andrews and Patel Associates, Harrisburg, Pennsylvania, United States|US Oncology - Medical Oncology Associates (Nahar), Kingston, Pennsylvania, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, United States|Berks Hematology Oncology Associates, Reading, Pennsylvania, United States|Hematology & Oncology Associates of Rhode Island, Cranston, Rhode Island, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|South Carolina Oncololgy Associates, PA, Columbia, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Butternut, Greenville, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - West Faris, Greenville, South Carolina, United States|US Oncology - Cancer Centers of the Carlinas - Eastside, Greenville, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|US Oncology - Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Sanford Clinic, Sioux Falls, South Dakota, United States|US Oncology - University of Tennessee Cancer Institute - Bartlett, Bartlett, Tennessee, United States|Family Cancer Center, PLLC, Collierville, Tennessee, United States|US Oncology - University of Tennessee Cancer Institute - Germantown, Germantown, Tennessee, United States|US Oncology - University of Tennessee Cancer Institute - Memphis, Memphis, Tennessee, United States|SCRI, Nashville, Tennessee, United States|US Oncology - Texas Cancer Center - Abilene (South), Abilene, Texas, United States|US Oncology - Texas Oncology, PA - Amarillo, Amarillo, Texas, United States|US Oncology - Texas Oncology - Arlington South, Arlington, Texas, United States|US Oncology - Texas Oncology, PA - Bedford, Bedford, Texas, United States|St. Joseph Regional Cancer Center, Bryan, Texas, United States|Scott & White Clinic, College Station, Texas, United States|South Texas Institute of Cancer, Corpus Christi, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|US Oncology - Texas Oncology, PA - Dallas, Dallas, Texas, United States|US Oncology - El Paso Cancer Treatment Center - West, El Paso, Texas, United States|US Oncology - El Paso Cancer Treatment Center, El Paso, Texas, United States|US Oncology - Texas Oncology, PA - Fort Worth, Fort Worth, Texas, United States|US Oncology - Southwest Fort Worth Cancer Center, Fort Worth, Texas, United States|US Oncology - Texas Oncology - Grapevine, Grapevine, Texas, United States|Oncology Consultants, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|US Oncology - San Antonio Tumor & Blood Clinic - Kerrville, Kerrville, Texas, United States|Wilford Hall Medical Center, Lackland Air Force Base, Texas, United States|US Oncology - Longview Cancer Center, Longview, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|US Oncology - Texas Oncology - McAllen, McAllen, Texas, United States|US Oncology - Texas Oncology - Mesquite, Mesquite, Texas, United States|US Oncology - Allison Cancer Center, Midland, Texas, United States|US Oncology - Texas Oncology - Paris, Paris, Texas, United States|US Oncology - Cancer Care Centers of South Texas, San Antonio, Texas, United States|US Oncology - San Antonio Tumor & Blood Clinic - M. Oak, San Antonio, Texas, United States|US Oncology - Texas Oncology - Sherman, Sherman, Texas, United States|Scott & White Healthcare Department of Research, Temple, Texas, United States|ETMC dba Blood and Cancer Center - East Texas, Tyler, Texas, United States|ETMC dba Tyler Hematology Oncology, Tyler, Texas, United States|US Oncology - Texas Oncology - Tyler, Tyler, Texas, United States|US Oncology - Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|US Oncology - Texas Oncology - Weslaco, Weslaco, Texas, United States|US Oncology - Texoma Cancer Center, Wichita Falls, Texas, United States|Central Utah Clinic, American Fork, Utah, United States|Northern Utah Associates, Ogden, Utah, United States|US Oncology - Arlington Fairfax Hematology Oncology, Arlington, Virginia, United States|US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Christiansburg, Christiansburg, Virginia, United States|US Oncology - Fairfax Northern VA Hem-Onc PC, Fairfax, Virginia, United States|US Oncology - Fairfax - Northern Virginia Hematology-Oncology, PC - Gainesville, Gainesville, Virginia, United States|US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Leesburg, Leesburg, Virginia, United States|US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Low Moor, Low Moor, Virginia, United States|US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Roanoke, Roanoke, Virginia, United States|US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Salem, Salem, Virginia, United States|US Oncology - Shenandoah Oncology - Winchester, Winchester, Virginia, United States|US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Woodbridge, Woodbridge, Virginia, United States|US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Wytheville, Wytheville, Virginia, United States|Peace Health Medical Group, Bellingham, Washington, United States|US Oncology - Puget Sound Cancer Center - Edmonds, Edmonds, Washington, United States|Providence Everett Medical Center, Everett, Washington, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|US Oncology - Puget Sound Cancer Center - Seattle, Seattle, Washington, United States|US Oncology - Cancer Care Northwest - Sherman, Spokane, Washington, United States|Medical Oncology Associates PS, Spokane, Washington, United States|US Oncology - Cancer Care Northwest - Holland, Spokane, Washington, United States|US Oncology - Cancer Care Northwest - Mission, Spokane, Washington, United States|US Oncology - Northwest Cancer Specialists, PC - Vancouver - 136th St., Vancouver, Washington, United States|US Oncology - Northwest Cancer Specialists, PC - Vancouver - 134th St, Vancouver, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|US Oncology - Yakima Valley Memorial Hospital/North Star Lodge (Boyd), Yakima, Washington, United States|St. Vincent Hospital/Green Bay Oncology, Green Bay, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01081015"
321,"NCT01074047","Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)",,"Completed","Has Results","Acute Myeloid Leukemia","Drug: Azacitidine|Drug: Conventional Care Regimen","Kaplan-Meier Estimates for Overall Survival|One-year Overall Survival Rate|Event-free Survival (EFS)|Relapse-Free Survival (RFS) for Participants Who Achieved a Complete Remission (CR) or Complete Remission With Incomplete Blood Count Recovery (CRi)|Percentage of Participants Who Achieved a Morphologic CR + CRi as Determined by the Independent Review Committee (IRC) Based on International Working Group (IWG) Response Criteria for Acute Myeloid Leukemia (AML)|Duration of Remission Assessed by the IRC Based on Kaplan-Meier Estimates|Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC.|Number of Participants With Adverse Events (AEs)|Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain|Health Related Quality of Life (HRQoL): Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Domain|HRQoL: Change From Baseline in the EORTC QLQ-C30 Dyspnea|HRQoL: Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain|HRQoL: Change From Baseline in the EORTC QLQ-C30 Global Health Status-/Quality of Life Domain|Healthcare Resource Utilization (HRU): Number of Inpatient Hospitalizations|Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year|HRU: Number of Participants Receiving Transfusions|HRU: Rate of Transfusions Per Patient Year|Number of Participants in the Extension Phase With Treatment Emergent Adverse Events (TEAEs)","Celgene","All","65 Years and older   (Older Adult)","Phase 3","488","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-AML-001","June 1, 2010","January 22, 2014","July 25, 2016","February 24, 2010","February 26, 2015","August 29, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital, Fitzroy, Australia|Klinikum Wels-Grieskirchen GmbH, Wels, Upper Austria, Austria|Wilhelminenspital, I Medizinische Abt., Wien, Vienna, Austria|Landeskliniken Salzburg Saint Johanns-Spital, III Medizinische Abteilung, Salzburg, Austria|Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Namur, Belgium|Universitair Ziekenhuis Gent, Ghent, Oost-vlaanderen, Belgium|Algemeen Ziekenhuis Sint-Jan, Brugge, West-vlaanderen, Belgium|Centre Hospitalier de Jolimont-Lobbes, La Louvière, Belgium|University of Alberta Hospital, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal pavilion Notre Dame, Montreal, Quebec, Canada|Hopital du Sacre Coeur de Montréal, Montreal, Quebec, Canada|Tom Baker Cancer Centre, Calgary, Canada|Princess Margaret Hospital, Ontario, Canada|The Third Hospital of Peking University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peoples Hospital of Jiangsu Province, Jiangsu, China|Shanghai Ruijin Hospital, Shanghai, China|Shanghai Changhai Hospital,the Second Military Medical University, Shanghai, China|West China Hospital,Sichuan University, Sichuan, China|Tianjin Blood Disease Hospital, Tianjin, China|Fakultni nemocnice Brno, Brno, Jihormoravsky Kraj, Czechia|Fakultni nemocnice Olomouc, hemato-onkologicka klinika, Olomouc, Olomoucký Kraj, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Praha, Czechia|Ustav hematologie a krevni transfuze, Praha 2, Praha, Czechia|Centre Hospitalier Régional Universitaire, Hôpital de Hautepierre, Strasbourg, Alsace, France|Hospital Avicenne, Service d'hematologie Clinique, Bobigny, ILE-DE-France, France|Hopital Percy Clamart, Clamart Cedex, Ile-de-france, France|Hôpital Saint Louis, Paris Cedex 10, Ile-de-france, France|Centre Hopitalier Universitaire Dupuytren, Limoges, Limousin Lorraine, France|Centre Hospitalier Universitaire de Toulouse, Toulouse Cedex 09, Midi-pyrénées, France|Centre Hospitalier Universitaire de Nice, Nice Cedex 3, Nice, France|CHRU d'Angers, Angers cedex 09, Pays de La Loire, France|Centre Hospitalier Universitaire Nantes, Hotel Dieu, Nantes Cedex 1, Pays de La Loire, France|Centre Hospitalier Universitaire d'Amiens, Groupe Hospitalier Sud, Amiens Cedex 1, Picardie, France|Hôpital de la Conception, Marseille, Provence Alpes Cote D'azur, France|Centre Hospitalier de la Cote Basque, Aquitaine, France|Centre Hospitalier Universitaire de Lyon-Hôpital Edouard Herriot, Lyon Cedex 03, France|Universitatsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|University of Rostock, Div. of Haematology and Oncology, Rostock, Mecklenburg-vorpommern, Germany|Heinrich-Heine-Universität Düsseldorf, Düesseldorf, Nordrhein-westfalen, Germany|Universitatsklinikum Essen, Zentrum fur Tumorforschung und Tumortherapie, Essen, Nordrhein-Westfallen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thueringen, Germany|Soroka Medical Center, Beer Sheva, Beersheva, Israel|Assaf Harofeh Medical Centre, Beer Yaakov, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center - Tel Hashomer, Heart Institute, Tel Hashomer, Israel|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Potenza, Italy|Azienda Sanitaria Ospedaliera ""San Luigi Gonzaga"", Orbassano, Turin, Italy|Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria, Alessandria, Italy|Azienda Ospedaliera Universitaria - Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliera Policlinico di Bari, Bari, Italy|Azienda Ospedaliera Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Udine, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|Yonsei University Health System, Seodaemun-gu, Seoul, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Saint Mary's Hospital Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Hospital at Guro, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroclaw, Dolnoslaskie, Poland|Dolnoslaskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku, Wroclaw, Dolnoslaskie, Poland|Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika, Lódz, Lodzkie, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland|Samodzielny Publiczny SK im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice, Slaskie, Poland|Central City Hospital # 7, Ekaterinburg, Russian Federation|City Clinical Hospital n.a. S. P. Botkin, Moscow, Russian Federation|State Healthcare Institution ""Nizhny Novgorod N.A. Semashko Regional Clinical Hospital"", Nizhniy Novgorod, Russian Federation|Saint Petersburg State Academician I.P. Pavlov Medical University, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Son Dureta, Palma de Mallorca, Baleares, Spain|Hospital Son Llàtzer, Palma de Mallorca, Baleares, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Chang Gung Memorial Hospital, Kaohsiung, Niao-Sung Hsiang, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital Pei-Tou District, Taipei, Taiwan|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Barts and the London NHS Trust, London, United Kingdom|King's College Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01074047"
322,"NCT01029262","A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q","MDS-005","Completed","Has Results","Anemia","Drug: Lenalidomide|Other: Placebo","Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)|Percentage of Participants With a Erythroid Gene Signature Who Achieved RBC Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)|Percentage of Participants Who Achieved RBC Transfusion Independence With a Duration of ≥ 24 Weeks (168 Days) as Determined by the Sponsor|Kaplan Meier Estimates of Duration of 56-day RBC Transfusion Independence Response as Determined by the Sponsor|Percentage of Participants Who Achieved an Erythroid Response Based on the Modified International Working Group (IWG) 2006 Criteria|Time to 56-Day RBC-Transfusion-Independent (TI) Response as Determined by the Sponsor|Kaplan Meier Estimates for Progression to Acute Myeloid Leukemia (AML)|Kaplan Meier Estimate for Overall Survival (OS)|Number of Participants With Treatment Emergent Adverse Events (TEAE)|Compliance Rates Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) From Baseline to Week 48|Mean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain at Week 12 and 24|Mean Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain at Week 12 and 24|Mean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain at Week 12 and 24|Mean Change From Baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life (QOL) Domain at Week 12 and 24|Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain at Week 12 and 24|Mean Change From Baseline in Fatigue Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24|Mean Change From Baseline in the Dyspnea Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24|Mean Change From Baseline in the Physical Functioning Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24|Mean Change From Baseline in the Global Health Status/QoL Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24|Mean Change From Baseline in the Emotional Functioning Domain Associated With the EORTC QLQ-C30 Scale at Weeks 12 and 24|Percentage of Participants With a Clinically Meaningful Improvement in QOL (EORTC QLQ-C-30 Scale) From Baseline in Fatigue Domain at Weeks 12 and 24|Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Dyspnea Domain at Weeks 12 and 24|Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline Within the Physical Functioning Domain at Weeks 12 and 24|Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Global Health Status/QOL Domain at Weeks 12 and 24|Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Emotional Functioning Domain at Weeks 12 and 24|Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Related to Adverse Events Per Person Year|Healthcare Resource Utilization (HRU): Duration of Hospitalizations Due to Adverse Events|Healthcare Resource Utilization (HRU): Number of Days of Hospitalization Due to Adverse Events Per Person-Years","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","239","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-MDS-005","January 26, 2010","March 17, 2013","May 9, 2018","December 9, 2009","June 18, 2015","June 25, 2019","University of California at Los Angeles, Los Angeles, California, United States|Southern Illinois Hematology Oncology, Centralia, Illinois, United States|Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medizinische Universitat Innsbruck, Innsbruck, Austria|Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Austria|Universitatsklinik fur Innere Medizin Salzburg, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Weis, Austria|Wiener Gebietskrankenkasse-Hanusch-Krankenhaus, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Center Hospitalier Universitaire Ambroise Pare, Mons, Belgium|Cliniques Universitaires UCL de Mont-Godine, Namur, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnepeg, Manitoba, Canada|Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada|Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada|Maisonneuve Rosemont, Montreal, Quebec, Canada|McGill University, Dept. Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Vseobecna Fakultni Nemocnice v Praze, Prague, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|CHU d'Angers, Angers, France|Hopital Avicenne, Bobigny Cedex, France|Hopital A. Michallon, La Tronche, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institut Paoli-Calmettes, Marseille cedex, France|Groupe hospitalier Cochin Saint-Vincent de Paul, Paris Cedex, France|BAG Freiberg-Richter, Jacobash, Illmer, Wolf, Dresden, Germany|Marien Hospital, Duesseldorf, Germany|Sankt Johannes Hospital Duisburg, Duisberg, Germany|Universitätsklinikum Düsseldorf, Düesseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum Mannheim der Universitat Heidelberg, Heidelberg, Germany|Universitat zu Koln, Köln, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|TU München - Klinikum rechts der Isar, München, Germany|Rabin Medical Center, Petach-Tikva, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Az. Osp. SS.Antonio e Biagio - SC Ematologia, Alessandria, Italy|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|P.O. Ospedale Roberto Binaghi (UNI CA/ASL 8), Cagliari, Italy|Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Cardarelli, Naples, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Roma, Italy|Policlinico Agostino Gemelli - Istituto di Ematologia, Roma, Italy|Policlinico Univeristario di Udine, Udine, Italy|Hiroshima University Hospital, Hiroshima, Japan|Tokai University School of Medicine, Isehara City, Kanagawa, Japan|Kameda General Hospital, Kamogawa, Japan|Kanazawa University Hospital, Kanazawa, Japan|Nagasaki Unversity Hospital, Nagasaki, Japan|National Hospital Organization Nagoya Medical Center, Nagoya, Japan|Osaka Red Cross Hospital, Osaka, Japan|Tohoku University Hospital, Sendai, Japan|Japanese Red Cross Medical Center, Shibuya, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|Kanto Medical Center NTT EC, Shinagawa, Japan|Katedra i Klinika Hematologii i Transplantacji Szpiku - SLASKIEGO UNIWERSYTETU MEDYCZNEGO, Gdansk, Poland|Uniwersytet Medyczny w Lodzi, Lodz, Poland|Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warsaw, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Gazi Universitesi Tip Fakltesi, Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Istanbul Universitesi Istanbul, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Faiultesi, Izimir, Turkey|Royal Bournemouth Hospital, Bournemouth, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom|King's College Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01029262"
323,"NCT01021423","A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).","RENEW","Terminated","Has Results","Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma","Drug: Lenalidomide|Other: Placebo","Progression-free Survival (PFS)|Overall Survival|Participants With Treatment Emergent Adverse Events (TEAEs)|Time to Progression|Time to Treatment Failure|Participants With a Tumor Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-MCL-003","April 1, 2010","March 1, 2011","March 1, 2011","November 30, 2009","December 2, 2011","November 19, 2019","Sharp Healthcare Oncology Associates of San Diego, San Diego, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Providence Cancer Center, Indianapolis, Indiana, United States|Nebraska Hematology-Oncology, PC, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Arena Oncology Associates, Lake Success, New York, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|Fakultni nemocnice Hradec Králové II. Interni klinika-Oddeleni klinicke hematologie, Hradec Králové, Czechia|Fakultni Nemocnice Olomouc, Hemato-Onkologicka Klinika, Olomouc, Czechia|Clinic of Oncology Faculty Hospital Motol, Prague 5, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna Fakultni Nemocnice, Praha 2, Czechia|CHU Amiens Sud, Centre de Recherche Clinique - Pharmacologie Clinique, Amiens Cedex, France|CHU Hôpital Hotel Dieu, Angers, France|CHU ESTAING, Service d'Hématologie, Clermont Ferrand Cedex 1, France|Hôpital Henri Mondor Unité Hémopathies Lymphoides, Créteil, France|CHD Les Oudairies, Service d'Oncologie Hématologie, La Roche sur Yon, France|Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard 1F Hématologie, La Tronche, France|CHRU - Hôpital Claude Huriez, Lille Cedex, France|CHU Montpellier - Hôpital Saint Eloi Hématologie et Oncologie Médicale, Montpellier cedex 5, France|CHRU - Hotel Dieu, Nantes Cedex 1, France|Hôpital Saint-Louis, Paris Cedex 10, France|CHRU - Hôpital du Haut Lévêque, maladies du sang, Centre François Magendie, Pessac, France|Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard 1F Hématologie, Pierre Bénite Cedex, France|CHU de Poitiers, Pôle Régional de Cancérologie, Service d'Oncologie Hématologie et Thérapie Cellulaire, Poitiers, France|CHU de Reims, Hôpital Robert Debré, Hématologie Clinique, Reims Cedex, France|Hôpital Pontchaillou Hématologie Clinique, Rennes Cedex, France|Centre Henri Becquerel, Rouen Cedex 1, France|Hôpital Purpan CHU de Toulouse, Toulouse cedex 9, France|Hôpital Bretonneau - CHU Tours, Tours, France|CHU de Nancy Hôpital de Brabois, Service d'Hématologie et Médecine Interne, Vandoeuvre Les Nancy, France|Universitätsklinikum Essen Zentrum für Innere Medizin, Essen, Germany|Universitätsklinikum Freiburg - Medizinische Klinik - Abteilung Innere Medizin I: Hämatologie und Onkologie, Freiburg, Germany|UKG Universitätsklinikum Göttingen Zentrum Innere Medizin Hämatologie / Onkologie, Göttingen, Germany|Asklepios Klinik St. Georg - Abteilung für Hämatologie und Stammzelltransplantation, Hamburg, Germany|Städtisches Klinikum Karlsruhe - Hämatologie / Onkologie Karlsruhe, Karlsruhe, Germany|Klinikum der Universität München - Großhadern, Medizinische Klinik III, München, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Soroka Medical Center The Institute of Hematology, Beer Sheva, Israel|Davidoff Cancer Center The Institute of Hematology, Petah Tiqwa, Israel|Az. Osp. SS.Antonio e Biagio SC Ematologia, Alessandria, Italy|Ospedale Regionale di Bolzano - Divisione di Ematologia, Bolzano, Italy|Hematology Dept, Azienda Ospedaliero Universitaria Careggi, Florence, Italy|Azienda Ospedaliera Universitaria ""San Martino"", Genova, Italy|Az. Osp. Ospedali Riuniti Papardo - Piemonte - S.C. Ematologia, Messina, Italy|Fondazione San Raffaele del Monte Tabor I.R.C.C.S., Milano, Italy|A,O Ospedale Niguarda Ca Granda Dept Hematology, Milan, Italy|Istituto Nazionale Tumori Fondazione ""G. Pascale"" - Oncoematologia, Napoli, Italy|Università del Piemonte Orientale ""Amedeo Avogadro"", Novara, Italy|Policlinico San Matteo - Dip. Di Ematologia, Pavia, Italy|Az. Osp. Bianchi Melacrino Morelli, Div. Di Ematologia, Reggio Calabria, Italy|Università Cattolica del Sacro Cuore Policlinico A. Gemelli, Roma, Italy|IRCCS Casa Sollievo della Sofferenza Div. Di Oncoematologia, S.Giovanni Rotondo (FG), Italy|Azienda Sanitaria Ospedaliera San Giovanni Battista (Molinette), Torino, Italy|Ospedale Cardinale G. Panico - Ematologia e Immunoematologia, Tricase, Italy|Clinica Ematologica - DIRM Azienda Ospedaliera Universitaria, Udine, Italy|Małopolskie Centrum Medyczne, Krakow, Poland|Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika, Lodz, Poland|Dolnoslaskie Centrum Transplantacji Komórkowych, Wroclaw, Poland|Serviço de Hematologia, Coimbra, Portugal|Instituto Português de Oncologia (IPO) de Lisboa, Lisboa, Portugal|Instituto Português de Oncologia (IPO) do Porto, Porto, Portugal|Centro de Cancer, Hospital Espanol Auxilio de Puerto Rico, San Juan, Puerto Rico|Sverdlovsk Regional Clinical Hospital - Volgogradskaya, Ekaterinburg, Russian Federation|Republican Clinical Oncological Dispensary, Kazan, Russian Federation|Russian Oncological Research Centre, Moscow, Russian Federation|Perm Regional Clinical Hospital, Perm, Russian Federation|Russian Scientific-research Institute of Hematology and Transfusiology of Federal Medical-biological agency, St. Petersburg, Russian Federation|State Educational Institution of High Professional Education, St. Petersburg, Russian Federation|Federal Center of Heart, Blood and Endocrinology n.a. V.A. Almazov Rosmedtechnologies, St. Petersburg, Russian Federation|State Healthcare Institution ""Volgograd Regional Clinical OncologyDispensary #1, Volgograd, Russian Federation|Hospital Universitario Vall d´Hebrón Hematology Department, Barcelona, Spain|Hospital de Madrid Norte- Sanchinarro, Madrid, Spain|Hospital Costa del Sol, Oncology, Marbella (Málaga), Spain|C. H. de Orense, Ourense, Spain|Clinica Universitaria de Navarra, Hematology, Pamplona, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Marques de Valdecilla, Santander, Spain|Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom|Torbay Hospital, County Of Devon, United Kingdom|Royal Devon & Exeter Hospital, Exeter, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Barts & The London NHS Trust Medical Oncology, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Salisbury NHS Foundation Trust, Haematology, Salisbury, United Kingdom|St Helens Hospital, Lilac Lower Ground, St. Helens, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01021423"
324,"NCT00988208","Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer","Mainsail","Completed","Has Results","Prostate Cancer","Drug: Lenalidomide|Drug: Docetaxel|Drug: Prednisone|Drug: Placebo","Overall Survival (OS)|Progression-Free Survival (PFS)|Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria|Number of Participants With Treatment Emergent Adverse Events (AEs)|Percentage of Participants Who Received Post-Study Therapies|Percentage of Participants With Secondary Primary Malignancies During the Course of the Trial|Time to Onset of Secondary Primary Malignancies","Celgene","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1059","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-PC-002|EudraCT Number 2008-007969-23","November 11, 2009","January 13, 2012","November 28, 2016","October 2, 2009","September 5, 2013","April 4, 2018","Hematology Oncology Associates, Phoenix, Arizona, United States|Northern AZ Hematology and Oncology Assoc, Sedona, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|City of Hope Cancer Center, Duarte, California, United States|Southwest Cancer Center - Escondido, Escondido, California, United States|Scripps Cancer Center - Clinical Research, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|The Angeles Clinc and Research Institute, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|Prostate Oncology Specialists, Marina Del Rey, California, United States|Stanford University Medical Center, Stanford, California, United States|Rocky Mountain Cancer Centers-Colorado Springs Circle, Colorado Springs, Colorado, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Cancer Institute - New Hope, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, P.A.- West Gore Street, Orlando, Florida, United States|South Florida Oncology - Hematology, Tamarac, Florida, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States|Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States|Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Hematology and Oncology Specialist, LLC, Metairie, Louisiana, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Summit Medical Group Overlook Oncology Center, Berkeley Heights, New Jersey, United States|Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, United States|Hematology Oncology Associates of South Jersey, Mount Holly, New Jersey, United States|New York Oncology Hematology P.C., Albany, New York, United States|Columbia Univ Medical Center, New York, New York, United States|Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States|New Bern Cancer Care, New Bern, North Carolina, United States|Cancer Centers of North Carolina, Raleigh, North Carolina, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Northwest Cancer Specialists-Tualatin, Tualatin, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Cancer Center of the Carolinas, Greer, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Sarah Cannon Research Institute UK, Nashville, Tennessee, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology, PA, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A.-Fort Worth, Fort Worth, Texas, United States|Longview Cancer Center, Longview, Texas, United States|Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A. - Paris, Paris, Texas, United States|Southlake Oncology, Southlake, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|Texas Oncology Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Texoma Cancer Center, Wichita Falls, Texas, United States|Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States|Cancer Outreach Associates, Abingdon, Virginia, United States|Fairfax Northern Virginia Hematology Oncology, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|VA Puget Sound HCS Seattle Division, Seattle, Washington, United States|Evergreen Hematology and Oncology, Spokane, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Chris O'Brien Lifehouse, Camperdown, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Port Macquarie Base Hospital, Port Macquarie, Australia|Redcliffe Hospital, Redcliffe, Australia|Royal North Shore Hospital, St Leonards, Australia|Newcastle Calvary Mater Hospital, Waratah, Australia|Westmead Hospital, Westmead, Australia|Border Medical Oncology, Wodonga, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medical University of Graz, Graz, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Krankenhaus der Barmherzigen Brueder, Vienna, Austria|Medizinische Universitat Wien, Vienna, Austria|ZNA Middelheim, Antwerpen, Belgium|Hopital Erasme, Brussels, Belgium|Edith Cavell Clinic, Bruxelles, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|The Health Institute for Men CMX Research Inc, Toronto, Ontario, Canada|Les Urologues Specialises, Montreal, Quebec, Canada|Krajska zdravotni, a.s. Nemocnice Chomutov, o.z., Chomutov, Czechia|Fakultni nemocnice Motol, Prague 5, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La, Usti Nad Labem, Czechia|Arhus Universitets hospital, Aarhus C, Denmark|Herlev Hospital, Herlev, Denmark|Rigshospitalet University Hospital, Kobenhavn, Denmark|Odense Universitetshospital, Odense C, Denmark|CRLCC Paul Papin, Angers 49, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Centre Georges Francois Leclerc, Dijon Cedex, France|Clinique Victor Hugo, Le Mans, France|Centre Oscar Lambret, Lille 59, France|Centre Leon Berard, Lyon, France|Clinique de Valdegour, Nimes, France|CHU de Poitiers, Poitiers Cedex, France|Centre Eugene Marquis, Rennes Cedex, France|CRLCC Centre Rene Gauducheau, Saint Herblain 44, France|Institut de Cancerologie de la Loire, Saint Priest En Jaroz, France|Hopital Civil de Strasbourg, Strasbourg, France|CHRU Hopital Bretonneau, Tours Cedex, France|Institut Gustave Roussy, Villejuif, France|Vivantes Klinikum am Urban, Berlin, Germany|Medizinisches Zentrum Bonn-Friedensplatz, Bonn, Germany|Diakonissenkrankenhaus Dessau gGmbH, Dessau-Rosslau, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Krankenhaus Nordwest, Frankfurt a.M., Germany|Onkologische Praxis Freiburg, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany|IORC- Innovation Onkologie Research and Consulting GmbH, Hamburg, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|Vituro GmbH & Co KG, Leipzig, Germany|TU München - Klinikum rechts der Isar, München, Germany|Universitaetsklinikum Muenster, Münster, Germany|University-Hospital Tübingen, Tuebingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Alexandra General Hospital of Athens, Athens, Greece|Agioi Anargyroi Hospital, Athens, Greece|University Hospital of Larissa, Larissa, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Fovarosi Onkirmanyzat Peterfy S.Utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, Hungary|Fovarosi Onkormanyzat Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Pecsi Tudomanyegytem Altalanos Orvostudomanyi Kar, Pecs, Hungary|The Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Ordine Mauriziano, Candiolo, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Ospedale Vito Fazzi, Lecce, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale di Mirano, Mirano (VE), Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Miserico, Udine, Italy|Hospital Angeles Lindavista, D.f, Df, Mexico|Consultorio de Especialidad en Urologia Privado, Durango, DGO, Mexico|Hospital Fatima, Sinaloa, SIN, Mexico|Consultorio Privado- Dr Jose Arturo Rodriguez Rivera, Zapopan, JAL, Mexico|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arhem, Netherlands|Amphia Ziekenhuis Molengracht, Breda, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Gemini Ziekenhuis, Den Helder, Netherlands|Albert Schweitzer Ziekenhuis Amstelwijck, Dordrecht, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Twee Steden Ziekenhuis Tilburg, Tilburg, Netherlands|VieCuri Medisch Centrum Venlo, Venlo, Netherlands|Isala Klinieken, Zwolle, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Regionalny Osrodek Onkologiczny WSS im. M. Kopernika, Lodz, Poland|ZOZ MSWiA z Warminsko- Mazurskim Centrum Onkologii, Olsztyn, Poland|NZOZ Olsztynski Osr. Onkologiczny Kopernik Sp.z o.o, Olsztyn, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, Poland|Moscow Oncology Clinical Dispensary 1, Moscow, Russian Federation|Medical Radiology Research Centre RAMS, Obninsk, Russian Federation|State Institution of Heath Omsk Regional Oncology Dispensary, Omsk, Russian Federation|Russian Scientific Center for Radiology and Surgical Technol, St. Petersburg, Pesochny Vlg Saint Petersburg, Russian Federation|NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russian Federation|Oncology Dispensary 2 of Krasnodar Region, Sochi, Russian Federation|Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Groote Schuur Hospital, Cape Town, W Cape, South Africa|The Oncology Centre Durban, Durban, KZ-Natal, South Africa|Westridge Medical Centre, Durban, KZ-Natal, South Africa|Netcare Oncology and Interventional Centre, Goodwood, W Cape, South Africa|Dr. H. Malan, Polokwane, South Africa|Pretoria Urology Hospital, Pretoria, South Africa|Hospital del Mar, Barcelona, Spain|Hospital Durán i Reynals - Instituto Catalàn de Oncologìa ICO, Hospitalet de Llobregat, Barcelona, Spain|Hospital Arnau de Vilanova, Lérida, Spain|Hospital 12 de Octobre, Madrid, Spain|HCU Virgen de la Victoria, Malaga, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Mutua de Terrassa, Terrassa (Barcelona), Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Lanssjukhuset Ryhov, Jönköping, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Centrallasarettet Vasteras, Västerås, Sweden|Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|St George's Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie NHS Trust Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, Scunthorpe, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00988208"
325,"NCT00975806","Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma",,"Terminated","Has Results","Renal Cell Carcinoma","Drug: Lenalidomide|Drug: Sunitinib","Phase 1: Maximum Tolerated Dose (MTD)|Phase 2: Tumor Response Rate According to Response Evaluation Criteria In Solid Tumors (RECIST 1.1)|Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Lenalidomide and Sunitinib|Phase 1 : Tumor Response Rate According to RECIST 1.1|Progression Free Survival (PFS)|Duration of Response|Overall Survival (OS)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-RCC-001","September 2009","October 2011","October 2011","September 11, 2009","December 29, 2014","May 31, 2017","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, United States|Tennessee Oncology, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00975806"
326,"NCT00963105","Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",,"Completed","Has Results","Relapsed or Refractory Chronic Lymphocytic Leukemia","Drug: lenalidomide","Number of Participants With Treatment-emergent Adverse Events|Overall Response Rate (ORR)|Kaplan-Meier Estimate of Duration of Response|Time to Response|Kaplan-Meier Estimate of Time to Progression|Kaplan-Meier Estimate of Event-Free Survival|Kaplan-Meier Estimate of Progression Free Survival|Kaplan-Meier Estimate of Overall Survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-CLL-009|2009-009836-54","October 19, 2009","September 5, 2017","September 5, 2017","August 21, 2009","October 2, 2018","October 31, 2018","UCSD Moores Cancer Center, La Jolla, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Stanford University School of Medicine, Stanford, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Northwestern University Medical Center Division of Hematology Oncology, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Long Island Jewish Medical Center CLL Research and Treatment Program, New Hyde Park, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Drexel University, College of Medicine, Clinical Research Group, Philadelphia, Pennsylvania, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|CHU Sud, Amiens, France|Hopital Avicenne, Bobigny Cedex, France|CHU Grenoble, Grenoble Cedex 09, France|Clinique Victor Hugo, Le Mans, France|Institut Paoli Calmettes, Marseille Cedex 9, France|CHU Montpellier - Hôpital Saint Eloi, Montpellier Cedex 5, France|Hopital Emile Muller, Mulhouse, France|Hopital Pitie Salpetriere, Paris, France|CH Perpignan - Hopital Saint-Jean, Perpignan, France|CHRU - Hopital du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Hopital Robert Debre, REIMS cedex, France|CHU Rennes Hematology, Rennes cedex, France|CHRU Hopital Brabois, Vandoeuvre les Nancy, France|Charite -Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Essen, Essen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Universitatsklinikum Schleswig Holstein, Kiel, Germany|Klinikum der Universitat zu Koln, Köln, Germany|University of Ulm Abteilung Innere Medizin III, Ulm, Germany|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera ""Vito Fazzi"" di Lecce, Lecce, Italy|I.R.C.C.S. Ospedale San Raffaele, Milano, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|Universita degli Studi di Padova, Padova, Italy|Universita' Degli Studi Di Perugia, Perugia, Italy|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Karolinska Universitetssjukhuset, Stockholm, Sweden|St James's Institute of Oncology, Leeds, United Kingdom|St.Bartholomew's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT00963105/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT00963105/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00963105"
327,"NCT00931606","Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer",,"Terminated","No Results Available","Chemotherapy Induced Anemia","Biological: Biological: ACE-011|Drug: Placebo","To evaluate the proportion of patients that have a hematopoietic response when ACE-011 is administered for the treatment of chemotherapy induced anemia in patients with metastatic breast cancer|To evaluate the safety and tolerability of ACE-011 for the treatment of chemotherapy induced anemia in patients with metastatic breast cancer","Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A011-08","June 1, 2009","November 18, 2010","November 18, 2010","July 2, 2009",,"October 24, 2019","Investigative Site, Sedona, Arizona, United States|Investigative Site, Hot Springs, Arkansas, United States|Investigative Site, Beverly Hills, California, United States|Investigative Site, Corona, California, United States|Investigative Site, Fountain Valley, California, United States|Investigative Site, Montebello, California, United States|Investigative Site, Riverside, California, United States|Investigative Site, Denver, Colorado, United States|Investigative Site, Boynton Beach, Florida, United States|Investigative Site, Hinsdale, Illinois, United States|Investigative Site, Evansville, Indiana, United States|Investigative Site, Wichita, Kansas, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Grand Rapids, Michigan, United States|Investigative Site, Tupelo, Mississippi, United States|Investigative Site, Kansas City, Missouri, United States|Investigative Site, Nyack, New York, United States|Investigative Site, Goldsboro, North Carolina, United States|Investigative Site, High Point, North Carolina, United States|Investigative Site, Winston-Salem, North Carolina, United States|Investigative Site, Bismarck, North Dakota, United States|Investigative Site, Middletown, Ohio, United States|Investigative Site, Philadelphia, Pennsylvania, United States|Investigative Site, Charleston, South Carolina, United States|Investigative Site, Austin, Texas, United States|Investigative Site, Dallas, Texas, United States|Investigative Site, Tyler, Texas, United States|Investigative Site, Lacey, Washington, United States|Investigative Site, Krasnodar, Russian Federation|Investigative Site, Moscow (1), Russian Federation|Investigative Site, Moscow (2), Russian Federation|Investigative Site, Nizhny Novgorod, Russian Federation|Investigative Site, Nizhny Novograd (2), Russian Federation|Investigative Site, Pyatigorsk, Russian Federation|Investigative Site, St. Petersburg (1), Russian Federation|Investigative Site, St. Petersburg (2), Russian Federation|Investigative Site, St. Petersburg (3), Russian Federation|Investigative Site, St. Petersburg (4), Russian Federation|Investigative Site, Stavropol, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00931606"
328,"NCT00928486","A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone","Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)|Myeloma Response Rate|Kaplan-Meier Estimates of Duration of Response (DoR)","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 3","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-022","April 28, 2009","September 10, 2010","September 10, 2010","June 26, 2009","June 14, 2016","November 20, 2019","Nagoya Medical Center, Nagoya-city, Aichi, Japan|Nagoya City University Hospital, Nagoya-city, Aichi, Japan|Fukuoka University Hospital, Fukuoka-city, Fukuoka, Japan|Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan|Osaka Red Cross Hospital, Osaka-city, Osaka, Japan|Tokushima University, Tokushima-city, Tokushima, Japan|Keio University Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00928486"
329,"NCT00915083","A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.",,"Completed","No Results Available","Advanced Solid Tumors","Drug: Amrubicin","To characterize the pharmacokinetics of amrubicin and amrubicinol (metabolite) in plasma, whole blood, and urine in patients given amrubicin as 5 minute IV infusions at 40 mg/m2 for 3 consecutive days; data will be obtained from blood & urine samples|To evaluate the potential effects on the QT/QTc interval in cancer patients when treated with 5 minute IV infusions of amrubicin 40 mg/m2 daily for 3 consecutive days; data will be obtained by ECG extraction from continuous 12-lead Holter monitoring|To determine the safety and tolerability of 40 mg/m2 amrubicin given as 5 minute IV infusions for 3 consecutive days; information will be collected by adverse event monitoring and laboratory safety tests.|1. Explore the relationship between pharmacokinetics and QTc interval change. Information will be obtained by further analysis of the datasets obtained from the primary outcome measures","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMR PH US 2008 PK002","June 1, 2009","May 1, 2011","May 1, 2011","June 5, 2009",,"November 1, 2019","University of California San Diego, La Jolla, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Indiana University Cancer Pavilion, Indianapolis, Indiana, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Sinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute, Baltimore, Maryland, United States|Montefiore Medical Center, Bronx, New York, United States|UT Health Science Center at San Antonio- Cancer Therapy and Research Center, San Antonio, Texas, United States|Hunstman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00915083"
330,"NCT00910910","Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)","ORIGIN","Completed","Has Results","B-Cell Chronic Lymphocytic Leukemia","Drug: Lenalidomide|Drug: Chlorambucil","Kaplan-Meier Estimate of Progression Free Survival (PFS)|Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014|Number of Participants With Adverse Events (AEs)|Number of Participants With Adverse Events With a Later Cut-off Date of 31 March 2014|Percentage of Participants With the Best Overall Response Based on the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines|Percentage of Participants With a Best Overall Response Based on IWCLL Guidelines With a Later Cut-off Date of 31 March 2014|Kaplan-Meier Estimate for Duration of Response|Kaplan-Meier Estimate for Duration of Response With a Later Cut-off Date of 31 March 2014|Time to Response|Time to Response for a Later Cut-off Date of 31 March 2014|Kaplan Meier Estimate of Overall Survival|Kaplan Meier Estimate for Overall Survival at the Final Analysis|Functional Assessment of Cancer Therapy-General to Create the FACT-Leukemia (FACT-Leu) Quality of Life Instrument|Euro Quality of Life Five Dimension (EQ-5D) Questionnaire|Number of Participants and Types of Subsequent Anti-cancer Therapies Received Post Treatment","Celgene","All","65 Years and older   (Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-CLL-008|2008-003079-32","October 13, 2009","March 31, 2014","May 9, 2018","June 1, 2009","December 21, 2016","July 9, 2019","California Cancer Associates for Research and Excellence cCARE, Escondido, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|University Hematology Oncology Inc., Centralia, Illinois, United States|North Chicago VA Medical Center, North Chicago, Illinois, United States|Medical Consultants, PC, Muncie, Indiana, United States|Floyd Memorial Cancer Center of Indiana, a division of Floyd Memorial Hospital and Health Services, New Albany, Indiana, United States|Purchase Cancer Group, Paducah, Kentucky, United States|University of Minnesota, Minneapolis, Minnesota, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Oncology and Hematology Associates, PA, Denville, New Jersey, United States|The Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Somerset Hematology-Oncology Associates, Somerville, New Jersey, United States|Roswell Park Cancer Center, Buffalo, New York, United States|New York Medical College, Valhalla, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States|Pottstown Memorial Medical Center, Pottstown, Pennsylvania, United States|Berks Hematology-Oncology Associates, West Reading, Pennsylvania, United States|Geisinger Health System, Wilkes-Barre, Pennsylvania, United States|Charleston Hematology Oncology P.A., Charleston, South Carolina, United States|South Carolina Cancer Specialists, Hilton Head Island, South Carolina, United States|Central Texas Veterans Health Care System, Temple, Texas, United States|Swedish Tumor Institute, Seattle, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|Columbia St Marys Cancer Center, Milwaukee, Wisconsin, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|IMVS, Adelaide, South Australia, Australia|Western Hospital, Footscray, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|St. Vincent Hospital, Fitzroy, Australia|Nepean Hospital, Kingswood, NSW, Australia|Calvary Mater Hospital, Waratah, Australia|Westmead Hospital Australia, Westmead, Australia|Universitaetsklinik Innsbruck, Innsbruck, Austria|Medical University of Vienna Internalmedicine 1, Hematology, Vienna, Austria|Institut Jules Bordet, Brussels, Belgium|Hopital Erasme, Brussels, Belgium|Hopital de Jolimont, Haine-Saint Paul, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHU Mont -Godinne, Yvoir, Belgium|Monte Tabor - Hospital Sao Rafael, Salvador, Bahia, Brazil|BIOCANCER - Centro de Pesquisa e Tratamento do Câncer S/A, Belo Horizonte, Minas Gerais, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Hospital Universitario de Brasilia, Brasílía, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|Pro Onco Centro de Tratamento Oncologico, Londrina, Brazil|Hospital Israelita Albert Einstein, Morumbi, Brazil|Instituto Estadual Arthur de Siqueira Cavalcanti - HEMORIO, Rio de Janeiro, Brazil|Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil|Centro de Estudos e Pesquisas de Hematologia e Oncologia da Faculdade de Medicina do ABC, Santo Andre, Brazil|Instituto de Ensino e Pesquisa Sao Lucas, São Paulo, Brazil|Fundação Antonio Prudente - AC Camargo Câncer center, São Paulo, Brazil|MHAT Georgi Stranski PlevenHematology Clinic, Pleven, Bulgaria|University hospital Sveti Georgi Hematology Clinic, Plovdiv, Bulgaria|Military Medical Academy, Sofia, Bulgaria|National Specialized Hospital for Active Treatment of Hematology Diseases, Sofia, Bulgaria|University hospital Sveta Marina, Varna, Bulgaria|Regional Health Authority B-Saint John Regional Hospital, Saint John, New Brunswick, Canada|General Hospital, Eastern Health, St John's, Newfoundland and Labrador, Canada|Hospital Charles LeMoyne, Greenfield Park, Quebec, Canada|Sacre-Couer Hospital, Montreal, Quebec, Canada|Instituto Oncologico, Renaca, Chile|Instituto Clinico Oncologico del Sur ICOS, Temuco, Chile|Oncomedica S.A., Monteria, Colombia|University Hospital Centre Split, Split, Croatia|General Hospital Sveti Duh, Zagreb, Croatia|Klinicka bolnica Dubrava Klinika za unutarnje bolesti Odjel za Hematologiju, Zagreb, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital2.Dep.Intern.Med. Hematology, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Faculty Hospital Kralovske Vinohrady, Prague, Czechia|Rigshospitalet University Hospital, Copenhagen, Denmark|Herlev University Hospital Dep of hematology, Harlev, Denmark|Roskilde University Hospital, Roskilde, Denmark|Bergonie Institut, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CHRU, Grenoble cedex 09, France|CHU Dupuytren, Limoges, France|Hopital de l'Archet 1, Nice, France|CHU Hautepierre, Strasbourg, France|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Szegedi TudomanyegyetemII Belgyogyaszati Klinika, Szeged, Hungary|Komarom-Esztergom Megye Onkormanyzat Szent Borbala Korhaza, Tatabanya, Hungary|Petz Aladar Country Hospital, Vasvari Pal U. 2, Hungary|Ha'Emek Medical Center, Afula, Israel|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Center, Beer Sheva, Israel|Bnei Zion Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Western Galilee Hospital, Naharia, Israel|Rabin Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel|Sheba Medical Center, Tel Hashomer, Israel|Azienda Ospedaliera Policlinico di Bari, Bari, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|IRCSS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy|Ospedale San Raffaele S.r.l., Milan, Italy|Istituto Europeo di Oncologia - IEO, Milan, Italy|Azienda Ospedaliero Universitaria di Modena, Modena, Italy|Ospedale Cardarelli, Naples, Italy|Universita del Piemonte Orientale, Novara, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|Universita degli Studi di Padova, Padova, Italy|Ospedale S. Chiara, Pisa, Italy|Azienda Ospedaliera Ospedale San Carlo, Potenza, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte, Siena, Italy|Ospedale Umberto I, Torrette Di Ancona, Italy|Maxima Medisch Centrum, Eindhoven, Netherlands|Spaame Ziekenhuis, Hoofddorp, Netherlands|Isala Klinieken, Zwolle, Netherlands|Christchurch Hospital, Christchurch, New Zealand|North Shore University Hospital, Takapuna, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika, Lodz, Poland|Specjalistyczny Szpital miejski im. Kopernika, Torun, Poland|Klinika Chorob wewnetrznych i Hematologii, Warszawa, Poland|Nowotworww Krwi i Transplantacji Szpiku, Wroclaw, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues Oncologia do Porto Francisco Gentil EPE, Porto, Portugal|Institutul Clinic Fundeni, Bucharest, Romania|Spitalul Clinic Coltea, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta Sf Spiridon Iasi, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania|Spitalul Clinic Municipal de Urgenta Timisoara, Timisoara, Romania|Archangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|City Hospital 8, Barnaul, Russian Federation|Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Russian Academy of Medical Sciences Institution, Moscow, Russian Federation|Moscow GUZ City Clinical Hospital, Moscow, Russian Federation|NUZ Central Clinical Hospital, Moscow, Russian Federation|GUZ Nizhegorodskaya Regional Clinical Hospital, Nizhniy Novgorod, Russian Federation|MUZ City clinical hospital, Novosibirsk, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation|GUS Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St. Petersburg, Russian Federation|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|Narodny onkologicky ustav, Bratislava, Slovakia|Martinska Fakultna Nemocnica, Martin, Slovakia|University Witwatersrand Oncology, Parktown, South Africa|Pretoria Academic Hospital, Pretoria, South Africa|Mary Potter Oncology Centre, Pretoria, South Africa|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain|Hospital General Universitario Morales Messeguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Donostia, San Sebastian, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario La Fe, Valencia, Spain|Royal Bournemouth General Hospital, Bournemouth, United Kingdom|St. Bartholomew's and The Royal London Hospital, London, United Kingdom|St George's Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00910910"
331,"NCT00875667","A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)","Sprint","Completed","Has Results","Mantle Cell Lymphoma|Lymphoma, Mantle-Cell","Drug: Lenalidomide|Drug: Investigators choice single agent","Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review|Kaplan Meier Estimate for Progression Free Survival by Investigator's Assessment at the Final Analysis|Percentage of Participants Who Achieved an Overall Response According to the IRC Central Review|Percentage of Participants Who Achieved an Overall Response as Assessed by the Investigator at the Final Analysis|Kaplan Meier Estimate for Duration of Response (DOR) According to the IRC Central Review|Kaplan Meier Estimate for Duration of Response as Assessed by the Investigator at the Final Analysis|Percentage of Participants With a Complete Response, Unconfirmed Complete Response, Partial Response and Stable Disease According to the IRC Central Review|Percentage of Participants With a Complete Response, Unconfirmed Complete Response, Partial Response and Stable Disease at the Final Analysis|Kaplan Meier Estimate of Time to Progression According to the IRC Central Review|Kaplan Meier Estimate of Time to Progression as Assessed by the Investigator at the Final Analysis|Kaplan Meier Estimate of Time to Treatment Failure (TTF) as Assessed by the Investigator|Kaplan Meier Estimate of Time to Treatment Failure as Assessed by the Investigator at the Final Analysis|Kaplan Meier Estimate of Time to First Response (TTFR) According to the IRC Central Review|Kaplan Meier Estimate of Time to First Response as Assessed by the Investigator at the Final Analysis|Kaplan Meier Estimate for Overall Survival (OS) According to the IRC Central Review|Kaplan Meier Estimate for Overall Survival as Assessed by the Investigator at the Final Analysis|Number of Participants With Treatment Emergent Adverse Events|Mean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Fatigue Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Pain Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Pain Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Nausea / Vomiting Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Nausea and Vomiting Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Constipation|Maximum Change From Baseline in the EORTC QLQ-C30 Constipation Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Diarhoea|Maximum Change From Baseline in the EORTC QLQ-C30 Diarhoea Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Insomnia Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Insomnia Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Dyspnoea Domain to Treatment Discontinuation Visit|Maximum Change From Baseline in the EORTC QLQ-C30 Dyspnoea Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain to Treatment Discontinuation Visit|Maximum Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Financial Problems Domain to Treatment Discontinuation Visit|Maximum Change From Baseline in the EORTC QLQ-C30 Financial Problems Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Global Health Status / QoL Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Global Health Status / QoL Domain to Treatment Discontinuation Visit|Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain|Maximum Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain to Treatment Discontinuation Visit","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MCL-002","April 30, 2009","June 28, 2018","October 9, 2018","April 3, 2009","September 16, 2019","September 16, 2019","UZ Brussels, Brussel, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Teaching Hospital BrnoHemato-oncology Dept, Brno, Czechia|University Hospital2.Dep. of Int.med. hematology, Hradec Kralove, Czechia|Charles University General Hospital, Prague, Czechia|Rigshospitalet Department of Haematology L4042, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Polyclinique Bordeaux Nord Aquitaine Service Onco-Hematologie, Bordeaux, France|Hotel Dieu, Clermont Ferrand, France|CHU Hopital Michallon, Grenoble cedex 09, France|Centre Hospitalier Departemental Les Oudrairies, La Roche sur Yon, France|Clinique Victor Hugo, Le Mans, France|CHRU-Hopital Claude Huriez, Lille, France|CHU Dupuytren, Limoges Cedex 1, France|Centre Leon Berard, Lyon, France|Institut Paoli-Calmettes, Marseille, France|CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, France|CHRU - Hotel Dieu, Nantes Cedex 1, France|Centre Antoine Lacassagne Oncologie medicale et Hematologie, Nice cedex 1, France|Hopital Saint-Louis, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite cedex, France|CHU Rennes Hematology, Rennes, France|Centre Henri Becquerel, Rouen Cedex, France|Hopital civil, Strasbourg, France|CHRU Hôpital de Hautepierre, Strasbourg, France|CHRU Hopitaux de Brabois, Vandoeuvre, France|Universitatsklinikum Essen, Essen, Germany|Universitaetsklinikum FreiburgInnere Med.1, Haematologie, Freiburg, Germany|UKG Universitatsklinikum Gottingen, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum des Saarlandes, Homburg-Saar, Germany|Stadtisches Klinikum Karlsruhe, Karlsruhe, Germany|Uniklinik Koln, Koeln, Germany|Universitatsklinik Munster, Muenster, Germany|University of Ulm, Ulm, Germany|Attikon General University Hospital of Athens, Athens, Greece|University of Patras, Patras, Greece|Rambam Medical Center, Haifa, Israel|Hadassah University Hospital, Jerusalem, Israel|Rabin Medical Center, Petach-Tikva, Israel|Sheba Medical Center, Tel Hashomer, Israel|A.O. Policlinico - Università di Bari, Bari, Italy|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|Ospedale Regionale di Bolzano, Bolzano, Italy|Ospedale Ferrarotto, Catania, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ematologia ed Immunologia, Lecce, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|San Raffaele Scientific Institute, Milano, Italy|Az. Osp. Vincenzo Cervello, Palermo, Italy|I.R.C.C.S. Policlinico San Matteo, Pavia, Italy|Az. Osp di Perugia, Perugia, Italy|Ospedale S. Chiara, Pisa, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Reference Cancer Center of Basilicata, Rionero in Vulture, Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Meander Medisch Centrum, Amersfoort, Netherlands|Medisch Spectrum Twente, Enshede, Netherlands|Isala Klinieken, Zwolle, Netherlands|Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland|Malopolskie Centrum medyczne s.c., Kraków, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie, Warsaw, Poland|Nowotworww Krwi i Transplantacji Szpiku, Wroclaw, Poland|Dolnoslaskie Centrum Transplantacji Komorkowych, Wroclaw, Poland|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Republic Clinical Oncology Dispensary, Kazan, Russian Federation|Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl, Moscow, Russian Federation|Nizhegorodskiy Regional Clinical Hospital named after N.A. Semashko, Nizhniy Novgorod, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Medical Radiology Research Centre RAMS, Obninsk, Russian Federation|Perm Territorial Oncology Dispensary, Perm, Russian Federation|Scientific Research Institute of OncologySoft Tissue Department, Rostov-na-Donu, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, Saint-Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, Saint-Petersburg, Russian Federation|Saratov Medical University Chair of Professional Pathology and Haematology, Saratov, Russian Federation|Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, St. Petersburg, Russian Federation|Volgograd Regional Clinical Oncology Dispensary 1, Volgograd, Russian Federation|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Lund University Hosptial, Lund, Sweden|University Hospital Uppsala, Uppsala, Sweden|Royal Bournemouth Hosp, Bournemouth, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Christie Hospital, Manchester, United Kingdom|Newcastle Hospital Foundation Trust, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT00875667/Prot_000.pdf|""Statistical Analysis Plan: CC-5013-MCL-002_SAP_Final_Redacted.19 December 2012"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT00875667/SAP_001.pdf|""Statistical Analysis Plan: CC05013-MCL-002_SAP_2011_Redacted 18 July 2011"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT00875667/SAP_002.pdf|""Statistical Analysis Plan: CC-5013-MCL-002_SAP_2010_Redacted 26 July 2010"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT00875667/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT00875667"
332,"NCT00866359","A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease",,"Completed","Has Results","Behcet Syndrome","Drug: Apremilast (CC-10004)|Drug: Placebo","Number of Oral Ulcers at Day 85|Pain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 85|Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) Scores at Day 85|Area Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85|Area Under the Curve for the Number of Genital Ulcers From Day 1 to 85|Area Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85|Sum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 85|Percentage of Participants Who Were Oral Ulcer-free (Complete Response), or Whose Oral Ulcers Were Reduced by ≥ 50%, (Partial Response)|Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85|Number of Treatment Emergent Adverse Events (TEAE) During the Placebo Controlled Treatment Phase|Number of New Manifestations of Behçet's Disease or Flare During the Placebo Controlled Treatment Phase|Number of Oral Ulcers at Day 169|Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 169|Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 169|Behçet's Disease (BD) Current Activity Index Form Score at Day 169|Number of New Manifestations of Behçet's Disease or Flare That Were Not Present at Day 1|Number of Oral Ulcers at Day 197|Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 197|Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 197|Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197|Summary of Treatment Emergent Adverse Events During the Active Treatment-Extension Phase","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-BCT-001|EudraCT#: 2008-002722-11","August 1, 2009","May 1, 2012","May 1, 2012","March 20, 2009","August 27, 2014","November 15, 2019","Mayo Clinic - Rheumatology and Internal Medicine, Jacksonville, Florida, United States|E5, Boston University School of Medicine, Boston, Massachusetts, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Eskişehir Osmangazi University, Eskişehir, Turkey|University of Istanbul, Istanbul, Turkey|Selçuk University, Konya, Turkey",,"https://ClinicalTrials.gov/show/NCT00866359"
333,"NCT00864253","A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma",,"Completed","Has Results","Malignant Melanoma","Drug: ABI-007|Drug: Dacarbazine","Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines|Participant Survival|Summary of Treatment-emergent Adverse Events (AEs)|Number of Participants Experiencing Dose Reductions, or Dose Interruptions, or Dose Delays of Study Drug|Nadir for the Absolute Neutrophil Count (ANC) Measurements|Nadir for White Blood Cells (WBCs) Measurements|Nadir for Platelet Count Measurements.|Nadir for the Hemoglobin Count Measurements|Pharmacokinetic Parameters","Celgene|University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 3","529","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA033","April 23, 2009","June 1, 2012","February 12, 2014","March 18, 2009","June 5, 2014","October 30, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|AZ Cancer Ctr, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Genesis Cancer Ctr - Hot Springs, Hot Springs, Arkansas, United States|University of Arkansa for Medical Sciences, Little Rock, Arkansas, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|San Diego Pacific Oncology and Hematology Associates, Encinitas, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|University of Southern California/Norris Cancer Center, Los Angeles, California, United States|University of CA Los Angeles, Los Angeles, California, United States|St. Mary's Medical Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|University of Miami Hospital and Clincs/SCCC, Miami, Florida, United States|Waren Billhartz Cancer Center, Maryville, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|IA Blood and Cancer Care, PLC, Cedar Rapids, Iowa, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|St. John's Medical Research, Springfield, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Piedmont Hematology, Winston-Salem, North Carolina, United States|OH State University Arthur G. James Cancer Hospital, Columbus, Ohio, United States|Integris Cancer Institute of OK, Oklahoma City, Oklahoma, United States|St. Luke's Hospital & Health Network, Bethlehem, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Mary Crowley Research Center, Dallas, Texas, United States|Univ of TX MD Anderson Cancer Ctr, Houston, Texas, United States|Univ of TX Med School at Houston, Houston, Texas, United States|Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Hope Oncology, Richardson, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Univ. of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Sydney West Cancer Trials Centre/Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands Perth, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA Centre for the Southern Interior, Kelowna, British Columbia, Canada|BCCA, Centre for the Southern Interior, Kelowna, British Columbia, Canada|BC Cancer Agency-Fraser Valley Ctr., Surrey, British Columbia, Canada|BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada|BC Cancer Agency-Vancouver Island Ctr., Victoria, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Credit Valley Hospital, Missiauga, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University Dept. of Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital Saint Andre' CHU de Bordeaux, Bordeaux, France|Centre Hospitaller Universitaire de Grenoble, Grenoble Cedex 09, France|CHRU Hopital Claude Huriez, Lile Cedax, France|Hopital Dypuytren-CHU de Limoges, Limoges cedex, France|Centre Leon Berad, Lyon, France|Hopital Sainte Marguerite, Marseille Cedex 9, France|CHU Hopital Saint Eloi, Montepellier Cedex 5, France|Centre Regional Val d' Aurelle Paul Lamarque, Montpellier, France|Hopital de 1 Archet 2, Nice Cedex 3, France|Hopital Saint-Louis, Paris Cedex, France|Hopital Bichat, Paris, France|Groupe hospitalier Cochin-St. Vincent de Paul, Paris, France|Institut Gustave Roussy (IGR) Centre de Lutte Contre le Canc, Villejuif Cedex, France|Charite Universitaetsmedizin Berlin, Berlin, BE, Germany|Universitaetsklinkum Heidelberg, Heidelberg, BW, Germany|Universitaetsklinkum Heidelberg, Heidelber, BW, Germany|Universitaetsklinkum Tuebingen, Tuebingen, BW, Germany|Universitaetsklinkum Wuerzburg PS, Wuerzburg, BY, Germany|Universitaetsklinkum Hamburg-Eppendorf, Hamburg, HH, Germany|Univeritaetsklinkum Goettingen, Gottington, NI, Germany|Medizinische Hochschuke Hannover, Hannover, NI, Germany|St. Josef-Hospital, Bochum, Northwest, Germany|Universitaetsklinkum Essen, Essen, Northwest, Germany|Universitaetklinkum Koeln, Koln, Northwest, Germany|Universitaetsklinkum Schegwig-Holstein, Keil, SH, Germany|Universitaetsklinkum Dresden, Dresden, SN, Germany|UniversitawtsklinKum Jena, Jena, Strasse 35, Germany|Universitaesklinkum Leipzig, Leipzig, Germany|Universitaetsklinkum Mainz, Mainz, Germany|Istituto Tumori ""Giovanni Paolo II"", Bari, BA, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei T, Meldola, FC, Italy|IST-Istituto Nazionale per la Ricera sul Cancro, Genova, GE, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Nazionale Tumori, Milano, MI, Italy|IOV-Instituto Oncologico IRCCS, Padova, PD, Italy|Azienda Ospedaliera Universitaria Sense, Siena, SI, Italy|Ist. Naz. per lo studio e la cura dei tumori G. Pascale, Napoli, Italy|Ospedale S. Chiara, Pisa, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Rijnstate ziekenhuis Arnhem, Amhem, Netherlands|Erasmus MC ae"" Daniel den Hoed, Rotterdam, Netherlands|H Clinic i Provincial, Barcelona, Spain|H CLINIC I Provincial, Barcelona, Spain|H Clinico San Carlos, Madrid, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Broomfield Hospital, Chelmsford, Essex, United Kingdom|Velindre Hospital, Cardiff, Glam, United Kingdom|St. George's Hospital, London, GT Lon, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nott, United Kingdom|Singleton Hospital, Sothwest Wales Inst., Swansea, S Glam, United Kingdom|Univ Hospital of North Staffordshire, Stroke On Kent, Staffs, United Kingdom|Weston Park Hospital, Sheffield, Syorks, United Kingdom|Newcross Hospital, Wolverhampton, Wstmid, United Kingdom|Royal Marsden Hospital London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00864253"
334,"NCT00844649","Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas",,"Completed","Has Results","Metastatic Pancreatic Cancer","Drug: Albumin-bound paclitaxel (ABI-007)|Drug: Gemcitabine","Overall Survival (OS)|Progression-free Survival (PFS) by Independent Radiological Review (IRR)|Percentage of Participants Who Achieved an Objective Confirmed Overall Response by Independent Radiological Review (IRR)","Celgene","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","861","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA046","March 2009","September 2012","April 2013","February 16, 2009","December 11, 2013","March 1, 2017","UAB Comprenhensive Cancer Center at University of Alabama, Birmingham, Alabama, United States|Clearview Cancer Institute Oncology Specialities, P.C., Huntsville, Alabama, United States|TGEN Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|Mayo Clinic-Scottsdale, Scottsdale, Arizona, United States|Northern Arizona Hematology and Oncology Associates-AOA, Sedona, Arizona, United States|Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|UCLA, Los Angeles, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University Cancer Institute, LLC, Boynton Beach, Florida, United States|Collaborative Research Group, Boynton Beach, Florida, United States|FL Cancer Specialist, Ft Myers, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Lake County Oncology and Hematology, Tavares, Florida, United States|Phoebe Putney Cancer Center, Albany, Georgia, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Piedmont Hospital Research Institute, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Atlanta Cancer Care, Atlanta, Georgia, United States|Cancer Care & Hemaotology Specialists of Chicagoland, Arlington Heights, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Cancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Orchard Research, Skokie, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Hutchinson Clinic, PA, Hutchinson, Kansas, United States|Owsley Brown Frazier Cancer Center, Louisville, Kentucky, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|Mercy Hospital Portland, ME, Portland, Maine, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|Sidney Kimmel Comphrensive Cancer Center, John Hopkins University, Baltimore, Maryland, United States|Center for Cancer & Blood Disorders, Bethesda, Maryland, United States|Lahey Clinic, Burlington, Massachusetts, United States|Cancer Center of Excellence/University of MA Medical School, Worcester, Massachusetts, United States|St. Mary's/ Duluth Clinic, Duluth, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|Saint Louis University, St. Louis, Missouri, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Hem Onc Associates-NM, Albuquerque, New Mexico, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York Oncology Hematology PC, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arena Oncology Associates, PC, Lake Sucess, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Piedmont Hematology Oncology, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Mid Ohio Oncology/Hematology Inc, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Cancer Centers of SW OK, Lawton, Oklahoma, United States|University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Mercy Physicians of Oklahoma, Oklahoma City, Oklahoma, United States|Cancer Care Associates- Tulsa, Tulsa, Oklahoma, United States|St. Mary Medical Center Hem-Onc Group, PC, Langhorne, Pennsylvania, United States|University of Pittsburg Medical Center, Pittsburg, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Medical City Dallas-US Oncology, Dallas, Texas, United States|Texas Oncology, PA, Dallas, Texas, United States|Texas Oncology, PA/ Methodist Charlton Cancer Center, Dallas, Texas, United States|Texas Oncology Laboratories, Fort Worth, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|The University of Texas Medical School at Houston, Houston, Texas, United States|Texas Oncology- Plano East, Plano, Texas, United States|Texas Oncology, PA, Round Rock, Texas, United States|Texas Oncology-Round Rock, Round Rock, Texas, United States|South Texas Oncology and Hematology, P.A, San Antonio, Texas, United States|Texas Oncology, PA, Wichita Falls, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Fairfax-Northern Virginia Hematology-Oncology, P.C., Fairfax, Virginia, United States|Virginia Cancer Specialist, PC, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Health Services, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Macarthur Cancer Therapy Center, Campbelltown, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Newcastle Hospital, Waratah, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Haemotology & Oncology Australasia (HOCA), Milton, Queensland, Australia|Haematology Oncology Clinics of Australasia-Gold Coast, Milton, Queensland, Australia|Adelaide Cancer Centre (T/A Ashford Cancer Ctr), Ashford, South Australia, Australia|Flinders Medical Center, Bedford Park, South Australia, Australia|Calvary North Adelaide Hospital, North Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Medical Oncology Unit, Bendigo Health, Bendigo, Victoria, Australia|Monash Medical Centre, East Bentleigh, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia, Australia|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Landesklinikum St. Pölten, St. Pölten, Austria|Medizinische Universität Wien, Vienna, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Imelda VZW , Gastro-Enterology, Bonheiden, Belgium|Hôpital Erasme, Gastro-Enterology, Brussels, Belgium|AZ Groeninge - Campus Sint-Niklaas, Kortrijk, Belgium|H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada|The Royal Victoria Hospital-Barrie, Barrie, Ontario, Canada|Hopital du Sacre-Coeur, Montreal, Quebec, Canada|Centre Hospitalier de L'Universite de Montreal St-Luc, Montreal, Canada|Princess Margaret Hospital, Ontario, Canada|Hotel-Dieu de Quebec, Quebec, Canada|Centre Regional de lutte contre le cancer Paul Papin, Angers, France|Hôpital Saint Antoine, Paris, France|Hôpital Beaujon, Paris, France|Kliniken Essen-Mitte, Essen, Germany|Klinikum Freising, Freising, Germany|Praxis für Innere Medizin, Dr. Oettle Helmut, Friedrichshafen, Germany|LMU Klinikum der Universität, Munich, Germany|Klinikum Oldenburg, Oldenburg, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|I.R.C.C.S. ""Giovanni Paolo II"" - Istituto Oncologico, Bari, Italy|E. O. Ospedali Galliera, Struttura Complessa Oncologia Medica, Genova, Italy|Nazionale per la Ricerca sul Cancro, Genova, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Oncologia Medica Falck, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero universitaria Pisana, Pisa, Italy|Arcispedale Santa Maria Nuova, Unità Operativa di Oncologia Medica, Reggio Emilia, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Istituto Nazionale Tumori ""Regina Elena"", Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Foggia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Med Radiological Centre of the Russian Academy of Med Sciences, Obninsk, Kaluga Region, Russian Federation|Tatarstan Republican Onc Ctr, Kazan, Republic of Tatarstan, Russian Federation|Altai Territorial Oncological Center, Barnaul, Russian Federation|Chelyabinsk Regional Onc Ctr, Chelyabinsk, Russian Federation|Ivanovo Regional Oncology Center, Ivanovo, Russian Federation|Regional Oncological Center # 2, Magnitogorsk, Russian Federation|Moscow Municipal Onc Hosp #62, Moscow Region, Russian Federation|Moscow City Clinical Hosp #57 Chemotherapy Dept, Moscow, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|Russian Res Ctr of Radiology under the Fed Agency for Hi-Tech Med Care, Moscow, Russian Federation|Russian Research Ctr of Surgery n.a. B.V. Petrovskiy under the Russian Academy of Med Sciences, Moscow, Russian Federation|Central Clinical Hosp of the President of the Russian Federation, Moscow, Russian Federation|Semashko Central Hosp #2, Moscow, Russian Federation|Omsk Regional Onc Ctr, Omsk, Russian Federation|Orenburg Regional Onc Ctr, Orenburg, Russian Federation|Pyatigorsk Affiliate of Stavropol Regional Onc Ctr, Pyatigorsk, Russian Federation|St. Petersburg State Med Academy n.a.Mechnikov, St Petersburg, Russian Federation|Russian Research Ctr for Radiology and Surgical Technologies, St Petersburg, Russian Federation|Clinical Hosp # 122 n.a. L.G. Sokolov, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hosp, St. Petersburg, Russian Federation|St. Petersburg City Onc Ctr, St. Petersburg, Russian Federation|Tula Regional Oncology Center, Tula, Russian Federation|Bashkortostan Republican Onc Ctr, Ufa, Russian Federation|Yaroslavl Regional Onc Ctr, Yaroslavl, Russian Federation|Hospital Vall D´Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Dnepropetrovsk City Hosp #4, Dnepropetrovsk, UK, Ukraine|Donetsk Regional Antitumor Ctr, Donetsk, UK, Ukraine|Kirovohrad Regional Oncology Center, Department of Chemotherapy, Kirovohrad, UK, Ukraine|National Institute of Cancer, Department of Tumors of Abdominal Cavity and Retroperitoneum, Kyiv, UK, Ukraine|Kyiv City Clinical Hospital #10, Center for Hepatic, Bile Duct and Pancreatic Surgery, Kyiv, UK, Ukraine|Volyn Regional Oncology Center Department of Oncochemotherapy, Lutsk, UK, Ukraine|Lviv Regional Diagnostics and Treatment and Diagnostics Onc Ctr, Lviv, UK, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Surgery Center, Zhytomyr, UK, Ukraine|Kharkov Regional Onc Ctr, Kharkov, Ukraine|Kherson Regional Onc Ctr, Kherson, Ukraine|Odessa Regional Onc Ctr, Odessa, Ukraine|Zaporizhia Medical Academy of Postgraduate Education, Zaporizhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT00844649"
335,"NCT00820768","A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies",,"Withdrawn","No Results Available","Solid Tumor","Drug: ABI-010","The primary objectives of this study are to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-010 given weekly for 3 weeks followed by 1 week of rest (Cycle 1); to determine MTD and DLTs of ABI-010 given in combination|To determine the pharmacokinetic parameters for ABI-010 when given on a weekly schedule alone and in combination with ABI-007; determine preliminary efficacy of ABI-010 when given on a weekly schedule in combination with ABI-007","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA501","April 1, 2012","April 1, 2013","April 1, 2014","January 12, 2009",,"April 11, 2018","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00820768"
336,"NCT00812968","Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: Lenalidomide","Number of Participants With Adverse Events (AE)|Maximum Observed Plasma Concentration (Cmax) of Lenalidomide|Time to Maximum Plasma Concentration (Tmax) of Lenalidomide|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide|Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide|Terminal Half-life (T1/2) of Lenalidomide|Apparent Volume of Distribution (VzF) of Lenalidomide|Apparent Total Plasma Clearance (CL/F) of Lenalidomide|Apparent Terminal Elimination Rate Constant of Lenalidomide|Number of Participants With a Erythroid Response|Time to Erythroid Response|Duration of Erythroid Response|Change From Baseline in Hemoglobin Concentration|Number of Participants With a Neutrophil Response|Number of Participants With a Platelet Response|Number of Participants With a Cytogenetic Response|Change From Baseline in Percentage of Bone Marrow Erythroblasts|Percentage of Bone Marrow Myeloblasts|Percentage of Bone Marrow Promyelocytes","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MDS-007","September 1, 2007","September 1, 2010","September 1, 2010","December 22, 2008","December 17, 2013","November 19, 2019","Celgene Clinical Site, Shimono, Tochigi, Japan|Celgene Clinical Site, Shibuya-ku, Tokyo, Japan|Celgene Clinical Site, Hiroshima, Japan|Celgene Clinical Site, Kyoto, Japan|Celgene Clinical Site, Osaka, Japan|Celgene Clinical Site, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT00812968"
337,"NCT00774345","A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy",,"Active, not recruiting","No Results Available","B-cell Chronic Lymphocytic Leukemia","Drug: Lenalidomide|Drug: Placebo","Overall Survival|240 Events For Progression Free Survival|The number, type, frequency and severity of adverse events (AEs)|Tumor Response|Duration of Response|Health Related Quality of Life-Fact Leukemia Survey Version 4.0|Health Related Quality of Life EQ5-D","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","317","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-CLL-002","January 27, 2009","October 27, 2020","October 27, 2020","October 17, 2008",,"January 15, 2019","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Pacific Coast Hematology Oncology, Fountain Valley, California, United States|Kaiser Permanente Medical Group, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Stanford University Stanford, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Boca Raton Community Hospital, Boca Raton, Florida, United States|Pasco Hernando Oncology Associates, PA, Brooksville, Florida, United States|Memorial Hospital, Hollywood, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Florida Cancer Specialist, Tavares, Florida, United States|Florida Hospital Cancer Institute Waterman, Tavares, Florida, United States|Augusta Oncology Associates, P.C., Augusta, Georgia, United States|Northwest Georgia Oncology Centers, PCWilliam S. Gibbons Center Research Institute, Marietta, Georgia, United States|Northwestern University, Division of Hematology Oncology, Dept. of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|North Chicago VA Medical Center, North Chicago, Illinois, United States|Hematology Oncology Assoc. of IL Orchard Research LLC, Skokie, Illinois, United States|Floyd Memorial Cancer Center of Indiana, a division of Floyd Memorial Hospital and Health Services, New Albany, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Ochsner Medical Institutions, New Orleans, Louisiana, United States|Clinical Unit for Research Trials in Skin CURTIS Massachusetts General Hospital, Boston, Massachusetts, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|The Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Biomedical Research Alliance of New York, LLC, New Hyde Park, New York, United States|SUNY Upstate Medical University Medicine Oncology, Syracuse, New York, United States|Westchester County Medical Center, Valhalla, New York, United States|Wake Forest Univ. Health Sciences Outpatient Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Hematology Oncology Consultants, Inc., Columbus, Ohio, United States|Gabrail Cancer Center Research, Dover, Ohio, United States|Trilogy Cancer Care, Wooster, Ohio, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Drexel University, College of Medicine, Clinical Research Group, Philadelphia, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Abington Hematology Oncology Associates Inc, Willow Grove, Pennsylvania, United States|Charleston Hematology Oncology P.A., Charleston, South Carolina, United States|M. Francisco Gonzalez, MD, PA, Sumter, South Carolina, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Gundersen Clinic Lutheran Hospital, La Crosse, Wisconsin, United States|Concord Hospital, Concord, New South Wales, Australia|Haematology and Oncology Clinics of Australasia, South Brisbane, Queensland, Australia|IMVS, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Peter MacCallum Cancer Centre, East Melbourne, Australia|Frankston Hospital, Farkston, Australia|St. Vincent Hospital, Fitzroy, Australia|Nepean Hospital, Kingswood, NSW, Australia|Clinical Trials Unit The St George Hospital, Kogarah, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Royal North Shore HospitalDepartment of HematologyLevel 4, St. Leonards, Australia|The Queen Elizabeth Hospital, Woodville, Australia|Universitaetsklinik Innsbruck, Innsbruck, Austria|Hospital Bamherzige Schwestern, Linz, Austria|Medical University of Vienna Internalmedicine 1, Hematology, Vienna, Austria|AZ Sint-Jan AV Brugge, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|UZ Gent Hematology, Gent, Belgium|Hopital de Jolimont, Haine-Saint Paul, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHU Mont -Godinne, Yvoir, Belgium|Regional Health Authority B-Saint John Regional Hospital, Saint John, New Brunswick, Canada|General Hospital, Eastern Health, St John's, Newfoundland and Labrador, Canada|CDHA Centre for Clinical Research, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal/Quebec, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Hopital De L'Enfant-Jesus, Quebec, Canada|Oncomedica S.A., Monteria, Colombia|Interni hematoonkologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Poliklinika Agel Novy Jicin, Novy Jicin, Czechia|Faculty Hospital Plzen, Plzen, Czechia|Faculty Hospital Kralovske Vinohrady, Prague, Czechia|General Faculty Hosital1.Internal Clinic, Prague, Czechia|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Hopital Aviecenne, Bobigny Cedex, France|Bergonie Institut, Bordeaux, France|CMRU-Hotel Dieu Service Hematologie Clinique et Therapie Cellulaire, Clermont Ferrand, France|CHU Hopital Michallon, Grenoble Cedex 09, France|Centre Hospitalier Lyon Sud, Lyon, France|Cetre Hospitalier Hotel-Dieu, Nantes cedex 01, France|Hopital de l'Archet 1, Nice, France|Hopital Petie- SalpetriereDepartment d'Hematologie, Paris, France|CHU La Miletrie, Poitiers, France|CHU de Reims, Reims cedex, France|CLCC H BecquerelHematology, Rouen, France|Hopital Bretonneau, Tours Cedex, France|Charite, Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany|Universitaetsklinikum EssenZentrum fuer Innere Medizin, Essen, Germany|Innere Medizin Klinikum Frankfurt Oder GmBH, Frankfurt (Oder), Germany|Universitaetsklinikum FreiburgInnere Med.1, Haematologie, Freiburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|Klinikum der Universitat zu Koln, Köln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Mannheimer Onkologie Praxis, Mannheim, Germany|Stadtisches Klinikum Munchen GmbH, München, Germany|TU München - Klinikum rechts der Isar, München, Germany|Facharzte fur Innere Medizin Hämatologie und Onkologie Gemeinschaftspraxis, Münster, Germany|University Hospital of Ulm, Ulm, Germany|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Petz Aladar Country Hospital, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Pecsi Tudomanyegytem Altalanos Orvostudomanyi Kar, Pecs, Hungary|Szegedi TudomanyegyetemII Belgyogyaszati Klinika, Szeged, Hungary|Komarom-Esztergom Megye Onkormanyzat Szent Borbala Korhaza, Tatabanya, Hungary|St James's Hospital, Dublin, Ireland|Midwestern Regional Hospital, Limerick, Ireland|Ha'Emek Medical Center, Afula, Israel|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Center, Beer Sheva, Israel|Bnei Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Western Galilee Hospital, Naharia, Israel|Rabin Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel|Sheba Medical Center, Tel Hashomer, Israel|Azienda Ospedaliera Poloclinico di Bari, Bari, Italy|Istituto dei Tumori Giovanni Paolo II di Bari, Bari, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliera Vittorio Emanuele-Ferrarotto, Catania, Italy|A.O. Pugliese Ciaccio, Catanzaro, Italy|Azienda Ospedaliera Annunziala, Cosenza, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Ferrara, Italy|Azienda Ospedaliera Universitaria Careggi, Florence, Italy|Azienda Ospedaliero Universitaria OORR Foggia, Foggia, Italy|Azienda Ospedaliera San Martino, Genova, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Istituto Oncologico Europeo, Milano, Italy|IRCSS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy|Azienda Ospedaliero Universitaria di Modena, Modena, Italy|Ospedale Cardarelli, Naples, Italy|Policlinico Universitario Federico II, Naples, Italy|Universita del Piemonte Orientale, Novara, Italy|Universita degli Studi di Padova, Padova, Italy|Azienda Ospedaliera Ospedale San Carlo, Potenza, Italy|Ospedale Sant'Eugenio, Rome, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Rome, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte, Siena, Italy|Osp. S.Giovanni Battista Le Molinette, Torino, Italy|Ospedale Umberto I, Torrette Di Ancona, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|Instituto Biomedico de Investigacion AC, Aguascalientes, Mexico|VU University Medical Center, Amsterdam, Netherlands|Christchurch Hospital, Christchurch, New Zealand|Middlemore Clinical Trials, Manukau, New Zealand|North Shore Hospital, Takapuna, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Specjalistyczny Szpital miejski im. Kopernika, Torun, Poland|Centralny Szpital Kliniczny MON, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Hospital de Dia de Hematologia, Lisbon, Portugal|Instituto Portugues Oncologia do Porto Francisco Gentil EPE, Porto, Portugal|Institutul Clinic Fundeni, Bucharest, Romania|Spitalul Clinic Coltea, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta Sf Spiridon Iasi, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania|Spitalul Clinic Municipal de Urgenta Timisoara, Timisoara, Romania|Archangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|City Hospital 8, Barnaul, Russian Federation|State Healthcare Institution Sverdlovsk regional clinical hospital 1, Ekaterinburg, Russian Federation|GMU Republic clinical hospital, Kazan, Russian Federation|Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation|Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl, Moscow, Russian Federation|State Budgetary Institution of the City of Moscow, Moscow, Russian Federation|NUZ Central Clinical Hospital, Moscow, Russian Federation|Nizhegorodskaya Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Russian Federation|MUZ City Clinical Hospital 2, Novosibirsk, Russian Federation|Federal State Budgetary Establishment Medical Radiological Research Center Ministry of Health and so, Obninsk, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|FGU Russian Scientific Research Institute of Haematology and Transfusiology of Federal Agency, St. Petersburg, Russian Federation|GUS Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|Federal State Institution Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical Univ, St.Petersburg, Russian Federation|GUZ Volgograd Regional Clinical Oncology, Volgograd, Russian Federation|Groote Schuur Hospital, Cape Town, South Africa|University Witwatersrand Oncology, Parktown, South Africa|Pretoria Academic Hospital, Pretoria, South Africa|Mary Potter Oncology Centre, Pretoria, South Africa|Wilgers Oncology CentreWilgrers Hospital, Pretoria, South Africa|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain|Virgen de la Victoria Hospital Malaga, Malaga, Spain|Hospital General Universitario Morales Messeguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Donostia, San Sebastian, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario, Valencia, Spain|Skane University Hospital, Lund, Sweden|Stockholm South Hospital, Stockholm, Sweden|Karolinska University, Stockholm, Sweden|Royal Bournemouth General Hospital, Bournemouth, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Gartnavel General Hospital, Glasgow, United Kingdom|John Radcliffe Hospital, Headington, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|St. Bartholomew's and The Royal London Hospital, London, United Kingdom|Guy's and St. Thomas' Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St George's Healthcare NHS Trust, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom|Singleton Hospital, Southwest Wales Cancer Inst, Swansea, United Kingdom|Sandwell Hospital, West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00774345"
338,"NCT00761722","Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma","RACE","Completed","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndromes|Lymphoma|Multiple Myeloma|Leukemia, Myelomonocytic, Chronic","Drug: azacitidine","To estimate the dose for a given oral formulation that would yield similar exposure [area under the curve (AUC)] to 75 mg/m2 of the subcutaneous formulation.|To determine the oral bioavailability of up to 6 different oral formulations in comparison to the subcutaneous formulation|To assess the safety and tolerability of subcutaneous and oral formulations of azacitidine|To assess response rates|To assess RBC transfusion independence|To investigate the pharmacokinetics of oral azacitidine|To assess the pharmacodynamic effects of oral azacitidine","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA PH US 2008 CL008","August 12, 2008","April 6, 2016","April 7, 2016","September 29, 2008",,"November 8, 2019","California Cancer Care Inc, Greenbrae, California, United States|Main Cancer Centers of Florida, P.A., Ocoee, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Northwest Cancer Specialists, P.C., Albuquerque, New Mexico, United States|Willamette Valley Cancer Institute, Springfield, Oregon, United States|University of Texas- MD Anderson, Houston, Texas, United States|Hematology and Oncology Assoc. of South Texas, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00761722"
339,"NCT00747123","A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Biological: ACE-011|Biological: Placebo","Participants with Treatment-emergent Adverse Experiences|Change from baseline at end of treatment in Bone Specific Alkaline Phosphatase (BSAP)|Change from baseline at end of treatment in Serum intact procollagen type I N terminal propeptide (PINP)|Change from Baseline at End of Treatment in Serum C-terminal type I collagen telopeptide (CTX)|Change from Baseline at End of Treatment in Serum tartrate-resistant acid phosphatase isoform-5b (Tracp-5b)|Change from Baseline at End of Treatment in Hip Bone Mineral Density|Change from Baseline at End of Treatment in Lumbar Spine Bone Mineral Density|Summary of Investigator's Bone Lesion Assessment Based on Skeletal X-rays During Follow-up|Change from Baseline to End of Treatment in Participant-reported Bone Pain Assessment Using a Visual Analog Scale (VAS) Score|Participants with Skeletal-related Adverse Events|Pharmacokinetics - AUC|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - t½|Pharmacokinetics - λz|Pharmacokinetics - Vz/F|Pharmacokinetics - CL/F|Pharmacokinetics - Ka","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A011-04","September 1, 2008","August 1, 2009","August 1, 2009","September 4, 2008",,"October 24, 2019","Investigative Site, Moscow, Russian Federation|Investigative Site, Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00747123"
340,"NCT00737529","A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The ""EMERGE"" Trial","EMERGE","Completed","Has Results","Mantle Cell Lymphoma","Drug: lenalidomide","Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC)|Kaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee|Percentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee|Kaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee|Kaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee|Kaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee|Kaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee|Time to Response (TTR)|Time to Complete Response (CR+CRu) According to the Independent Review Committee|Overall Survival (OS)|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","134","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MCL-001","December 22, 2008","April 6, 2016","November 8, 2017","August 19, 2008","September 9, 2013","December 13, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Tower Cancer Research Foundation, Los Angeles, California, United States|Boca Raton Community Hospital, Inc., Research Dept., Boca Raton, Florida, United States|Pasco Hernando Oncology Associates, PA, Brooksville, Florida, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|MD Anderson Cancer Center, Orlando Regional Healthcare, Orlando, Florida, United States|Lake County Oncology and Hematology, The Villages, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Medical Center - Smith, Maywood, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Alvin and Lois Lapidus Cancer Institute Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU School of Medicine, New York, New York, United States|University of Rochester Cancer Center, James P. Wilmot Cancer Center, Rochester, New York, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Hillman Cancer Institute at UPMC, Pittsburgh, Pennsylvania, United States|South Carolina Cancer Specialists, Hilton Head Island, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|University of Virginia Cancer Center Clinical Trials Office, Charlottesville, Virginia, United States|Universitaetsklinik Innsbruck, Innsbruck, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|AZ Sint-Jan AV Brugge, Brugge, Belgium|UZ Gent, Gent, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|Hospital Universitario San Ignacio, Bogota, Colombia|Oncologos del occidente S.A., Pereira, Colombia|Hopital Sud, CHU d'Amiens, Amiens, France|Institut Bergonie, Bordeaux, France|Hopital Henri Mondor, Créteil, France|Hopital Emile Muller, Mulhouse, France|Hopital Cochin, Paris, France|Institut Curie, Paris, France|Hopital Robert Debre, Reims Cedex, France|Institut de Cancerologie de la Loire, Saint Jean Priest En Jarez, France|Hopital Hautepierre, Strasbourg, France|University Hospital Wuerzburg, Wuerzburg, Germany|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|University of Debrecen, DEOEC, Institute of Internal Medicine, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petch Tikva, Israel|Sheba Medical Center, Tel Hashomer, Israel|Universita Federico II di Napoli Nuovo Policlinico, Napoli, Italy|Ospedale Civile dello Spirito Santo, Pescara, Italy|Universita Cattololica del Sacro Cuore, Roma, Italy|Centro De Cancer, Hospital Espanol Auxilio De Puerto Rico, San Juan, Puerto Rico|Singapore General Hospital, Singapore, Singapore|Hospital General De Elche, Alicante, Spain|Duran i Reynals Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario La Fe, Valencia, Spain|Gazi Universitesi, Besevler Ankara, Turkey|Istanbul Universitesi Istanbul, Istanbul, Turkey|Ankara Universitesi Tip Fakultesi, Sihhiye Ankara, Turkey|Royal Cornwall Hospitals Trust, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00737529"
341,"NCT00717522","Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma",,"Terminated","Has Results","Soft Tissue Sarcoma","Drug: Pomalidomide","Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs|Tumor Response as Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee Guidelines","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-STSAR-001","August 1, 2008","January 1, 2009","January 1, 2009","July 17, 2008","April 16, 2013","November 19, 2019","Sarcoma Oncology Center, Santa Monica, California, United States|Kootenai Cancer Center, Coeur d'Alene, Idaho, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00717522"
342,"NCT00689936","Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","FIRST","Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide and low-dose dexamethasone|Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|Drug: Melphalan, Prednisone and Thalidomide","Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)|Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis|Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)|Percentage of Participants With an Objective Response Based on IRAC Review|Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis|Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC|Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis|Time to First Response Based on the Review by the IRAC|Time to First Response Based on the Investigator Assessment at the Time of Final Analysis|Kaplan Meier Estimates of Time to Treatment Failure (TTF)|Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis|Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)|Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis|Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis|Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.|Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review|Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review|Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain|Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Fatigue Domain|Change From Baseline in the EORTC QLQ-C30 Pain Domain|Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain|Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain|Change From Baseline in the EORTC QLQ-C30 Insomnia Domain|Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain|Change From Baseline in the EORTC QLQ-C30 Constipation Domain|Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain|Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale|Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score|Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year|Number of Participants With Adverse Events (AEs) During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.|Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","1623","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-020|2007-004823-39","August 21, 2008","July 14, 2016","July 14, 2016","June 4, 2008","August 11, 2017","November 20, 2019","University of AL Birmingham, Birmingham, Alabama, United States|Cedar Sinai Medical Center Dept of Medicine, Los Angeles, California, United States|University of California, San Francisco- California, San Francisco, California, United States|Stanford University Stanford, Stanford, California, United States|Gainesville Heme Oncology Associates, Gainesville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Integrated Community Oncology Network, Orange Park, Florida, United States|Gulf Coast Oncology, Saint Petersburg, Florida, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States|Southern Illinois Hematology Oncology, Centralia, Illinois, United States|Orchard Healthcare Research, Inc., Chicago, Illinois, United States|John H Stroger Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Ingalls Cancer Institute, Harvey, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Maine Center for Cancer Medicine Blood Disorders, Scarborough, Maine, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Arena Oncology Associates, PC, Lake Success, New York, United States|Dakota Cancer Institute, Fargo, North Dakota, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|St. Luke's Hospital and Health Network, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Cancer Center, Collierville, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|University of Texas Medical Branch, Galveston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology, E. Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Geelong Hospital, Geelong, Australia|Gosford Hospital, Gosford, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Cabrini Hospital, Malvern, Australia|The Royal Melbourne Hospital, Parkville, Australia|Royal Perth Hospital, Perth, Australia|Gold Coast Hospital, Southport, Australia|Royal North Shore Hospital, St Leonards, Australia|Westmead Hospital, Wentworthville, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital, Wollongong, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Hospital Leoben, Leoben, Austria|Hospital of Barmherzige Schwestern Linz, Linz, Austria|Hospital of Elisabethinen Linz, Linz, Austria|General Hospital Linz, Linz, Austria|MM-015. Salzburger Landkliniken, St. Johanns-Spital, Universitätsklinik fur Innere Medizin III, Salzburg, Austria|Hospital St. Polten, St. Pölten, Austria|Hospital of the Barmherzigen Bruder Vienna, Vienna, Austria|MM-015.Wihelminenspital, Vienna, Austria|MM-015. Medizinische Universität Wien, Vienna, Austria|Hospital Wels, Wels, Austria|Hospital Wiener Neustadt, Wiener Neustadt, Austria|ZNA Stuivenberg Centrumziekenhuis, Antwerpen, Belgium|Les Cliniques du Sud Luxembourg, Arlon, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Hopital Erasme, Brussels, Belgium|AZ-VUB, Brussels, Belgium|Jules Bordet Institut, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|Virga Jesse Ziekenhuis, Hasselt, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat, Roeselare, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|University of Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp, Vancouver, British Columbia, Canada|Vancouver Island Cancer Center, Victoria, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Science Centre, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Hospital Charles LeMoyne, Greenfield Park, Quebec, Canada|Hopital de la Cite-de-la-Sante, Laval, Quebec, Canada|Hotel-Dieu de Levis, Levis, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Hospital Maisonneuve - Rosemont, Montreal, Quebec, Canada|CHUM- Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Sir Mortimer B. Davis - Jewish Genl, Montreal, Quebec, Canada|CHUQ - Hotel-Dieu de QuebecHematology - Oncology, Quebec, Canada|Chaoyang Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|West China Hospital of Sichuan University, Chengdu, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China|Clinique Claude BernardOncologie, Albi, France|CHU Sud, Amiens, France|CHRU Hopital du bocage, Angers cedex 01, France|CH Argenteuil Victor Dupouy, Argenteuil, France|Centre Hospitalier de la cote basque, Bayonne, France|Centre Hospitalier, Blois cedex, France|Hopital Avicenne, Bobigny Cedex, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital de Fleyriat, Bourg en Bresse cedex, France|Hopital Augustin Morvan, Brest cedex, France|Centre Francois Baclesse, Caen cedex 5, France|CHU, Caen, France|CH, Cannes Cedex, France|CH Rene Dubois, Cergy-Pontoise, France|Centre Hospitalier William Morey, Chalon/Saone Cedex, France|Hopital dinstruction des armees Percy, Clamart Cedex, France|Hopital Antoine Beclere, Clamart, France|Chu Estaing, Clermont Ferrand, France|CH Louis Pasteur, Colmar cedex, France|Hopital Henri Mondor, Creteil, France|CHRU Hopital du bocage, Dijon, France|Centre Hospitalier General, Dunkerque, France|CHRU, Grenoble cedex 09, France|Institut Prive de Cancerologie, Grenoble, France|Centre Hospitalier Departemental, La Roche -Sur-Yon cedex 9, France|CH, Le Chesnay Cedex, France|Hopital J MonodRhumato Nord, Le Havre, France|Kremlin Bicetre, Le Kremlin bicetre CDX, France|Centre Hospitalier, Le Mans cedex, France|Centre Jean Bernard, Le Mans, France|CHRU-Hopital Claude Huriez, Lille cedex, France|GH de Institut Catholique St Vincent, Lille, France|CH - Hôpital Dupuytren, Limoges Cedex 1, France|CHU Hopital Edouard Herriot, Lyon cedex, France|Centre Leon Berard, Lyon, France|Centre Hospitalier de Valence, Lyon, France|Institut Paoli-Calmettes, Marseille Cedex 9, France|Hopital de Mercy, METZ cedex 3, France|Clinique Pont de chaume Oncologie et Radiotherapie, Montauban cedex, France|CHU Montpellier - Hôpital Lapeyronie, Montpellier Cedex 5, France|Hopital Emile Muller, Mulhouse, France|CHRU - Hotel Dieu, Nantes, France|Centre Antoine Lacassagne Oncologie medicale et Hematologie, Nice cedex 1, France|Hopital de lArchet 1, Nice cedex 3, France|CH La Source, Orleans, France|Hopital Cochin, Paris Cedex 14, France|Hopital Saint Louis, Paris, France|Hopital Necker, Paris, France|CHU Hôpital St-Antoine, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|CU CHU Clemenceau, Poitiers cedex, France|Hopital R. Debre, Reims cedex, France|CHU Reims - Hôpital Maison Blanche, Reims, France|CHRU Hopital sud Medecine Interne, Rennes cedex 02, France|CHRU Hôpital de Pontchaillou, Rennes Cedex, France|CHG Rodez, Rodez, France|Centre Henri Becquerel, Rouen cedex, France|Centre Rene Huguenin, Saint Cloud, France|Institut de Cancerologie de Loire, St Priest en Jarez, France|Centre Hospitalier Yves Le Foll, St-Brieuc cedex 1, France|CHRU Hôpital de Hautepierre, Strasbourg, France|CHRU Hopital Purpan, Toulouse cedex 9, France|CHRU Hopital Bretonneau, Tours cedex, France|CHRU Hopital Trousseau, Tours, France|CHRU Hôpitaux de Brabois, Vandoeuvre Cedex, France|CH P. Chubert, Vannes cedex, France|Institut Gustave Roussy, Villejuif, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Dusseldorf, Germany|Universitatsklinikum Essen-, Essen, Germany|Staedtische Kliniken Frankfurt am Main Hochst, Frankfurt am Main, Germany|Universitatsklinikum Giessen, Giessen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Askepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Jena, Jena, Germany|Medizinische Klinik und Poliklinik II, Leipzig, Germany|Universitatsklinikum schleswig-Holstein, Lübeck, Germany|Poliklinik A, Muenster, Germany|Klinikum der Johann-Wolfgang-Goethe-Universtat, München, Germany|Medizinische Klinik III Klinikum der Universität München-Großhadern, München, Germany|Medizinische Fakultat der Universitat Rostock, Rostock, Germany|Zentrum F. Innere Medizin II Robert- Bosch-Krankenhaus GmBH, Stuttgart, Germany|Medizinische Klinik - Abteilung II, Tübingen, Germany|Klinik fur Innere Medizin III, Ulm, Germany|Alexandra Hospital, University of Athens, Athens, Greece|Attiko Hospital of Athens, Athens, Greece|Evangelismos Hospital of Athens, Athens, Greece|University of Athens, Athens, Greece|Metaxa Hospital Peiraias, Piraeus, Greece|Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki, Greece|Adelaide and Meath Hospital, Dublin, Ireland|Mater Misercordiae Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Policlinico S. Orsola, Bologna, Italy|Oncologia Medica, Università della Magna Grecia, Catanzaro, Italy|Clinica Ematologica, A.O.U. San Martino di Genova, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce, Lecce, Italy|Unità Operativa di Oncoematologia, Ospedale di Matera, Matera, Italy|U.O. di Ematologia e Trapianto di Midollo Osseo, Milano, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|Presidio Ospedaliero A. Perrino, Milano, Italy|Policlinico di Modena, Modena, Italy|Oncoematologia, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy|Casa di Cura La Maddalena, Divisione di Ematologia, Palermo, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Ospedale Civile, Piacenza, Italy|A.O. Universitaria Ospedale S.Chiara Dip.Oncologia, Div. Ematologia, Pisa, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Istituto Nazionale Tumori Regina Elena, Struttura Complessa Ematologia ed Unita di Cellule Staminali, Roma, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Rome, Italy|Ospedale Molinette, Torino, Italy|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Daegu Catholic University Medical Center 3056-6, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejon, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Hwasun Chonnam National University Hospital, Hwasun-goon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital 42, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Severance Hospital, Seongsanno, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Wellington Hospital, Newtown, New Zealand|Hospital de Sao Marcos, Braga, Portugal|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Instituto Português de Oncologia Porto, Porto, Portugal|Hospital de Santo Antonio- Porto, Porto, Portugal|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Univ. Josep Trueta, Girona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario Morales Messeguer, Murcia, Spain|Hospital Clinico Virgen de la Victoria, Málaga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clinica Universitaria de Navarra,, Pamplona, Spain|Hospital Sant Pau, Reus, Spain|Hospital de Donosti, San Sebastian, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain|Hospital Clinico Santiago de Compostela, Santiago de Compostela, Spain|Hosptial La Fe, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Linkoping University Hospital, Linkoping, Sweden|Karolinska University HospitalSolna, Stockholm, Sweden|St. Görans Hospital, Stockholm, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Abteilung Onkologie Haematologie des Kantonsspitals Aarau, Aarau, Switzerland|UniversitatsSpital Basel, Basel, Switzerland|Inselsspital Bern, Berne, Switzerland|Kantonsspital Graubunden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland|Kantonsspital Munsterlingen, Münsterlingen (TG), Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|China Medical University Hospital, Taichung City, Taiwan|Veteran General Hospital - Taipei, Taipei, Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Gwynedd Hospital, Bangor, United Kingdom|Royal United Hospital, Bath, United Kingdom|Belfast City Hospital Haematology Department, Belfast Northern Ireland, United Kingdom|Birminghman QE, Birmingham West Midlands, United Kingdom|Royal Bournemouth Hosp, Bournemouth Dorset, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|University Hospital of Wales - Cardiff, Cardiff, United Kingdom|The Beatson West of Scotland Centre, Glasgow, United Kingdom|Dept of Haematology St Bartholomews Hospital, London, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Churchhill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth Crownhill Devon, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom|Pinderfields General Hospital, West Yorkshire, United Kingdom|New Cross Hospital- Wolverhampton, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00689936"
343,"NCT00688415","Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer",,"Completed","No Results Available","Advanced Solid Tumors|Lymphoma","Drug: VTX-2337","Safety and identification of dose-limiting toxicities|Pharmacokinetics|Pharmacodynamics|Identification of the MTD","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","VRXP-A101","November 7, 2008","August 2010","November 2010","June 3, 2008",,"September 25, 2019","Mayo Clinic, Scottsdale, Arizona, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00688415"
344,"NCT00667082","NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",,"Completed","No Results Available","Non-Small Cell Lung Cancer|Pancreatic Cancer|Melanoma|Lymphoma|Multiple Myeloma","Drug: NPI-0052 (marizomib) + vorinostat","To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat|To evaluate the pharmacokinetics and pharmacodynamics of NPI-0052 and vorinostat|To evaluate the safety and toxicity profile of the combination of NPI-0052 and vorinostat|To evaluate the anti-tumor activity of NPI-0052 and vorinostat","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NPI-0052-103","March 2008","January 2010","January 2010","April 25, 2008",,"November 22, 2017","Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT00667082"
345,"NCT00657488","Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide","all cause mortality|response rate","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LATH0102/IFM0102","December 1, 2001","October 1, 2005","April 1, 2006","April 14, 2008",,"October 18, 2019","Hopital St Joseph, Gilly, Belgium|UCL de Mont Godine, Yvoir, Belgium|Chu D'Angers - Medecine D, Angers, France|Centre Hospitalier D'Annecy - Service d'oncohématologie, Annecy, France|Centre Hospitalier H. Duffaut - Hematologie, Avignon, France|HOPITAL JEAN MINJOZ - Médecine interne/Hématologie, Besancon, France|Centre Hospitalier de Blois - Unité d'Onco-Hématologie, Blois, France|Hopital Avicenne - Medecine Interne/Hematologie, Bobigny, France|Centre Hospitalier Du Dr Duschene - Hematologie, Boulogne Sur Mer, France|Hopital Morvan - Service Hematologie, Brest, France|Polyclinique Du Parc - Hematologie, Caen, France|Centre François Baclesse, Caen, France|Centre Hospitalier - Service Hematologie, Chambery, France|H.I.A. Percy Hematologie, Clamart, France|Centre Hospitalier General - Medecine Interne, Dunkerque, France|Hopital Albert Michallon - Hematologie, Grenoble, France|CENTRE HOSPITALIER DEPARTEMENTAL - Sce Médecine A, La Roche Sur Yon, France|Centre Hospitalier La Rochelle - Unité d'Oncologie Médicale, La Rochelle, France|Centre Hospitalier - Service de Médecine 7, Laval, France|Clinique Victor Hugo, Le Mans, France|CHRU CLAUDE HURIEZ - Maladies du sang, Lille, France|Chu Edouard Herriot, Lyon, France|INSTITUT PAOLI CALMETTE - Unité transplantation, Marseille, France|CHR Hôp N.D. de Bon Secours - Service de Médecine A, Metz, France|Hopital Jacques Monod - Rhumatologie, Montivilliers, France|CHRU Hôtel Dieu, Service des Maladies du Sang, Nantes, France|Centre Lacassagne, Nice, France|Institut Curie - Service d'hématologie, Paris, France|HOPITAL ST ANTOINE - Maladies du Sang, Paris, France|Centre Hospitalier Général - Service d'Hématologie, Perpignan, France|Hopital Du Haut Leveque - Hematologie, Pessac, France|Centre Hospitalier de Lyon Sud, Pierre Benite, France|CHRU Jean Bernard - Hématologie, Poitiers, France|Centre Hospitalier Laennec - Service de Médecine A, Quimper, France|Hôpital Robert Debré - Hématologie, Reims, France|C.H.R. de Pontchaillou - Hématologie, Rennes, France|CHRU Hôpital Sud - Médecine Interne, Rennes, France|Centre Henri Becquerel - Service Hématologie, Rouen, France|C.H.U. de Saint Etienne - Hôpital Bellevue - Sce Rhumatologie, Saint Etienne, France|Hôpital Nord - Hématologie, Saint Etienne, France|CHU Hautepierre - Service Hématologie, Strasbourg, France|HOPITAL HAUTEPIERRE - Service Rhumatologie, Strasbourg, France|C.H.U. Rangueil - Service Rhumatologie, Toulouse, France|C.H.U. PURPAN - Service Hématologie, Toulouse, France|C.H.U. Bretonneau, Tours, France|Centre Hospitalier - Service de Rhumatologie, Tulle, France|Centre Hospitalier - Hématologie, Valence, France|CHU Hôpital Brabois - Médecine interne-Hématologie, Vandoeuvre Les Nancy, France|Centre Hospitalier Chubert - Médecine Interne, Vannes, France",,"https://ClinicalTrials.gov/show/NCT00657488"
346,"NCT00655668","A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma","EXPECT","Terminated","Has Results","T-cell Non-Hodgkin's Lymphoma","Drug: Lenalidomide","Participants Categorized by Best Response as Determined by Investigator|Duration of Response|Time-to-Progression|Progression-Free Survival|Safety","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-TCL-001|2007-002171-13","March 2008","March 2010","April 2010","April 10, 2008","January 5, 2012","March 1, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|The Canberra Hospital Building 3, L 2, Garran, Australian Capital Territory, Australia|Cancer Therapy Centre, Liverpool, New South Wales, Australia|Clinical Research Unit Cairns Base Hospital, Cairns, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Ashford Cancer Centre, Ashford, South Australia, Australia|Royal Adelaide Hospital L3 East Wing, North Terrace, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, 4th Floor, Clive Ward Centre, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|St Vincents Hospital, Fitzroy, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Institute Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|KUL, Leuven, Belgium|Clinique St Pierre, Ottignies, Belgium|Cliniques universitaires UCL de Mont-Godinne, Yvoir, Belgium|CHU Hôtel Dieu, Nantes, Cedex 01, France|Hôpital Bretonneau, Tours, Cédex 1, France|CHU Hôpital Hôtel Dieu, Angers, Cédex 9, France|Hôpital Claude Huriez, Place de Verdun Cedex, Lille, France|Hôpital Lapeyronie, Cedex, Montpellier, France|Centre Hospitalier Lyon Sud, Lyon Sud, Pierre-Bénite, France|CHRU Hôpitaux de Brabois - Hématologie, Vandoeuvre Les Nancy, rue Morvan Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hôtel Dieu Pavillon Villemur Pasteur, Clermont-Ferrand, France|Hopital Henri Mondor, Creteil, France|CHU de Dijon, Dijon, France|Hopital Michallon, Grenoble, France|CHD Les Oudairies, La Roche Sur Yon, France|CHU Dupuytren, Limoges, France|Hôpital N.D.de Bon Secours, Metz, France|Hôpital Saint-Louis, Paris, France|Hôpital Necker, Paris, France|Hôpital de la Pitié Salpétriere, Paris, France|CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Centre René Huguenin, Saint Cloud, France|Hôpital Purpan, Toulouse, France|Centre Hospitalier, Valence, France",,"https://ClinicalTrials.gov/show/NCT00655668"
347,"NCT00652626","Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function","RENAL","Completed","Has Results","MDS|AML|Solid Tumors|Multiple Myeloma|Non-Hodgkin's Lymphoma|Hodgkin's Disease","Drug: azacitidine","Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity|Maximum Plasma Concentration of Azacitidine (Cmax)|Time to Maximum Plasma Concentration of Azacitidine (Tmax)|Terminal Phase Half-life of Azacitidine (t½)|Apparent Total Clearance of Azacitidine (CL/F)|Apparent Volume of Distribution of Azacitidine (Vz/F)|Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine|Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine|Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine|Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine|Terminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine|Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine|Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine|Number of Participants With Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AZA PH US 2007 PK006","November 1, 2008","July 1, 2012","July 1, 2012","April 4, 2008","October 17, 2013","November 19, 2019","Sutter East Bay Hospitals, Berkeley, California, United States|Palm Springs Research Institute, Hialeah, Florida, United States|MCG Cancer Center, Augusta, Georgia, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|University of Kentucky-Markey Cancer Center Clinical Research Organization, Lexington, Kentucky, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Mid Dakota Clinical P.C. - Cancer Treatment and Research Center, Bismarck, North Dakota, United States|Gabrail Cancer Center, Canton, Ohio, United States|Pharma Resource, East Providence, Rhode Island, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00652626"
348,"NCT00635284","ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies",,"Completed","No Results Available","Solid Tumors","Drug: ABI-009","Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009.|Efficacy of ABI-009 in this patient population","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA401","December 1, 2007","June 1, 2011","June 1, 2011","March 13, 2008",,"October 18, 2019","Sarcoma Oncology Center, Santa Monica, California, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00635284"
349,"NCT00629473","Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies",,"Completed","No Results Available","Advanced Cancer","Drug: NPI-0052 on Days 1, 8, 15 every 28 days|Drug: NPI-0052 on Days 1, 4, 8, 11 every 21 days|Drug: Dexamethasone","Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of NPI-0052|To evaluate the pharmacokinetics activity of NPI-0052|To evaluate the safety and tolerability of NPI-0052|To evaluate the pharmacodynamics of NPI-0052","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPI-0052-102","July 2007","April 2013","April 2013","March 6, 2008",,"November 22, 2017","Mater Adult Hospital, South Brisbane, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Peter MacCallum Cancen Center, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT00629473"
350,"NCT00622336","A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: CC-5013|Drug: Lenalidomide","Number of Participants With Adverse Events (AE) During the Treatment Phase|Number of Participants With Adverse Events (AE) During the Extension Phase|Time to Progression|Myeloma Response Rate|Duration of Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-012|2004-002102-30","April 1, 2003","November 25, 2013","November 25, 2013","February 25, 2008","December 30, 2014","November 20, 2019","Republican Clinical Hospital #1, Izhevsk, Russian Federation|Nizhny Novgorod Clinical Hospital n.a.Semashko, Nizhny Novgorod, Russian Federation|Novosibirsk State Regional Clinical, Novosibirsk, Russian Federation|Samara Regional Clinical Hospital, Samara, Russian Federation|Kharkov Postgraduate Medical Academy Kharkov Regional Clinical, Kharkov, Ukraine|Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine|Odessa Regional Clinical Hospital, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00622336"
351,"NCT00606450","Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis","PSOR-003","Completed","No Results Available","Psoriasis","Drug: CC-10004|Drug: Placebo","To compare the clinical efficacy of 2 oral doses of CC-10004 with placebo when taken for 12 weeks in subjects with moderate-to-severe plaque-type psoriasis|To evaluate the safety of CC-10004 compared with placebo in subjects with moderate-to-severe placque-type psoriasis|To evaluate the effects of CC-10004 compared to placebo on the quality of life in subjects with moderate-to-severe plaque-type psoriasis.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-003","April 1, 2006","February 1, 2007","May 1, 2007","February 4, 2008",,"September 19, 2017","Division of Dermatology and Cutaneous Science, Edmonton, Alberta, Canada|Division of Dermatology, Vancouver, British Columbia, Canada|Duronder C.P. Inc, Moncton, New Brunswick, Canada|Eastern Canada Cutaneous Research Associates, Halifax, Nova Scotia, Canada|Ultranova Skincare, Barrie, Ontario, Canada|Dermatrials Research, Hamilton, Ontario, Canada|The Lynde Center for Dermatology, Markham, Ontario, Canada|North Bay Dermatology Centre, North Bay, Ontario, Canada|K. Papp Clinical Research, Waterloo, Ontario, Canada|Innovaderm, Montreal, Quebec, Canada|Dr Yves Poulin, Quebec City, Quebec, Canada|Department of Dermatology, Brno, Czechia|Department of Dermatology, Hradec Kralove, Czechia|Department of Dermatovererology, Olomouc, Czechia|Department of Dermatovererology, Praha, Czechia|Depart of Dermatology, Usti nad Labem, Czechia|Celgene Clinical Site, Ausburg, Germany|Celgene Clinical Site, Berlin, Germany|Department of Dermatologie and Venerology, Dresden, Germany|Department of Dermatology and Venerology, Frankfurt Main, Germany|Celgene Clinical Site, Hamburg, Germany|Celgene Clinical Site, Heidelberg, Germany|Celgene Clinical Site, Herborn, Germany|Celgene Clinical Site, Homburg, Germany|Celgene Clinical Site, Leipzig, Germany|Celgene Clinical Site, Mannheim, Germany|Celgene Clinical Site, Munster, Germany|Celgene Clinical Site, Salzwedel, Germany|Celgene Clinical Site, Schwerin, Germany|Celgene Clinical Site, Wiesbaden, Germany|Celgene Clinical Site, Wurzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00606450"
352,"NCT00604682","Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis","PSOR-001","Completed","No Results Available","Psoriasis","Drug: CC10004","To evaluate the pharmacodynamic effect of orally administered CC10004 when taken for 29 days in reducing epidermal thickness in subjects with severe plaque-type psoriasis.|To evaluate the safety of orally administered CC10004 in subjects with severe plaque-type psoriasis during the treatment and follow up phases.|To explore the clinical efficacy of orally administered CC10004 when taken for 29 days in subjects with severe plaque-type psoriasis.|To explore the clinical efficacy of CC10004 when taken for 29 days in subjects with psoriatic arthritis.","Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-10004-PSOR-001","January 1, 2005","October 1, 2005","December 1, 2005","January 30, 2008",,"September 19, 2017","University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States|NYU School of Medicine, New York, New York, United States|Mt Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00604682"
353,"NCT00555100","Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: lenalidomide|Drug: dexamethasone","DLT|Efficacy (M-protein)","Celgene","All","20 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-017","July 1, 2007","December 1, 2010","December 1, 2010","November 7, 2007",,"November 11, 2019","Nagoya City University Hospital, Nagoya, Aichi, Japan|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Keio University Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00555100"
354,"NCT00547651","AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: Amrubicin|Drug: Topotecan","The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.|To further characterize the clinical benefit of amrubicin compared with topotecan in terms of objective response rate|To further characterize the clinical benefit of amrubicin compared with topotecan in terms of progression-free survival.|To further characterize the clinical benefit of amrubicin compared with topotecan in terms of duration of response|To further characterize the clinical benefit of amrubicin compared with topotecan in terms of time to tumor progression|To further characterize the clinical benefit of amrubicin compared with topotecan in terms of safety|To further characterize the clinical benefit of amrubicin compared with topotecan in terms of quality of life","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","637","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMR PH GL 2007 CL001","September 1, 2007","May 1, 2011","May 1, 2011","October 22, 2007",,"November 6, 2019","Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Little Rock Hematology Oncology Associates, Little Rock, Arkansas, United States|Cancer Care Associates of Fresno Medical Group, Inc., Fresno, California, United States|Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States|University of Colorado Health Science Centre, Aurora, Colorado, United States|Rocky Mountain Cancer Center - Midtown (Main), Denver, Colorado, United States|Advanced Medical Specialties, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, P.A., Ocoee, Florida, United States|Florida Oncology Associates, Orange Park, Florida, United States|Sacred Heart Medical Oncology, Pensacola, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Cancer & Hematology Specialists of Chicago (Main), Niles, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Cancer Care at Blessing Hospital, Quincy, Illinois, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Hope Center, Terre Haute, Indiana, United States|Kansas City Cancer Center (Main), Overland Park, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Jayne Gurtler MD, Laura Brizn MD, Angelo Russo MD, and Janet Burroff MD, APMC, Metairie, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Inc., Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Alliance Hematology Oncology, P.A. (Main), Westminster, Maryland, United States|Kalamazoo Hematology and Oncology, Kalamazoo, Michigan, United States|Michigan Hematology & Oncology Institute, Southgate, Michigan, United States|University of Minnesota Medical Center, Cancer Center, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|St. Joseph Oncology, Inc., Saint Joseph, Missouri, United States|Comprehensive Care Centers of Nevada (Main), Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Latham, New York, United States|SUNY Upstate Medical University - Regional Oncology Center, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Regional Cancer Care, Durham, North Carolina, United States|Cancer Centers of North Carolina (Main), Raleigh, North Carolina, United States|Piedmont Hematology Oncology Associates, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Greater Dayton Cancer Center (Main), Kettering, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Willamette Valley Cancer Center (Main), Eugene, Oregon, United States|Medical Oncology Associates, Kingston, Pennsylvania, United States|Thomas Jefferson Memorial Hospital, Philadelphia, Pennsylvania, United States|UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Cancer Centers of the Carolinas (Main), Greenville, South Carolina, United States|The Sarah Cannon Research Institute/TN Oncology, Nashville, Tennessee, United States|Texas Oncology, P.A., Amarillo, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Texas Cancer Center at Medical City (Main), Dallas, Texas, United States|Texas Oncology, P.A. (Main), Dallas, Texas, United States|West Texas Cancer Center-Texas Oncology, Odessa, Texas, United States|Texas Oncology, P.A., Webster, Texas, United States|Texoma Cancer Center, Wichita Falls, Texas, United States|Fairfax Northern Virginia Hematology/Oncology, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Cancer Specialists - Vancouver (Main), Vancouver, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|New South Wales Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|The Princess Alexandra Hospital, Dept of Respiratory Medicine, Woolloongabba, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Allgemeines Krankenhaus der Stadt Linz, Abteilung fur Atem und Lungenkrankheiten, Linz, Austria|Klinikum Weis-Grieskirchen GmbH, Wels, Austria|Allegemeines Krankenhaus Wien, Univ. Klinik fur Innere, Medizin I, Wien, Austria|Krankenhaus Hietzing, 5 Med. Abteilung mit Onkologie, Wien, Austria|UZ Brussel, Medical Oncology and Hematology, Brussel, Belgium|Centre Hospitalier Notre-Dame et Reine Fabiola, Charleroi, Belgium|Universitair Ziekenhuis Antwerpen, Dept. Respiratory Diseases, Edegem, Belgium|UZ Gasthuisberg, UZ Leuven, Leuven, Belgium|C.H.U. Sart-Tilman, Liege, Belgium|III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU), Plovdiv, Bulgaria|DDOncDIU Sofia District, Sofia, Bulgaria|MHAT ""Tsaritsa Yoanna"", Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Fraser Valley Cancer Centre-Surrey Memorial Hospital, Surrey, British Columbia, Canada|London Regional Cancer Centre, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Humber River Regional Hospital, Weston, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia|Faculty Hospital Motol, Praha 5, Czechia|Fakultní Thomayerova nemocnice s poliklinikou, Praha, Czechia|Masarykova nemocnice v Ústí nad Labem, Ústí nad Labem, Czechia|Rikshospitalet, Finsen Center, Copenhagen, Denmark|Herlev Hospital, Onkologisk afdeling R, Herlev, Denmark|Odense Universitetshospital,Onkologisk afdeling R, Odense C, Denmark|Centre François Baclesse, Caen Cedex 5, France|Hôpital de la Croix-Rousse, Lyon Cedex 04, France|CHU Montpellier - Unité de Cancérologie Thoracique, Montpellier Cedex, France|Institut Gustave Roussy, Villejuif, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Essen Innere Klinik und Poliklinik, Essen, Germany|Asklepios Fachkliniken Muenchen Gauting, Gauting, Germany|Krankenhaus Grosshansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grosshansdorf, Germany|Staedtisches Krankenhaus Martha-Maria Halle-Doelau, Halle (Saale), Germany|Thoraxklinik am Universitätsklinikum Heidelberg AG, Heidelberg, Germany|St. Vincentius-Kliniken Karlsruhe, Hamatologie, Med Onkologie und Immunologie, Karlsruhe, Germany|Katholisches Klinikum Mainz, St. Hildegardis Krankenhaus, Mainz, Germany|Klinikum Mannheim GmbH, Chirugische Klinik, Thorakale Onkologie, Mannheim, Germany|Semmelweis University of Medicine, Budapest, Hungary|Országos Korányi Tbc és Pulmonológiai Intézet, Budapest, Hungary|DEODEC, Debrecen, Hungary|Matrai Gyogyintezet, Matrahaza, Hungary|County Hospital Baranya, Pecs, Hungary|Erzsébet Hospital Sopron, Sopron, Hungary|Policlinico di Modena - University of Modena & Reggio Emilia, Dept Oncology & Hematology, Modena, Italy|Ospedale S. Maria della Misericordia, Perugia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Ospedale S.S. Trinita, Sora, Italy|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|VU University Medical Center Amsterdam, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Elkerliek Ziekenhuis, Locatie Helmond, Helmond, Netherlands|Erasmus MC - Daniel den Hoed, Rotterdam, Netherlands|Specjalistyczny Zespol Chorob Pluc i Gruzlicy w Bystrej, Bystra, Poland|Akademickie Centrum Kliniczne, Gdansk, Poland|Zespol nr 1 Szpitala im. St. Leszczynskiego, Katowice, Poland|Klinika Nowotworow Ukladowych i Uogolnionych Centrum Onkologii, Instytut im. Marii Sklodowskiej-Curie, Kraków, Poland|Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland|Wielkopolskie Centrum Pulmonologii i Tarakochirurgii Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii, Poznan, Poland|Szpital Specjalistyczny w Prabutach, Prabuty, Poland|Wojewódzki Szpital Chorób Pluc im Alojzego Pawelca w Wodzislawiu Slaskim, Wodzislaw Slaski, Poland|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Duran i Reynals Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain|Fundación Jiménez Díaz. Universidad Autónoma de Madrid, Madrid, Spain|Hospital Universitario Virgin de la Victoria, Malaga, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Universitätsspital Zürich, Zurich, Switzerland|Edinburgh Cancer Research Centre, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00547651"
355,"NCT00540514","Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer",,"Completed","Has Results","Non-Small Cell Lung Carcinoma","Drug: Albumin-bound paclitaxel|Drug: Paclitaxel|Drug: Carboplatin","Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment|Progression-free Survival by Blinded Radiology Assessment|Overall Participant Survival|Percentage of Participants With Controlled Disease|Duration of Response in Responding Patients|Number of Participants With Adverse Events (AEs)|Pharmacokinetic (PK) Parameters|SPARC Status and Correlation With Overall Survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","1052","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA031","November 1, 2007","October 1, 2009","February 1, 2013","October 8, 2007","August 19, 2013","October 29, 2019","Clearview Cancer Institute Oncology Specialties, P.C., Huntsville, Alabama, United States|Genesis Cancer Center- Hot Springs, Hot Springs, Arkansas, United States|Little Rock Hematology Oncology Associates, Little Rock, Arkansas, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Southwest Cancer Care, Escondido, California, United States|Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Comprehensice Cancer Ctr., Palms Springs, California, United States|Gulf Coast Oncology Associates, Saint Petersburg, Florida, United States|Lake County Oncology and Hematology, PA, Tavares, Florida, United States|Phoebe Cancer Center, Albany, Georgia, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Kentuckiana Cancer Institute, PLLC, Louisville, Kentucky, United States|Mercy Hospital, Portland, Maine, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|Mercy Medical Center, Baltimore, Maryland, United States|St. Louis University, Saint Louis, Missouri, United States|Essex Oncology of North Jersey, Belleville, New Jersey, United States|Mary Imogene Bassett Hospital, Cooperstown, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|St. Mary Medical Center- Oncology, Hematology PC, Langhorne, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Dallas Oncology Consultants, PA, Duncanville, Texas, United States|The Center for Cancers and Blood Disorders, Fort Worth, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Blood and Cancer Center of East Texas, Tyler, Texas, United States|Tyler Hematology Oncology, Tyler, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Cancer Outreach Associates, PC, Abingdon, Virginia, United States|Royal Columbian Hospital, New Westminster, British Columbia, Canada|William Osler Health Centre, Brampton Clinic, Brampton, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University- Dept. of Oncology, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00540514"
356,"NCT00537511","A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide",,"Terminated","Has Results","Carcinoma, Small Cell","Drug: Pomalidomide|Drug: Cisplatin|Drug: Etoposide","Maximum Tolerated Dose (MTD)|Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase|Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response|Overall Survival|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-SCLC-002","February 1, 2008","November 1, 2010","December 1, 2010","October 1, 2007","April 17, 2013","November 19, 2019","Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology, Cleveland, Ohio, United States|Pennsylvania State University, Hershey, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Juranvinski Cancer Center - Medical Oncology, Hamilton, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Mc Gill University - Department of Oncology - Clinical Research Program, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00537511"
357,"NCT00531271","ABI-008 Trial in Patients With Metastatic Breast Cancer",,"Terminated","No Results Available","Metastatic Breast Cancer","Drug: ABI-008 (nab-docetaxel)","To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every three weeks.|To evaluate the safety and tolerability of ABI-008 in the metastatic breast cancer patient population; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA302","November 1, 2007","December 1, 2008","December 1, 2008","September 18, 2007",,"November 14, 2019","University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00531271"
358,"NCT00528983","Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia",,"Completed","No Results Available","Myelodysplastic Syndromes (MDS)|Chronic Myelomonocytic Leukemia (CMML)|Acute Myelogenous Leukemia (AML)","Drug: Subcutaneous (SC) Azacitidine|Drug: Oral Azacitidine","Safety evaluation as measured by monitoring AEs, dose limiting toxicities, scheduled lab assessments, vital sign measurements, ECGs, & physical exams for study duration. Adverse changes in physical signs/symptoms will be graded according to CTC AE V.3.0.|Maximum-tolerated dose|Pharmacodynamic blood and bone marrow samples will be collected and evaluated.|Efficacy assessed by evidence of response (MDS subjects) and/or hematologic improvement (MDS subjects) examined using IWG criteria.|Biologically active dose based on safety, PK and PD data.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","133","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA PH US 2007 CL005","September 11, 2007","July 31, 2013","April 5, 2016","September 14, 2007",,"November 8, 2019","University of Florida, Gainesville, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Kansas University Medical Center, Westwood, Kansas, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City VA Medical Center University of Kansas Medical Center, Kansas City, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology P.C., Albany, New York, United States|Institute for Translational Oncology Research IRB, Greenville, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Cancer Care, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|HOAST, San Antonio, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00528983"
359,"NCT00521339","Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis",,"Completed","Has Results","Psoriasis-Type Psoriasis|Plaque-Type Psoriasis","Drug: Apremilast","Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase|Treatment Emergent Adverse Events (TEAEs) During the Extension Phase|Percentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 12|Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12|Percentage of Participants Who Achieved a PASI-75 Score at Week 12|Percentage of Participants Who Achieved a PASI-50 Score at Week 12|Maximal PASI Response Documented for Each Participant During Treatment Phase|Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12|Time to Clinically Relevant Response (Time to Achieve PASI-50) During Treatment Phase|Time to Achieve PASI-75 During Treatment Phase|Time to Relapse of Psoriasis (50% Loss of Maximal PASI Score Improvement in Participants Who Achieved at Least PASI-50 During the Treatment Phase) During the Observational Follow up Phase|Percent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 12|Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase|Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12)|Peak (Maximum) Plasma Concentration of Medication (Cmax)|Trough Plasma Concentration (Cmin)|Time to Maximum Plasma Concentration (Tmax) During the Treatment Phase|Terminal Phase Elimination Half Life of Apremilast (t½)|Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase|Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase|Accumulation Index (R)|Mean Residence Time (MRT) During the Treatment Phase|Change From Baseline in Peripheral Blood T Cell, B Cell, and NK Cell Subsets at Week 12|Percent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12|Percent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies|Percent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies|Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12|Change From Baseline in the Medical Outcome Study Short Form 36-item Health Survey (SF-36) Scores, Mental and Physical Components to Week 12|Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase|Peak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase|Time to Maximum Plasma Concentration (Tmax) During the Extension Phase|Terminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase|Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase|Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase|Accumulation Index During the Extension Phase|Mean Residence Time (MRT) During the Extension Phase","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-10004-PSOR-004","August 1, 2007","April 1, 2009","May 1, 2009","August 27, 2007","October 21, 2014","November 6, 2017","Tufts-New England Medical Center Hospitals, Boston, Massachusetts, United States|Central Dermatology, Saint Louis, Missouri, United States|Oregon Medical Research Center, P.C., Portland, Oregon, United States|Baylor Research Institute, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00521339"
360,"NCT00481273","AVIDA The Vidaza® (Azacitidine) Patient Registry","AVIDA","Completed","No Results Available","Myelodysplastic Syndromes","Drug: Azacitidine","Vidaza usage|Concomitant care and treatment|Duration and number of cycles|Publication","Celgene","All","Child, Adult, Older Adult",,"479","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AVIDA","October 31, 2006","August 31, 2010","August 31, 2010","June 1, 2007",,"May 3, 2018","AVIDA Registry Help, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00481273"
361,"NCT00477529","ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer",,"Completed","No Results Available","Hormone Refractory Prostate Cancer","Drug: ABI-008","DLT's and MTD's|Efficacy of ABI-008 in this patient population","Celgene","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","102","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA301","April 1, 2007","June 2, 2011","June 2, 2011","May 23, 2007",,"November 19, 2019","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00477529"
362,"NCT00463385","A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia",,"Completed","Has Results","Myelofibrosis With Myeloid Metaplasia|Myeloid Metaplasia|Myelofibrosis","Drug: Pomalidomide|Drug: Prednisone|Drug: Placebo to pomalidomide|Drug: Placebo to prednisone","Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment|Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment|Time to the First Clinical Response|Duration of First Clinical Response|Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores|Change From Baseline in Hemoglobin Concentration for Responders|Change From Baseline in Hemoglobin Concentration for Non-Responders|Change From Baseline in Likert Abdominal Pain Scale|Percentage of Participants With Clinical Response by Baseline JAK2 Assessment|Number of Participants With Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-4047-MMM-001","April 1, 2007","May 1, 2009","December 31, 2013","April 20, 2007","October 28, 2013","November 20, 2019","UCLA School of Medicine Hematology/Oncology, Los Angeles, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian HospitalWeill Medical College of Cornell University, New York, New York, United States|MD Anderson Cancer Center Leukemia Department, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical University of Vienna, Department of Internal Medicine, Hematology, Vienna, Austria|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy|Hematology DepartmentHospital Clinic, Barcelona, Spain|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00463385"
363,"NCT00461045","Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: MRZ 0.5 mg/m^2","Number of Patients Exhibiting a Given Overall Response as Determined by Investigator|Duration of MRZ Treatment|Number of Cycles of Marizomib (MRZ)|Number of Patients Receiving Marizomib (MRZ) in Each Cycle|Number of Patients With Treatment Emergent Adverse Events (TEAEs)|Number of Treatment Emergent Adverse Events (TEAEs)|Maximum Observed Blood Drug Concentration (Cmax)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPI-0052-101","March 2007","September 2014","October 2014","April 17, 2007","September 13, 2017","December 19, 2017","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, School of Medicine, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00461045"
364,"NCT00456092","Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis",,"Completed","Has Results","Psoriatic Arthritis","Drug: Apremilast|Drug: Placebo","Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12|Number of Participants With Adverse Events During the Treatment Phase|Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 12|Percentage of Participants With a Modified ACR 50 Response at Week 12|Percentage of Participants With a Modified ACR 70 Response at Week 12|Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 12|Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 12|Percentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 12|Percentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 12|Number of Participants Who Withdrew Prematurely Due to Lack of Efficacy|Number of Participants With Adverse Events Leading to a Dose Reduction|Maximal ACR Response During the Treatment Phase|Time to ACR 20 Response During the Treatment Phase|Time to ACR 50 Response During the Treatment Phase|Time to ACR 70 Response During the Treatment Phase|Change From Baseline in Dactylitis Severity Score at Week 12|Percentage of Participants With Enthesitis|Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase|Number of Participants Who Relapsed During the Observational Follow-up Phase|Change From Baseline in Short Form 36 (SF-36) Summary Physical and Mental Component Scores at Week 12|Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12|Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12|Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12|Number of Participants With Adverse Events During the Extension Phase|Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24|Percentage of Participants With a Modified ACR 20 Response at Week 24|Percentage of Participants With a Modified ACR 50 Response at Week 24|Percentage of Participants With a Modified ACR 70 Response at Week 24|Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 24|Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 24|Maximal ACR Response During the Extension Period|Time to ACR 20 Response During the Study|Time to ACR 50 Response During the Treatment and Extension Phase|Time to ACR 70 Response During the Treatment and Extension Phase|Change From Baseline and Week 12 in Dactylitis Severity Score at Week 24|Percentage of Participants With Enthesitis in the Extension Phase|Time to Relapse of Psoriatic Arthritis After Extension Phase|Number of Participants Who Relapsed After the Extension Phase|Change From Baseline and Week 12 in SF-36 at Week 24|Change From Baseline and Week 12 in Dermatology Life Quality Index (DLQI) at Week 24|Change From Baseline and Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 24","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSA-001","March 5, 2007","May 9, 2009","May 9, 2009","April 4, 2007","October 23, 2019","October 23, 2019","CHU Brugmann, Brussels, Belgium|Universiteit Hasselt, Diepenbeek, Belgium|University Hospital, Leuven, Belgium|Jan Palfijn Ziekenhuis, Merksem, Belgium|The Arthritis Research Centre of Canada, Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Nexus Clinical Research, St Johns, Newfoundland and Labrador, Canada|Burlington Rheumatology and Osteoporosis Clinic, Burlington, Ontario, Canada|MAC Research Inc., Hamilton, Ontario, Canada|K-W Musculoskeletal Research Inc., Kitchener, Ontario, Canada|Credit Valley Rheumatology, Mississauga, Ontario, Canada|Arthritis Program Research Group Inc, Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Center for Prognosis Studies in the Rheumatic Diseases University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Probity Medical, Waterloo, Ontario, Canada|Clinical Research and Arthritis Centre, Windsor, Ontario, Canada|West Island Rheumatology Research Associates, Pointe-Claire, Quebec, Canada|Saskatoon Osteoporosis Center, Saskatoon, Saskatchewan, Canada|Capio Franz von Prümmer Klinik, Bad Brückenau, Germany|Free University of Berlin, Berlin, Germany|Universitaetsklinikum Frankfurt, Frankfurt, Germany|Klinikum Eilbek, Hamburg, Germany|Universitaet Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaet Leipzig, Leipzig, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|University of Munich, Munich, Germany|Klinikum der Universität Munster, Munster, Germany|Friedrich-Alexander University, Erlangen, Nuremberg, Germany|Hagaziekenhuis, Den Haag, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Radboud University, Nijmegen, Netherlands|Hope Hospital, Salford, Manchester, United Kingdom|Haywood Hospital, Stoke on Trent, Staffs, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Freeman Hospital, Newcastle-upon-Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00456092"
365,"NCT00452569","Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma","OPTIMUM","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Dexamethasone","The evaluation of Independent Review Committee-documented time to progression (TTP).|Response rate (CR + PR), according to the EBMT criteria|Response duration|Clinical benefit as measured by ECOG performance status, transfusion requirement and Grade ≥3 infections (assessed by the National Cancer Institute Common Toxicity Criteria)|Progression-free survival (PFS)|Overall survival (OS)|Composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death)|Quality of life as determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)|Adverse events (AEs)|Assessment of peripheral neuropathy|Vital signs and physical examination|Clinical laboratory tests","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","499","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","THA PH INT 2005 CL001","February 1, 2006","December 1, 2008","January 1, 2009","March 27, 2007",,"November 18, 2019","Clinic of Haematology, University Multiprofiled Hospital for Active Treatment ""G. Stranski"", Pleven, Bulgaria|Clinic of Haematology, University Multiprofiled Hospital for Active Treatment, Plovdiv, Bulgaria|University of Multiprofiled Hospital for Active Treatment ""Alexandrovska"" - Sofia, Sofia, Bulgaria|Military Medical Academy/Dept Haematology and Oncology, Sofia, Bulgaria|National Center of Haematology & Transfusiology, Sofia, Bulgaria|Clinic of Haematology, Multiprofiled Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Klinicki Bolnicki Centar Rijeka Interna Klinika, Rijeka, Croatia|Klinika Bolnica SPLIT - Klinika za Unutarnje Bolesti, Split, Croatia|KBC Zagreb - Klinika za Unutarnje Bolesti, Zagreb, Croatia|Klinicka Bolnica ""Dubrava"" Klinika za Unutarnje Bolesti, Zagreb, Croatia|Klinicka Bolnica ""Sestre milosrdnice"" Klinika za Unutarnje Bolesti, Zagreb, Croatia|Klinicka Bolnica MERKUR - Klinika za Unutarnje Bolesti, Zagreb, Croatia|Interni Hemato-Onkologicka Klinika, Brno, Czechia|Hematologicka Klinika, Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Onkologicke Centrum J.G. Mendela, Novi Jicin, Czechia|Interni Klinika, Oddeleni Hematoonkologie, Olomouc, Czechia|Hematologicka Klinika, Fakultni Nemocnice Kralovske Vinohrady Srobarova, Prague 10, Czechia|Interni Klinika, Oddeleni Hematoonkologie, Prague 2, Czechia|CHRU de Lille - Hopital Claude Huriez, Lille, France|CHU de Nancy - Hopital Brabois, Nancy Cedex, France|Hematologie - CHU Purpan Place du Dr. Baylac, Toulouse, France|Charite, Universitatsmedizin Berlin, Campus Robert-Rossle Klinik, Berlin, Germany|Med. Klinik I/University Bonn, Bonn, Germany|Medizinische Klinik und Poliklinik I/Carl-Gustav-Carus University, Dresden, Germany|Hematology, Oncology & Clinical Immunology/Heinrich-Heine-University, Duesseldorf, Germany|Abt. Haematologie - Onkologie/ Allg. Krankenhaus, Hamburg, Germany|Allgemeinse Krankenhaus St. Georg Hamatologische Abteilung, Hamburg, Germany|Medizinische Klinik Abteilung Innere V/Universitatsklinikum, Heidelberg, Germany|Universitat Schleswig Holstein II Med. Klinik, Kiel, Germany|Universitaetsklinik - Klinik fur innere Medizin, Koeln, Germany|Medizinische Klinik und Poliklinik III/Klinikum der Universitaet Muenchen, Muenchen, Germany|Innere Medizin University Hospital, Muenster, Germany|Abteilung Haematologie - Univeresitaetsklinikum, Saale, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Stuttgart, Germany|Universitaetsklinik - Abteilung Innere Medizin III, Ulm, Germany|Med. Klinik II/Klinikum of the Julius-Maximilians-University, Wuerzburg, Germany|National Medical Centre Dpt Haematology, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, II. Belgyogyaszat, Gyor, Hungary|Pandy Kalman Megyei Korhaz, Megyei Onkologiai Centrum, Gyula, Hungary|Szent-Gyorgyi Albert University II Clinic of Internal Medicine, Szeged, Hungary|Nizam's Institute of Medical Sciences, Department of Medical Oncology, Hyderabaad, India|Department of Medical Oncology, Amrita Institute of Medical Sciences, Kerala, India|Orchid Nursing Home, Kolkata, India|Department of Medical Oncology, Dayanand Medical College DMCH, Ludhiana, India|Department of Medical Oncology/Tata Memorial Hospital, Mumbai, India|Department of Medical Oncology, S.L. Raheja Hospital, Mumbai, India|Department of Medical Oncology, Jaslok Hospital and Research Centre, Mumbai, India|Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, India|Department of Medical Oncology/Regional Cancer Centre, Trivandrum, India|Instituto di Ematologia e Oncologia Medica, Bologna, Italy|Dipartimento Medicina ed Oncologia Sperimentale - Divisione Universitaria di Ematologia Azienda Ospedaliera S. Giovanni Battista, Torino, Italy|Department of Internal Medicine - Baguio General Hospital & Medical Center, Baguio City, Philippines|Chong Hua Hospital, Cebu City, Philippines|Doctors Clinic Makati Medical Center, Makati City, Philippines|University of Sto Tomas Hospital, Manila City, Philippines|Doctors Clinic - National Kidney & Transplant Institute, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|SPSK, Klinika Hematologii Akademii Medycznej, Bialystok, Poland|Klinika Hematologii Akademii Medycznej w Gdanskuul, Gdansk, Poland|Katedra i Klinika Hematologii i Transplantacji Szpiku - Slaska Akademia Medyczna, Katowice, Poland|Swietokrzyskie Centrum Onkologii SPZOZ Poradnia Hematologii, Kielce, Poland|Klinika Hematologii Uniwersytetu Medycznego, Lodz, Poland|Klinika Chorob Wewnetrznych i Hemagologii, Warszawa, Poland|Katedra i Klinika Hematologii, Onkologii I Chorob Wewnetrznych, Warszawa, Poland|Instytut Hematologii i Transfuzjologii - Klinika Hematologiczna, Warszawa, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Klinika Hematologii Nowotworow Krwi i Transplantacji - Szpiku Akademii Medycznej, Wroclaw, Poland|Hospital da Universidade de Coimbra - Servico de Hematologia Clinica, Coimbra, Portugal|Instituto Portugues de Oncologia, Lisboa, Portugal|Hospital Geral de Santo Antonio - Servico de Hematologia Clinica, Porto, Portugal|Institute of Hematology, Clinical Centre of Serbia, Belgrade, Serbia|Clinic for Hematology, Clinical Centre Nis, Nis, Serbia|Clinic for Hematology, Clinical Centre Novi Sad, Novisad, Serbia|Department of Internal Medicine, National Cancer Institute, Bratilslava, Slovakia|Hematology Department University Hospital, Bratilslava, Slovakia|Hematology Department, University Hospital PJS, Kosice, Slovakia|University of Free State, Faculty of Health Science, Dept of Hematology & Cell Biology, Bloemfontein, South Africa|Tygerberg Hospital, University of Stellenbosch, Department of Haematology, Cape Town, South Africa|Department of Haematology, UCT Medical School, Cape Town, South Africa|Chris Hani Baragwanath Hospital, Clinical Haematology Unit, Johannesburg, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Johannesburg Hospital, Department of Medical Oncology, Parktown, South Africa|Oncology Research Unit Heartlands Hospital, Birmingham, United Kingdom|Clinical Haematology, Guy's Hospital, London, United Kingdom|Haematology Department - King's College Hospital, London, United Kingdom|Department of Haematology-Oncology, The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00452569"
366,"NCT00426764","A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma",,"Completed","Has Results","Peripheral T-cell Lymphoma","Drug: Romidepsin","Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an Independent Review Committee|Percentage of Participants With Objective Disease Response|Duration of Objective Disease Response|Duration of Complete Disease Response|Time to Disease Progression|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GPI-06-0002|2006-006228-21","June 19, 2007","November 11, 2010","May 17, 2018","January 25, 2007","August 13, 2012","May 30, 2019","Moore UCSD Cancer Center, La Jolla, California, United States|UCLA Division of Hematology Oncology, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University IRB, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|Cancer Centers of Florida, PA, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Augusta Oncology Associates, P.C., Augusta, Georgia, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Cancer Care and Hematology Specialists of Chicagoland, Arlington Heights, Illinois, United States|Hematology Oncology Assoc. of IL Orchard Research LLC, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|St. Agnes - Medical Center, Baltimore, Maryland, United States|Center for Cancer And Blood Disorders, Bethesda, Maryland, United States|Center for Cancer Research CAMC, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Oncology Hematology, PA, Burnsville, Minnesota, United States|St. Joseph Oncology, Inc, Saint Joseph, Missouri, United States|Arch Medical Services, Saint Louis, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Taussig Cancer Center Cleveland Clinic Foundation, Cleveland, Ohio, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Accelerated Community Oncology Research Network Inc ACORN, Memphis, Tennessee, United States|Mamie McFadden Ward Center, Beaumont, Texas, United States|Methodist Charlton Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States|El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology, P.A.-Fort Worth, Fort Worth, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Allison Cancer Center, Midland, Texas, United States|US Oncology, Plano, Texas, United States|HOAST, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texas Oncology, PA, Waco, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Mater Private Medical Centre - Haematology and Oncology Clinics of Australasia Research Centre, South Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, East Melbourne, Australia|St. Vincent Hospital, Fitzroy, Australia|Royal North Shore Hospital, St Leonards, Australia|University Hospital Brno, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital of Kralovske Vinohrady, Prague 10, Czechia|Charles University General Hospital, Prague 2, Czechia|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital Henri Mondor, Créteil, France|Hopital Claude Huriez, Lille, France|CHU Nantes Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Service des Maladies du Sang, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Centre Eugene Marquis, Rennes, France|Centre Henri Becquerel, Rouen Cedex, France|Charite Universitatsmedizin Berlin campus Virchow Klinikum Centrum fur Tumormedizin, Berlin, Germany|Krankenhaus Nordwest, Frankfurt a.M., Germany|Georg-August-Universität Göttingen, Göttingen, Germany|Uniklinik Koln, Köln, Germany|Klinikum der Universitat Munchen-Grosshadern, Muenchen, Germany|Klinikum Nurnberg Nord, Nürnberg, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|Klinika Hematologii Akademickie Centrum Kliniczne Akademii Medycznej w Gdansku, Gdansk, Poland|Oddzial Kliniczny Kliniki Hematologii, Kraków, Poland|Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika, Lodz, Poland|Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Hospital Universitario Vall D Hebron, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Marques de Valdecilla, Santandar, Spain|Lund University Hosptial, Lund, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine|National Cancer Institute Department Of Conservative Methods Of Treatment, Kyiv, Ukraine|R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the AMS of Ukraine, Lviv, Ukraine|Royal Free Hospital, London Hampstead, United Kingdom|Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom|Guy's and St. Thomas' Hospital, London, United Kingdom|Catherine Lewis Centre - Hematology Department, London, United Kingdom|Somers Cancer Research Building, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00426764"
367,"NCT00424047","A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: CC-5013 plus dexamethasone|Drug: Dexamethasone plus Placebo","Kaplan-Meier Estimate of Time to Tumor Progression (TTP)|Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)|Kaplan-Meier Estimate of Overall Survival (OS)|Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)|Summary of Myeloma Response Rates Based on Best Response Assessment|Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)|Number of Participants With Adverse Events (AE)|Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)|Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale|Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","351","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-MM-010","January 1, 2003","November 1, 2005","November 12, 2013","January 18, 2007","March 4, 2015","October 19, 2017","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Peter MacCallum Cancer Centre Divsion of Haematology/Medical Oncology, East Melbourne, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Box Hill Hospital, Box Hill, Australia|Frankston Hospital Oncology Research, Frankston, Australia|Royal Brisbane Hospital, Herston, Australia|The Royal Melbourne Hospital, Parkville, Australia|Mater Public Hospital, South Brisbane, Australia|University Hospital of Salzburg St Johanns Spital, Salzburg, Austria|Wilhelminenspital, Vienna, Austria|CHU Saint-Luc, Brussel, Belgium|UZ Gasthuisberg, Leuven, Belgium|Centre Hospitalier Lyon Sud, Chemin Grand Revoyet, France|Hopital Claude Huriez, Lille, France|Centre Hospitalier Hotel-Dieu, Nantes, France|Hopital Saint-Loius, Paris, France|Chu de Bordeaux Groupe Hospitalier Sud, Pessac, France|CHU Purpan, Toulouse cedex 9, France|CHU Nancy - Hopital Brabois, Vandoeuvre, France|Universitaetsklinikum Charite, Berlin, Germany|Universitatsklinik ChariteMedizinische Fakultaet der HumboldtUniversitaet zu Berlin, Berlin, Germany|Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Dusseldorf, Germany|Universitaetsklinkum Erlangen, Erlangen, Germany|Klininkum der Johann-Wolfgang-Goethe-Universtat, Frankfurt am Main, Germany|Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V, Heidelberg, Germany|Universitatsklinik Muenster Medizinische Klinik A, Muenster, Germany|Klinikum der Univeristact Muenchen, Munchen, Germany|Universitaetsklinikum Tuebingen, Tubingen, Germany|""Alexandras"" General Hospital of Athens, Athens, Greece|University Hospital GalwayHaematology Department, Galway, Co. Galway, Ireland|Belfast City HospitalHaematology Department, Belfast, Ireland|Hope Directorate Haematology Oncology Service St. James Hospital, Dublin 8, Ireland|MidWestern Regional Hospital, Limerick, Ireland|Rambam Medical Center, Haifa, Israel|Hadassah University Hospital, Jerusalem, Israel|Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera San Martino, Genova, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Policlinico San Matteo, Pavia, Italy|Univerita La Sapien, Roma, Italy|Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Torio, Italy|Policlinico Universitario a Gesttione diretta di Udine, Udine, Italy|Institute of Internal Diseases University of Medicine, Gdansk, Poland|University School of Medicine, Lublin, Poland|Institute of Haematology and Blood Transfusion, Warsaw, Poland|Hospital Clinic, Barcelona, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain|Sahlgrenska University Hospital Department of Hematology and Coagulation, Goteborg, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine|Kiev Bone Marrow Transplantation Center Bone Marrow Department, Kiev, Ukraine|Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the UAMS, Lviv, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department, Lvov, Ukraine|Odess Regional Clinical Hospital, Odessa, Ukraine|Zhitomir Regional Clinical Hospital, Zhitomir, Ukraine|University College Hospital Trust, London, Bloomsbury, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Haematology Dept, 4th Floor Thomas Guy House, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00424047"
368,"NCT02433457","Relative Bioavailability Study of CC-292",,"Completed","No Results Available","Healthy Volunteers","Drug: CC-292|Drug: Oral Omeprazole (OMP)","Pharmacokinetics ‐ Cmax|Pharmacokinetics - AUC 0-t|Pharmacokinetics - AUC 0-24|Pharmacokinetics - AUC 0-∞|Pharmacokinetics - %AUCextrap|Pharmacokinetics - Frel|Pharmacokinetics - Tmax|Pharmacokinetics - λz|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Adverse Events (AEs)","Celgene Corporation|Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-292-CP-002","May 2014","September 2014","September 2014","May 5, 2015",,"May 5, 2015","Covance Clinical Research unit, Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02433457"
369,"NCT00419250","A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Chronic Lymphocytic Leukemia|Leukemia, B-Cell, Chronic","Drug: lenalidomide","Safety|Response|Duration of response|Time to response|Progression free survival|Overall survival|Absolute lymphocyte count|Evaluation of minimal residual disease (MRD) by flow cytometry","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-CLL-001","December 1, 2006","February 1, 2010","June 1, 2010","January 8, 2007",,"November 8, 2019","Arizona Cancer Center, Tucson, Arizona, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|Northwest Georgia Oncology Centers, PC., Wellstar Health System, Marietta, Georgia, United States|Mountain States Tumor Institute, Boise, Idaho, United States|Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Medical center, Indianapolis, Indiana, United States|LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, Louisiana, United States|Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Medical College of Cornell University, Division of Hematology & Oncology, New York, New York, United States|SUNY Upstate Medical Center, Syracuse, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Abington Hematology Oncology Assoc., Inc., Willow Grove, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Helath Science Centre, London, Ontario, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Charité, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, Berlin, Germany|Uniklinik Köln, Klinik I für Innere Medizin, Klinisches Studienzentrum Hämatologie, Bettenhaus Ebene 04, Raum 001/048, Kerpener Str. 62, Koln, Germany|University of Schleswig Holstein, Director Medizinische Klinik II, Campus Kiel, Chemnitzstrasse 33, Kiel, Germany|University of Ulm, Abteilung Innere Medizin III, Robert-Koch-Strasse 8, Ulm, Germany|Clinica Ematologica- A.O.U. San Martino, Clinica Ematologica Dipartimento di Medicina Interna, Genova, Italy|Hospital Clinic Provincial de Barcelona, Servicio de Hematología, Institute of Haematology and Oncology, Villaroel, 170, Barcelona, Spain|Karolinska Universitetssjukhuset, Hematologiskt Centrum, Karolinska Universitetssjukhuset,, Stockholm, Sweden|St James's Institute of Oncology, Dept. of Haematology, Level 3, Bexley Wing, Beckett Street, Leeds, United Kingdom|Bart's and the London NHS Trust, St. Bartholomew's Hospital, 7th Floor Gloucester House, Cancer Services, London, United Kingdom|Christie Hospital NHS Foundation Trust, Haematology and Transplant Unit,, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00419250"
370,"NCT00413036","A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma, Non-Hodgkin's","Drug: lenalidomide","Participants Categorized by Best Response as Determined by Central Review|Duration of Response as Determined by Central Review|Time to Progression as Determined by Central Review|Progression-free Survival as Determined by Central Review|Proportion of Participants Who Experienced Stable Disease or Better as Determined by Central Review","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","217","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NHL-003","June 2006","April 2011","May 2011","December 19, 2006","April 11, 2013","March 1, 2017","Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Lalita Pandit, MD, Inc, Fountain Valley, California, United States|Access Clinical Research, Rancho Mirage, California, United States|Kaiser Permanente Medical Group, San Diego, California, United States|Pasco Hernando Oncology Associates, Brooksville, Florida, United States|Sylvester Cancer Center/ Univeristy of Miami, Miami, Florida, United States|Hematology Oncology Associates of Central Brevard, Rockledge, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Cancer Care Center, Inc., New Albany, Indiana, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Michigan Hematology and Oncology Institute, Southgate, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska, Omaha, Nebraska, United States|Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Our Lady of Mercy Cancer Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|HIllman Cancer Center -UPMC, Pittsburg, Pennsylvania, United States|Palmetto Hematology Oncology, Spartanburg, South Carolina, United States|Family Cancer Center, Collierville, Tennessee, United States|London Health Science Center, London, Ontario, Canada|Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Canada|Service d'Hématologie Clinique, Créteil, France|Clinical Haematology Department, Dijon, France|Institute Paoli-Calmettes Départmentd 'Hématologie, Marseille, France|CHU Hopital Lapeyronie, Hematologie et Oncologie Medicale, Montpellier, France|Hopital Saint Louis Service d'Hémato-Oncologie, Paris, France|Hopital du Haut-Lévèque, Pessac, France|Centre Hospitalier Lyon Sud, Hematologie Clinique, Pierre Bénite, France|Department d'Hématologie Centre Henri Becquerel, Rouen, France|Research Site, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Research Site, Goettingen, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Koeln, Germany|Institute of Hematology and Medical Oncology ""L. & A. Seràgnoli"", Bologna, Italy|O.U. di Clinica Ematologica, Genova, Italy|Ospedale Policlinico S. Matteo, Pavia, Italy|Dipartimento di Oncologia dei Trapianti e delle Nuove Tecnologie in Medicina, Roma, Italy|Azienda Sanitaria Ospedaliera San Giovanni Battista (Molinette),, Torino, Italy|Hospital Clinic I Provincial, Servicio de Hematologia, Barcelona, Spain|Hospital Clinicio San Carlos, Servivio de Hematologia Clinica, Madrid, Spain|Hospital Universitario 12 de Octubre,, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Servicio de oncologia, Malaga, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complexo Hospitalario de Pontevedra Oncology Department, Pontevedra, Spain|Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Salamanca, Spain|Research Site, Valencia, Spain|Somers Cancer Research Building, Southampton, United Kingdom|Royal Marsden Hospital NHS Foundation Trust London and Surrey, Surrey, United Kingdom|Medical Oncology, Christie Hospital NHS Trust, Withington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00413036"
371,"NCT00407407","ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma",,"Terminated","No Results Available","Fallopian Tube Neoplasms|Peritoneal Neoplasms|Ovarian Neoplasms","Drug: ABI-007|Drug: Carboplatin","Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities|Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug","Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA034","November 1, 2006","February 1, 2008","February 1, 2008","December 5, 2006",,"October 18, 2019","University of Texas, MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00407407"
372,"NCT00396864","Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma",,"Completed","No Results Available","Cancer|Lymphomas","Drug: NPI-0052","Safety|Maximum Tolerated Dose (MTD)|Pharmacokinetics|Pharmacodynamics|Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPI-0052-100","May 2006","March 2010","March 2010","November 8, 2006",,"November 22, 2017","Premiere Oncology of America, Scottsdale, Arizona, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Univ. of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00396864"
373,"NCT00388960","Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: Amrubicin|Drug: Cisplatin|Drug: Etoposide","Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)|Toxicity|Progression-free survival|Overall survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EORTC Protocol 08062|2006-001956-11","November 1, 2006","April 1, 2010","December 1, 2010","October 17, 2006",,"November 19, 2019","Algemeen Ziekenhuis Middelheim, Antwerpen, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universiteit Gent, Gent, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Domaine Universitaire du Sart-Tilman, Liege, Belgium|Centre Hospitalier Regional de la Citadelle, Liege, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Instituto Nazionale per la Ricerca sul Cancro, Genova, Italy|Universita Degli Studi Di Udine, Udine, Italy|Academisch Medisch Centrum, Amsterdam, Netherlands|The Netherlands Cancer Institute Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Medisch Spectrum Twente - Dept of Pulmonary Diseases, Enschede, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Isala Kliniek, Zwolle, Netherlands|Medical University of Gdansk - Dept Radiotherapy, Gdansk, Poland|Clatterbridge Centre for Oncology NHS Trust, Bebington, Merseyside, United Kingdom|University of Dundee - Ninewells Hospital, Dundee, Scotland, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Princess Royal Hospital, Hull, United Kingdom|Royal Marsden Hospital, London, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Sir Bobby Robson Cancer Trials Research Centre, Newcastle-Upon-Tyne, United Kingdom|Royal Marsden Hospital Lung Unit, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00388960"
374,"NCT00379639","A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors",,"Completed","Has Results","Pancreatic Cancer","Drug: Romidepsin|Drug: Gemcitabine","Number of Participants With a Dose-limiting Toxicity (DLT)|Number of Participants With Adverse Events (AEs)|Best Overall Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GPI-06-0003","July 1, 2006","July 1, 2008","July 1, 2008","September 22, 2006","August 13, 2012","October 30, 2019","Sarah Cannon Research Institute, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00379639"
375,"NCT00375193","Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: Amrubicin","Objective tumor response rate according to RECIST|Duration of overall response|Time to tumor progression|Progression free survival|Overall survival|Toxicity profile|Incidence of cardiomyopathy|Incidence of CNS progression|Pharmacokinetic parameters","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNF3140-SCLC-002","November 1, 2006","May 1, 2008","March 1, 2009","September 12, 2006",,"October 24, 2019","Hematology Oncology Associates, Phoenix, Arizona, United States|Rocky Mountain Cancer Center - Sky Ridge, Lone Tree, Colorado, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, PA, Ocoee, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Cancer Care & Hematology Specialists of Chicago, Niles, Illinois, United States|Oncology & Hematology of Central Illinois, Peoria, Illinois, United States|Blessing Cancer Center, Quincy, Illinois, United States|Central Indiana Cancer Centers - Indianapolis, Indianapolis, Indiana, United States|Norton Healthcare - Louisville Oncology, Louisville, Kentucky, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, United States|Alliance Hematology Oncology, PA - Carroll County Cancer Center, Westminster, Maryland, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Minnesota Onc/Hem, PA - Minneapolis, Minneapolis, Minnesota, United States|University of MN/Division of Hematology, Oncology & Transplantation, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|St. Joseph Oncology, Inc., Saint Joseph, Missouri, United States|Arch Medical Group - Arch Medical Services, Inc., Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, PC, Albany, New York, United States|SUNY Upstate Medical Center, Syracuse, New York, United States|Northwestern Carolina Oncology & Hematology, Hickory, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Medical Oncology Associates, Kingston, Pennsylvania, United States|University of Tennessee Medical Center, Knoxville, Knoxville, Tennessee, United States|Sarah Cannon, Nashville, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States|Texas Oncology, PA - Bedford, Bedford, Texas, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Texas Oncology, P.A. - Dallas, Dallas, Texas, United States|Texas Oncology, P.A., Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, PA - Fort Worth, Fort Worth, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|Texas Oncology, PA - Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology - Wichita Falls, Wichita Falls, Texas, United States|Virginia Oncology Associates - Norfolk, VA, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, United States|Puget Sound Cancer Center, Seattle, Washington, United States|Northwest Cancer Specialists - Vancouver Cancer Center, Vancouver, Washington, United States|Yakima Regional Cancer Care Center - North Star Lodge Cancer Center, Yakima, Washington, United States|Free University Medical Center, Amsterdam, Netherlands|Royal Marsden Hospital in Downs Road, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00375193"
376,"NCT02321644","Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study",,"Completed","No Results Available","Healthy Subjects","Drug: CC-90001","Pharmacokinetics- Cmax|Pharmacokinetics- Tmax|Pharmacokinetics- AUC∞|Pharmacokinetics- AUCt|Pharmacokinetics- AUCτ|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Pharmacodynamics: Phospho-c-Jun IHC data will be subjectively scored on a scale of 0 to 4 based on the intensity and number of epidermal keratinocyte nuclei stained within the tissue section by trained individuals blinded to treatment|Adverse Event (AE)","Celgene Corporation|Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90001-CP-002","November 2014","February 2015","February 2015","December 22, 2014",,"August 19, 2015","Covance-Daytona Beach, Daytona Beach, Florida, United States|TKL Research, Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02321644"
377,"NCT00274456","Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer",,"Completed","Has Results","Metastatic Breast Cancer","Drug: ABI-007|Drug: Docetaxel","Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator|Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response|Kaplan-Meier Estimates for Progression-free Survival (PFS)|Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression|Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression|Kaplan-Meier Estimate for Overall Survival (OS)|Participants With Treatment-Emergent, Treatment-Related Adverse Events","Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA024","November 1, 2005","March 1, 2008","July 1, 2011","January 11, 2006","July 2, 2013","November 21, 2019","Study Sites in Russia and the Ukraine, Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT00274456"
378,"NCT00274443","An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin",,"Completed","No Results Available","Non-Small Cell Lung Cancer (NSCLC)","Drug: ABI-007 (Abraxane) and Carboplatin","Safety Outcomes: incidence of treatment emergent adverse events.|Efficacy Outcomes: percentage of patients who achieve an objective confirmed complete or partial overall antitumor response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA028","March 1, 2005","June 1, 2007","June 1, 2007","January 11, 2006",,"November 11, 2019","Study Sites in Russia, St. Petersburg, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00274443"
379,"NCT02110420","First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001",,"Completed","No Results Available","Healthy Volunteers","Drug: CC-90001|Drug: Placebo","Adverse Events|Concentrations of CC-90001 in plasma|Cmax: Maximum observed plasma concentration|Tmax: Time to Cmax|AUCinf: Area under the plasma concentration-time curve from time zero extrapolated to infinity|AUCt: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration|AUCtau: Area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval|AUCtau will be estimated for CC-90001 using a non-compartmental approach|CL/F: Apparent total plasma clearance when dosed orally|Vz/F: Apparent total volume of distribution when dosed orally, based on the terminal phase|Ratio of Accumulation based on Day 1 and Day 14 AUCtau","Celgene Corporation|Celgene","All","18 Years to 50 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)","CC-90001-CP-001","February 2014","September 2014","September 2014","April 10, 2014",,"October 15, 2014","PPD Development, LP, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02110420"
380,"NCT00179608","Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy",,"Completed","No Results Available","Malignant Melanoma","Drug: CC-5013","To determine MTD of intravenous DTIC during the first 2 cycles (6 wks) of treatment|To evaluate the safety profile of combination lenalidomide plus DTIC, the preliminary efficacy of combination lenalidomide plus DTIC|To define the recommended phase II doses of lenalidomide and DTIC when administered as combination therapy.","Celgene|Prologue Research International","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MEL-003","September 1, 2005","June 1, 2007","June 1, 2007","September 16, 2005",,"November 8, 2019","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00179608"
381,"NCT02034773","3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule",,"Completed","No Results Available","Healthy Volunteers","Drug: CC-220|Drug: Placebo","Adverse Events|Concentrations of CC-220 and its R-enantiomer in plasma|Pharmacodynamic Assessmens|Pharmacokinetics - Cmax|Pharmacokinetics - tmax|Pharmacokinetics - AUCinf|Pharmacokinetics - AUCt|Pharmacokinetics - AUCtau|Pharmacokinetics - t1/2,z|Pharmacokinetics - CL/F|Pharmacokinetics - Vz/F|Accumulation Ratio (RA)","Celgene Corporation|Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)","CC-220-CP-002","May 2013","December 2013","December 2013","January 13, 2014",,"January 13, 2014","Covance Clinical Research Unit, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02034773"
382,"NCT01933061","Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma",,"Withdrawn","No Results Available","Metastatic Melanoma","Drug: Abraxane","Progression-free survival (PFS)|Overall survival (OS)|PFS|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Safety","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-MEL-001","January 2014","January 2014","January 2014","August 30, 2013",,"February 4, 2014",,,"https://ClinicalTrials.gov/show/NCT01933061"
383,"NCT01908387","Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms",,"Terminated","No Results Available","Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Multiple Myeloma|Non-Hodgkin Lymphoma|Hodgkin Lymphoma","Drug: Oral azacitidine","Dose limiting toxicities|Number of participants with adverse events.|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUCt|Pharmacokinetics - AUC Zero to Infinity|Pharmacokinetics - AUCext%|Pharmacokinetics - Terminal Phase|Pharmacokinetics - Terminal Half-Life|Pharmacokinetics - Total Clearance|Pharmacokinetics - Volume of distribution|Pharmacokinetics - Aet|Pharmacokinetics - fet|Pharmacokinetics - Renal Clearance|Investigator's response assessment","Celgene Corporation|Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-MDS-001","July 2013","July 2015","July 2015","July 25, 2013",,"July 28, 2015","National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01908387"
384,"NCT00106613","A Research Study for Patients With Metastatic Renal Cell Carcinoma",,"Completed","No Results Available","Carcinoma, Renal Cell|Neoplasm Metastasis","Drug: FK228 (romidepsin)","To evaluate the rate of objective response (the best response of Complete Response (CR), Partial Response (PR)).|Rate of disease control, Complete Response, Partial Response, or Stable Disease|Time to objective disease progression.|Number of Participants with Adverse Events|Change from screening assessment to the final study visit in Karnofsky performance status.|Steady state plasma concentrations","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FJ-228-0001","May 1, 2003","August 1, 2004","August 1, 2004","March 29, 2005",,"October 18, 2019","City of Hope National Medical Center, Duarte, California, United States|University of Chicago, Chicago, Illinois, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00106613"
385,"NCT00106418","A Research Study for Patients With Prostate Cancer",,"Completed","No Results Available","Prostate Cancer|Metastases","Drug: Romidepsin","Rate of objective disease control","Celgene","Male","18 Years and older   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FJ-228-0002","May 7, 2003","September 1, 2006","September 1, 2006","March 25, 2005",,"November 18, 2019",,,"https://ClinicalTrials.gov/show/NCT00106418"
386,"NCT00106301","Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228",,"Completed","No Results Available","Carcinoma, Renal Cell|Prostatic Neoplasms","Drug: FK228 (romidepsin)","Number of participants with adverse events|To evaluate the effect of depsipeptide therapy on performance status as measured by the Karnofsky score assessment|To evaluate the time to objective disease progression.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FJ-228-0007","April 1, 2004","September 1, 2006","September 1, 2006","March 23, 2005",,"November 18, 2019","City of Hope National Medical Center, Duarte, California, United States|University of Florida, Gainesville, Florida, United States|University of Chicago, Chicago, Illinois, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Royal Marsden Hospital, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00106301"
387,"NCT00093223","A Safety Study of ABI-007 for In-Stent Restenosis",,"Completed","No Results Available","Angina Pectoris|Coronary Artery Disease","Drug: Paclitaxel Nanoparticle Albumin Bound","Incidence of treatment-emergent adverse events and serious adverse events.|Major Adverse Cardiac Events at 2 months following the stent procedure.|Safety and tolerability for ABI-007|Evaluation of restenosis at 6 months.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVR001","September 1, 2001","December 1, 2007","December 1, 2007","October 7, 2004",,"November 18, 2019","Abraxis BioScience, Inc., Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00093223"
388,"NCT00093119","Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma",,"Completed","No Results Available","Melanoma|Metastases","Drug: ABI-007","Determine anti-tumor activity of ABI-007 in patients with metastatic melanoma.|Evaluate number of cycles required before patients achieve maximum response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA014","July 2003","February 2005",,"October 4, 2004",,"April 26, 2017","Abraxis BioScience Inc., Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00093119"
389,"NCT02820935","Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects",,"Completed","No Results Available","Pharmacokinetics","Drug: CC-220|Drug: Rifampin|Drug: Itraconazole","Pharmacokinetics- Cmax|Pharmacokinetics- AUC∞|Adverse Events (AEs)","Celgene Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-220-CP-003","July 2016","September 2016","September 2016","July 1, 2016",,"October 18, 2016","PPD Development, LP, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02820935"
390,"NCT02655159","Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice","AMBER","Terminated","No Results Available","Breast Neoplasms",,"Overall response rate (ORR)|Overall Response Rate (ORR)|Disease control rate (DCR)|Time to disease progression (TTP)|Progression-free survival (PFS)|Overall survival (OS)|Adverse Events (AEs)","Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)",,"46","Industry","Observational","Observational Model: Case Control|Time Perspective: Retrospective","CEL-CMM-2015-01","January 2016","August 2016","August 2016","January 13, 2016",,"November 1, 2016","Complejo Hospitalario Jaén, Jaén, Andalucía, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Virgen Salud, Toledo, Castilla La Mancha, Spain|Hospital Universitario Burgos, Burgos, Castilla y León, Spain|Hospital Clínico Salamanca, Salamanca, Castilla y León, Spain|Hospital Clínico Valladolid, Valladolid, Castilla y León, Spain|Hospital Vall d´Hebron, Barcelona, Cataluña, Spain|Hospital Universitario San Joan Reus, Reus, Cataluña, Spain|Hospital Infanta Cristina, Badajoz, Extremadura, Spain|Capio Clideba, Badajoz, Extremadura, Spain|Complejo Hospitalario Orense, Orense, Galicia, Spain|Hospital Santa Lucía, Cartagena, Murcia, Spain|Hospital Navarra, Pamplona, Navarra, Spain|Hospital Gregorio Marañón, Madrid, Spain|MD Anderson, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital 12 octubre, Madrid, Spain|Hospital Quirón, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT02655159"
391,"NCT00071799","A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: Azacitidine|Other: Physician Choice","Kaplan-Meier Estimates for Median Time to Death From Any Cause|Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause|Number of Participants Who Died|Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First|Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)|Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline|Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline|Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline|Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline|Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)|Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee|Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause|Duration of Any Hematologic Improvement|Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals|Number of Participants in Different Categories of Adverse Experiences During Core Study Period","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","358","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","AZA PH GL 2003 CL001","November 1, 2003","July 1, 2007","July 1, 2007","November 5, 2003","July 5, 2010","October 29, 2019","University of Alabama School of Medicine, Birmingham, Alabama, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mount Sinai Medical Center, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Oregon Cancer Center, Portland, Oregon, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|The Newcastle Mater Miseriecordiae Hospital, Warratah, New South Wales, Australia|Royal Brisbane Hospital, Hersten, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Perth Hospital, Perth, Western Australia, Australia|First Clinical Base - Clinic of Hematology, MHAT - Pleven, Pleven, Bulgaria|MHAT ""St George"" Clinic of Hematology, Plovdiv, Plovdiv, Bulgaria|III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU), Plovdiv, Bulgaria|National Centre of Hematology and Transfusiology, Sofia, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment (MHAT), ""St. Marina"" Clinic of Hematology, Varna, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Fakultni nemocnice Brno, Jihlavska, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Sokolska, Hradec Kralove, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|Vseobecna Fakultni Nemocnice, Praha, Czechia|Uslav Hematologie a Krevni Transfuze, Praha, Czechia|Chu D'Angers, Angers, France|Hopital Beaujon, Clichy, France|Che De Lille, Lille, France|Hospital Edouard Herriot, Lyon, France|Institute Paoli Calmettes, Marseille, France|Chu De Nantes, Nantes, France|Hospital Saint Louis, Paris, France|Hopital Cochin, Paris, France|Centre Henri Becquerel, Rouen, France|Chu Purpan, Toulouse, France|Universitatsklinikum Benjamin Franklin, Hindenburgdamm, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|St Johannes Hospital, Duisburg, Germany|Heinrich-Heine University Dusseldorf, Dusseldorf, Germany|University Essen, Essen, Germany|Gerorg-August-Universitat Gottingen, Gottingen, Germany|Allgemeines Krankenhaus St. Georg, Hamburg, Germany|Universitatsklinikum Hambur-Eppendorf, Hamburg, Germany|Universitatsklinikum Kiel II, Kiel, Germany|Universitatsklinikum Ulm, Ulm, Germany|University Hospital-Attikon, Haidari, Athens, Greece|University General Hospital of Heraklio Voutes, Heraklio, Crete, Greece|District General Hospital of Athens, Athens, Greece|General Hospital of Chest Disease, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Patra Rio, Patra, Greece|Orszagos Gyogyintezeti Kozpont, Budapest, Hungary|University of Pecs, 1st Dept of Internal Medicine, Pecs, Hungary|University of Szeged, 2nd Department of Internal Medicine, Szeged, Hungary|Policlinico S. Orsola-Malpighi, Bologna, Italy|Universita di Firenze, Firenze, Italy|Ospedale San Martino, Genova, Italy|Instituto Nazionale Dei Tumori, Milano, Italy|Centro Oncologico Modenese, Modena, Italy|Ospedale San Eugenio, Roma, Italy|Policlinico Gemelli, Roma, Italy|Instituto Nazionale Tumori ""Regina Elena"", Roma, Italy|Ospedale Casa Sollievo Della Sofferenza - Irrc, San Giovanni Rotondo, Italy|Universita Degli Studi Di Sassari, Sassari, Italy|VU University Medical Center Amsterdam, Amsterdam, Netherlands|Univ Hospital St. Radboud, Nijmejen, Netherlands|Samodzielny Publiczny Szpital Kliniczny Nr 1, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Samodzelny Publiczny Centralny Szpital Kliniczny, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Wroclaw, Poland|Burdenko Central Military Clinical Hospital, Moscow, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|Scientific Haematology Center, Moscow, Moscow, Russian Federation|Institute of Haematology & Blood Transfusion, St. Petersburg, Russian Federation|Pavlov State Medical University, St. Petersburg, Russian Federation|Pavlov State Medical University, St. Petersburg, Russian Federation|City Hospital #31, St. Petersburg, Russian Federation|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Germans Trias I Pujol, Barcelona, Spain|Hospital de Leon, Leon, Spain|Hospital Universitario De La Princesa, Madrid, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital La Paz, Madrid, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario Del Salamanca, Salamanca, Spain|Hospital Universitario La Fe, Valencia, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Lund Universtiy Hospital, Lund, Sweden|University Hospital MAS, Malmo, Sweden|Huddinge University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden|Royal Bournemouth General Hospital, Bournemouth, United Kingdom|St. Bartholomew's Hospital, London, United Kingdom|Kings College Hospital NHS Trust, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00071799"
392,"NCT00065351","Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: CC-5013","Myeloma response|Time to tumor progression|Duration of response|Survival (1-year and overall survival)|Time to first skeletal-related event (SRE) (clinical need for radiation or surgery to bone)|Safety (type, frequency, severity, and relationship of adverse events to study drug)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","222","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-014","July 1, 2003","October 1, 2006","March 1, 2007","July 23, 2003",,"November 11, 2019","Palo Verde Hematology Oncology, Glendale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|Providence St. Joseph Medical Center/Cancer Center, Burbank, California, United States|Wilshire Oncology Medical Group, Inc., La Verne, California, United States|Institute for Myeloma and Bone, Los Angeles, California, United States|Cancer Care Associates, Redondo Beach, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Atlanta Cancer Care-Roswell, Roswell, Georgia, United States|Northwestern University Med Ctr, Chicago, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|SUNY Health Science Center at Brooklyn, Brooklyn, New York, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, United States|Carolina Hematology-Oncology Associates, Charlotte, North Carolina, United States|Cleveland Clinic Myeloma Program Hematology & Medical Oncology /R35, Cleveland, Ohio, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00065351"
393,"NCT00065156","Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: lenalidomide","Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence|Participants With Adverse Experiences|Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study|Time to Transfusion Independence|Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study|Kaplan Meier Estimate for Duration of Transfusion Independence Response|Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders|Participant Counts of Cytogenetic Response|Participant Counts of Platelet Response|Participant Counts of Absolute Neutrophil Count (ANC) Response|Participants With Complete or Partial Bone Marrow Improvement|Participants With Bone Marrow Progression","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","148","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MDS-003","June 1, 2003","August 1, 2008","August 1, 2008","July 18, 2003","June 9, 2010","November 19, 2019","Arizona Cancer Center, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Desert Hematology & Oncology Medical Group, Rancho Mirage, California, United States|Stanford University Medical Center, Stanford, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|University of Miami Sylvester Comp Cancer Center, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northwest Georgia Oncology - Wellstar Cancer Research, Marietta, Georgia, United States|Rush-Presbyterian- St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Wayne State University School of Medicine, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York Hospital-Cornell, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|University of Rochester- James P. Wilmot Cancer Center, Rochester, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Kaiser Permanente Northwest Region, Portland, Oregon, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|St. Johannes Hospital, Duisburg, Germany",,"https://ClinicalTrials.gov/show/NCT00065156"
394,"NCT00057616","Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.",,"Completed","No Results Available","Melanoma|Neoplasm Metastasis","Drug: CC-5013",,"Celgene|ICON Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 3","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","CC-5013-MEL-002","October 1, 2002",,"July 15, 2005","April 7, 2003",,"November 8, 2019","The Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Sydney Cancer Centre, Camperdown, New South Wales, Australia|Royal Newcastle Hospital, Newcastle, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Roayl Brisbane Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Mount HospitalOncology, Perth, Western Australia, Australia|North-Estonian Regional Hospital, Tallinn, Estonia|Tartu University Clinics Onkology & Haematology Clinic, Tartu, Estonia|Klinick fur Dermatologie, Berlin, Germany|Dermatologie Klinik der Ruhr Universitat Bochum- St. Joseph's Hospital, Bochum, Germany|Klinick fur Dermatolgie, Bonn, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitatsklinik Eppendorf, Hamburg, Germany|Kinkum der Christian-Albrecht-Universitat KielDepartment of Dermatologie, Kiel, Germany|Klinik fur DermatologieVenerologie und Allergologie, Mannheim, Germany|Latvian Onkology Centre, Riga, Latvia|Klaipeda Hospital, Klaipeda, Lithuania|Vilnius University Onkology Institute, Vilnius, Lithuania|Daniel DenHoed Kliniek, Rotterdam, Netherlands|Panorama Medi-Clinic / Panorama Oncology Unit, Cape Town, South Africa|Addington Hospital, Durban, South Africa|Wilgers Hospital / Wilgers Oncology Centre, Hatfield, Pretoria, South Africa|Sandton Oncology Centre, Morningside, Johannesburg, South Africa|St. Georges Hospital, Port Elizabeth, South Africa|Little Company of Mary / Mary Potter Oncology Centre, Pretoria, South Africa|Pretoria Academic Hospital / Department Medical Oncology, Pretoria, South Africa|Durban Oncology Centre, Westridge, Durban, South Africa|Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine|Kharkov Postgraduate Medical Academy, Kharkov Regional Clinical Oncology Center, Kharkov, Ukraine|Scientific Research Institute of OncologySoft Tissue Department, Kiev, Ukraine|Kiev City Oncology Hospital, Kiev, Ukraine|Lviv State Medical University Regional Oncology Centre, Lviv, Ukraine|Odessa Regional Oncology DispensaryChemotherapy Dept, Odessa, Ukraine|Uzhgorod Regional Oncology Diepensary, Uzhgorod, Ukraine|Cancer Centre, Egbaston, Birmingham, United Kingdom|Christies Hospital, Withington, Manchester, United Kingdom|Beatson Oncology CentreWestern InfirmaryOncology, Glasgow, United Kingdom|Cancer Research BldgDivsion of Cancer Medicine Research, Leeds, United Kingdom|Roayl Free Hospital, London, United Kingdom|St. George's Hospital, London, United Kingdom|Royal Marsden Hospital Department of Oncology, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Newcastle GeneralOncology, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00057616"
395,"NCT00056160","CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: CC-5013|Drug: Dexamethasone","Time to Tumor Progression (TTP)|Overall Survival|Myeloma Response|Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","353","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-MM-009","January 1, 2003","November 1, 2005","October 1, 2008","March 7, 2003","March 3, 2010","October 19, 2017","Clinical Research Consultants, Inc., Hoover, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|UCLA School of Medicine, Los Angeles, California, United States|UCSF California, San Francisco, California, United States|Stanford University Medical Center, Division of Hematology, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic- Jacksonville, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Oncology Hematology Consultants, Sarasota, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Northwestern University Med Ctr, Chicago, Illinois, United States|Rush Cancer Institute Section of Hematology, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana Cancer Research Institute, Indianapolis, Indiana, United States|University of Iowa Hospital Clinic, Iowa City, Iowa, United States|Ocshner Clinical Foundation, New Orleans, Louisiana, United States|Johns Hopkins Medicine Department of Oncology, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University School of Medicine- Sherman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|MBCCOP Our Lady of Mercy Cancer Center New York Medical College, The Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Cleveland Clinic Myeloma Program, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Kaiser Permanente Northwest Region Center for Health Research, Portland, Oregon, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Charleston Hematology/Oncology P.A., Charleston, South Carolina, United States|Medical University of SC, Charleston, South Carolina, United States|South Carolina Oncology Group, West Columbia, South Carolina, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Froedtert Hospital/BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Hospital Charles LeMoyne, Greenfield Park, Quebec, Canada|McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00056160"
396,"NCT00046735","Phase 1 Study OF CDC-501 in Patients With Solid Tumors",,"Completed","No Results Available","Neoplasms","Drug: Lenalidomide","To identify the MTD and safety of CDC-501 when given in a 6-wk cycle of daily administration of CDC-501 for 4 wks followed by a 2-wk rest in doses of 5 mg/day up to 25 mg/day in pts with solid tumors that are refractory after standard treatment.","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-ST-003","June 1, 2002","August 1, 2006","September 28, 2006","October 3, 2002",,"November 18, 2019","Wake Forest University, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00046735"
397,"NCT00045786","Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes",,"Completed","No Results Available","Myelodysplastic Syndrome","Drug: CC-1088",,"Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-1088-MDS-801-001","October 2001","December 2001","November 2003","September 11, 2002",,"April 25, 2017","Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00045786"
398,"NCT00044382","Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome",,"Completed","No Results Available","Myelodysplastic Syndrome","Drug: CC-5013",,"Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MDS-501-001","February 1, 2002","January 1, 2007","January 30, 2007","August 29, 2002",,"November 8, 2019","Arizona Cancer Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00044382"
399,"NCT00044018","CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: CDC-501","Confirmed M-Protein Response During Single Agent CDC-501 Therapy","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-007","April 1, 2002","December 1, 2004","February 15, 2007","August 20, 2002",,"November 11, 2019","H Lee Moffit Cancer Center, Tampa, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|St Vincent's Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00044018"
400,"NCT02103062","Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer",,"Completed","Has Results","Colorectal Neoplasms","Drug: ABI-007","Progression Free Survival (PFS) Rate as Measured at Week 8|Overall Survival|Overall Response Rate (ORR)|Percentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)|Duration of Response (DOR)|Number of Participants With Adverse Events","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-007-COLO-001","May 2014","November 2014","January 2015","April 3, 2014","January 20, 2016","April 22, 2016","Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique, Lille 59, France|Centre Regional de Lutte contre le Cancer Val d'Aurelle, Montpellier cedex 5, France|CRLCC Centre René Gauducheau, Saint Herblain 44, France|Institut Curie, Saint-Cloud, France|Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, France|Institut Gustave RoussyHématologie, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT02103062"
401,"NCT02011113","Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone","Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria|Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)|Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria|Time to Response|Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)|Time to Response (Later Cut-off Date)|Kaplan-Meier Estimates of Duration of Response|Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)|Kaplan-Meier Estimates of Progression-free Survival (PFS)|Kaplan-Meier Estimates of PFS (Later Cut-off Date)|Number of Participants With Adverse Events","Celgene Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-011","December 2013","September 2014","September 2015","December 13, 2013","November 10, 2015","November 1, 2016","Celgene Trial Site, Nagoya, Aichi, Japan|Celgene Trial Site, Kamogawa, Chiba, Japan|Celgene Trial Site, Mito, Ibaragi, Japan|Celgene Trial Site, Isehara, Kanagawa, Japan|Celgene Trial Site, Fukuoka, Japan|Celgene Trial Site, Hiroshima, Japan|Celgene Trial Site, Kyoto, Japan|Celgene Trial Site, Niigata, Japan|Celgene Trial Site, Okayama, Japan|Celgene Trial Site, Osaka, Japan|Celgene Trial Site, Tokyo, Japan|Celgene Trial Site, Tokyo, Japan|Celgene Trial Site, Tokyo, Japan|Celgene Trial Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02011113"
402,"NCT01988103","Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis",,"Completed","No Results Available","Psoriasis;|Psoriatic Arthritis;|Psoriasis Arthropatica","Drug: Apremilast|Drug: Placebo","Psoriasis Area and Severity Index-75 (PASI-75).|Static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1)|Percent Change from baseline in the psoriasis affected Body Surface Area (BSA %)|Percent Change in the Psoriasis Area and Severity Index (PASI ) score|Proportion of subjects who achieve PASI-50|Change from baseline in Pruritus (itch) Visual Analogue Scale (VAS)|Change from baseline in Dermatology Life Quality Index (DLQI) total score|Change from baseline in Mental Component Summary (MCS) score of SF-36|Adverse Events|American College of Rheumatology criteria for a 20% improvement (ACR 20)|Psoriatic Arthritis Pain Visual Analogue Scale (VAS)|Health Assessment Questionnaire Disability Index (HAQ-DI)|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC0-8 and AUC0-τ|Pharmacokinetics - t1/2|Pharmacokinetics - CLss/F|Pharmacokinetics - Vss/F|Population Pharmacokinetics (sparse sampling) - CL/F|Population Pharmacokinetics (sparse sampling) - Vc/F|Population Pharmacokinetics (sparse sampling) - KA","Celgene Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 2","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-011","July 2013","November 2014","December 2015","November 20, 2013",,"May 25, 2016","Ekihigashi Hifuka Clinic, Fukuoka-shi, Fukuoka, Japan|Tsutsui Clinic Dermatology & Plastic Surgery, Fukuoka-shi, Fukuoka, Japan|Yano Hifuka Hinyokika Clini, Fukuoka-shi, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan|HATAMOTO Derma Clinic, Fukuoka-shi, Fukuoka, Japan|Tomoko Matsuda Dermatological Clinic, Fukuoka-shi, Fukuoka, Japan|TASHIRO Dermatological Clinic, Iizuka-shi, Fukuoka, Japan|Okubo Skin Care and Clinic, Itoshima-shi, Fukuoka, Japan|Matsuda Dermatology Clinic For Skin, Hair, Nail Diseases, Itoshima-shi, Fukuoka, Japan|Kyusyu Rosai Hospital, Kitakyushu-shi, Fukuoka, Japan|Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan|Kyushu Kosei Nenkin Hospital, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Matsuo Clinic, Nishi-Ku, Fukuoka, Japan|Yame General Hospital, Yame, Fukuoka, Japan|Kokubu Medical Office Abashiri Dermatology Clinic, Abashiri-shi, Hokkaido, Japan|Chitose Dermatology Plastic Surgery Clinic, Chitose-shi, Hokkaido, Japan|Asanuma Dermatology Clinic, Chitose-shi, Hokkaido, Japan|Kokubu Dermatology, Kitami-shi, Hokkaido, Japan|Sapporo Skin Clinic, Sapporo-shi, Hokkaido, Japan|Fukuzumi Dermatology Clinic, Sapporo-shi, Hokkaido, Japan|Kobe City Medical Center, Kobe City, Hyogo, Japan|Hitachi General Hospital, Hitachi, Ibaraki, Japan|Tokyo Medical University Ibaraki Medical Center, Inashiki-gun, Ibaraki, Japan|Kanto Rosai Hospital, Kawasaki City, Kanagawa, Japan|Kawasaki Saiwai Clinic, Kawasaki-shi, Kanagawa, Japan|Teikyo University School of Medicine University Hospital, Kawasaki, Kanagawa, Japan|Sagamihara National Hospital, Sagamihara, Kanagawa, Japan|Queen's Square Medical Facilities, Yokohama-shi, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Nomura Dermatology Clinic, Yokohoma City, Kanagawa, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto City, Kumamoto, Japan|Kosumi lin, Kumamoto-shi, Kumamoto, Japan|Kume Derma Clinic, Sakai-Shi, Osaka, Japan|SANRUI Dermatology, Saitama-shi, Saitama, Japan|Jichi Medical University Hospital, Shimotsuke-shi, Tochigi, Japan|Sugai Dermatologist Park Side Clinic, Utsunomiya-shi, Tochigi, Japan|Kayaba Dermatology Clinic, Cyu-o-ku, Tokyo, Japan|Tokai University School of Medicine, Hachioji, Tokyo, Japan|Inagi Municipal Hospital, Inagi, Tokyo, Japan|TSUTSUMI Clinic, Itabasi‐Ku, Tokyo, Japan|Koto Hospital, Koto-ku, Tokyo, Japan|Maruyama Dermatology Clinic, Koto-ku, Tokyo, Japan|OIZUMI HANAWA Clinic, Nerima-ku, Tokyo, Japan|Kitahara Dermatology Clinic, Setagaya-ku, Tokyo, Japan|NAOKO Dermatology Clinic, Setagaya-ku, Tokyo, Japan|Mita Dermatology Clinic, Shiba Minato-k, Tokyo, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjyuku-ku, Tokyo, Japan|Taneda Dermatology Clinic, Suginami-ku, Tokyo, Japan|Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Tachikawa, Tokyo, Japan|Shakaihoken Simonoseki Kosei Hospital, Shimonoseki-shi, Yamaguchi, Japan|Matsuo Clinic, Fukuoka, Japan|AMC Nishiumeda Clinic, Osaka, Japan|Tokyo Center Clinic, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01988103"
403,"NCT01032291","A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer",,"Terminated","Has Results","Colorectal Cancer","Drug: cetuximab|Drug: lenalidomide","Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period|Percentage of Participants With a Response to Treatment During the Proof of Concept Period|Kaplan-Meier Estimates for Progression Free Survival (PFS)|Kaplan-Meier Estimates for Duration of Response|Percentage of Participants With Disease Control|Kaplan-Meier Estimates for Overall Survival|Participants With Treatment-Emergent Adverse Events (TEAE)","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-COLO-001|2009-012665-61","December 2009","January 2011","January 2011","December 15, 2009","May 21, 2013","May 21, 2013","Flinders Medical Centre, Dept. of Oncology, Bedford Park, South Australia, Australia|UZ Antwerpen Dept. of Medical Oncology, Antwerp, Belgium|ULB Erasme Service de Gastroenterologie, Brussels, Belgium|Grand hôpital de Charleroi, Oncologie, Charleroi, Belgium|Algemeen Ziekenhuis Maria Middelares, Gent, Belgium|Universitaire Ziekenhuis Gasthuisberg K.U. Leuven Gastroenterologie, Oncologie, Leuven, Belgium|Centre Hospitalier Universitaire Sart Tilman Liège, Liège, Belgium|Klinikum Oldenburg gGmbH Klinik für Innere Medizin II, Oldenburg, Niedersachsen, Germany|Azienda Osperdaliero Universitaria Riuniti Umberto I-GM Lancisi-G. Salesi di Ancona Clinica di Oncologia Medica, Ancona, Italy|Azienda Ospedaliera Universitaria San Martino Unità Operativa Oncologia Medica, Genova, Italy|Azienda Ospedaliera Niguarda Ca' Grande, Oncologia Medica Falck, Milano, Italy|Hospital Vall D'Hebron Servicio de Oncología. Unidad de ensayos clínicos, Barcelona, Spain|Hospital Universitario Marques de Valdecilla Servicio de Oncología, Santander, Spain|Hospital Clinico Universitario de Valencia Servicio de Oncologia, Valencia, Spain|Östra Sjukhuset Kirurgkliniken, Gothenburg, Sweden|Karolinska University Hospital, Solna, Karolinska Institutet Dept of Oncology, Stockholm, Sweden|Akademiska Sjukhuset Onkologkliniken, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01032291"
404,"NCT01744626","Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",,"Completed","No Results Available","Leukemia Lymphocytic Chronic B-Cell","Drug: CC-292|Drug: Rituximab","Adverse Events|PK-Cmax|PK-Tmax|PK-λz|PK-t1/2|PK-AUC (0-t)|PK-AUC0-∞|Efficacy","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-292-CLL-002|2012-003767-21","December 2012","December 2015","December 2015","December 7, 2012",,"April 19, 2016","Clearview Cancer Institute, Huntsville, Alabama, United States|Horizon Oncology Research, Inc, Lafayette, Indiana, United States|Hackensack UMC, Hackensack, New Jersey, United States|The West Clinic, Memphis, Tennessee, United States|Universitätsklinik Ulm, Ulm, Bayern, Germany|Städt. Klinikum München-Schwabing, Bayern, Germany|Universitatsklinikum Wurzburg, Bayern, Germany|Universitätsklinik Köln, Köln, Germany",,"https://ClinicalTrials.gov/show/NCT01744626"
405,"NCT00910858","A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes",,"Completed","Has Results","Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)","Drug: Lenalidomide|Drug: Recombinant human erythropoietin","PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide|Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide|PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)|Monotherapy Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)|PK Phase: Terminal Half-life (t1/2)|PK Phase: Percent of Administered Lenalidomide Excreted Over 24 Hours After a Single, Oral Dose|Monotherapy Phase: Percent of Lenalidomide Excreted Over 5 Hours Post Day 14 Dose|Time to Grade 4 Neutropenia or Thrombocytopenia|Percentage of Participants With a Erythroid Response Across All Phases|Percentage of Participants Overall With Erythroid Response by Baseline Erythropoietin Level|Change From Baseline in Bone Marrow Cellularity and Correlation With Grade 4 Myelosuppression|Marrow-infiltrating Lymphocyte (MIL) Number and Cytolytic Activity","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-PK-002","January 2005","April 2006","May 2009","June 1, 2009","September 30, 2013","September 30, 2013","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00910858"
406,"NCT00596999","A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders","HPDSC","Unknown status","No Results Available","Hematologic Malignancies","Procedure: UCB and HPDSC","Incidence of GVHD, time to engraftment and survival","Celgene Corporation|Celgene","All","up to 55 Years   (Child, Adult)",,"6","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CCT-HPDSC-001","May 2007","July 2013","December 2013","January 17, 2008",,"April 10, 2012","Louisiana State University Children's Hospital, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00596999"
407,"NCT01353664","A Rollover Study for Patients Who Participated in Other Romidepsin Protocols",,"Completed","Has Results","Lymphoma|Cancer","Drug: Romidepsin","Summary of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROMI-ADVM-004|2010-023040-32","May 2011","September 2012","September 2012","May 16, 2011","December 19, 2013","April 19, 2016","Florida Cancer Specialists, Sarasota, Florida, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research UK, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01353664"
408,"NCT01324323","Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer",,"Completed","Has Results","Hematologic Malignancy|Malignant Lymphoma","Drug: Romidepsin|Drug: Rifampin","Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin|Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin|Area Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).|Maximum Observed Plasma Concentration (Cmax)of Romidepsin|Time to Maximum Observed Plasma Concentration (Tmax)|Estimate of the Terminal Elimination Half-life in Plasma (t1/2)|Clearance (CL): Apparent Total Plasma Clearance.|Apparent Total Volume of Distribution (Vz).|Summary of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","ROMI-ADVM-002|2010-022149-75","April 2011","February 2012","March 2012","March 29, 2011","May 13, 2013","May 4, 2016","Florida Cancer Specialists, Sarasota, Florida, United States|Sarah Canon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research UK, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01324323"
409,"NCT01324310","Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer",,"Completed","Has Results","Hematologic Malignancy|Malignant Lymphoma","Drug: Romidepsin|Drug: Ketoconazole","Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin|Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC 0-24)|Area Under the Plasma Concentration Time-curve From Time 0 Extrapolated to Infinity (AUC0-∞)|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Observed Plasma Concentration (Tmax)|Estimate of the Terminal Elimination Half-life in Plasma (t1/2)|Apparent Total Plasma Clearance (CL)|Apparent Total Volume of Distribution (Vz)|Summary of Participants With Treatment Emergent Adverse Events (TEAEs)","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","ROMI-ADVM-001|2010-022144-20","April 2011","January 2012","January 2012","March 29, 2011","May 15, 2013","May 4, 2016","Florida Cancer Specialists, Sarasota, Florida, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research UK, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01324310"
410,"NCT00518284","Prevention of Restenosis Following Revascularization",,"Terminated","Has Results","Vascular Disease, Peripheral","Drug: Nanoparticle Paclitaxel","Target Vessel Revascularization at 9 Months|Systolic Velocity Ratio (SVR) > 2.0|Change From Baseline in Walking Impairment Questionnaire (WIQ) Score|Decrease in Ankle Brachial Index (ABI) > 0.15|Target Lesion Revascularization (TLR) at 9 Months|Number of Deaths|Number of Participants With Myocardial Infarction (MI)|Number of Participants With a Stroke|Minimum Lumen Diameter|Late Loss|Percentage of Participants With Binary Restenosis|Diameter Stenosis","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CVR002","January 2008","August 2009","September 2009","August 20, 2007","March 13, 2012","March 13, 2012","UC Davis Medical Center, Ellison Ambulatory Care Center Cardiology Suite 3400, Sacramento, California, United States|Vascular & Interventional Physicians, Gainsville, Florida, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|Michigan Vascular Research Center, Flint, Michigan, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Lindner Clinical Trials Center, Cincinnati, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00518284"
411,"NCT00478777","A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma",,"Completed","Has Results","Relapsed or Refractory Multiple Myeloma","Drug: Lenalidomide|Drug: dexamethasone","Kaplan Meier Estimate for Time to Disease Progression|Participant's Best Overall Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Criteria|Participants With Treatment-emergent Adverse Experiences (TEAEs)|Time to Partial Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Determination Criteria","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-019|2006-004532-73","March 2007","November 2007","August 2009","May 25, 2007","November 3, 2011","November 3, 2011","Medizinische Klinik und Poliklinik II der Charité Universitätsmedizin Berlin Campus Mitte, Berlin, Germany|Poliklinik I, Hämatologie/ Onkologie, Universitätsklinikum Bonn, Bonn, Germany|Johanniter-Krankenhaus Bonn Friedrich-Wilhelm-Stift gGmbH, Bonn, Germany|Medizinische Klinik Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Interne Klinik Dr. Argirov, Schön-Kliniken, Burg, Germany|Klinik für Innere Medizin III Klinikum Chemnitz gGmbH, Chemnitz, Germany|Medizinische Klinik und Poliklinik, Uniklinikum Dresden, Dresden, Germany|Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Düsseldorf, Germany|Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum EssenInnere Klinik und Poliklinik, Essen, Germany|Klinik für Innere Medizin, Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|Medizinische Klinik II (ZIM),Hämatologie / Onkologie Uniklinik Frankfurt, Frankfurt am Main, Germany|Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum GöttingenHamatologie und Onkologie, Göttingen, Germany|Interdisziplinäre Klinik und Poliklinik für Stammzellentransplantation Universitätsklinik Hamburg - Eppendorf, Hamburg, Germany|II. Medizinische Abteilung, Asklepios Klinikum Altona, Hamburg, Germany|Abt. Hämatologie, Hämatologie und Onkologie, Medizinische Hochschule Hannover, Hannover, Germany|Medizinische Klinik und Poliklinik V Universitaetsklinikum Heidelberg, Heidelberg, Germany|Klinik für Innere Medizin II Hämatologie / Onkologie Universitätsklinikum Jena, Jena, Germany|EPS - Early Phase Solutions GmbH, Jena, Germany|Hämatologie / Onkologie / Infektionskrankheiten, Palliativmedizin Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|2. Med. Klinik , Sektion f. Stammzell- + Immuntherapie Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Institut für Versorgungsforschung in der Onkologie Praxisklinik für Hämatologie und Onkologie, Koblenz, Germany|Ärzte f. Innere Medizin Gemeinschaftspraxis f. Hämatologie u. Onkologie, Köln, Germany|Klinik f. Innere Medizin, Klinikum der Universität zu Köln, Köln, Germany|Medizinische Klinik und Poliklinik II Abt. Hämatologie / Onkologie, Universitätsklinikum Leipzig AÖR, Leipzig, Germany|III. Med. Klinik, Johannes Gutenberg Universität, Mainz, Germany|Klinikum Mannheim der Universität Heidelberg, Mannheim, Germany|Hämatologisch-Onkologisches Institut für medizinische Service Leistungen, Mönchengladbach, Germany|Medizinische Klinik III Klinikum der Universität München-Großhadern, München, Germany|Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster, Münster, Germany|Fachärzte für Innere Medizin Hämatologie und Onkologie Gemeinschaftspraxis, Münster, Germany|Onkologie Praxis Oldenburg, Oldenburg, Germany|Abt. Onkologie/ Hämatologie, Klinikum Oldenburg, Oldenburg, Germany|Abteilung Hämatologie und Onkologie, Hämatologie und Onkologie, Medizinische Klinik, Klinikum Ernst v. Bergmann, Potsdam, Germany|Klinikum der Universität Regensburg, Regensburg, Germany|Abteilung Hämatologie und Onkologie, Medizinische Fakultät der Universität Rostock, Rostock, Germany|Caritasklinik St. Theresia, Saarbrucken, Germany|ms² Medizinische Statistik Saarbrücken, Saarbrucken, Germany|Med. Klinik III , St. Marienkrankenhaus Siegen, Siegen, Germany|Zentrum für Innere Medizin II Robert- Bosch-Krankenhaus GmBH, Stuttgart, Germany|Krankenanstalt Mutterhaus der Borromäerinnen, Trier, Germany|Abt. II Hämatologie, Onkologie und Immunologie Medizinische Klinik Abt.II, Tübingen, Germany|Medizinische Universitätsklinik, Ulm, Germany|Praxis Dres. Maintz & GroschekHämatologie / Onkologie, Wuerselen, Germany|Med. Klinik 1, Helios Klinikum Wuppertal, Wuppertal, Germany|Med. Klinik u. Poliklinik IIKlinikum der Universität Würzburg, Würzburg, Germany|Hämatologisch-onkologische Praxis, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00478777"
412,"NCT00474188","A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Terminated","Has Results","Diffuse Large B-cell Lymphoma","Drug: CC-5013 (lenalidomide)|Drug: dexamethasone","Tumor Response Rate|Tumor Control Rate|Duration of Response|Time to Progression|Progression-free Survival","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NHL-005","May 2007","December 2008","December 2008","May 16, 2007","August 13, 2009","September 2, 2009","Palo Verde Hematology/Oncology, Ltd., Glendale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Advanced Medical Specialties, Miami, Florida, United States|Hematology/Oncology Associates of Treasure Coast, Port St. Lucie, Florida, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights, Illinois, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Southwest Oncology Associates, Lafayette, Louisiana, United States|Washington County Hospital, The Center for Clinical Research, Hagerstown, Maryland, United States|Kalamazoo Hematology & Oncology, Kalamazoo, Michigan, United States|Oncology & Hematology Specialists, PA, Denville, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Northwestern Carolina, Oncology and Hematology PA, Hickory, North Carolina, United States|New Bern Cancer Care, New Bern, North Carolina, United States|James Cancer Hospital, Columbus, Ohio, United States|SouthWest Regional Cancer Center, Austin, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|The Alfred Hospital, Melbourne, Victoria, Australia|Frankston Hospital, Frankston, Australia|HOCA, South Brisbane, Australia|Border Medical Oncology, Wodonga, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00474188"
413,"NCT01201811","Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: Azacitidine","Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator|Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor|Number of Red Blood Cell (RBC) Transfusions by Cycle|Number of Platelet Transfusions by Cycle|Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days|Number of Participants With Adverse Events (AE)|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine|Maximum Observed Plasma Concentration (Cmax) of Azacitidine|Time to Maximum Plasma Concentration (Tmax) of Azacitidine|Terminal Phase of Half-life (T1/2) of Azacitidine|Apparent Total Plasma Clearance (CL/F) of Azacitidine|Apparent Volume of Distribution (Vd/F) of Azacitidine","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-MDS-001","October 2010","May 2013","May 2013","September 15, 2010","June 24, 2014","April 22, 2016","Changhua Christian Hospital, Changhua, Taiwan|Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital-Hualien Tzu Chi Medical Center, Hualien, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan|Kaohsiung Medical Hospital University, Kaohsiung, Taiwan|Shuang-ho Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01201811"
414,"NCT00458159","A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes",,"Terminated","No Results Available","Myelodysplastic Syndrome","Drug: CC-11006","Maximum Tolerated Dose of CC-11006|Safety of CC-11006-MDS-001","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-11006-MDS-001","May 2007","October 2008","December 2008","April 9, 2007",,"August 31, 2009","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, United States|Wake Forest University School of Medicine Bowman Gray Campus, Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00458159"
415,"NCT00420849","A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone","Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment|Participants With Adverse Events of Special Interest: Peripheral Neuropathy|Time to First Peripheral Neuropathy Treatment-Emergent Adverse Event (TEAE)|Participants With Adverse Events of Special Interest: Venous Thromboembolic Events|Time to First Venous Thromboembolic Treatment-Emergent Adverse Event (TEAE)|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Cognitive Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea/Vomiting Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhea Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Problems Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","587","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-018|2006-002517-12","November 2006","October 2009","November 2009","January 11, 2007","March 14, 2012","May 21, 2012","The Mater Private Centre for Haematology & Oncology, South Brisbane, Australia|Wilhelminenspital, Vienna, Montlearstrasse 37, Austria|St James's Hospital, Dublin, Ireland|H. Clínico de Salamanca, Salamanca, Spain|Royal Free Hospital & Medical School, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00420849"
416,"NCT00394251","Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Adriamycin and Cytoxan (AC)|Drug: ABI-007|Drug: Taxol|Drug: Bevacizumab|Drug: pegfilgrastim","Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy|Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy|The Cumulative Dose of Taxane Delivered During Study|Mean Taxane Dose Intensity Per Week|Percent of Protocol Taxane Dose|Summary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays|Myelosuppression During Taxane Dosing Cycles|Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation|Summary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)","Celgene Corporation|Celgene","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA045","August 2006","March 2007","February 2008","October 31, 2006","July 18, 2013","August 15, 2013","Birmingham, Alabama, United States|Sedona, Arizona, United States|Denver, Colorado, United States|Torrington, Connecticut, United States|Indianapolis, Indiana, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|St. Louis, Missouri, United States|Henderson, Nevada, United States|Raleigh, North Carolina, United States|Eugene, Oregon, United States|Greenville, South Carolina, United States|Austin, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Fort Worth, Texas, United States|Fredericksburg, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|McAllen, Texas, United States|Tyler, Texas, United States|Waco, Texas, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00394251"
417,"NCT00380835","Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer",,"Withdrawn","No Results Available","Metastatic Breast Cancer","Drug: Amrubicin","Incidence of cardiac toxicity|Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)|Duration of overall response|Time to tumor progression|Progression free survival|Toxicity profile","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNF3140-MBC-001",,,"December 2007","September 27, 2006",,"September 23, 2008","New Milford, Connecticut, United States|Sharon, Connecticut, United States|Torrington, Connecticut, United States|Burnsville, Minnesota, United States|Edina, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|St. Paul, Minnesota, United States|Woodbury, Minnesota, United States|Columbia, Missouri, United States|Albany, New York, United States|Amsterdam, New York, United States|Hudson, New York, United States|Latham, New York, United States|Rexford, New York, United States|Schenectady, New York, United States|Troy, New York, United States|Asheville, North Carolina, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Midland, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00380835"
418,"NCT00319969","Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: Amrubicin|Drug: Topotecan","Objective tumor response rate|Time to tumor progression|Progression free survival|Overall survival (median survival time; 1 year survival)|Toxicity profile|Incidence of cumulative cardiomyopathy|Regression of CNS metastases","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNF3140-SCLC-05004","April 2006","July 2008","January 2009","April 27, 2006",,"September 30, 2009","Birmingham Hematology & Oncology, Birmingham, Alabama, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Alta Bates Medical Center - Comprehensive Cancer Center, Berkeley, California, United States|Moores UCSD Cancer Center, La Jolla, California, United States|Rocky Mountain Cancer Center - Denver, Denver, Colorado, United States|Rocky Mountain Cancer Center - Sky Ridge, Lone Tree, Colorado, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, PA, Ocoee, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Cancer Care & Hematology Specialists of Chicago, Niles, Illinois, United States|Oncology & Hematology of Central Illinois, Peoria, Illinois, United States|Blessing Cancer Center, Quincy, Illinois, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Hope Center, Terre Haute, Indiana, United States|Norton Healthcare - Louisville Oncology, Louisville, Kentucky, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, United States|Alliance Hematology Oncology, PA - Carroll County Cancer Center, Westminster, Maryland, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Arch Medical Services - Center for Cancer Care & Research, St Louis, Missouri, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|Hematology/Oncology Consultants, St. Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, PC, Albany, New York, United States|SUNY Upstate Medical University - Regional Oncology Center, Syracuse, New York, United States|Northwestern Carolina Oncology & Hematology, Hickory, North Carolina, United States|Cancer Centers of North Carolina, Raleigh, North Carolina, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Medical Oncology Associates, Kingston, Pennsylvania, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Texas Oncology, PA, Dallas, Texas, United States|Texas Oncology - Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, PA, Fort Worth, Texas, United States|Alison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texas Oncology Cancer Care & Research Center, Waco, Texas, United States|Texas Oncology, PA - Deke Slayton Cancer Center, Webster, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of SW Virginia, Inc., Salem, Virginia, United States|Puget Sound Cancer Center, Seattle, Washington, United States|Northwest Cancer Specialists - Vancouver Cancer Center, Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00319969"
419,"NCT00179751","A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas",,"Terminated","No Results Available","Pancreatic Cancer","Drug: CC-5013|Drug: gemcitabine","Phase I-To determine the maximum tolerated dose (MTD) and evaluate the safety profile of oral lenalidomide days 1- 21 in combination with gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.|Phase II-To explore the anti-tumor activity of the combination of lenalidomide on days 1 - 21 and gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.|Phase I-To explore the anti-tumor activity of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.|Phase II-To evaluate the safety profile of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.","Celgene Corporation|Prologue Research International|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-PANC-001","April 2005",,"August 2006","September 16, 2005",,"November 7, 2005","Cancer and Blood Institute, Metairie, Louisiana, United States|Bernard Cancer Center, St. Louis, Missouri, United States|Case Western Reserve University Hospitals Ireland Cancer Center, Cleveland, Ohio, United States|Charleston Cancer Center, Charleston, South Carolina, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00179751"
420,"NCT00179738","A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.",,"Terminated","No Results Available","Prostate Cancer","Drug: CC5013","To determine the activity of lenalidomide monotherapy in subjects with androgen independent prostate cancer (AIPC).|To evaluate the safety of lenalidomide monotherapy as treatment for subjects with AIPC.","Celgene Corporation|Prologue Research International|Celgene","Male","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-PC-001","April 2005",,"April 2007","September 16, 2005",,"November 23, 2005","Alta Bates Cancer Center, Berkeley, California, United States|Moffit Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00179738"
421,"NCT00179725","Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma",,"Terminated","No Results Available","Ovarian Cancer","Drug: CC-5013|Drug: liposomal doxorubicin","Phase I-To determine the maximum tolerated dose (MTD) and evaluate the safety profile of oral lenalidomide on days 1 – 21 and liposomal doxorubicin on day 1 every 28 days, as combination therapy to subjects with advanced ovarian or primary peritoneal ca|Phase II-To explore the anti-tumor activity of the combination of oral lenalidomide on days 1 – 21 and liposomal doxorubicin on day 1 every 28 days when given to subjects with advanced ovarian or primary peritoneal carcinoma.|Phase I-To explore the anti-tumor activity of the combination of lenalidomide and liposomal doxorubicin when given to subjects with advanced ovarian or primary peritoneal carcinoma.|Phase II-To evaluate the safety profile of the combination of lenalidomide and liposomal doxorubicin when given to subjects with advanced ovarian or primary peritoneal carcinoma","Celgene Corporation|Prologue Research International|Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-OVRY-001","November 2005",,"June 2007","September 16, 2005",,"April 12, 2006","University of California at San Francisco, San Francisco, California, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|OU Health Sciences Center, Oklahoma City, Oklahoma, United States|Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00179725"
422,"NCT00179699","Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: CC-5013|Drug: pemetrexed","To determine the maximum tolerated dose (MTD) and evaluate the safety profile of oral lenalidomide on days 1-14 and pemetrexed on day 1 every 21 days, as combination therapy to subjects with advanced Non-Small Cell Lung Cancer|To explore the anit-tumor activity of the combination of lenalidomide and pemetrexed when given to subjects with advanced NSCLC","Celgene Corporation|Prologue Research International|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NSCL-002","September 2005",,"November 2006","September 16, 2005",,"November 7, 2005","MD Anderson - Orlando, Orlando, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Norton Healthcare, Louisville, Kentucky, United States|Washington University, St. Louis, Missouri, United States|North Shore Hem/Onc Associates, East Setauket, New York, United States",,"https://ClinicalTrials.gov/show/NCT00179699"
423,"NCT00179686","A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: CC-5013","To determine the activity of lenalidiomide in recurrent non-small cell lung cancer. Activity will be assessed by measuring the response rate, tumor control rate, and time to tumor progression.|To evaluate the safety of lenalidomide monotherapy as treatment for subjects with recurrent non-small cell lung cancer.","Celgene Corporation|Prologue Research International|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NSCL-001","March 2005",,"July 2006","September 16, 2005",,"December 20, 2006","Birmingham Cancer Center, Birmingham, Alabama, United States|Rush Cancer Institute, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Cancer and Blood Institute, Metairie, Louisiana, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00179686"
424,"NCT00179673","Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkins Lymphoma","Drug: Lenalidomide","Percentage of Participants With Response|Percentage of Participants With Tumor Control|The Duration of Response|Progression Free Survival (PFS)|Number of Participants With Adverse Events (AEs)","Celgene Corporation|Prologue Research International|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NHL-001","August 2005","April 2008","April 2008","September 16, 2005","October 14, 2013","November 28, 2013","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Alta Bates Cancer Center, Berkeley, California, United States|Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley, California, United States|Rush University Medical Center, Chicago, Illinois, United States|Harvard University, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska, Omaha, Nebraska, United States|New York Medical Center, MBCCOP, Bronx, New York, United States|Signal Point Hematology/Oncology, Middletown, Ohio, United States|Swedish Cancer Institute, Seattle, Washington, United States|Gunderson Clinic, Ltd., La Crosse, Wisconsin, United States|BC Community Oncology Trialist, Burnaby, British Columbia, Canada|BC Community Oncology, North Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|University of Saskatchewan, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00179673"
425,"NCT00179660","Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Non-Hodgkins Lymphoma","Drug: Lenalidomide","Percentage of Participants With Response|Percentage of Participants With Tumor Control|Duration of Response|Duration of Tumor Control|Progression-free Survival|Number of Participants With Adverse Events (AEs)","Celgene Corporation|Prologue Research International|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NHL-002","August 2005","June 2008","June 2008","September 16, 2005","September 2, 2013","January 21, 2016","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley, California, United States|UC David Cancer Center, Sacramento, California, United States|Sylvester Cancer CenterUniversity Of Miami, Miami, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska, Omaha, Nebraska, United States|New York Medical Center, MBCCOP, Bronx, New York, United States|Gunderson Clinic, Ltd, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00179660"
426,"NCT00179647","Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: lenalidomide|Drug: dexamethasone","Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.|Overall Incidence of Adverse Events","Celgene Corporation|Prologue Research International|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","1913","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-016","September 2005","December 2008","April 2009","September 16, 2005","March 3, 2010","March 16, 2010","Mayo Clinic, Scottsdale, Arizona, United States|Alta Bates Cancer Center, Berkeley, California, United States|Scripps Cancer Center, La Jolla, California, United States|Cedar Sinai Medical CenterDept of Medicine, Los Angeles, California, United States|Kaiser Permanente Medical Group, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|University of ColoradoHealth Science Center, Aurora, Colorado, United States|Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Hematology Oncology, PC, Stamford, Connecticut, United States|Delaware Clinical & Laboratory Physicians, PA, Newark, Delaware, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Miami Medical School, Miami, Florida, United States|Gulf Coast Oncology, St. Petersburg, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|The Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Med CtrDivision of Hem/Onc, Chicago, Illinois, United States|Rush Cancer Institute, Chicago, Illinois, United States|Indiana Univ Cancer Center Bone Marrow Transplantation Program Indiana Cancer Research Institute, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wichita CCOP, Wichita, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland Medical Center Greenbaum Cancer Ctr, Baltimore, Maryland, United States|Center for Cancer And Blood Disorders, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Siteman Cancer Center, St. Louis, Missouri, United States|Deaconess Billings Clinic, Billings, Montana, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center-Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|New York Medical Center, MBCCOP, Bronx, New York, United States|SUNY Health Science Center - Brooklyn, Brooklyn, New York, United States|North Shore Hematology/Oncology Associates, PC, East Setauket, New York, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, United States|NY Presbyterian Hospital/Weill Medical College-Cornell University, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Hematology-Oncology Associates, Charlotte, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Dakota Cancer Institute, Fargo, North Dakota, United States|Mid Ohio Oncology & Hematology, Inc., Columbus, Ohio, United States|Kaiser Permanente Northwest RegionCenter for Health Research, Portland, Oregon, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology/Oncology P.A., Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|South Carolina Oncology Assoc, Columbia, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Intermountain Hematology/Oncology, Salt Lake City, Utah, United States|Medical College of Virginis, North Hospital, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Gunderson Clinic, LaCrosse, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Oncology Alliance, Milwaukee, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp, Vancouver, British Columbia, Canada|Dalhousie University Queen Elizabeth II Health Services Centre, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00179647"
427,"NCT00179621","Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: Lenalidomide 5 mg|Drug: Lenalidomide 10 mg|Drug: Placebo","Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)|Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days|Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days|Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days|Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period|Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period|Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period|Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review|Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study|Kaplan Meier Estimates of Overall Survival by Randomized Group|Participant Count of Deaths During Double-blind and Open-label by Randomized Group|Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12|Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12|Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12|Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period","Celgene Corporation|ICON Clinical Research|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","205","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-MDS-004|2005-000454-73","July 2005","June 2008","June 2010","September 16, 2005","March 17, 2011","April 14, 2011","AZ St-Jan Brugge AV, Brugge, Belgium|UZ Gent, Gent, Belgium|UZ Gasthuisberg, Leuven, Belgium|CHU Mont Godine, Yvoir, Belgium|Institut Paoli-Calmettes, Marseille, Cedex 9, France|CHU d'Angers Service des Maladies du Sang, Angers, France|Hopital Avicenne, Bobigny Cedex, France|CHRU Lille Service des Maladies du Sang, Lille, France|CHU Nantes Hematologie et Medicine interne, Nantes, France|CHU Archet 1Hematologie Clinique, Nice, France|Hôpital Cochin Hematologie Clinique, Paris, France|Centre Jean Bernhard Service Onco-Hematologie, Poitiers, France|Centre Henri Becquerel Service d'Hematologie Clinique, Rouen, France|CHU Purpan, Place du Dr Baylac, Pavillon des Médecines, Toulouse, France|CHU Purpan, Place du Dr. Baylac, Pavillion des Medecines, Toulouse, France|CHU Nancy Hematologie et Medecine interne, Vandoeuvre, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|St Johannes Hospital, Duisburg, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Hannover Medical School, Hannover, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Ospedale Niguarda Ca Granda, Milano, Italy|University of Pavia Division of Hematology, Pavia, Italy|University of Medical Centre, Nijmegen, Netherlands|Hematologie Erasmus MC, Rotterdam, Netherlands|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario La Fe, Valencia, Spain|SU/Sahlgrenska Section of Hematology & Coagulation, Goteborg, Sweden|Department of Medicine University Hospital, Lund, Sweden|Korolinska Institutet Department of Hematology, Stockholm, Sweden|University Hospital of Wales, Dept of Haematology, Cardiff, Wales, United Kingdom|Leed General Infirmary, Leeds, West Yorkshire, United Kingdom|The Royal Bournemouth Hospital, Bournemouth, United Kingdom|Ninewells Hospital and Medical School, Dundee, United Kingdom|Kings College Hospital, Denmark Hill, London, United Kingdom|Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|John Radcliffe Hospital and the Weatherall Institute of Molecular Medicine, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00179621"
428,"NCT00140140","A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer",,"Terminated","Has Results","Stage IV (Metastatic) Breast Cancer","Drug: ABI-007|Drug: vinorelbine|Drug: Trastuzumab|Biological: G-CSF","Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)|Participants With Dose Limiting Toxicities|Percentage of Participants With Discontinued, Delayed or Interrupted Therapy|Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)|Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count|Nadir Measurement for Hemoglobin (Hgb)|Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)|Kaplan Meier Estimate for Time to Disease Progression (TTP)|Kaplan-Meier Estimate for Duration of Response|Kaplan Meier Estimate for Progression-Free Survival (PFS)|Kaplan-Meier Estimates for Participant Survival","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA025","August 2005","February 2008","February 2008","September 1, 2005","October 24, 2013","October 24, 2013","City of Hope Comprehensive Cancer Care Center, Duarte, California, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00140140"
429,"NCT00833833","MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Aspirin","Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1|Phase 2: Kaplan-Meier Estimates of Progression-free Survival (PFS) as of the 01 April 2011 Cut-off|Phase 2: Percentage of Participants With Progression-Free Survival (PFS) Events as of the 01 April 2011 Cut-off|Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Single-Agent Pomalidomide as of the 01 April 2011 Cut-off|Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Pomalidomide and Dexamethasone as of the 01 April 2011 Cut-off|Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as of the 01 April 2011 Cut-off|Phase 2: Summary of Best Myeloma Response As Assessed by Independent Response Adjudication Committee (IRAC) Using European Group for Blood and Bone Marrow Transplant (EBMT) Criteria as of the 01 April 2011 Cut-off|Phase 2: Kaplan-Meier Estimates of Duration of Response as of the 01 April 2011 Cut-off|Phase 2: Time to Response as of the 01 April 2011 Cut-off|Phase 2: Kaplan-Meier Estimates of Overall Survival as of the 01 April 2011 Cut-off","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","259","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-MM-002","June 2008","April 2011","September 2015","February 2, 2009","April 25, 2013","April 27, 2016","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Mass General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer CenterDivision of Hematology/Oncology, Ann Arbor, Michigan, United States|Mayo Clinic - Arizona, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute Department of Medicine, Buffalo, New York, United States|Mt. Sinai Hospital, New York, New York, United States|Ohio State University Arthur G. James Cancer Hospital, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada|Royal Victoria Hosptial, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00833833"
430,"NCT00126893","Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia",,"Terminated","No Results Available","Myeloid Leukemia","Drug: CC-401",,"Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-401-AML-001","October 2005",,"September 2006","August 5, 2005",,"May 15, 2007","Indiana University Medical Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00126893"
431,"NCT00124943","Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis","SNAPIST-III","Completed","Has Results","Coronary Restenosis","Drug: Nanoparticle Paclitaxel","Phase I: Number of Participants With Dose-limiting Toxicities|Number of Participants With Procedural Complications|Number of Participants With Treatment Emergent Adverse Events (AEs)|Number of Participants With Major Adverse Cardiac Events (MACE) at 1 Month|Number of Participants With Major Adverse Cardiac Events (MACE) at 6 Months|Percentage of Participants With Binary Restenosis|Late Lumen Loss|Percentage of In-Stent Volume Obstruction at 6 Months","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVR003","July 2005","August 2009","August 2009","July 29, 2005","March 8, 2012","April 2, 2012",,,"https://ClinicalTrials.gov/show/NCT00124943"
432,"NCT00120120","Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy",,"Completed","No Results Available","Radiculopathy","Drug: Lenalidomide (CC-5013)","Change from baseline in RAD pain intensity ratings using PI-NRS|Safety (type, frequency, severity, and relationship to study drug)|Change from baseline in the PM PI NRS value|Change from baseline in the AM PI NRS value|Change from baseline inactivity level rating using an NRS|Change from baseline in SLR angle of elevation without induced pain|Change from baseline in the SF-MPQ total score and subscale scores|Changes from baseline in the BPI score relative to baseline pain ratings and interference scales|Changes from baseline in the POMS total mood score and six dimension subscale scores|Change from baseline in the PDI score|Change from baseline in the Modified Oswestry Low Back Pain Disability Questionnaire total score|Patient global impression of change","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-RAD-001","January 2005","October 2007","November 2007","July 15, 2005",,"September 23, 2009","Arizona Research Center, Phoenix, Arizona, United States|Genova Clinical Research, Inc, Tucson, Arizona, United States|Loma Linda Institution, Loma Linda, California, United States|Space Coast Neurology, Palm Bay, Florida, United States|Gold Coast Research, LLC, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Rehab Institute of Chicago, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins Pain Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States|North Shore University Hospital, Bethpage, New York, United States|University of Rochester Medical CenterPain Services, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Carolinas Pain Institute, P.A. & the Center for Clinical Research, LLC, Winston Salem, North Carolina, United States|Research Institute of Greater Dayton, Dayton, Ohio, United States|Attn: Maryjane CerroneLehigh Valley Hospital, Allentown, Pennsylvania, United States|Drexel University College of MedicineDepartment of Neurology Rm 7102, Philadelphia, Pennsylvania, United States|Texas Tech Medical Center Department of Anesthesiology, Lubbock, Texas, United States|KRK Medical Research, Richardson, Texas, United States|Fletcher Allen Healthcare for Pain Medicine, South Burlington, Vermont, United States|University of Virginia Pain Management Center, Charlottesville, Virginia, United States|Swedish Pain Services, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00120120"
433,"NCT00773734","Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)",,"Completed","Has Results","Psoriasis|Plaque-type Psoriasis","Drug: Apremilast 10mg|Drug: Apremilast 20mg|Drug: Apremilast 30 mg|Drug: Placebo|Drug: Apremilast 30mg","Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16|Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in PASI Score at Week 24|Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in PASI Score at Week 16|Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 24|Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) From Baseline in the PASI Score at Week 16|Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 24|Core Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 16|Core Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 24|Core Study: Time to Achieve a PASI-100 Response During the Placebo Controlled Phase|Core Study: Percent Change From Baseline in PASI Score at Week 16|Core Study: Percent Change From Baseline in PASI Score at Week 24|Core Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 16|Core Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 24|Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Placebo Controlled Phase|Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Active Treatment Phase at Week 24|Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16|Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24|Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 16|Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Physical Component Summary Score at Week 16|Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 24|Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 Physical Component Summary Score at Week 24|Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)|Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast|Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)|Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 52|Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 32|Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 40|Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 32|Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 40|Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 52|Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 32|Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 40|Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 52|Extension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 32|Extension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 40|Extension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 52|Extension Study: Time to Achieve PASI-75 During the Extension Study|Extension Study: Time to Achieve PASI-50 During the Extension Study|Extension Study: Time to Achieve PASI-90 During the Extension Study|Extension Study: Time to Achieve PASI-100 During the Extension Study|Extension Study: Percent Change in PASI Score at Week 32|Extension Study: Percent Change in PASI Score at Week 40|Extension Study: Percent Change in PASI Score at Week 52|Extension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 32|Extension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 40|Extension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 52|Extension Study: Percent Change From Baseline in the Affected BSA at Week 32|Extension Study: Percent Change From Baseline in the Affected BSA at Week 40|Extension Study: Percent Change From Baseline in the Affected BSA at Week 52|Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 32|Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 40|Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52|Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 32|Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score (PCS) at Week 32|Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 40|Extension Study: Change From Baseline in Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 40|Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 52|Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 52|Extension Study: Dose-response Relationship Using the Percent Reduction of PASI Scores at Week 52|Extension Study: Time to Loss of Response During the Treatment Phase of the Extension Study.|Time to Loss of 50% of the PASI Response During the Observational Follow-up Phase Relative to the End of Treatment (Participants Who Had at Least a PASI-50 Response at the End of Treatment Phase)|Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period|Core Study: Time to Achieve a PASI-50 Response During the Placebo Controlled Phase|Core Study: Time to Achieve a PASI-75 Response During the Placebo Controlled Phase|Core Study: Time to Achieve a PASI-90 Response During the Placebo Controlled Phase|LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 18 Months|LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 2 Years|LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 3 Years|LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 4 Years|LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 18 Months|LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 2 Years|LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 3 Years|LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 4 Years|LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 18 Months|LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 2 Years|LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 3 Years|LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 4 Years|LTE Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at 18 Months, 2 Years, 3 Years and 4 Years|LTE Study: Percent Change From Baseline in PASI Score at 18 Months|LTE Study: Percent Change From Baseline in PASI Score at 2 Years|LTE Study: Percent Change From Baseline in PASI Score at 3 Years|LTE Study: Percent Change From Baseline in PASI Score at 4 Years|Core Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Month 18, and Years 2, 3 and 4|LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 18 Months|LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 2 Years|LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 3 Years|LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 4 Years|LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 18 Months|LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 2 Years|LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 3 Years|LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 4 Years|LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 18 Months|LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 2 Years|LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 3 Years|LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 4 Years|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 18 Months|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 2 Years|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 3 Years|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 4 Years|LTE Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at 18 Months|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 2 Years|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 3 Years|LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 4 Years","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","352","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-10004-PSOR-005","September 2008","August 2009","May 2015","October 16, 2008","November 13, 2014","December 12, 2016","Associates In Research Inc, Fresno, California, United States|Dermatology Associates, Los Angeles, California, United States|Stanford University School of Medicine, Redwood City, California, United States|Atlantic Skin & Cosmetic Surgery Group, PC, Wilmington, Delaware, United States|Renstar Medical Research, Ocala, Florida, United States|Atlanta Dermatology, Vein & Research Center, Alpharetta, Georgia, United States|NorthShore University HealthSystem, Skokie, Illinois, United States|Dawes/Fretzin Dermatology Group Inc, Indianapolis, Indiana, United States|Dermatology & Advanced Aesthetics, Lake Charles, Louisiana, United States|Minnesota Clinical Study Center, Fridley, Minnesota, United States|Central Dermatology, St. Louis, Missouri, United States|UMDNJ Robert Wood Johnson, New Brunswick, New Jersey, United States|Wright State University, Dayton, Ohio, United States|Allergy, Asthma and Dermatology Research Center, Lake Oswego, Oregon, United States|Northwest Cutaneous Research Specialists, Portland, Oregon, United States|Oregon Med. Research Center, PC, Portland, Oregon, United States|Rivergate Dermatology Clinical Research, Goodlettsville, Tennessee, United States|Modern Research Associates, Dallas, Texas, United States|Dermatology Associates of Seattle, Seattle, Washington, United States|Aurora Advanced Healthcare, Inc, Milwaukee, Wisconsin, United States|Stratica Medical, Edmonton, Alberta, Canada|Dr. Lorne E. Albrecht, Surrey, British Columbia, Canada|Alpha Clinical Research Centre, St. John's, Newfoundland and Labrador, Canada|Eastern Canada Cutaneous Research Associates, Halifax, Nova Scotia, Canada|Ultranova Skincare, Barrie, Ontario, Canada|Dermatrials Research Division, Hamilton, Ontario, Canada|Guenther Dermatology Research Centre, London, Ontario, Canada|North Bay Dermatology Centre, North Bay, Ontario, Canada|Dr. Michael Robern, Ottawa, Ontario, Canada|K. Papp Clinical Research Inc., Waterloo, Ontario, Canada|XLR8 Research, Windsor, Ontario, Canada|Innovaderm Research Laval Inc., Laval, Quebec, Canada|Centre De Recherche Dermatologique du Qu, MetSte-Foy, Quebec, Canada|Innovaderm Research Inc., Montreal, Quebec, Canada|International Dermatology Research, Inc., Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00773734"
434,"NCT00109772","Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1","CRPS-002","Terminated","Has Results","Complex Regional Pain Syndrome, Type I","Drug: lenalidomide|Drug: Placebo","Percentage of Participants Who Have a >= 30% Reduction (Improvement) in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score From Baseline to the Last Assessment|Change From Baseline in the Total Score of the Short Form McGill Pain Questionnaire (SF-MPQ) at Week 12|Change From Baseline in the Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score Using Averaged Morning and Evening Readings at Week 12|Change From Baseline in the Morning Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12|Change From Baseline in the Evening Complex Regional Pain Syndrome (CRPS) Pain Intensity Numeric Rating Scale (PI-NRS) Score at Week 12|Change From Baseline in Daily Sleep Assessment Average Score at Week 12|Change From Baseline in Activity Level Rating Using a Numeric Rating Scale (NRS) at Week 12|Change From Baseline in Participant Assessment of CRPS Symptoms Total Score at Week 12|Change From Baseline in ""Mechanically Evoked"" (Allodynia) Numeric Rating Scale (NRS) Score at Week 12|Difference in Allodynia Rating Between the CRPS-affected Limb and the Normal Limb at Week 12|Change From Baseline in the Brief Pain Inventory (BPI) Total Score at Week 12|Change From Baseline in the Profile of Mood States (POMS) at Week 12|Patient Global Impression of Change (PGIC) at Week 12|Participants Who Had a Change to CRPS Pain Medication During the Treatment Period|Change From Baseline in the Maximal Composite Motor Nerve Conduction Velocity at Week 12|Change From Baseline in the Maximal Composite Sensory Nerve Conduction Velocity at Week 12|Participants With Treatment-Emergent Adverse Events in the Double-Blind Period or the Extension Period","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-CRPS-002","February 2005","April 2008","April 2008","May 4, 2005","August 28, 2013","August 28, 2013","Pivotal Research Centers, Peoria, Arizona, United States|UCSD Center for Pain and Palliative Medicine, La Jolla, California, United States|Loma Linda Institution, Loma Linda, California, United States|Space Coast Neurology, Palm Bay, Florida, United States|Northwestern University, Chicago, Illinois, United States|Rehab Institute of Chicago, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States|Hospital for Joint Disease, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|UNC Hospitals University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Womack Army Medical Center, Fort Bragg, North Carolina, United States|Carolinas Pain Institute, P.A. & the Center for Clinical Research, LLC, Winston Salem, North Carolina, United States|Research Institute of Greater Dayton, Dayton, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Knobler Institute of Neurologic Disease, Ft. Washington, Pennsylvania, United States|Drexel University College of Medicine Department of Neurology Rm 7102, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Tech Medical Center Department of Anesthesiology, Lubbock, Texas, United States|University of Virginia Pain Management Center, Charlottesville, Virginia, United States|Swedish Pain Services, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00109772"
435,"NCT00765102","Trial of Romidepsin and Bortezomib for Multiple Myeloma",,"Terminated","Has Results","Multiple Myeloma","Drug: Bortezomib|Drug: Romidepsin","Count of Participant Best Overall Response As Assessed by the Investigator|Participants With Treatment-emergent Adverse Events (TEAEs)|Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)|Maximum Observed Concentration (Cmax)|Time to Maximum Observed Concentration (Tmax)|Terminal Half-life (t1/2)|Total Clearance (CL)|Total Volume of Distribution (Vz)|Kaplan Meier Estimate for Time to Progression Assessed by the Investigator|Kaplan Meier Estimate for Time to Response Assessed by the Investigator|Kaplan Meier Estimate for Duration of Response Assessed by the Investigator|Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator|Kaplan Meier Estimates for Overall Survival","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GPI-08-0006","September 2008","March 2010","March 2010","October 2, 2008","December 20, 2012","May 4, 2016","Loma Linda University Cancer Center, Loma Linda, California, United States|Desert Cancer Care, Inc, Rancho Mirage, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|James R Berenson, MD, Inc., West Hollywood, California, United States|Georgia Cancer Specialists I, PC, Atlanta, Georgia, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Mecklenburg Medical Group, Charlotte, North Carolina, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Dallas Oncology Consultants, P.A., Duncanville, Texas, United States|Oncology Consultants, P.A, Houston, Texas, United States|Central Utah Clinic, PC, Provo, Utah, United States|Virginia Mason Medical Centre, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00765102"
436,"NCT00102687","Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes",,"Completed","Has Results","Myelodysplastic Syndromes","Drug: azacitidine","Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.|Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.|Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period|Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period|Baseline Hemoglobin Values|Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)|Change From Baseline in Hemoglobin at the End of the Maintenance Study Period|Baseline Platelet Values|Change From Baseline in Platelets at the End of Initial Study Period (6 Months)|Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)|Baseline Absolute Neutrophil Count (ANC) Values|Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)|Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)|Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)|Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)|Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)|Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)|Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period|Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA PH US 2004 CL 003","January 2005","August 2008","August 2008","February 1, 2005","May 28, 2010","July 7, 2010","Comprehensive Blood and Cancer Center, Research Department, Bakersfield, California, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Cancer Center of Colorado Springs, The Oncology Clinic, PC, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Florida Cancer Institute, New Port Richey, Florida, United States|Cancer Centers of Florida, P.A., Ocoee, Florida, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Oncology/Hematology Associates of Central Illinois, PC, Peoria, Illinois, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Hematology & Oncology Specialists LLC, Metairie, Louisiana, United States|Great Lakes Cancer Institute Breslin Cancer Center, Lansing, Michigan, United States|The Center for Cancer Care and Research, St. Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Oncology Services of Aberdeen, Aberdeen, South Dakota, United States|Avera Cancer Institute Leukemia-Bone Marrow Transplant Center, Sioux Falls, South Dakota, United States|McLeod Cancer and Blood Center, Johnson City, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Texas Oncology, PA, Fort Worth, Texas, United States|San Antonio Tumor & Blood Clinic, Fredericksburg, Texas, United States|Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States|Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk, Virginia, United States|Highline Medical Oncology, Burien, Washington, United States|Puget Sound Cancer Center, Edmonds, Washington, United States|Puget Sound Cancer Center, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00102687"
437,"NCT00093145","Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Albumin-bound paclitaxel|Drug: Carboplatin|Drug: Herceptin®","Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response|Percentage of Participants With a Total Response|Time to Disease Progression|Duration of Response|Overall Patient Survival|Number of Participants With Adverse Events (AEs)","Celgene Corporation|Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA016","June 2004","October 2008","October 2008","October 5, 2004","July 17, 2013","July 17, 2013","Breastlink Med Group, Long Beach, California, United States|Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center, Stamford, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|Lombardi Cancer Center Georgetown University Hospital, Washington, District of Columbia, United States|Florida Cancer Institute, Hudson, Florida, United States|Gulf Coast Oncology Associates, St. Petersburg, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Gerogia Cancer Specialist, Atlanta, Georgia, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarbough, Maine, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00093145"
438,"NCT00074646","Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas",,"Completed","No Results Available","Glioblastoma|Malignant Gliomas","Drug: CC-8490",,"Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CC-8490-GLIO-001","December 2003",,"June 2005","December 19, 2003",,"January 4, 2007","Neuro Oncology BranchNational Cancer Institute, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00074646"
439,"NCT00072722","Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)",,"Completed","No Results Available","Prostate Cancer","Drug: CC-4047",,"Celgene Corporation|Celgene","Male","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-4047-PC-002","September 2003",,"April 2005","November 13, 2003",,"December 19, 2006","University of Colorado Health Science Center, Denver, Colorado, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00072722"
440,"NCT00456846","First Line Therapy for Patients With Metastatic Breast Cancer",,"Terminated","Has Results","Metastatic Breast Cancer","Drug: ABI-007","Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Based on Investigator and Independent Reviewers|Percentage of Participants With Disease Control|Progression-free Survival (PFS)|Duration of Response Based on Independent Reviewer Assessment|Duration of Response Based on Investigator Assessment|Patient Survival|Number of Participants Experiencing Dose Reductions, Interruptions, or Dose Delays of Study Drug|Number of Participants With Treatment-Emergent Adverse Events","Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","123","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA042","February 2008","December 2012","May 2013","April 5, 2007","July 18, 2014","May 27, 2016","BC Cancer Agency-Burnaby, Burnaby, British Columbia, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|B.C.C.A Vancouver Island Center, Victoria, British Columbia, Canada|Dr. H. Bliss Murphy Cancer Center, St. Johns, Newfoundland and Labrador, Canada|The Royal Victoria Hospital, Barrie, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Synnybrook Cancer Centre, Toronto, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Hospital de la Cite-de-la Sante-de-Laval, Laval, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal-Hotel-Dieu, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|CHA: Saint Sacrement Hospital, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00456846"
441,"NCT00446433","A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease",,"Completed","No Results Available","Crohn's Disease","Drug: CC-5013",,"Celgene Corporation","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CC-5013-CD-001","March 2002",,"December 2003","March 12, 2007",,"December 1, 2016","Advanced Clinical Therapeutics, Tucson, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Washington Hospital Center Physicians Office Building, Washington, District of Columbia, United States|Springfield Clinic, Springfield, Illinois, United States|Wake Research Associates, Raleigh, North Carolina, United States|Hopital Saint Louis, Paris, France|Rambam Hospital, Haifa, Israel|Department of Medicine A, Liver & Gastroenterology Units, Jerusalem, Israel|Department of Gastroenterology and Hepatology, Tel-Hashomer, Israel|Department of Gastroenterology, Dartford, Kent, United Kingdom|Department of Gastroenterology, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Department of Medicine, Cardiff, United Kingdom|Department of Gastroenterology, London, United Kingdom|Department of Gastroenterology, London, United Kingdom|Department of Gastroenterology, London, United Kingdom|Department of Gastroenterology, Manchester, United Kingdom|St. Mark's Hospital, Middlesex, United Kingdom|Department of Gastroentroerology, Newcastle, United Kingdom|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00446433"
442,"NCT00067743","A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)","CRPS","Completed","No Results Available","Complex Regional Pain Syndrome (RSD)","Drug: Lenalidomide","Safety|Change in CRPS pain rating in index limb compared to baseline","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-CRPS-001","August 2003","October 2004","August 2007","August 27, 2003",,"January 3, 2008","UCSD Center for Pain and Palliative Medicine, La Jolla, California, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|UNC Hospitals University of North Carolina, Chapel Hill, North Carolina, United States|The Center for Clinical Research, Winston Salem, North Carolina, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Swedish Pain Management, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00067743"
443,"NCT00064974","Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: CC-5013","RBC Transfusion Independence|≥ 50% decrease in RBC transfusion requirement|Platelet Response|Neutrophil Response|Bone marrow Response|Duration of Response|Hemoglobin concentration|Number of Participants with Adverse Event","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","215","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MDS-002","June 2003","January 2007","February 2007","July 17, 2003",,"April 4, 2013","Arizona Cancer Center, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Alta Bates Cancer Center, Berkeley, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Stanford University Medical Center, Stanford, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|University of Miami- Sylvester Comp Cancer Center, Miami, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northwest Georgia Oncology - Wellstar Cancer Research, Marietta, Georgia, United States|Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Wayne State University School of Medicine, Detroit, Michigan, United States|St. Luke's Oncology and Hematology Associates, Duluth, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|St. Vincents Comprehensive Cancer Center, New York, New York, United States|New York Hospital- Cornell, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|University of Rochester-James P. Wilmot Cancer Center, Rochester, New York, United States|Wake Forest University School of Medicine, Winston Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Kaiser Permanente Northwest Region, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Royal Adelaide Hospital - SA Pathology Haematology, Adelaide, South Australia, Australia|Princess Alexandra Hospital - Haematology, Brisbane, Australia|Royal Prince Alfred Hospital - Institute of Haematology, Camperdown, Australia|Peter McCallum Cancer Institute - Directorate of Cancer Medecine, East Melbourne, Australia|Frankston Hospital-peninsula Health - Oncology Day Unit, Frankston, Australia|The Alfred Hospital - malignant haematology & stem cell transplantation, Melbourne, Australia|Calvary Mater Newcastle - Haematology, Waratah, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital - Haematology, Wollongong, Australia|UZ Gent - Hematology, Gent, Belgium|University Hospital Leuven - Hematology, Leuven, Belgium|Cliniques Universitaires ULC de Mont-Godinne - Hematology, Yvoir, Belgium|Fakultní nemocnice Hradec Králové - Hematology, Hradec Kralove, Czech Republic|Charles university Hospital - Internal Medicine, Prague, Czech Republic|Aalborg Sygemus - Haematology, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital - Hematology, Vejle, Denmark|CHU Angers - Service des maladies du sang, Angers, France|Centre Hospitalier de la côte basque - Hematologie, Bayonne, France|Centre Hospitalier Départemental Vendée - Onco-hematologie, La Roche sur Yon, France|CHRU de Lille - Service des maladies du sang, Lille, France|Institut Paoli Calmette - Hematology 1, Marseille, France|CHU Hôtel-Dieu - Hematologie, Nantes, France|Hôpital Saint Louis - Immuno-hematologie, Paris, France|CHU Saint Antoine - Service des maladies du sang, Paris, France|CHRU - Hôpital du Haut Lévêque - Centre François Magendie, Pessac, France|Centre Hospitalier Lyon sud - Hematologie, Pierre-Benite, France|CHRU Hôpital Purpan - Hematologie, Toulouse, France|Hôpital Bretonneau - Hématologie & Thérapie cellulaire, Tours, France|CHU Nancy - Hematologie, Vandoeuvre-les-Nancy, France|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany|Universitätsklinikum Heidelberg - Medizinische Klinik und Poliklinik V, Heidelberg, Germany|Universitätsklinikum Jena - Klinik fur Innere Medizin II-Hamatologie/Onkologie, Jena, Germany|Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik II, Leipzig, Germany|Universitätsklinikum Münster - Medizinische Klinik und Poliklinik A, Münster, Germany|Universitätsklinikum Tübingen - Medizinische Klinik und Poliklinik - Abteilung II, Tübingen, Germany|Universitätsklinikum Ulm - Klinik fur Innere Medizin III, Ulm, Germany|Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik II, Würzburg, Germany|University of Athens - Alexandra Hospital; Clinical Therapeutics, Athens, Greece|Università degli Studi di Bologna - Policlinico S. Orsola - Hematology, Bologna, Italy|AO Universitaria San Martino - hematooncology, Genova, Italy|Fondazione ""G. Pascale"" - Hematology, Napoli, Italy|Ospedale San Luigi AO Luigi Gonzaga - Hematology, Orbassano, Italy|Universita degli Studi di Padova - Clinical & Experimental Medicine, Padova, Italy|Ospedale Guglielmo da Saliceto - hematooncology, Piacenza, Italy|Unità di Ematologia Arcispedale S. Maria Nuova - Haematology, Reggio Emilia, Italy|Policlinico Umberto I, Università ""La Sapienza"" di Roma - Hematology, Roma, Italy|A.O.U. San Giovanni Battista - Hematology, Torino, Italy|VUMC - Hematology, Amsterdam, Netherlands|Erasmus Medical Center - Hematology, Rotterdam, Netherlands|University Medical Center - Hematology, Utrecht, Netherlands|Medical Sciences - Hematology & BMT, Moscow, Russian Federation|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin - Hematology, Moscow, Russian Federation|Russian Research Institute of Hematology and Blood Transfusion - Hematology, St. Petersburg, Russian Federation|State Higher Educational Institution St. Petersburg State Medical University - Onco-hematology, St. Petersburg, Russian Federation|Hospital Germans Trias i Pujol - Hematology, Badalona, Spain|Hospital Clinic i Provincial de Barcelona - Hematology, Barcelona, Spain|Hospital de Donostia - Hematology, Guipúzcoa, Spain|Hospital de La Princesa - Hematology, Madrid, Spain|Hospital 12 de Octubre - Hematology, Madrid, Spain|Hospital de Salamanca - Hematology, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla - Hematology, Santander, Spain|Hospital La Fe - Hematology, Valencia, Spain|Sahlgrenska Hospital, University of Goteborg - Hematology, Goteborg, Sweden|Karolinska University Hospital Huddinge - Center of hematology, Stockholm, Sweden|Karolinska University Hospital Solna- medicine, Stockholm, Sweden|Overlakare Medocomcentrum - Hematology, Uppsala, Sweden|Inselspital, Institut für Medizinische Onkologie, Bern, Switzerland|Hôpitaux Universitaire de Genève - Oncologie, Genève, Switzerland|Klinik und Poliklinik für Onkologie - UniversitätsSpital Zürich, Zurich, Switzerland|Royal Bournemouth Hospital - Haematology, Bournemouth, United Kingdom|St James's University Hospital - Haematology, Leeds, United Kingdom|St Bartholomew's Hospital - Medical Oncology, London, United Kingdom|King's College Hospital - Haematology Clinical Trials, London, United Kingdom|Freeman Hospital - Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital - Centre for Clinical Haematology, Nottingham, United Kingdom|Derriford Hospital - Haematology, Plymouth, United Kingdom|Royal hallamshire Hospital - Haematology, Sheffield, United Kingdom|Royal Marsden NHS Foundation Trust - Haematology, Surrey, United Kingdom|Royal Wolverhampton hospitals trust - Research and development, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00064974"
444,"NCT00405756","A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.",,"Completed","Has Results","Newly Diagnosed Multiple Myeloma","Drug: Lenalidomide: Double-blind Induction|Drug: Melphalan|Drug: Prednisone|Drug: Aspirin|Drug: Placebo|Drug: Lenalidomide: Double-blind Maintenance|Drug: Lenalidomide: Open-label","Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)|Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)|Kaplan Meier Estimates of Overall Survival (OS)|Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)|Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period|Time to First Response|Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)|Kaplan Meier Estimates for Time to Next Antimyeloma Therapy|Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale","Celgene Corporation","All","65 Years and older   (Older Adult)","Phase 3","459","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-MM-015|2006-001865-41","January 2007","November 2009","April 2016","November 30, 2006","May 11, 2012","January 11, 2017","Hematology Oncology Clinics of Australia, Level 5, Mater Medical Centre, South Brisbane, Queensland, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology, East Melbourne, Australia|Frankston Hospital, Frankston, Australia|The Alfred Hospital, Melbourne, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|University Hospital Innsbruck, Innsbruck, Austria|University Hospital of Salzburg St Johanns Spital, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|Medical University of Vienna, Vienna, Austria|Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology, Gomel, Belarus|City Clinical Hospital 9, Minsk, Belarus|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|AZ-VUB, Brussels, Belgium|UZ Gasthuisberg, Leuven, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Fakultni nemocnice Brno, Brno, Czech Republic|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic|Fakultni Nemocnice Olomouc, Olomouc, Czech Republic|Vseobecna Fakultni Nemocnice v Praze, Prague, Czech Republic|Hæmatologisk afd. B Aalborg Sygehus Syd, Aalborg, Denmark|Medicinsk afd. Vejle Sygehus, Vejle, Denmark|CHU, Caen, France|CH - Hôpital Dupuytren, Limoges Cedex 1, France|CHU Montpellier- Hopital Lapeyronie, Montpellier Cedex 5, France|Assistance Publique - Hôpitaux de Paris AP-HP, Paris, France|CHU Purpan, Toulouse cedex 9, France|Ltd M.Zodelava Hematology Centre, Tbilisi, Georgia|Institute of Hematology and Transfusiology, Tbilisi, Georgia|Medizinische Klinik und Poliklinik II der Charite Campus Mitte, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V, Heidelberg, Germany|Medizinische Klinik und Poliklinik II, Leipzig, Germany|Poliklinik A, Münster, Germany|Medizinische Klinik - Abteilung II, Tübingen, Germany|Medizinische Universitatsklinik, Ulm, Germany|Medizinische Klinik und Poliklinik II des Universitatsklinikums Wurzburg, Würzburg, Germany|G. GENNIMATAS General Hospital of Athens Department of Hematolgosy, Athens, Greece|General Air Force Hospital, Athens, Greece|Alexandra General Hospital of Athens, Athens, Greece|Hope Directorate Haematology Oncology Service St. James Hospital, Dublin, Ireland|Midlands Regional, Tullamore / Co Offally, Ireland|Rambam Medical Center, Haifa, Israel|Hadassah University Hospital, Jerusalem, Israel|Hematology Institute, Hemato-Oncology Division,Davidoff Cancer Center, Rabin MC Beilinson Hospital, Petch Tikva, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Policlinico S. Orsola, Bologna, Italy|A.O.U. San Martino, Genova, Italy|Dipartmento Oncologico Struttura Complessa di ematlologiaA.O. Ospedale Niguarda Ca Granda, Milano, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Divisione Di Ematologia Ospedale Cattedra di Ematologia, Rome, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Rome, Italy|Dipartimento di Onco-Ematologia, San Giovanni Rotondo (FG), Italy|Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Turin, Italy|VU Medical Center, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Klinika Hematologii Samodzielny Publiczny Szpital Kliniczny Akademii, Bialystok, Poland|Institute of Internal Diseases University of Medicine, Gdansk, Poland|Oddzial Kliniczny Kliniki Hematologii, Krakow, Poland|Uniwersytet Medyczny w Lodzi, Lodz, Poland|University School of Medicine, Lublin, Poland|Akademia Medyczna w Warszawie Samodzielny Publiczny Centralny Szpital Kliniczny, Warsaw, Poland|Burdenko Central Military Clinical Hospital, Moscow, Russian Federation|Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl, Moscow, Russian Federation|Moscow Regional Research Institute n.a. Vladimirsky, Moscow, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Medical Radiological Research Center RAMS, Obninsk, Russian Federation|Samara Regional Clinical Hospital, Samara, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation|Hospital Clinic, Barcelona, Spain|Hospital Universitaro Puerta del MarServicio de Hematologia, Cadiz, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio Servicio de Hematologia, Sevilla, Spain|Medicinkliniken, Boras, Sweden|Medicinska kliniken, Malmö, Sweden|UniversitatsSpital ZurichKlinik fur Onkologie, Zurich, Switzerland|Ankara University, Ankara, Turkey|Marmara School of Medicine, Istanbul, Turkey|Ege University Medical School, Izmir, Turkey|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|Dnepropetrovsk City Clinical Hospital 4, Dnepropetrovsk, Ukraine|Institute of Urgent and Recovery Surgery, Donetsk, Ukraine|Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the AMS of Ukraine, Lviv 79044, Ukraine|Zhitomir Regional Clinical Hospital, Zhitomir, Ukraine|Monklands Hospital, Aidrie, United Kingdom|St James's University Hospital, Leeds, United Kingdom|University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing, London, United Kingdom|Kings College Hospital, London, United Kingdom|Christie NHS Trust Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00405756"
445,"NCT00398086","Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer",,"Completed","Has Results","Metastatic Pancreatic Cancer","Drug: Gemcitabine|Drug: Albumin-bound paclitaxel","Number of Participants With Dose-limiting Toxicities|Number of Participants With Adverse Events (AE)|Percentage of Participants Who Achieved an Objective Confirmed Overall Response|Percentage of Participants With Disease Control|Progression-free Survival|Duration of Response|Overall Survival|Maximal Degree of Myelosuppression|Maximal Degree of Anemia","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","67","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA040","November 2006","September 2008","December 2010","November 10, 2006","August 21, 2013","April 25, 2016","University of Alabama at Birmingham Comprehensive Cancer Ctr, Birmingham, Alabama, United States|Scottsdale Healthcare/Virginia Pipe Cancer Institute, Scottsdale, Arizona, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States|Virigina Piper Cancer Institute, Minneapolis, Minnesota, United States|South Texas Oncology & Hematology, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00398086"
446,"NCT00394082","ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer",,"Completed","Has Results","Metastatic Breast Cancer","Drug: ABI-007|Drug: Bevacizumab","Participants With At Least One Treatment-Emergent Adverse Event (TEAE)|Kaplan-Meier Estimates for Progression-free Survival|Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST)|Kaplan-Meier Estimate for Duration of Response|Kaplan-Meier Estimates for Participant Survival","Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA043","June 2006","September 2009","February 2011","October 31, 2006","May 22, 2013","April 25, 2016","Melbourne, Florida, United States|Ocoee, Florida, United States|Niles, Illinois, United States|Terre Haute, Indiana, United States|Columbia, Maryland, United States|Westminister, Maryland, United States|St. Joseph, Missouri, United States|Rochester, New York, United States|Bedford, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Tyler, Texas, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Salem, Virginia, United States|Burien, Washington, United States|Edmonds, Washington, United States|Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00394082"
447,"NCT00057564","A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: A (Thalidomide + Dexamethasone)|Drug: B (Placebo + Dexamethasone)","Time to tumor progression (TTP)|Number of patients who survived|Time to first symptomatic skeletal-related event (SRE)(clinical need for radiation therapy or surgery to bone)|Myeloma response rate|Number of participants with adverse events","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","470","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","THAL-MM-003","February 2003","April 2006","August 2013","April 7, 2003",,"September 11, 2015","Clinical Research Consultants, Inc., Hoover, Alabama, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|UCLA School of Medicine, Los Angeles, California, United States|James Berenson, West Hollywood, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Melbourne Internal Medicine Associates Oncology, Melbourne, Florida, United States|Jackson Memorial Hospital and Clinics, Miami, Florida, United States|University of Miami Miller School/Jackson Memorial Hospital, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Oncology Hematology Group of South Florida, Miami, Florida, United States|Medical College of Georgia, Augusta, Georgia, United States|Southern Illinois Hematology /Oncology, Centralia, Illinois, United States|Rush Cancer Institute Section of Hematology, Chicago, Illinois, United States|University of Iowa Hospital of Clinic, Iowa City, Iowa, United States|Ocshner Clinic Foundation, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Hackensack University Hospital, Hackensack, New Jersey, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Cleveland Clinic- Taussig Cancer Center, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|South Carolina Oncology Group, West Columbia, South Carolina, United States|The Family Centre, PLLC, Collierville, Tennessee, United States|East Tennessee Oncology/Hematology Associates, Knoxville, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Brisbane Hospital, Herston, Queensland, Australia|Haematology Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Frankston Hospital, Frankston, Victoria, Australia|Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Bone Marrow Transplant Service Dept of Clinical Haematology and Medical Oncology, Parkville, Victoria, Australia|Institut Jules Bordet Dep't of Clinical Haematology, Brussels, Belgium|Dept. Of Haematology Academisch Ziekenhuis VUB, Brussels, Belgium|University Hospital Ghent Dep't of Haematology, Ghent, Belgium|UMHAT Alexandrovska, Alexandrovska, Bulgaria|National Center of Haematology and Transfusiology, Sofia, Bulgaria|Military Medical Academy, Sofia, Bulgaria|Dalhousie University, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|University Health Network Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hopitalier Universitaire de Sherbrooke Hospital Fleurimont, Fleurimont, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Saskatoon Cancer Centre University of Saskatoon, Saskatoon, Saskatchewan, Canada|Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Dusseldorf, Germany|St. Laszlo Hoszpital, Budapest, Hungary|Petz Aladar County Hospital, Gyor, Hungary|MidWestern Regional Hospital Haematology Dpt., Dooradoyle, Limerick, Ireland|Hope Directorate Dep't. Haematology St. James's Hospital, Dublin, Ireland|Hadassah University Hospital Hematology Dep't, Ein Kerem, Jerusalem, Israel|Rambam Medical Center Dep't. Of Hematology, Haifa, Israel|Tel Aviv Sourasky Medical Center Hematology Institute, Tel Aviv, Israel|Director of Hematology Division BMT and CBB The Chaim Sheba Medical Center, Tel Hashomer, Israel|Universita di Bari Dipartimento di Scienze Umana Sezione de Medicina Interna e Oncologia Medica Policlinico, Bari, Italy|Istituto di Ematologia e Oncologia Medica ""L. e. A. Seragnoli"", Bologna, Italy|Azienda Ospedaliera San Martino, Genova, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Policlinico San Matteo, Pavia, Italy|Università La Sapienza Dipartimento di Biotecnologie Cellulari ed Ematologia, Roma, Italy|Clinica Ematologica Policlinico Universitario, Udine, Italy|Medical Academy of Bialystok, Bialystok, Poland|Institute of Internal Diseases University of Medicine, Gdansk, Poland|Jagiellonian University Collegium Medicum Department of Hematology, Krakow, Poland|Medical University of Lodz, Lodz, Poland|Private Medical Practice Centre of Clinical Laboratory of Densitometry At 'Officers of Professors', Lublin, Poland|Medical University of Warsaw Dep't of Hematology, Oncology and Internal Diseases, Warsaw, Poland|Chelyabinsk Regional Clinical Hospital Hematology Dpt, Chelyabinsk, Russian Federation|Ekaterinburg 1st Regional Clinical Hospital Regional Hematology Centre, Ekaterinburg, Russian Federation|Republican Clinical Hospital #1 Hematology Dpt., Izhevsk, Russian Federation|Burdenko Central Military Clinical Hospital Hematology Center, Moscow, Russian Federation|Russian Academy of Medical Sciences Scientific Center of Hematology, Moscow, Russian Federation|Nizhny Novgorod Clinical Hospital, Novgorod, Russian Federation|Novosibirsk State Regional Clinical Hospital Hematology Centre, Novosibirsk, Russian Federation|Samara Regional Clinical Hospital Dep't. of Hematology and Bone Marrow Transplantation, Samara, Russian Federation|Blokhin Cancer Research Center Dpt of Myeloproliferative Disorders Chemotherapy, Shosse, Russian Federation|Research Institute of Hematology and Blood Transfusion,Clinical Department of Hematology with Bone Marrow Transplantation Unit, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University Bone Marrow Transplantation Clinic, St. Petersburg, Russian Federation|Clinical Hospital #31 Dpt of Bone Marrow Transplantation and Chemotherapy of Patients with Myeloproliferative Disorders, St. Petersburg, Russian Federation|Hospital Clinic, Barcelona, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Universitatsspital Zurich, Zurich, Switzerland|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|Dnepropetrovsk City Clinical Hospital #4 Regional Hematology Centre, Dnepropetrovsk, Ukraine|Ivano-Frankovsk Regional Clinical Hospital - Hospital Therapy Department, Ivano-Frankovsk, Ukraine|Kharkov Regional Clinical Oncology Center Dep't of Oncology and Pediatric Oncology, Kharkov, Ukraine|Kiev Institute of Oncology of the UAMS Systemic Malignancies Department, Kiev, Ukraine|Kiev Bone Marrow Transplantation Center Bone Marrow Transplantation Department, Kiev, Ukraine|Institute of Hematology and Transfusiology of the UAMS Department of Blood Diseases with Clinical Biochemistry Group, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the UAMS, Lvov, Ukraine|Odessa Regional Clinical Hospital Hematology Dep't, Odessa, Ukraine|Zaporozhje Regional Clinical Hospital Hematology Dpt, Zaporozhye, Ukraine|Zhitomir Regional Clinical Hospital Hematology Centre, Zhitomir, Ukraine|Belfast City Hospital Haematology Dpt., Belfast, United Kingdom|Guys Hospital, London, United Kingdom|Guys Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00057564"
448,"NCT00055562","Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma",,"Completed","No Results Available","Melanoma|Neoplasm Metastasis","Drug: CC 5013",,"Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CDC-5013-MEL-001","January 2003",,"December 2004","March 6, 2003",,"June 24, 2005","University of Arizona Cancer Center, Tucson, Arizona, United States|University of Southern California Norris Cancer Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|St. Francis Memorial Hospital, San Francisco, California, United States|Outpatient Clinic, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|The Harold Lever Regional Cancer Center, Waterbury, Connecticut, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Lutheran General, Park Ridge, Illinois, United States|Carle Clinic, Urbana, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Ctr, Boston, Massachusetts, United States|Spectrum Health, Grand Rapids, Michigan, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Melanoma Center of St Louis, St. Louis, Missouri, United States|Biomedical Research Alliance of New York, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Linder Clinical Trial Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Qell Health Sciences Center, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|L'Hotel Dieu de Quebec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00055562"
449,"NCT00051116","A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: CC-5013",,"Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-008","May 2002","October 2006","October 2006","January 7, 2003",,"September 23, 2009","Myeloma Institute University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00051116"
450,"NCT00050843","A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: thalidomide",,"Celgene Corporation|Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","THAL-MDS-001","August 2001",,"February 2004","December 24, 2002",,"June 24, 2005","Scripps Cancer Center, La Jolla, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|Desert Hematology Oncology Medical Group INC, Rancho Mirage, California, United States|Whittingham Cancer Center, Norwalk, Connecticut, United States|VA Connecticut Healthcare System, West Haven, Connecticut, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Southeast Florida Hematology-Oncology, Ft. Lauderdale, Florida, United States|Northwest Medical Specialists, Arlington Heights, Illinois, United States|Oncology Associates, Cedar Rapids, Iowa, United States|Beaumont Cancer Center, Royal Oak, Michigan, United States|SMDC Health Systems, Duluth, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Jackson Oncology Associates PLLC, Jackson, Mississippi, United States|Hematology Oncology Consultants Inc, St. Louis, Missouri, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Hematology Oncology Associates of NJ, Paramus, New Jersey, United States|Summit Medical Group/Overlook Oncology Center, Summit, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Ctr, New York, New York, United States|VAMC Northport, Northport, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|South Shore Hem-Onc Assoc. PA, Rockville Centre, New York, United States|Staten Island Unversity Hospital, Staten Island, New York, United States|Westchester County Medical Center, Valhalla, New York, United States|Buffalo Medical Group PC, Williamsville, New York, United States|Northwestern Carolina Hematology Oncology PA, Hickory, North Carolina, United States|Wake Forest Univ School of Medicine, Winston Salem, North Carolina, United States|Oncology/Hematology Care Inc, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical Oncology Associates, Kingston, Pennsylvania, United States|Lancaster Cancer Center LTD, Lancaster, Pennsylvania, United States|MCP Hahnemann University, Philadelphia, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Texas Oncology PA-BMT Center, Dallas, Texas, United States|Central Utah Medical Clinic, Provo, Utah, United States|InterMountain Hematology/Oncology, Salt Lake City, Utah, United States|Swedish Cancer Institute, Seattle, Washington, United States|Yakima Regional CancerCenter, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00050843"
451,"NCT00047476","D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients",,"Completed","No Results Available","Fatigue|Neoplasms","Drug: dexmethylphenidate(d-mph)",,"Celgene Corporation|Celgene","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","d-MPH-COG-002","June 2002",,"March 2004","October 9, 2002",,"June 24, 2005","Cooper Green Hospital, Jefferson Clinic, Birmingham, Alabama, United States|University of Alabama Palliative Care Institute, Birmingham, Alabama, United States|Peak Performance Wellness, Flagstaff, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|California Cancer Care Inc, Greenbrae, California, United States|Clinical Trials and Research Associates, Montebello, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|Comprehensive Cancer Center, Boca Raton, Florida, United States|Osler Clinical Research/Osler Medical Inc, Melbourne, Florida, United States|University of Miami, Sylvester Cancer Research Center, Miami, Florida, United States|Cancer Research Network Inc, Plantation, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Markey Cancer Center, Lexington, Kentucky, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Beth Israel Cancer Center, New York, New York, United States|Gynecologic Oncology Associates and Development LLC, Greenville, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Medical Specialists, PLLC, Tacoma, Washington, United States|UW Comprehensive Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00047476"
452,"NCT00281528","Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer",,"Terminated","Has Results","Breast Neoplasms|Neoplasm Metastasis","Drug: ABI-007 (Abraxane)|Drug: bevacizumab","The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)|Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)|Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)|Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)|Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)|The Number of Participants With at Least One Dose Reduction for ABI-007|The Number of Participants With at Least One Dose Delay for ABI-007|The Number of Participants With a Dose Interruption of ABI-007|Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)|Kaplan Meier Estimate for Time to Disease Progression (TTP)|Kaplan Meier Estimate for Duration of Response|Kaplan Meier Estimate for Participant Survival|Kaplan Meier Estimate for Progression-Free Survival (PFS)","Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA023","February 2006","July 2010","March 2011","January 25, 2006","March 13, 2012","December 7, 2016","Division of Hematology/Oncology University of Alabama at Birmingham, Birmingham, Alabama, United States|Little Rock Hematology Oncology Associates, Little Rock, Arkansas, United States|California Oncology of the Central Valley, Fresno, California, United States|Glendale Memorial Hospital & Health Center, Glendale, California, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Oncology Associates of Bridgeport, Bridgeport, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Memorial Cancer Institute/Breast Cancer Center, Hollywood, Florida, United States|Florida Cancer Institute, Hudson, Florida, United States|Hematology Oncology Associates, Lake Worth, Florida, United States|Medical Specialist of the Palm Beaches, Inc, Lake Worth, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Peachtree Hematology & Oncology Associates, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Center of Hope for Cancers and Blood, Stockbridge, Georgia, United States|Maine Center for Cancer Medicine & Blood Disorders, Scarborough, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Harbor View Cancer Center, Baltimore, Maryland, United States|Boston Medical Center Moakley Building, Solomont Center for Hematology & Medical Oncology, Boston, Massachusetts, United States|North Shore Medical Cancer Center, Peabody, Massachusetts, United States|St. John's Mercy Medical Center, St. Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Drs. Forte, Schleidere, & Attas, PA, Englewood, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Rosewell Park Cancer Institute Elm & Carlton Carlton Building, Buffalo, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Medical Oncology Aultman Hospital, Canton, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|Abington Hematology Oncology, Willow Grove, Pennsylvania, United States|Family Cancer Center, Collierville, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|TX Oncology, PA, Austin, Texas, United States|South Texas Oncology & Hematology Clinical Research Dept., San Antonio, Texas, United States|Virginia Commonwealth University Medical Oncology, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Metropolitan Oncology Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00281528"
453,"NCT00249002","Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis",,"Terminated","Has Results","Hemodialysis Graft Dysfunction","Drug: ABI-007","Percentage of Participants With Discontinued, Delayed or Interrupted Therapy|Percentage of Participants Without Graft Failure or Need for Intervention|Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12|Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24|Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9|Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12|Stenosis (%) of a Non-index Lesion Using Angiography at Week 12|Stenosis (%) of a Non-index Lesion Using Angiography at Week 24|Stenosis (%) of a Non-index Lesion Using Angiography at Month 9|Stenosis (%) of a Non-index Lesion Using Angiography at Month 12|Participants With Arthrosclerotic Cardiovascular Complications|Kaplan Meier Estimates for Time to Graft Failure or Intervention|Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks","Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HD001","November 2005","November 2007","November 2007","November 7, 2005","March 13, 2012","May 4, 2016","Peoria, Illinois, United States|Shreveport, Louisiana, United States|Rochester, New York, United States|Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00249002"
454,"NCT00179712","Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma",,"Completed","No Results Available","Ovarian Cancer","Drug: CC-5013|Drug: topotecan","Phase I-To determine the MTD and evaluate the safety profile of oral lenalidomide and topotecan|Phase II-To explore the anti-tumor activity based on objective response rate (CR + PR) of the combination of oral lenalidomide and topotecan|Phase I-To explore the anti-tumor activity based on response of the combination of lenalidomide and topotecan.|Phase II-To explore the safety profile of the combination of lenalidomide and topotecan","Celgene Corporation|Prologue Research International","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","CC-5013-OVRY-002","April 2005",,"November 2006","September 16, 2005",,"December 1, 2016","Medical College of GeorgiaDept of OBGYN, Augusta, Georgia, United States|University of MinnesotaObstetrics & Gynecology, MMC, Minneapolis, Minnesota, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00179712"
455,"NCT00107094","Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Abraxane","Safety/tolerability endpoints:|incidence of treatment-emergent/related adverse events and serious adverse events|laboratory abnormalities|nadir of myelosuppression|incidence of patients experiencing dose modifications, dose interruptions, and/or premature discontinuation of study drug","Celgene Corporation","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA030","March 2005",,,"April 6, 2005",,"July 20, 2007","Abraxis BioScience Inc., Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00107094"
456,"NCT00091624","A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)",,"Completed","No Results Available","Multiple Myeloma","Drug: CC-5013",,"Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-MM-011","March 2003","September 2007","September 2007","September 15, 2004",,"December 1, 2016","Cleveland Clinic Myeloma Program, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00091624"
457,"NCT00073723","Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: ABI-007",,"Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA015","December 2003",,"January 2007","December 5, 2003",,"December 15, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00073723"
458,"NCT00046527","Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer",,"Completed","No Results Available","Breast Neoplasms|Metastases, Neoplasm","Drug: ABI-007",,"Celgene Corporation","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA012-0","June 2001",,,"October 3, 2002",,"July 13, 2006","Abraxis Bioscience, Inc, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00046527"
459,"NCT00046514","ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer",,"Completed","No Results Available","Breast Neoplasms|Metastases, Neoplasm","Drug: ABI-007",,"Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA013","June 2001",,,"October 3, 2002",,"December 15, 2016","Abraxis BioScience, Inc., Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00046514"
460,"NCT00046423","A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies",,"Completed","No Results Available","Neoplasms|Metastases, Neoplasm","Drug: ABI-007",,"Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-005-0","April 2000",,,"October 3, 2002",,"November 25, 2016","Abraxis Bioscience, Inc., Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00046423"
461,"NCT00040391","A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer",,"Terminated","No Results Available","Colorectal Neoplasms|Diarrhea","Drug: Investigational drug|Drug: Irinotecan|Drug: 5-fluorouracil|Drug: Leucovorin",,"Celgene Corporation|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Primary Purpose: Treatment","440E-ONC-0020-315","June 2002",,,"June 27, 2002",,"December 1, 2016","Research Center, Little Rock, Arkansas, United States|Research Center, Anaheim, California, United States|Research Center, Concord, California, United States|Research Center, Gilroy, California, United States|Research Center, Los Angeles, California, United States|Research Center, Jacksonville, Florida, United States|Research Center, New Port Richey, Florida, United States|Research Center, New Orleans, Louisiana, United States|Research Center, Scarborough, Maine, United States|Research Center, Pittsfield, Massachusetts, United States|Research Center, East Lansing, Michigan, United States|Research Center, St. Joseph, Michigan, United States|Research Center, Minneapolis, Minnesota, United States|Research Center, St. Joseph, Missouri, United States|Research Center, Las Vegas, Nevada, United States|Research Center, East Setauket, New York, United States|Research Center, Northport, New York, United States|Research Center, Burlington, North Carolina, United States|Research Center, Greenville, North Carolina, United States|Research Center, Zanesville, Ohio, United States|Research Center, Lancaster, Pennsylvania, United States|Research Center, Philadelphia, Pennsylvania, United States|Research Center, Charleston, South Carolina, United States|Research Center, Charleston, South Carolina, United States|Research Center, Germantown, Tennessee, United States|Research Center, Dallas, Texas, United States|Research Center, Madison, Wisconsin, United States|Research Center, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00040391"
462,"NCT00002157","Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome",,"Completed","No Results Available","HIV Infections|HIV Wasting Syndrome","Drug: Thalidomide",,"Celgene Corporation|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Not Applicable",,"Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","230B|W-002",,,,"August 31, 2001",,"June 24, 2005","Celgene Corp, Warren, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00002157"
463,"NCT00002127","A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome",,"Completed","No Results Available","HIV Infections|HIV Wasting Syndrome","Drug: Thalidomide",,"Celgene Corporation|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Masking: Double|Primary Purpose: Treatment","230A|W-001",,,,"August 31, 2001",,"June 24, 2005","Marin County Specialty Clinic, Greenbrae, California, United States|AIDS Community Research Consortium, Redwood City, California, United States|UCSD Med Ctr - Owen Clinic, San Diego, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|Kaiser Permanente Med Ctr, San Francisco, California, United States|Gottlieb Med Group, Sherman Oaks, California, United States|George Washington Univ Med Ctr, Washington, District of Columbia, United States|Community Research Initiative of South Florida, Coral Gables, Florida, United States|Kansas City AIDS Research Consortium, Kansas City, Missouri, United States|Saint Michael's Med Ctr, Newark, New Jersey, United States|Rockefeller Univ, New York, New York, United States|Thomas Jefferson Med College, Philadelphia, Pennsylvania, United States|Advanced Research Management, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00002127"
464,"NCT04119362","PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer","PARAGON","Recruiting","No Results Available","Pancreatic Adenocarcinoma","Other: Quality of live questionnaires|Other: Optional translational project","The course of Quality of Life (QoL) throughout the entire course of therapy for patients with pancreatic adenocarcinoma|Other patient reported outcome (PRO)|Progression- free survival (PFS)|Disease-free survival (DFS)|Overall survival (OS)","IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest|Celgene","All","18 Years and older   (Adult, Older Adult)",,"800","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PARAGON","October 24, 2019","January 2029","January 2029","October 8, 2019",,"November 11, 2019","KHNW Frankfurt, Frankfurt, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT04119362"
465,"NCT03920995","Multi-center Database Registry to Study Thalamus Changes Using AI in MS",,"Not yet recruiting","No Results Available","Multiple Sclerosis",,"Multi-center registry of MRI scans","University at Buffalo|Celgene","All","18 Years to 85 Years   (Adult, Older Adult)",,"1000","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","N/A-NI-MS-PI-13632","April 2019","September 30, 2020","March 31, 2021","April 19, 2019",,"April 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03920995"
466,"NCT03915444","Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma",,"Recruiting","No Results Available","Pancreatic Ductal Adenocarcinoma","Drug: nab-Paclitaxel + Cisplatin + Gemcitabine","12- Month Overall Survival|Change in tumor markers|Quality of Life: MD Anderson Symptom Inventory (MDASI-GI)|Pain Control: Brief Pain Inventory (BPI)|Potential tumor biomarkers|Disease Response","HonorHealth Research Institute|Celgene","All","18 Years to 105 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AX-CL-PANC-PI-13301","July 15, 2019","April 15, 2020","April 15, 2021","April 16, 2019",,"August 7, 2019","HonorHealth Research Institute, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03915444"
467,"NCT03809780","Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone","LENDER","Recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone","Survival","Kosin University Gospel Hospital|Celgene","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 2","102","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LENDER","March 11, 2019","December 1, 2023","December 3, 2024","January 18, 2019",,"August 14, 2019","Kosin University Gospel Hospital, Busan, Western, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03809780"
468,"NCT03807999","Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer",,"Completed","No Results Available","Pancreatic Neoplasm","Drug: Nab-paclitaxel|Drug: Gemcitabine","3-months deterioration-free rate|Overall Survival","Hacettepe University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AX-PANC-SY001","February 19, 2015","April 1, 2018","November 1, 2018","January 17, 2019",,"January 17, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03807999/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03807999"
469,"NCT03780504","Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece","APROACH","Recruiting","No Results Available","Psoriatic Arthritis",,"evaluate the apremilast impact on peripheral PsA disease activity|estimate the moderate cDAPSA response rate|estimate the major cDAPSA response rate|classify the study population into the PsA disease activity states|evaluate the effect of apremilast treatment on enthesitis (complete resolution)|evaluate the effect of apremilast treatment on enthesitis (change in LEI score)|evaluate the effect of apremilast treatment on dactylitis (complete resolution)|evaluate the effect of apremilast treatment on dactylitis (change from baseline)|evaluate the effect of apremilast treatment on dactylitis (change in digits)|evaluate the effect of apremilast treatment on patients' physical function using the HAQ-DI (change from baseline)|evaluate the effect of apremilast treatment on patients' physical function using the HAQ-DI (percentage of patients)","Genesis Pharma S.A.|Celgene","All","18 Years and older   (Adult, Older Adult)",,"170","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GEN-NIS-APR-002","April 15, 2019","October 1, 2020","February 1, 2021","December 19, 2018",,"November 8, 2019","Euromedica Private Clinic, Thessaloníki, Greece",,"https://ClinicalTrials.gov/show/NCT03780504"
470,"NCT03690544","Apremilast for RAS",,"Recruiting","No Results Available","Recurrent Aphthous Stomatitis","Drug: Apremilast 30mg","Improvement in duration of RAS lesions|Percentage change in number of RAS lesions|Improvement in duration of the remission period between ulcer episodes|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Discontinuation of study participants|Frequency of clinically significant changes in vital signs and/or laboratory findings","Mayo Clinic|Celgene","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-002914","October 12, 2018","September 30, 2019","December 15, 2019","October 1, 2018",,"December 7, 2018","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03690544"
471,"NCT03655080","Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression",,"Recruiting","No Results Available","Cord Compression","Radiation: Radiation therapy|Drug: nab-Paclitaxel","Ambulatory status|Strength of lower extremities|Pain in the irradiated area"" measured on a scale|Pain in the irradiated area measured on a scale","Washington University School of Medicine|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201809175","January 9, 2019","February 28, 2021","January 31, 2022","August 31, 2018",,"May 1, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03655080"
472,"NCT03620188","Treatment Goals in Psoriatic Arthritis","PaGoPsA","Recruiting","No Results Available","Psoriatic Arthritis","Other: Standard of care","Predictors of reaching PsA treatment goals/treatment success from a patient perspective.|To define a status of PsA treatment where patient treatment goals have been met.|Improvement thresholds (treatment success) that correspond to a patient transition from goals not met to met.|Worsening thresholds (treatment failure) if transition is from goals met to not met.|Prevalence of treatment success in guideline -based treatment in psoriatic arthritis from the patients' perspective|Stability of a state of treatment goals met at subsequent study visits.","Johns Hopkins University|Celgene","All","18 Years to 95 Years   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00184580","December 20, 2018","June 15, 2020","December 31, 2022","August 8, 2018",,"January 9, 2019","Johns Hopkins Bayview, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03620188"
473,"NCT03593018","Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL",,"Recruiting","No Results Available","Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma","Drug: Oral azacitidine|Drug: Romidepsin|Drug: Bendamustine|Drug: Gemcitabine","Progression Free Survival (PFS)|Overall survival (OS)|PFS by the Independent Review Committee (IRC)|Overall response rate|Complete response rate (CRR)|Duration of response (DoR)|Time to response (TtR)|PFS 2 using local assessment of progressive disease|Quality of Life Questionnaire (QLQ-C30)|Number of Serious Adverse Events (SAE)","The Lymphoma Academic Research Organisation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","86","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORACLE","November 9, 2018","December 2021","December 2021","July 19, 2018",,"June 10, 2019","A. Z. Sint-Jan Brugge-Oostende AV, Bruges, Belgium|Cliniques Universitaires de Bruxelles - Hôpital Erasme, Bruxelles, Belgium|Université Catholique de Louvain Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liège, Belgium|CHU UCL Namur - Site Godinne, Yvoir, Belgium|Institut d'Hématologie de Basse Normandie, Caen, France|CHU de Clermont-Ferrand - Hôpital Estaing, Clermont-Ferrand, France|CHU Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, France|CHU de Limoges, Limoges, France|CHU de Montpellier - Hôpital Saint-Eloi, Montpellier, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Hôpital Necker, Paris, France|Hôpital Saint-Louis, Paris, France|CHU Haut-Lévèque - Centre François Magendie, Pessac, France|CHU Lyon-Sud, Pierre-Bénite, France|CH Annecy Genevois, Pringy, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|IUCT - Oncopole, Toulouse, France|CHRU de Nancy - Hôpital de Brabois, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT03593018"
474,"NCT03579771","Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer",,"Recruiting","No Results Available","Resectable Cholangiocarcinoma|Stage IB Intrahepatic Cholangiocarcinoma AJCC v8|Stage II Intrahepatic Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Drug: Cisplatin|Drug: Gemcitabine|Drug: Nab-paclitaxel","Completion of all preoperative and operative therapy|Incidence of adverse events|Radiological response rate defined as the percentage of patients who will have complete response (CR), partial response (PR) or stable disease (SD) after the neoadjuvant therapy|Recurrence-free survival (RFS)|Overall survival (OS)","Emory University|Celgene","All","19 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00104175|NCI-2018-00998|EU4339-18","September 26, 2018","September 30, 2021","September 30, 2024","July 9, 2018",,"May 20, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Mayo Clinic, Rochester, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03579771"
475,"NCT03567616","A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma",,"Suspended","No Results Available","Multiple Myeloma","Drug: Venetoclax|Drug: Pomalidomide|Drug: Dexamethasone","Number of Participants With Adverse Events|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Duration of Response (DOR)|Time-to-progression (TTP)","AbbVie|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-085|2017-004232-11","October 18, 2018","January 22, 2021","January 22, 2021","June 25, 2018",,"November 13, 2019","John B. Amos Cancer Center - C /ID# 202055, Columbus, Georgia, United States|University of Kansas Cancer Center /ID# 201292, Fairway, Kansas, United States|Dana-Farber Cancer Institute /ID# 201297, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 201287, Saint Louis, Missouri, United States|Duke University Hospital /ID# 200805, Durham, North Carolina, United States|Ohio State Cancer Center /ID# 202443, Columbus, Ohio, United States|Oregon Health and Science University /ID# 205582, Portland, Oregon, United States|Aurora Health Care, Aurora Cancer Center /ID# 201153, Wauwatosa, Wisconsin, United States|Hospital Clinic de Barcelona /ID# 200957, Barcelona, Spain|Hospital Vall d'Hebron /ID# 200967, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 200959, Barcelona, Spain|Hospital Universitario La Paz /ID# 200969, Madrid, Spain|Hospital Clinico Univ de Salamanca /ID# 200958, Salamanca, Spain|Leicester Royal Infirmary /ID# 202238, Leicester, England, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 203188, Birmingham, United Kingdom|St. James University Hospital /ID# 202243, Leeds, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 202240, Norwich, United Kingdom|Royal Marsden Hospital, The Ro /ID# 202242, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03567616"
476,"NCT03529175","Scheduling Nab-paclitaxel With Gemcitabine","SIEGE","Completed","No Results Available","Pancreatic Adenocarcinoma Metastatic","Drug: Abraxane (nab-paclitaxel)|Drug: Gemcitabine","Progression free survival|Patient Safety|Treatment Efficacy","CCTU- Cancer Theme|Celgene|Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIEGE (AX-PANC-PI-0101)","January 2014","June 2016","June 2016","May 18, 2018",,"July 16, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Peterborough City Hospital, Peterborough, Cambridgeshire, United Kingdom|Ysbyty Gwynedd, Bangor, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Colchester Hospital, Colchester, United Kingdom|University Hospitals Coventry & Warwickshire, Coventry, United Kingdom|Edinburgh Cancer Research Centre, Edinburgh, United Kingdom|The Beatson Oncology Centre, Glasgow, United Kingdom|The Royal Surrey County Hospital, Guildford, United Kingdom|St James' Institute of Oncology, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|The Royal Free Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03529175"
477,"NCT03515512","IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia","Drug: Enasidenib","Maximum Tolerated Dose (MTD)|Number of participants with dose limiting toxicities (DLT)|The number of participants with Enasidenib related adverse events|Cumulative incidence of acute GVHD|Cumulative incidence of chronic GVHD|Plasma and marrow 2-hydroxyglutarate levels|IDH clonal evolution via whole genome sequencing|IDH Mutational burden via next-generation sequencing","Massachusetts General Hospital|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-022","July 17, 2018","May 31, 2021","May 31, 2024","May 3, 2018",,"June 13, 2019","Johns Hopkins Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03515512"
478,"NCT03493646","Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486",,"Recruiting","No Results Available","Myelodysplastic Syndromes|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia","Drug: Azacitidine|Drug: CC-486","DNA incorporation of Vidaza® compared to CC-486|DNA incorporation in bone marrow mononuclear cells|DNA AZA derivative uptake|Proportion of cells undergoing the cell cycle|Inflammatory markers, as measured by AUC, between responders and non-","Kirby Institute|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-01-AZA|VZ-CL-MDSAML-PI-13085","June 18, 2018","December 31, 2019","December 31, 2021","April 10, 2018",,"December 6, 2018","Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Nepean Hospital, Penrith, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Gosford and Wyong Hospitals, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St Vincent's hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT03493646"
479,"NCT03433521","Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia",,"Completed","No Results Available","Acute Myeloid Leukemia",,"AML diagnosis","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Celgene","All","Child, Adult, Older Adult",,"15000","Other|Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","EO 100/2017_FJD-HRJC","January 1, 2018","January 15, 2019","January 15, 2019","February 14, 2018",,"February 28, 2019","Instituto Investigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03433521"
480,"NCT03422640","Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia",,"Recruiting","No Results Available","Frontal Fibrosing Alopecia","Drug: Apremilast","Lichen Planopilaris index|Physicians global assessment|Visual Analogue Scale Pruritus|Frontal Fibrosing Alopecia Index|Dermatology Quality of Life (DLQI) (Appendix E) Dermatology Quality of Life (DLQI) (Appendix E) Dermatology Quality of Life (DLQI)","Bellevue Dermatology|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BD1-1","July 12, 2018","January 2019","January 2019","February 6, 2018",,"July 16, 2018","Bellevue Dermatology, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03422640"
481,"NCT03392571","Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients",,"Withdrawn","No Results Available","Resectable Pancreatic Cancer","Drug: NGC-Triple regimen","To evaluate 2 year survival from date of entry into study|Determine the number and type of treatment-related adverse events as assessed by CTCAE 4.0|Histological Response to Pre-Operative Therapy|Radiological Response Rate to Pre-Operative Therapy in the Primary Tumor|CA 19-9 response to preoperative therapy|Resectability (RO and R1) Rate Following Preoperative Therapy|Determine Postoperative Complications of Surgery|Time to Recurrence","Pancreatic Cancer Research Team|Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCRT 17-001","August 15, 2018","December 30, 2020","December 30, 2020","January 8, 2018",,"May 7, 2019",,,"https://ClinicalTrials.gov/show/NCT03392571"
482,"NCT03241017","Durvalumab in DLBCL After Autologous Transplant","IDA-D","Withdrawn","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Durvalumab","Progression-free survival|Response Rate|Adverse Events|Hematologic engraftment|The quality of life|Overall Survival","University Hospital Inselspital, Berne|Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDA-D Trial","October 2017","October 2021","December 2021","August 7, 2017",,"April 9, 2018",,,"https://ClinicalTrials.gov/show/NCT03241017"
483,"NCT03123016","Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo",,"Completed","No Results Available","Vitiligo","Drug: Apremilast|Procedure: NB-UVB phototherapy","Change in proportion of responders to treatment from Week 16 to Week 32|Body Surface Area (BSA)|VASI score - Vitiligo Area and Severity Index (VASI)|VETF score - Vitiligo European Task Force (VETF) score|Dermatology Life Quality Index|Visual Analogue Scale (VAS)|Number of Adverse Events","Icahn School of Medicine at Mount Sinai|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 16-1261","April 14, 2017","August 5, 2019","August 5, 2019","April 21, 2017",,"August 27, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03123016"
484,"NCT03118466","Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","AML","Drug: Etoposide|Drug: Cytarabine|Drug: Lenalidomide|Drug: Mitoxantrone","Complete Response Rate|Days to ANC recovery|Days of platelet recovery|Treatment-related mortality|Transfusion support: Number of red blood cell and platelet transfusions|Explore Associations Between Somatic Mutations and CR","Massachusetts General Hospital|Celgene","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-574","September 25, 2017","September 30, 2020","September 30, 2024","April 18, 2017",,"June 26, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts general Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03118466"
485,"NCT03059485","DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission",,"Recruiting","No Results Available","Acute Myelogenous Leukemia","Biological: DC/AML Fusion Vaccine|Other: Observation","Progression Free Survival|Overall Survival|Assessing Toxicity using CTCAE version 4.03","Dana-Farber Cancer Institute|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-593","June 1, 2017","September 30, 2020","September 30, 2024","February 23, 2017",,"November 1, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03059485"
486,"NCT03054532","Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma",,"Not yet recruiting","No Results Available","LYMPHOMA","Drug: Durvalumab|Drug: Lenali","Efficacy as measured by overall response rate measured at the time of best response.|Progression-free survival (PFS)|Overall survival (OS)|Time-to-response (TTR)|Duration of response (DoR)","Singapore General Hospital|Celgene","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SDBCC-LYM-16-01","July 2017","January 2021","July 2021","February 15, 2017",,"February 16, 2017","National University Hospital Singapore, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Raffles Hospital Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03054532"
487,"NCT03049267","Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis","SMASH","Completed","No Results Available","Hidradenitis Suppurativa","Drug: Apremilast|Drug: Placebo Oral Tablet","Change of expression levels of inflammatory cytokine mRNA in HS lesional skin.|Change of expression levels of inflammatory cytokine protein in HS lesional skin.|Abscesses count|Nodule count|Fistula count|Hidradenitis Suppurativa Physician's Global Assessment (HS-PGA) score|Hidradenitis Suppurativa Clinical Response (HiSCR)|Numerical Rating Scale (NRS)|Dermatology Life Quality Index (DLQI)|Incidence of Treatment-Emergent Adverse Events","M.B.A. van Doorn|Celgene|Erasmus Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SMASH trial","February 2, 2017","December 6, 2017","June 28, 2018","February 10, 2017",,"July 24, 2018","Erasmus University Medical Center, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03049267"
488,"NCT03022617","An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis",,"Enrolling by invitation","No Results Available","Psoriatic Nail|Psoriasis Vulgaris|Psoriasis","Drug: Apremilast","Mean percent change of mNAPSI (modified nail area psoriasis severity index) at week 36 compared to baseline for all nails.|Mean percent change in mNAPSI of target nail at weeks 12, 24, 36, 48, and 52 compared to baseline.|Proportion of patients achieving mNAPSI of 0 in all fingernails at weeks 36 and 52.|Change in patient reported nail pain, as based on the Nail Pain VAS score, at week 52 compared to baseline score.|Pain Change in psoriatic arthritis symptoms at week 52 compared to baseline, in patients who self-identify as having psoriatic arthritis at baseline.|Safety Adverse effects will be assessed at each visit|Proportion of patients achieving a mNAPSI 75 response, as defined by 75% or greater reduction over baseline in mNAPSI score at weeks 12, 24, 36, 48, and 52 for the target fingernail.|Mean change in the total number of nails involved assessed at weeks 36 and 52 compared to baseline.","University of Alabama at Birmingham|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-160720004","January 2017","December 2019","December 2019","January 16, 2017",,"March 4, 2019","The Kirklin Clinic, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03022617"
489,"NCT03000309","Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy",,"Completed","Has Results","Plaque Psoriasis","Drug: Apremilast","Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16|Percent Change in Product of BSA and sPGA|Mean Change in DLQI|Mean Change in Pruritus Scores|Mean Change in BSA|Percent Change in BSA|Proportion of Patients Who Achieve PASI 50|Proportion of Patients Who Achieve PASI 75|% of Patients Achieving Clear or Almost Clear on the PtGA","Derm Research, PLLC|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APR-2015","December 29, 2016","April 2018","April 25, 2018","December 22, 2016","March 28, 2019","March 28, 2019","DermResearch, PLLC, Louisville, Kentucky, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03000309/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03000309"
490,"NCT02985190","A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders",,"Recruiting","No Results Available","MDS|Systemic Autoimmune Diseases","Drug: Azacitidine","Overall response rate of Myelodysplastic syndrome and systemic autoimmune and inflammatory diseases (SAID)|Number of participants with treament-related adverse events as assessed by CTCAE v4.0","Groupe Francophone des Myelodysplasies|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GFM-AZA-SAID|2016-000918-30","January 26, 2017","July 2021","February 2023","December 7, 2016",,"May 27, 2019","CHU Amiens, Amiens cedex 01, France|CHU d'Angers, Angers cedex 9, France|Centre hospitalier Victor Dupouy, Argenteuil, France|CH Henri Duffaut d'Avignon, Avignon, France|Centre hospitalier de la Côte Basque, Bayonne cedex, France|Hôpital Nord Franche-Comté, Belfort, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier de Boulogne Sur Mer, Boulogne-sur-Mer, France|CHRU de Brest - Hôpital Morvan, Brest, France|CHU Côte de Nacre, Caen, France|CH René Dubos, Cergy-Pontoise, France|Centre Hospitalier William Morey, Chalon-sur-Saône, France|CHU Estaing, Clermont-Ferrand, France|CHSF Gilles de Corbeil, Corbeil-Essonnes, France|CHU Henri Mondor, Créteil, France|CHU François Mitterrand, Dijon, France|CHU de Grenoble, Grenoble cedex 09, France|Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France|CH Le Mans, Le Mans cedex 09, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Centre Hospitalier de Lens, Lens, France|Hôpital Claude Huriez, Lille cedex, France|Hôpital Saint Vincent de Paul, Lille, France|CHRU de Limoges - Hôpital Dupuytren, Limoges, France|Institut Paoli Calmettes, Marseille, France|Centre Hospitalier de Meaux, Meaux cedex, France|CH de Mont de Marsan, Mont-de-Marsan, France|Clinique Beausoleil, Montpellier, France|CHRU de Montpellier - Service de Médecine Interne, Montpellier, France|CHU de Montpellier - Service d'hématologie Oncologie, Montpellier, France|CHU Nantes - Hôtel Dieu, Nantes cedex 1, France|Centre Catherine de Sienne, Nantes, France|Hôpital Archet 1, Nice cedex 3, France|Centre Antoine Lacassagne, Nice, France|CHU de Nîmes, Nîmes cedex 9, France|CHR d'Orléans, Orléans, France|Hôpital Saint-Louis, Paris, France|Hôpital Saint Antoine - Service de Médecine Interne, Paris, France|Hôpital Saint Antoine - Service d'Hématologie Clinique, Paris, France|Hôpital Cochin, Paris, France|Hôpital Necker, Paris, France|Centre Hospitalier Joffre, Perpignan, France|CHU de Haut-Lévèque, Pessac, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier Annecy Genevois, Pringy, France|CHU de Reims, Reims, France|Hôpital PONTCHAILLOU, Rennes, France|Centre Hospitalier de Rochefort, Rochefort, France|Centre Henri Becquerel, Rouen, France|CH Yves Le Foll, Saint-Brieuc, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|IUCT Oncopole, Toulouse, France|Hôpital Bretonneau, Tours, France|Centre Hospitalier de Troyes, Troyes, France|CH Valence, Valence, France|CHU Brabois, Vandoeuvre-les-Nancy, France",,"https://ClinicalTrials.gov/show/NCT02985190"
491,"NCT02900560","Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer",,"Active, not recruiting","No Results Available","Epithelial Ovarian Cancer","Drug: CC-486|Biological: Pembrolizumab","Number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03|Number of subjects with with irPR, irCR or irSD as assessed by irRECIST|Number of subjects with treatment emergent adverse events as assessed by CTCAE v4.03","Translational Research in Oncology|Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRIO026","December 20, 2016","January 31, 2020","May 31, 2020","September 14, 2016",,"September 18, 2019","UCLA, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02900560"
492,"NCT02887248","Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma",,"Active, not recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer|Transitional Cell Carcinoma","Drug: nab-paclitaxel|Drug: Gemcitabine","6 month progression-free survival (PFS6)|Overall Response Rate|Clinical Benefit Rate|Overall Survival|The number of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as a measure of safety.","SCRI Development Innovations, LLC|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GU 124","January 12, 2017","December 20, 2019","December 30, 2019","September 2, 2016",,"June 3, 2019","Florida Cancer Specialists - South, Fort Myers, Florida, United States|Florida Cancer Specialists-North, Saint Petersburg, Florida, United States|Florida Cancer Specialists-East, West Palm Beach, Florida, United States|Tennessee Oncology, Nashville, Tennessee, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02887248"
493,"NCT02863458","DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US",,"Active, not recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndromes",,"Number of Participants on hypomethylating agents (HMA) and the effectiveness of HMA in the SEER-Medicare MDS population|Develop predictive models of HMA treatment outcomes using SEER-Medicare data|Effectiveness of lenalidomide in the SEER-Medicare MDS population|Identify the role of HMA (with its salient features of better tolerability and lesser toxicity) as a new treatment paradigm for older AML patients and enable comparison of outcomes with HMA vs other ""conventional"" leukemia therapies.","The Cleveland Clinic|Celgene","All","66 Years and older   (Older Adult)",,"50000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","15-1066","September 1, 2018","September 30, 2020","September 30, 2020","August 11, 2016",,"April 10, 2019","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02863458"
494,"NCT02767557","Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients","PACTO","Recruiting","No Results Available","Unresectable Pancreatic Carcinoma","Drug: Tocilizumab|Drug: Gemcitabine|Drug: nab-Paclitaxel","Overall survival at 6 months|Performance status at 3 and 6 months assessed by investigator|Performance status at 3 and 6 months, assessed by patient|Progression free survival (PFS), defined as the time from the date of randomization until the earliest date of disease progression|Overall survival (OS), defined as the time from the date of randomization until death due to any cause.|Overall response rate (ORR) (ORR = CR + PR), according to RECIST 1.1.RECIST 1.1|Disease control rate (DCR), (DCR = CR + PR + SD), according to RECIST 1.1.|Safety (Data on safety parameters) Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.|Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).","Herlev Hospital|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GI1612","January 26, 2017","January 26, 2020","January 26, 2021","May 10, 2016",,"November 4, 2019","Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark|Department of Oncology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02767557"
495,"NCT02632305","A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer","AX-CSARC","Recruiting","No Results Available","Unresectable Biliary Tract Cancer","Drug: nab-paclitaxel in combination with gemcitabine + cisplatin","Overall response rates","AHS Cancer Control Alberta|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AX-CSARC-PI-0001","July 13, 2016","January 2020","June 2020","December 16, 2015",,"July 4, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02632305"
496,"NCT02631044","Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",,"Recruiting","No Results Available","Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma","Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule|Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule","Treatment-related adverse events (AEs) as assessed by CTCAE v4.03|Dose-limiting toxicities of JCAR017|Objective response rate (ORR)|Complete response (CR) rate|Duration of response|Progression-free survival (PFS)|Overall survival|Health-related quality of life|Maximum concentration of JCAR017 (Cmax) in the peripheral blood|Time to maximum concentration of JCAR017 (Tmax) in the peripheral blood|Area-under-the-concentration-vs-time-curve (AUC) in the peripheral blood","Juno Therapeutics, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","274","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017001","January 2016","December 2020","December 2020","December 15, 2015",,"November 4, 2019","University of Alabama-Birmingham, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Blood Marrow Transfer Group of Georgia - Northside Hospital, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02631044"
497,"NCT02569320","HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma",,"Suspended","No Results Available","Recurrent Plasma Cell Myeloma","Drug: Dexamethasone|Drug: HDAC Inhibitor AR-42|Other: Laboratory Biomarker Analysis|Drug: Pomalidomide","Maximum tolerated dose (MTD) of HDAC inhibitor AR-42 in combination with pomalidomide, defined as the highest dose level at which less than 20% of patients experience a dose-limiting toxicity|Change in biomarker levels|Clinical benefit, defined as the proportion of patients experiencing complete response, very good partial response, or partial response|Duration of response|Incidence of toxicity, evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 standard toxicity grading|Number of patients experiencing objective response, based on criteria adapted from the International Myeloma working Group Uniform Response Criteria|Progression-free survival|Time to progression","Yvonne Efebera|Celgene|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-15004|NCI-2015-01557|PO-CL-MM-PI-003687","May 9, 2016","December 31, 2019","December 31, 2019","October 6, 2015",,"November 15, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02569320"
498,"NCT02523040","A Study of Lenalidomide for Adult Histiocyte Disorders",,"Active, not recruiting","No Results Available","Langerhans Cell Histiocytosis (LCH)|Histiocytoses Erdheim-chester Disease|Histiocytic Sarcoma (HS)","Drug: Lenalidomide","Response Rate|Progression Free Survival (PFS)|Overall Survival|Number of Participating with Grade 3-4 toxicity|Quantitative serial measurements of urine cell free DNA for BRAF mutation as a biomarker of response|Quantitative serial measurements of serum TNF-alpha levels as a biomarker of response|Quantitative serial measurements of plasma cell free DNA for BRAF mutation as a biomarker of response","Dana-Farber Cancer Institute|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-197","August 2015","August 2020","August 2022","August 14, 2015",,"November 13, 2019","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02523040"
499,"NCT02501902","Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC",,"Completed","No Results Available","Metastatic Pancreatic Ductal Adenocarcinoma","Drug: Palbociclib|Drug: Nab-Paclitaxel","Number of participants with Dose-limiting toxicities (DLT)|Palbociclib Area Under the Curve (AUC)|Nab-Paclitaxel Area Under the Curve (AUC)|Palbociclib Maximum Observed Plasma Concentration (Cmax)|Nab-Paclitaxel Maximum Observed Plasma Concentration (Cmax)|Palbociclib Plasma Decay Half-Life (t1/2)|Nab-Paclitaxel Plasma Decay Half-Life (t1/2)|Palbociclib Time to Reach Maximum Observed Plasma Concentration (Tmax)|Nab-Paclitaxel Time to Reach Maximum Observed Plasma Concentration (Tmax)|Palbociclib Apparent Oral Clearance (CL/F)|Nab-Paclitaxel Apparent Oral Clearance (CL/F)|Palbociclib Volume of Distribution at Steady State (Vss)|Nab-Paclitaxel Volume of Distribution at Steady State (Vss)|Palbociclib Systemic Clearance (CL)|Nab-Paclitaxel Systemic Clearance (CL)|Blood CA 19-9 Levels|Objective Response Rate - Percentage of Participants With Complete or Partial Response|Duration of Response (DR)|Progression-Free Survival (PFS)|Six-Month PFS Rate|Overall Survival (OS)|Tumor Tissue Biomarkers (p16 and Rb1 expression)","Pfizer|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","A5481059|2015-001307-31","November 2015","October 2018","December 2018","July 17, 2015",,"May 30, 2019","Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States|Virginia G. Piper Cancer Pharmacy, Scottsdale, Arizona, United States|UC San Diego Medical Center - La Jolla (Thornton Hospital), La Jolla, California, United States|UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Denver, CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora, Colorado, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Hospital Universitario de Fuenlabrada. Unidad de Farmacia, Fuenlabrada, Madrid, Spain|Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitari Vall D'Hebron, Servicio de Oncología Médica, Barcelona, Spain|Hospital Universitario 12 de Octubre Servicio de Farmacia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02501902"
500,"NCT02434965","Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy","HPDSC+HIE","Not yet recruiting","No Results Available","Severe Hypoxic-ischemic Encephalopathy","Drug: HPDSC|Drug: Cord blood","Number of subjects with infusion reaction as a measure of safety and tolerability|Improvement in neurological condition","New York Medical College|Celgene","All","up to 6 Hours   (Child)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NYMC-554","December 2019","January 2021","January 2022","May 6, 2015",,"October 1, 2019","New York Medical College, Valhalla, New York, United States",,"https://ClinicalTrials.gov/show/NCT02434965"
501,"NCT02414100","Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy",,"Withdrawn","No Results Available","Pancreatic Ductal Adenocarcinoma|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer","Other: Laboratory Biomarker Analysis|Other: Cytology Specimen Collection Procedure","Genomic profiles of post-treatment samples with acquired resistance against pre-treatment and germline controls|Identification of germline mutations in known cancer genes from whole blood genomic deoxyribonucleic acid, and somatic mutations in conditionally reprogrammed cells derived from pre-treatment and post-treatment (e.g., resistant) tumors","Sidney Kimmel Cancer Center at Thomas Jefferson University|Celgene|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)",,"0","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","13C.628|2013-077","December 12, 2013","December 15, 2016","December 15, 2016","April 10, 2015",,"September 8, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02414100"
502,"NCT02412644","Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis",,"Completed","Has Results","Plaque Psoriasis","Drug: apremilast","Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36|Number of Subjects Achieving Psoriasis Area Severity Index Score (PASI) 75 Response at Week 12|Number of Subjects Achieving Psoriasis Area Severity Index Score 90 at Week 36|Number of Subjects Achieving Physician Global Assessment Score of 0 or 1 at Week 36","Psoriasis Treatment Center of Central New Jersey|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","29","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AP-CL-PSOR-PI-004893","May 28, 2015","July 2016","July 2016","April 9, 2015","January 28, 2019","January 28, 2019","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02412644"
503,"NCT02400749","Apremilast in Palmo-Plantar Psoriasis",,"Completed","Has Results","Palmo-plantar Psoriasis","Drug: Apremilast|Drug: Placebo","Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1|Palmoplantar Psoriasis Physician Global Assessment (PPPGA)|Palmoplantar Psoriasis Area Severity Index (PPPASI)|Palmoplantar Psoriasis Surface Area (PPPSA)|Palmoplantar Pustulosis Physician Global Assessment (PPPGA) of 0 or 1","Innovaderm Research Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Inno-6040|AP-CL-PSOR-CARE-005313","May 2015","September 2016","November 2016","March 27, 2015","October 24, 2018","November 20, 2018","Innovaderm Investigational Site, Arlington Heights, Illinois, United States|Innovaderm Investigational Site, Calgary, Alberta, Canada|Innovaderm Investigational Site, Saint John's, Newfoundland and Labrador, Canada|Innovaderm Investigational Site, Barrie, Ontario, Canada|Innovaderm Investigational Site, Markham, Ontario, Canada|Innovaderm Investigational Site, North Bay, Ontario, Canada|Innovaderm Investigational Site, Peterborough, Ontario, Canada|Innovaderm Investigational Site, Drummondville, Quebec, Canada|Innovaderm Investigational Site, Montreal, Quebec, Canada|Innovaderm Investigational Site, Saint-Jerome, Quebec, Canada|Innovaderm Investigational Site, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT02400749"
504,"NCT02392637","Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers",,"Active, not recruiting","No Results Available","Biliary Tract Cancer","Drug: Abraxane (Nab-Paclitaxel)|Drug: Cisplatin|Drug: Gemcitabine|Behavioral: Phone Calls","Progression-Free Survival (PFS) of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers|Response Rate (RR) of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0524|NCI-2015-00578","April 2, 2015","April 2019","April 2019","March 19, 2015",,"July 24, 2018","Mayo Clinic, Rochester, Minnesota, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02392637"
505,"NCT02392507","A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC",,"Active, not recruiting","Has Results","Carcinoma, Non-small-Cell Lung","Drug: Necitumumab|Drug: Nab-Paclitaxel|Drug: Carboplatin","Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])|Progression Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin|PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin|Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab","Eli Lilly and Company|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15529|I4X-MC-JFCP","October 12, 2015","January 29, 2018","December 17, 2019","March 19, 2015","February 12, 2019","July 30, 2019","Florida Hospital Cancer Institute, Orlando, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02392507/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02392507/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02392507"
506,"NCT02328105","LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer",,"Active, not recruiting","Has Results","Lung Cancer","Drug: Carboplatin|Drug: Abraxane","Number of Participants With a Response|Number of Subjects With Stable Disease or Response|Progression Free Survival|Overall Survival|Duration of Response|Duration of Disease Control","Kathryn Mileham|Celgene|Atrium Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-LUN-ABR-001|00010224","December 2014","June 15, 2017","November 2019","December 31, 2014","July 11, 2018","July 25, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02328105/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02328105"
507,"NCT02317991","Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer",,"Active, not recruiting","No Results Available","Gastroesophageal Cancer","Drug: nab-paclitaxel|Biological: ramucirumab","Progression-Free Survival (PFS)|Overall Response Rate (ORR)|Time to Progression (TTP)|Overall Survival (OS)","SCRI Development Innovations, LLC|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GI 201","May 5, 2015","January 2021","May 2021","December 17, 2014",,"September 16, 2019","Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Specialists-South, Fort Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists-North, Saint Petersburg, Florida, United States|Ingalls Cancer Research Center, Harvey, Illinois, United States|Research Medical Center, Kansas City, Missouri, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Spartanburg Medical Center/Gibbs Cancer Center, Spartanburg, South Carolina, United States|Tennessee Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02317991"
508,"NCT02230917","A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: Sotatercept|Drug: Placebo","Presence of biochemical bone turnover|Number of Adverse Events related to sotatercept|Bone marrow density|Change in biochemical myeloma markers|Size of target bone lesions","Rebecca Silbermann|Celgene|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","IUCRO-0428","October 2014","April 2016","June 2016","September 3, 2014",,"September 1, 2016","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02230917"
509,"NCT02181218","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",,"Active, not recruiting","No Results Available","Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Disease|Lymphoma, Large B-Cell, Diffuse","Drug: Romidepsin|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Dexamethasone|Drug: Pegfilgrastim","Maximum tolerated dose (recommended Phase II dose)|Complete response rate|Partial response rate|Overall response rate|Progression free survival|Duration of response","Washington University School of Medicine|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201407160","February 4, 2015","March 28, 2019","August 31, 2020","July 3, 2014",,"November 13, 2019","University of Chicago, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02181218"
510,"NCT02158702","Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib",,"Active, not recruiting","No Results Available","Multiple Myeloma|Relapse After Use of Lenalidomide and Bortezomib","Drug: Pomalidomide and Dexamethasone","To assess the progression free survival (PFS) for pomalidomide and dexamethasone in patients who have relapsed and are refractory to lenalidomide and have previously been treated with bortezomib|To assess Overall Response Rate (ORR)|To see if addition of cyclophosphamide with induce additional response in patient who do not achieve an minimal response (MR) after 3 months|To assess Overall Survival (OS)|To assess Duration of Response (DOR)|To assess Safety and Tolerability","National University Hospital, Singapore|Celgene","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014/00498","November 2014","February 2018","November 2018","June 9, 2014",,"May 17, 2018","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02158702"
511,"NCT01998035","Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies",,"Active, not recruiting","No Results Available","Lymphoid Malignancies|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma","Drug: Romidepsin|Drug: Oral 5-Azacitidine","Phase I: Maximum tolerated dose (MTD) of the combination of oral 5-azacitidine & romidepsin|Phase I: Number of dose limiting toxicities (DLTs) of the combination of oral 5-azacitidine & romidepsin|Phase I: Number of toxicities experienced by patients with the combination of oral 5-azacitidine and romidepsin|Phase II: Overall response rate (ORR) (complete + partial response) of the combination of oral 5-azacitidine and romidepsin in patients with relapsed/refractory T-Cell Lymphoma|Phase I: Maximum number of cycles received|Phase I: Number of dose delays at the maximally tolerated dose (MTD)|Phase I: Number of dose reductions at the maximally tolerated dose (MTD)|Phase I: Overall response rate (ORR) of the study population|Phase I & II: Progression free survival (PFS) of the study population|Phase I & II: Duration of response (DOR) of the study population|Phase II: Prevalence of overall survival of the patients with T-cell lymphoma on study|Phase II: Positive response to clinical outcome indicating potential pre-treatment biomarkers by relating correlative sample data to clinical data on each patient.","Owen A, O'Connor, M.D., Ph.D.|Celgene|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","52","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAM3752","November 2013","December 2019","December 2019","November 28, 2013",,"May 15, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01998035"
512,"NCT01846390","Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Peripheral T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma","Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Romidepsin","Maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.|Efficacy of romidepsin when combined with gemcitabine, dexamethasone and cisplatin|Number of patients with adverse events","Canadian Cancer Trials Group|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY15","April 30, 2013","July 6, 2016","September 19, 2018","May 3, 2013",,"June 11, 2019","Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01846390"
513,"NCT01827111","Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma",,"Active, not recruiting","No Results Available","Melanoma","Drug: ABI-007|Drug: Ipilimumab|Behavioral: Phone Call","Progression-Free Survival (PFS)","M.D. Anderson Cancer Center|Celgene","All","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-1157|NCI-2014-01238","April 2013","September 2019","September 2020","April 9, 2013",,"May 9, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01827111"
514,"NCT01815242","Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer","ADAPT","Active, not recruiting","No Results Available","Breast Cancer","Drug: nab-Paclitaxel|Drug: Gemcitabine|Drug: Carboplatin","Comparison: pCR in nab-paclitaxel/carboplatin vs. nab-paclitaxel/gemcitabine|Comparison: pCR in responders vs. non-responders","West German Study Group|Celgene","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","336","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WSG-AM06 / ADAPT TN","June 2013","March 2015","May 2020","March 21, 2013",,"July 23, 2019","Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany, Moenchengladbach, Germany",,"https://ClinicalTrials.gov/show/NCT01815242"
515,"NCT01807286","Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis",,"Terminated","No Results Available","Myeloma","Drug: Pomalidomide|Drug: Melphalan|Drug: Dexamethasone|Behavioral: Questionnaires","Maximum Tolerated Dose (MTD) of Pomalidomide with Melphalan and Dexamethasone (PMD).|Complete Response (CR) Rate","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0215|NCI-2013-02276","January 2014","February 2016","February 2016","March 8, 2013",,"May 13, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01807286"
516,"NCT01788189","Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas","LeMLAR","Active, not recruiting","No Results Available","B-cell Lymphoma","Drug: Lenalidomide","Dose-limiting toxicity|Progression-free survival","University Hospital, Essen|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT No. 2012-001891-13","January 2013","December 31, 2019","March 31, 2020","February 11, 2013",,"October 1, 2019","Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany",,"https://ClinicalTrials.gov/show/NCT01788189"
517,"NCT01757288","Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC",,"Active, not recruiting","No Results Available","STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER","Drug: NAB-PACLITAXEL|Drug: PACLITAXEL","2-year overall survival from randomization for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|the feasibility of concurrent carboplatin/nab-paclitaxel and radiation therapy|overall response rate for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|the progression-free survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|the median overall survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|quality of life (QOL) of patients receiving either nab-paclitaxel or paclitaxel when given with concurrent radiotherapy|correlate outcomes (survival, toxicity, QOL) with biological parameters","University of Texas Southwestern Medical Center|Celgene","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","98","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 062012-053","March 25, 2013","February 2020","February 2021","December 28, 2012",,"March 8, 2019","University of Rochester, Rochester, New York, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01757288"
518,"NCT01754402","Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Bendamustine|Drug: Pomalidomide|Drug: Dexamethasone","Maximum Tolerated Dose of Pomalidomide and Bendamustine|Initial Response Rate|Overall Response Rate|Time to Progression|Time to Next Therapy|Progression Free Survival","Cristina Gasparetto|Celgene|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00040206|PO-MM-PI-0045","January 7, 2013","December 6, 2016","January 1, 2023","December 21, 2012","February 27, 2017","July 25, 2018","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01754402"
519,"NCT01743859","Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia",,"Completed","Has Results","Acute Myeloid Leukemia","Drug: Azacitidine|Drug: Lenalidomide|Other: Off Therapy","Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts|Overall Response Rate|Response or Remission Duration|Toxicity and SAEs Related to Treatment|Overall Survival|Progression-free Survival|Determine Biomarkers That Predict Response/Toxicity","University of Colorado, Denver|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-1283.cc|NCI-2012-03191","December 6, 2012","April 27, 2016","August 3, 2016","December 6, 2012","October 8, 2019","October 8, 2019","University of Colorado Cancer Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01743859"
520,"NCT01730586","Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas",,"Completed","No Results Available","Colorectal Cancer|Cancer of Gastrointestinal Tract","Drug: Abraxane","Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma|Progression-Free Survival","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0776|NCI-2013-00077","November 2012","August 2016","August 2016","November 21, 2012",,"August 16, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01730586"
521,"NCT01703364","Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL",,"Completed","No Results Available","CLL|Chronic Lymphocytic Leukemia","Drug: Lenalidomide","Tolerability of escalated starting dose|Establishment of maximal tolerated dose (MTD) of Lenalidomide in combination with FR|Time to MTD|Safety profile of the FRL combination|Response rates in all phases by 4-colour flow cytometric and ASO-PCR MRD analysis|Risk factor analysis (FISH cytogenetics, CD38/ZAP-70 expression, mutation status)|Longitudinal definition of T cell subsets (including prognostic EM T cells and Treg cells)+/- PD1","Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGMT_CLL-9|2011-004912-43","June 2012","March 2015","October 2015","October 10, 2012",,"May 26, 2016","Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie, Innsbruck, Tirol, Austria|Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III, Salzburg, Austria",,"https://ClinicalTrials.gov/show/NCT01703364"
522,"NCT01702844","Single Arm on the Tolerability of Weekly Nab-paclitaxel",,"Active, not recruiting","No Results Available","Non Small Cell Lung Cancer (NSCLC)","Drug: Nab-Paclitaxel","Number of subjects with adverse events|Post-baseline efficacy assessment","UNC Lineberger Comprehensive Cancer Center|Celgene","All","70 Years and older   (Older Adult)","Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1210","June 25, 2013","January 2020","January 2021","October 8, 2012",,"February 19, 2019","Highlands Oncology Group, Fayetteville, Arkansas, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Rex Healthcare, Raleigh, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Bon Secours Virginia Health System, Midlothian, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01702844"
523,"NCT01684150","A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving",,"Completed","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders","Drug: EPZ-5676","The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676 as determined by incidence of protocol-specified dose-limiting adverse events.|Pharmacokinetic profile of EPZ-5676|The incidence of adverse events in patients treated with EPZ-5676|Anti-leukemic activity of EPZ-5676 in patients with acute leukemia harboring a MLL-rearrangement|Effects of EPZ-5676 on histone H3K79 methylation in peripheral blood mononuclear cells (PBMC).|Effects of EPZ-5676 on histone H3K79 methylation in leukemia cells","Epizyme, Inc.|Celgene","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPZ-5676-12-001","September 2012","November 2015","February 2016","September 12, 2012",,"August 4, 2016","Mayo Clinic Scottsdale-Phoenix, Scottsdale, Arizona, United States|Northwestern University, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Health System, Durham, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|UT MD Anderson Cancer, Houston, Texas, United States|Universitätsklinikum Ulm, Ulm, Germany|Erasmus University Medical Center, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01684150"
524,"NCT01615042","Phase I Study of Lenalidomide in Patients With Acute Leukemia",,"Terminated","No Results Available","Acute Leukemia","Drug: Lenalidomide","Maximum Tolerated Dose (measured by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0)|Rates of complete response (CR) and complete response without platelet recovery (CRi)|Pharmacokinetics of high-dose lenalidomide cell activity.|Define the effects of lenalidomide on T and Natural Killer (NK) cell activity.","University of California, Davis|Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#228|318008|RV_AML_PI_0696","August 2012","May 2017","May 2017","June 8, 2012",,"January 9, 2018","University of California Comprehensive Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01615042"
525,"NCT01578954","Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction",,"Active, not recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Lenalidomide","Determine the rate of dose limiting toxicities.|Frequency of toxicity|Duration of toxicity|Response rates","UNC Lineberger Comprehensive Cancer Center|Celgene","All","60 Years and older   (Adult, Older Adult)","Phase 1","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1111|12-0040","June 2012","August 3, 2016","March 2022","April 17, 2012",,"August 8, 2019","University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01578954"
526,"NCT01566435","Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer",,"Active, not recruiting","Has Results","Head and Neck Neoplasms","Drug: paclitaxel albumin-stabilized nanoparticle formulation|Drug: Cisplatin|Drug: Fluorouracil|Radiation: Intensity modulated radiation therapy|Drug: Cetuximab|Procedure: Quality-of-life assessment","Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site|Percentage of Participants With Partial Response (PR) at Primary Tumor Site|Number of Participants Per Anatomic Tumor Response by CT Scan|Metabolic Tumor Responses as Measured by FDG-PET/CT|Overall Survival Rate|Adverse Events as Measured by Number of Participants That Experienced Each Common Adverse Event During ACF Induction Therapy|Changes in Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue|Quality of Life (QOL)|Complete Response (CR) or Partial Response (PR) at Regional (Neck) Nodes as Measured by Clinical Exam|Changes in Ki-67 Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue|Disease-free Survival (DFS) Rate|Progression-free Survival (PFS)","Washington University School of Medicine|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201202113","August 9, 2012","October 31, 2013","October 31, 2023","March 29, 2012","December 14, 2015","July 23, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01566435"
527,"NCT01565499","Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Nab-paclitaxel","The residual cancer burden grade III (RCB-III).|Analyses for pathological Response Rate|Analyses for objective response|Analyses for rate of conversion to BCS|Time-to-event Analyses|Toxicity and tolerability of nab-paclitaxel analysis.","Spanish Breast Cancer Research Group|Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEICAM/2011-02","April 2012","December 2012","August 2019","March 28, 2012",,"February 14, 2018","Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Instituto Oncológico de Guipúzcoa, Donostia-San Sebastián, Guipúzcoa, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Morales Meseguer, Murcia, Spain|Hospital Virgen de la Salud, Toledo, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01565499"
528,"NCT01556776","A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: lenalidomide|Drug: Placebo","Progression-free survival (PFS) based on independent review committee|Progression-free survival (PFS) based on investigator's assessment|Overall survival (OS)|Safety - adverse events (AEs)|Miminimal residual disease (MRD) levels in peripheral blood (PB)","German CLL Study Group|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","89","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLLM1|2011-004698-98|RV-CLL-GCLLSG-0725","July 20, 2012","March 2016","January 2021","March 16, 2012",,"August 1, 2019","University Hospital Cologne, Cologne, Germany|German CLL Study Group, Cologne, Germany",,"https://ClinicalTrials.gov/show/NCT01556776"
529,"NCT01484626","Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma","BVRD","Terminated","Has Results","Multiple Myeloma","Drug: Bendamustine","Number of Patients Experiencing a Toxicity","Loyola University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","203145","May 5, 2011","June 18, 2014","June 18, 2014","December 2, 2011","July 10, 2018","July 10, 2018","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01484626"
530,"NCT01472562","Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma",,"Active, not recruiting","Has Results","Mantle Cell Lymphoma","Drug: lenalidomide|Biological: rituximab","Overall Response Rate|2-year Progression-free Survival","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1103011566","July 29, 2011","April 2014","October 2022","November 16, 2011","April 7, 2017","February 28, 2019","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01472562"
531,"NCT01433965","Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",,"Recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome","Drug: Lenalidomide","Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0 and Graft versus Host Disease Staging|Disease relapse|Disease-free survival|Incidence of Graft versus Host disease","University of California, Davis|Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","111792|UCDCC#227","August 2012","October 2018","December 2019","September 14, 2011",,"March 2, 2018","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01433965"
532,"NCT01432600","Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide",,"Completed","Has Results","Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","Phase I - Maximum Tolerated Dose (MTD)|Phase II - Overall Response Rate (ORR)|Phase II - Median Progression Free Survival (PFS)|Phase II - Median Overall Survival (OS)|Phase II - Occurrence of Possibly Related Adverse Events (AEs)","H. Lee Moffitt Cancer Center and Research Institute|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16705|PO-MM-PI-0039","November 2011","August 2016","August 2016","September 13, 2011","May 23, 2017","May 23, 2017","University of California San Francisco, San Francisco, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Mount Sinai School of Medicine, The Tisch Cancer Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01432600"
533,"NCT01364727","A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies",,"Completed","Has Results","Thymoma|Thymus Cancer|Thymic Carcinoma","Drug: Amrubicin","Overall Response Rate (ORR)|Median Progression-free Survival (PFS)|Disease Control Rate (DCR)","Heather Wakelee|Celgene|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB-20444|SU-01142011-7369|THOR0003","June 2011","July 2014","December 31, 2018","June 2, 2011","March 14, 2017","April 16, 2019","Stanford University School of Medicine, Stanford, California, United States|Indiana University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01364727"
534,"NCT01350947","A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia",,"Completed","Has Results","Chronic Myelomonocytic Leukemia","Drug: 5-Azacitidine","Percentage of Patients With Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine.","University of Utah|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI47081","April 2011","September 2014","September 2014","May 10, 2011","October 29, 2015","June 13, 2016","Roswell Park Cancer Institute, Buffalo, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01350947"
535,"NCT01342172","Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma",,"Terminated","Has Results","Urinary Bladder Neoplasms","Drug: Lenalidomide","Maximum Tolerated Dose (MTD) of Lenalidomide|Phase II: Progression-free Survival at 1 Year|The Objective Response Rate to Treatment With Gemcitabine, Cisplatin, Plus Lenalidomide|Number of Grade >=3 Adverse Events|Best Overall Response|To Determine the Impact of Treatment on Peripheral Blood Immune Cell Subsets|To Determine the Impact of Treatment on Circulating Tumor Cells","Icahn School of Medicine at Mount Sinai|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 10-1339","March 2011","June 2013","June 2013","April 27, 2011","November 26, 2014","April 23, 2019","National Cancer Institute, Bethesda, Maryland, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01342172"
536,"NCT01331824","Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma",,"Terminated","Has Results","Bladder Cancer","Drug: Amrubicin","Objective Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Progression-free Survival|Overall Survival|Safety as Measured by the Frequency and Type of Adverse Events as Per the Common Terminology for Adverse Events (CTCAE) Version 4.0.","Matthew Galsky|Celgene|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 10-1341","February 2011","July 2014","July 2015","April 8, 2011","December 24, 2015","April 23, 2018","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01331824"
537,"NCT01316523","Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Non Hodgkin's Lymphoma","Drug: Rituximab|Drug: Lenalidomide","Response rate to treatment|Time to progression|Overall survival|Tolerability|Duration of response from start of therapy","University of California, Davis|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","215856|UCDCC#224|RV_PI_NHL_0488","December 2010","September 2019","September 2019","March 16, 2011",,"January 25, 2019","University of California Davis Cancer Center, Sacramento, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States",,"https://ClinicalTrials.gov/show/NCT01316523"
538,"NCT01193517","Azacitidine and CAPOX in Metastatic Colorectal Cancer",,"Completed","No Results Available","Colorectal Cancer","Drug: Azacitidine|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Azacitidine MTD","Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)|Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0625|NCI-2010-01973","August 2010","November 2016","November 2016","September 2, 2010",,"December 9, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01193517"
539,"NCT01183663","Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",,"Completed","No Results Available","Advanced Cancers","Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil","Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)|Tumor Response","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","180","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0108|NCI-2012-01790","August 2010","May 2016","May 2016","August 17, 2010",,"June 3, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01183663"
540,"NCT01177735","Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Pomalidomide","Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy","University of Arkansas|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UARK 2010-01","October 2011","September 2013","September 2013","August 9, 2010","March 4, 2015","November 20, 2017","University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01177735"
541,"NCT01159574","Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: dexamethasone|Drug: clarithromycin|Drug: Pomalidomide","Overall Response Rate|Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response|Time to Disease Progression (Progression Free Survival)","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1004011012|PO-MM-PI-0023","August 2010","May 5, 2015","May 5, 2015","July 9, 2010","April 12, 2017","June 11, 2019","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01159574"
542,"NCT01142232","Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation|Drug: Lenalidomide maintenance","Phase I: Number of Patients With Dose Limiting Toxicity|Phase II: Overall Response Rate|Phase II: Treatment-Related Adverse Events Grade 3 or Higher","Attaya Suvannasankha|Celgene|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1005-06; IUCRO-0290","August 27, 2010","November 6, 2015","May 18, 2019","June 11, 2010","October 22, 2019","October 22, 2019","IU Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01142232"
543,"NCT01127386","Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome",,"Completed","No Results Available","Cancer Cachexia Syndrome","Drug: Lenalidomide|Other: basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)","Lean Body Mass|and Handgrip Strength|SAEs|nutritional intake|physical functioning|inflammation|eating related symptoms (FAACT)|tumour dynamics (CT)","Florian Strasser, MD ABHPM|Celgene|Cantonal Hospital of St. Gallen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EKSG 09/040","March 2009","September 2012","December 2012","May 20, 2010",,"August 1, 2017","Kantonsspital St.Gallen, St.Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT01127386"
544,"NCT01125176","Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL","ThRiL","Active, not recruiting","Has Results","Chronic Lymphocytic Leukemia","Drug: thalidomide|Drug: lenalidomide|Biological: rituximab","Overall Response Rate as Defined as the Number of Patients Who Experience a Response (Complete or Partial) to Treatment at the Time of Best Response|Progression Free Survival|Duration of Response|Time to Response|Overall Survival","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1112012062|RV-CLL-PI-0391","March 30, 2012","December 20, 2018","March 2020","May 18, 2010","August 26, 2019","August 26, 2019","Weill Cornell Medical College, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01125176/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01125176"
545,"NCT01121757","Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma",,"Terminated","Has Results","Follicular Lymphoma|Marginal Zone Lymphoma","Drug: azacitidine|Drug: lenalidomide","Response Predicted by Molecular Signatures Compared to True Response|Overall Response|Number of Participants With Grade 3 and 4 Toxicities","Duke University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00019069","April 2010","March 2013","January 2016","May 12, 2010","May 7, 2015","September 12, 2016","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01121757"
546,"NCT01088373","Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q","GFM-AZA-REV-09","Completed","No Results Available","Myelodysplastic Syndromes","Drug: Azacitidine combined to Lenalidomide","To identify the ""safe most successful dose""(sMSD) that is the dose level where the probabilities of success is maximized across the dose levels and the toxicity rate is kept within acceptable boundaries.|response rate and safety","Groupe Francophone des Myelodysplasies|Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-REV-09","March 25, 2010","July 25, 2016","July 25, 2016","March 17, 2010",,"December 15, 2017","Hôpital kremlin Bicêtre, Le Kremlin-Bicêtre, IDF, France|Chu Brabois, Nancy, Vandoeuvre, France|CHU d'Amiens, Amiens, France|CHU Angers, Angers, France|Hôpital de la cote basque, Bayonne, France|Hôpital Avicenne, Bobigny, France|CHU Haut-Lévèque, Bordeaux, France|CH René Dubos, Cergy-pontoise, France|CHU de, Clermont Ferrand, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|CHU Henri Mondor, Creteil, France|CHU de Grenoble, Grenoble, France|CH Le mans, Le mans, France|Centre Hospitalier de Lens, Lens, France|CHRU de Limoges, Limoges, France|Hôpital Edouard Heriot, dpt Hématologie Clinique, Lyon, France|Institut Paoli-Calmette, Département d'hématologie, Marseille, France|Centre Hospitalier de Meaux, Meaux, France|Hopital de l'Hotel Dieu, Hematology Dpt, Nantes, France|CHU Archet, Nice, France|CHR La Source orléans, Orléans, France|Hôpital Saint Louis, Paris, France|Saint-Louis Hospital, Paris, France|Hôpital Saint-Antoine, Paris, France|Hôpital la pitié-Salpétrière, Paris, France|Hopital Cochin Service d'Hématologie, Paris, France|Hôpital Maréchal Joffre, Perpignan, France|Hôpital Jean-Bernard, Poitiers, France|centre hospitalier Jacques Puel, Rodez, France|Hôpital Henri Becquerel, Rouen, France|Hôpital Purpan, médecine Interne, Toulouse, France|Hôpital PURPAN, Service d'Hématologie Clinique, Toulouse, France|CHU Bretonneau, Tours, France|Institut gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT01088373"
547,"NCT01076504","A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer",,"Completed","Has Results","Extensive-Stage Small Cell Lung Cancer","Drug: Amrubicin|Drug: Carboplatin|Drug: Pegfilgrastim","1-year Survival|Objective Response Rate|Time to Progression|Overall Survival|Toxicity/Safety","SCRI Development Innovations, LLC|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LUN 199","December 2009","March 2012","March 2015","February 26, 2010","December 10, 2015","May 5, 2016","Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Baptist Hospital East, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Research Medical Center, Kansas City, Missouri, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Family Cancer Center, Collierville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01076504"
548,"NCT01074502","Apremilast in the Treatment of Moderate to Severe Acne",,"Terminated","Has Results","Acne","Drug: apremilast","Percentage of Patients With a Success Rate (Based on the Researcher's Global Assessment (RGA) Sum of Clear (0) or Almost Clear (1))|Percentage of Patients With a Minimum 2-grade Improvement in the Researcher Global Assessment (RGA) From Baseline to Week 12.|Mean Percentage Change From Baseline in Individual Lesion Counts (Total, Inflammatory, Non-inflammatory) at Week 12|Percentage of Patients Achieving a Clear or Almost Clear PGA at 16 Weeks|The Absolute Change in Lesion Counts (Total, Inflammatory, Non-inflammatory) From Baseline to Week 12|Safety of Apremilast 20 Mgs BID for 12 Weeks Will be Assessed by Evaluating Adverse Events (AEs), Vital Signs, Laboratory Evaluations and Withdrawals From the Study","University of North Carolina, Chapel Hill|Celgene","All","18 Years to 45 Years   (Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CELG0001","February 2010","July 2010","October 2010","February 24, 2010","March 12, 2012","March 13, 2017","University Of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01074502"
549,"NCT01054196","Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study",,"Recruiting","No Results Available","Multiple Myeloma","Drug: lenalidomide|Drug: melphalan","to determine MTD of lenalidomide that can be added to melphalan|to determine response rate and duration of response","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0909010623","August 2010","December 2022","December 2025","January 22, 2010",,"May 31, 2019","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01054196"
550,"NCT01054144","Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Prednisone|Drug: Dexamethasone","Combined Therapy - Number of Participants With Progression Free Survival (PFS)|Number of Participants With Desired Response|Number of Participants With Adverse Events|Single Agent - Number of Participants With Progressive Free Survival (PFS)|Number of Participants With 1 Year Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Celgene","All","65 Years and older   (Older Adult)","Phase 2","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16018|108562|RV-MM-PI-0454","January 14, 2010","April 2020","April 2021","January 22, 2010",,"October 3, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01054144"
551,"NCT01038635","5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",,"Completed","Has Results","Leukemia","Drug: 5-Azacytidine|Drug: Lenalidomide","Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA)|Overall Response Rate (ORR) of Lenalidomide in Combination With 5-azacytidine (5-AZA) in Participants With Leukemia|Overall Response: Number of Participants With CR or CRi Response","M.D. Anderson Cancer Center|Celgene","All","Child, Adult, Older Adult","Phase 1|Phase 2","94","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0467|NCI-2011-01941","December 2009","November 2015","November 2015","December 24, 2009","February 10, 2017","February 10, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01038635"
552,"NCT01004991","Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma",,"Completed","Has Results","Diffuse Large B Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: doxorubicin|Drug: prednisone|Drug: azacytidine","Complete Response","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0907010513","January 2010","September 2013","February 2016","October 30, 2009","April 10, 2017","April 10, 2017","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01004991"
553,"NCT00946270","Pomalidomide for Myelofibrosis Patients",,"Completed","Has Results","Polycythemia Vera|Thrombocythemia","Drug: CC-4047|Drug: Prednisone","Number of Participants With Best Overall Response","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0199|NCI-2012-00360","July 22, 2009","May 22, 2018","May 22, 2018","July 24, 2009","June 10, 2019","June 10, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT00946270/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00946270"
554,"NCT00934440","A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma","5-AZ","Terminated","Has Results","Renal Cell Carcinoma","Drug: Bevacizumab|Drug: Azacitidine","Toxicities by Dose Level|Time to Progression","University of Kansas Medical Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","11","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11570","June 2009","November 2015","November 2015","July 8, 2009","June 14, 2017","June 14, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States|Stormont-Vail Cotton O'Neil Cancer Center, Topeka, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00934440"
555,"NCT00901069","Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma",,"Completed","No Results Available","Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin","Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide","Determine the maximal tolerated dose (MTD) of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma","Shams Shakil|Celgene|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-NHL-06-UK/CC","May 2009","January 2012","November 2012","May 13, 2009",,"October 17, 2016","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00901069"
556,"NCT00887068","Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)",,"Completed","No Results Available","Leukemia|AML|MDS","Drug: Azacitidine","Relapse-free survival (RFS) Time","M.D. Anderson Cancer Center|Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","187","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0503|NCI-2012-01259","April 21, 2009","August 20, 2018","August 20, 2018","April 23, 2009",,"August 31, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00887068"
557,"NCT00848328","Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Biological: Rituximab|Drug: Lenalidomide","Response, as defined by complete response (CR), near CR, partial response, or stable disease at 4 months|Time to disease progression|Tolerability (type, frequency, severity, and relationship of adverse events to study treatment as assessed by NCI CTCAE v3.0)|Duration of response|Overall survival","University of California, Davis|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","220942|CDR0000634775|CELGENE-RV-PI-NHL-0163|UCD-197","March 2008","April 2020","April 2020","February 20, 2009",,"June 11, 2019","University of California Davis Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00848328"
558,"NCT00843310","Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma",,"Terminated","Has Results","Multiple Myeloma","Drug: Lenalidomide (Revlimid)|Drug: Melphalan|Drug: Dexamethasone","Toxicity, Time to Progression & Progression Free Survival","NYU Langone Health|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-919|Celgene # RV-MM-PI-289","November 2008","October 2011","October 2011","February 13, 2009","October 18, 2013","July 19, 2017","Bellevue Hospital, New York, New York, United States|NYU Cancer Center, New York, New York, United States|NYU Tisch Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00843310"
559,"NCT00840931","Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)",,"Active, not recruiting","No Results Available","Leukemia","Drug: lenalidomide|Biological: bystander vaccine","Maximum Tolerated Dose (MTD)|Number of Participants with Toxicities|Number of Participants with Augmentation of Specific T Cell Immunological Functions|Number of Participants with Reduction of Bone Marrow Myeloblast|Number of Participants with Improvement of Hemoglobin and/or red blood cell (RBC) Transfusion Independence|Number of Participants with Resolution of Karyotypic Changes|Number of Participants with Augmentation of Other T Cell Parameters|Duration of Response","H. Lee Moffitt Cancer Center and Research Institute|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14998|105861|RV-MDS-PI-202|BB-IND 13478|0803-907","February 2, 2009","February 17, 2014","June 2020","February 11, 2009",,"July 4, 2019","H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00840931"
560,"NCT00840827","Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes",,"Terminated","Has Results","Myelodysplastic Syndrome","Drug: lenalidomide|Drug: cyclosporine A","Efficacy of Lenalidomide in Combination With Cyclosporine A (CSA) to Achieve Red Cell Transfusion Independence in Subjects With Low- or Intermediate-1 Risk IPSS MDS Without a Del (5q31-33) Cytogenetic Abnormality.|Efficacy of Lenalidomide in Combination With Cyclosporine A (CSA) to Achieve Red Cell Transfusion Independence in Subjects With Low- or Intermediate-1 Risk IPSS MDS Without a Del (5q31-33) Cytogenetic Abnormality by Hemoglobin Change.|Safety of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by Type of Adverse Events.|Tolerability of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by Frequency of Adverse Events.|Tolerability of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by Severity of Adverse Events.|Tolerability of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by the Relatedness of Adverse Events.|Safety of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by Frequency of Adverse Events.|Safety of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by Relatedness of Adverse Events to the Combination of Treatments.|Safety of Lenalidomide in Combination With CSA in Subjects With Low- or Intermediate-1 Risk MDS Without a Del (5q31-33) Cytogenetic Abnormality by Severity of Adverse Events.","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0810010063","December 2008","December 2010","December 2010","February 10, 2009","November 19, 2019","November 19, 2019","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00840827"
561,"NCT00831766","Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)",,"Active, not recruiting","Has Results","Myelodysplastic Syndrome|Acute Myeloid Leukemia","Drug: Idarubicin|Drug: Cytarabine|Drug: Lenalidomide (Revlimid®)","Phase I: Recommended Phase II Dose|Phase II: Complete Response Rate of Participants Treated at Maximum Tolerated Dose (MTD)|Rate of Lenalidomide Related Toxicity During Maintenance Therapy|Median Progression-Free Survival (PFS)|Median Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","51","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-15625|RV-AML/MDS-PI-0269","January 22, 2009","February 17, 2015","December 2019","January 29, 2009","March 28, 2016","August 6, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00831766"
562,"NCT00790842","Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction","PrE1003","Terminated","Has Results","Multiple Myeloma|Plasma Cell Neoplasm","Drug: Lenalidomide|Drug: Dexamethasone|Drug: Anticoagulants","Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy|Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]|Overall Survival Time|Duration of Response|Worst Degree Treatment-Related Adverse Events Across All Event Types Per Patient|Renal Function Over Time|Pharmacokinetics of Lenalidomide in Impaired Renal Function|Progression-free Survival","PrECOG, LLC.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","63","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PrE1003|RV-MM-PrECOG-0394","January 21, 2009","September 30, 2017","March 8, 2018","November 14, 2008","October 24, 2018","October 24, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Emory University Winship Cancer, Atlanta, Georgia, United States|University of IL at Chicago, Chicago, Illinois, United States|McFarland Clinic, Ames, Iowa, United States|Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States|Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro MN CCOP, Saint Louis Park, Minnesota, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Reading Hospital and Medical Center, West Reading, Pennsylvania, United States|WVU Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|Waukesha Memorial Hospital (ProHealth Care), Waukesha, Wisconsin, United States|Aurora Cancer Center, Wauwatosa, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT00790842/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT00790842/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00790842"
563,"NCT00751296","Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)","Rev-CLL","Terminated","Has Results","Chronic Lymphocytic Leukaemia","Drug: Lenalidomide","To Assess the Efficacy (Response Rate) of Oral Lenalidomide in the Treatment of Patients With Symptomatic, Previously Untreated, Chronic Lymphocytic Leukemia (CLL)|Percentage of Participants With Progression-free Survival (PFS) and Overall Survival (OS).","University Health Network, Toronto|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rev-06-0099|RV-CLL-PI-0099","August 2006","April 2014","April 2014","September 11, 2008","May 12, 2016","June 16, 2016","University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00751296"
564,"NCT00744536","Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS","REMMYDYS","Completed","No Results Available","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Angiogenesis","Drug: Lenalidomide and melphalan","Overall Response Rate (RR) (as defined by modified international working group standardized response criteria)|Percent with hematologic improvement|Percent with cytogenetic remission|Overall, progression-free and leukemia-free-survival|Percent reduction in baseline biomarkers of angiogenesis including: circulating endothelial cells (CEC) and precursors (CEP), plasma and marrow VEGF and VEGFR 1-2 levels|Safety (type, frequency, severity, and relationship of adverse events to study therapy)","Sunnybrook Health Sciences Centre|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-MDS-PI-128","January 2008","January 2012","December 2012","September 1, 2008",,"June 9, 2017","Sunnybrook Health Sciences Centre, Odette Cancer Center, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00744536"
565,"NCT00671801","Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I",,"Terminated","No Results Available","Malignant Gliomas","Drug: Irinotecan|Drug: Lenalidomide","Maximum Tolerated Dose (MTD) of Lenalidomide and Irinotecan","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0472|NCI-2012-01684","April 29, 2008","February 2014","February 2014","May 5, 2008",,"November 12, 2018","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00671801"
566,"NCT00540644","Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: lenalidomide (Revlimid®)|Drug: Cyclophosphamide|Drug: Prednisone","Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria|Treatment Related Adverse Events Grade 3 or Higher|Quality of Life Using the FACT-G Data","Attaya Suvannasankha|Celgene|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0704-06; IUCRO-0170","October 2007","December 2012","August 2014","October 8, 2007","June 21, 2016","June 21, 2016","Indiana University Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00540644"
567,"NCT00538824","Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma","DexTR","Terminated","Has Results","Multiple Myeloma","Drug: dexamethasone|Drug: thalidomide|Drug: lenalidomide","Effect of Drug Combination on Multiple Myeloma","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0708009381|RV-MM-PI-0132","December 2007","September 22, 2010","September 22, 2010","October 3, 2007","June 8, 2017","June 5, 2018","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00538824"
568,"NCT00538733","Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma","T-BiRD","Active, not recruiting","Has Results","Multiple Myeloma","Drug: thalomid|Drug: lenalidomide|Drug: clarithromycin|Drug: dexamethasone","Effect of Drug Combination on Multiple Myeloma|Median Time to Maximum Response|Event Free Survival|Progression Free Survival","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0707009285|RV-MM-PI-238","October 2007","July 2010","December 2020","October 3, 2007","June 23, 2017","June 11, 2019","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00538733"
569,"NCT00535873","Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older",,"Completed","Has Results","Leukemia|CLL|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: Lenalidomide","Overall Response Rate (ORR)","M.D. Anderson Cancer Center|Celgene","All","65 Years and older   (Older Adult)","Phase 2","61","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0715","October 2007","February 2013","February 2013","September 26, 2007","September 2, 2013","August 21, 2018","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00535873"
570,"NCT00096044","Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",,"Completed","Has Results","Leukemia","Biological: rituximab|Drug: lenalidomide","Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months|Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Combination Therapy of CC-5013+Rituximab|Number of Participants With Adverse Events on Single Agent CC-5013|Number of Participants With Adverse Events on Combination Therapy of CC-5013+Rituximab|Time to Progression for Single Agent CC-5013|Time to Progression for the Combination Therapy of CC-5013+Rituximab","Roswell Park Cancer Institute|Celgene","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000391767|RPCI-I-18103|CELGENE-RV-CLL-PI-005","March 2004","June 2015","June 2015","November 9, 2004","July 11, 2017","July 11, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT00096044"
571,"NCT03941496","Azacytidine During Anti-tuberculosis Therapy","AZA","Not yet recruiting","No Results Available","Tuberculosis, Pulmonary","Drug: Azacitidine Injection [Vidaza] - Phase A Group|Drug: Azacitidine Injection [Vidaza] - Phase B Group|Drug: Azacitidine Injection [Vidaza] - Phase C Group|Drug: Azacitidine Injection [Vidaza] - Phase D Group","Overall incidence of all IP-related adverse events|Overall severity of all IP-related adverse events|Measurement of epigenetic-mediated immune exhaustion","Andrew Dinardo|Celgene Corporation|Baylor College of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-45051","July 2019","July 2021","July 2021","May 8, 2019",,"May 9, 2019","Harris Health System - Ben Taub Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03941496"
572,"NCT00038246","Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma",,"Completed","No Results Available","Prostate Cancer","Drug: Estramustine|Drug: Thalidomide|Drug: Paclitaxel (Taxol)","Maximum tolerated dose (MTD) Thalidomide","M.D. Anderson Cancer Center|Celgene","Male","Child, Adult, Older Adult","Phase 1|Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID00-087","October 2000","February 2004","December 2004","May 30, 2002",,"October 31, 2018","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00038246"
573,"NCT00038181","Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: Thalidomide",,"M.D. Anderson Cancer Center|Celgene","Male","Child, Adult, Older Adult","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID00-089","October 5, 2000","November 29, 2005","November 29, 2005","May 30, 2002",,"November 15, 2018","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00038181"
574,"NCT03744676","A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND - OUTREACH)",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Neoplasms|Neoplasms by Histologic Type|Lymphoproliferative Disorders|Lymphatic Diseases|Immunoproliferative Disorders|Immune System Disorder","Biological: lisocabtagene maraleucel","Adverse events|Adverse Events|Objective response rate (ORR)|Complete response (CR) rate|Duration of response (DOR) and duration of complete response (DoCR)|Progression-free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics- Maximum concentration (Cmax)|Pharmacokinetics- Time of the maximum concentration (Tmax)|Pharmacokinetics- area under the curve|Health-related quality of life questionnaires|Health economics and outcomes research","Juno Therapeutics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017007","November 29, 2018","August 30, 2022","August 30, 2022","November 16, 2018",,"November 14, 2019","Cedars-Sinai Medical Group, Los Angeles, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Advent Health Medical Group Blood & Marrow Transplant at Orlando, Orlando, Florida, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Regional Cancer Center Associates, East Brunswick, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|USOR - New York Oncology Hematology - Albany Cancer Center, Albany, New York, United States|USOR - Oncology Hematology Care - Blue Ash, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Prisma Health Cancer Institute - Eastside Cancer Center, Greenville, South Carolina, United States|Tennessee Oncology - Nashville - Centennial, Nashville, Tennessee, United States|Texas Transplant Institute, San Antonio, Texas, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, United States|USOR - Texas Oncology - Tyler, Tyler, Texas, United States|Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant, Salt Lake City, Utah, United States|USOR - Virginia Oncology Associates, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03744676"
575,"NCT03741933","Apremilast and Moderate to Severe Chronic Hand Dermatitis","CHD","Not yet recruiting","No Results Available","Chronic Hand Dermatitis","Drug: Apremilast 30mg","To evaluate the efficacy of Apremilast 30mg twice daily administered as monotherapy in the treatment of moderate-to-severe CHD as assessed by improvement of the Physician Global Assessment (PGA).|To evaluate the safety and tolerability of Apremilast 30mg twice daily through incidence of adverse events.|To evaluate CHD lesion time to response (TTR) as assessed by Modified Total Lesion Symptom Score (mTLSS).|To evaluate the patient's perception of CHD severity improvement as assessed by the Patient Global Assessment (PaGA).|To evaluate the patient's health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) questionnaire a measurement of the patient's subjective symptoms.","Alison Ehrlich|Celgene Corporation|George Washington University","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP-CL-DERMAT-PI-13069","February 2019","December 2019","March 2020","November 15, 2018",,"January 18, 2019","George Washington University Department of Dermatology, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03741933"
576,"NCT03656666","The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus",,"Recruiting","No Results Available","Lichen Planus of Vulva|Female Genital Disease","Drug: Apremilast|Drug: Placebo","Mean GELP score at week 24 in apremilast-treated patients versus placebo-treated patients|Mean GELP score improvement from week 0 to week 24 in all patients|Weekly use of topical steroid, collected from patient diary|Weekly VAS pain score, collected from patient diary|Number of patients with GELP score improvement at week 16 and 24|Separate GELP score assessments: Area of involvement (in cm²)|Separate GELP score assessments: Intensity of erythema|Separate GELP score assessments: Number of erosions|Separate GELP score assessments: Striae|Separate GELP score assessments: Pressure-induced pain (VAS)|Physician Global Assessment (PGA)|Patient Global Assessment (PtGA)|DLQI score|GHQ-28 score|Sexual function assessments","Oslo University Hospital|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AP-GELP","August 27, 2019","December 1, 2020","December 1, 2020","September 3, 2018",,"September 4, 2019","Oslo University Hospital HF, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT03656666"
577,"NCT03587194","Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis",,"Recruiting","No Results Available","Psoriasis","Drug: Otezla","Psoriasis Area Severity Index 75 at week 12","Psoriasis Treatment Center of Central New Jersey|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP-CL-PSOR-PI-13156","July 23, 2018","July 1, 2019","September 1, 2019","July 16, 2018",,"August 29, 2018","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03587194"
578,"NCT03542266","CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma",,"Recruiting","No Results Available","Previously Untreated Peripheral T-cell Lymphoma","Drug: CC-486 Administration|Drug: CHOP Administration","Complete Response Rate|Overall Survival|Progression-Free Survival","Weill Medical College of Cornell University|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1711018777","June 1, 2018","May 30, 2021","May 30, 2022","May 31, 2018",,"October 8, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03542266"
579,"NCT03507491","Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors",,"Recruiting","No Results Available","Cancer","Drug: Gemcitabine|Drug: Nab-paclitaxel","Maximum dose tolerated of nab-paclitaxel|Toxicity of nab-paclitaxel|Antitumor activity of nab-paclitaxel|Change in secreted protein acidic and rich in cysteine (SPARC) expression|Blood concentrations of paclitaxel","Emory University|Celgene Corporation","All","6 Months to 30 Years   (Child, Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00098777","August 27, 2018","May 2021","May 2022","April 25, 2018",,"August 20, 2019","Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Chilldren's Healthcare of Atlanta, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03507491"
580,"NCT03483103","Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, Nonhodgkin|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse","Biological: lisocabtagene maraleucel","Antitumor activity|Adverse events|Laboratory abnormalities|Maximum concentration (Cmax) of lisocabtagene maraleucel in blood|Time of the maximum concentration (Tmax) of lisocabtagene maraleucel in blood|Area under the curve of (AUC) lisocabtagene maraleucel concentration in blood|Progression-free survival|Event-free survival|Overall survival|Health-related quality of life and health economics and outcomes research","Juno Therapeutics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017006","July 26, 2018","December 30, 2021","December 30, 2021","March 30, 2018",,"October 22, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute - Brownsboro, Louisville, Kentucky, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Regional Cancer Care Associates, East Brunswick, New Jersey, United States|New York Oncology Hematology - Albany Cancer Center, Albany, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System - Cancer Institute - Faris Road, Greenville, South Carolina, United States|Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant, Salt Lake City, Utah, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Medical College of Wisconsin, Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03483103"
581,"NCT03450343","Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Large B-Cell Diffuse Lymphoma","Drug: Oral azacitidine|Drug: R-ICE","Presence or absence of a dose limiting toxicity in the combination of oral azacitadine and R-ICE|Response rate|progression free survival|Adequate peripheral stem cell collection","Medical University of South Carolina|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","102732|OA-CL-DLBCL-PI-13065","April 4, 2019","March 28, 2020","March 28, 2021","March 1, 2018",,"April 8, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03450343"
582,"NCT03430011","Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma","EVOLVE","Recruiting","No Results Available","Multiple Myeloma","Biological: JCARH125","Phase 1: Incidence of dose-limiting toxicities (DLTs)|Phase 1: Incidence and severity of adverse events|Phase 1: Incidence and severity of clinically significant laboratory abnormalities|Phase 2: Overall response rate|Phase 1 and Phase 2: Maximum concentration (Cmax) of JCARH125 in the blood|Phase 1 and Phase 2: Time to maximum concentration (Tmax) of JCARH125 in the blood|Phase 1 and Phase 2: Area under the concentration vs time curve (AUC) of JCARH125 in the blood|Phase 1 and Phase 2: Duration of persistence of JCARH125 CAR T cells in the blood|Phase 1 and Phase 2: Duration of persistence of JCARH125 CAR T cells in the bone marrow|Phase 1: Overall response rate|Phase 1 and Phase 2: Complete response (CR) rate|Phase 2: Duration of response|Phase 2: Duration of CR|Phase 2: incidence and severity of adverse events|Phase 2: Incidence and severity of clinically significant laboratory abnormalities|Phase 2: Overall survival|Phase 2: Progression-free survival|Phase 2: Time to response|Phase 2: Time to CR|Phase 2: Changes in measures of health-related quality of life (HRQoL)|Phase 2: Numbers of days in the intensive care unit (ICU)|Phase 2: Number of non-ICU inpatient days","Juno Therapeutics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H125001","February 1, 2018","March 2021","March 2021","February 12, 2018",,"October 7, 2019","University of Alabama, Birmingham, Alabama, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California, San Francisco, California, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Kansas University Medical Center, Westwood, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03430011"
583,"NCT03331198","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",,"Recruiting","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Small Lymphocytic","Biological: JCAR017 (lisocabtagene maraleucel)|Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib","Phase 1 monotherapy arm: recommended dose|Phase 1 combination therapy arm: adverse events|Phase 1 combination therapy arm: laboratory abnormalities|Phase 2: rate of complete remission (CR)|Phase 2: overall response rate|Phase 2: minimal residual disease (MRD)-negative response rate|Phase 2: adverse events|Phase 2: laboratory abnormalities|Phase 2: overall survival|Phase 2: progression-free survival (PFS)|Phase 2: PK|Phase 2: health economics and outcomes research|Phase 2: health-related quality of life","Juno Therapeutics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017004|TRANSCEND-CLL-004","December 26, 2017","December 1, 2020","March 1, 2022","November 6, 2017",,"November 1, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|The Blood and Marrow Transplant Group of Georgia (BMTGA), Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Seidman Cancer Center (Case Western), Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center (Stephenson Cancer Center), Oklahoma City, Oklahoma, United States|University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03331198"
584,"NCT03239106","A Study Examining the Medication Apremilast as Treatment for Chronic Itch",,"Active, not recruiting","No Results Available","Itch","Drug: Apremilast","Absolute change in NRS itch score form Baseline to Week 16 (end of treatment)|Absolute change in DLQI from Baseline to Week 16|NRS at Screening, Baseline and Weeks 2,4,8,12,16,and 18|DLQI at Screening, Baseline, and Weeks 2,4,8,12,16 and 18","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIP-ApremilastCC-10004","December 1, 2017","December 31, 2019","December 31, 2019","August 3, 2017",,"September 4, 2019","Washington University Division of Dermatology, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03239106"
585,"NCT03196401","A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma",,"Withdrawn","No Results Available","Solitary Bone Plasmacytoma","Drug: Durvalumab|Radiation: Radiation therapy","Response assessment","Memorial Sloan Kettering Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-269","July 27, 2017","June 2020","June 2020","June 22, 2017",,"August 3, 2018","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT03196401"
586,"NCT03191539","Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis","APREMILAST","Unknown status","No Results Available","Arthritis; Psoriasis (Etiology)","Drug: Apremilast","Reduction in the ultrasound index|Disease Activity Score (DAS 28)|Psoriasis activity and severity index (PASI)|Leeds Enthesitis Index (LEI)|Number of tender and swollen joints assessed by (Number of Tender Joints (NTJ) )|Patient Visual Analog Scale (VAS) for pain|Ultrasonic nail injuries|Clinical Disease Activity Index (CDAI)|Simple Disease Activity Index (SDAI)|Number of tender and swollen joints assessed by (Number os swollen joints (NSJ))|doctor Visual Analog Scale (VAS) for pain","Hospital Universitari Vall d'Hebron Research Institute|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSA‐PI‐006421","November 2, 2017","June 14, 2019","June 14, 2019","June 19, 2017",,"October 17, 2017",,,"https://ClinicalTrials.gov/show/NCT03191539"
587,"NCT03160248","An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema","APREMINUM","Recruiting","No Results Available","Nummular Eczema|Eczema|Dermatitis Eczema|Nummular Dermatitis","Drug: Apremilast|Drug: Placebo Oral Tablet","PGA|EASI|Transepidermal Waterloss (TEWL)|Histology|Use of topical steroids|PGA score Arm 2|DLQI|Pruritus Visual Analog Scale (VAS)|TSQM|Safety: Safety of Apremilast will be Assessed by Evaluating Adverse Events (AEs) - Type, frequency, severity, and relationship of the AEs to apremilast","Technische Universität München|Celgene Corporation","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AP-CL-ECZ-PI-006539","July 5, 2017","December 2019","March 2020","May 19, 2017",,"September 18, 2018","Technical University Munich - Department of Dermatology, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT03160248"
588,"NCT02833883","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer|Castration Resistant Prostate Cancer","Drug: Enzalutamide|Drug: CC-115","establish the maximum tolerated dose (MTD)","Memorial Sloan Kettering Cancer Center|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 1","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-074|c15-160","July 2016","July 2020","July 2020","July 14, 2016",,"August 2, 2019","University of California San Francisco, San Francisco, California, United States|John Hopkins Medical Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Washington School of Medicine, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02833883"
589,"NCT02813252","Long-Term Follow-up Study for Patients Previously Treated With JCAR015",,"Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia","Genetic: JCAR015","Proportion of patients with adverse events|Proportion of patients with detectable JCAR015 vector sequences during first 5 years post-treatment|Proportion of patients with detectable JCAR015 vector sequences between 5 and 15 years post-treatment|Survival","Juno Therapeutics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)",,"15","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","015002","August 30, 2016","September 2032","September 2032","June 24, 2016",,"December 7, 2018","City of Hope, Duarte, California, United States|University of California, San Francisco, California, United States|Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02813252"
590,"NCT02799862","Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC","NEPTUN","Active, not recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Nab-Paclitaxel|Drug: Carboplatin","Progression Free Survival (PFS) rate|Median Overall Survival (OS)|Overall Response Rate (ORR)|Safety - Adverse events (AEs)|Patient-reported outcomes on Quality of Life|Rationale for physicians' treatment decision","iOMEDICO AG|Celgene Corporation","All","18 Years to 99 Years   (Adult, Older Adult)",,"408","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOM-110333","August 29, 2016","December 2019","July 2021","June 15, 2016",,"August 8, 2019","iOMEDICO, Freiburg, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT02799862"
591,"NCT02769832","Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer",,"Recruiting","No Results Available","Small Cell Lung Cancer (SCLC)","Drug: Nab-paclitaxel|Drug: Gemcitabine","Response Rate (change at evaluations)|To estimate the time to progression|To estimate the overall survival|To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients.","Muhammad Furqan|Celgene Corporation|University of Iowa","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201512799","August 29, 2016","April 2023","April 2024","May 12, 2016",,"July 23, 2019","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT02769832"
592,"NCT02722954","A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors",,"Completed","No Results Available","Locally Advanced or Metastatic Solid Tumors","Drug: Demcizumab|Drug: Pembrolizumab","Dose limiting toxicities (DLT) of demcizumab given in combination with pembrolizumab|Pharmacokinetics (PK) of demcizumab and pembrolizumab","OncoMed Pharmaceuticals, Inc.|Celgene Corporation","All","21 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M18-008","January 2016","May 10, 2017","May 19, 2017","March 30, 2016",,"April 9, 2018","Rocky Mountain Cancer Center, Denver, Colorado, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The START Center for Cancer Care, San Antonio, Texas, United States|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02722954"
593,"NCT02705638","Treatment of IgG4-Related Disease With Revlimid and Rituximab","TIGR2","Completed","No Results Available","Immunoglobulin G Subclass 4 Related Disease|IgG4-related Disease|Autoimmune Pancreatitis|IgG4-related Sclerosing Cholangitis|Retroperitoneal Fibrosis","Drug: Rituximab|Drug: Lenalidomide","Number of subjects in remission for Immunoglobulin G subclass 4 Related Disease at 24 months","Mayo Clinic|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-003700","April 2016","April 2019","April 2019","March 10, 2016",,"July 8, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02705638"
594,"NCT02661815","A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer",,"Terminated","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma","Drug: Paclitaxel|Drug: Ricolinostat|Drug: Bevacizumab","Analysis Report on the MTD In The Dose Escalation Portion Of The Study|Best Overall Response Measured From, Start Of Treatment To The End|Peripheral Neurotoxicity Assessed Using TNS by Measuring 5 Categories|Duration Of Overall Response, Measured From The Time Measurement Criteria Are Met For PR or CR Until The First Date Recurrent Or Progressive Disease Is Objectively Documented.|Progression-free Survival (PFS)","Dana-Farber Cancer Institute|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-483","June 15, 2016","June 28, 2017","July 28, 2017","January 25, 2016","November 8, 2019","November 8, 2019","Massacusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02661815/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02661815"
595,"NCT02633137","Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma",,"Active, not recruiting","No Results Available","Mantle Cell Lymphoma|Untreated","Drug: Lenalidomide|Drug: R-CHOP|Drug: high-dose cytarabine (HIDAC)","3-year progression-free survival (PFS)","Memorial Sloan Kettering Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-196","December 14, 2015","December 2020","December 2020","December 17, 2015",,"August 8, 2019","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT02633137"
596,"NCT02632708","Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation",,"Active, not recruiting","No Results Available","Newly Diagnosed Acute Myeloid Leukemia (AML)|Untreated AML|AML Arising From Myelodysplastic Syndrome (MDS)|AML Arising From Antecedent Hematologic Disorder (AHD)|AML Arising After Exposure to Genotoxic Injury","Drug: AG-120|Drug: AG-221|Drug: cytarabine|Drug: daunorubicin|Drug: idarubicin|Drug: mitoxantrone|Drug: etoposide","Safety/tolerability of AG-120 and AG-221 when administered with induction and consolidation therapy: incidence of adverse events|Establish the recommended Phase 2 dose (RP2D) of AG-120 and AG-221 when administered with induction and consolidation therapy|Pharmacokinetics of AG-120 and AG-221 in plasma when administered with induction and consolidation therapy|2-hydroxyglutarate (2-HG) levels in plasma|Clinical Activity of AG-120 and AG-221 according to the 2003 revised International Working Group (IWG) criteria for AML","Agios Pharmaceuticals, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","153","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG120-221-C-001","December 31, 2015","December 13, 2018","July 2020","December 17, 2015",,"October 24, 2019","City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Universitatsklinikum Ulm, Ulm, Germany|VU Medisch Centrum, Amsterdam, Noord-Holland, Netherlands|Erasmus MC, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02632708"
597,"NCT02589145","Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype",,"Terminated","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Vorinostat|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Rituximab|Drug: Dexamethasone|Drug: Caphosol|Drug: Glutamine|Drug: Pyridoxine|Drug: Enoxaparin|Procedure: Stem Cell Transplant|Drug: Palifermin","Maximum Tolerated Dose (MTD) of Lenalidomide with Vorinostat, Gemcitabine, Busulfan, Melphalan and Autologous Stem-Cell Transplant z(ASCT)|Event Free Survival of Lenalidomide with Vorinostat, Gemcitabine, Busulfan, Melphalan and Autologous Stem-Cell Transplant (ASCT)","M.D. Anderson Cancer Center|Celgene Corporation","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0558|NCI-2015-01938","June 22, 2016","April 8, 2019","April 8, 2019","October 28, 2015",,"May 29, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02589145"
598,"NCT02573493","Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","APA","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of the Head and Neck|Cancer of Head and Neck|Cancer of the Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck","Drug: nab-Paclitaxel|Drug: Cisplatin|Biological: Cetuximab|Radiation: Intensity-Modulated Radiation Therapy","Arm 1 and Arm 2: Complete response rate as measured by clinical exam at the primary tumor site|Arm 3: Median percent weight loss|Arms 1, 2, and 3: Partial response rate as measured by clinical exam at the primary tumor site|Arms 1, 2 and 3: Complete response rate as measured by clinical exam at the involved regional nodes|Arms 1, 2, and 3: Partial response rate as measured by clinical exam at the involved regional nodes|Arms 1, 2, and 3: Anatomic tumor response as assessed by CT using RECIST 1.0 criteria|Arms 1, 2, and 3: Document and quantify Ki-67 expression by IHC in primary tumor tissue and correlate with clinical primary tumor site response|Arms 1, 2, and 3: Grade 3-4 adverse events as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0|Arms 1, 2, and 3: Overall survival (OS)|Arms 1, 2, and 3: Disease-free survival (DFS)|Arms 1, 2, and 3: Progression-free survival (PFS)|Arms 1, 2, and 3: Quality of life as measured by FACT-H&N and FACT/GOG-NTX-4|Overall survival (OS) rate|Disease-free survival (DFS) rate|Progression-free survival (PFS) rate|Arm 3: Complete response rate as measured by clinical exam at the primary tumor site|Arm 1 and Arm 3: Comparison of response rate|Arm 1 and Arm 3: Comparison of overall survival|Arm 1 and Arm 3: Comparison of disease-free survival|Arm 1 and Arm 3: Comparison of progression-free survival|Arm 1 and Arm 3: Comparison of the rate of grade 3/4 adverse events|Comparison of median absolute weight loss in Arms 2 and 3 to Arm 1|Comparison of median percent weight loss in Arms 2 and 3 to Arm 1","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201510013","April 13, 2016","March 31, 2020","October 31, 2029","October 9, 2015",,"November 20, 2019","The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sanford Cancer Center, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02573493"
599,"NCT02548962","Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma",,"Terminated","Has Results","Multiple Myeloma","Drug: Ibrutinib|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Placebo","Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment|Clinical Benefit Response (CBR)|Duration of Response (DOR)","Pharmacyclics LLC.|Celgene Corporation","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PCYC-1138-CA|PCI-32765","March 2016","June 13, 2018","June 13, 2018","September 14, 2015","April 23, 2019","November 21, 2019","City of Hope, Duarte, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, Czechia|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|'Alexandra' General Hospital of Athens, Athens, Attiki, Greece|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital de La Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Doctor Peset, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02548962/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02548962/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02548962"
600,"NCT02516696","BiRd vs. Rd as Initial Therapy in Multiple Myeloma","BiRd vs Rd","Recruiting","No Results Available","Multiple Myeloma","Drug: Clarithromycin|Drug: Lenalidomide|Drug: Dexamethasone","Survival duration without disease progression|Number of subjects who demonstrate a response to BiRd treatment regimen|Number of adverse events experienced|Overall Survival|Number of months after initiating treatment with BiRd regimen to disease progression, as compared to subjects on Rd treatment regimen.","Weill Medical College of Cornell University|Celgene Corporation","All","65 Years and older   (Older Adult)","Phase 3","320","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1411015662|RV-CL-MM-PI-004078","February 2016","August 2020","August 2021","August 6, 2015",,"October 15, 2019","University of Colorado - Anschutz Cancer Center, Aurora, Colorado, United States|Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02516696"
601,"NCT02512497","Romidepsin Maintenance After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma","Drug: Romidepsin|Drug: Busulfan|Drug: Fludarabine|Procedure: Stem Cell Transplant|Drug: Thymoglobulin","Toxicity of Romidepsin with Busulfan and Fludarabine Conditioning Therapy for Allogeneic Stem Cell Transplantation|Efficacy of Romidepsin with Busulfan and Fludarabine Conditioning Therapy for Allogeneic Stem Cell Transplantation","Ohio State University Comprehensive Cancer Center|Celgene Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-16242|NCI-2015-01555","December 8, 2017","October 31, 2019","October 31, 2019","July 31, 2015",,"July 19, 2019","The Ohio State University Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02512497"
602,"NCT02486601","NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma","FOXAGAST","Recruiting","No Results Available","Cancer of Stomach","Drug: nab-paclitaxel|Drug: FOLFOX","Complete pathological response rate|Disease Free Survival (DFS)|Overall Survival (OS)|Health related to Quality of Life (QoL)|Safety profile of the combination of nab-paclitaxel + FOLFOX regimen assessed by adverse events|Assessment of biomarkers when appropriate|Assessment of genetic polymorphism involved in tumor-response when appropriate","GERCOR - Multidisciplinary Oncology Cooperative Group|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FOXAGAST -D14-1","June 2015","October 2017","June 2022","July 1, 2015",,"February 27, 2019","Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France|Centre Hospitalier Universitaire Henri Mondor, Creteil, France|Centre Léon Bérard, Lyon, France|Hôpital Privé Jean Mermoz, Lyon, France|CHU Pitie-Salpetriere, Paris, France|Hopital Saint Antoine, Paris, France|Institut Mutualiste Montsouris, Paris, France",,"https://ClinicalTrials.gov/show/NCT02486601"
603,"NCT02472691","Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT","AZALENA","Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic","Drug: Lenalidomide|Drug: Azacitidine|Biological: Donor Lymphocyte Infusions","Number of Participants with Adverse Events as a Measure of Safety|Type of Adverse Events as a Measure of Safety|Severity of Adverse Events as a Measure of Safety|Number of participants with responses according to International Working Group (IWG) criteria as a measure of efficacy|Days from the beginning of treatment to best response in individual patients as a measure of efficacy|Number of participants achieving complete donor chimerism as a measure of efficacy|Number of participants with molecular response determined by disease-specific marker (e.g. FISH, mutations like TET2, ASXL1 etc.) or WT1 mRNA expression as a measure of efficay|Days from beginning of remission to relapse as a measure of efficacy|Days from start of treatment until death or last follow up as a measure of efficacy|Number of participants with a positive correlation between response and cytogenetics as a measure of efficacy|Number of participants with acute GvHD according to Glucksberg Criteria as a measure of safety.|Type of manifestations of acute GvHD according to Glucksberg Criteria as a measure of safety.|Severity of acute GvHD manifestations according to Glucksberg Criteria as a measure of safety.|Number of hospitalizations per patients as a measure of safety|Number of participants with Adverse events specifying seriousness and expectedness (AE, SAE, SUSAR) according to ICH-GCP as a measure of safety.|Type of Adverse events specifying seriousness and expectedness (AE, SAE, SUSAR) according to ICH-GCP as a measure of safety.|Severity of Adverse events specifying seriousness and expectedness (AE, SAE, SUSAR) according to ICH-GCP as a measure of safety.|Days from the beginning of treatment to complete donor chimerism as a measure of efficacy|Number of participants with relapse as a meassure of efficacy|Number of participants with chronic GvHD according to NIH Consensus Criteria as a measure of safety.|Type of manifestations of chronic GvHD according to NIH Consensus Criteria as a measure of safety.|Severity of manifestations of chronic GvHD according to NIH Consensus Criteria as a measure of safety.","Heinrich-Heine University, Duesseldorf|Celgene Corporation","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZALENA-2013/RV-MDS-PI-0777","May 2015","September 2020","September 30, 2020","June 16, 2015",,"January 30, 2019","University Hospital Duesseldorf, Dept. of Hematology, Oncology and Clinical Immunology, Duesseldorf, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT02472691"
604,"NCT02405910","Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.",,"Withdrawn","No Results Available","Non-small Cell Lung Cancer","Drug: Nab-paclitaxel|Drug: Gemcitabine","Progression Free Survival|To explore differences in progression free survival (PFS) between two dose combinations of nab-paclitaxel with Gemcitabine in patients with advanced NSCLC.","West Virginia University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WVU020514","March 15, 2015","December 2017","April 2023","April 1, 2015",,"November 6, 2017","West Virginia University Hospitals - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02405910"
605,"NCT02371577","Evaluation of the Immune Restoration Potential Of Lenalidomide","Revlimid","Withdrawn","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: Lenalidomide","Immunoglobulin G level|Treatment-emergent adverse events, including infections|Progression free survival rate at 6 months, determined by International Working Group in CLL (iwCLL) criteria.","University of California, San Diego|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","141671","February 1, 2017","December 2018","December 2020","February 25, 2015",,"April 28, 2017","UC San Diego Moores Cancer Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02371577"
606,"NCT02370888","Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease","UF-BMT-MRD-101","Terminated","No Results Available","Leukemia, Myeloid|Myelodysplastic Syndromes","Drug: Lenalidomide","Maximum tolerated dose (MTD) of lenalidomide|CD34+ mixed chimerism","University of Florida|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WIRB20151509|RV-CL-AML-PI-002987","May 16, 2016","May 31, 2019","May 31, 2019","February 25, 2015",,"August 26, 2019","University of Florida Shands Cancer Center, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02370888"
607,"NCT02347904","Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer","SOX","Completed","No Results Available","Esophageal Cancer","Drug: S-1 and Oxaliplatin","The percentage of patients completing the preplanned number of 6 cycles of SOX.|Percentage of patients completing 6 cycles of S-1 (with or without oxaliplatin)|Dose modifications for S-1|Dose modifications for Oxaliplatin|Dose intensity for S-1|Dose intensity for Oxaliplatin|Toxicity|Disease free survival|Overall survival","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL49889.018.14","December 2014","November 2019","November 2019","January 28, 2015",,"November 18, 2019","Academic Medical Center, Medical Oncology, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02347904"
608,"NCT02302469","Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia","RV-WM-0426","Completed","No Results Available","Waldenstrom Macroglobulinemia","Drug: Revlimid","Number of Participants with dose limiting toxicities (DLT) of lenalidomide as a Measure of Safety and Tolerability.|number of patients with a response to lenalidomide|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Measurements of free light chain assays.|Response duration.|progression free survival","University Hospital, Lille|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008_15/0837|2008-006370-15","March 2009","March 2017","April 2017","November 27, 2014",,"June 7, 2017","Centre Hospitalier de la côte basque, Bayonne, France|Ch Clermond Ferrand, Clermond Ferrand, France|CH LENS, Lens, France|Chru Lille, Lille, France|Ch Nantes, Nantes, France|Groupe hospitalier Pitié Salpétrière, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France",,"https://ClinicalTrials.gov/show/NCT02302469"
609,"NCT02289898","Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma","YOSEMITE","Completed","Has Results","Pancreatic Cancer","Drug: Demcizumab|Drug: Abraxane®|Drug: gemcitabine|Drug: Placebo","Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms","OncoMed Pharmaceuticals, Inc.|Celgene Corporation","All","21 Years and older   (Adult, Older Adult)","Phase 2","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M18-006","April 20, 2015","May 2017","September 2017","November 13, 2014","August 8, 2018","August 8, 2018","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|City of Hope, Duarte, California, United States|Scripps Cancer Center, La Jolla, California, United States|University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States|Soulhern California Permanente Medical Group, San Marcos, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|University of Rochester, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kaiser Permanente NW Oncology Research, Portland, Oregon, United States|Thomas Jefferson University, Sydney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Joe Arrington Cancer Research Treatment Center, Lubbock, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Monash Medical Centre, Moorabbin, Bentleigh East, Victoria, Australia|Western Health (Sunshine Hospitals), St Albans, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|St. John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Hopital Erasme, Brussels, Brussels Capital, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|St Josephs Health Centre, Toronto, Ontario, Canada|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitari Germans Trias i Pujol - lnstituto Catalan d'Oncologia (!CO), Barcelona, Spain|Hospital General Universitario Gregorio Marafi6n, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02289898/SAP_000.pdf|""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02289898/Prot_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02289898"
610,"NCT02273713","The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)","ACTION","Completed","No Results Available","Esophageal Cancer|Toxicity","Drug: Nab-paclitaxel","Dose Limiting Toxicity|Progression Free survival|Adverse events|Response rate|Progression free survival|Neurotoxicity|Overall survival","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","154","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL 49837.018.14","October 2014","March 2017","March 2017","October 24, 2014",,"May 31, 2017","Academic Medical Center, Medical Oncology, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02273713"
611,"NCT02270814","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","CACTUX","Recruiting","No Results Available","Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Head and Neck","Drug: nab-paclitaxel|Drug: Cisplatin|Drug: Carboplatin|Biological: Cetuximab","Progression-free survival (PFS) - with first line therapy|Overall survival (OS)|Overall response rate|Grade 3 and 4 adverse events|Quality of life|Progression-free survival (PFS) - with maintenance therapy|Disease control","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201410073","February 2, 2015","May 31, 2020","June 30, 2020","October 21, 2014",,"May 2, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02270814"
612,"NCT02259582","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer","DENALI","Completed","Has Results","Nonsquamous Nonsmall Cell Neoplasm of Lung","Drug: Pemetrexed|Drug: Carboplatin|Drug: demcizumab","To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms.","OncoMed Pharmaceuticals, Inc.|Celgene Corporation","All","21 Years and older   (Adult, Older Adult)","Phase 2","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M18-007","February 2015","April 7, 2017","April 7, 2017","October 8, 2014","August 20, 2018","August 20, 2018","Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|University of California, San Francisco, San Francisco, California, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Ocala Oncology Center, Ocala, Florida, United States|Edward H. Kaplan MD & Associates, Skokie, Illinois, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Broome Oncology, LLC, Binghamton, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology Oncology Associates of Rockland, Nyack, New York, United States|Gaston Hematology & Oncology, Gastonia, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|Compass Oncology, Vancouver, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|North Coast Cancer Institute Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Royall Brisbane & Women's Hospital, Herston, Queensland, Australia|Icon Cancer Foundation, Milton, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Monash Health, Monash Cancer Centre-Moorabbin, Bentleigh East, Victoria, Australia|St. John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Ziekenhuisnetwerk Antwerpen- Koningin Paola Kinderzickenhuis, Antwerpen, Belgium|Grand Hopital de Charleroi- Site Notre-Dame, Charleroi, Belgium|Centre Hospitalier Jolimont-Lobbes, La Louviere, Belgium|CHR de Ia Citadelle, Liege, Belgium|Azienda Ospedaliera Istituti Ospitalieri, Cremona, Lombardia, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Smilow Cancer Hospital at Yale-New Haven, Aviano, Pordenone, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Nuestra Senora de Sonsoles, Avila, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Institute Catalan de Oncologia (ICO L'Hospitalet), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Madrid Universitario Sanchinarro, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02259582/SAP_000.pdf|""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02259582/Prot_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02259582"
613,"NCT02255162","Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML",,"Terminated","No Results Available","Acute Myeloid Leukemia (AML)|Acute Myelocytic Leukemia|Acute Myelogenous Leukemia|Acute Granulocytic Leukemia|Acute Non-Lymphocytic Leukemia","Drug: Lenalidomide|Genetic: HLA-mismatched stem-cell Microtransplantation|Drug: Cytarabine","Maximum Tolerated Dose (MTD) of lenalidomide after microtransplantation|Disease Free Survival|Overall Survival|To assess immunomodulatory effects of this combination through measurement of T cell subsets by flow cytometric techniques and through microchimerism analysis at multiple points on study|To identify incidence and severity of acute and chronic graft versus host disease (GVHD).|To detect and categorize, according to severity, the cumulative incidences of toxicities","Massachusetts General Hospital|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-265","January 2015","December 2016","December 2016","October 2, 2014",,"August 18, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02255162"
614,"NCT02218346","Food Effect Study of AG-221 in Healthy Male Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: AG221","Pharmacokinetic (PK) profile of AG-221|Incidence of adverse events","Agios Pharmaceuticals, Inc.|Celgene Corporation","Male","18 Years to 56 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG221-C-002","August 2014","December 2014","March 2015","August 18, 2014",,"December 14, 2015","Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02218346"
615,"NCT02188368","Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients",,"Recruiting","No Results Available","Multiple Myeloma","Drug: POM|Drug: Steroids|Drug: PLD|Drug: CFZ|Drug: BTZ|Drug: CLA|Drug: Other drugs|Drug: CY","Maximum Tolerated Dose (MTD)|Number of subjects with adverse events|Overall Response Rate|Clinical Benefit Rate (CBR)|Time to Progression|Progression-free survival (PFS)|Time to first response (TTP)|Duration of response (DOR)|Overall survival (OS)","Oncotherapeutics|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PO-CL-MM-PI-003854","August 2014","December 2019","December 2019","July 11, 2014",,"August 27, 2019","California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Fountain Valley, California, United States|Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States|Inland Hematology Oncology Medical Group, Inc, San Bernardino, California, United States|Wellness Oncology and Hematology, West Hills, California, United States|James R. Berenson, MD, Inc., West Hollywood, California, United States|VA Sierra Nevada, Reno, Nevada, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Gabrail Cancer Center, Canton, Ohio, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Wellmont Medical Associates Oncology and Hematology, Kingsport, Tennessee, United States|Vista Oncology, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02188368"
616,"NCT02181634","Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma","PrE0204","Completed","Has Results","Cholangiocarcinoma","Drug: Nab-Paclitaxel and Gemcitabine","Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months)|Overall Survival (OS)|Progression-free Survival (PFS)|Time To Progression (TTP)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Association Between PFS and Maximum Change in Carbohydrate Antigen (CA) 19-9 From Baseline|Association Between OS and Maximum Change in Carbohydrate Antigen (CA) 19-9 From Baseline","PrECOG, LLC.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PrE0204|AX-CL-OTHER-PrECOG-004080|2015-002066-24","December 9, 2014","September 24, 2016","October 1, 2017","July 4, 2014","May 28, 2018","October 3, 2018","Colorado Cancer Research Program, Denver, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Siouxland Hematology-Oncology Associates, Sioux City, Iowa, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|University Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Metro Minnesota CCOP, Saint Louis Park, Minnesota, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pennsylvania; Abramson Cancer Center at Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Gundersen Health System, La Crosse, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Aurora Cancer Care, Wauwatosa, Wisconsin, United States|Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02181634"
617,"NCT02176213","Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma in Relapse|Multiple Myeloma, Refractory","Drug: Pomalidomide|Drug: Cyclophosphamide|Drug: Dexamethasone","Best overall response rate (ORR)|Stringent complete response (sCR)|Complete response (CR)|Very good partial response (VGPR)|Partial response (PR)|Time to progression (TTP)|Duration of response (DOR)|Clinical benefit response (CBR)|Progression free survival (PFS)|Overall survival (OS)","Ajai Chari|Celgene Corporation|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 14-0825|PO-CL-MM-PI-002404","June 2014","May 7, 2019","May 7, 2019","June 27, 2014",,"June 18, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02176213"
618,"NCT02142049","Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma",,"Completed","Has Results","Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory","Drug: Ibrutinib|Drug: DA-EPOCH-R|Drug: Lenalidomide","Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability|Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR|Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy|Number of Subjects With Adverse Events as a Measure of Safety and Tolerability|Progression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy|Duration of Response (DOR)","Pharmacyclics LLC.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1124-CA","May 2014","August 2017","August 2017","May 20, 2014","February 5, 2019","February 5, 2019","SITE-1, Duarte, California, United States|SITE-2, Los Angeles, California, United States|SITE-10, Orange, California, United States|SITE-3, Chicago, Illinois, United States|SITE-5, Baltimore, Maryland, United States|SITE-6, Bethesda, Maryland, United States|SITE-4, Ann Arbor, Michigan, United States|SITE-8, Albuquerque, New Mexico, United States|SITE-9, Stony Brook, New York, United States|SITE-7, Charleston, South Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02142049/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02142049/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02142049"
619,"NCT02141828","A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene",,"Completed","No Results Available","Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Leukemias","Drug: EPZ-5676","Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676.|To assess the safety and tolerability of EPZ-5676 administered as a continuous intravenous (CIV) infusion|Determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPZ-5676|Evaluate early evidence of anti-tumor activity","Epizyme, Inc.|Celgene Corporation","All","3 Months to 18 Years   (Child, Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPZ-5676-12-002","May 2014","May 2016","June 2016","May 20, 2014",,"August 3, 2016","Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Emory Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Hospital for Sick Kids, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02141828"
620,"NCT02106884","Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel","QOLINPAC","Completed","Has Results","Pancreatic Cancer","Drug: Nab-paclitaxel|Drug: Gemcitabine","Deterioration-free Survival Rate of the QOL Global Health Status at 3, 6 and 12 Months (Mos)|QOL Global Health Status Deterioration-free Median Survival|Overall Response|Duration of Response (in Responders)|Disease Control|Progression Free Survival|Overall Survival|Laboratory Safety Assessment","Universitaire Ziekenhuizen Leuven|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s56122|2013-004101-75|AX-CL-PANC-PI-003568","April 2014","April 29, 2019","April 29, 2019","April 8, 2014","October 24, 2019","November 6, 2019","OLV Ziekenhuis Aalst, Aalst, Belgium|AZ Klina, Brasschaat, Belgium|AZ St Lucas, Brugge, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|CHU de Charleroi, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|AZ Maria Middelares, Gent, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHC St Joseph, Liege, Belgium|CHR Citadelle, Liege, Belgium|CHU Sart-Tilman, Liege, Belgium|Heilig Hartziekenhuis Lier, Lier, Belgium|AZ Sint Maarten, Mechelen, Belgium|Clinique St Elisabeth, Namur, Belgium|AZ Delta, Roeselare, Belgium|AZ Turnhout, Turnhout, Belgium","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02106884/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02106884"
621,"NCT02092116","Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV‐1 Reservoir","REDUC","Completed","Has Results","HIV I Infection","Drug: Romidepsin|Biological: Vacc-4x|Biological: rhuGM-CSF","Part A: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Part B: Changes From Baseline in HIV-1 Reservoir (Total HIV-1DNA; Integrated HIV-1 DNA in Unfractionated CD4+ T Cells and Replication Competent Provirus.|Part A: Changes From Baseline in HIV-1 Reservoir (Total HIV-1DNA; Integrated HIV-1 DNA in Unfractionated CD4+ T Cells and Replication Competent Provirus. Estimates of Change From Baseline of the Size of the Latent HIV-1 Reservoir in CD4+ Cells.|Part B: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Part B: Level of HIV-1 Transcription.","Bionor Immuno AS|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BPC01-001|2013-004747-23","March 2014","August 2015","December 2015","March 19, 2014","March 1, 2017","March 1, 2017","Aarhus University Hospital, Skejby Sygehus, Aarhus N, Denmark",,"https://ClinicalTrials.gov/show/NCT02092116"
622,"NCT02076243","Treatment With Nab-paclitaxel in Cutaneous SCC",,"Terminated","Has Results","Cutaneous Squamous Cell Carcinoma","Drug: nab-paclitaxel","Response Rate|Median Progression Free Survival|Prevalence of SPARC Expression|Treatment Response|Safety and Tolerability","Icahn School of Medicine at Mount Sinai|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-1697","March 2014","October 2015","October 2015","March 3, 2014","October 25, 2017","October 25, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02076243"
623,"NCT02075021","Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma","rev/abraxane","Terminated","Has Results","Relapsed or Refractory Multiple Myeloma","Drug: Lenalidomide|Drug: nab-paclitaxel","Maximum Tolerated Dose (Phase I)|the Number of Patients Who Achieve Complete Response (CR) or Partial Response (PR) (Phase II)","NYU Langone Health|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-02519","March 2014","November 2015","November 2015","March 3, 2014","September 5, 2017","October 15, 2018","NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02075021"
624,"NCT02066454","Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs","MYELAXAT","Unknown status","No Results Available","Myeloma|Venous Thromboembolism","Drug: Apixaban","Total VTE and VTE-related death. Major and clinically relevant non major bleeding - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis|incidence of venous thromboembolic complications|incidence of major and clinically relevant non major bleeding|incidence of arterial cardiovascular events","University Hospital, Grenoble|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","105","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCIC 1320|2013-003190-99","April 2014","January 2017","July 2017","February 19, 2014",,"December 9, 2014","CHRA, Annecy, France|Ch La Cote Basque, Bayonne, France|Hia Percy, Clamart, France|Chu Hopital Henri Mondor, Creteil, France|Centre Hospitalier, Dunkerque, France|Chu Grenoble, Grenoble, France|Chd Vendee, La Roche Sur Yon, France|Clinique Victor Hugo, Le Mans, France|Hopital St Vincent - Ghicl, Lille, France|Chru Hopital Huriez, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Du Havre, Montivilliers, France|Hopital de L'Archet, Nice, France|Hopital Pitie Salpetriere, Paris, France|Ch de Perigueux, Perigueux, France|Chu Bordeaux, Pessac, France|Ch Lyon Sud, Pierre Benite, France|Chu Poitiers, Poitiers, France|Chru de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02066454"
625,"NCT02060656","Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","LEGEND","Active, not recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Gemcitabine|Drug: Methylprednisolone|Drug: Rituximab|Drug: Cisplatin|Drug: Lenalidomide","Complete response rate (CRR)|Overall Response Rate|Event-free Survival|Overall Survival|Rates of successful stem cell harvest","Royal Marsden NHS Foundation Trust|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMH CCR: 3862|2012-002620-32","September 2013","February 2018","August 2023","February 12, 2014",,"September 19, 2019","Royal Marsden NHS Foundation Trust - London and Surrey, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02060656"
626,"NCT01985477","Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma",,"Terminated","No Results Available","Myeloma","Drug: Lenalidomide|Drug: Dexamethasone|Drug: All-Trans Retinoic Acid (ATRA)","Maximum Tolerated Dose (MTD) of Lenalidomide/Dexamethasone and All-Trans Retinoic Acid (ATRA)|Objective Response","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0624|NCI-2014-01098","December 2013","September 2015","September 2015","November 15, 2013",,"September 14, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01985477"
627,"NCT01979276","Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma","Romi Poma","Terminated","Has Results","Multiple Myeloma","Drug: Romidepsin|Drug: pomalidomide|Drug: Dexamethasone","Maximum Tolerated Dose (MTD) of Romidepsin in Combination With Pomalidomide and Dexamethasone|Efficacy of Study Regimen Combination|Time to Disease Progression (Progression Free Survival)","Weill Medical College of Cornell University|Celgene Corporation","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1306014005","November 2013","October 2016","October 2016","November 8, 2013","January 31, 2018","June 5, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01979276"
628,"NCT01964534","Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer","AFUGEM","Unknown status","No Results Available","Metastatic Pancreatic Cancer","Drug: ABI-007|Drug: Gemcitabine|Drug: simplified LV5FU2","Progression-free survival (PFS)|Tumor Response Rate|Duration of disease control (DDC)|Overall Survival|Quality of life|Number of Adverse Events","GERCOR - Multidisciplinary Oncology Cooperative Group|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFUGEM D12-2|2013-001463-23","December 12, 2013","February 2017","July 2017","October 17, 2013",,"January 31, 2017","Institut de cancérologie de l'Ouest - Paul Papin, Angers, France|Institut Sainte Catherine, Avignon, France|Hôpital Avicenne, Bobigny, France|Hôpital Beaujon, Clichy, France|Hôpital Henri Mondor, Créteil, France|Hôpital Privé Jean Mermoz, Lyon, France|CHU la Timone, Marseille, France|Centre Hospitalier Layné, Mont de Marsan, France|Hôpital Européen Georges Pompidou, Paris, France|Hôpital Pitié-Salpêtrière, Paris, France|Hôpital Saint Antoine, Paris, France|Institut Mutualiste Montsouris, Paris, France|CHU de Reims Hôpital Robert Debré, Reims, France|Institut de Cancérologie de l'Ouest - Réné Gauducheau, Saint Herblain, France|Hôpital Trousseau - CHRU Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01964534"
629,"NCT01938833","Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer",,"Terminated","Has Results","HER2-negative Breast Cancer|Inflammatory Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer","Drug: Romidepsin|Drug: Abraxane","Maximum-Tolerated Dose of Romidepsin (Phase I)|Progression-Free Survival (PFS)|Incidence of Adverse Events, Graded According to NCI CTCAE Version 4.0|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Celgene Corporation|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13C.387|2013-035","April 2014","August 18, 2016","December 8, 2016","September 10, 2013","September 29, 2017","December 28, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01938833"
630,"NCT01927718","Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)",,"Terminated","Has Results","Myeloma","Drug: Thalidomide|Drug: Lenalidomide|Behavioral: Questionnaires","Number of Participants With Response","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0806|NCI-2014-00157","January 2014","November 2016","November 2016","August 23, 2013","April 29, 2019","April 29, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01927718"
631,"NCT01924169","Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)",,"Terminated","Has Results","Hematologic Disorder","Drug: Lenalidomide|Biological: Influenza Vaccine|Biological: Pneumovax Vaccine","Number of Participants With IgG Response|Seroconversion Response","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2013-0371|NCI-2014-01058","November 24, 2014","February 21, 2017","February 21, 2017","August 16, 2013","March 27, 2018","September 20, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01924169/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01924169/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01924169"
632,"NCT01913119","A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma","Ro-ENKTL","Completed","No Results Available","Histologically Proven Extranodal NKTcell Lymphoma","Drug: Romidepsin","Rate of overall disease control including CR, PR, and SD|Number of participants with adverse events|Time to progression|overall survival","Samsung Medical Center|Celgene Corporation","All","20 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-10-059","July 2013","July 2013","July 2013","July 31, 2013",,"July 31, 2013","National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Korea Cancer Center Hospital, Nowon-gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01913119"
633,"NCT01902225","Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma|T-Cell Lymphoma|Cutaneous Lymphoma","Drug: Istodax|Drug: Doxil","Maximum Tolerated Dose|Complete response (CR) rate|Overall response rate (CR + PR)|Time to response (TTR)|Duration of response (DOR)|Time to progression (TTP)|Changes in degree of pruritus|Quality of life during therapy|Changes in skin related symptoms","Weiyun Ai|Celgene Corporation|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112516|NCI-2014-01722","March 4, 2014","July 11, 2018","April 1, 2020","July 18, 2013",,"August 13, 2019","University of California, San Francisco, San Francisco, California, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01902225"
634,"NCT01874223","Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)",,"Unknown status","No Results Available","Interstitial Lung Disease|Idiopathic Pulmonary Fibrosis",,"Correlation of LCQ scores with physiologic markers of IPF severity","Stanford University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","23346","June 2013","June 2015","September 2015","June 10, 2013",,"June 10, 2013","Stanford University Medical Center, Chest Clinic, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01874223"
635,"NCT01829568","Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma",,"Active, not recruiting","No Results Available","Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Pharmacological Study|Biological: Rituximab","Maximally tolerated dose (MTD) of lenalidomide and ibrutinib for combination with rituximab, determined by dose-limiting toxicities (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Toxicities by attribute and grade, assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Complete response rate|Overall response rate|Progression-free survival (PFS)|Overall survival (OS)","National Cancer Institute (NCI)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-00792|A051103|CALGB-A051103|U10CA180821|U10CA031946","June 21, 2013","May 11, 2015",,"April 11, 2013",,"November 19, 2019","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01829568"
636,"NCT01816620","Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome",,"Completed","No Results Available","POEMS Syndrome","Drug: Lenalidomide, Dexamethasone","Hematological response rate|Neurological response rate defined by ONLS score|response rate of critical organs|Response rate of serum vascular endothelial growth factor (VEGF) level|Time to initial neurological response|Overall survival|Relapse free survival|adverse events|time to the best neurological response","Peking Union Medical College Hospital|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POEMS-01","March 2014","October 2015","April 2017","March 22, 2013",,"April 25, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01816620"
637,"NCT01794169","Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML",,"Terminated","No Results Available","Acute Myeloid Leukemia","Drug: Azacitidine|Drug: DA","Leukemia free survival|Overall survival|Treatment related morbidity and mortality|Severe Adverse Events (SAE)|Number of days admitted in hospital|Quality of life|Number of participants with AE grade 3 or more|Number of consolidation courses actually given within the study","Karolinska University Hospital|Celgene Corporation","All","65 Years and older   (Older Adult)","Phase 2","130","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SWEAML12-a","March 2013","September 2015","March 2018","February 18, 2013",,"September 22, 2015","Karolinska University Hospital, Solna, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01794169"
638,"NCT01779167","Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia","THRiL for WM","Terminated","Has Results","Waldenstrom Macroglobulinemia","Drug: Thalidomide|Drug: Lenalidomide|Drug: Rituximab","Number of Patients Who Demonstrate a Response (Complete, Partial, Minor) to Treatment|Number of Adverse Events Experienced With Alternating Thalidomide and Lenalidomide Plus Rituximab for Subjects With Previously Treated Waldenstrom's Macroglobulinemia|Survival of Subjects Treated With THRiL for WM.|Rate of Rituximab Related IgM Flare|Time to Response|Response Duration of Subjects Treated With THRiL for WM","Weill Medical College of Cornell University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1112012086|RV-WM-PI-0690","June 2012","October 2013","April 2014","January 30, 2013","April 7, 2017","July 11, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01779167"
639,"NCT01766583","A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma","CLEAR","Completed","No Results Available","Relapsed/Refractory B-cell Lymphoma","Drug: CC-292 + lenalidomide","Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma|preliminary efficacy signals of the CC-292 + Lenalidomide combination|Observed maximum plasma concentration|time to reach maximum observed plasma concentration (Tmax)|Terminal phase rate constant (λz)|plasma decay half-life (t1/2)|Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)]|Area under the curve from time zero to extrapolated infinity [AUC(0-∞)]|BTk receptor occupancy","The Lymphoma Academic Research Organisation|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEAR","February 2013","November 2014","January 2018","January 11, 2013",,"March 7, 2018","Hopital henri mondor, Créteil, France|CHU de Lille, Lille, France|Institut Paoli Calmette, Marseille, France|CHU de Nantes, Nantes, France|CHU Lyon Sud, Pierre Bénite, France|CHU de Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01766583"
640,"NCT01745640","Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)","IFM2010-02","Completed","No Results Available","Multiple Myeloma","Drug: POMALIDOMIDE|Drug: Dexamethasone","Time to disease progression (from the date of the first dose to the date of the first observation of disease progression)|Safety of pomalidomide and dexamethasone|Overall Response rate (Partial Response and better), Very Good Partial Response (VGPR) + Complete Response (CR) rate and stringent Complete Response (sCR) rate to pomalidomide and dexamethasone in MM patients|Time to response and Response duration of pomalidomide and dexamethasone.|Overall Survival of pomalidomide and dexamethasone and event free survival|Response and Time to disease progression with regards to cytogenetic abnormalities in the bone marrow tumor plasma cells","University Hospital, Lille|Celgene Corporation","All","19 Years and older   (Adult, Older Adult)","Phase 2","63","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010_52|2011-002081-20","January 2012","December 2015","December 2015","December 10, 2012",,"December 4, 2015","CHRU-Hôpital Sud Amiens, Amiens, France|Chru Caen, Caen, France|CHU DIJON, Hôpital d'Enfants, Dijon, France|CHRU, Hôpital A.Michallon, Grenoble, France|Centre hospitalier départemental La Roche sur Yon, La Roche sur Yon, France|Chru Lille, Lille, France|Institut Paoli Calmette,, Marseille, France|CHRU, Hôtel Dieu, Nantes, France|Hôpital Saint-Louis, Paris, France|CHU - Hôpital St Antoine,, Paris, France|Hôpital Haut-Leveque, PESSAC cedex, France|Centre Hospitalier Lyon Sud -1, Pierre Benite, France|Centre Hospitalier Lyon Sud -2, Pierre Benite, France|CHRU POITIERS-Hôpital Jean Bernard, Poitiers, France|Hôpital Robert Debré, CHU Reims, Reims, France|CHRU RENNES 2, Hôpital Pontchaillou, Rennes, France|CHRU RENNES 1, Hôpital Sud, Rennes, France|CHRU, Hôpital Purpan, Toulouse, France|CHRU- Hôpital Bretonneau, Tours, France|CHRU, Hôpitaux de Brabois, Vandoeuvre, France",,"https://ClinicalTrials.gov/show/NCT01745640"
641,"NCT01723839","Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide","FCR","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide","Complete Response|Overall Response Rate","Hackensack Meridian Health|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00002262 RV-CLL-PI-0530","February 22, 2012","December 2019","December 2019","November 8, 2012",,"October 7, 2019","John Theurer Cancer Center at HackensackUMC, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01723839"
642,"NCT01715142","Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer","NEOPAX-001","Unknown status","No Results Available","Pancreatic Adenocarcinoma Resectable|Pancreatic Adenocarcinoma Locally Advanced|Pancreatic Adenocarcinoma Metastatic","Drug: Gemcitabine|Drug: Abraxane","Dynamic tumor response rate as defined by a 40% modification of tumoral perfusion and cellular density parameters.|Number of participants with adverse events as assessed by National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0.","Jean-Luc Van Laethem|Celgene Corporation|Erasme University Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003592-19","December 2012","June 2014","September 2015","October 26, 2012",,"October 26, 2012","Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium|Erasme University Hospital (ULB), Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT01715142"
643,"NCT01704781","Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)","IMID","Completed","Has Results","HIV-1 Infection","Drug: Lenalidomide|Drug: Lenalidomide placebo|Drug: Vacc-4X|Drug: rhuGM-CSF","Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity|Part A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over Time|Part B: Change in CD4 Count|Part B: Change in CD8 Count|Part B: Evaluate the Effect on HIV Viral Load|Part B: Incidents of Delayed-type Hypersensitivity|Part A and B: Safety and Tolerability","Bionor Immuno AS|Celgene Corporation","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CT-BI Vacc-4x/IMiD-2010/1","September 2012","August 2014","August 2014","October 11, 2012","March 8, 2017","March 8, 2017","EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125, Berlin, Germany|Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1, Berlin, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Klinik I für Innere Medizin Klinikum Der Universität zu Köln, Köln, Germany",,"https://ClinicalTrials.gov/show/NCT01704781"
644,"NCT01675141","Lenalidomide Maintenance Therapy for Multiple Myeloma",,"Terminated","Has Results","Multiple Myeloma","Drug: Lenalidomide","Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts|Number of Participants With Serious and Non-serious Adverse Events|Duration of Response|Progression Free Survival (PFS)|Natural Killer (NK) Cell Function and Activity|Changes in B Cell Subsets, Myeloid Derived Suppressor Cells and T Regulatory Cells by Phenotypic Analysis During the Course of Therapy|Expression of Cereblon (CRBN) and How it Relates to Natural Killer (NK) Cell Number and Activity","National Cancer Institute (NCI)|Celgene Corporation|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","11","NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120192|12-C-0192","August 20, 2012","May 5, 2016","March 10, 2017","August 29, 2012","May 12, 2017","February 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01675141/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01675141/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01675141"
645,"NCT01652781","5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome",,"Unknown status","No Results Available","Myelodysplastic Syndrome","Drug: Azacitidine","Overall response rate by modified IWG 2006 response criteria|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Cytogenetic response rate by IWG 2006 response criteria","Seoul St. Mary's Hospital|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VZ-MDS-PI-0267","March 2012","June 2016","December 2016","July 30, 2012",,"November 20, 2015","Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01652781"
646,"NCT01650701","A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","RELEVANCE","Active, not recruiting","No Results Available","Follicular Lymphoma","Drug: Rituximab|Drug: Lenalidomide|Drug: Rituximab - CHOP|Drug: Rituximab - CVP|Drug: Rituximab - Bendamustine","COMPLETE RESPONSE RATE|Progression Free Survival (PFS)|Number of participants with adverse events|Time to Treatment Failure (TTF)|Event Free Survival (EFS)|Time to Next Anti-Lymphoma Treatment (TTNLT),|Time to Next Chemotherapy Treatment (TTNCT)|Overall Survival (OS)|Overall response rate at 120 weeks by International Working Group (IWG) 1999 criteria|Health related quality of life as measured by the EORTC QLQ-C30","The Lymphoma Academic Research Organisation|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","1030","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-FOL-GELARC-0683|2011-002792-42","February 2012","December 2023","September 2024","July 26, 2012",,"April 22, 2019","Concord Repatriation General Hospital, Concord, New South Wales, Australia|Nepean Hospital, Penrith, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|CHU Mont-Godinne, Yvoir, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Moncton Hospital, Moncton, New Brunswick, Canada|Atlantic Health Sciences Corp - Saint John Regional Hospital, Halifax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|UHN-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada|Hôpital de l'Enfant-Jesus, CHU de Quebec, Quebec city, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|CHU Claude Huriez, Lille, France|Medizinische Klinik der Universität Tübingen, Tübingen, Baden Wurtemberg, Germany|Uniklinik Köln, Köln, Nordrhein, Germany|LMU Munchën - Klinikum Grosshadern, Munchen, Germany|Sant'Andrea Hospital, Roma, Lazio, Italy|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Instituto Português Oncologia, Lisboa, Portugal|Hospital Virgen del Rocio, Sevilla, Andaloucia, Spain|Hospital Universitario Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain|Hospital Son Llatzer, Palma, Mallorca, Spain|Hospital Clínico de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Spain|Institut Català d'Oncologia de Girona (ICO Girona), Girona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01650701"
647,"NCT01638533","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",,"Active, not recruiting","No Results Available","Glioma|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Solid Neoplasm","Other: Pharmacological Study|Drug: Romidepsin","Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0|Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0|Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method|Child-Pugh classification of hepatic dysfunction|Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria","National Cancer Institute (NCI)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","38","NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01040|CDR0000737061|NCI-2013-01545|J11105|NA_00052587|9008|U01CA132123|U01CA062505|U01CA069912|U01CA070095|UM1CA186644|UM1CA186686|UM1CA186689|UM1CA186690|UM1CA186691|UM1CA186716|UM1CA186717|ZIABC011078","June 12, 2012","November 29, 2018",,"July 11, 2012",,"November 19, 2019","City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Case Western Reserve University, Cleveland, Ohio, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01638533"
648,"NCT01629082","Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia",,"Completed","No Results Available","Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML)","Drug: Clofarabine|Drug: Lenalidomide","Identification of the maximum tolerated dose.|Overall Survival|Characterization of response rate and duration|Feasibility of lenalidomide maintenance therapy","National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","4","NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120146|12-H-0146","June 6, 2012","October 27, 2015","June 27, 2018","June 27, 2012",,"November 20, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01629082"
649,"NCT01600053","Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia",,"Terminated","Has Results","Chronic Lymphocytic Leukemia","Drug: Lenalidomide","Eradication of Residual Disease From the Marrow|Recording of the Occurrence of Adverse Events","Thomas Kipps|Celgene Corporation|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101955","November 2011","May 2014","May 2014","May 16, 2012","December 15, 2016","December 15, 2016","Moores UCSD Cancer Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01600053"
650,"NCT01570387","A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis",,"Active, not recruiting","No Results Available","AL Amyloidosis","Drug: Pomalidomide|Drug: Dexamethasone","Determining dose-limiting toxicity and maximal tolerated dosage|Response to the maximal tolerated dose","Vaishali Sanchorawala|Celgene Corporation|Boston Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-31082|PO-AMYL-PI-0024","June 2012","November 2018","February 2030","April 4, 2012",,"January 4, 2019","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01570387"
651,"NCT01553357","Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia",,"Completed","No Results Available","Primary Plasma Cell Leukemia","Drug: Lenalidomide, dexamethasone","Overall response rate|Complete remission rate|At least Very good partial remission rate|Progression free survival|Overall survival|Percentage of patients able to perform stem cell transplantation|Safety","IRCCS Centro di Riferimento Oncologico della Basilicata|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CROB0108/1 -- RV-PCL-PI-350|2008-003246-28","March 2009","August 2011","September 2011","March 14, 2012",,"March 14, 2012","IRCCS - CROB Ethic Committee, Rionero in Vulture, Pz, Italy",,"https://ClinicalTrials.gov/show/NCT01553357"
652,"NCT01541332","Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Pegylated Liposomal Doxorubicin (PLD)|Drug: Dexamethasone","MTD of Pomalidomide|Overall Response Rate|Number of Patients with Adverse Events|Time to Progression|Progression-free Survival|Time to First Response|Duration of Response|Overall Survival","Oncotherapeutics|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PO-MM-PI-0049|PDD-2011","February 2012","December 2016","December 2016","February 29, 2012",,"March 10, 2016","Roy and Patricia Disney Family Cancer Center, Burbank, California, United States|California Cancer Associates for Research and Excellence, Encinitas, California, United States|Hematology Oncology Medical Group, Fresno, California, United States|Pacific Cancer Care, Salinas, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Mission Hope Cancer Center, Santa Maria, California, United States|James R Berenson, MD, Inc., West Hollywood, California, United States|Illinois Cancer Specialists, Niles, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01541332"
653,"NCT01537744","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma",,"Completed","No Results Available","Solid Tumors|Virally Mediated Cancers and Liposarcoma","Drug: oral 5-azacitidine in combination with romidepsin","Incidence of adverse events|Maximum Tolerated Dose (MTD)|Clinical responses associated with oral 5-azacitidine and romidepsin|Peak plasma concentration (Cmax)|Determine whether changes in DNA methylation, histone acetylation, and/or gene expression correlates with clinical response to oral 5-azacitidine and romidepsin","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J11102|NA_00052054","February 2012","March 2016","September 2016","February 23, 2012",,"March 24, 2017","Sidney Kimmel Cancer Center @ Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01537744"
654,"NCT01465230","Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia",,"Terminated","Has Results","Chronic Lymphocytic Leukemia","Drug: Maintenance lenalidomide","Response Rate","Yale University|Celgene Corporation","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1105008515","March 2012","November 2013","November 2013","November 4, 2011","October 23, 2014","October 23, 2014","Yale Cancer Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01465230"
655,"NCT01460498","Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)",,"Completed","No Results Available","Leukemia","Drug: Azacitidine (AZA)|Drug: Tyrosine kinase inhibitor (TKI)|Drug: Azacitidine","Maximum Tolerated Dose (MTD) of Azacitidine|Number of Participants with Decrease of Transcript Levels by at Least One Log (or Undetectable Transcript Level) Within 12 Months","M.D. Anderson Cancer Center|Celgene Corporation","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0254|NCI-2011-03531","August 8, 2012","August 7, 2019","August 7, 2019","October 27, 2011",,"August 16, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01460498"
656,"NCT01446133","Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)",,"Active, not recruiting","No Results Available","Leukemia|Lymphoma","Drug: Rituximab|Drug: Lenalidomide","Overall Response Rate","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0509|NCI-2012-01119","December 12, 2011","December 1, 2019","December 2020","October 5, 2011",,"May 10, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01446133"
657,"NCT01442714","Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS",,"Terminated","Has Results","Leukemia|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)","Drug: Azacitidine|Drug: Lenalidomide","Overall Response Rate (ORR)|Median Duration of Response|Overall Survival","Stanford University|Celgene Corporation","All","60 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-21686|SU-08122011-8268|HEM0022|VIREL2","August 2011","March 2014","May 2014","September 28, 2011","January 3, 2018","January 3, 2018","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01442714"
658,"NCT01412229","Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck",,"Active, not recruiting","Has Results","Head and Neck Cancer","Drug: Cetuximab|Drug: Nab-paclitaxel|Drug: Carboplatin","Clinical Response Rate Following Induction Chemotherapy|Rate of Complete Response Following Induction Chemotherapy|Progression Free Survival|Objective Response Rate (CR+PR)|Complete Response Rate (CR)|Overall Survival|Number of Participants With at Least One Grade 3-4 Toxicity|Number of Participants With at Least One Grade 3-4 Toxicity, Listed by Event|Patient-reported Quality of Life Scores","UNC Lineberger Comprehensive Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1103","February 2012","June 2015","April 2020","August 9, 2011","July 2, 2017","February 5, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01412229"
659,"NCT01401322","Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia",,"Terminated","Has Results","Leukemia|Relapsed Adult Acute Lymphocytic Leukemia","Drug: Lenalidomide","Time-to-Progression (TTP)","Stanford University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-19607|SU-01142011-7364|RV_ALL_PI_0616|HEMALL0006","January 2011","January 2012","May 2012","July 25, 2011","November 10, 2014","November 28, 2016","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01401322"
660,"NCT01393158","Apremilast for Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: Apremilast",,"Oregon Health and Science University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","AP-PI-AD-0034",,,,"July 13, 2011",,"July 13, 2011",,,"https://ClinicalTrials.gov/show/NCT01393158"
661,"NCT01386346","Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer","VEOX","Completed","No Results Available","Esophageal Cancer|Malignant Neoplasm of Cardio-esophageal Junction of Stomach","Drug: Azacitidine|Drug: Oxaliplatin|Drug: Epirubicin|Drug: Capecitabine","Evaluation of dose limiting toxicity (DLT)","Weill Medical College of Cornell University|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1012011450|VZ-ESOPH-PI-273","June 2011","August 2014","September 2018","July 1, 2011",,"December 12, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01386346"
662,"NCT01379274","A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes",,"Terminated","No Results Available","MDS","Drug: Lenalidomide and azacitidine combination","safety and tolerability of revlimid and azacitidine combination","Rush University Medical Center|Celgene Corporation","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDS 2008-01","January 2011","November 2013","November 2013","June 23, 2011",,"November 28, 2013","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01379274"
663,"NCT01378091","Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: Lenalidomide|Drug: Docetaxel|Drug: Prednisone","Maximum tolerated dose (MTD) of lenalidomide","Columbia University|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 1","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAB3212","August 2005","September 2013","September 2013","June 22, 2011",,"May 9, 2016","Columbia University Medical Center, New York, New York, United States|Cornell Weill Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01378091"
664,"NCT01373294","Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer",,"Completed","Has Results","Bladder Cancer","Drug: Bacille Calmette-Guerrin (BCG)|Drug: Lenalidomide","Arm A: Progression Free Survival (PFS)|Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)","H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16295|RV-BLD-PI-0330","November 30, 2011","January 9, 2015","December 10, 2018","June 14, 2011","May 12, 2016","August 6, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01373294"
665,"NCT01368757","Lenalidomide in Patients With Chronic Myelomonocytic Leukemia",,"Unknown status","No Results Available","Chronic Myelomonocytic Leukemia","Drug: Revlimid","Maximum tolerated dose (MTD)|Number and seriousness of adverse events to evaluate safety and tolerability|Number of patients achieving transfusion independence|Progression free survival, Overall survival|Patients achieving cytogenetic response","Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGMT_CMML 1|2009-017147-33","June 2010","May 2015","May 2015","June 8, 2011",,"March 9, 2015","Krankenhaus d. Barmherzigen Schwestern Linz, Interne I, Linz, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, 1. Interne, Linz, Oberösterreich, Austria|AKH Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie, Linz, Oberösterreich, Austria|Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung, Wels, Oberösterreich, Austria|Universitätsklinik f. Innere Medizin Graz, Klinische Abteilung f. Hämatologie, Graz, Steiermark, Austria|Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie, Innsbruck, Tirol, Austria|LKH Feldkirch, Interne E, Feldkirch, Vorarlberg, Austria|Universitaetsklinik der PMU Salzburg, UK f. Innere Medizin III, Salzburg, Austria|MUW/ AKH Wien Univ. Klinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseologie, Wien, Austria|Hanusch Krankenhaus, 3. Med. Abtlg. Für Hämatologie und Onkologie, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT01368757"
666,"NCT01355705","Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Amrubicin|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Aspirin|Drug: Pegfilgrastim","Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria|Duration of Response (DOR)|Progression-free Survival (PFS)|Time-to-next Treatment","Michaela Liedtke|Celgene Corporation|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-19092|AR_MM_PI_007|SU-05062011-7711|HEMMYL0018","August 2011","July 2016","July 2017","May 18, 2011","March 3, 2017","September 18, 2018","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01355705"
667,"NCT01352338","Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)","REPEAT","Completed","No Results Available","Multiple Myeloma","Drug: Lenalidomide, endoxan, prednisone|Drug: lenalidomide, endoxan, prednisone","Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT)|phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)|phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)","UMC Utrecht|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","82","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-MM-PI-0630","August 2011","November 2014","February 2016","May 11, 2011",,"February 26, 2016","Antonius Ziekenhuis Nieuwegein, Nieuwegein, Utrecht, Netherlands|VU Medical Center, Amsterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01352338"
668,"NCT01349569","Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide|Biological: Allogeneic Myeloma Vaccine|Biological: Prevnar-13","Response Conversion Rate|Time to Response|Effect on Clonogenic Myeloma Precursors|Grade 3-4 Toxicity|Tumor-specific Immunity as Assessed by Percentage of CD3+/CSFSE-low/IFN-gamma+ Cells","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1115|NA_00044463","January 2012","October 2016","October 2016","May 6, 2011","January 15, 2019","January 15, 2019","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01349569"
669,"NCT01348503","Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma",,"Terminated","No Results Available","Hepatocellular Carcinoma","Drug: Lenalidomide|Drug: Sorafenib","Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.","Indiana University School of Medicine|Celgene Corporation|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1004-05; IUCRO-0298","May 2011","December 2012","March 2014","May 5, 2011",,"August 31, 2015","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01348503"
670,"NCT01319422","Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Pomalidomide","Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria|To Compare the Effect of Continuous Versus Intermittent Regimens on F Actin Polymerization in Peripheral Blood Mononuclear Cells and Activation of Tumor Antigen-specific T Cells, as Well as Innate Lymphocytes (Natural Killer or Natural Killer T Cells).|To Correlate Drug Induced Changes in F Actin Polymerization With Adverse Effects and Clinical Responses.|To Correlate Drug Induced Changes in F Actin With Cytokine Profile.","Yale University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIC 1011007607","June 2011","November 2014","November 2014","March 21, 2011","August 11, 2016","August 11, 2016","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01319422"
671,"NCT01310114","Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke",,"Terminated","No Results Available","Stroke, Acute|Middle Cerebral Artery Stroke|Posterior Cerebral Artery Stroke","Biological: Human Placenta-Derived Cells PDA001- (cenplacel-L)|Drug: Placebo","Safety (Type, frequency, severity and potential relationship to study drug of adverse events)|Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at Day 91 post treatment|Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at Day 181 post treatment|Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at 24 months post treatment|Clinical response defined as a ≥ 4 point decrease from baseline in the National Institute of Health Stroke Scale (NIHSS)|Clinical response defined as a clinically significant improvement (at least 20-point increase from baseline) in the Barthel Index (BI)","Celularity Incorporated|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-PDA001-SK-001","March 2011","March 2013","March 2013","March 8, 2011",,"March 1, 2018","Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01310114"
672,"NCT01303965","Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)",,"Terminated","Has Results","Multiple Myeloma","Drug: Sirolimus|Drug: Tacrolimus|Drug: Lenalidomide","Phase I: Number of Participants With Dose Limiting Toxicity|Phase II: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant|Phase II - Percent of Patients With Acute Graft Versus Host Disease (GvHD)|Phase II - Percent of Patients With Chronic Graft Versus Host Disease (GvHD)|Phase II - Percent of Patients With Treatment-related Deaths at 100 Days|Phase II - Percent of Patients With Treatment-related Deaths at 1 Year|Phase II - Time to Neutrophil Engraftment|Phase II - Time to Platelet Engraftment","Sherif S. Farag|Celgene Corporation|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1012-24; IUCRO-0307","February 7, 2011","September 23, 2014","July 28, 2017","February 25, 2011","December 6, 2018","January 8, 2019","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01303965"
673,"NCT01301820","Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)",,"Completed","No Results Available","Acute Myeloid Leukemia","Drug: azacitidine|Drug: Lenalidomide","DFS|relapse incidence OS EFS Infectious events|gene expression and promoter methylation signatures associated with CR","French Innovative Leukemia Organisation|Celgene Corporation","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAMSA-maintenance Rev-5Aza","January 2011","February 2013","February 2013","February 23, 2011",,"March 16, 2016","Mathilde HUNAULT BERGER, Angers, France",,"https://ClinicalTrials.gov/show/NCT01301820"
674,"NCT01298011","Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer",,"Completed","No Results Available","Resectable Pancreatic Cancer","Drug: Gemcitabine and Abraxane","Grade III/IV histological response in tumor specimen rate after induction therapy.|Number of participants with adverse events.|Tumor response rate to therapy.|Change in CA 19-9|Resection rate at surgery|Time to recurrence|SPARC protein expression in tumor|Overall Survival","Pancreatic Cancer Research Team|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCRT 10-001","May 2011","December 2013","May 2015","February 17, 2011",,"June 17, 2015","TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|St Mary's / Trinity Health Care, Grand Rapids, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|University of Pittsburg Medical Center, Pittsburg, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01298011"
675,"NCT01282047","Lenalidomide in Kaposi Disease Associated With HIV Infection","LENAKAP","Terminated","No Results Available","HIV Infection Associated Kaposi Disease","Drug: Lenalidomide","Evaluate the efficacy of treatment with Lenalidomide in progressive Kaposi disease in Human immunodeficiency virus (HIV)-infected patients receiving Combined Antiretroviral Therapy (cART).|To estimate the safety of lenalidomide|To estimate the time to the response and the duration of the response|To evaluate the efficacy of treatment at 48 weeks|To evaluate the efficacy using ACTG criteria|To evaluate the survival and the survival with no progression|To describe the evolution of virologic and immunological parameters","French National Agency for Research on AIDS and Viral Hepatitis|Celgene Corporation|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","All","19 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-022898-33|ANRS 154 LENAKAP","October 2011","February 2014","February 2014","January 24, 2011",,"August 1, 2014","Valerie Martinez, Clamart, France",,"https://ClinicalTrials.gov/show/NCT01282047"
676,"NCT01274533","Lenalidomide in HTLV-1 Adult T-Cell Leukemia",,"Completed","Has Results","Adult T Cell Leukemia/Lymphoma","Drug: Lenalidomide","Response Rate (CR + Cru + PR)|Safety of Lenalidomide Monotherapy","Columbia University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAE5097","December 2010","January 2013","May 2013","January 11, 2011","April 22, 2016","May 23, 2016","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01274533"
677,"NCT01261403","Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis",,"Terminated","No Results Available","Rheumatoid Arthritis","Biological: PDA001|Drug: Vehicle Controlled Placebo","Number/Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response within 12 weeks following the initial dose of study drug|Number/Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at 6 months|Number/percent of subjects achieving an ACR 20 clinical response at each scheduled visit during the first 12 months following the first infusion of study drug.|Number/percent of subjects achieving an ACR 50 clinical response at each scheduled visit during the first 12 months following the first infusion of study drug.|Number/percent of subjects achieving an ACR 70 clinical response at each scheduled visit during the first 12 months following the first infusion of study drug.|Number/percent of subjects achieving a clinical response based on their Clinical Disease Activity Index (CDAI) at each scheduled visit during the first 12 months following the first infusion of study drug.|Number/percent of subjects achieving a clinical response based on their Disease Activity Score (DAS 28) score at each scheduled visit during the first 12 months following the first infusion of study drug|Number/Percent of Participants Who Achieve the European League Against Rheumatism (EULAR) Response Criteria Using CRP at Month 12|The change from baseline in the ACR core components. ACR Core Component #1: Percentage Change From Baseline in the Swollen Joint Count at each scheduled visit.|ACR Core Component #2: Percentage Change From Baseline in the Swollen Joint Count at each scheduled visit through Month 12 following the initial infusion of study drug|ACR Core Component #3 Percentage Change From Baseline in the Subject Assessment of Pain at each scheduled visit through Month 12 following the initial dose of study drug|ACR component #4 Percentage Change From Baseline in the Subject Global Assessment of Disease Activity at each scheduled visit through Month 12 following the initial dose of study drug|ACR Component #5 Percentage Change From Baseline in the Physician Global Assessment of Disease Activity at each scheduled visit through Month 12 following the initial dose of study drug|ACR Component #6; Percentage Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at each scheduled visit through Month 12 following the initial dose of study drug|ACR Component#7 Percentage Change From Baseline in the High Sensitivity C-Reactive Protein (CRP) at each scheduled visit through Month 12 following the initial dose of study drug|ACR Component #8 Percentage Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at each scheduled visit through Month 12 following the initial dose of study drug|Change from baseline in rheumatoid factors at each scheduled visit through Month 12 following the initial dose of study drug|Time to flare of Rheumatoid Arthritis (RA) symptoms|Changes in inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum amyloid A (SAA), and IL-6|Change From Baseline in the Disease Activity Score 28 (DAS 28) Using CRP|Change From Baseline in the Clinical Disease Activity Index (CDAI) at Month 3|Change From Baseline in the Clinical Disease Activity Index (CDAI) at Month 6","Celularity Incorporated|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-PDA001-RA-001","December 2010","February 2012","September 2013","December 16, 2010",,"March 2, 2018","Pinnacle Research Group, Anniston, Alabama, United States|Advanced Pain Research Institute, Arcadia, California, United States|UCLA, Los Angeles, California, United States|Desert Medical Advances, Palm Desert, California, United States|Sanitas Research, Coral Gables, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Arthritis and Diabetes Clinic, Inc, Monroe, Louisiana, United States|St. Paul Rheumatology, PA, Eagan, Minnesota, United States|SNS Rheumatology, Lakewood, New Jersey, United States|David R. Mandel, MD, Inc., Mayfield, Ohio, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01261403"
678,"NCT01243476","Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome","SINTRA-REV","Active, not recruiting","No Results Available","Myelodysplastic Syndrome","Drug: Lenalidomide|Other: Placebo","Period until the progression of myelodysplastic syndrome|Safety|Erythroid response|Duration of the red blood cells transfusion independency|Change of the hemoglobin concentration (Hb) in relation to baseline levels|Variation in platelets and neutrophils absolute count in relation to baseline levels|Cytogenetic response|Bone marrow response|Global survival, Event Free Survival and Rate of Transformation to Acute Leukemia.|Time from diagnose to transfusion independence.","Fundación General de la Universidad de Salamanca|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","61","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SINTRA-REV|2009-013619-36","January 2010","September 2021","January 2022","November 18, 2010",,"April 26, 2018","Hospital de Cabueñes, Gijón, Asturias, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Barcelona, Spain|Hospital Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario José Maria Morales Meseguer, Murcia, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01243476"
679,"NCT01241786","Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL",,"Terminated","No Results Available","Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)","Drug: Revlimid|Drug: Azacitidine","The primary objective of this study is to estimate the rate of response, using International Working Group response criteria, to the combination of azacitidine + lenalidomide in patients with relapsed/refractory CLL and small lymphocytic lymphoma (SLL).|1. Assess for treatment related toxicity following administration of lenalidomide/ azacitidine.|2. Estimate the progression free survival and overall survival of patients treated with the combination of lenalidomide and azacitidine|3. Bank tumor samples for planned correlative analyses to identify epigenetically silenced, clinically relevant genes in CLL.","Hackensack Meridian Health|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VZ-CLL-PI-0146","July 2010","October 2011","October 2011","November 16, 2010",,"November 8, 2012","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01241786"
680,"NCT01241734","Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL","RICER","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma.","Drug: Revlimid","Stage 1 - Safety (type, frequency, severity and relationship of adverse events to study treatment) and tolerability|Stage 1 - Overall response rate (CR, PR, SD)|Stage 2 - Proportion of patients with a stem cell collection of at least 3x106 CD34+ cells prior to ASCT|Stage 3 - Overall response rate (CR, PR, SD) and complete response rate, and conversion to higher quality of response during maintenance (e.g. from PR to CR)|Stage 2 • Incidence of DLT for determination of MTD to be used in Stage II conversion to higher quality of response during maintenance (e.g. from PR to CR)|Time to Response|Stage 2 - 1 and 2 year Overall Survival (OS)","Hackensack Meridian Health|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","67","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00001132 - RV-DLBCL-PI-0463","June 2010","December 2014","December 2014","November 16, 2010",,"February 4, 2014","John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01241734"
681,"NCT01222195","Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)",,"Terminated","Has Results","Leukemia","Drug: Lenalidomide|Drug: Darbepoetin alfa","Number of Patients With a Transfusion Independence Response","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0657","February 2008","July 2010","July 2010","October 18, 2010","April 26, 2011","August 7, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01222195"
682,"NCT01207921","Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma",,"Active, not recruiting","No Results Available","Hodgkin Disease","Drug: Lenalidomide","To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT, as measured by dropout rate.|Overall survival (OS)|Adverse event profile|Conversion of partial response/stable disease post-ASCT to complete response.|Evaluate immune response|Event-free survival (EFS)|Progression-free survival (PFS)","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201010719","April 28, 2011","September 19, 2016","September 30, 2026","September 23, 2010",,"November 30, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01207921"
683,"NCT01207102","Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer",,"Terminated","Has Results","Metastatic Breast Cancer","Drug: Abraxane|Drug: Carboplatin","PFS|To Assess the Safety and Tolerability of a Combination Regimen of Weekly Abraxane® and Carboplatin to Treat Women With ""Triple Negative"" Stage IV Metastatic Breast Cancer","Duke University|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00019321","August 2011","June 2014","June 2014","September 22, 2010","December 15, 2014","December 15, 2014","Duke University Medical Center, Durham, North Carolina, United States|Peking University School of Oncology/Beijing Cancer Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01207102"
684,"NCT01204138","Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA","CATARA","Withdrawn","No Results Available","Arthritis, Rheumatoid","Drug: Apremilast|Drug: Placebo","20% improvement based on ACR responder criteria|ACR 50/70 and DAS","Stanford University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SU-08312010-6811","September 2010","August 2011","December 2011","September 17, 2010",,"February 5, 2016","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01204138"
685,"NCT01202890","Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer",,"Terminated","No Results Available","Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma","Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab|Drug: Revlimid, Doxil, Avastin","Maximum Tolerated Dose (MTD) of the 3 drug combination and recommend a dose for phase II studies.|Progression-free survival (PFS) after treatment with Revlimid plus Avastin and Doxil.|Acute and subacute toxicities of Lenalidomide plus Doxil and Avastin for the treatment of ovarian cancer.","New Mexico Cancer Care Alliance|Celgene Corporation","Female","Child, Adult, Older Adult","Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 1001","September 2010","May 2011","May 2012","September 16, 2010",,"January 8, 2014","University of New Mexico Cancer Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT01202890"
686,"NCT01200472","Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis",,"Completed","No Results Available","Erosive Osteoarthritis of the Hand","Drug: Apremilast|Drug: Placebo","Proportion of subjects in each treatment group who achieve a significant 50% improvement in AUSCAN Index at day 84 after treatment start compared with baseline|Absolute values and change from baseline of the Patient self Assessment score (VAS) from baseline, day 84 and day 168 as well as proportion of patients in each treatment group who achieve improvements|Change of the Physicians and Patients self assessment of global status (VAS)score from baseline, day 84 and day 168.|Change of the HAQ score from baseline, day 84 and day 168 in each treatment group who achieve improvements|Change of the SACRAH score from baseline, day 84 and day 168 in each treatment group who achieve improvements|Change of the duration of the joint stiffness from baseline, day 84 and day 168 in each treatment group who achieve improvements|Change of swollen and tender joints from baseline compared to day 84 and day 168 in each treatment group.|Measuring radiology changes from baseline, day 84 and day 168 using the RAMRIS score in each treatment.|Changes of the SF36 from baseline, day 84 and day 168 in each treatment group.","University of Erlangen-Nürnberg Medical School|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACCOST Version 22-Oct-09|2008-005365-61","August 2010","August 2013","October 2013","September 13, 2010",,"October 21, 2013","Prof. G. Schett, University Hospital Erlangen, Erlangen, Bavaria, Germany|Prof. Ulf Müller-Ladner, Kerckhoff-Klinik, Bad Nauheim, Germany|Prof. Matthias Schneider, Universitätsklinikum Düsseldorf, Klinik für Endokrinologie, Diabetologie und Rheumatologie, Düsseldorf, Germany",,"https://ClinicalTrials.gov/show/NCT01200472"
687,"NCT01199575","Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",,"Active, not recruiting","Has Results","Chronic Lymphocytic Leukemia|CLL","Drug: Revlimid|Drug: Rituximab","Overall Response Rate (ORR)|Adverse Events to Study Treatment|Progression Free Survival.|Conversion of MRD-positive Complete Response or Partial Response (PR) to a MRD-negative Complete Response (CR) or Complete Response (CR) Respectively Following an Additional 6 Cycles of Revlimid Consolidation|Overall Survival|Treatment Free Survival.","University of California, San Diego|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRC022","August 2010","January 2015","March 2021","September 13, 2010","October 23, 2018","July 18, 2019","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01199575"
688,"NCT01185262","Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia","LLC-LENAR-08","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lenalidomida and Rituximab","Phase I: To determine Starting Recommended Dose for the first cycle and the subsequent cycles (Maximal Tolerated Dose)in relapsed B-cell CLL patients.|To determine the toxicity profile of LenRtx.|To determine the time to treatment failure.|To determine the molecular response rate.|To determine the clinical response rate (combined morphological and flow cytometry criteria).","MD Anderson International Spain SA|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LLC-LENAR-08","April 2009","December 2012","September 2013","August 19, 2010",,"September 30, 2013","Hospital Universitario Reina Sofía, Córdoba, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01185262"
689,"NCT01180569","Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma",,"Withdrawn","No Results Available","Lymphoma|Follicular Lymphoma","Drug: lenalidomide","Response rate (CR + PR).|Response rate (CR + PR) and time to disease progression|Immune monitoring and analysis of signal transduction in the lymph node.|Immune monitoring and analysis of signal transduction in the blood.","Memorial Sloan Kettering Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-022","August 2010","May 2011","May 2011","August 12, 2010",,"September 25, 2015",,,"https://ClinicalTrials.gov/show/NCT01180569"
690,"NCT01178814","Revlimid in Transfusion Dependent Patients",,"Active, not recruiting","No Results Available","Myelodysplastic Syndrome","Drug: Revlimid (Lenalidomide)","Change in response signature in transfusion dependent MDS patients","Columbia University|Celgene Corporation","All","21 Years and older   (Adult, Older Adult)","Phase 2","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAF2696","July 2010","February 2020","March 2021","August 10, 2010",,"March 13, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01178814"
691,"NCT01167816","Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer",,"Terminated","No Results Available","Pancreatic Cancer","Drug: Vidaza","Determine maximum tolerated dose|Toxicity|Determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells","University of Oklahoma|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VZ-PANC-PI-0244","July 2010","January 2014","January 2014","July 22, 2010",,"May 20, 2014","Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01167816"
692,"NCT01161186","Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma",,"Completed","No Results Available","Pancreatic Neoplasms|Pancreatic Cancer|Adenocarcinoma","Drug: nab-paclitaxel, gemcitabine, capecitabine","to establish the maximal tolerated dose (MTD) of the AGX combination in patients with previously untreated, metastatic pancreatic adenocarcinoma.|To assess the safety profile of this combination (AGX) using NCI-CTCAE v.4 criteria.|To obtain a preliminary assessment of the clinical efficacy of AGX as measured by time to tumor progression, overall survival, objective radiographic response (ORR), and CA 19-9 biomarker response","University of California, San Francisco|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC#10451","July 2010","October 2012","October 2012","July 13, 2010",,"October 11, 2012","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01161186"
693,"NCT01160484","Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: DVD-R","International Myeloma Working Group (IMWG) Response Criteria|Time to First Response|Time to Best Response|Duration of Response|Time to Progression|Progression-free Survival|Follow-up Time","Oncotherapeutics|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-MM-PI-0533","September 2009","December 2011","September 2012","July 12, 2010","April 21, 2014","May 4, 2015","Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Hematology-Oncology Medical Group of Fresno, Inc., Fresno, California, United States|Loma Linda University, Loma Linda, California, United States|Santa Barbara Hematology Oncology, Santa Barbara, California, United States|James R. Berenson, M.D., Inc., West Hollywood, California, United States|Watson Clinic, LLP, Center for Care and Research, Lakeland, Florida, United States|Bassett Cancer Institute, Cooperstown, New York, United States|Broome Oncology, Johnson City, New York, United States",,"https://ClinicalTrials.gov/show/NCT01160484"
694,"NCT01155505","Lenalidomide and Paclitaxel in Advanced Solid Tumors",,"Unknown status","No Results Available","Advanced Solid Tumors","Drug: Lenalidomide (CC-5013)","Define the MTD of the combination of CC-5013 and paclitaxel in patients with advanced solid tumors|Safety profile of the drug combination|Pharmacokinetics of CC-5013 and paclitaxel given in combination|the pharmacodynamic effects of CC-5013 and paclitaxel given in combination|Evidence of antitumor activity in selected tumor types","Southern Europe New Drug Organization|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S095LEPT01","November 2009","December 2011","March 2012","July 1, 2010",,"September 13, 2011","Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy|Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland",,"https://ClinicalTrials.gov/show/NCT01155505"
695,"NCT01155362","A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease",,"Completed","No Results Available","Crohn's Disease","Biological: Human Placenta-Derived Cells PDA001 Intravenous Infusion|Drug: Vehice Control","A reduction from baseline by 25% and/or > 100 points in the Crohn's Disease Activity Index (CDAI) scores at both Week 4 (Day 29) and at Week 6 (Day 43).|The induction of a clinical remission defined as a Crohn's Disease Activity Index score of < 150 points at both Week 4 (Day 29) and Week 6 (Day 43)","Celularity Incorporated|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-PDA001-002","August 2010","February 2012","April 2014","July 1, 2010",,"February 21, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|Yale School of Medicine Digestive Diseases, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Mt Sinai Hospital, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Stony Brook University, Stony Brook, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|McGuire VA Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01155362"
696,"NCT01135199","Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis",,"Withdrawn","No Results Available","Pulmonary Fibrosis","Drug: pomalidomide (CC-4047","Outcome Measure: Cough related QOL as measured by Cough-Specific Quality of LIfe instrument (CQLQ)|Outcome Measure: Cough severity as measured by Leicester Cough Questionnaire (LCQ), Visual Analog Scale (VAS), St. George Respiratory Questionnaire (SGRQ)","Stanford University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-05302008-1189|Protocol # 15447",,,,"June 2, 2010",,"April 8, 2015","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01135199"
697,"NCT01133743","Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lenalidomide and Dexamethasone","Response rate|Time to progression","University Health Network, Toronto|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-CLL-PI-0411","May 2010","December 2016","December 2016","May 31, 2010",,"May 3, 2017","University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01133743"
698,"NCT01133665","Cetuximab and Lenalidomide in Head and Neck",,"Completed","Has Results","Squamous Cell Carcinoma","Drug: Cetuximab and Lenalidomide","Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN.|Number of Participants With Fatigue Related to Cetuximab/Lenalidomide|Number of Participants With Maculopapular Rash Related to Cetuximab/Lenalidomide|Number of Participants With Constipation Related to Cetuximab/Lenalidomide|Number of Participants With Anemia Related to Cetuximab/Lenalidomide|Number of Participants With Anorexia Related to Cetuximab/Lenalidomide|Number of Participants With Nausea Related to Cetuximab/Lenalidomide|Number of Participants With Hypoalbuminemia Related to Cetuximab/Lenalidomide|Number of Participants With Lymphopenia Related to Cetuximab/Lenalidomide|Number of Participants With Oral Mucositis Related to Cetuximab/Lenalidomide|Number of Participants With Pain Related to Cetuximab/Lenalidomide|Number of Participants With Vomiting Related to Cetuximab/Lenalidomide|Number of Participants With White Blood Cell Decreased Related to Cetuximab/Lenalidomide|Number of Participants With Diarrhea Related to Cetuximab/Lenalidomide|Number of Participants With Hyponatremia Related to Cetuximab/Lenalidomide|Number of Participants With Neutropenia Related to Cetuximab/Lenalidomide|Number of Participants With Headache Related to Cetuximab/Lenalidomide|Number of Participants With Hypokalemia Related to Cetuximab/Lenalidomide|Number of Participants With Hypophosphatemia Related to Cetuximab/Lenalidomide|Number of Participants With Thrombocytopenia Related to Cetuximab/Lenalidomide|Number of Participants With Acneiform Rash Related to Cetuximab/Lenalidomide|Number of Participants With Hyperglycemia Related to Cetuximab/Lenalidomide|Number of Participants With Alkaline Phosphatase Increased Related to Cetuximab/Lenalidomide|Number of Participants With Aspartate Aminotransferase Increased Related to Cetuximab/Lenalidomide|Number of Participants With Xerostomia Related to Cetuximab/Lenalidomide|Number of Participants With Fever Related to Cetuximab/Lenalidomide|Number of Participants With Hypocalcaemia Related to Cetuximab/Lenalidomide|Number of Participants With Neck Pain Related to Cetuximab/Lenalidomide|Number of Participants With Peripheral Sensory Neuropathy Related to Cetuximab/Lenalidomide|Number of Participants With Alanine Aminotransferase Increased Related to Cetuximab/Lenalidomide|Number of Participants With Back Pain Related to Cetuximab/Lenalidomide|Number of Participants With Dyspnea Related to Cetuximab/Lenalidomide|Number of Participants With Weight Loss Related to Cetuximab/Lenalidomide|Number of Participants With Blood Bilirubin Increased Related to Cetuximab/Lenalidomide|Number of Participants With Infusion Related Reaction Related to Cetuximab/Lenalidomide|Number of Participants With C. Diff Infection Related to Cetuximab/Lenalidomide|Number of Participants With Febrile Neutropenia Related to Cetuximab/Lenalidomide|Number of Participants With Lymphocyte Count Increased Related to Cetuximab/Lenalidomide","University of Chicago|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-206-B","February 2010","August 2011","August 2012","May 31, 2010","November 24, 2014","November 24, 2014","The University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01133665"
699,"NCT01133275","Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS",,"Active, not recruiting","Has Results","Myelodysplastic Syndrome|MDS","Drug: Prednisone|Drug: Lenalidomide","Number of Participants With Erythroid Response|Number of Participants With Grade 3 or 4 Adverse Events Possibly Related to Treatment","H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16099|RV-MDS-PI-0456|25005/1","April 28, 2010","January 31, 2015","December 2019","May 28, 2010","January 18, 2016","September 9, 2019","University of Florida Shands Cancer Center, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01133275"
700,"NCT01132989","Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma","REvMM2009","Unknown status","No Results Available","Cutaneous T Cell Lymphoma","Drug: Lenalidomide","Response rate(RR measurements are based on skin scoring using mSWAT (modified severity weighted assessment tool), Sezary cell count, and lymph node assessment.|The assessment of patient-reported changes of pruritus during treatment|The assessment of the patient-reported improvement in quality of life during treatment|The assessment of the safety and tolerability of lenalidomide in the study population","Florida Academic Dermatology Centers|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RevMM2009","May 2010","December 2010","December 2010","May 28, 2010",,"May 28, 2010","Florida Academic Dermatology Center, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01132989"
701,"NCT01116193","Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia","RV-405 LAL","Completed","No Results Available","Leukemia, Lymphoid|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","Drug: Lenalidomide plus dexamethasone","Disease-Free survival (DFS)|Time to response|Duration of response|To determine quality of life (QOL): European Organization for Research and Treatment of Cancer QOL questionnaire for patients with cancer (EORTC QLQ-C30)|Progression-free survival|Feasibility of stem cell transplantation (SCT), in case of response, after one or more cycles of lenalidomide plus dexamethasone therapy|Safety of lenalidomide plus dexamethasone: adverse events (type, frequency, severity of adverse events, and relationship of adverse events to study drug).|To assess the efficacy of lenalidomide plus low-dose dexamethasone: complete response (CR), complete response without platelets (CRp), partial response (PR), and overall response (CR + CRp + PR).|Overall survival","Institut de Cancérologie de la Loire|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-01b|2009-009372-13","January 2010","July 2012","August 2013","May 4, 2010",,"September 14, 2017","CHU de Clermont-Ferrand, Clermont-Ferrand, France|Hôpital Michallon, Grenoble, France|Hôpital Edouard Herriot, Lyon, France|Institut de Cancerologie de la Loire, St Priest en Jarez, France",,"https://ClinicalTrials.gov/show/NCT01116193"
702,"NCT01090128","Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer","NAC","Terminated","No Results Available","Stages II-III Breast Cancer","Drug: Nanoparticle Albumin Bound Paclitaxel|Drug: doxorubicin|Drug: cyclophosphamide","Type, incidence, severity, timing, seriousness and relatedness of adverse events and laboratory abnormalities|Pathologic complete response|Overall clinical response rate (OcRR)","University of Utah|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI53989","September 2008","March 24, 2017","March 24, 2017","March 19, 2010",,"March 31, 2017","University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01090128"
703,"NCT01078974","Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia",,"Terminated","Has Results","Waldenstrom's Macroglobulinemia","Drug: pomalidomide|Drug: dexamethasone|Drug: rituximab","Maximum Tolerated Dose of Pomalidomide|Tolerability of Pomalidomide","Steven P. Treon, MD, PhD|Celgene Corporation|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-007|PO-WM-PI-0005","May 2010","September 2015","March 2016","March 2, 2010","July 25, 2016","July 25, 2016","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01078974"
704,"NCT01053949","IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma","IFM2009-02","Completed","No Results Available","Multiple Myeloma","Drug: Pomalidomide","To determine Response rate to pomalidomide and dexamethasone in MM patients who are progressive and did not achieve at least a partial response to bortezomib and lenalidomide|To determine response and safety profile of 2 dose-regimens of pomalidomide|To determine Safety of pomalidomide and dexamethasone|To determine Time to response and Response duration of pomalidomide and dexamethasone|To determine Time to disease progression to pomalidomide and dexamethasone|Overall Survival of pomalidomide and dexamethasone|To determine response in both arms with regards to cytogenetic of the bone marrow tumor plasma cells","University Hospital, Lille|Celgene Corporation","All","19 Years and older   (Adult, Older Adult)","Phase 2","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009_28/0924|2009-013319-36","October 2009","April 2014","April 2015","January 22, 2010",,"November 4, 2015","CHRU-Hôpital Sud, avenue Laennec,, Amiens, France|Hématologie, Hôpital Avicenne, Bobigny, France|Hématologie, CHU, avenue G.Clemenceau, Caen, France|Hématologie Clinique, CHU, Hôpital d'Enfants, Dijon, France|Hématologie, CHRU, Hôpital A.Michallon, Grenoble, France|Service des Maladies du Sang, CHRU, Lille, France|Hôpital Edouard HERRIOT, Lyon, France|Hématologie, Institut Paoli Calmette, Marseille, France|Hématologie, CHRU, Hôpitaux de Brabois, Nancy, France|Maladies du Sang, CHRU, Hôtel Dieu, Nantes, France|Service Immuno-Hématologie, Hôpital Saint-Louis, Paris, France|Maladies du Sang, CHU - Hôpital St Antoine, Paris, France|Service des Maladies du Sang, Hôpital Haut-Levèque, Pessac, France|Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France|Hématologie Clinique, Hôpital Robert Debré, CHU Reims, Reims, France|Hôpital PONTCHAILLOU, CHU de RENNES, Rennes, France|Médecine Interne, CHRU, Hôpital Sud, Rennes, France|Hématologie, CHRU, Hôpital Purpan, Toulouse, France|Onco-Hématologie, CHRU- Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT01053949"
705,"NCT01045551","Open Label Pilot Study of Apremilast in Treatment of Rosacea",,"Completed","Has Results","Erythematotelangiectatic Rosacea|Papulopustular Rosacea","Drug: Apremilast","Change From Baseline in the Total Number of Papulopustular Lesions at Week 12|Change in Physician 7 Point Global Assessment From Baseline to Week 12|Change From Baseline in Erythema Rating Visit 8 (Week 12)|Change From Baseline in Telangiectasia Count at Visit 8 (Week 12)|Change From Visit 8 (Week 12) in Telangiectasia Count at Visit 9 (Week 16)","Julian M. Mackay-Wiggan|Celgene Corporation|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAE1745|AP-ROS-PI 0033","June 2010","January 2013","April 2014","January 11, 2010","October 4, 2016","December 13, 2016","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01045551"
706,"NCT01041625","Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus",,"Unknown status","No Results Available","Lichen Planus","Drug: Apremilast (CC-10004)","Proportion of subjects achieving significant clinical response in cutaneous disease defined as a 2 or more grade improvement of the physician global assessment (PGA) after 12 weeks of treatment.|Proportion of subjects with mucosal involvement who achieve a significant clinical response in mucosal disease defined as physician global assessment of mucosal disease (PGAMD) of ""complete resolution"" or ""marked improvement"" after 12 weeks of treatment.|Change in the subjects' target area lesion count after 12 weeks of treatment relative to baseline.|Change in the subjects' target area lesion severity score (TALSS) after 12 weeks of treatment relative to baseline.|Proportion of subjects who achieve a subject global assessment of ""complete resolution"" or ""marked improvement"" after 12 weeks of treatment.|Change in the subjects' dermatology life quality index (DLQI) score after 12 weeks of treatment relative to baseline.|Change in the subjects' assessment of itching on a visual analogue scale (VAS) after 12 weeks of treatment relative to baseline.|Safety and tolerability of Apremilast (type, frequency, severity, and relationship of adverse events to study treatment)","Virginia Clinical Research, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCR 001|107047","February 2010","February 2012","February 2012","January 1, 2010",,"January 1, 2010","Virginia Clinical Research Inc., Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01041625"
707,"NCT01034592","Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia",,"Terminated","Has Results","Anemia|Leukemia|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)","Drug: Lenalidomide","Red Blood Cell (RBC) Transfusion Independence|Red Blood Cell (RBC) Transfusions|Hemoglobin Concentration|Neutrophil Response|Platelet Response|Duration of Response|Toxicity","Jason Robert Gotlib|Celgene Corporation|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-16822|SU-12082009-4523|RV-0365|HEMMDS0022","November 2009","October 2012","December 2012","December 17, 2009","February 7, 2017","August 2, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01034592"
708,"NCT01033032","Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer",,"Completed","Has Results","Metastatic Breast Cancer","Drug: Amrubicin","Progression-free Survival (PFS)|Number of Patients With Adverse Events as a Measure of Safety and Tolerability|Overall Survival (OS)|Overall Response Rate (ORR)","SCRI Development Innovations, LLC|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 161","December 2009","July 2013","October 2014","December 16, 2009","January 6, 2015","January 6, 2015","NEA Baptist Clinic, Jonesboro, Arkansas, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Baptist Hospital East, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Oncology Hematology Care, Inc, Cincinnati, Ohio, United States|Berks Hematology Oncology Associates, West Reading, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01033032"
709,"NCT01028781","Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis",,"Terminated","No Results Available","Endometriosis","Drug: Thalidomide","pain report","University of North Carolina, Chapel Hill|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","65681","October 2006","August 2009","August 2009","December 9, 2009",,"December 20, 2011","UNC Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01028781"
710,"NCT01016600","Azacitidine and Lenalidomide for Acute Myeloid Leukemia",,"Completed","Has Results","Leukemia, Myeloid, Acute","Drug: Lenalidomide|Drug: Azacitidine","Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs)|Phase I Only - Maximum Tolerated Dose (MTD)|Phase II Only - Complete Remission Rate (CRm + CRi) in Participants With Untreated AML ≥60 Years of Age|Response Rate (CRm + CRc + CRi + PR)|Morphologic Leukemia-free State|Morphologic Complete Remission Rate (CRm)|Cytogenetic CR (CRc) Rate|CR With Incomplete Blood Counts Rate|Partial Remission Rate (PR)|Overall Survival|Event Free Survival|Time to Progression (TTP)|Relapse Free Survival (RFS)|Duration of CR for Complete Responders|Toxicity Profile (Grade 3/4 Toxicities)","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-1816 / 201101749","April 2010","November 2013","October 2014","November 19, 2009","September 7, 2015","September 7, 2015","Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01016600"
711,"NCT01011894","Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age",,"Completed","Has Results","Chronic Lymphocytic Leukemia|Leukemia","Drug: lenalidomide","Best Response","Memorial Sloan Kettering Cancer Center|Celgene Corporation","All","65 Years and older   (Older Adult)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-045","November 6, 2009","February 23, 2016","February 23, 2016","November 11, 2009","May 18, 2017","May 18, 2017","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01011894"
712,"NCT01005979","A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)",,"Terminated","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic","Drug: Lenalidomide, Rituximab, and Cyclophosphamide","The primary endpoint is to determine the maximum tolerated dose of lenalidomide in combination with cyclophosphamide and rituximab for the treatment of CLL or SLL.|Assess response criteria, including complete response rate, survival at 1 year, time to progression, duration of response, and eradication of minimal residual disease.","Emory University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00024085|WCI1642-09","July 2010","October 2012",,"November 2, 2009",,"August 13, 2014","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01005979"
713,"NCT00997581","Apremilast Therapy for Acute Gouty Arthritis",,"Withdrawn","No Results Available","Acute Gout","Drug: apremilast|Drug: indomethacin SR","Subject-reported number of swollen joints, the number of tender joints, the number of warm joints, as well as self-report pain, global assessment, and functional status. Subject-reported time to resolution of symptoms will be measured.|Safety (type, frequency, severity, and relationship of adverse events to apremilast, laboratory, ECG, physical exam or other changes) and tolerability|Quality of Life","Dartmouth-Hitchcock Medical Center|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","AP-GOUT-PI-0038","April 2010","December 2010","December 2010","October 19, 2009",,"April 2, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT00997581"
714,"NCT00995488","Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer",,"Terminated","Has Results","Urothelial Cancer|Bladder Cancer","Drug: ABI-007 (Abraxane®)","Percentage of Participants With a Partial or Complete Response|Median Overall Survival","University of Michigan Rogel Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009.025|HUM00029138","October 2009","November 2013","November 2013","October 15, 2009","September 19, 2014","September 11, 2015","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00995488"
715,"NCT00981903","Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer",,"Terminated","No Results Available","Venous Thromboembolism|Cancer","Drug: Tinzaparin sodium","Development of recurrent venous thromboembolism and major hemorrhage.|Secondary outcome measures will evaluate other thrombotic events, clinical cancer outcome, and plasma markers of hemostasis, fibrinolysis, and angiogenesis","University of Southern California|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0S-04-5","July 2005","October 2012","October 2015","September 22, 2009",,"July 6, 2017","University of Southern California, Los Angeles, California, United States|Cornell Weill Scholl of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00981903"
716,"NCT00974233","Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL",,"Completed","Has Results","Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: Bendamustine|Drug: Rituximab|Drug: Lenalidomide","Progression Free Survival|Progression-free Survival|Objective Response Rate (Complete + Partial Responses)|Toxicities Observed With Induction Chemotherapy and Maintenance Therapy|Overall Survival","University of Wisconsin, Madison|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO08405|RV-CLL/SLL-PI-397","October 2009","July 2013","April 2015","September 10, 2009","July 13, 2017","July 13, 2017","St Vincent Regional Cancer Center, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Mercy Health System Heme/Onc, Janesville, Wisconsin, United States|Gundersen Clinic, La Crosse, Wisconsin, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Riverview Hospital, Wisconsin Rapids, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00974233"
717,"NCT00957385","Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients",,"Completed","No Results Available","Acute Myeloid Leukemia","Drug: Revlimid","To assess the feasibility and assess the effect on relapse free survival by giving Revlimid in the post complete remission maintenance setting|To determine the toxicity of Revlimid when given in the maintenance setting.","University Health Network, Toronto|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-AML-PI-166","June 2008","April 2015","April 2015","August 12, 2009",,"June 19, 2015","University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00957385"
718,"NCT00953615","Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)",,"Terminated","Has Results","Primary Sclerosing Cholangitis","Drug: Thalidomide","Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase|Overall Toxicity and Tolerability|Mayo Risk Score|Soluble Tumor Necrosis Factor - Alpha","Mayo Clinic|Celgene Corporation","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","342-06","April 2006","May 2009","May 2009","August 6, 2009","February 27, 2012","February 27, 2012","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00953615"
719,"NCT00944658","Spondylitis Trial of Apremilast for Better Rheumatic Therapy","START","Completed","No Results Available","Ankylosing Spondylitis","Drug: Apremilast|Drug: Placebo (sugar pill)","To demonstrate the effect of apremilast on MRI lesions in AS|To explore the effect of apremilast on the signs and symptoms of AS|To explore the safety and tolerability of apremilast in AS","Imperial College London|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","112008|2008-004229-40","August 2009","January 2011","January 2011","July 23, 2009",,"July 8, 2019","The Kennedy Institute Clinical Trials Unit, 4 West, Charing Cross Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00944658"
720,"NCT00944047","Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression",,"Completed","Has Results","Breast Cancer","Drug: nab-paclitaxel|Drug: trastuzumab|Drug: Doxorubicin|Drug: cyclophosphamide|Biological: Growth Factor Support|Procedure: Surgery","Pathologic Complete Response","University of Kansas Medical Center|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11368","July 2009","May 2014","August 2017","July 22, 2009","April 23, 2018","April 23, 2018","Hays Medical Center, Hays, Kansas, United States|University of Kansas Medical Center Cancer Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00944047"
721,"NCT00933426","Lenalidomide and Paclitaxel in Prostate Cancer",,"Terminated","No Results Available","Prostate Cancer","Drug: Lenalidomide|Drug: Paclitaxel","Maximum tolerated dose (MTD) of Lenalidomide in Combination with Low-Dose Weekly Paclitaxel|Progression-Free (PFS) Time in Patients with a Lymph Node Dominant Clinical Phenotype","M.D. Anderson Cancer Center|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0606|NCI-2010-01039","August 2009","December 2015","December 2015","July 7, 2009",,"October 26, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00933426"
722,"NCT00931242","Study of Apremilast in Atopic or Contact Dermatitis",,"Completed","Has Results","Atopic Dermatitis|Allergic Contact Dermatitis","Drug: Apremilast","Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points|Number of Patients Achieving 75% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0|Number of Patients Achieving 50% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0","Tufts Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AD / CD|AP-ECZ-PI-0030","June 2009","March 2010","March 2010","July 2, 2009","December 20, 2010","December 20, 2010","Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00931242"
723,"NCT00923234","Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes","AZALE","Terminated","No Results Available","Myelodysplastic Syndromes|Acute Myelogenous Leukemia","Drug: Azacitidine|Drug: Lenalidomide","Maximum tolerated dose (MTD) of Revlimid® (lenalidomide)in combination with Vidaza®(5-azacitidine)|Clinical and cytogenetic response|Safety (type, frequency, severity, and relationship of adverse events to study treatment)","Technische Universität Dresden|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1",,"Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUD-AZALE1-037","June 2009","July 2012","July 2012","June 18, 2009",,"December 18, 2013","Medizinische Klinik und Poliklinik I, Uniklinik, Dresden, Germany|Universitätsklinikum Düsseldorf, Klinik für Hämatologie/Onkologie/klinische Immunologie, Düsseldorf, Germany|Klinikum der J.W. Goethe-Universität, Medizinische Klink II, Frankfurt, Germany|Technische Universität München, Klinikum Rechts der Isar, München, Germany",,"https://ClinicalTrials.gov/show/NCT00923234"
724,"NCT00903942","Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)",,"Withdrawn","No Results Available","Non-small Cell Lung Cancer, Stage III","Radiation: radiation therapy|Drug: Paclitaxel Protein-Bound, and CARBOPLATIN","To assess feasibility of one cycle induction chemotherapy of Abraxane plus Carboplatin followed by low-dose sensitizing Abraxane and radiation followed by consolidation Abraxane and carboplatin for stage III NSCLC.|To estimate the local tumor response rate|To estimate 2-year in-field tumor control.|To estimate 2-year disease free survival (DFS).|To estimate 2-year overall survival (OS).","University of Rochester|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RSRB00022397","March 2008","March 2012",,"May 19, 2009",,"April 27, 2015","University of Rochester, Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00903942"
725,"NCT00903630","Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",,"Terminated","Has Results","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: Lenalidomide|Drug: liposomal doxorubicin","Phase 1 - Maximum Tolerated Dose (MTD) of Lenalidomide When Combined With Fixed Dose Liposomal Doxorubicin in Women With Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Phase 1 - Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Phase 2 - Number of Subjects Achieving a Partial or Complete Response|Phase 2 - Number of Subjects Who Are Progression-Free and Alive","Masonic Cancer Center, University of Minnesota|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008LS047|0805M32463|WCC #50|RV-OVAR-PI-0447","April 2009","August 2011","August 2011","May 18, 2009","January 18, 2017","December 28, 2017","University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00903630"
726,"NCT00899431","Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)",,"Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lenalidomide|Drug: Fludarabine|Drug: Rituximab|Drug: Thymoglobulin|Procedure: Stem Cell Transplantation|Drug: Bendamustine|Drug: Allopurinol","Number of Patients Needing Immunomanipulation After Non-Myeloablative Allogeneic Transplantation for Chronic Lymphocytic Leukemia (CLL) With or Without Lenalidomide Maintenance","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0871|NCI-2012-01620","May 6, 2009","October 7, 2018","October 7, 2018","May 12, 2009",,"May 15, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00899431"
727,"NCT00890929","Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)",,"Completed","Has Results","Acute Myeloid Leukemia (AML)|Adult Acute Myeloblastic Leukemia","Drug: Lenalidomide|Drug: Azacitidine","Compete Remission (CR) Rate|4-week Survival Rate|Maximum Tolerated Dose (MTD) of Lenalidomide|Remission Duration|Overall Response Rate (ORR)|Overall Survival (OS)|Time to CR|Time to PR|OS of Responders","Stanford University|Celgene Corporation","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-15611|SU-04242009-2385|RV-AML-0410|HEMAML0011","April 2009","June 2011","June 2012","April 30, 2009","October 20, 2014","June 18, 2018","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00890929"
728,"NCT00890552","A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis",,"Completed","Has Results","Leukemia|Amyloidosis","Drug: Lenalidomide|Drug: Melphalan|Drug: Dexamethasone","Hematologic Response Rate|Overall Survival (OS)|Event-free Survival (EFS)|Duration of Response","Stanford University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-15213|RV-AMYL-PI-0375|SU-09192008-1300|HEM0010","April 2009","August 2012","October 2012","April 30, 2009","March 22, 2017","March 22, 2017","Stanford University Cancer Institute, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00890552"
729,"NCT00889421","Apremilast in the Treatment of Uveitis",,"Terminated","Has Results","Uveitis","Drug: Apremilast","Improvement by 2 or More Lines of Best-corrected Snellen Visual Acuity in at Least One Eye|Reduction in Dose of Systemic Corticosteroid or Other Immunosuppressive Therapy by at Least 50%|Control of Ocular Inflammation, as Judged on Clinical Criteria, According to Standard Methods (Reduction of Anterior Chamber Cellular Activity and/or Chorioretinal Infiltrates and/or Retinal Vasculitis)|Reduction in Cystoid Macular Edema|Type, Frequency, Severity, and Relationship of Adverse Events to Study Treatment","Oregon Health and Science University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","e4235","November 2009","June 2011","June 2011","April 28, 2009","July 8, 2014","July 8, 2014","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00889421"
730,"NCT00885508","A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q","GFM-Chimio-Rev","Unknown status","No Results Available","Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia","Drug: Lenalidomide","Response (CR, mCR and Cri, according to IWG criteria for AML and IWG 2006 criteria for MDS) to the combination of lenalidomide and chemotherapy in adult high and int 2 MDS (IPSS) or AML with deletion 5q[31]|Duration of response|Progression to AML|Survival and safety of the combination of lenalidomide and chemotherapy","Groupe Francophone des Myelodysplasies|Celgene Corporation","All","Child, Adult, Older Adult","Phase 2","85","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GFM-Chimio-Rev-08","February 2009","December 2015","December 2015","April 22, 2009",,"April 24, 2015","CH Angers, Angers, France|hopital Victor Dupouy, Argenteuil, France|Centre Hospitalier de La Cote Basque, Bayonne, France|Hôpital Avicenne, Bobigny, France|CHU Haut-Lévèque, Bordeaux, France|Centre hospitalier de Chambéry, Chambéry, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|Centre henri Mondor, Creteil, France|Centre Hospitalier du Mans, Le Mans cedex, France|Centre Hospitalier de Lens, Lens, France|centre hospitalier de Lens, Lens, France|Hôpital Limoges, Limoges, France|Centre Hospitalier Lyon Sud, Lyon, France|Institut Paoli Calmettes, Marseille, France|CHU Brabois, Nancy, France|CHU de nantes, Nantes, France|Hôpital Archet1, Nice, France|Hoiptal St Louis, Paris, France|Hopital Cochin-Hematology, Paris, France|Centre Hospitalier Joffre, Perpignan, France|Centre Henri Becquerel, Rouen, France|Hôpital Hautepierre, Strasbourg, France|Hopital Purpan Service d'Hématologie Clinique, Toulouse, France|CH de Valence, Valence, France|Institut gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT00885508"
731,"NCT00876070","Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer",,"Describe patient demographics, disease and treatment characteristics.|Describe detailed treatment and response characteristics.|Describe resource utilization and cost variables.","SCRI Development Innovations, LLC|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)",,"198","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","SCRI OUTCOMES 02","November 2008","November 2009","February 2011","April 6, 2009",,"November 21, 2011","Georgia Cancer Specialists, Atlanta, Georgia, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00876070"
732,"NCT00869089","Safety and Efficacy of CC-10004 for Prurigo Nodularis",,"Completed","Has Results","Prurigo Nodularis","Drug: CC-10004","Improvement in Prurigo Nodularis","University Hospitals Cleveland Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","102652|12-07-24","September 2008","January 2011","January 2011","March 25, 2009","June 20, 2014","November 2, 2016","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00869089"
733,"NCT00860457","Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)",,"Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Rituximab|Drug: Fludarabine|Drug: Lenalidomide","Complete Response Rate","Georgetown University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-CLL-PI-089","February 2008","March 2011","February 2012","March 12, 2009","August 18, 2014","November 21, 2018","Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00860457"
734,"NCT00842582","Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer",,"Withdrawn","No Results Available","Ovarian Cancer","Drug: Azacitidine","The primary goal is to find the lowest dose of azacitidine combined with carboplatin and Paclitaxel, at which toxicity is reasonable, and methylation changes are clinically significant (at which there is a change in gene expression.|Secondary endpoints are disease free survival, overall survival, toxicity, quality of life as measured by the Functional Assessment of Cancer Therapy-Ovarian Cancer symptom (FOSI) index, and basic science correlate.","Loyola University|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200777","February 2009","March 2011","March 2011","February 12, 2009",,"November 2, 2016","Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Central Dupage Hospital, Winfield, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00842582"
735,"NCT00837031","Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas",,"Completed","Has Results","Metastatic Pancreatic Cancer","Drug: Lenalidomide|Drug: Gemcitabine","Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment|Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease|Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death","SCRI Development Innovations, LLC|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GI 106","February 2009","April 2010","June 2012","February 5, 2009","March 13, 2013","March 13, 2013","Florida Cancer Specialists, Fort Myers, Florida, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Virginia Cancer Institute, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00837031"
736,"NCT00833807","Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver",,"Completed","No Results Available","Melanoma|Liver Metastasis","Drug: Nab-Paclitaxel (Abraxane)","Maximum Tolerated Dose (MTD) of Nab-Paclitaxel|Survival Rate","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0603|NCI-2010-01023","February 2009","November 2014","November 2014","February 2, 2009",,"November 26, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00833807"
737,"NCT00828802","Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: Lenalidomide, Decitabine","Maximally tolerated dose (MTD)as defined by the protocol|response duration|effect on cytogenetic abnormalities","Duke University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00010179","March 2009","August 2012","November 2012","January 26, 2009",,"September 9, 2013","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00828802"
738,"NCT00814632","CC-10004 For The Treatment Of Vulvodynia",,"Completed","Has Results","Vulvodynia","Drug: CC-10004","Global Response Assessment","Kenneth Peters, MD|Celgene Corporation|William Beaumont Hospitals","Female","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-134","December 2008","February 2011","February 2011","December 25, 2008","September 29, 2014","August 13, 2015","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00814632"
739,"NCT00799513","Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Lenalidomide","1-year progression-free survival|Median overall survival, response rate, response duration","IRCCS San Raffaele|Celgene Corporation","All","65 Years and older   (Older Adult)","Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-003729-18","October 2009","October 2013","November 2013","December 1, 2008",,"March 22, 2012","San Raffaele Scientific Institute, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT00799513"
740,"NCT00787436","Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE",,"Withdrawn","No Results Available","Gastrointestinal Hemorrhage|Portal Hypertension","Drug: Thalidomide","The proposed study would use a novel approach to prophylaxis, using thalidomide, an oral TNF inhibitor, in conjunction with a betablocker to prevent rebleeding of upper gastrointestinal bleeding in patients with cirrhosis and portal hyperte|The secondary endpoint is to examine the impact on progression of liver disease in this population, including development of other complications of chronic liver disease, such as encephalopathy, hepatorenal syndrome and patient survival","The Cleveland Clinic|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CEL-20237|IRB00000536|FWA00005367|34-0714585|OSR-20070905-01","May 2006","January 2010","January 2010","November 7, 2008",,"July 31, 2013","Cleveland Clinic Foundation, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00787436"
741,"NCT00759603","Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia",,"Completed","Has Results","Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: Lenalidomide|Drug: Rituximab","Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group Guidelines","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0208|NCI-2012-01674","September 2008","July 2014","July 2014","September 25, 2008","August 27, 2015","August 27, 2015","The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00759603"
742,"NCT00748553","A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer","VA","Completed","Has Results","Advanced or Metastatic Solid Tumors|Advanced or Metastatic Breast Cancer","Drug: Azacitidine (Vidaza)|Drug: Nab-paclitaxel (Abraxane)","Phase I: Percentage of Participants Responding to Treatment|Phase II: Percentage of Participants With Objective Response Rate (ORR) Measured Using RECIST 1.0 Criteria|Number of Participants With ER+ Status|Progression-free Survival","University of Utah|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI53993","September 2008","October 2015","October 2015","September 8, 2008","July 26, 2017","July 26, 2017","University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00748553"
743,"NCT00736944","Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer",,"Active, not recruiting","Has Results","Squamous Cell Carcinoma of the Head and Neck","Drug: Abraxane|Drug: Cetuximab|Drug: Cisplatin|Drug: 5-FU|Radiation: Radiation (Post induction)","Clinical Complete Response Rate at the Primary Tumor|Clinical Partial Response Rate at the Primary Tumor|Clinical Complete and Partial Response Rates to the Involved Regional Nodes|Clinical Overall Complete and Partial Response Rates|Complete and Partial Response Rates of Primary Tumor by FDG Uptake on PET Scan|Complete and Partial Response Rates of Involved Lymph Nodes by FDG Uptake on PET Scan|Radiographic Complete and Partial Response Rates of Primary Tumor as Assessed by Conventional CT Scan Using RECIST Criteria|Radiographic Complete and Partial Response Rates of Involved Lymph Nodes as Assessed by Conventional CT Scan Using RECIST Criteria|Radiographic Overall Complete and Partial Response Rates as Assessed by Conventional CT Scan Using RECIST Criteria|Correlate Primary Tumor Site Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT|Correlate Nodal Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT|Correlate Overall Tumor Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT|Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy|Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy|Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy|Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy|Adverse Events Experienced During Induction Chemotherapy in the First Ten Patients for a Pre-planned Safety Analysis|Overall Survival|Disease Free Survival|Progression-free Survival","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-0911 / 201105501","December 19, 2008","August 31, 2010","August 31, 2020","August 18, 2008","January 7, 2014","March 5, 2019","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00736944"
744,"NCT00731380","A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: ABI-007","The maximum tolerated dose of ABI-007 with Cisplatin and 5-Fluorouracil (APF)|safety and tolerability profiles for ABI-007","University Health Network, Toronto|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APF-001","July 2008","June 2016","June 2016","August 11, 2008",,"June 22, 2016","Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00731380"
745,"NCT00721214","5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome",,"Completed","Has Results","Myelodysplastic Syndrome","Drug: 5-azacytidine","One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation|Two Year Overall Survival of Allogeneic Transplant Recipients After Transplantation|One Year Event Free Survival (EFS) for Allogeneic Transplant Recipients After Transplantation|Two Year Event Free Survival (EFS) for Allogeneic Transplant Recipients After Transplantation|One-year Overall Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts|Two-year Overall Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts.|One-year Event-free Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts|Two-year Event-free Survival From Time of Treatment Initiation With 5-Azacytidine for All Study Cohorts","Virginia Commonwealth University|Celgene Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-11328","July 2008","June 2014","June 2014","July 24, 2008","August 3, 2015","March 2, 2016","Massey Cancer Center / Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00721214"
746,"NCT00720850","Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)","LENAMAINT","Terminated","No Results Available","Myelodysplastic Syndromes|Acute Myelogenous Leukemia","Drug: lenalidomide","Cumulative incidence of relapse rate|Overall survival, Incidence and severity of acute and chronic GVHD, Safety","Technische Universität Dresden|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUD-LENAMA-022","April 2008","January 2011","January 2011","July 23, 2008",,"September 27, 2013","Dresden University of Technology, Medizinische Klinik und Poliklinik 1, Dresden, Saxony, Germany|Universitätsklinikum Düsseldorf, Medizinische Klinik und Poliklinik, Klinik für Hämatologie, Onkologie und klinische Immunologie, Düsseldorf, Germany|Universitätsklinikum Essen, Klinik für Knochenmarktransplantation, Essen, Germany|Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Hamburg, Germany|Medizinische Hochschule Hannover, Zentrum Innere Medizin, Hämatologie, Hannover, Germany|Universitätsklinikum Ulm, Klinik für Innere Medizin III, Ulm, Germany|Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00720850"
747,"NCT00708916","Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients",,"Completed","No Results Available","Discoid Lupus Erythematosus","Drug: CC-10004","Cutaneous LE Diseases Area and Severity Index (CLASI)|Dermatology Quality of Life Index (DQLI)|Common Terminology Criteria for Adverse Events v3.0 (CTCAE)|Dermal and circulating blood plasmacytoid dendritic cell levels|Dermal and circulating blood T regulatory cell levels|Plasma cytokine levels","NYU Langone Health|Celgene Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP016","June 2008","August 2010","August 2010","July 3, 2008",,"December 11, 2012","New York University Tisch Hospital, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT00708916"
748,"NCT00701311","An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome",,"Completed","Has Results","Prostatitis|Chronic Prostatitis With Chronic Pelvic Pain Syndrome","Drug: CC-10004","Global Response Assessment","Kenneth Peters, MD|Celgene Corporation|William Beaumont Hospitals","Male","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-135","June 2008","January 2011","March 2011","June 19, 2008","May 16, 2014","October 6, 2014","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00701311"
749,"NCT00699842","A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients",,"Terminated","Has Results","Myelodysplastic Syndrome|MDS|Low to Intermediate-1 MDS|Non-deletion 5q","Drug: Lenalidomide","Determine CR, PR, and Rate of Stable Disease in MDS Patients|Safety With Dose Escalation","Sidney Kimmel Cancer Center at Thomas Jefferson University|Celgene Corporation|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07C.446|RV-MDS-PI-244|2007-31","July 2008","January 2011","May 2012","June 18, 2008","June 3, 2014","November 29, 2016","Associates in Hematology-Oncology, PC, Chester, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00699842"
750,"NCT00691704","Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide Induction|Drug: Sequential Maintenance Therapy","Progression Free Survival|Time to Response|Overall Survival|Time to Progression|Duration of Response","Cristina Gasparetto|Celgene Corporation|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00002869","August 2008","December 2012","May 2014","June 5, 2008","April 10, 2014","August 19, 2014","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00691704"
751,"NCT00684242","Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain",,"Terminated","Has Results","Advanced Cancer|Pain","Drug: Lenalidomide","Change in Cancer Pain Intensity Determined by Edmonton Symptom Assessment Scale (ESAS)","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0750","May 2008","October 2011","October 2011","May 26, 2008","January 28, 2013","January 28, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00684242"
752,"NCT00683059","Single Agent Abraxane as Second Line Therapy in Bladder Cancer",,"Completed","No Results Available","Transitional Cell Carcinoma","Drug: Paclitaxel","Response rate|safety|overall survival","Sunnybrook Health Sciences Centre|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABX207-GU07CA","March 2008","June 2012","June 2012","May 23, 2008",,"October 17, 2016","Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00683059"
753,"NCT00675441","Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)",,"Terminated","Has Results","Graft-versus-Host Disease","Drug: Lenalidomide","Number of Participants' With Treatment Response of Complete or Partial Response","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0321","April 2008","August 2011","August 2011","May 9, 2008","December 11, 2013","December 11, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00675441"
754,"NCT00665652","Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance","MGUS","Terminated","Has Results","Neuropathy|Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)","Drug: Lenalidomide","Change in Total Neuropathy Score in Subjects With MGUS Associated Neuropathy After Treatment With Lenalidomide.","Dartmouth-Hitchcock Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RV-PN-PI-235 D0713","April 2008","May 19, 2011","May 19, 2011","April 24, 2008","September 11, 2018","September 11, 2018","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT00665652"
755,"NCT00660400","Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant",,"Completed","Has Results","Leukemia","Drug: 5-azacitidine|Procedure: Allogeneic Hematopoietic Cell Transplantation (HCT)","Percentage of Participants With Relapse-free Survival (RFS)|Overall Response Rate (ORR)|Percentage of Participants Who Proceed to Hematopoietic Cell Transplantation (HCT)|Percentage of Participants With Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation","All","18 Years to 68 Years   (Adult, Older Adult)","Not Applicable","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-15158|106349","March 2008","December 2013","June 2014","April 17, 2008","July 16, 2014","September 22, 2014","H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00660400"
756,"NCT00654186","Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients",,"Completed","Has Results","Prostate Cancer","Drug: Revlimid","Number of Participants With Overall Clinical Benefit (OCB), Defined as the Sum of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) Divided by the Number of Participants|Time to PSA Progression|Time to Disesase Progression as Measured by Radiographic Progression","Oncology Specialists, S.C.|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-PCA-PI-327","February 2008","September 2012","September 2012","April 7, 2008","February 28, 2014","March 28, 2014","Oncology Specialists, S.C, Niles, Illinois, United States|Oncology Specialists, S.C, Park Ridge, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00654186"
757,"NCT00633945","Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)",,"Completed","Has Results","Cutaneous Lupus Erythematosus (CLE)","Drug: Lenalidomide","Cutaneous Lupus Area and Severity Index (CLASI)|Number of Participants With Change in IFN and CD4 Levels at 6 Weeks|Physician Global Assessment (PGA) for Skin|Patient General Assessment (PtGA) for Skin|Pain in Skin|Itch in Skin|Fatigue|Skindex Symptoms|Skindex Function","University of Pennsylvania|Celgene Corporation","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","806259","November 2007","July 2009","October 2009","March 12, 2008","November 13, 2019","November 13, 2019","Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00633945"
758,"NCT00632359","Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease",,"Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lenalidomide","Time to Progression","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0213|NCI-2012-01690","February 2008","October 2015",,"March 10, 2008",,"October 15, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00632359"
759,"NCT00629499","Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: nab paclitaxel|Drug: Cyclophosphamide|Drug: Trastuzumab","Tolerability of Adjuvant Nab Paclitaxel Using Weekly Dosing Schedule Assessed by Patient Survival, Disease Recurrence, and Treatment-related Toxicity.|Disease-free Survival|Overall Survival","SCRI Development Innovations, LLC|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 116","April 2008","October 2008","September 2010","March 6, 2008","December 20, 2012","September 9, 2013","Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Mercy Hospital, Portland, Maine, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Cancer Care of Western North Carolina, Asheville, North Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00629499"
760,"NCT00629447","Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients",,"Completed","No Results Available","Primary Brain Tumor","Drug: Innohep","Neurologic evaluation, CBC, Coagulation test (PT w/ INR, aPTT),Karnofsky performance status, Thrombosis panel, Adverse events assessment|Bone densitometry study (DEXA-Scan)d","Duke University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00008486|4930","February 2004","March 2007","October 2009","March 6, 2008",,"January 7, 2013","Duke University Health Systems, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00629447"
761,"NCT00628238","Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)",,"Unknown status","No Results Available","Chronic Lymphocytic Leukemia|CLL|Untreated|Front-line|First-Line|Initial Therapy","Drug: Lenalidomide and Rituximab","Efficacy to be assessed by clinical response rate following 3 cycles of treatment and the NCI-CLL working group response rate assessed after completion of all treatment.|Safety - type, frequency, severity, and relationship of adverse events to study treatment|Time To Progression|Evaluate response to lenalidomide in relationship to molecular and genetic prognostic features in CLL; including ZAP-70 status, IgVH gene mutational status, and FISH.|Compare the efficacy and tolerability of the combination of Revlimid and rituximab for patients younger than 65 years, and for those 65 and older. •|Evaluate change in hematological parameters including neutropenia, anemia, and thrombocytopenia following treatment with the combination of Revlimid and rituximab.","Chronic Lymphocytic Leukemia Research Consortium|Celgene Corporation","All","Child, Adult, Older Adult","Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRC014|Celgene # RV-CLL-PI-0223","February 2008","February 2011","July 2011","March 5, 2008",,"September 10, 2010","University of California San Diego, La Jolla, California, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00628238"
762,"NCT00625573","Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)","ABX067","Completed","No Results Available","Colorectal Cancer","Drug: Abraxane","To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy|To evaluate overall survival, time to progression, response duration, time to response and safety of this combination","Mt. Sinai Medical Center, Miami|Celgene Corporation","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COL-01","September 2007","February 2009","March 2009","February 28, 2008",,"September 18, 2009","Mount Sinai Medical Center, Miami Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00625573"
763,"NCT00609869","Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab",,"Completed","Has Results","Lymphocytic Leukemia|Mantle Cell Lymphoma","Drug: Lenalidomide|Drug: Rituximab","Overall Response Rate (ORR)|Clinical Benefit Rate|Median Time to Treatment Failure (TTF)","H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14978|RV-CLL-PI-067","October 2007","February 2014","August 2015","February 7, 2008","September 1, 2014","September 17, 2015","Center for Cancer Care & Research/Watson, Lakeland, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00609869"
764,"NCT00607581","Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis",,"Completed","No Results Available","Amyloidosis","Drug: cyclophosphamide|Drug: lenalidomide|Drug: dexamethasone","hematologic response rate|organ response rate|time to response|time to progression|survival|toxicity","IRCCS Policlinico S. Matteo|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-003-IT|RV-AMYL-PI-303","February 2008","December 2011","January 2012","February 5, 2008",,"February 10, 2012","Amyloidosis Research and Treatment Center - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT00607581"
765,"NCT00585689","Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer",,"Completed","Has Results","Bladder Cancer","Drug: ABI-007|Drug: Carboplatin|Drug: Gemcitabine|Procedure: Radical Cystectomy","Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment","University of Michigan Rogel Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2007.061|HUM 13486","December 2007","April 2013","April 2013","January 3, 2008","June 5, 2014","November 30, 2015","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00585689"
766,"NCT00583349","Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer","Abraxane","Unknown status","No Results Available","Bladder Cancer","Drug: Paclitaxel, nanoparticle albumin-bound","To determine the safety, toxicity and efficacy profiles of intravesically administered Abraxane at the Maximum Tolerated Dose.|To evaluate the utility (potential for clinical efficacy) of Abraxane in the treatment of refractory superficial TCC as measured by response rate (defined as negative cytology and bladder biopsy).|To further evaluate the safety and toxicity profile of intravesically administered Abraxane therapy.","Columbia University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAC1114","December 2007","June 2013",,"December 31, 2007",,"November 6, 2012","Herbert Irving Pavillion 11th Floor, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00583349"
767,"NCT00570674","Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck",,"Terminated","Has Results","Squamous Cell Carcinoma of the Head and Neck|Basaloid Squamous Cell Carcinoma|Undifferentiated Carcinoma|Adenosquamous Cell Carcinoma","Drug: Abraxane|Drug: Erbitux|Drug: Carboplatin|Radiation: Intensity Modulated Radiation Therapy","Abraxane Maximum Tolerated Dose (MTD) [Phase I]|Dose Limiting Toxicity (DLT) [Phase I]|2-Year Disease-Free Survival [Phase II]|Overall Response Rate [Phase I]|2-Year Overall Survival [Phase I]|Duration PEG Therapy|Change in FACT-H&N Score From Baseline to 4 Months|Change in FACT-H&N Score From Baseline to 6 Months|Change in FACT-H&N Score From Baseline to 12 Months|Change in FACT-H&N Score From Baseline to 24 Months","Dana-Farber Cancer Institute|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","29","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-069","November 2007","October 2013","October 2013","December 11, 2007","December 12, 2016","November 13, 2017",,,"https://ClinicalTrials.gov/show/NCT00570674"
768,"NCT00569660","Ph II Study of Azacitidine in Myelofibrosis",,"Completed","Has Results","Myelofibrosis","Drug: Azacitidine","Number of Participants With Objective Clinical Response","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0033","June 2005","April 2008","April 2008","December 7, 2007","March 30, 2011","August 7, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00569660"
769,"NCT00569010","Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)",,"Completed","Has Results","Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia","Drug: Azacitidine|Drug: Ara-C","Number of Participants With Complete Remission","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0291","December 2005","October 2009","October 2009","December 6, 2007","February 14, 2011","August 1, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00569010"
770,"NCT00540579","CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas",,"Completed","Has Results","Pancreatic Cancer","Drug: Pomalidomide|Drug: Gemcitabine","Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects|The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0","SCRI Development Innovations, LLC|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GI 105|PO-PANC-PI-009","November 2007","December 2008","January 2011","October 8, 2007","March 13, 2013","March 13, 2013","University of Colorado Cancer Center, Aurora, Colorado, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00540579"
771,"NCT00540007","Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma",,"Completed","Has Results","Hodgkin Disease","Drug: Lenalidomide","Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL.|Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL.|Cytostatic Overall Response Rate|Participant Response Rate in Relapsed or Refractory cHL.|Time to Progression (TTP).|Overall Survival (OS)|Relapse Free Survival (RFS)|Event Free Survival (EFS).|Duration of Response","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-0233 / 201104227","September 6, 2007","September 1, 2016","September 1, 2016","October 5, 2007","November 6, 2017","November 6, 2017","Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Wake Forest University Medical School, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00540007"
772,"NCT00529022","Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer",,"Completed","No Results Available","Solid Tumors","Drug: Azacitidine|Drug: Valproic Acid|Drug: Carboplatin","Response Rate","M.D. Anderson Cancer Center|Celgene Corporation","All","Child, Adult, Older Adult","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0030","August 2007","October 2012","October 2012","September 14, 2007",,"February 20, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00529022"
773,"NCT00527657","Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",,"Completed","No Results Available","Brain Neoplasms|Melanoma","Drug: Lomustine|Drug: Temozolomide|Drug: Thalidomide","Maximum tolerated dose (MTD)|Objective (CR+PR) response rate at the MTD","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0595|NCI-2012-01587","February 9, 2006","February 2, 2012","February 2, 2012","September 11, 2007",,"November 14, 2018","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00527657"
774,"NCT00521781","Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer",,"Terminated","No Results Available","Prostatic Neoplasms","Drug: Abraxane|Drug: Leuprolide|Drug: Bicalutamide","Assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate.|Assess safety and tolerability of the study drug regimen. Overall survival Duration of response PSA ""lead-time"" to symptomatic or radiographic progression.","The Methodist Hospital System|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMRI IRB#0407-0035|PCa-07-102","August 2007","September 2008","October 2008","August 28, 2007",,"March 17, 2016","Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00521781"
775,"NCT00496444","Azacytidine and Valproic Acid in Patients With Advanced Cancers",,"Completed","No Results Available","Advanced Cancers","Drug: Azacitidine|Drug: Valproic Acid","To find the highest safe dose of the drug azacitidine that can be given in combination with valproic acid in the treatment of solid tumors.","M.D. Anderson Cancer Center|Celgene Corporation","All","2 Years and older   (Child, Adult, Older Adult)","Phase 1","69","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0735","May 2005","October 2009","October 2009","July 4, 2007",,"August 1, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00496444"
776,"NCT00482261","A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: dexamethasone|Drug: aspirin","Overall response rate|Overall Survival|Time To Progression|Duration of Response|Safety and toxicity|Prognostic factors associated with ORR, TTP, OS|Compare OTT, TTP an toxicities to MM-009/MM-010 data","Peter MacCallum Cancer Centre, Australia|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-PI-0103|07/04","June 2007","August 2010","September 2013","June 5, 2007",,"January 10, 2013","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00482261"
777,"NCT00480363","QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression","QUIREDEX","Completed","No Results Available","Multiple Myeloma","Procedure: Maintenance with lower doses of lenalidomide and dexamethasone","The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM|Evaluate the efficacy of the treatment in response rate terms|Evaluate the safety and tolerability of the treatment","PETHEMA Foundation|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-000649-36|QUIREDEX","May 2007","December 2008","July 2013","May 30, 2007",,"July 31, 2013","Hospital germans Trias i Pujol, Badalona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del SAS de Jerez de la Frontera, Jerez de la Frontera, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Dode de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital General Univeristario Morales Messeguer, Murcia, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Universitario la Fe, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00480363"
778,"NCT00478959","Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma",,"Completed","No Results Available","Hodgkin Disease","Drug: Lenalidomide (Revlimid®)","To assess the response rate (CR + CRu + PR) of Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma","University Health Network, Toronto|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-HL","December 2006","June 2014","June 2014","May 25, 2007",,"October 10, 2018",,,"https://ClinicalTrials.gov/show/NCT00478959"
779,"NCT00469703","Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis",,"Terminated","No Results Available","Chronic Pancreatitis","Drug: Thalidomide","Safety and efficacy|reduction of frequency of hospitalizations|quality of life|reduction of pain","Winthrop University Hospital|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chronic Pancreatitis","August 2005","November 2007","November 2007","May 4, 2007",,"January 16, 2008",,,"https://ClinicalTrials.gov/show/NCT00469703"
780,"NCT00466986","Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer",,"Completed","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: Abraxane","Response Rate|Time to Response|Duration of Response|Overall Survival|Progression Free Survival|Safety|Tolerability","Southeastern Gynecologic Oncology|Celgene Corporation","Female","Child, Adult, Older Adult","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WIRB#20051730","November 2005","October 2011","October 2011","April 27, 2007",,"October 12, 2011","Southeastern Gynecologic Oncology, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00466986"
781,"NCT00466895","Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.",,"Completed","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia","Drug: lenalidomide","Maximum tolerable dose|Toxicities of lenalidomide|preliminary clinical activity|plasma and cellular pharmacokinetics|pharmacodynamics","Leslie Andritsos|Celgene Corporation|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-06003|NCI-2011-03218","April 2007","December 2014","July 2016","April 27, 2007",,"November 14, 2017","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00466895"
782,"NCT00454324","Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer","NRR","Terminated","Has Results","Small Cell Lung Cancer","Drug: Carboplatin|Drug: Abraxane","Overall Response Rate|1-year Overall Survival (OS)|Progression Free Survival (PFS)|Number of Individuals With Adverse Events","UNC Lineberger Comprehensive Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0519|CDR0000542753","April 2006","July 2010","December 2014","March 30, 2007","June 12, 2017","July 11, 2017","University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00454324"
783,"NCT00446303","A Phase II Study of Maintenance With Azacitidine in MDS Patients",,"Terminated","No Results Available","Leukemia, Myelocytic, Acute|Myelodysplastic Syndromes","Drug: Azacitidine","Reponse duration and cumulative incidence of relapses|Toxicity according to WHO|Overall survival","Groupe Francophone des Myelodysplasies|Celgene Corporation","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GFM aza05","July 2006","July 2010","July 2010","March 12, 2007",,"January 19, 2012","CHU d'Amiens, Amiens, France|CHU Angers, Angers, France|CH d'Avignon, Avignon, France|CHU de Caen, Caen, France|Hopital d'Instruction des Armées Percy, Clamart, France|Hopital Henri Mondor, Creteil, France|CHU de Dijon, Dijon, France|CHU Albert Michallon, Grenoble, France|CHRU Hurriez, Lille, France|CHRU de Limoges, Limoges, France|Hopital Edouard Herriot, Lyon, France|Hopital Paoli Calmette, Marseille, France|Hopital Hotel Dieu, Nantes, France|Hopital Archet, Nice, France|Hopital Saint Louis, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Cochin, Paris, France|Hopital Haut Leveque, Pessac, France|Hopital Jean-Bernard, Poitiers, France|CHRU de Reims, Reims, France|CHU Pontchaillou, Rennes, France|Hopital Hautepierre, Strasbourg, France|Hopital Purpan, Toulouse, France|CHU Brabois, Vandoeuvre, France|CH Versailles, Versailles, France",,"https://ClinicalTrials.gov/show/NCT00446303"
784,"NCT00443261","Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",,"Terminated","Has Results","Squamous Cell Carcinoma","Drug: Azacitidine|Drug: Cisplatin","Evaluate the Safety and Toxicity of Azacitidine (5-azacytidine, Vidaza®) and Cisplatin Combination","University of Kansas Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10498","February 2007","June 2008","June 2008","March 5, 2007","February 27, 2017","February 27, 2017","Kansas City VA Medical Center, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00443261"
785,"NCT00434239","Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia",,"Unknown status","No Results Available","Myelodysplasia","Drug: Lenalidomide + Ancestim","Toxicity as defined by NCI-CTCv3.0|Response|Pharmacodynamics|Change in Biomarkers","Peter MacCallum Cancer Centre, Australia|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06/49","February 2007","May 2011","May 2014","February 13, 2007",,"January 10, 2013","Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00434239"
786,"NCT00413478","5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia",,"Terminated","Has Results","Chronic Lymphocytic Leukemia|Leukemia","Drug: 5-Azacytidine","Tumor Response Rate (Complete, Partial) of Azacytidine","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0428|NCI-2010-00552","September 2006","November 2014","November 2014","December 19, 2006","June 30, 2015","June 30, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00413478"
787,"NCT00412581","Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma",,"Completed","No Results Available","Melanoma","Drug: Lenalidomide|Drug: Dacarbazine","To find out the highest safe dose of DTIC that can be given in combination with a steady dose of Lenalidomide, to patients with malignant melanoma that has spread to other parts of the body and has not been treated with chemotherapy.","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0487","September 2005","March 2008","March 2008","December 18, 2006",,"April 29, 2016","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00412581"
788,"NCT00412542","Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas",,"Completed","Has Results","Glioblastoma Multiforme|Glioma","Drug: Thalidomide|Drug: CPT-11|Procedure: MRI Scan|Procedure: Quantitative Sensory Tests (QST)","Number of Participants Progression Free at 6 Months With Malignant Gliomas","M.D. Anderson Cancer Center|Celgene Corporation","All","Child, Adult, Older Adult","Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM02-595","October 2003","October 2009","October 2009","December 18, 2006","February 28, 2012","February 28, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00412542"
789,"NCT00387647","Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy",,"Completed","Has Results","Leukemia","Drug: Azacitidine","Rate of Disease Free Survival at One Year|Overall Survival (OS)|Number of Participants With Adverse Events","H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation","All","60 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14496","August 2006","October 2013","August 2014","October 13, 2006","June 30, 2014","August 22, 2014","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00387647"
790,"NCT00379353","The Effects of Thalidomide on Symptom Clusters",,"Completed","Has Results","Advanced Cancers","Drug: Thalidomide|Drug: Placebo","Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS)|Functional Assessment of Anorexia/Cachexia Therapy (FAACT)|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Hospital Anxiety and Depression Scale (HADS) HADS-A (Anxiety)|Hospital Anxiety and Depression Scale (HADS) HADS-D (Depression)|Pittsburgh Sleep Quality Index (PSQI)|Change in Body Composition as Measured by Body Mass Index (BMI)|Change in Serum Cytokines and Receptors","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2005-0980","September 2006","January 2013","January 2013","September 21, 2006","January 1, 2013","February 4, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00379353"
791,"NCT00360672","Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome",,"Completed","Has Results","Acute Myelogenous Leukemia|Myelodysplastic Syndrome","Drug: Revlimid","Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses)","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0293","January 2009","May 2012","May 2012","August 7, 2006","August 1, 2013","August 14, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00360672"
792,"NCT00352794","Lenalidomide for Patients With Myelofibrosis (MF)",,"Completed","Has Results","Myelofibrosis","Drug: Lenalidomide|Drug: Prednisone","Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement)","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0206","July 7, 2006","March 8, 2018","March 8, 2018","July 17, 2006","July 23, 2019","July 23, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT00352794/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00352794"
793,"NCT00350818","Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)",,"Completed","No Results Available","Myelodysplastic Syndrome|Leukemia","Drug: Azacitidine","Time to Toxicity","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0417","October 2005","August 2010","August 2010","July 11, 2006",,"July 30, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00350818"
794,"NCT00349115","TCD Followed by autoSCT for Newly Diagnosed MM Patients",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Thalidomide","Response rate of TCD induction Therapy|Progression free survival and Overall survival of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance|To evaluate toxicities of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance.","Korean Multiple Myeloma Working Party|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KMM53","June 2006",,"June 2008","July 6, 2006",,"May 6, 2008","Je-Jung Lee, Hwsun-eup, Hwasun-gun, Jeollanam-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00349115"
795,"NCT00348595","Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer",,"Completed","Has Results","Prostate Cancer","Drug: Revlimid","Safety, Feasibility and Tolerance of Revlimid as Assessed by Number of Participants Experiencing Grade 3 and 4 Adverse Events.|Number of Participants With Prostate-specific Antigen (PSA) Progression|Change in of PSA Slope|Plasma Concentration of Revilimid at Steady State","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","77","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","J0798|RV-PCA-PI-069|NA_00013597","July 20, 2006","June 29, 2016","June 29, 2016","July 4, 2006","April 12, 2019","April 12, 2019","The Harry and Jeanette Weinberg Building, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00348595"
796,"NCT00337376","A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers",,"Terminated","No Results Available","Advanced Solid Cancers","Drug: Rapamune|Drug: Abraxane","To determine the safety, dose-limiting toxicities, and maximum tolerated dose of weekly oral Rapamycin in combination with weekly intravenous Abraxane for three out of four consecutive weeks in patients with advanced solid cancers.|to determine if weekly administration of Rapamycin changes the pharmacokinetic profile of weekly Abraxane|To determine pre and post therapy changes in p70S6K in peripheral mononuclear cells in patients treated with oral Rapamycin and Abraxane|To evaluate changes in the phosphorylation of p70S6K on tumor tissue and to determine the correlation with phosphorylation of p70S6K in the peripheral mononuclear cells, in patients who give consent to pre and post tumor biopsies","Yale University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0511000860","February 2006","July 2010","July 2010","June 15, 2006",,"January 14, 2014","Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00337376"
797,"NCT00326170","Phase II 5-Azacytidine Plus VPA Plus ATRA",,"Completed","Has Results","Myelodysplastic Syndrome|Acute Myelogenous Leukemia","Drug: 5-Azacytidine (5-aza)|Drug: Valproic Acid|Drug: All-Trans Retinoic Acid (ATRA)","Number of Participants With Response","M.D. Anderson Cancer Center|Celgene Corporation","All","3 Years and older   (Child, Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0799","July 2005","July 2007","December 2007","May 16, 2006","July 11, 2011","June 15, 2012","The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00326170"
798,"NCT00319865","PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Thalidomide|Drug: Adriamycin|Drug: Dexamethasone","Response rate of PAD induction Therapy|Response rate of PAD followed by Thal/Dex maintenance|Progression free survival and Overall survival of PAD/Thal-Dex.|To evaluate toxicities of PAD/Thal-Dex","Korean Multiple Myeloma Working Party|Celgene Corporation","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","47","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KMM55","November 2005",,"September 2008","April 27, 2006",,"April 27, 2006","Gachon University Gil Hospital, Inchon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00319865"
799,"NCT00314665","Use of Thalidomide in Chronic Uveitis",,"Terminated","No Results Available","Uveitis","Drug: Thalidomide","Need for corticosteroids to control eyes|Global assessment of ocular status|Toxicity","University of Cincinnati|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-08-28-05","January 2004",,"August 2006","April 14, 2006",,"December 6, 2007","University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00314665"
800,"NCT00294632","Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Rituximab","Maximum Tolerated Dose (MTD) of Lenalidomide in Combination with Rituximab i|Objective Response Rate","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","112","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0461|NCI-2012-01356","February 2006","February 2016","February 2016","February 22, 2006",,"February 4, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00294632"
801,"NCT00287287","REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas",,"Active, not recruiting","No Results Available","Thyroid Neoplasms","Drug: Lenalidomide","Tumor response","Kenneth Ain|Celgene Corporation|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-701-F3R","February 2006","April 2021","April 2021","February 6, 2006",,"March 19, 2019","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00287287"
802,"NCT00284752","Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: Abraxane","Evaluate the efficacy of Abraxane in first line chemotherapy of patients with|hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response|Evaluate the effect of Abraxane on,Time to PSA progression, Measurable tumor response rate (if measureable disease at baseline), Overall survival|Evaluate the toxicity of Abraxane in this group of patients.","Kaiser Permanente|Celgene Corporation","Male","18 Years and older   (Adult, Older Adult)","Phase 2","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TK001","August 2005","October 2007","December 2011","February 1, 2006",,"October 1, 2012","Kaiser Permanente, Vallejo, California, United States",,"https://ClinicalTrials.gov/show/NCT00284752"
803,"NCT00284505","Use of Thalidomide in Patients With Arachnoiditis",,"Completed","No Results Available","Arachnoiditis","Drug: thalidomide","1. To evaluate the change in pain as measured by the McGill Pain Questionnaire, short form, (SF-MPQ) and consumption of adjuvant opioid medications in three patients with arachnoiditis who receive thalidomide.|2. To evaluate the change in physical functionality as measured by the Roland-Morris Low Back Pain and Disability Questionnaire in three patients with arachnoiditis who receive thalidomide.|1. To measure change in the patient's health status as measured by the SF36 in three patients with arachnoiditis who receive thalidomide.","Washington University School of Medicine|Celgene Corporation","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CG0678","July 2005",,"July 2006","January 31, 2006",,"December 5, 2008","Washington University Pain Management Center, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00284505"
804,"NCT00267059","Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)",,"Completed","Has Results","Chronic Lymphocytic Leukemia|Leukemia","Drug: Lenalidomide","Number of Patients in Overall Response Categories","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0175","December 2005","August 2009","August 2009","December 20, 2005","April 21, 2011","August 7, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00267059"
805,"NCT00251472","A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer","Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension","To assess the response rate of Abraxane given weekly as first-line treatment for patients with locally advanced or metastatic breast cancer.|To assess time to progression (TTP), overall survival (OS), and toxicities of Abraxane as first-line treatment for patients with locally advanced or metastatic breast cancer.","Veeda Oncology|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I-04-012","March 2005","May 2010","May 2010","November 10, 2005",,"May 11, 2012","Veeda Oncology, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00251472"
806,"NCT00226980","A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma",,"Completed","No Results Available","Kidney Neoplasms","Drug: Thalidomide|Drug: Capecitabine","Efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma.|Safety of the combination","Stanford University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RENAL0001","October 2002","July 2005","July 2006","September 27, 2005",,"April 14, 2009","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00226980"
807,"NCT00209014","Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease",,"Terminated","No Results Available","B-Cell Lymphoma|Hodgkin's Disease","Drug: Thalidomide",,"Emory University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0544-2003","July 2003",,"June 2006","September 21, 2005",,"May 7, 2009","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00209014"
808,"NCT00193102","Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Drug: Thalidomide|Drug: Capecitabine","Overall response rate","SCRI Development Innovations, LLC|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 60","April 2001","February 2005","June 2010","September 19, 2005",,"May 3, 2011",,,"https://ClinicalTrials.gov/show/NCT00193102"
809,"NCT00177814","Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit",,"Completed","No Results Available","Gram-negative Bacterial Infections",,"dead or alive","University of Pittsburgh|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)",,"1000","Other|Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","IRB # 0508074","September 2005","June 2017","June 2017","September 15, 2005",,"June 12, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00177814"
810,"NCT00162760","Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide",,"Completed","No Results Available","Idiopathic Pulmonary Fibrosis (IPF)","Drug: Thalidomide","To determine the safety, feasibility and efficacy of 400 mg of thalidomide administered daily for one year in patients with IPF who have failed or are not candidates for treatment with corticosteroids and/or cytotoxic drug.|The efficacy of thalidomide in preventing progressive pulmonary fibrosis and clinical deterioration measured objectively with changes in PFTs and radiographs as well as with dyspnea scales and quality of life measures.","Johns Hopkins University|Celgene Corporation","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CG00519","October 2003",,"July 2007","September 13, 2005",,"June 22, 2010","Johns Hopkins School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00162760"
811,"NCT00151203","Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Clarithromycin, Lenalidomide, Dexamethasone","Response rate, time to maximum response, toxicities","Weill Medical College of Cornell University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0409007427","December 2004","April 2007","August 2022","September 8, 2005",,"May 31, 2019","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00151203"
812,"NCT00140452","Phase II Study Using Thalidomide for the Treatment of ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis|ALS","Drug: Thalidomide","To evaluate the effect of Thalidomide in the rate of progression in ALS at 9 months and hence determine preliminary efficacy in the treatment of ALS|To evaluate 1) toxicity 2) quality of life 3) cytokine profile 4) PFT's 5) sleep questionnaire and 6) survival of thalidomide in the treatment of ALS","Dartmouth-Hitchcock Medical Center|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALS-001","February 2005",,"November 2007","September 1, 2005",,"November 21, 2007","Dartmouth Hichcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT00140452"
813,"NCT00110695","Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer",,"Completed","No Results Available","Breast Neoplasms","Drug: Nanoparticle albumin bound paclitaxel followed by FEC","pathologic complete response rate in the breast for patients with locally advanced breast cancer (LABC) who receive Abraxane|pathologic complete response rate in the breast and axillary nodes (pCR breast and nodes) in all patients|complete clinical response rate (cCR) of the sequential regimen in patients who present with palpable measurable disease|complete clinical and imaging response rate (ciCR) of the sequential regimen in all patients|complete clinical response rate (cCR)of Abraxane in patients who present with palpable measurable disease|toxicity of the sequential chemotherapy regimen|toxicity of the sequential chemotherapy regimen when administered concurrently with trastuzumab|2-year progression-free survival|2-year overall survival (OS)|exploration of molecular and genetic correlates of response","NSABP Foundation Inc|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSABP FB-AX-003","April 2005","December 2006","July 2008","May 13, 2005",,"March 26, 2010","NSABP Operations Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00110695"
814,"NCT00091260","CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis",,"Completed","Has Results","Multiple Myeloma","Drug: dexamethasone|Drug: lenalidomide","Number of Patients Removed From Study Treatment Due to Toxicities|Number of Patients With Hematologic Response With Single-agent CC-5013|Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response","Vaishali Sanchorawala|Celgene Corporation|Boston Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","82","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000385687|BUMC-H-23235|CELGENE-RV-AMYL-PI-003","January 2004","July 2012","May 2015","September 9, 2004","February 20, 2017","February 20, 2017","Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00091260"
815,"NCT00087672","A Phase II Study of CC-5013 in Myelofibrosis",,"Completed","Has Results","Myelofibrosis","Drug: CC-5013","Efficacy of CC-5013 in Myelofibrosis","M.D. Anderson Cancer Center|Celgene Corporation","All","Child, Adult, Older Adult","Phase 2","41","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003-0648","July 2004","February 2009","February 2009","July 14, 2004","February 21, 2011","August 7, 2012","M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00087672"
816,"NCT00083876","D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide","1.1 To evaluate, in a randomized phase III clinical trial in previously treated multiple myeloma patients whether angio-chemotherapy with D.T. PACE may be equivalent or superior to tandem transplant.","University of Arkansas|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UARK 98-035","September 1998",,"November 2007","June 4, 2004",,"July 2, 2010","University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00083876"
817,"NCT00083707","Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia",,"Completed","No Results Available","Waldenstrom Macroglobulinemia","Drug: Thalidomide","To determine tumor response, overall and progression free survival following thalidomide therapy in patients with Waldenstrom's Macroglobulinemia (WM)|To determine toxicities associated with thalidomide in patients with Waldenstrom's Macroglobulinemia","University of Arkansas|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UARK 99-006","January 1999",,"February 2003","May 31, 2004",,"July 5, 2010","University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00083707"
818,"NCT00083694","Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia",,"Completed","No Results Available","Leukemia","Drug: Thalidomide","To evaluate the efficacy and safety of Thalidomide in patients with leukemia.","University of Arkansas|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UARK 98-032","August 1998",,"May 2005","May 31, 2004",,"July 2, 2010","University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00083694"
819,"NCT00083551","UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy",,"Completed","Has Results","Multiple Myeloma","Drug: Thalidomide|Drug: Ara-C|Drug: BCNU|Drug: Cisplatin|Drug: Cytoxan|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Filgrastim|Drug: Recombinant GM-CSF|Drug: Interferon-alpha-2b|Drug: Melphalan|Drug: Vincristine","Overall Survival","University of Arkansas|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","668","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5226","August 1998","August 2014","August 2014","May 27, 2004","September 22, 2015","November 23, 2015","University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00083551"
820,"NCT00038233","Thalidomide for Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide","Maximum Tolerated Dose of Thalidomide","M.D. Anderson Cancer Center|Celgene Corporation","All","Child, Adult, Older Adult","Phase 3","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM98-359","May 1999","April 2005","April 2005","May 30, 2002",,"October 31, 2018","University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00038233"
821,"NCT00038090","Thalidomide-Dexamethasone for Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Dexamethasone","Response Rate","M.D. Anderson Cancer Center|Celgene Corporation","All","Child, Adult, Older Adult","Phase 2|Phase 3","83","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID00-070","June 2000","May 2005","May 2005","May 29, 2002",,"October 31, 2018","University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00038090"
822,"NCT00000812","A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection",,"Completed","No Results Available","HIV Infections","Drug: Thalidomide",,"National Institute of Allergy and Infectious Diseases (NIAID)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","NIH|Industry","Interventional","Masking: Double|Primary Purpose: Treatment","ACTG 267|42,240|11243",,,"July 2000","August 31, 2001",,"April 4, 2012","University of Colorado Hospital CRS, Aurora, Colorado, United States|University of Minnesota, ACTU, Minneapolis, Minnesota, United States|Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States|Unc Aids Crs, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00000812"
823,"NCT03331640","A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy","PANTHEON","Recruiting","No Results Available","Metastatic Pancreatic Ductal Adenocarcinoma","Drug: OFF|Drug: FOLFIRI Protocol","Progression-free survival during 2nd line therapy (PFS2)","AIO-Studien-gGmbH|Celgene International II SARL","All","18 Years and older   (Adult, Older Adult)","Phase 2","204","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AIO-PAK-0116","January 2, 2018","January 2022","January 2023","November 6, 2017",,"April 18, 2019","Praxis für Innere Medizin, Friedrichshafen, Germany",,"https://ClinicalTrials.gov/show/NCT03331640"
824,"NCT04092179","Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers",,"Not yet recruiting","No Results Available","Acute Myeloid Leukemia|Relapsed Cancer|Refractory Cancer|IDH2 Gene Mutation","Drug: Enasidenib|Drug: Venetoclax","Overall response rate (ORR)|Dose Limiting Toxicity|Maximum tolerated dose or Recommended Phase 2 Dose|Duration of Response|Overall Survival|Event Free Survival","University Health Network, Toronto|Celgene|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-5939|ENAVEN-AML","December 2019","December 2022","June 2023","September 17, 2019",,"September 17, 2019","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04092179"
825,"NCT03836885","Apremilast - Oral Lichen Planus Trial","APOLP","Not yet recruiting","No Results Available","Oral Lichen Planus","Drug: Apremilast|Drug: Placebo","Assessing treatment success defined as Physician Global Assessment (PhGA) of 0 or 1|Achieving complete remission defined as achieving a score of 0 on PhGA scale|Physician Global Assessment (PhGA)|Patient Assessment (PtA)|Achieving partial response|Visual Analogue Scale (VAS)|Oral Health Impact Profile (OHIP-14) Scale|Modified Oral Mucositis Index (MOMI) Scale|Safety and tolerability of Apremilast|Standardized steroid and anti-fungal rinses used|Body Mass Index (BMI)","Sunnybrook Health Sciences Centre|Celgene|Sunnybrook Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","049-2018","April 15, 2019","April 15, 2021","April 15, 2021","February 11, 2019",,"April 8, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03836885"
826,"NCT03413800","Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant",,"Recruiting","No Results Available","Relapsed Hematologic Malignancy|Multiple Myeloma","Drug: Lenalidomide-Dexamethasone-DLI","Efficacy of Len-Dex-DLI in patients with relapsed myeloma measured by progression-free survival|Incidence of grade ≥III non hematologic toxicity and incidence of grade ≥IV hematologic toxicity|Incidence of acute GVHD|Incidence of chronic GVHD|Maximum grades of acute and chronic GVHD|Response to treatment|Non-relapse mortality after DLIs|Overall survival at 2 years|Incidence of progression at 2 years|Disease status assessment by flow cytometry|Disease status assessment by PET scan|Evaluation of quality of life (QoL) during treatment|Evaluation of the BM microenvironment by transcriptome analysis before and after treatments","Ciusss de L'Est de l'Île de Montréal|Celgene|Centre de Commercialisation en Immunothérapie du Cancer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMR003","February 12, 2018","January 29, 2021","January 29, 2023","January 29, 2018",,"August 6, 2019","CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03413800"
827,"NCT03376477","Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission",,"Recruiting","No Results Available","Multiple Myeloma","Biological: GM-CSF vaccine|Drug: Lenalidomide|Drug: Prevnar13|Other: Placebo Prevnar13|Other: Placebo GM-CSF Vaccine","2-year progression free survival|Response Conversion Rate|MRD Conversion Rate|Time to Response|Progression Free Survival (PFS)|Evaluate toxicity of allogenic myeloma vaccine|Measure tumor specific immunity and correlate with systemic immunity","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene|Aduro Biotech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J16118|IRB00112179","September 2019","October 16, 2021","October 16, 2023","December 18, 2017",,"August 2, 2019","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03376477"
828,"NCT03345095","A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma",,"Recruiting","No Results Available","Newly Diagnosed Glioblastoma","Drug: Marizomib|Drug: Temozolomide|Radiation: radiotherapy","Overall Survival (OS)|Progression Free Survival (PFS)|Health-related Quality of life (HRQol)|Mini Mental State Examination (MMSE)","European Organisation for Research and Treatment of Cancer - EORTC|Celgene|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Older Adult)","Phase 3","750","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EORTC-BTG-1709","July 26, 2018","July 2022","July 2023","November 17, 2017",,"June 17, 2019","Kepler University Hospital, Linz, Austria|Medical University Vienna - General Hospital AKH, Vienna, Austria|Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium|GasthuisZusters Antwerpen - Sint-Augustinus, Antwerpen, Belgium|Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|C.H.U. Sart-Tilman, Liège, Belgium|London Regional Cancer Center, London, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|BCCA - Abbotsford Centre, Abbotsford, Canada|Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, Canada|Kingston Health Sciences Centre, Kingston, Canada|CHUM - Centre Hospitalier de l'Université de Montreal - Hopital Notre-Dame, Montréal, Canada|Hopital Du Sacre-Coeur De Montreal, Montréal, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec, Canada|Allan Blair Cancer Centre, Regina, Canada|Sault Area Hospital, Sault Ste. Marie, Canada|Regional Cancer Program of Hopital Reg. de Sudbury Reg. Hospital, Sudbury, Canada|Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Canada|University Health Network - Oci / Princess Margaret Hospital, Toronto, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivières, Canada|Cancercare Manitoba, Winnipeg, Canada|Aarhus University Hospitals - Aarhus University Hospital (440), Aarhus, Denmark|CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron, France|CHRU de Lille, Lille, France|Institut de Cancerologie de l'Ouest, Nantes, France|Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere, Paris, France|Gustave Roussy, Villejuif, France|Universitaetsklinik Erlangen-Neurologische Klinik (3031), Erlangen, Germany|UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg, Germany|Universitaetsklinikum Leipzig-Klinik für Strahlentherapie und Radioonkologie, Leipzig, Germany|Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center, Mainz, Germany|UniversitaetsMedizin Mannheim, Mannheim, Germany|Technische Universitaet Muenchen - Klinikum Rechts Der Isar, Muenchen, Germany|Universitaetskliniken Regensburg, Regensburg, Germany|Spaarne Gasthuis - Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Radboud University Medical Center Nijmegen, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum - Academisch Ziekenhuis, Utrecht, Netherlands|Oslo University Hospital - Radiumhospitalet, Oslo, Norway|Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Badalona, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Clinica Universidad de Navarra - Clinica Universitaria De Navarra, Pamplona, Spain|University Hospital of Geneva, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital, Saint Gallen, Switzerland|UniversitaetsSpital, Zürich, Switzerland|NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03345095"
829,"NCT03143049","Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma",,"Recruiting","No Results Available","Relapse Multiple Myeloma","Drug: PCD|Drug: PD","Progression free survival (PFS)|Overall response rate (ORR)|Overall survival (OS)|Duration of response (DOR)|Number of Participants affected by Adverse Events","National University Hospital, Singapore|Celgene|International Myeloma Foundation","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMN003","September 13, 2017","June 1, 2018","June 1, 2022","May 8, 2017",,"November 6, 2017","Queen Mary Hospital, Hong Kong, Hong Kong|Japan, Japan|South Korea, Korea, Republic of|National University Hospital, Singapore, Singapore|National Taiwan University, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03143049"
830,"NCT02992522","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Suspended","No Results Available","B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Drug: Lenalidomide|Biological: Obinutuzumab|Drug: Venetoclax","MTD defined as the highest level at which no more than 6 patients experience a DLT assessed by National Cancer Institute Common Terminology Criteria of Adverse Events version 4|Objective response rate (ORR) defined as the proportion of patients achieving a complete or partial, response according to the Lugano Lymphoma Response Criteria|Progression-free survival","Beth Christian|Celgene|Genentech, Inc.|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-16187|NCI-2016-01723","February 21, 2017","January 31, 2020","January 31, 2021","December 14, 2016",,"June 3, 2019","Emory University, Atlanta, Georgia, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02992522"
831,"NCT02983097","Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","R²-DHAP","Terminated","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III°)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)","Drug: Rituximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Dexamethasone|Drug: Cytarabine|Drug: Lenalidomide|Drug: PegFilgrastim|Procedure: peripheral stem cell collection","Overall Response Rate (ORR)|Maximum tolerated dose (MTD)|Rate of complete remission|Rate of primary progression|Rate of treatment related deaths|Relapse Rate|Overall Survival|Progression free survival|tumour control|feasibility of stem cell mobilization|incidence of non-hematological toxicities > grade 2 CTC|incidence and duration of neutropenia and thrombopenia grade 4","Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Celgene|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSHNHL 2008 R6|2009-010824-25","November 2010","January 2014","April 28, 2015","December 6, 2016",,"January 19, 2018","Diakonie Krankenhaus Bremen, Bremen, Germany|Klinikum Chemnitz, Chemnitz, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany|Universitätsklinikum Göttingen, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Westpfalz Klinikum, Kaiserslautern, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|LMU Klinikum München-Großhadern, München, Germany",,"https://ClinicalTrials.gov/show/NCT02983097"
832,"NCT02966782","A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes (MDS)",,"Active, not recruiting","No Results Available","Myelodysplastic Syndromes (MDS)","Drug: venetoclax|Drug: azacitidine","AUCt for azacitidine|Clearance (CL) for azacitidine|Cmax for azacitidine|Tmax for venetoclax|Recommended Phase 2 Dose (RPTD) and dosing schedules of venetoclax as monotherapy and in combination with azacitidine|AUC[0 to infinity] for azacitidine|Tmax for azacitidine|AUC [0-24] for venetoclax|AUCt for venetoclax|Cmax of venetoclax|Half-life (t[1/2]) for azacitidine|Event-Free Survival (EFS)|Overall Survival (OS)|Rate of bone marrow blast response|Time to next treatment (TTNT)|Duration of Response (DOR)|Rate of platelet (PLT) transfusion independence|Time to Transformation acute myeloid leukemia (AML)|Progression-Free Survival (PFS)|Overall Response Rate (ORR)|Complete Remission (CR) Rate|Rate of red blood cell (RBC) transfusion independence|Rate of complete cytogenetic response|Rate of Hematologic Improvement (HI)|Rate of marrow complete remission (mCR)","AbbVie|Celgene|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-522|2016-001904-46","March 7, 2017","October 17, 2020","October 17, 2020","November 17, 2016",,"October 17, 2019","University of Arizona Cancer Center - North Campus /ID# 157503, Tucson, Arizona, United States|University of Colorado /ID# 155365, Aurora, Colorado, United States|Yale University /ID# 162544, New Haven, Connecticut, United States|University of Chicago /ID# 155364, Chicago, Illinois, United States|Mass General Hospital /ID# 171227, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 155361, Boston, Massachusetts, United States|University of Massachusetts Wo /ID# 155366, Worcester, Massachusetts, United States|Weill Cornell Medicine /ID# 156388, New York, New York, United States|Oregon Health and Science University /ID# 155360, Portland, Oregon, United States|University of Texas MD Anderson Cancer Center /ID# 155362, Houston, Texas, United States|St George Hospital /ID# 156037, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 155952, Liverpool, New South Wales, Australia|St. Vincents Hosp Melbourne /ID# 155950, Fitzroy, Victoria, Australia|Royal Perth Hospital /ID# 155951, Shenton Park, Western Australia, Australia|Royal Melbourne Hospital /ID# 155949, Melbourne, Australia|Universitatsklinikum Mannheim /ID# 156038, Mannheim, Baden-Wuerttemberg, Germany|Univ Klinikum Duesseldorf /ID# 154899, Dusseldorf, Nordrhein-Westfalen, Germany|Marien Hospital Dusseldorf /ID# 155518, Dusseldorf, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 155519, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gus /ID# 154898, Dresden, Sachsen, Germany|Universitaetsklinikum Leipzig /ID# 154897, Leipzig, Sachsen, Germany|Universitatsklinikum Halle /ID# 158643, Halle, Germany|Klinikum Rechts der Isar /ID# 154896, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT02966782"
833,"NCT02916771","Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma",,"Recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone","Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy|Progression Free Survival|Time To Progression|Duration of Response|Objective Response Rate|Overall Survival","Dana-Farber Cancer Institute|Celgene|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-313","October 2016","April 2020","April 2024","September 27, 2016",,"January 7, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02916771"
834,"NCT02886065","A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM",,"Recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: Hiltonol|Drug: Citarinostat|Drug: Lenalidomide|Biological: PVX-410","Safety And Tolerability Of The PVX-410 Tumor Vaccine Regimen|Immune Responses Of Lymphocytes To HLA A2+|Change In Monoclonal (M) Serum Protein|Change In Free Light Chain (FLC)|Change In Urinary FLC Level|Correlation of Immune Response and Clinical Anti-tumor Responses","Massachusetts General Hospital|Celgene|OncoPep, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-237","November 2016","May 2021","May 2021","September 1, 2016",,"August 13, 2019","Massachusetts general Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Hospital of Cleveland- Seidman Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02886065"
835,"NCT02775500","Apremilast Pregnancy Exposure Registry",,"Recruiting","No Results Available","Psoriatic Arthritis|Psoriasis","Drug: apremilast","The number of major structural malformations identified in the children of study participants|A pattern of major malformations identified in the children of study participants|Pattern of minor structural malformations identified by study physical exam in the children of study participants|Pregnancy Outcome; rate of live born infants, spontaneous abortions, stillbirths, and terminations between cohort groups|Gestational age at delivery among infants in the cohort groups|Pregnancy Complication rates between cohort groups|Neonatal Complication rates between cohort groups|Pre- and post-natal fetal and infant growth percentiles|Any serious and opportunistic infections rates occurring in infants whose mothers are enrolled in the study|Any malignancies diagnosed in infants of mothers enrolled in the study","University of California, San Diego|Celgene|The Organization of Teratology Information Specialists","Female","Child, Adult, Older Adult",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","141041","November 2014","February 2022","July 2024","May 17, 2016",,"October 9, 2019","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02775500"
836,"NCT02654132","An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone","Progression-free Survival (PFS)|Objective Response Rate (ORR)|Overall Survival (OS)","Bristol-Myers Squibb|Celgene|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-125|2014-003282-19","March 16, 2016","January 17, 2018","December 1, 2020","January 13, 2016","June 3, 2019","June 3, 2019","Winship Cancer Institute, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Rochester General Hospital, Rochester, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Northern Utah Associates, Ogden, Utah, United States|University Of Washington, Seattle, Washington, United States|Local Institution, South Brisbane, Queensland, Australia|Local Institution, London, Ontario, Canada|CISSS de l'Outaouais, Gatineau, Quebec, Canada|CIUSSS de l'Est-de-L'Ile-de-Montreal - Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Local Institution, Nantes Cedex 1, France|Local Institution, Paris Cedex 12, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Saint Pierre Cedex, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|St. Barbara-Klinik, Hamm, Germany|Universitasklinikum Heidelberg, Heidelberg, Germany|Universitasklinikum Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Laiko University Hospital, Athens, Greece|Alexandra General Hospital Of Athens, Athens, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Local Institution, Roma, Italy|Universita' La Sapienza, Roma, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Shibuya-ku, Tokyo, Japan|Local Institution, Tachikawa-shi, Tokyo, Japan|Local Institution, Kasama-shi, Japan|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Utrecht, Netherlands|Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzow, Poland|Local Institution, Lublin, Poland|Oddzial Hematologii i Transplantacji Szpiku, Poznan, Poland|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02654132/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02654132/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02654132"
837,"NCT02529852","A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Maximum Tolerated Dose (MTD) of Lenalidomide, Obinutuzumab, and CHOP|Overall Response Rate","M.D. Anderson Cancer Center|Celgene|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","59","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0069|NCI-2015-01517","November 4, 2015","November 2021","November 2021","August 20, 2015",,"May 16, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02529852"
838,"NCT02406144","Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: MLN9708|Drug: Lenalidomide|Drug: Dexamethasone","Progression-free survival|Minimal Residual Disease (MRD)|Overall survival","PETHEMA Foundation|Celgene|Millennium Pharmaceuticals, Inc.","All","18 Years to 67 Years   (Adult, Older Adult)","Phase 3","316","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM2014MAIN","November 2014","September 2017","November 2017","April 2, 2015",,"November 30, 2017","Complejo Hospitalario Universitario de Santiago, A Coruña, Spain|Hospital Txagorritxu, Alava, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Del Vinalopo, Alicante, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital de Cabueñes, Asturias, Spain|Hospital Universitario Central de Asturias, Asturias, Spain|Hospital Clinic, Barcelona, Spain|H.Universitari Germans Trias I Pujol de Badalona, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital de Sabadell (Parc Taulí), Barcelona, Spain|Hospital de Sant Joan de Déu, Barcelona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitari Mútua de Terrasa, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Ico L'Hospitalet, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Marqués de Valdecilla, Cantabria, Spain|Hospital General de Castellón, Castello, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Hospital de Especialidades de Jerez de La Frontera, Cádiz, Spain|Hospital Universitari Dr. Josep Trueta de Girona, Girona, Spain|Hospital de Gran Canaria Doctor Negrín, GRAN Canaria, Spain|Hospital Universitario Virgen de Las Nieves, Granada, Spain|Hospital Universitario Guadalajara, Guadalajara, Spain|Hospital Universitario Donostia, Guipúzcoa, Spain|Hospital Son Llatzer, Illes Balears, Spain|Hospital Universitari Son Espases, Illes Balears, Spain|Hospital San Pedro, La Rioja, Spain|Hospital de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Centro Oncológico Md Anderson International España, Madrid, Spain|Fundación Jiménez Díaz-Ute, Madrid, Spain|Hm Universitario San Chinarro, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Del Tajo, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Infanta Sofía, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Complejo Hospital Costa Del Sol (Ivcs), Malaga, Spain|Hospital General Universitario Santa Lucia, Murcia, Spain|Hospital J.M. Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, Spain|Clinica Universidad de Navarra, Navarra, Spain|Complejo Hospitalario de Navarra, Navarra, Spain|Complejo Hospitalario de Ourense, Ourense, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Santa Bárbara, Soria, Spain|Hospital Universitari Joan Xxiii de Tarragona, Tarragona, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital Nuestra Señora Del Prado, Toledo, Spain|Hospital Clínico Universitario Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|HOSPITAL CLíNICO UNIVERSITARIO DE VALLADOLID, Valladolid, Spain|Hospital Universitario Del Rio Hortega, Valladolid, Spain|Hospital de Cruces, Vizcaya, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02406144"
839,"NCT04161456","Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata","APACCO","Recruiting","No Results Available","Acne Conglobata","Drug: Apremilast","50% reduction in number of lesion|Proportionof subjects in Investigator global assessment (IGA)|proportion of subjects in Investigator global assessment (IGA)|change in skin condition|change in pain of the inflammatory lesions|change in itch of the inflammatory lesions measured by a VAS|change in quality of life|change in depression profile|compliance to therapy (drug accountability)|Frequency of adverse events (AEs)|Seriousness of adverse events (AEs)","Dr. Frank Behrens|Dermatology Department University Hospital Frankfurt|Celgene|Fraunhofer Institute for Molecular Biology and Applied Ecology","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMP‐0517","October 9, 2019","September 2020","September 2020","November 13, 2019",,"November 13, 2019","University Hospital Frankfurt, Frankfurt, Hessia, Germany",,"https://ClinicalTrials.gov/show/NCT04161456"
840,"NCT02300935","Study of Trametinib and Nab-paclitaxel in Patients With Melanoma",,"Withdrawn","No Results Available","Melanoma","Drug: trametinib|Drug: nab-paclitaxel","Number of patients with Adverse Events (AEs) as a Measure of Safety and Tolerability","SCRI Development Innovations, LLC|Celgene|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI MEL 40","December 2015","January 20, 2016","January 20, 2016","November 25, 2014",,"May 30, 2019","Colorado Blood Cancer Institute, Denver, Colorado, United States|Florida Cancer Center, Sarasota, Florida, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02300935"
841,"NCT02232516","Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma",,"Recruiting","No Results Available","Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome","Drug: romidepsin|Drug: lenalidomide|Other: laboratory biomarker analysis","Objective response rate (ORR), as defined per Cheson criteria|Incidence of toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Progression-free survival (PFS)|Overall survival (OS)|Duration of response, defined per Cheson criteria|Delay to cytotoxic chemotherapy","Northwestern University|Celgene|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 14H04|NCI-2014-01770|RV-CL-PTCL-PI-003974|STU00097620|P30CA060553","June 2015","July 2019","August 2020","September 5, 2014",,"August 29, 2018","City of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|Weill Cornell Medicine, New York, New York, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02232516"
842,"NCT03881735","Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation",,"Not yet recruiting","No Results Available","Blasts Under 5 Percent of Peripheral Blood White Cells|Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level|IDH2 Gene Mutation|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia","Drug: Enasidenib|Procedure: Hematopoietic Cell Transplantation","Event-free survival (EFS) in each cohort|Success rate of hematopoietic cell transplantation (HCT)|Median duration of maintenance therapy in both cohorts|Overall survival in each cohort","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 67118|NCI-2019-00332|P30CA016056","November 15, 2019","November 19, 2021","November 19, 2022","March 19, 2019",,"November 15, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03881735"
843,"NCT03837132","Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer",,"Recruiting","No Results Available","Advanced Cancer","Behavioral: Palliative care assessment","Impact of early palliative care on quality of life in patients with advanced pancreatic cancer|To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer","University of Manitoba|CancerCare Manitoba|Celgene","All","18 Years and older   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","H2018:291","October 15, 2018","February 28, 2020","June 30, 2020","February 11, 2019",,"February 11, 2019","Victoria General Hospital Buhler Cancer Centre, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT03837132"
844,"NCT02086604","Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Brentuximab vedotin|Drug: Lenalidomide","Safety as measured by grade and frequency of adverse events|Maximum Tolerated Dose (MTD) as measured by the number of dose-limiting toxicities in each dose level (cohort)|Objective response rate as measured by CD30 expression|Overall response rate|Duration of response|Progression-free survival (PFS)","Washington University School of Medicine|Celgene|Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201404056","September 18, 2014","June 9, 2017","November 30, 2019","March 13, 2014",,"June 11, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States|Ohio State University, James Cancer Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02086604"
845,"NCT02047513","Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer","NEONAX","Active, not recruiting","No Results Available","Resectable Pancreatic Cancer|Ductal Adenocarcinoma of the Pancreas","Drug: perioperative nab-paclitaxel/gemcitabine|Drug: adjuvant nab-paclitaxel/gemcitabine","Time to Disease free survival (DFS)|Safety|morbidity and mortality|toxicity|Disease progression|resection rate|Tumor response|Correlation of tumor regression and R0 resection|Overall survival|tumor recurrence|quality of life|pharmacogenomic markers, tumor-biomarkers and molecular analyses|Tumor recurrence","AIO-Studien-gGmbH|Celgene|ClinAssess GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","127","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO-PAK-0313|2013-005559-34|AX_CL_PANC_AIO_003710","July 2015","April 2021","October 2022","January 28, 2014",,"November 20, 2019","University of Ulm, Dept. of Internal Medicine I, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT02047513"
846,"NCT02024009","Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2","SCALOP-2","Recruiting","No Results Available","Pancreatic Neoplasms (Locally Advanced Non-metastatic)","Drug: nab-paclitaxel|Radiation: 60Gy in 30#|Radiation: 50.4Gy in 28#|Drug: Nelfinavir|Drug: Capecitabine|Drug: Gemcitabine","Overall survival|Progression free survival|Toxicity|Quality of life","University of Oxford|Celgene|Cancer Research UK","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","289","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCTO_063","March 2016","August 2020","August 2020","December 31, 2013",,"October 16, 2018","Oxford University Hospitals, Churchill Cancer Centre, Headington, Oxfordshire, United Kingdom|Bristol Haematoloy and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|University Hospital, Coventry, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|St James' Hospital, Leeds, United Kingdom|University College London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02024009"
847,"NCT03383575","Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome",,"Recruiting","No Results Available","Acute Myeloid Leukemia|Blasts 20-30 Percent of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia|IDH2 Gene Mutation|Myelodysplastic Syndrome With Excess Blasts|Recurrent High Risk Myelodysplastic Syndrome|Refractory High Risk Myelodysplastic Syndrome","Drug: Azacitidine|Drug: Enasidenib|Other: Quality-of-Life Assessment","Incidence of adverse events|Overall response rate|Event-free survival (EFS)|Overall survival (OS)|Anti-tumor activity|Pharmadynamics (PDn) markers|Drug exposure levels","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Celgene","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","105","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0981|NCI-2018-00987|P30CA016672","January 17, 2018","February 28, 2022","February 28, 2023","December 26, 2017",,"July 19, 2019","Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03383575"
848,"NCT03361319","Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma","N3","Not yet recruiting","No Results Available","NSCLC, Recurrent|Adenocarcinoma of Lung","Drug: Vargatef|Drug: Abraxane|Other: placebo","Part 1: Maximum Tolerated Dose|Part 1 and 2: Adverse Events Review|Part 1 and 2: RECIST Response|Cycles Tolerated|Part 2: Overall Survival","Royal Marsden NHS Foundation Trust|Boehringer Ingelheim|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","194","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCR 4448","October 2019","January 2023","January 2023","December 4, 2017",,"August 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03361319"
849,"NCT03345810","Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)","DURATION","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Metastatic Lung Cancer|Non Small Cell Lung Cancer|Lung Adenocarcinoma Metastatic|Large Cell Lung Carcinoma Metastatic","Drug: Durvalumab|Drug: Vinorelbine|Drug: Gemcitabine|Drug: nab-Paclitaxel|Drug: Carboplatin","Rate of treatment related Grade III/IV adverse events (CTCAE V4.03)|PFS|ORR using assessment according to RECIST 1.1|OS|Adverse Events /Serious Adverse Events|Health related Quality of Life (HR-QoL)|Geriatric assessment","AIO-Studien-gGmbH|AstraZeneca|Celgene","All","70 Years and older   (Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO-YMO/TRK-0416|2016-003963-20|ESR-15-11003|AX-CL-NSCLC-AIO-008260","December 14, 2017","June 2022","December 2022","November 17, 2017",,"July 30, 2018","Gesundheitszentrum St. Marien GmbH, Amberg, Germany|DRK-Kliniken Berlin Mitte, Berlin-Mitte, Germany|Ev. Lungenklinik Berlin, Berlin, Germany|Klinikum Darmstadt, Darmstadt, Germany|Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany|Klinikum Esslingen, Esslingen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Klinik Schillerhöhe, Gerlingen, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Onkodoc GmbH, Gütersloh, Germany|Krankenhaus Martha-Maria Halle Dölau, Halle (Saale), Germany|Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|""Vincentius-Diakonissen-Kliniken gAG, Karlsruhe, Germany|Kliniken der Stadt Köln gGmbH, Köln, Germany|Ortenau-Klinikum Lahr, Lahr, Germany|Ev. Diakonissenkrankenhaus Leipzig, Leipzig, Germany|Klinikum Ludwigsburg, Ludwigsburg, Germany|Klinik Löwenstein gGmbH, Löwenstein, Germany|Klinikum der Universität München, München, Germany|Pius Hospital Oldenburg, Oldenburg, Germany|Krankenhaus Barmherzige Brüder, Regensburg, Germany|""Klinikum Rheine, Rheine, Germany|Marienhospital, Stuttgart, Germany|Krankenhaus der Barmherzigen Brüder, Trier, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany|SHG-Kliniken-Völklingen, Völklingen, Germany|Hämatologisch-Onkologische Praxis Würselen, Würselen, Germany|Klinikum Würzburg Mitte gGmbH, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03345810"
850,"NCT01729104","Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma",,"Terminated","No Results Available","Lymphoma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Rituximab","Maximum Tolerated Dose (MTD) of Carfilzomib and Lenalidomide in Combination With Rituximab|Objective Response Rate (ORR)","M.D. Anderson Cancer Center|Celgene|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0188|NCI-2013-00117","April 25, 2013","October 3, 2018","October 3, 2018","November 20, 2012",,"October 22, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01729104"
851,"NCT01718379","Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: Lenalidomide|Drug: Epoetin beta","Comparing the efficacy of Lenalidomide alone to Lenalidomide with Epoetin beta in transfusion-dependent ESA-resistant|will be to assess the safety of Lenalidomide and of its combination with Epoetin beta","Groupe Francophone des Myelodysplasies|Celgene|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GFM-Len-Epo-08","July 2010","November 2012","June 2016","October 31, 2012",,"November 8, 2016","Hematology Dpt, Service d'Hématologie Clinique, CHU Albert Michallon, Grenoble, France|Hematology Dpt, CHU de Bicêtre, Le Kremlin-Bicêtre, Ile de France, France|Hematology Dpt, CHU Cochin, Paris, Ile de France, France|Chu Amiens, Amiens, France|CHU Angers, Angers, France|Hematology Dpt, CH d'Avignon-305 rue Follereau-, Avignon, France|CH de la Cote Basque, Bayonne, France|centre de Blois, Blois, France|Hopital Avicenne, Bobigny, France|Hematology Dpt, CHU Haut-Lévèque, Bordeaux, France|Hôpital Boulogne Sur Mer, Boulogne Sur Mer, France|hôpital Morvan, Brest, France|CHU Clémenceau, Caen, France|CH de Carcassonne, Carcassonne, France|Hematology Dpt, CH René Dubos, Cergy-pontoise, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CH de Compiègne, Compiègne, France|Hematology Dpt, Hôpital Sud Francilien, Corbeil-essonnes, France|hopital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|Hematology Dpt, Hôpital Versailles, Le Chesnay, France|Hematology Dpt,CH Le mans, Le mans, France|CHRU Huriez, Lille, France|Hopital Saint-Vincent de Paul, Lille, France|CHRU de Limoges, Limoges, France|Hematology Dpt, Centre Hospitalier Lyon Sud, Lyon, France|CH de Mantes-la-jolie, Mantes-la-jolie, France|Institut Paoli Calmettes, Marseille, France|Hematology Dpt, CHU Brabois, Nancy, France|Hematology Dpt, CHU de nantes, Nantes, France|Hematology Dpt, CHU Archet, Nice, France|Hematology Dpt, CHU Caremeau, Nimes, France|Hematology Dpt, CHR La Source orléans, Orléans, France|centre René Huguenin, Paris Saint Cloud, France|Hematology Dpt, Hôpital la pitié-Salpétrière, Paris, France|Hematology Dpt, Hopital Saint Louis, Paris, France|Hopital Saint Antoine, Paris, France|Hematology Dpt, Hôpital Maréchal Joffre, Perpignan, France|Hôpital Jean Bernard, Poitiers, France|Hematology Dpt, Centre Hospitalier de la région d'Annecy, Pringy cedex, France|CHRU de Reims, Reims, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|CH de Saint Quentin, Sint Quentin, France|Chu Strasbourg, Strasbourg, France|Hematology Dpt, CHU PURPAN, Toulouse, France|Hematology Dpt, CH CHU Bretoneau, Tours, France|centre hopitalier princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT01718379"
852,"NCT01690702","Study of Nab-Paclitaxel in High Risk Early Breast Cancer","GAIN-2","Active, not recruiting","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: nab-Paclitaxel|Drug: Cyclophosphamide|Drug: Docetaxel","invasive disease-free survival (IDFS)|locoregional relapse-free survival (LRRFS)|overall survival (OS)|distant disease-free survival (DDFS)|local relapse-free survival (LRFS)|regional relapse-free survival (RRFS)|brain metastasis free survival (in the subgroup of TNBC and HER2+)|compliance|safety|side effects of taxane|treatment effects by intrinsic subtypes|Ovarian substudy|Pharmacogenetic substudy|biology of lymph node metastases","German Breast Group|Celgene|Amgen","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2886","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 68","September 2012","January 2020","December 2020","September 24, 2012",,"July 13, 2017","Klinikum Frankfurt Höchst, Frankfurt, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT01690702"
853,"NCT03174275","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",,"Recruiting","No Results Available","Carcinoma, Squamous Cell|Oral Cancer|Oropharynx Cancer|Larynx Cancer|Lip Cancer|Esophageal Cancer","Drug: Durvalumab|Drug: Carboplatin|Drug: Nab-paclitaxel|Drug: Cisplatin|Procedure: Surgical resection|Radiation: IMRT","Pathologic complete response rate (pCRR) after induction chemotherapy with carboplatin, nab-paclitaxel, and durvalumab in previously untreated stage III and IV SCCHN amenable to surgical resection|Clinical complete response rate and (cCRR) and clinical response rate (cRR) following induction chemotherapy|Percent of patients who have a change in estimated risk level|Progression free survival (PFS) associated with 3 part therapy consisting of induction chemotherapy, surgery and risk-adapted use of chemoradiation|Overall survival (OS) associated with 3 part therapy consisting of induction chemotherapy, surgery and risk-adapted use of chemoradiation|Toxicity profile associated with both induction therapy and total 3 part therapy consisting of induction chemotherapy, surgery and risk-adapted use of chemoradiation","UNC Lineberger Comprehensive Cancer Center|AstraZeneca|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1621","December 19, 2017","September 1, 2021","September 1, 2026","June 2, 2017",,"June 18, 2019","Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03174275"
854,"NCT03030261","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma in Relapse","Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone|Procedure: Autologous stem cell transplant|Drug: Melphalan","Event-free survival (EFS) rate|Overall response rate (ORR)|Complete response rate (CRR)|Minimal residual disease negative (MRD-negative) rate|Event-free survival (EFS)|Progression-free survival (PFS)|Overall survival (OS)|Toxicity of regimen as measured by frequency of adverse events per the number of participants treated","Washington University School of Medicine|Bristol-Myers Squibb|Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201701084|CA204-225|PO-CL-MM-PI-008341","November 22, 2017","May 31, 2021","February 28, 2026","January 24, 2017",,"November 5, 2019","Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03030261"
855,"NCT02963610","Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer",,"Terminated","No Results Available","Relapsed or Refractory Solid Tumors|Nonsmall Cell Lung Cancer","Drug: Lenalidomide|Drug: Pembrolizumab","To determine the maximum tolerated dose (MTD) of lenalidomide in combination with a fixed dose of pembrolizumab in subjects with relapsed and/or refractory solid tumors.|To determine efficacy as measured by progression free survival (PFS) in Non-small cell lung cancer patients|Assess antitumor activity of the combination as measured by objective response rate (ORR)|Assessment of PD-L1 expression by immunohistochemistry|Proportions of blood immune cells by flow cytometry|Assesment of cytokine profiles using Luminex|Determine specific NK cell responses by NK degranulation assay by flow cytometry|Assessment of activation markers on immune cells by flow cytometry|Determine immune composition of tumors using PanCancer Immune Profiling Panel by Nanostring technology|From patients that were previously treated with an anti-PD1 antibody, we will determine resistance overcome due to the treatment with combination assessed by overall response rate.|Determine specific T cell responses by determining differentiation status of T cells by flow cytometry","Fox Chase Cancer Center|Merck Sharp & Dohme Corp.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-088","March 29, 2017","October 3, 2017","March 20, 2018","November 15, 2016",,"February 20, 2019","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02963610"
856,"NCT01542918","Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma",,"Active, not recruiting","No Results Available","Recurrent/Refractory CNS|Intraocular Lymphoma","Drug: Lenalidomide|Drug: Rituximab","To establish the maximal tolerated dose (MTD) of Lenalidomide in patients with recurrent CNS NHL and intraocular NHL|To define the extent of cerebrospinal fluid (CSF) penetration of lenalidomide.|To assess the clinical efficacy Lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular (for patients with intraocular lymphoma) response criteria.|To define the immunological effects of lenalidomide using flow-cytometry CSF as well as genomic markers of recurrent/refractory CNS lymphoma.|To assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria.|To determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the CSF after intraventricular rituximab administration.","University of California, San Francisco|Celgene|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112530|NCI-2013-00056","December 17, 2012","April 7, 2016","January 2019","March 2, 2012",,"January 29, 2018","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01542918"
857,"NCT02942758","Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML","AML-ViVA","Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: low-dose Azacitidine|Drug: Pioglitazone|Drug: ATRA|Drug: standard-dose AZA","overall Survival|complete remission (CR) rate|complete remission with incomplete blood count recovery (CRi) rate|partial remission (PR) rate|hematological improvement (HI) rate|cumulative incidence of relapse (CIR)|cumulative incidence of death (CID)|cumulative incidence of relapse event free survival (EFS)|event free survival (EFS)|Quality of Life (QLQ-C30)|Incidence and intensity of adverse events (AEs)","University Hospital Regensburg|Anticancer Fund, Belgium|Celgene","All","60 Years and older   (Adult, Older Adult)","Phase 2","94","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMLSG26-16","April 10, 2017","February 2020","February 2020","October 24, 2016",,"October 11, 2018","University Hospital Regensburg, Regensburg, Germany",,"https://ClinicalTrials.gov/show/NCT02942758"
858,"NCT02937571","High Dose Carfilzomib for Newly Diagnosed Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Number of patients with dose limiting toxicity","Memorial Sloan Kettering Cancer Center|Onyx/Amgen|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-326","October 2016","October 2019","October 2019","October 18, 2016",,"February 20, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT02937571"
859,"NCT02897830","Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma","IFM2014-03","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone","rate of stringent complete response|Adverse events|response rates|Progression free survival|overall survival|Percentage of patients for whom more than 5X106 CD34 cells will be collected.|Correlation between presence of deletion 17p and response rate|Correlation between presence of translocation4-14 and response rate","University Hospital, Toulouse|Takeda|Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14 7261 03","August 5, 2016","November 2018","April 2021","September 13, 2016",,"September 30, 2019","University Hosptial Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02897830"
860,"NCT01460940","A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma",,"Completed","Has Results","Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma","Drug: panobinostat|Drug: lenalidomide","Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR)|Assess the Safety and Tolerability of Combined Lenalidomide and Panobinostat in Patients With Previously Treated Hodgkin's Lymphoma.|Progression-free Survival in Patients With Previously Treated Hodgkin's Lymphoma Receiving Combined Lenalidomide and Panobinostat","Ohio State University Comprehensive Cancer Center|Celgene|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-10049|NCI-2011-03323","October 13, 2011","November 16, 2016","November 16, 2016","October 27, 2011","March 14, 2017","November 14, 2017","Washington University, Saint Louis, Missouri, United States|The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01460940"
861,"NCT02816021","Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma",,"Recruiting","No Results Available","Melanoma and Other Malignant Neoplasms of Skin|Metastatic Melanoma","Drug: Azacitidine|Drug: Pembrolizumab","Objective Response Rate in Participants with Metastatic Melanoma That Are PD-1 Naïve (Arm A) or That Have Progressed on PD-1 Directed Therapy (Arm B)|Overall Survival in Participants with Metastatic Melanoma That Are PD-1 Naïve (Arm A) or That Have Progressed on PD-1 Directed Therapy (Arm B)|Progression Free Survival in Participants with Metastatic Melanoma That Are PD-1 Naïve (Arm A) or That Have Progressed on PD-1 Directed Therapy (Arm B)","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0069|NCI-2016-01185","February 14, 2017","February 2025","February 2026","June 28, 2016",,"September 6, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02816021"
862,"NCT01402284","Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Number of Participants With Serious and Non-serious Adverse Events|Overall Response Rate|Progression Free Survival (PFS) at 48 Months|Percentage of Responders With Duration of Response (DOR) at 48 Months|Overall Survival (OS) Rate|Cluster of Differentiation 138 (CD138) + Plasma Cells Gene Expression Profiling on Pre and Post Carfilzomib Exposure Bone Marrow Samples|Rate of Minimal Residual Disease (MRD) by Flow Cytometry|Complete Response (CR) and Minimal Residual Disease Neg (MRDneg) CR Rates at Treatment Intervals With Carfilzomib, Lenalidomide & Dexamethasone (CRd) in New Multiple Myeloma Patients After 8 Cycles of Induction, 1 Year Maintenance, and 2 Years Maintenance","National Cancer Institute (NCI)|Celgene|Onyx Therapeutics, Inc.|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","45","NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110221|11-C-0221","July 21, 2011","July 10, 2016","September 1, 2026","July 26, 2011","May 16, 2017","May 7, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT01402284/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT01402284/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01402284"
863,"NCT02685059","Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","GeparNuevo","Unknown status","No Results Available","Breast Cancer","Drug: MEDI4736 (Anti PD-L1)|Drug: Placebo|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","pathological complete response (pCR= ypT0 ypN0)|pCR rates per arm|Rates of ypT0/is ypN0|Rates of ypT0/is ypN0/+|Rates of ypT(any) ypN0|Rates of ypT0 ypN0/+|Clinical response|Breast conservation rate|Toxicity and compliance as measured by number of participants with treatment-related|Molecular markers and gene expression|Survival","German Breast Group|AstraZeneca|Celgene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","174","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GBG89","June 2016","March 2018","March 2018","February 18, 2016",,"November 21, 2017","Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus, Frankfurt, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT02685059"
864,"NCT02544308","Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma","IDRIS","Recruiting","No Results Available","Plasmacytoma","Drug: Lenalidomide|Drug: Dexamethasone|Other: No further treatment","Progression-free survival (progression defined as development of myeloma or a new plasmacytoma outside the radiotherapy field)|Overall survival|Time to next treatment|Response to treatment|Safety and toxicity of adjuvant lenalidomide + dexamethasone|Surveillance for secondary malignancies|Treatment Compliance","University College, London|Cancer Research UK|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/13/0291","March 10, 2017","October 2022","December 2026","September 9, 2015",,"October 23, 2019","Royal United Hospital, Bath, United Kingdom|Blackpool Victoria Hospital, Blackpool, United Kingdom|University Hospital Wales, Cardiff, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James University Hospital, Leeds, United Kingdom|University College London Hospital, London, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Salisbury District Hospital, Salisbury, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02544308"
865,"NCT02542657","Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma",,"Recruiting","No Results Available","Myeloma","Drug: Clarithromycin|Drug: Dexamethasone|Drug: Ixazomib Citrate|Drug: Pomalidomide","MTD of clarithromycin when given in combination with ixazomib citrate, pomalidomide, and dexamethasone assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Clinical best response","Joseph Tuscano|Takeda|Celgene|University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","728937|UCDCC#253|X16043|PO-TR-MM-PI-004614","October 2015","May 2020","July 2020","September 7, 2015",,"November 1, 2019","University of California San Diego, La Jolla, California, United States|University of California Irvine, Orange, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT02542657"
866,"NCT01218555","Study of Everolimus (RAD001) in Combination With Lenalidomide",,"Completed","No Results Available","Solid Organ Malignancies|Adenoidcystic Carcinoma|Neuroendocrine Tumors","Drug: Lenalidomide|Drug: Everolimus","The maximum doses of both drugs that can be administered without inducing dose limiting toxicity (DLT) in ≥ 33% of the treated patient cohort|The frequency of achieving a complete plus partial response with the 2 drug combination by dose cohort to be assessed by non-investigational cross sectional imaging after every 2 cycles","Emory University|Celgene|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00031088|WCI1717-09","September 2010","May 2017","May 2017","October 11, 2010",,"March 19, 2018","Grady Health System, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01218555"
867,"NCT02441686","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone","Overall Response Rate|Rate and Severity of Peripheral Neuropathy|Time to Progression|Progression Free Survival|Duration of Response|Overall Response","Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-508","December 2015","December 2019","August 2022","May 12, 2015",,"September 24, 2019","Colorado Blood Cancer Institute, Denver, Colorado, United States|Eastern Maine Medical Center, Brewer, Maine, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Virginia Piper Cancer Institute, Coon Rapids, Minnesota, United States|Virgina Piper Cancer Institute, Minneapolis, Minnesota, United States|Hematology Oncology of Northern New Jersey, Morristown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02441686"
868,"NCT02406222","Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)","MUKseven","Recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","Progression free survival|Maximum response overall|Response to treatment|Clinical benefit rate overall|Time to maximum response|Duration of response|Overall survival|Treatment compliance|Safety and Toxicity","University of Leeds|Myeloma UK|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM13/10758","March 2016","March 2019","March 2023","April 2, 2015",,"June 16, 2017","Belfast Health & Social Care Trust, Belfast, United Kingdom|University of Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Queens Hospital, Burton on Trent, United Kingdom|University Hospital of Wales NHS Trust, Cardiff, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|St James's Hopsital, Leeds, United Kingdom|University Hospital of Leicester NHS Trust, Leicester, United Kingdom|St Bartholomew Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Imperial College Hospital, London, United Kingdom|Central Manchester Univeristy Hospital NHS Trust, Manchester, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Sheffield Teaching Hospitals NHS FoundationTrust, Sheffield, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02406222"
869,"NCT02405364","Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction","IFM-CRd","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib/Lenalidomide/Dexamethasone","rate of stringent complete response","University Hospital, Toulouse|Onyx Therapeutics, Inc.|Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12 568 03","February 2014","June 2017","December 2019","April 1, 2015",,"September 21, 2018","CHU de Toulouse, Toulouse, France|University hospital of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02405364"
870,"NCT02391662","Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma",,"Completed","No Results Available","Pancreatic Carcinoma Metastatic","Drug: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Drug: Gemcitabine 1000 weeks 1,2,3/4","Efficacy of treatment through 3-months deterioration free rate|Evaluate safety profile of gemcitabine and nab-paclitaxel, measured by Number of events per patient according to NCI-CTC-AE criteria|Time to tumor progression|Overall survival|Objective radiographic response (ORR)|CA 19.9 biomarker response","Asociación de Oncología Médica del Hospital de Cruces|Apices Soluciones S.L.|Celgene","All","70 Years and older   (Older Adult)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIBABRAX|2014-003596-27","June 23, 2015","March 2019","March 2019","March 18, 2015",,"August 27, 2019","Hospital General de Granollers, Granollers, Barcelona, Spain|Centre Hospitalari de Manresa, Manresa, Barcelona, Spain|Hospital Universitario de Cruces, Barakaldo, Gipuzkoa, Spain|Hospital Clinico Universitario Virgen de La Arrixaca, El Palmar, Murcia, Spain|Hospital Xeral de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Tenerife, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Universitario Vall D'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Ico Girona, Girona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|C. Hospitalario Universitario Insularmaterno-Infantil, Las Palmas de Gran Canaria, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Hm Sanchinarro, Madrid, Spain|Hospital Quirón Madrid, Madrid, Spain|Complexo Hospitalario Universitario de Ourense, Ourense, Spain|Complejo Hospitalario Regional Virgen Macarena, Sevilla, Spain|Hospital Virgen Del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02391662"
871,"NCT02334865","SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy",,"Recruiting","No Results Available","Partial Response of Multiple Myeloma or Plasma Cell Leukemia|Plasma Cell Myeloma","Biological: Incomplete Freund's Adjuvant|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Sargramostim|Biological: SVN53-67/M57-KLH Peptide Vaccine","Toxicity profile of the SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant plus sargramostim, given before or after the start of lenalidomide maintenance|Immune response using interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and multimer assays","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 247913|NCI-2014-02621|P30CA016056","March 9, 2016","November 9, 2022","November 9, 2023","January 8, 2015",,"April 26, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02334865"
872,"NCT01120834","Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)",,"Completed","Has Results","Lymphoma","Drug: azacytidine|Drug: vorinostat","Overall Response Rate (ORR)","Weill Medical College of Cornell University|Celgene|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0912010795","September 2010","April 2013","October 20, 2016","May 11, 2010","April 10, 2017","April 10, 2017","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01120834"
873,"NCT02033993","Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.",,"Unknown status","No Results Available","Urothelial Cancer","Drug: Nab-Paclitaxel|Drug: Paclitaxel","Progression-Free Survival|Overall Survival|Clinical Benefit Rate|Time to Response and Response Duration|Nature, severity and frequency of toxicities|Quality of Life|Cost and cost utility ratios between the two arms","Canadian Cancer Trials Group|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","199","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BL12","January 27, 2014","January 11, 2018","September 2018","January 13, 2014",,"February 1, 2018","Townsville Hospital, Douglas, Queensland, Australia|Nambour General Hospital, Nambour, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ashford Cancer Care Research, Kurralta Park, South Australia, Australia|Prince of Wales Hospital, Sydney, South Australia, Australia|Concord Cancer Centre, Sydney, South Australia, Australia|Liverpool Hospital, Sydney, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|University Hospital Geelong, Geelong, Victoria, Australia|Epworth Healthcare Freemasons Hospital, Richmond, Victoria, Australia|Western Hospital (renamed to Footscray Hospital), St Albans, Victoria, Australia|Border Medical Oncology (Murray Valley Private Hospital), Wodonga, Victoria, Australia|Royal Perth Hospital (renamed to Fiona Stanley Hospital), Perth, Western Australia, Australia|Port Macquarie Base Hospital, Port Macquarie, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Hopital Charles LeMoyne, Greenfield Park, Quebec, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|The Jewish General Hospital, Montreal, Quebec, Canada|The Research Institute of the McGill University, Montreal, Quebec, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT02033993"
874,"NCT00470548","Abraxane and Alimta in Advanced Solid Tumors",,"Terminated","Has Results","Breast Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: Abraxane|Drug: Alimta","Number of Participants With Dose Limiting Toxicities|Number of Patients With Toxicities|Duration of Overall Survival|Number of Participants With Complete Response|Number of Participants With Stable Disease|Number of Participants With Partial Response|Number of Participants With Disease Control","University of California, Davis|Celgene|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","49","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#185|224355|ABX027|H3E-US-I017","April 2007","October 2014","October 2014","May 7, 2007","March 8, 2017","January 10, 2018","University of California Davis Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00470548"
875,"NCT01029054","Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: carfilzomib, lenalidomide plus dexamethasone","The Maximum Tolerated Dose (MTD) of Carfilzomib|The Percentage of Patients That Achieve a Response to Treatment|The Percentage of Patients Alive Without Progression","University of Michigan Rogel Cancer Center|Onyx Therapeutics, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","53","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","UMCC 2009.056|HUM30396","September 2009","December 2011","July 2015","December 9, 2009","November 20, 2014","January 30, 2017","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mt. Sinai Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01029054"
876,"NCT00698776","Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma",,"Completed","No Results Available","Myeloma","Drug: Lenalidomide|Biological: Monocyte derived DCs loaded with KRN7000","Number of Dose Limiting Toxicities (DLTs)|Number of Natural Killer Cells(NKT)that make IFNγ in Vitro","Yale University|Kyowa Kirin Co., Ltd.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0712003357","April 2009","May 2011","May 2011","June 17, 2008",,"June 21, 2016","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00698776"
877,"NCT00633594","Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma",,"Completed","Has Results","Mantle Cell Lymphoma","Drug: Rituximab|Drug: Bortezomib|Drug: Lenalidomide","Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants|Incidence of Non-Serious Adverse Events as a Measure of Safety and Tolerability, Phase II|Overall Response Rate (ORR) of Phase I and Phase II Participants|Overall Response Rate (ORR) of Previously Treated and Previously Untreated Participants|Time to Best Response of Phase I and Phase II Participants|Time to Best Response of Previously Treated and Previously Untreated Participants|Duration of Response (DoR) of Phase I and Phase II Participants|Duration of Response (DoR) of Previously Treated and Previously Untreated Participants|Progression Free Survival (PFS) of Phase I and Phase II Participants|Progression Free Survival (PFS) of Previously Treated and Previously Untreated Participants|Overall Survival of Phase I and Phase II Participants|Overall Survival of Previously Treated and Previously Untreated Participants","SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LYM 58","June 2008","April 2015","November 2016","March 12, 2008","January 31, 2017","January 31, 2017","Providence Medical Group, Terre Haute, Indiana, United States|RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Oncology Hematology Care Inc., Cincinnati, Ohio, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00633594"
878,"NCT00430365","Maintenance Therapy Using Lenalidomide in Myeloma","IFM2005-02","Completed","No Results Available","Myeloma","Drug: lenalidomide|Drug: placebo","Determine the efficacy of Revlimid® at prolonging the duration of the post-transplant response.|Assess the impact of Revlimid® on the post-transplant complete response rate|Compare survival without events and overall survival of patients in the lenalidomide arm with the control|Evaluate the long-term tolerance of Revlimid® in post-transplant maintenance therapy.","University Hospital, Toulouse|Intergroupe Francophone du Myelome|Celgene","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","614","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0400401|French PHRC","June 2006","September 2017","September 2018","February 1, 2007",,"April 26, 2019","ZNA Middelheim, Antwerpen, Belgium|Algemeen Centrumziekenhuis Antwerpen, Antwerpen, Belgium|UZA Antwerpen, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UCL St Luc, Bruxelles, Belgium|Hôpital Saint Joseph, Gilly, Belgium|Hôpital Jolimont, Haine Saint Paul, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|UCL Mont-Godinne, Yvoir, Belgium|CH, Aix-en-Provence, France|CHRU, Amiens, France|CHRU Hôpital du Bocage, Angers, France|Centre hospitalier Argenteuil Victor Dupouy, Argenteuil, France|Centre hospitalier Duffaut, Avignon, France|Centre hospitalier de la côte basque, Bayonne, France|Hôpital Jean Minjoz, Besançon, France|CH, Blois, France|Hôpital Avicenne, Bobigny, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CHRU Hôpital haut Lévêque, Bordeaux, France|Hôpial Morvan, Brest, France|Polyclinique du Parc, Caen, France|Centre Baclesse, Caen, France|CH, Chartres, France|CH William Morey, Châlon-sur-Saône, France|Hôpital Antoine Béclère, Clamart, France|Hôpital d'instruction des Armées Percy, Clamart, France|CHRU Hôtel Dieu, Clermont Ferrand, France|CH Louis Pasteur, Colmar, France|CHU Henri Mondor, Créteil, France|CHRU Dijon, Dijon, France|Centre hospitalier général, Dunkerque, France|CHRU Hôpital Michallon, Grenoble, France|Centre hospitalier départemental, La Roche sur Yon, France|CH, Le Mans, France|CHRU Hôpital Claude Huriez, Lille, France|Centre hospitalier Bodelio, Lorient, France|Centre Léon Bérard, Lyon, France|CHU Hôpital Edouard Herriot, Lyon, France|Institut Paoli Calmette, Marseille, France|Hôpital Nord, Marseille, France|Hôpital Notre Dame de Bon Secours, Metz, France|CHRU Hôpitaux de Brabois, Nancy, France|CHRU Hôtel Dieu, Nantes, France|Centre Antoine Lacassagne, Nice, France|Hôpital Archet, Nice, France|Hôpital de l'Archet, Nice, France|Hôtel Dieu, Paris, France|Hôpital Cochin, Paris, France|CHU Hôpital St Antoine, Paris, France|Centre hospitalier Lyon Sud, Pierre Bénite, France|CHRU Hôpital Jean Bernard, Poitiers, France|Centre hospitalier de la région d'Annecy, Pringy, France|Hôpital Debré, Reims, France|CHRU Hôpital de Pontchaillou, Rennes, France|CHRU Hôpital Sud, Rennes, France|Centre hospitalier de Roanne, Roanne, France|Centre Henri Becquerel, Rouen, France|Centre hospitalier de la Réunion, Saint-Denis, France|Centre hospitalier Yves Le Foll, St Brieuc, France|Institut de Cancérologie de la Loire, St-Priest-en-Jarez, France|CHRU Hôpital de Hautepierre, Strasbourg, France|CHU Toulouse Purpan, Toulouse, France|CHU Toulouse Rangueil, Toulouse, France|CHRU Hôpital Bretonneau, Tours, France|Centre hospitalier, Troyes, France|CH Chubert, Vannes, France|Center of Oncology/Hematology and transfusion Medicine, Kantonsspital, Aarau, Switzerland|Universitäts Spital, Basel, Switzerland|Istituto Oncologico Sviss. Italiana IOSI Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital, Bern, Switzerland|Hôpital cantonal, Genêve, Switzerland|CHUV, Lausanne, Switzerland|Onkologie/Hämatologie Kantonsspital st Gallen, St Gallen, Switzerland|Spital Thun-Simmental Onkologiezentrum, Thun, Switzerland|Institute of Oncology and Hematology Stadtspital Triemli, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00430365"
879,"NCT03283761","FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma",,"Recruiting","No Results Available","Gastro-Esophageal Junction Adenocarcinoma|Gastric Cancer","Drug: Nab-paclitaxel 150 mg/m^2|Drug: Oxaliplatin 85 mg/m^2|Drug: 5-FU 1200 mg/m^2 x 2 D|Drug: Leucovorin 400 mg/m^2","Overall Objective Response Rate|Overall Survival (OS)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Best Overall Response Rate (ORR)|Best Disease Control Rate (DCR)|Adverse Events","Al B. Benson, III, MD|Celgene Corporation|Big Ten Cancer Research Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTCRC-GI15-015","September 21, 2017","June 30, 2020","June 30, 2021","September 14, 2017",,"August 14, 2019","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Univeristy of Illinois Cancer Center, Chicago, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Michigan State University, Lansing, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03283761"
880,"NCT03082729","Vascular Inflammation in Psoriasis - Apremilast","VIP-A","Recruiting","No Results Available","Psoriasis|Cardiovascular Diseases","Drug: Apremilast","Change in total vascular inflammation of the aorta as measured by [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) / computed tomography (CT) (FDG-PET/CT) between baseline and week 16.|Changes in cardiometabolic markers between baseline and week 16.|Changes in body composition as measured by FDG-PET/CT between week 52 and and earlier time points (baseline and week 16).|Changes in physician reported outcomes (Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA)) between week 52 and and earlier time points (baseline and week 16).|Changes in patient reported outcomes (DLQI, pruritis by Visual Analog Scales (VAS)) between week 52 and and earlier time points (baseline and week 16).|Change in total vascular inflammation of the aorta as measured by [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) / computed tomography (CT) (FDG-PET/CT) between week 52 and earlier time points (baseline and week 16).|Change in cardiometabolic markers between week 52 and earlier time points (baseline and week 16).|Adverse events AE) and serious AEs reported by study participants will be monitored and a complete review of systems and blood laboratory evaluation will be conducted during screening, week 16, and week 52 for safety endpoints.","University of Pennsylvania|Celgene Corporation|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","70","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","826652|97509210","April 24, 2017","May 2020","January 2021","March 17, 2017",,"November 27, 2018","University of Southern California, Los Angeles, California, United States|Derm Associates, P.C., Rockville, Maryland, United States|Buffalo Medical Group, P.C., Buffalo, New York, United States|Oregon Medical Research Center, Portland, Oregon, United States|Dermatology and Skin Surgery Center, Exton, Pennsylvania, United States|The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Center for Clinical Studies, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03082729"
881,"NCT02967133","A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Non-Small-Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Nonsmall Cell Lung Cancer|Non Small Cell Lung Cancer Recurrent","Drug: Nivolumab|Drug: nab-paclitaxel","Progression-Free Survival","Alliance Foundation Trials, LLC.|Celgene Corporation|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFT-31","December 2016","December 2020","December 2020","November 18, 2016",,"July 30, 2019","St. Elizabeth's Healthcare, Edgewood, Kentucky, United States|Metro Minnesota community oncology research consortium, Saint Louis Park, Minnesota, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02967133"
882,"NCT02525653","Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers",,"Completed","No Results Available","Lung Cancer|Untreated Stage IV or Recurrent Squamous Cell Lung Cancers","Drug: albumin-bound paclitaxel|Drug: gemcitabine","best objective response (BOR) rate|Toxicity data (AEs, laboratory data and vital sign data)","Memorial Sloan Kettering Cancer Center|Celgene Corporation|Miami Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-054","August 2015","May 2019","May 2019","August 17, 2015",,"September 26, 2019","Miami Cancer Institute Baptist Health South Florida, Miami, Florida, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Westchester, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT02525653"
883,"NCT02415413","Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma",,"Active, not recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Melphalan","Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT|Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance|Efficacy- Months to progression free survival|Efficacy -Months to overall survival","PETHEMA Foundation|Celgene Corporation|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","90","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM-CESAR","May 2015","July 31, 2017","May 2020","April 14, 2015",,"October 4, 2018","Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital de Son Llàtzer, Plama De Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Reina Sofía, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02415413"
884,"NCT02393794","Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",,"Recruiting","No Results Available","Triple-Negative Breast Cancer|Breast Cancer","Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab","Phase I: Recommended Phase II Dose of romidepsin in combination with cisplatin|Phase II: Objective response rate of treated subjects according to RECIST v1.1 criteria|Phase II: Clinical Benefit Rate at 16 weeks of study treatment for subjects treated at the recommended phase II dose of romidepsin plus cisplatin and nivolumab|Pharmacokinetics - romidepsin plasma concentration vs time profile when given with cisplatin and nivolumab|Pharmacokinetics - cisplatin plasma concentration vs time profile when given with romidepsin|Median Progression-Free Survival and Overall Survival","Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT-2014-CISRomiNivoTNBC|RM-CL-BRST-PI-002783|IIT-2014-PS-BRST-CISRomiTNBC","July 17, 2015","February 2020","July 2020","March 19, 2015",,"September 30, 2019","University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center - West, Kansas City, Kansas, United States|University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States|University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States|University of Kansas Cancer Center - South, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02393794"
885,"NCT02371590","Lenalidomide and Obinutuzumab for Previously Untreated CLL",,"Withdrawn","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lenalidomide|Drug: Obinutuzumab","The incidence of dose limiting toxicity|Complete Response Rate|Number of patients with adverse events associated with lenalidomide-obinutuzumab|Progression free survival rate|Overall response rate","University of California, San Diego|Celgene Corporation|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150342/161104","February 2018","December 2019","December 2022","February 25, 2015",,"February 23, 2018","UC San Diego Moores Cancer Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02371590"
886,"NCT02312102","Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation",,"Active, not recruiting","No Results Available","Myelodysplastic Syndrome|Acute Myeloid Leukemia","Drug: Lenalidomide|Drug: Velcade","MTD of Bortezomib and Lenalidomide,|Assess clinical efficacy in terms of the number of patients experiencing a decrease in blast percentage.|Document the remission frequency in patients receiving up to 2 induction cycles of high-dose lenalidomide combined with Velcade.|Percentage of Complete Response|Percentage of Participants with Disease Free Survival( DFS )|Percentage of Overall Survival","Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-213","February 2015","April 2017","December 2019","December 9, 2014",,"June 26, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02312102"
887,"NCT03863184","Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",,"Recruiting","No Results Available","Mantle Cell Lymphoma","Drug: Acalabrutinib|Drug: Lenalidomide|Drug: Rituximab","Peripheral blood minimum residual disease (MRD)-negative complete response (CR) rate of the combination of acalabrutinib + lenalidomide + rituximab at the conclusion of 12 cycles of induction therapy|Safety of combination treatment with acalabrutinib, lenalidomide, and rituximab as measured by the percentage of subjects that experience 1 or more adverse event|Overall response rate|Complete response rate|Progression free survival|Overall survival","Weill Medical College of Cornell University|AstraZeneca|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1807019439","October 11, 2019","November 1, 2022","November 1, 2024","March 5, 2019",,"October 15, 2019","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03863184"
888,"NCT03834623","Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma",,"Recruiting","No Results Available","Melanoma","Drug: CC-122|Drug: Nivolumab","Objective Response Rate of CC-122 in combination with Nivolumab|Number of Participants who Experience Treatment Related Adverse Events|Tumor Response|Progression Free Survival|Overall Survival","H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19706","May 14, 2019","May 14, 2023","May 14, 2023","February 8, 2019",,"August 1, 2019","H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03834623"
889,"NCT02125136","Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","NEOLAP","Recruiting","No Results Available","Ductal Adenocarcinoma of the Pancreas","Drug: Gem/nab-Pac|Drug: FOLFIFINOX","Conversion Rate|Safety|objective tumour response rate|disease control rate (DCR)|CA 19-9 change|R0 and R1 resections|pathological responses|relapse-free survival (RFS)|Progression-free survival (PFS)|perioperative morbidity and mortality|Tolerability|Overall Survival (OS)","AIO-Studien-gGmbH|Celgene Corporation|ClinAssess GmbH","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","168","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO-PAK-0113|AX-CL-PANC-PI-003324|2013-004796-12","November 2014","March 1, 2019","October 2020","April 29, 2014",,"March 6, 2019","Universitätsklinikum Würzburg/Comprehensive Cancer Center Mainfranken, Würzburg, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT02125136"
890,"NCT03785184","A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: venetoclax|Drug: lenalidomide|Drug: dexamethasone","Percentage of Participates Who Achieve CR|Percent of Participants Who Achieve MRD Negativity|Percent of Participants Who Achieve VGPR or Better|Overall Response Rate (ORR)|Time to Response (TTR)|Duration of response (DOR)|Progression-free Survival (PFS)|Minimal Residual Disease (MRD) Negativity Rate at 12 Months|Time to Disease Progression (TTP)|Time to Next Treatment (TTNT)|Overall Survival (OS) Rate","AbbVie|Genentech, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-104","April 29, 2019","August 22, 2019","August 22, 2019","December 24, 2018",,"August 27, 2019","City of Hope /ID# 212211, Duarte, California, United States|Marin Cancer Care /ID# 208476, Greenbrae, California, United States|University of California, Los Angeles /ID# 208516, Los Angeles, California, United States|Karmanos Cancer Institute /ID# 208805, Detroit, Michigan, United States|Henry Ford Hospital /ID# 208481, Detroit, Michigan, United States|Duke University Hospital /ID# 208306, Durham, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208121, Pittsburgh, Pennsylvania, United States|Westmead Hospital /ID# 210267, Westmead, New South Wales, Australia|Flinders Centre for Innovation /ID# 210697, Bedford Park, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia|Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia|Monash Medical Centre /ID# 210269, Melbourne, Victoria, Australia|Tom Baker Cancer Centre /ID# 208549, Calgary, Alberta, Canada|Princess Margaret Cancer Centr /ID# 208923, Toronto, Ontario, Canada|Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada|McGill Univ HC /ID# 208486, Montreal, Quebec, Canada|Clinica Universitar de Navarra - Pamplona /ID# 209883, Pamplona, Navarra, Comunidad, Spain|Hospital Clinic de Barcelona /ID# 209888, Barcelona, Spain|Hspital Universitario Gregorio Maranon /ID# 209926, Madrid, Spain|Clinica Universitar de Navarra - Madrid /ID# 210131, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 209887, Madrid, Spain|Hospital Univ Dr. Peset /ID# 209884, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03785184"
891,"NCT03745430","RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","RACING","Recruiting","No Results Available","Pancreatic Adenocarcinoma","Drug: Ramucirumab","Phase Ib: Assessment of safety by identifying the Recommended Dose (RD) of the combination of Ramucirumab with Nabpaclitaxel and Gemcitabine.|Phase II: Overall Response Rate is defined as the proportion of patients with confirmed Complete Response or confirmed Partial Response as best overall response to treatment, based on RECIST v. 1.1 guidelines in the considered analysis population.|Overall survival (OS)|Progression-free survival|Phase I:Toxicity profile of the combination during the first 2 cycles of therapy|Phase II: Number of participants with Serious and Non-Serious Adverse Events graded according to National Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Investigation of SPARC gene mutation, m-RNA and protein expression|Investigation of PTEN gene mutation, m-RNA and protein expression|Investigation of MEK gene mutation, m-RNA and protein expression|Investigation of AREG gene mutation, m-RNA and protein expression|Investigation of EREG gene mutation, m-RNA and protein expression|Investigation of VEGF-A gene mutation, m-RNA and protein expression|Investigation of VEGF-B gene mutation, m-RNA and protein expression|Investigation of PlGF gene mutation, m-RNA and protein expression|Investigation of TSP1 gene mutation, m-RNA and protein expression|Investigation of MMP2 gene mutation, m-RNA and protein expression|Investigation of MMP9 gene mutation, m-RNA and protein expression|Investigation of VEGFR1-3 gene mutation, m-RNA and protein expression","Hellenic Cooperative Oncology Group|Eli Lilly and Company|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE3/16|2017-004792-30","January 29, 2019","September 2021","September 2021","November 19, 2018",,"February 5, 2019","3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Nea Kifisia, Greece|Haematology- Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens ""Alexandra"", Athens, Greece|Department of Medical Oncology, Ioannina University Hospital, Ioánnina, Greece",,"https://ClinicalTrials.gov/show/NCT03745430"
892,"NCT02030483","Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma","PD + RD","Terminated","No Results Available","Multiple Myeloma","Drug: Palbociclib|Drug: Dexamethasone|Drug: Lenalidomide","Establish a maximum-tolerated dose of Palbociclib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma|Number of subjects who demonstrate a response to Palbociclib, Lenalidomide, and dexamethasone|Survival duration without disease progression of relapsed/refractory study subjects treated with palbociclib, lenalidomide, and dexamethasone|Toxicity profile associated with the study regimen (palbociclib, lenalidomide, and dexamethasone)","Weill Medical College of Cornell University|Celgene Corporation|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1306014004|WS2335828|RV-MM-PI-0675","February 2014","July 2016","July 2016","January 8, 2014",,"August 22, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02030483"
893,"NCT02018523","Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer",,"Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Lenalidomide","Progression free survival|Number of participants with adverse events|Change in circulating immune cells","Jun Zhang|Celgene Corporation|Baylor College of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-32774","June 2014","August 2016","August 2016","December 23, 2013",,"January 18, 2018","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02018523"
894,"NCT02017457","Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.",,"Active, not recruiting","No Results Available","Acute Myelogenous Leukemia|Myelodysplastic Syndrome","Biological: Donor lymphocyte infusion|Drug: Azacytidine","Response rate|Disease-free survival|Overall survival|Evaluation of the treatment Toxicity|Incidence and severity of GvHD|Incidence and severity of infections","Carlos Graux, MD, PhD|Celgene Corporation|Belgian Hematological Society|University Hospital of Mont-Godinne","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHS-TC-10","December 2013","November 2019","August 2020","December 20, 2013",,"April 19, 2019","Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|AZ Sint-Jan Brugge, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Hopital de Jolimont, Haine-St-Paul, Belgium|Universitair Ziekenhuis Brussel, Jette, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|CHU Liège, Liège, Belgium|Hartziekenhuis Roeselare Menen, Roeselare, Belgium|Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium|CHU Mont-Godinne, Yvoir, Belgium",,"https://ClinicalTrials.gov/show/NCT02017457"
895,"NCT03289819","Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC","NIB","Recruiting","No Results Available","Malignant Neoplasm of Breast","Drug: Pembrolizumab|Drug: nab-paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","Pathological Complete Response (pCR) rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Clinical Response|EORTC QLQ-BR23|EORTC QLQ-C30","Institut fuer Frauengesundheit|Merck Sharp & Dohme Corp.|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFG-NIB-01|2016-003102-14|U1111-1188-3915","March 23, 2018","November 2019","December 2019","September 21, 2017",,"August 7, 2019","Department of Gynecology, Tübingen University Hospital, Tübingen, Baden-Württemberg, Germany|Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Bavaria, Germany|Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Bottrop, North Rhine-Westphalia, Germany|Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03289819"
896,"NCT01754870","Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)",,"Withdrawn","No Results Available","Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)","Drug: Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance","Progression Free Survival (PFS)|Objective Response Rates|Toxicity|Overall survival","University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO11415|2012-0639|A534260|SMPH/MEDICINE/MEDICINE*H|NCI-2013-00905","November 2013","August 2014","August 2014","December 21, 2012",,"November 15, 2019",,,"https://ClinicalTrials.gov/show/NCT01754870"
897,"NCT01754857","Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL",,"Recruiting","No Results Available","Lymphoid Leukemia|Small Lymphocytic Lymphoma|Lymphoma, Non-Hodgkin","Drug: Bendamustine|Drug: Rituximab|Drug: Lenalidomide","Time to progression|Objective Response Rates|Incidence of Toxicity|Time to Death","University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO11414|2017-0072|A534260|SMPH\MEDICINE\HEM-ONC|NCI-2013-00485","November 2013","October 1, 2020","December 1, 2022","December 21, 2012",,"November 20, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01754857"
898,"NCT01583426","Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)","GeparSepto","Unknown status","No Results Available","Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|Tubular Breast Cancer Stage III|HER-2 Positive Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Cancer","Drug: nab-Paclitaxel|Drug: Paclitaxel","Pathological complete response (pCR=ypT0 ypN0) rates of neoadjuvant treatment of nab-paclitaxel with solvent-based paclitaxel as part of neoadjuvant treatment of operable or locally advanced primary breast cancer.|Rates of ypT0/is ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0, and regression grade|Clinical and imaging response|Tolerability and safety|pCR rates per arm|Breast conservation rate|Onset of grade 3 neuropathy|Resolution of grade 3/4 neuropathy|Regional recurrence free survival (RRFS) in patients with initial node-positive axilla|pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy|Examination and comparison of molecular markers|CTC Substudy|Pharmacogenetic substudy|Ovarian substudy|Loco-regional invasive recurrence free survival (LRRFS) in both arms and according to stratified subpopulations.|Distant-disease-free survival (DDFS) in both arms and according to stratified subpopulations.|Invasive disease-free survival (IDFS) in both arms and according to stratified subpopulations.|Overall survival (OS) in both arms and according to stratified subpopulations.|Surgical substudy in patients with high probability for pCR","German Breast Group|Celgene Corporation|Roche Pharma AG","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 69|2011-004714-41","July 2012","December 2018","December 2018","April 24, 2012",,"October 12, 2016","Helios-Klinikum Berlin-Buch, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01583426"
899,"NCT02716038","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",,"Active, not recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: MPDL3280A|Drug: Carboplatin|Drug: Nab-paclitaxel","Number of subjects with major pathologic response (MPR)","Columbia University|Genentech, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAQ3153","June 7, 2016","April 2020","December 2020","March 22, 2016",,"October 22, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02716038"
900,"NCT01373229","Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)",,"Completed","Has Results","Leukemia, Lymphocytic, Chronic, B-Cell","Drug: Lenalidomide + Plerixafor (+ Rituximab)","Maximum Tolerated Dose|Overall Response (Complete Response/Partial Response)|Progression-free Survival (PFS)|Overall Survival (OS)|Reduction in Severity of B Symptoms|Reduction in the Frequency of Blood and Platelet Transfusions","David Rizzieri, MD|Celgene Corporation|Genzyme, a Sanofi Company|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00026715|RV0622","January 2012","March 2014","March 2015","June 14, 2011","February 5, 2018","February 5, 2018","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01373229"
901,"NCT02682693","Denosumab as an add-on Neoadjuvant Treatment (GeparX)","GeparX","Active, not recruiting","No Results Available","Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III","Drug: Denosumab|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab","pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC.|pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks|To test for interaction of denosumab treatment with RANK expression.|To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors.","German Breast Group|Amgen|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","780","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 88","February 13, 2017","October 2019","December 2019","February 15, 2016",,"April 1, 2019","Charité Campus Mitte, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02682693"
902,"NCT02616965","A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma",,"Recruiting","No Results Available","Cutaneous T-cell Lymphoma (CTCL)","Drug: Romidepsin|Drug: Brentuximab vedotin","Maximum tolerated dose (MTD)|Dose-limiting toxicities (DLTs)|overall safety and tolerability of the combination of brentuximab vedotin & romidepsin assessed by adverse events.|Estimate complete and partial response rate of the combination treatment|Overall survival (OS)|Progression free survival (PFS)","Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-085","February 22, 2017","December 2019","July 2021","November 30, 2015",,"August 13, 2019","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02616965"
903,"NCT01302808","Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",,"Completed","No Results Available","Lung Cancer|Metastatic Cancer","Drug: erlotinib hydrochloride|Drug: romidepsin|Other: laboratory biomarker analysis|Other: pharmacological study","Toxicity of erlotinib hydrochloride plus romidepsin|Maximum-tolerated dose (MTD) of erlotinib hydrochloride plus romidepsin|Time to response, progression-free survival, and overall survival|Pharmacokinetic profile of romidepsin in combination with erlotinib hydrochloride","University of Texas Southwestern Medical Center|Celgene Corporation|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCCC-12508|CDR0000653093|NCI-2011-01035","September 2009","December 2014","December 2014","February 24, 2011",,"June 1, 2015","Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01302808"
904,"NCT02564146","First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine","ALPACA","Recruiting","No Results Available","Metastatic Pancreatic Cancer|Adenocarcinoma of the Pancreas","Drug: nab-paclitaxel and gemcitabine|Drug: gemcitabine mono and nab-paclitaxel and gemcitabine","Overall survival (OS)|Progression-free survival (PFS)|Overall response rate (ORR)|Disease control rate (DCR)|Quality of life QLQ-C30|Adverse Events (AE)|Time of treatment without toxicity|Neurotoxicity Assessment FACT taxane score","AIO-Studien-gGmbH|ClinAssess GmbH|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","325","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO-PAK-0114|2014-004086-24|AX-CL-PANC-AIO-004415","December 2016","January 2020","June 2020","September 30, 2015",,"March 6, 2019","Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Germany",,"https://ClinicalTrials.gov/show/NCT02564146"
905,"NCT02512172","A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer",,"Active, not recruiting","No Results Available","Colorectal Cancer","Drug: Oral CC - 486|Drug: Romidepsin|Drug: MK - 3475","Degree of change in tumor infiltrating lymphocytes","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme Corp.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","J1538|IRB00060125","June 2015","January 23, 2019","December 2019","July 30, 2015",,"July 25, 2019","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02512172"
906,"NCT01206205","Frontline Therapy in de Novo Multiple Myeloma Patients Under 65","IFM2008","Completed","No Results Available","Multiple Myeloma","Drug: Lenalidomide, Bortezomib","Evaluation of the best response after consolidation|Response Evaluation after 3 cycles|Safety and tolerability : number and nature of Adverse Events|Stem Cells Collection|Response After HDT-ASCT and 2 cycles|Progression Free Survival","University Hospital, Toulouse|Celgene Corporation|Janssen-Cilag Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0805603","August 2009","October 2012","October 2012","September 21, 2010",,"May 12, 2017","Centre François Baclesse, Caen, cedex 5, France|University Hospital of Dijon, Hôpital des Enfants, Dijon, France|University Hospital of Grenoble, Hôpital A.Michallon, BP 217 X, Grenoble Cedex 09, France|University Hospital Of Lille, Hôpital Claude Huriez, Lille Cedex, France|Institut Paoli Calmette, Marseille Cedex, France|University Hospital of Bordeaux, ""Hôpital du Haut Lévêque "", Pessac, France|University Hospital of Toulouse, Purpan, Toulouse, France|Hôpital Bretonneau, Tours, Tours Cedex, France|Hôpitaux de Brabois Nancy, Vandoeuvre cedex, France",,"https://ClinicalTrials.gov/show/NCT01206205"
907,"NCT01166035","Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors","TEXO","Unknown status","No Results Available","Solid Tumors","Drug: Lenalidomide|Drug: Cetuximab","Maximum tolerated dose","Medical University Innsbruck|Celgene Corporation|Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TEXO0309","March 2010","September 2011","December 2011","July 20, 2010",,"July 20, 2010","Medical University of Innsbruck, Department for Internal Medicine I, Innsbruck, Tyrol, Austria",,"https://ClinicalTrials.gov/show/NCT01166035"
908,"NCT02384083","Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Filanesib, pomalidomide and dexamethasone","Maxim Tolerability Dose measured by common toxicity criteria v4.0|Eficcacy measured by the rate of responses","PETHEMA Foundation|Array BioPharma|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POMDEFIL","September 2015","February 2018","December 2019","March 10, 2015",,"December 11, 2018","Instoitut Català d'Oncologia, Badalona, Spain|Hospital Clinico Universitario, Barcelona, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hoapital Clinico Universitario Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Universitario Dr Peset, Valencia, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02384083"
909,"NCT02358161","Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","MATRIX","Unknown status","No Results Available","Pancreatic Cancer","Drug: gemcitabine and nab paclitaxel","Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel|Median survival|Progression free survival","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Novartis|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMCMEDONC 2013-215|2013-002370-51","September 2013","September 2015","September 2015","February 6, 2015",,"February 6, 2015","Academic Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02358161"
910,"NCT01127542","RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial","RESPeCT","Terminated","No Results Available","Chronic Lymphocytic Leukaemia","Drug: Lenalidomide","Complete Remission with clearance of Minimal Residual Disease (MRD)|Event free survival|Safety & tolerability of treatment (occurrence of adverse events)|Time to next treatment","The Christie NHS Foundation Trust|Celgene Corporation|Leukemia Research Fund","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09_DOG06_99|2009-011078-14|ISRCTN","May 2010",,"December 2011","May 21, 2010",,"December 5, 2011","The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|St James's University Hospital, Leeds, United Kingdom|The Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01127542"
911,"NCT02280525","Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma",,"Active, not recruiting","No Results Available","Leukemia","Drug: Lenalidomide|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: NK Cells|Drug: Cytarabine","Maximum Tolerated Dose (MTD) of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy|Response Rate of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy Determined by Bone Marrow Biopsy/Aspiration","M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0297|P-TRP-1996-14|NCI-2014-02678","March 5, 2015","March 2021","March 2021","October 31, 2014",,"May 10, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02280525"
912,"NCT01083706","Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant",,"Completed","Has Results","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes","Drug: azacitidine|Other: laboratory biomarker analysis","Overall Survival|Rate of Response by IWG Criteria|Incidence of Grades II-IV Graft-versus-host Disease (GVHD)","Fred Hutchinson Cancer Research Center|Celgene Corporation|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 2","43","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2240.00|NCI-2010-00281|P30CA015704|P01CA078902","April 2010","December 2013",,"March 10, 2010","May 24, 2017","May 24, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01083706"
913,"NCT01060384","Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: Lenalidomide|Drug: ofatumumab","Phase I: Maximum Tolerated Dose (MTD) of Lenalidomide|Phase I and Phase II: Event Free Survival and Overall Survival","University of Nebraska|Celgene Corporation|GlaxoSmithKline","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","514-09-FB","March 2010","October 25, 2016","January 2018","February 2, 2010","August 8, 2018","March 5, 2019","Saint Francis Medical Center, Grand Island, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01060384"
914,"NCT02244125","A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial","PCD","Active, not recruiting","No Results Available","Multiple Myeloma|First Relapse","Drug: PCD|Procedure: Autologous transplantation (ASCT)","Response rate (Partial response (PR) or better)|Safety : incidence of Adverse Events and Serious Adverse Events and laboratory abnormalities","Institut Curie|Intergroupe Francophone du Myelome|Celgene Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IC 2013-05","April 2014","January 2017","December 2020","September 18, 2014",,"April 6, 2018","CHRU Hopital Sud, Amiens, France|Centre Hospitalier de la côte Basque, Bayonne, France|Hôpital Avicenne, Bobigny, France|ICH - Hôpital A. Morvan, Brest, France|Institut d'Hématologie de Basse Normandie - IHBN, Caen, France|Chu Estaing, Clermont Ferrand, France|CHU Henri Mondor, Creteil, France|CHRU Dijon, Dijon, France|Centre Hospitalier Général, Dunkerque, France|Chru Grenoble, Grenoble, France|Centre Hospitalier départemental de Vendée, La Roche sur Yon, France|Clinique Victor Hugo, Le Mans, France|CHRU - Hôpital Claude Huriez, Lille, France|CHU de Limoges, Limoges, France|Institut Paoli Calmette, Marseille, France|Hopital Emile Muller, Mulhouse, France|CHU de Nantes, Nantes, France|CHU Carémeau, Nimes, France|Institut Curie, Paris, France|CHRU Hopital Saint Antoine, Paris, France|CHRU Hôpital Haut Lévêque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Hospitalier Annecy Genevois, Pringy, France|CHRU Hopital Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Centre Hospitalier Yves Le Foll, Saint Brieuc, France|Centre René Huguenin, Saint Cloud, France|Institut Universitaire du Cancer Toulouse-Oncopôle (IUCT-O), Toulouse, France|CHRU Hopital Bretonneau, Tours, France|CHRU Hopitaux de Brabois, Vandoeuvre les Nancy, France",,"https://ClinicalTrials.gov/show/NCT02244125"
915,"NCT01036087","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Panitumumab|Drug: Nab-paclitaxel|Drug: Carboplatin|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","Pathologic Complete Response (CR) Rate","M.D. Anderson Cancer Center|Celgene Corporation|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0372|NCI-2012-00935","November 2010","November 2021","November 2022","December 21, 2009",,"May 16, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01036087"
916,"NCT01015352","Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: Azacitidine|Drug: Epoetin beta","To determine the major erythroid response rate after 6 courses, assessed according to IWG 2000 criteria|Degree and duration of erythroid response (including red blood cell transfusion independence),overall survival and time to progression and toxicity","Groupe Francophone des Myelodysplasies|Celgene Corporation|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","98","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GFM-Aza-Epo-2008-01","February 2009","March 2014","March 2014","November 18, 2009",,"March 19, 2014","CHU d'Amiens, Amiens, France|Hôpital Angers, Angers, France|Hôpital Avignon, Avignon, France|Hôpital de la Côte Basque, Bayonne, France|Hopital Avicenne, Bobigny, France|Hôpital Boulogne Sur Mer, Boulogne Sur Mer, France|Hopital Clémenceau, Caen, France|Hôpital le Bocage, Dijon, France|Hôpital kremlin Bicêtre, Kremlin Bicêtre, France|Hôpital Versailles, Le Chesnay, France|Hôpital Saint Vincent, Lille, France|Hôpital Huriez, Lille, France|Hôpital Limoges, Limoges, France|Hôpital Edouard Herriot, Lyon, France|Hôpital Paoli-Calmettes, Marseille, France|Hôpital Brabois, Nancy, France|Hôpital Hôtel Dieu, Nantes, France|Hôpital Archet1, Nice, France|Hôpital La Source, Orléans, France|Hôpital Lariboisière, Paris, France|Hôpital Saint Louis, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Cochin, Paris, France|Hôpital Maréchal Joffre, Perpignan, France|Hôpital Jean-Bernard, Poitiers, France|Hôpital Reims, Reims, France|Hôpital Henri Becquerel, Rouen, France|Hôpital Hautepierre, Strasbourg, France|Hôpital Purpan, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01015352"
917,"NCT02077166","Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Ibrutinib|Drug: Lenalidomide|Drug: Rituximab","Phase 1: Determine the maximally tolerated dose (MTD) and /or the recommended Phase 2 (RP2) dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in subjects with relapsed or refractory DLBCL.|Phase 2: Overall response rate (ORR)|Phase 1: Overall response rate(ORR)|Phase 2: Duration of response (DOR)|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS)|Phase 2: Complete response (CR)|Phase 2: Safety and tolerability of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed or refractory non-GCB DLBCL.","Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","129","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1123-CA","February 2014","October 2019","October 2020","March 4, 2014",,"August 26, 2019","University of Alabama, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Cedar Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Summit Medical Group, Morristown, New Jersey, United States|Weill Cornell Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Cincinnati Health Barrett Center, Cincinnati, Ohio, United States|Mid-Ohio Oncology/ Hematology, Columbus, Ohio, United States|University of TN Medical Center, Knoxville, Tennessee, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Baylor Charles Sammons Cancer Center, Dallas, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Northwest Medical Specialities, PLLC, Tacoma, Washington, United States|Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg, Antwerpen, Belgium|CHU Brugmann, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Universiaetsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany|Klinikum der Universitaet Muenchen - Campus Grosshadern, Muenchen, Bayern, Germany|Klinikum rechts der Isar - Technische Universitaet Muenchen, III. Medizinische Klinik und Polyklinik, Muenchen, Bayern, Germany|Universitaetsklinikum Wuerzburg, Medizinische Klinik und Poliklinik II, Wuerzburg, Bayern, Germany|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|The Leeds Teaching Hospitals, Leeds, United Kingdom|Kings College Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02077166"
918,"NCT00915252","Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","AML-AZA","Completed","No Results Available","Acute Myeloid Leukemia","Drug: azacitidine|Drug: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine","Median Event Free Survival (EFS) of all AML patients|Median event free survival of AML patients with different cytogenetic and molecular risk groups|Median overall survival of all AML patients|Median overall survival of AML patients with different cytogenetic and molecular risk groups|Relapse free survival","University Hospital Muenster|Celgene Corporation|Amgen","All","61 Years and older   (Adult, Older Adult)","Phase 2","214","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101010","July 2009","December 2012","December 2012","June 5, 2009",,"December 17, 2012","RWTH Aachen, Medizinische Klinik IV, Aachen, Germany|Sozialstiftung Bamberg, Klinikum am Bruderwald, Med. Klinik V, Bamberg, Germany|Klinikum Bayreuth, Medizinische Klinik IV, Bayreuth, Germany|Charite Campus Benjamin Franklin, Universitätsmedizin Berlin, Medizinische Klinik III, Berlin, Germany|Städt. Kliniken Bielefeld gem. GmbH, Klinikum Mitte, Klinik für Hämatologie, Onkologie, Palliativmedizin, Bielefeld, Germany|Klinikum Chemnitz, Krankenhaus Küchenwald, Klinik für Innere Medizin III, Chemnitz, Germany|Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany|Katholische Krankenhaus Duisburg, Duisburg, Germany|Universitätsklinikum Erlangen, Medizinische Klinik 5, Erlangen, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|Klinikum der Johann Wolfgang Goethe-Universität Frakfurt am Main, Frankfurt am Main, Germany|Asklepios Klinik St. Georg, Hämatologische Abteilung, Hamburg, Germany|St. Bernward Krankenhaus Hildesheim, Medizinische Klinik II, Hildesheim, Germany|Westpfalz-Klinikum GmbH, Med. Klinik I, Kaiserslautern, Germany|Stiftungsklinikum Mittelrhein, Hämatologie/ Onkologie, Koblenz, Germany|Johannes Gutenberg-Universität Mainz Klinikum, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Phillips Universität Marburg, Fachbereich 20, ZIM, Marburg, Germany|Klinikum rechts der Isar, III. Medizinische Klinik, Muenchen, Germany|Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A, Münster, Germany|Klinikum Nürnberg, Medizinische Klinik 5, Nurnberg, Germany|Klinikum Osnabrück, Klinik für Onkologie, Hämatologie, Immunologie, Osnabruck, Germany|Klinikum der Universität Regensburg, Klinik und Poliklinik für Innere Medizin I, Regensburg, Germany|Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I, Trier, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany|Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Wurzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00915252"
919,"NCT00890955","Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies",,"Completed","No Results Available","Lung Cancer","Drug: Amrubicin|Drug: Cyclophosphamide","To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.|To determine the toxicities of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.|To assess response to the combination of amrubicin and cyclophosphamide","Lawrence Einhorn|Celgene Corporation|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOG LUN07-130","March 2009","July 2010","July 2010","April 30, 2009",,"December 23, 2015","Highlands Oncology Group, Springdale, Arkansas, United States|Helen F. Graham Cancer Center, Newark, Delaware, United States|Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Siteman Cancer Center, St. Louis, Missouri, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center Extramural Research Program, Rockledge, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00890955"
920,"NCT00864942","Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)","Phase I BLR","Completed","No Results Available","Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma","Drug: bendamustine and lenalidomide|Drug: BL-NHL|Drug: BLR-CLL|Drug: BLR-NHL","Maximum tolerated dose|Dose limiting toxicity|Recommended Phase II dose|overall safety profile|Plasma pharmacokinetics|Preliminary antitumor activity","Georgetown University|Celgene Corporation|Cephalon","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-CLL-NHL-PI-356|2008-186","February 2009","October 2014","October 2014","March 19, 2009",,"March 13, 2015","Georgetown University Hospital/Lombardi Cancer Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00864942"
921,"NCT00794274","The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis",,"Completed","No Results Available","Sarcoidosis|Cutaneous Sarcoidosis","Drug: CC-100004","Improvement in skin lesions as assessed by a Sarcoidosis Skin Activity and Severity Index (SASI) .|To determine the safety (type, frequency, severity, and relationship of adverse events to study treatment) of CC-10004 in patients with chronic cutaneous sarcoidosis.|Improvement of global score of sarcoidosis using a visual analogue scale (VAS) by both the patient and a separate VAS by the physician.|Change in the quality of life using the Sarcoidosis Health Questionnaire and Short Form-36 (SF-36).|Change in genomic and proteomic expression of cytokines in paired skin biopsies (non-facial lesions).|Improvement in pulmonary status, specifically the six-minute walk test, dyspnea score, and forced vital capacity (FVC).","University of Cincinnati|Celgene Corporation|Medical University of South Carolina","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP0005","November 2008","December 2011","December 2011","November 20, 2008",,"April 12, 2013","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00794274"
922,"NCT00766116","Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)",,"Completed","Has Results","Acute Myeloid Leukemia","Drug: 5-Azacitidine|Drug: Gemtuzumab ozogamicin","Number of Participants With Dose Limiting Toxicities|Number of Participants With Response to the Combination Treatment of Mylotarg With 5-azacitidine","University of California, San Diego|Celgene Corporation|Pfizer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090516","July 2005","September 26, 2014","September 26, 2014","October 3, 2008","February 18, 2019","February 18, 2019","UCSD Moores Cancer Center, La Jolla, California, United States|Stanford University, Stanford, California, United States|Northside Hospital/BMTGA, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00766116"
923,"NCT00738829","Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL",,"Completed","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell","Drug: Lenalidomide|Drug: Fludarabine|Biological: Rituximab","Lenalidomide Maximum Tolerated Dose|Safety profile of Lenalidomide/Fludarabine/Rituximab treatment|Safety Profile of Lenalidomide/Rituximab|Response rate for Lenalidomide/Fludarabine/Rituximab combination treatment|Response rate for Lenalidomide/Rituximab combination therapy|Response rate by 4-colour flow cytometric MRD analysis|Changes in Quality of Life scores|Risk factors and clonal evolution","Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene Corporation|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLL-5|EudraCT Nr. 2008-001430-27|ML21718","October 2008","January 2012","January 2012","August 21, 2008",,"August 30, 2013","Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck, Tirol, Austria|Landeskrankenhaus Feldkirch, Feldkirch, Austria|Krankenhaus d. Barmherzigen Schwestern Linz, Linz, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Krankenhaus der Stadt Linz, Linz, Austria|Universitaetsklinik f. Innere Medizin III, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria",,"https://ClinicalTrials.gov/show/NCT00738829"
924,"NCT00736619","Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)",,"Completed","No Results Available","HEAD & NECK Cancer","Other: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)","To establish the phase II recommended dose of weekly intravenous albumin-bound paclitaxel (Abraxane®) given concurrently with weekly cetuximab + definitive radiation therapy (IMRT) for patients with HNSCC.|To establish the safety and tolerability of weekly albumin-bound paclitaxel + cetuximab + RT for patients with HNSCC.","Memorial Sloan Kettering Cancer Center|Celgene Corporation|National Comprehensive Cancer Network","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-084","August 2008","August 2016","August 2016","August 18, 2008",,"August 10, 2016","Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT00736619"
925,"NCT00675259","Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: bevacizumab|Drug: carboplatin|Drug: nab-paclitaxel|Procedure: Surgery|Drug: Adjuvant chemotherapy","Number of Patients With Pathologic Complete Response (pCR)|Side Effects of Weekly Nab-paclitaxel, Carboplatin and Bevacizumab|Evaluation of Dynamic Contrast-enhanced Magnetic Resonance Imaging in Assessing pCR at Baseline and After 2 Cycles of Neoadjuvant Therapy|Overall Expression of LZTS1 Before and After Neoadjuvant Therapy as Assessed by Immunohistochemistry","Ohio State University Comprehensive Cancer Center|Celgene Corporation|Genentech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-07074|NCI-2011-03188","July 2008","May 2011","March 2014","May 9, 2008","August 24, 2016","July 24, 2018","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00675259"
926,"NCT00617591","Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide|Drug: Pegylated Liposomal Doxorubicin (PLD)|Drug: Dexamethasone","Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen|Percentage of Participants With Very Good Partial Remission (VGPR) or Better|Median Progression Free Survival (PFS) in Months|2 Year Overall Survival (OS) Rate|Occurrence of Induction Toxicities","H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 2","57","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-14986|106095d|RV-MM-PI-107|07OBCA990185","January 2008","April 2013","April 2013","February 18, 2008","December 17, 2013","January 17, 2014","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00617591"
927,"NCT01685814","Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance",,"Active, not recruiting","No Results Available","Previously Untreated Symptomatic Multiple Myeloma","Drug: Lenalidomide, Bortezomib|Biological: autologous stem cell transplant|Biological: allogeneic stem cell transplant","The primary efficacy endpoint for the induction phase is the rate of patients with CR at first restaging|In the consolidation phase the primary efficacy endpoint for comparison II (response <VGPR after first ASCT) is the PFS rate|ORR following 3 cycles of induction treatment (VRD vs RAD)|CR and ORR at the end of the whole treatment programme|Overall survival (OS)|Incidence, severity and relationship of SAEs|Numbers of hospital stays and hospitalization days","Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","406","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSMM XIV|2009-016616-21","May 2012","September 2016","May 2020","September 14, 2012",,"February 8, 2017","Universitätsklinikum Aachen, Med. Klinik IV, Hämatologie u. Onkologie, Aachen, Germany|Schön Klinik Starnberger See, Hämatologie und Onkologie, Berg, Germany|Campus Virchow-Klinikum Charite´, Charite´- Centrum 14, Med. Klinik Hämatologie u. Onkologie, Berlin, Germany|Klinikum Bremen-Mitte gGmbH, Klinik für Innere Medizin I, Bremen, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitätsklinikum Erlangen, Medizinische Klinik 5, Erlangen, Germany|Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I, Flensburg, Germany|Klinikum der Johann Woflgang Goethe Universität, Frankfurt am Mai, Frankfurt am Main, Germany|Klinikum Frankfurt (Oder) GmbH Medizinische Klinik I, Frankfurt/Oder, Germany|Universitätsklinikum Freiburg, Abteilung für Innere Medizin I, Freiburg, Germany|Universitätmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C, Greifswald, Germany|St. Marien-Hospital gem. GmbHKna, Hamm, Germany|Universitätsklinikum des Saarlandes Innere Medizin I, Homburg/Saar, Germany|Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II, Jena, Germany|Städtisches Klinikum Karlsruhe Medizinische Klinik III, Abt. Hämatologie u. Onkologie, Karlsruhe, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik, Kiel, Germany|Universitätsklinikum Schleswig-Holstein, Medizinische Klinik und Poliklinik II im städtischen Krankenhaus Kiel, Kiel, Germany|Stiftungsklinikum Mittelrhein GmbH, Klinik für Innere Medizin, Koblenz, Germany|Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I, Lübeck, Germany|Universitätsmedizin Mannheim medizinische Klinik III, Mannheim, Germany|Klinikum Schwabing, München, Germany|Klinikum der Universität München-Großhadern, München, Germany|III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München, München, Germany|Universitätsklinikum Münster, Medizinische Klinik u. Poliklinik A, Münster, Germany|Klinikum Nürnberg Nord, 5. Medizinische LKinik, Onkologie/Hämatologie, Nürnberg, Germany|Klinikum Oldenburg GmbH, Klinik für Innere Medizin II, Oldenburg, Germany|Klinikum Ernst von Bergmann, Klinik für Hämatologie, Onkologie, Potsdam, Germany|Uniklinikum Regensburg, Abteilung für Hämatologie und internistische Onkologie, Regensburg, Germany|Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany|Robert-Bosch-Krankenhaus, Abt. Hämatologie, Onkologie u. Palliativmedizin, Stuttgart, Germany|Universitätsklinikum Ulm,Klinik für Innere Medizin III, Ulm, Germany|Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH, Villingen-Schwenningen, Germany|Dr. Horst Schmidt Kliniken, Klinik Innere Medizin III, Wiesbaden, Germany|Universitätsklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany",,"https://ClinicalTrials.gov/show/NCT01685814"
928,"NCT00580242","A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia",,"Completed","No Results Available","Myelodysplasia","Drug: Bortezomib|Drug: Lenalidomide","Establish the maximally tolerated dose of bortezomib, up to 1.3 mg/m2/day, that can be administered in combination with lenalidomide in patients with primary and secondary non 5q del myelodysplasia who are untreated or previously treated.|Assess efficacy in terms of the number of patients experiencing a decrease in blast percentage|Assess efficacy in terms of the number of patients experiencing a decrease in transfusion requirements|Determine the toxicity profile of bortezomib when used in combination with lenalidomide for patients with myelodysplasia|Determine the time (days) to transfusion independence|Determine the duration of response|Determine if molecular markers can predict responsiveness to treatment (for consenting patients)","Massachusetts General Hospital|Celgene Corporation|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-006|RV-MDS-PI-0161","November 2007","March 2012","March 2012","December 24, 2007",,"March 8, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00580242"
929,"NCT01649791","Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia",,"Terminated","Has Results","B-cell Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia","Drug: lenalidomide|Other: laboratory biomarker analysis|Procedure: lymph node biopsy|Procedure: bone marrow aspiration|Other: pharmacological study|Other: flow cytometry","Median Progression-free Survival|Overall Response Rate (CR+PR)|Incidence of Immune Mediated Flare Reaction|Expression of B-CLL Co-stimulatory Ligands, Mic-A, and Mic-B Assessed by Flow Cytometry","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 136908|NCI-2009-01327","January 2010","May 2012","October 2014","July 25, 2012","February 27, 2014","June 30, 2016","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01649791"
930,"NCT01639898","POEMS Syndrome Treatment With Lenalidomide","POEMS","Completed","No Results Available","POEMS Syndrome","Drug: Lenalidomide and dexamethasone","Biological outcome|Clinical response","University Hospital, Limoges|Ministry of Health, France|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I10 015","July 2012","June 2018","July 2018","July 13, 2012",,"July 4, 2019","CHU d'Angers, Angers, France|CHU de Caen, Caen, France|CHU de Lille, Lille, France|CHU de Limoges, Limoges, France|Hospices Civil de Lyon, Lyon, France|Centre Léon Bérard, Lyon, France|CHU de Nantes, Nantes, France|Hôpital Saint-Louis, Paris, France|Pitié Salpétrière, Paris, France|Hôpital Necker, Paris, France|CHU de Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01639898"
931,"NCT00536341","Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",,"Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: lenalidomide|Drug: Rituximab|Drug: Fludarabine","Number of Adverse Events as a Measure of Safety and Tolerability|Complete Response Rate|Progression-Free Survival|Overall Survival","SCRI Development Innovations, LLC|Celgene Corporation|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI CLL 02","January 2008","April 2013","November 2016","September 27, 2007","May 4, 2016","January 16, 2017","Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00536341"
932,"NCT01518465","Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma",,"Terminated","No Results Available","Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: dalteparin|Drug: lenalidomide|Drug: dexamethasone|Other: laboratory biomarker analysis","Number of patients who experienced grade 4 hemorrhage regardless of attribution, or grade 3 hemorrhage that is possibly, probably, or definitely attributable to dalteparin (Arm II)|Toxicities observed at each dose level, in terms of type (organ affected, laboratory determination), severity (by Common Toxicity Criteria [CTC])","University of Southern California|National Cancer Institute (NCI)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16M-11-1|NCI-2011-03784","January 9, 2012","December 31, 2016","October 31, 2017","January 26, 2012",,"November 29, 2017","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01518465"
933,"NCT00483301","A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",,"Completed","No Results Available","Malignant Melanoma","Drug: Sorafenib (BAY 43-9006)|Drug: ABI-007(Abraxane)","Primary Objective|Secondary Objective","Mt. Sinai Medical Center, Miami|Celgene Corporation|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEL0205","May 2007","August 2009","August 2009","June 7, 2007",,"May 3, 2012","Dr. Steven O'Day, Los Angeles, California, United States|Mt. Sinai Medical Center, Miami Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00483301"
934,"NCT01497496","Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: High Dose Methylprednisolone (HDMP)|Drug: Ofatumumab|Drug: Lenalidomide","Objective Response Rate (ORR)|Rate of Progression-free Survival (PFS)|Rate of Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16631|COMB157AUS08T|RV-CLL-PI-0560","January 20, 2012","December 2019","December 2020","December 22, 2011",,"August 6, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01497496"
935,"NCT01496976","Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: High Dose Methylprednisolone (HDMP)|Drug: Ofatumumab|Drug: Lenalidomide","Number of Participants With Complete Response (CR)|Number of Participants With Partial Response (PR)|Number of Participants With Progression/Relapse Free Survival (PFS)|Number of Participants With Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-16622|COMB157BUS21T|RV-CLL-PI-0560","January 20, 2012","December 2019","December 2020","December 22, 2011",,"September 6, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01496976"
936,"NCT01488565","A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia","Aza-E","Completed","No Results Available","Myelodysplastic Syndromes (MDS)|Acute Myeloid Leukaemia (AML)","Drug: Azacitidine and eltrombopag","Number of events of non-haematological toxicities related to the combination of eltrombopag and azacitidine|Number of patients with improved platelet counts and the dose at which this may be achieved.|Correlation of the laboratory findings with the response of the combination of 5-azacitidine and eltrombopag in patients with MDS and low marrow blast count AML","Peter MacCallum Cancer Centre, Australia|GlaxoSmithKline|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10/78","December 2010","May 2014","May 2015","December 8, 2011",,"February 15, 2016","Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01488565"
937,"NCT00462423","Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study","AbraxAvast","Completed","Has Results","Metastatic Malignant Melanoma","Drug: Avastin|Drug: Abraxane","Progression-free Survival (PFS) at 4 Months|Progression-free Survival|Overall Survival (OS)|Objective Response Rate (RR) in Patients With Measurable Lesions Time to Objective Response|Safety and Tolerability of This Combination","Lynn E. Spitler, MD|Celgene Corporation|Genentech, Inc.|Northern California Melanoma Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070223","April 2007","April 2011","January 2012","April 19, 2007","January 8, 2014","January 8, 2014","Northern California Melanoma Center, San Francisco, California, United States|The Angeles Clinic and Research Institute, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT00462423"
938,"NCT01464034","A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Pomalidomide|Drug: Dexamethasone","Adverse Events as a Measure of Safety and Tolerability|Overall Response in Phase II|Overall Response in Phase I|Time to Progression|Progression Free Survival|Time to next therapy","Criterium, Inc.|Amgen|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","117","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMyC 10-MM-01|IST-CAR-521|PO-MM-PI-0034","November 2011","December 2017","June 2018","November 3, 2011",,"October 18, 2017","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|The John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01464034"
939,"NCT00431990","A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: depsipeptide|Drug: bortezomib|Drug: dexamethasone","Toxicity|Overall response|Time to progression|Overall survival","Peter MacCallum Cancer Centre, Australia|Celgene Corporation|Janssen-Cilag Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06/34","November 2006","December 2011","January 2012","February 6, 2007",,"August 12, 2011","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00431990"
940,"NCT01429025","Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",,"Completed","No Results Available","Refractory/Relapsed Indolent Non-Hodgkin Lymphoma","Biological: rituximab|Drug: bendamustine|Drug: lenalidomide","Maximum-tolerated dose of lenalidomide in combination with bendamustine hydrochloride and rituximab|Toxicity profile|Progression-free survival|Overall response rate|Complete response rate","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N1088|CDR0000710726|NCI-2011-03535","May 2012","November 2014","July 1, 2019","September 5, 2011",,"October 8, 2019","Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01429025"
941,"NCT00392392","Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: nab-paclitaxel|Drug: Bevacizumab|Drug: Trastuzumab","Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery","SCRI Development Innovations, LLC|Celgene Corporation|Genentech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 83","October 2006","April 2008","December 2011","October 26, 2006","February 13, 2013","September 20, 2013","Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00392392"
942,"NCT00384839","Vidaza to Restore Hormone Thx Prostate",,"Completed","Has Results","Prostate Cancer","Drug: azacitidine for injectable suspension","Percentage of Patients With PSA Doubling Time >=3 Months.|PSA Response Rate|Objective Response Rate by Recist (ORR)|Progression-free Survival|1-year Overall Survival (OS)|Changes in Fetal Hemoglobin (HbF) With Time.","US Oncology Research|Celgene Corporation|University of Southern California","Male","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05015","April 2006","November 2009","November 2009","October 6, 2006","October 25, 2018","October 25, 2018","Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States|Cancer Centers of Florida, P.A., Ocoee, Florida, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Raleigh Hematology Oncology Associates, Cary, North Carolina, United States|Northwestern Carolina Oncology Hematology, Hickory, North Carolina, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Deke Slayton Cancer Center, Webster, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Cancer Care Nrothwest-South, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00384839"
943,"NCT00322985","A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","T-cell Lymphoma","Drug: Lenalidomide","overall response rate|complete response rate|Time To Progression [TTP]|survival|safety","AHS Cancer Control Alberta|Celgene Corporation|Alberta Cancer Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22409","June 2006","May 2014","July 2014","May 9, 2006",,"March 16, 2016","Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II, Health Services Centre, Halifax,, Nova Scotia, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00322985"
944,"NCT01246622","Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",,"Active, not recruiting","No Results Available","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia","Drug: cytarabine|Drug: lenalidomide","MTD of lenalidomide following intermediate dose cytarabine|Overall response rate","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 179510|NCI-2010-02080|P30CA016056","February 7, 2011","May 15, 2014","December 15, 2019","November 23, 2010",,"October 30, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01246622"
945,"NCT00301405","Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain",,"Terminated","No Results Available","Chronic Prostatitis|Pelvic Pain","Drug: Thalidomide","Decrease in pain as measured by visual analog scale","Kenneth Peters, MD|Celgene Corporation|William Beaumont Hospitals","Male","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-149 IND #74,062","March 2006","November 2006","November 2006","March 10, 2006",,"August 5, 2013","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00301405"
946,"NCT01202877","PKC412 and 5-Azacytidine",,"Completed","Has Results","Leukemia","Drug: 5-azacytidine|Drug: PKC412","Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1|Overall Response (OR) Within 6 Months","M.D. Anderson Cancer Center|Novartis Pharmaceuticals|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0374|NCI-2012-01896","March 2011","July 2015","July 2015","September 16, 2010","November 7, 2016","October 16, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01202877"
947,"NCT01129180","Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma",,"Completed","No Results Available","Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|T-cell Large Granular Lymphocyte Leukemia","Drug: azacitidine|Drug: bortezomib|Procedure: Correlative studies","Maximum tolerable dose (MTD) of bortezomib in combination with azacitidine|Specific toxicities and the dose limiting toxicity (DLT) of bortezomib in combination with azacitidine as assessed by NCI CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0|Overall response rate|Correlation of the biological activity of Azacitidine as a demethylating agent with clinical endpoints and plasma pharmacokinetics|Biological activity of bortezomib as a potential demethylating agent|Correlation of intracellular concentration of azacitidine-triphosphate with global DNA methylation and other biological endpoints as well as clinical response|Biologic role of microRNAs in determining clinical response to the bortezomib plus azacitidine combination and achievement of the other pharmacodynamic endpoints","Pierluigi Porcu|Millennium Pharmaceuticals, Inc.|Celgene Corporation|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-08067|NCI-2010-01081","May 2010","May 2012","December 2012","May 24, 2010",,"December 3, 2013","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01129180"
948,"NCT01123356","Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab",,"Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Ofatumumab|Drug: Lenalidomide","Overall Response Rate|Frequency of Adverse and Severe Adverse Events|Biomarkers Changes During Treatment.|Frequency of Adverse Events|Dose Reductions Due to Adverse Events.","Medical University of South Carolina|GlaxoSmithKline|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101376 OFT113297","May 2010","May 2013","June 2013","May 14, 2010","December 3, 2015","December 3, 2015","Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01123356"
949,"NCT01096394","Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer",,"Completed","No Results Available","Ovarian Cancer",,"Establishment of a ""live"" library of primary ovarian epithelial tumors","Vanderbilt University|National Cancer Institute (NCI)|Celgene Corporation","Female","18 Years to 80 Years   (Adult, Older Adult)",,"20","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","090075|P30CA068485|VU-VICC-GYN-0917|IRB# 090075","November 2009","October 2015","October 2015","March 31, 2010",,"December 10, 2015","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01096394"
950,"NCT01050790","Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Azacitidine","Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment|Complete Response Rate at 6 Months|Toxicity as Assessed by NCI CTCAE v3.0|Time to Progression Post Transplant|Progression-free and Overall Survival|Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)|CTA Expression Before and After Azacitidine Therapy","Virginia Commonwealth University|National Cancer Institute (NCI)|Celgene Corporation","All","18 Years to 69 Years   (Adult, Older Adult)","Not Applicable","17","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000663409|P30CA016059|MCC-12430","January 2010","August 2014","September 2016","January 15, 2010","October 5, 2015","June 26, 2018","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01050790"
951,"NCT01038388","A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Vorinostat","To determine the maximum tolerated dose (MTD) and recommended phase II doses (RP2D) of vorinostat in combination with lenalidomide, bortezomib, and dexamethasone.|Efficacy by standard myeloma measurements (SPEP, UPEP [urine protein electrophoresis], bone marrow)","Emory University|Merck Sharp & Dohme Corp.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00017528|1591|RV-MM-PI-0420","January 15, 2010","February 2020","February 2020","December 24, 2009",,"February 18, 2019","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01038388"
952,"NCT00972842","Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)","LenVoDex","Terminated","No Results Available","Peripheral T-Cell Non-Hodgkin's Lymphoma","Drug: Vorinostat, Lenalidomide","The primary objective of this study is to determine the maximum tolerated dose (MTD) of a Lenalidomide, Vorinostat, and Dexamethasone combination regimen in terms of occurrence of dose-limiting toxicities (DLT) at any dose level.|Remission rate of a combination therapy with Lenalidomide, Vorinostat, and Dexamethasone in a treatment refractory or relapsed population, defined as the percentage of patients achieving a complete response (CR) or partial response (PR)","Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme Corp.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGMT_PTCL1|EudraCT 2008-006919-20","September 2009","July 2012","July 2012","September 9, 2009",,"December 24, 2013","Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck, Tirol, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|Krankenhaus der Stadt Linz, Linz, Austria|Universitaetsklinik f. Innere Medizin III, Salzburg, Austria|Hanusch Krankenhaus, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00972842"
953,"NCT00948064","Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)",,"Unknown status","Has Results","Leukemia","Drug: Vorinostat|Drug: Azacitidine","Survival at Day 60|Response Rate","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0685|NCI-2009-01495","September 2009","April 2015","September 2018","July 29, 2009","July 2, 2015","February 28, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00948064"
954,"NCT00847639","Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma","07-REV","Completed","No Results Available","Multiple Myeloma","Drug: lenalidomide","To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.|To estimate the incidences of ≥ grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide.|To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT.|To determine time to disease progression and overall survival after lenalidomide.","Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Celgene Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-REV","February 2009","January 2013","March 2014","February 19, 2009",,"April 4, 2014","City of Hope National Medical Center, Duarte, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of Pennsylvania Hospital Center, Philadelphia, Pennsylvania, United States|The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00847639"
955,"NCT00829647","A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia",,"Withdrawn","No Results Available","Chronic Lymphocytic Leukemia|Leukemia","Drug: dasatinib and lenalidomide","Safety and maximum tolerated dose (phase I) and overall response rate (phase II)|Assess responses in subgroups of high-risk patients, including 17p- and 11q- deletion, and CD38 and ZAP-70 positive expression","Scripps Health|Bristol-Myers Squibb|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLL084993","January 2009","December 2009","March 1, 2016","January 27, 2009",,"April 11, 2019",,,"https://ClinicalTrials.gov/show/NCT00829647"
956,"NCT00813124","Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)",,"Completed","No Results Available","Stem Cell Transplantation|Leukemia","Drug: Fludarabine|Drug: Busulfan|Drug: Thymoglobulin|Drug: Azacitidine|Procedure: Stem Cell Transplant","Complete Molecular Remission Rate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0087|NCI-2012-02122","December 2008","September 2014",,"December 22, 2008",,"October 1, 2014","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00813124"
957,"NCT00738361","Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery",,"Completed","Has Results","Intraocular Melanoma","Drug: nab-paclitaxel","Overall Response Rate|Progression-free Survival|Overall Survival","Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-08076|NCI-2011-03176","August 2008","July 2012","April 2013","August 20, 2008","February 12, 2016","February 12, 2016","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00738361"
958,"NCT00729612","Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",,"Completed","Has Results","Lung Cancer","Drug: carboplatin|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Genetic: protein expression analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria.|Progression Free Survival|Overall Survival|Incidence and Intensity of Adverse Events Graded According to NCI CTCAE v. 3.0","Greg Otterson|National Comprehensive Cancer Network|Celgene Corporation|Ohio State University Comprehensive Cancer Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","63","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-08059|NCI-2011-03196","August 14, 2008","December 16, 2011","December 16, 2011","August 7, 2008","June 6, 2016","April 2, 2018","Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00729612"
959,"NCT00667147","Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib",,"Completed","No Results Available","Solid Tumors","Drug: Weekly Abraxane and Daily Vandetanib|Drug: Abraxane every three weeks and daily vandetanib","Dose Limiting Toxicity|RECIST Response|Toxicity","University of Southern California|AstraZeneca|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0C-07-3","March 2008","May 2012","June 2014","April 25, 2008",,"November 19, 2014","University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00667147"
960,"NCT00654836","Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer","Biological: bevacizumab|Drug: Carboplatin|Drug: ABI-007","Progression-free Survival|Response Rate at End of Treatment|Overall Survival","Loyola University|Genentech, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200027","October 2007","February 2012","September 2015","April 9, 2008","September 14, 2017","September 14, 2017","Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital, Downers Grove, Illinois, United States|Delnor Community Hospital - Geneva, Geneva, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Edward Hospital Cancer Center, Naperville, Illinois, United States|Swedish-American Regional Cancer Center, Rockford, Illinois, United States|Central Dupage Cancer Center, Winfield, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00654836"
961,"NCT00629343","Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide",,"Unknown status","No Results Available","Soft Tissue Sarcoma|Mesothelioma","Drug: Azacitidine In Combination With Temozolomide","The primary endpoint is dose limiting toxicity.|Clinical response, time to progression and overall survival.","Columbia University|Schering-Plough|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAC3255","October 2007","October 2012","August 2014","March 6, 2008",,"November 8, 2012","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00629343"
962,"NCT00624936","Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes",,"Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: Vidaza|Drug: Velcade","Maximum tolerated dose of bortezomib in combination with azacytidine|Overall response rate|Rate of complete remission|Biological activity of azacytidine and bortezomib as demethylating agents|Correlation of intracellular concentration of azacytidine-triphosphate with global DNA methylation and other biological endpoints as well as clinical response|Biologic role of microRNAs in determining clinical response to study drugs|Achievement of other pharmacodynamic endpoints","Ohio State University Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-07095|NCI-2011-03146","April 2008","December 2009","June 2014","February 28, 2008",,"August 22, 2017","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00624936"
963,"NCT00607438","A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|Drug: Sorafenib (Nexavar)","To evaluate the progression-free survival (PFS)and duration of response of the combination of weekly Abraxane and continuous Nexavar as first-line treatment for patients with locally advanced or metastatic breast cancer.|To evaluate the response rate.|Evaluate the 1 and 2 year survival rate.|Evaluate the toxicities of the combination of Abraxane and Nexavar","Veeda Oncology|Bayer|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I-06-025","September 2007","May 2009","May 2009","February 5, 2008",,"May 11, 2012","Veeda Oncology, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00607438"
964,"NCT00495547","SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome","SIMIDIS","Terminated","No Results Available","Myelodysplastic Syndrome","Drug: Azacitidine|Drug: Beta Erythropoietin","Evaluate the efficacy of the treatment in response rate terms|Evaluate the safety of the treatment","PETHEMA Foundation|Roche Pharma AG|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-000972-18|SIMIDIS","February 2009","June 2011","June 2011","July 3, 2007",,"April 7, 2014","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic Universitari, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Virgen Blanca, Leon, Spain|Hospital la Paz, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de mallorca, Spain|Hospital Clinico Universitario, Salamanca, Spain|Hospital La Fe de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00495547"
965,"NCT00479674","Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer","ABC","Completed","Has Results","Breast Cancer","Drug: Abraxane|Drug: Bevacizumab|Drug: Carboplatin","Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III ""Triple Negative"" Metastatic Breast Cancer.|Median Proportion Progression-free as Estimated by Kaplan-Meier Methods|To Evaluate Sequential Plasma Samples for Presence of Selected Angiogenic Markers|to Determine if Apolipoprotein Alleles (Apo-E) Correlate With Treatment-related Neuropathy|to Determine if SPARC Expression in Breast Tumors Predicts Progression-free Survival (PFS)","Duke University|Genentech, Inc.|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00014837|AVF3962s","May 2007","March 2014","March 2014","May 28, 2007","February 18, 2015","February 18, 2015","Presbyterian Health Care, Charlotte, North Carolina, United States|Northeast Oncology Associates, Concord, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Forsyth Regional Cancer Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00479674"
966,"NCT00407563","Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer",,"Completed","Has Results","Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma","Drug: Bevacizumab|Drug: Abraxane","6-month Progression-Free Rate|Best Overall Response|Overall Survival|Progression-free Survival (PFS)|Best Overall Response at Six Months","Accelerated Community Oncology Research Network|Genentech, Inc.|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACORN ALSSOPR0501","January 2007","February 2011","February 2011","December 5, 2006","April 5, 2012","April 5, 2012","Little Rock Hematology Oncology, Little Rock, Arkansas, United States|Wilshire Oncology Medical Group, Inc., La Verne, California, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Southeastern Gynecologic Oncology, LLC, Atlanta, Georgia, United States|North Idaho Cancer Center, Coeur d'Alene, Idaho, United States|Hematology-Oncology Centers of the Northern Rockies, Billings, Montana, United States|Mid-Ohio Oncology/Hematology, Columbus, Ohio, United States|Pennsylvania Oncology Hematology Assoc., Philadelphia, Pennsylvania, United States|Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Cancer Specialists of Tidewater, Ltd, Chesapeake, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00407563"
967,"NCT00331630","Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: lapatinib ditosylate|Drug: paclitaxel albumin-stabilized nanoparticle formulation","Clinical response rate as measured by clinical exam and imaging studies|Pathologic complete response rate|Correlation of proliferation (Ki67) with tumor response as measured at baseline and after completion of study treatment|Correlation of apoptosis (cleaved caspase-3) with tumor response as measured at baseline and after completion of study treatment|Correlation of angiogenesis (vW, CD34) markers with tumor response as measured at baseline and after completion of study treatment|Correlation of other studies with tumor response, including epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β) as measured at baseline and after completion of study treatment|Side effects from the combination of Abraxane and Lapatinib|Circulating tumor cell measurement","Northwestern University|GlaxoSmithKline|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 05B2|STU00007257","May 2006","August 2014","August 2021","May 31, 2006",,"May 3, 2019","Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Midwest Center for Hematology/Oncology, Joliet, Illinois, United States|Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields, Olympia Fields, Illinois, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00331630"
968,"NCT00256776","MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Velcade (Bortezomib)|Drug: Thalidomide|Drug: Dexamethasone","Time to progression, the interval between the date of randomization and date of disease progression (death without progression is a competing risk)|Overall survival (interval between date of randomization and death from any cause|Response rate (proportion of subjects who achieve complete, partial, or minimal response)","European Group for Blood and Marrow Transplantation|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","269","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT: 2005-001628-35|EBMT-CLWP: 42206611","July 2005",,"June 2013","November 22, 2005",,"August 7, 2012","Karl-Franzens, Graz, Austria|Universitatsklinik, Innsbruck, Austria|Medizinische Universitaet Wien, Vienna, Austria|Wilhelminenspital, Vienna, Austria|St Joseph, Arlon, Belgium|RHMS, Baudour, Belgium|AZ St Jan, Brugge, Belgium|Bordet, Brussels, Belgium|Erasme CHU, Brussels, Belgium|Saint Luc, Brussels, Belgium|University Hospital, Brussels, Belgium|Saint Joseph, Gilly, Belgium|CH Jolimont, Haine-Saint-Paul, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|UCL Mont-Godinne, Yvoir, Belgium|University Hospital, Brno, Czech Republic|Faculty Hospital, Olomouc, Czech Republic|CHU Amiens, Amiens, France|CHU Angers, Angers, France|Centre Hospitalier d'Antibes, Antibes, France|CHU Jean Minjoz, Besancon, France|Avicenne, Bobigny, France|Polyclinique Bordeaux Nord, Bordeaux, France|Morvan CHU, Brest, France|Hotel Dieu, Clermont-Ferrand, France|ARC CHU Dijon, Dijon, France|Hospitalier de Dunkerque, Dunkerque, France|Hopital Michallon, Grenoble, France|La Roche sur Yon, France|Centre Hospitalier du Havre, Le Havre, France|CHRU de Lille, Lille, France|Edouard Herriot, Lyon, France|Pierre Benite, Lyon, France|Metz, France|Centre Hospitalier de Mulhouse, Mulhouse, France|CHU Nancy, Nancy, France|Hotel Dieu, Nantes, France|Archet, Nice, France|Hopital Cochin, Paris, France|Hotel Dieu, Paris, France|Saint Antoine, Paris, France|Hopital Jean Bernard, Poitiers, France|Robert Debre, Reims, France|CHU Hopital Sud, Rennes, France|Henri Becquerel, Rouen, France|CHRU Tours, Tours, France|Klinikum Bremen, Bremen, Germany|University of Cologne, Cologne, Germany|University Hospital, Dresden, Germany|University Hospital, Hamburg, Germany|Medizinische Hochschule, Hannover, Germany|Uniklinik Leipzig, Leipzig, Germany|Universitatsklinikum Schleswig-Hostein, Lubeck, Germany|DKD Wiesbaden, Wiesbaden, Germany|Medizinische und Poliklinik II, Wurzburg, Germany|St Laszlo Hospital, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Rambam MC, Haifa, Israel|Sheba MC, Tel Hashomer, Israel|Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Ospedale Riuniti, Bergamo, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Ospedale Maggiore, Catania, Italy|Ospedale Maggiore, Milan, Italy|Federico II, Naples, Italy|V. Cervello, Palermo, Italy|Azienda Ospedale BMM, Reggio di Calabria, Italy|A.O.S. Andrea, Rome, Italy|IOSI, Ospedale Civico, Ticino, Italy|Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Kantonsspital, Basel, Switzerland|Inselspital, Bern, Switzerland|Hopital Cantonal Universitaire, Geneva, Switzerland|CHUV, Lausanne, Switzerland|LA Onkologie/Medizin, Thun, Switzerland|Stadtdpital Triemli, Zurich, Switzerland|UniversitatsSpital, Zurich, Switzerland|Heartlands Hospital, Birmingham, United Kingdom|Addenbrookes, Cambridge, United Kingdom|Great Western Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00256776"
969,"NCT00193206","Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Gemcitabine|Drug: Epirubicin|Drug: Albumin-bound Paclitaxel","Pathologic Complete Response|Clinical Response Rates|Time to Disease Progression|Rates of Breast Preservation","SCRI Development Innovations, LLC|Eli Lilly and Company|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","123","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 73","September 2005","October 2008","May 2009","September 19, 2005","November 30, 2012","November 30, 2012","Florida Cancer Specialists, Fort Myers, Florida, United States|Integrated Community Oncology Network, Jacksonville, Florida, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Hematology Oncology Life Center, Alexandria, Louisiana, United States|Mercy Hospital, Portland, Maine, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00193206"
970,"NCT03590652","Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma",,"Recruiting","No Results Available","Relapsed/Refractory Multiple Myeloma","Drug: Ixazomib|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Daratumumab","Overall Response Rate|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Clinical benefit rate|Progression free survival (PFS)|Time to progression|Overall survival (OS)|Minimal Residual Disease (MRD)|Quality of life (QOL) scores","Caitlin Costello, MD|Celgene|Takeda|Janssen, LP|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180638","October 17, 2018","October 1, 2020","October 1, 2021","July 18, 2018",,"January 15, 2019","UCSD Moores Cancer Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT03590652"
971,"NCT03023527","Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma",,"Terminated","No Results Available","Multiple Myeloma","Drug: Nivolumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Elotuzumab","Safety of Nivolumab: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","PETHEMA Foundation|Celgene|Bristol-Myers Squibb|Adknoma Health Research, S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM-NIVOPOMDEX","January 2017","January 2018","January 2018","January 18, 2017",,"May 23, 2018","ICO Badalona, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario de Canarias, Las Palmas de Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03023527"
972,"NCT02871323","Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis",,"Withdrawn","No Results Available","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Primary Myelofibrosis","Biological: Durvalumab|Other: Laboratory Biomarker Analysis","Incidence of Adverse Events|Changes in MF symptom burden|Changes in spleen size|Response to anti-PDL1 treatment in blood|Response to anti-PDL1 treatment in bone marrow","Northwestern University|Celgene|The Leukemia and Lymphoma Society|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16H05|STU00202833|P30CA060553|NCI-2016-01024","November 2016","November 2016",,"August 18, 2016",,"August 20, 2019","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02871323"
973,"NCT02718833","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Elotuzumab|Drug: Pomalidomide|Drug: Bortezomib|Drug: Dexamethasone","Overall response rate by International Myeloma Working Group criteria.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression Free Survival","Massachusetts General Hospital|Celgene|Bristol-Myers Squibb|Multiple Myeloma Research Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-475","June 2016","September 2020","September 2020","March 24, 2016",,"August 14, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02718833"
974,"NCT02460276","A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma","PHILEMON","Recruiting","No Results Available","Relapsed/Refractory Mantle Cell Lymphoma","Drug: Lenalidomide|Drug: Ibrutinib|Drug: Rituximab","Overall response rate.","Lund University Hospital|Celgene|Janssen, LP|Nordic Lymphoma Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-MCL6","April 2015","March 2020","March 2020","June 2, 2015",,"August 27, 2019","Rigshospitalet, Copenhagen, Denmark|Helsinki University Hospital, Helsinki, Finland|Norwegian Radium Hospital, Oslo, Norway|Lund University Hospital, Lund, Sweden|Uppsala Akademiska Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02460276"
975,"NCT04113018","Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma",,"Not yet recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab","Complete Response|Progression Free Survival (PFS)|Overall Survival (OS)|Time to Next Treatment (TTNT)|Duration of Response (DoR)|Time to Disease Progression (TTP)|Overall Response (OR)","Saad Z. Usmani, MD|Amgen|Celgene|Janssen, LP|Atrium Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-HEM-MYE-KRDD-001|00037709","November 2019","October 2026","October 2026","October 2, 2019",,"November 20, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04113018"
976,"NCT03376672","Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Ixazomib|Drug: Lenalidomide|Drug: Dexamethasone","Flow cytometric assessment < 0.01%|Flow cytometry negativity","Raija Silvennoinen|Nordic Myeloma Study Group|Celgene|Takeda|Helsinki University Central Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NMSG#23/15","May 31, 2018","December 31, 2027","December 31, 2027","December 18, 2017",,"January 8, 2019","Helsinki University Central Hospital, Helsinki, Finland|Central Finland Central Hospital, Jyväskylä, Finland|Kainuu Central Hospital, Kajaani, Finland|Kymenlaakso Central Hospital, Kotka, Finland|Kuopio University Hospital, Kuopio, Finland|Päijät-Häme Cebtral Hospital, Lahti, Finland|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|VIlnius University Hospital, Vilnius, Lithuania|Forde Central Hospital South, Forde, Norway|Oslo University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|Trondheim University Hospital, Trondheim, Norway|Borås University Hospital, Borås, Sweden|Göteborg University Hospital, Göteborg, Sweden|Halmstad Hospital Region Halland, Halmstad, Sweden|Linköping University Hospital, Linköping, Sweden|Sunderby Hospital Region Norrbotten, Luleå, Sweden|Lund University Hospital, Lund, Sweden|Helsingborg Hospital Skane, Skane, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Uppsala University Hospital, Uppsala, Sweden|Varberg Hospital, Varberg, Sweden|Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT03376672"
977,"NCT03359460","Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome",,"Recruiting","No Results Available","Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Refractory High Risk Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Therapy-Related Myelodysplastic Syndrome","Drug: Ibrutinib|Drug: Lenalidomide","Maximum tolerated dose|Disease free survival|Disease response|Hematologic normalization rate|Overall survival|Progression free survival|Time to response","Brian Jonas|Pharmacyclics LLC.|Celgene|National Cancer Institute (NCI)|University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1043625|UCDCC#265|P30CA093373|NCI-2017-01827","December 1, 2017","June 1, 2020","December 1, 2020","December 2, 2017",,"March 22, 2019","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03359460"
978,"NCT03188172","MUK Nine b: OPTIMUM Treatment Protocol","MUKnineb","Recruiting","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Lenalidomide|Drug: Daratumumab|Drug: Dexamethasone|Drug: Melphalan|Drug: Filgrastim","Progression free survival|Occurrence of Serious Adverse Events(SAE) and Suspected, Unexpected Serious Adverse Reactions (SUSAR)|Progression free survival at 100 days post autologous stem cell transplant|Minimal residual disease (MRD) negative disease|Overall survival|Maximum response|Overall response|Second progression free survival|Overall treatment benefit|Quality of Life","University of Leeds|Myeloma UK|Celgene|Janssen, LP","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","95","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM16/235","September 28, 2017","October 1, 2020","December 31, 2021","June 15, 2017",,"April 16, 2019","Queen Elizabeth Hospital, Birmingham, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Blackpool Victoria Hospital, Blackpool, United Kingdom|Royal Hampshire County Hospital, Bournemouth, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|Kettering General Hosptial, Kettering, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Kings College Hosptial, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham University Hosptial, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Royal Stoke Hospital, Stoke-on-Trent, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom|Worcester Royal Hospital, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03188172"
979,"NCT03141203","Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients","RomiCar","Recruiting","No Results Available","Peripheral T Cell Lymphoma","Drug: Romidepsin|Drug: Carfilzomib","Maximum Tolerated Dose of the combination of romidepsin and carfilzomib|Best overall response rate (PR + CR) at the MTD|Toxicity of the combination of romidepsin and carfilzomib|Best overall response at the MTD|Maximum percentage change in the radiological sum of the product of the diameters from baseline, assessed using the Revised Response Criteria for Malignant Lymphoma|Duration of response from time of first documented response until relapse or progression|Progression free survival|Overall survival","University of Birmingham|Bloodwise|Celgene|Amgen","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","58","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG_13-107|2013-001879-20","July 13, 2015","August 2019","February 2021","May 5, 2017",,"June 12, 2018","Queen Elizabeth Hospital, Birmingham, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|Guy's Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03141203"
980,"NCT03069326","A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis",,"Recruiting","No Results Available","Myelofibrosis","Drug: Ruxolitinib|Drug: Thalidomide","best objective response rate (ORR)","Memorial Sloan Kettering Cancer Center|Incyte Corporation|Celgene|M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1498","February 27, 2017","February 2020","February 2020","March 3, 2017",,"November 15, 2019","Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Md Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03069326"
981,"NCT01554852","Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","Myeloma XI","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)","Overall survival|Progression-free survival|Response|Toxicity","University of Leeds|Celgene|Merck Sharp & Dohme Corp.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","4420","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT number: 2009-010956-93","May 2010","December 2021","December 2022","March 15, 2012",,"June 11, 2018","112 sites UK wide, United Kingdom, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01554852"
982,"NCT02431559","Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer",,"Active, not recruiting","Has Results","Ovarian Cancer","Drug: Durvalumab|Drug: Pegylated Liposomal Doxorubicin|Drug: Motolimod","Number of Subjects With Treatment-emergent Adverse Events (TEAEs)|Progression-free Survival Rate at 6 Months (PFS-6) by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Estimated Using the Kaplan-Meier Method|Number of Subjects With Best Overall Tumor Response by RECIST 1.1|Median PFS by RECIST 1.1 as Estimated Using the Kaplan-Meier Method|PFS-12 by RECIST 1.1 as Estimated Using the Kaplan-Meier Method|Number of Subjects With Best Overall Tumor Response by the Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)|PFS-6 by irRECIST as Estimated Using the Kaplan-Meier Method|PFS-12 by irRECIST as Estimated Using the Kaplan-Meier Method|Median PFS by irRECIST as Estimated Using the Kaplan-Meier Method|Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method","Ludwig Institute for Cancer Research|MedImmune LLC|Celgene|Cancer Research Institute, New York City","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","53","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUD2014-001","December 2, 2015","December 11, 2018","June 2020","May 1, 2015","September 23, 2019","October 17, 2019","Research Facitlity, Phoenix, Arizona, United States|Research Facility, New York, New York, United States|Research Facility, Hilliard, Ohio, United States|Research Facility, Providence, Rhode Island, United States|Research Facility, Lausanne, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02431559/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02431559/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02431559"
983,"NCT03720041","Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma","FiTNEss","Not yet recruiting","No Results Available","Multiple Myeloma","Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|Drug: R2: Lenalidomide plus placebo maintenance|Drug: R2: Lenalidomide + ixazomib maintenance","Randomisation 1: Number of participants with early treatment cessation|Randomisation 2: Progression-free survival (PFS-R2)|Progression-free survival (PFS-R1)|Time to disease progression|Progression-free survival two (PFS2)|Overall survival (OS)|Survival after progression|Deaths within 12 months of Randomisation 1 (R1)|Overall response rate (ORR)|Attainment of ≥VGPR|Attainment of Minimal Residual Disease (MRD) negativity|Duration of response (DoR)|Time to improved response|Time to next treatment|Treatment compliance and total amount of therapy delivered|Incidence of treatment-emergent adverse events (Toxicity and safety, including incidence of second malignancies)|EORTC QLQ-C30_questionnaire|EORTC QLQ-MY20_questionnaire|EQ-5D-3L_questionnaire","University of Leeds|Cancer Research UK|Takeda|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","740","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MyelomaXIV","January 2019","December 2024","December 2024","October 25, 2018",,"October 25, 2018","Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Nevill Hall Hospital, Abergavenny, United Kingdom|Bronglais General Hospital, Aberystwyth, United Kingdom|Wrightington Hosptial, Appley Bridge, United Kingdom|Wansbeck General Hospital, Ashington, United Kingdom|Ysbyty Gwynedd, Bangor, United Kingdom|North Devon District Hospital, Barnstaple, United Kingdom|Furness General Hospital, Barrow In Furness, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Royal United Hospital, Bath, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Blackburn Hospital, Blackburn, United Kingdom|Blackpool Victoria Hospital, Blackpool, United Kingdom|Royal Bolton Hospital, Bolton, United Kingdom|Pilgrim Hospital, Boston, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Southmead Hospital, Bristol, United Kingdom|Queen's Hospital, Burton Upon Trent, United Kingdom|Kent and Canterbury Hospital, Canterbury, United Kingdom|Chelmsford & Essex Hospital, Chelmsford, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|Countess of Chester Hospital, Chester, United Kingdom|St Richard's Hospital, Chichester, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Croydon University Hospital, Croydon, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|Russells Hall Hospital, Dudley, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Royal Devon & Exeter Hospital, Exeter, United Kingdom|Medway Maritime Hospital, Gillingham, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Grantham and District Hospital, Grantham, United Kingdom|Diana Princess of Wales Hospital, Grimsby, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Calderdale Royal Hospital, Halifax, United Kingdom|Harrogate District Hospital, Harrogate, United Kingdom|Withybush General Hospital, Haverfordwest, United Kingdom|Hereford County Hospital, Hereford, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Airedale Hospital, Keighley, United Kingdom|Westmorland General Hospital, Kendal, United Kingdom|Kettering General Hospital, Kettering, United Kingdom|Kidderminster Hospital & Treatment Centre, Kidderminster, United Kingdom|Victoria Hospital, Kirkcaldy, United Kingdom|Royal Lancaster Infirmary, Lancaster, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Royal Liverpool Hospital, Liverpool, United Kingdom|Guy's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Queen Elizabeth Hospital Greenwich, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|University Hospital Lewisham, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Royal Gwent Hospital, Newport, United Kingdom|North Tyneside General Hospital, North Shields, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Royal Oldham Hospital, Oldham, United Kingdom|Princess Royal University Hospital, Orpington, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Whiston Hospital, Prescot, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Alexandra Hospital, Redditch, United Kingdom|Glan Clwyd Hospital, Rhyl, United Kingdom|Queen's Hospital, Romford, United Kingdom|Salford Royal Hospital, Salford, United Kingdom|Salisbury District Hospital, Salisbury, United Kingdom|Scarborough General Hospital, Scarborough, United Kingdom|Scunthorpe General Hospital, Scunthorpe, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|St Helens Hospital, St Helens, United Kingdom|Stafford County Hospital, Stafford, United Kingdom|Stepping Hill Hospital, Stockport, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Sunderland Royal Hospital, Sunderland, United Kingdom|Good Hope Hospital, Sutton Coldfield, United Kingdom|Singleton Hospital, Swansea, United Kingdom|St George's Hospital, Tooting, United Kingdom|Torbay District General Hospital, Torquay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital, Tunbridge Wells, United Kingdom|Hillingdon Hospital, Uxbridge, United Kingdom|Pinderfields General Hospital, Wakefield, United Kingdom|Warwick Hospital, Warwick, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom|Royal Albert Edward Infirmary, Wigan, United Kingdom|Royal Hampshire County Hospital, Winchester, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom|Worcestershire Royal Hospital, Worcester, United Kingdom|Worthing Hospital, Worthing, United Kingdom|Wrexham Maelor Hospital, Wrexham, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03720041"
984,"NCT01916252","Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old","GEM2012MENOS65","Completed","No Results Available","Multiple Myeloma","Drug: bortezomib (Velcade ®)|Drug: lenalidomide (Revlimid®)|Drug: busulfan (Busilvex ®)|Drug: Dexamethasone acetate|Drug: Melphalan","Progression Free Survival to measure the treatment efficacy|Complete response rates to measure the treatment efficacy|Evaluation of minimal residual disease immunofixation negative-CR after each phase of treatment|Overall survival|Describe the adverse events to evaluate the safety and tolerability","PETHEMA Foundation|Janssen, LP|Celgene|Pierre Fabre Medicament","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","460","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM2012MENOS65","September 2013","November 16, 2016","November 16, 2016","August 5, 2013",,"September 27, 2017","Hospital Durán i Reynals - ICO L´Hospitalet, L'Hospitalet, Barcelona, Spain|H. Althaia, Xarxa Asistencial de Manresa, Manresa, Barcelona, Spain|Hospital Esp. de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Son Espases (Son Dureta), Mallorca, Illes Balears, Spain|Hospital Son Llátzer, Palma de Mallorca, Illes Balears, Spain|Hospital de Gran Canaria Dr. Negrín, Palmas de Gran Canaria, Islas Canarias, Spain|Hospital Nuestra Señora del Prado, Talavera de la Reina, Madrid, Spain|Complejo Universitario de Toledo, Toledo, Madrid, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Univ. Fundación de Alcorcón, Alcorcón, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Torrevieja Salud UTE, Alicante, Spain|Hospital del Tajo, Aranjuez, Spain|Hospital German Trias i Pujol, Badalona, Spain|Hospital de Cruces, Barakaldo, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Univ. Santa Lucía, Cartagena, Spain|Hospital General de Castellón, Castellón, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Hospital San Pedro de Alcántara (Complejo Hospitalario de Cáceres), Cáceres, Spain|Hospital del Vinalopó, Elche, Spain|Hospital de Fuenlabrada, Fuenlabrada, Spain|Hospital de Cabueñes, Gijón, Spain|H. Univ. de Girona Dr. Josep Trueta (ICO), Girona, Spain|Complejo Hosp. Virgen de las Nieves, Granada, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Severo Ochoa, Leganés, Spain|Hospital de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Centro Oncológico MD Anderson, Madrid, Spain|Fundación Jiménez Díaz-UTE, Madrid, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital General Univ. Gregorio Marañón, Madrid, Spain|Hospital Infanta Cristina, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Infanta Sofía, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain|Complejo Hospitalario Costa del Sol, Marbella, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Complejo Hospitalario Ourense, Orense, Spain|Hospital Universitario Central Asturias, Oviedo, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra (Hospital Virgen del Camino), Pamplona, Spain|Complejo Hospitalario Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Hospital Univ. Marqués de, Santander, Spain|Complejo Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|Complejo Hosp. Regional Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Santa Bárbara, Soria, Spain|H. Universitari de Tarragona Joan XXIII, Tarragona, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Hospital Universitario Río Hortega, Valladolid, Spain|Hospital de Txagorritxu, Vitoria, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01916252"
985,"NCT03161223","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",,"Recruiting","No Results Available","Lymphoma, T-Cell","Drug: Durvalumab|Drug: Pralatrexate|Drug: Romidepsin|Drug: 5-Azacitidine","Maximum Tolerated Dose (MTD)|Overall Response Rate (ORR)|Duration of Response (DoR)|Progression Free Survival (PFS)","Columbia University|University of Bologna|Samsung Medical Center|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","148","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAR0365","June 1, 2018","February 2020","February 2021","May 19, 2017",,"May 15, 2019","Center for Lymphoid Malignancies at CUMC, New York, New York, United States|University of Bologna, Bologna, Italy|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03161223"
986,"NCT03140943","Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Relapsed and/or Refractory Multiple Myeloma","Drug: Carfilzomib, Thalidomide and Dexamethasone","Progression free survival (PFS)|Overall survival (OS)|Overall Rate of Response (ORR)|Duration of response (DOR)|Time to progression (TTP)|Number of Participants affected by Adverse Events|Quality of life of participants on treatment","National University Hospital, Singapore|The Australasian Leukaemia & Lymphoma Group (ALLG)|International Myeloma Foundation|Celgene","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMN002","September 13, 2017","June 1, 2019","June 1, 2022","May 4, 2017",,"November 6, 2017","Queen Mary Hospital, Hong Kong, Hong Kong|South Korea, Korea, Republic of|National University Hospital, Singapore, Singapore|National Taiwan University, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03140943"
987,"NCT01617226","Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS","RAvVA","Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: Azacitidine|Drug: Vorinostat","Phase II - Overall Response Rate|Phase II - Overall Survival|Phase II - Toxicities measured by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)|Phase II - Complete Remission (CR) within 6 cycles of treatment|Phase II - Duration of response|Phase II - Dose intensity|Phase II - Quality of Life measured by questionnaires|Phase II - Medical Resource Use","University of Birmingham|Leukemia Research Fund|Celgene|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG_11-187","September 2012","March 2016","September 2019","June 12, 2012",,"October 11, 2018","Barts and the London NHS Trust, London, Greater London, United Kingdom|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|The Christie Hospital, Manchester, Greater Manchester, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom|University Hospital of Wales, Cardiff, South Wales, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01617226"
988,"NCT01237249","Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone",,"Completed","No Results Available","Multiple Myeloma","Drug: Melphalan|Drug: Prednisone|Drug: Velcade|Drug: Revlimid|Drug: Dexamethasone","To evaluate the efficacy in terms of time to progression (TTP) at 18 months of MPV and Rd used as either in a sequential or alternating approach in newly diagnosed MM patients older than 65 years.|To evaluate the toxicity (safety and tolerability) of the sequential versus the alternating use of MPV and Rd,in terms of adverse events presented in both groups of patients|To evaluate the response in both groups of patients|To identify, within the group of patients treated with the alternating scheme, the biological characteristics (including a comprehensive genomic analysis) of those patients resistant to one or the other, and patients refractory to both treatments|Duration of response in two groups of patients|Progression free survival (PFS) in two different groups of patients|Time to next therapy (TNT)|Overall survival (OS) in the two different groups of patients","PETHEMA Foundation|Janssen-Cilag Ltd.|Celgene|TFS Trial Form Support","All","65 Years and older   (Older Adult)","Phase 2","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM2010MAS65","February 2011","August 2014","May 2016","November 9, 2010",,"January 18, 2017","H. Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Fundación Hospital Alcorcón, Alcorcón, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|H. Vall d'Hebron, Barcelona, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|ICO - Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Cruces, Bilbao, Spain|Hospital General de Castellón, Castellón, Spain|Hospital General, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Donostia, Donostia, Spain|Hospital Francesc Borja, Gandía, Spain|ICO - Josep Trueta, Girona, Spain|Hospital General de Guadalajara, Guadalajara, Spain|H. de Jerez, Jerez de la Frontera, Spain|Complejo Hospitalario León, Leon, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre. Madrid, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital de Madrid, S.A.- Norte Hospital General, Madrid, Spain|Hospital del Tajo, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Infanta Sofia, Madrid, Spain|Hospital la Paz, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|MD Anderson, Madrid, Spain|Althaia, Manresa, Spain|Hospital General Univeristario Morales Messeguer, Murcia, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Complejo Hospital Costa del Sol, Málaga, Spain|Hospital Nuestra Señora de Valme, Málaga, Spain|Hospital de la Diputación de Navarra, Navarra, Spain|Hospital de Gran Canaria Doctor Negrín, Palma de Gran Canaria, Spain|Complejo Asistencial Son Dureta, Palma de Mallorca, Spain|Hospital Virgen del Camino, Pamplona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hoaspital Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Nuestra Señora del Prado, Toledo, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico de Valencia., Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Clinico Lozano Blesa, Zaragoza, Spain|Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01237249"
989,"NCT00963534","Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.","LENA-BERIT","Completed","No Results Available","Mantle Cell Lymphoma","Drug: lenalidomide, bendamustine, rituximab","MTD of lenalidomide (phase I) Progression free survival (phase II)","Lund University Hospital|Mundipharma Pte Ltd.|Celgene|Roche Pharma AG","All","65 Years and older   (Older Adult)","Phase 1|Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-MCL4","September 2009","August 2017","August 2017","August 21, 2009",,"March 12, 2018","Herlev Hospital, Copenhagen, Denmark|Rigshospitalet, Department of Hematology, Copenhagen, Denmark|Århus University Hospital, Århus, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Haukeland University Hospital, Department of Oncology, Bergen, Norway|Norwegian Radium Hospital, Oslo, Norway|Ulleval University Hospital, Department of Oncology, Oslo, Norway|University Hospital of Stavanger, Department of Haematology and Oncology, Stavanger, Norway|University Hospital of Tromso, Department of Oncology, Tromso, Norway|Sahlgrenska University Hospital, Department of Hematology, Göteborg, Sweden|University Hospital Linköping, Department of Hematology, Linköping, Sweden|Sunderbyn Hospital, Department of Medicine, Luleå, Sweden|University Hospital Lund, Department of Oncology, Lund, Sweden|Karolinska University Hospital, Department of Hematology, Stockholm, Sweden|Sundsvall Hospital, Department of Medicine, Sundsvall, Sweden|University Hospital of Norrland, Department of Oncology, Umeå, Sweden|Uppsala University Hospital, Department of Oncology, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00963534"
990,"NCT02124369","Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)","PRICKLE","Terminated","No Results Available","Pancreatic Adenocarcinoma","Drug: Abraxane|Drug: Gemcitabine","Tumour resection rate|Number of Participants with Serious and Non-Serious Adverse Events","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust|Cancer Research UK|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRICKLE|2013-004200-19","July 2014","July 2017","December 2017","April 28, 2014",,"July 16, 2019","Addenbrookes Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02124369"
991,"NCT04102449","Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast","PSA-ULTRA","Not yet recruiting","No Results Available","Psoriatic Arthritis","Drug: Apremilast","The difference in the change-score of the PsASon22|The difference in the change-score of the PsASon13|Convergent construct validity of PsAson22 and PsASon13|Sensitivity to Change of PsASon22 and PsASon13|Interrater reliability of PsASon22 and PsASon13|Intrarater reliability of PsASon22 and PsASon13|Differences in PsASon22 and PsASon13 change","Medical University of Graz|Celgene Corporation|Medical University of Vienna|Medical University Innsbruck","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AP-CL-PSA-PI-12856","November 2019","October 2021","October 2021","September 25, 2019",,"October 8, 2019",,,"https://ClinicalTrials.gov/show/NCT04102449"
992,"NCT01558167","A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia","CLL2P","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Bendamustine, Rituximab, Lenalidomide","dose limiting toxicity|Response rate|progression free survival|Overall Survival","German CLL Study Group|Mundipharma Research GmbH & Co KG|Roche Pharma AG|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLL2P|2009-012957-39","February 2011","October 2013","June 2015","March 20, 2012",,"May 15, 2018","University Hospital of Cologne, Cologne, Germany",,"https://ClinicalTrials.gov/show/NCT01558167"
993,"NCT01254890","Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome",,"Completed","Has Results","Leukemia","Drug: Azacitidine|Drug: Sorafenib","Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine|Phase II: Number of Participants With Response","M.D. Anderson Cancer Center|Bayer|Onyx Therapeutics, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0511|NCI-2011-00257","January 2011","March 2015","March 2015","December 7, 2010","May 6, 2016","May 6, 2016","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01254890"
994,"NCT02723331","Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates",,"Recruiting","No Results Available","Pancreatic Cancer|Pancreatic Adenocarcinoma|Pancreas Ductal Adenocarcinoma","Drug: Nab-paclitaxel and gemcitabine for R-PDAC Patients|Drug: Nab-paclitaxel and gemcitabine for BR-PDAC Patients","R0 resection rates in each cohort as measured by macroscopically complete tumor removal with negative microscopic surgical margins|Number of participants with treatment related adverse events as assessed by CTCAE v.4.03|Number of participants with progression-free occurence|Number of participants with disease recurrence","Academic Thoracic Oncology Medical Investigators Consortium|Celgene Corporation|Criterium, Inc.|University of Colorado, Denver","All","18 Years to 101 Years   (Adult, Older Adult)","Phase 2","50","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-0150.cc","December 30, 2016","August 2020","May 2021","March 30, 2016",,"November 20, 2019","Mayo Clinic Hospital, Scottsdale, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|New York University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02723331"
995,"NCT02340936","Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: LR-ESHAP (lenalidomide 5 mg)|Drug: LR-ESHAP (lenalidomide 10 mg)|Drug: LR-ESHAP (lenalidomide 15 mg)|Drug: LR-ESHAP (lenalidomide 20 mg)","Phase I of the study: to evaluate the safety and the maximum-tolerated dose (MTD) of the combination R-ESHAP with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (determine maximum tolerated dose)|Phase II of the study: Phase II: to evaluate ORR of LR-ESHAP in patients with relapsed or refractory DLBCL candidates to HDT and ASCT (determine the overall response rate)|Phase I of the study: to analyze the adverse events of LR-ESHAP (frequency and severity of the adverse events)|Phase I of the study: preliminarily analyze effectiveness (response rates (CR and PR), duration of response and survival (DFS and OS)|Phase I of the study: evaluate haematopoietic progenitor cells mobilization after treatment with LR-ESHAP (Evaluate CD34+ cell count)|Phase I of the study: evaluate hematologic recovery after HSCT (recovery of blood parameters)|Phase II of the study: analyze effectiveness (Complete remission (CR) rate (determined by positron emission tomography [PET]/CT), event-free survival (EFS) and overall survival (OS)|Phase II of the study: rate of transplanted patients (number of patients that undergo HSCT)|Phase II of the study: to analyze the adverse events of LR-ESHAP and ASCT. (frequency and severity of the adverse events)|Phase II of the study: evaluate mobilization after treatment with LR-ESHAP (number of stem cells (2 x 106/Kg Hematopoietic progenitor cell antigen (CD34)+ cells) collected after the salvage therapy.)|Phase II of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological (such as cell of origin) prognostic factors on response rates and survival.)","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Celgene Corporation|Dynamic Science S.L.|Thermo Fisher Scientific","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","53","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LR-ESHAP","January 2011","September 2016","February 20, 2019","January 19, 2015",,"February 21, 2019","ICO- Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO- Hospital Duran i Reynals, L´Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Alejandro Martín, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02340936"
996,"NCT04009109","Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM",,"Not yet recruiting","No Results Available","Myeloma, Multiple","Drug: Lenalidomide|Drug: Ixazomib|Drug: Daratumumab Injection|Drug: Dexamethasone","Impact of Study Treatment on Progression Free Survival (PFS)|Minimal Residual Disease (MRD)|Toxicity Profile of Treatment Arm Based on Patient Response|Overall Response Rate (ORR)|Overall Survival (OS)|Quality of Life with the EQ 5D 5L Questionnaire|Quality of Life with the EORTC QLQ-MY20 Questionnaire|Quality of Life with the EORTC QLQ-C30 Questionnaire|Rate of Adherence to Lenalidomide and Ixazomib|Alliance Geriatric Assessment with IMWG Fragility Score","Alliance Foundation Trials, LLC.|Janssen Scientific Affairs, LLC|Celgene Corporation|Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","188","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFT-41","October 1, 2019","October 1, 2024","December 31, 2024","July 4, 2019",,"July 31, 2019",,,"https://ClinicalTrials.gov/show/NCT04009109"
997,"NCT02073487","Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel","TEAL","Completed","No Results Available","Breast Cancer","Drug: T-DM1|Drug: Trastuzumab|Drug: Lapatinib|Drug: Abraxane|Drug: Paclitaxel|Drug: Pertuzumab","pathological complete response rate (pCR)|Clinical Response Rate|breast imaging response to treatment|objective response rate|toxicity, safety and efficacy of study treatment","Jenny C. Chang, MD|Celgene Corporation|Novartis|The Methodist Hospital System","Female","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00010074|1013-0164","February 2014","January 2019","January 2019","February 27, 2014",,"April 16, 2019","Houston Methodist Hospital, Houston, Texas, United States|Houston Methodist Hospital Willowbrook, Houston, Texas, United States|Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02073487"
998,"NCT00047281","Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma",,"Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: celecoxib|Drug: cyclophosphamide|Drug: etoposide|Drug: thalidomide",,"Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Schering-Plough|Celgene","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2",,"Other|NIH|Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","01-278|P30CA006516|CDR0000257584|NCI-G02-2117|CELGENE-2001-P-001757/3","March 2004","August 2005","February 2006","January 27, 2003",,"July 11, 2017","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00047281"
999,"NCT01002703","Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Lenalidomide, Bendamustine, Prednisone","To determine the maximum tolerable dose (MTD) of lenalidomide in combination with bendamustine and prednisone (RBP) in refractory and relapsed MM stage I/III|To determine the safety of lenalidomide, bendamustine and prednisone at MTD","University of Leipzig|Celgene Corporation|Mundipharma Pte Ltd.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RBP-01/08|OSHO77","September 2009","October 2012","October 2014","October 27, 2009",,"August 12, 2011","University of Leipzig, Leipzig, Germany",,"https://ClinicalTrials.gov/show/NCT01002703"
1000,"NCT02004275","Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma in Relapse","Drug: pomalidomide|Drug: ixazomib|Drug: dexamethasone","Maximum Tolerated Dose (MTD) of pomalidomide and ixazomib, determined according to incidence of dose limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Progression free survival (PFS) (Phase II)|Incidence and type of dose limiting toxicities (DLTs), serious adverse events, and adverse events, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Incidence of dose reductions/delays (Phase I)|Overall response rate (ORR), defined as partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II)|Clinical benefit rate (CBR), defined as minimal response (MR) and better according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II)|Disease control rate (DCR), defined as stable disease (SD) and better according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II)|Duration of response (DOR), calculated for all patients achieving an objective response, partial response (PR) or better (Phase II)|Overall survival (OS) (Phase II)|Time to next treatment (TNT) (Phase II)|Incidence, type and severity of adverse events, graded according to National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE) version 4.0 (Phase II)|Response rates (overall response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR) for all patients on the pomalidomide/dexamethasone arm at the time of cross-over to pomalidomide/dexamethasone/ixazomib (Phase II)|Progression free survival (PFS) for all patients on the pomalidomide/dexamethasone arm at the time of cross-over to pomalidomide/dexamethasone/ixazomib (Phase II)|Baseline level of perceived fatigue and QOL, assessed using the Registration Fatigue/Uniscale Assessment form (Phase II)","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","73","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A061202|NCI-2013-01702|U10CA031946","February 2014","March 2021",,"December 9, 2013",,"November 20, 2019","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT02004275"
1001,"NCT03015922","Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma","MUKeleven","Recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide or Pomalidomide|Biological: REOLYSIN","Dose-limiting toxicities|Safety profile of REOLYSIN® and lenalidomide|Safety profile of REOLYSIN® and pomalidomide|Toxicity profile of REOLYSIN® and lenalidomide|Toxicity profile of REOLYSIN® and pomalidomide|Response rate (stable disease or better) after 6 cycles of therapy|Maximum response within 6 cycles of therapy|Maximum response overall|Time to maximum response|Progression-free survival|Overall survival","University of Leeds|Myeloma UK|Oncolytics Biotech|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM16/118","June 5, 2017","July 1, 2019","October 1, 2020","January 10, 2017",,"June 14, 2017","St James's University Hospital, Leeds, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03015922"
1002,"NCT00379912","Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes",,"Terminated","Has Results","Myelodysplastic Syndromes","Drug: Azacitidine|Drug: Erythropoietin|Drug: Azacitidine (Monotherapy)","Overall Response After Cycle 3|Overall Response Rate After Six Cycles|Safety Profile of the Modified Dose/Schedule of Azacitidine and Erythropoietin or a Modified Dose of Azacitidine Alone|Duration of Significant Responses|Quality of Life|Analysis of CD34, CD71, CD36 Cells in Aspirated Bone Marrow for Both Responders and Non-responders at Baseline and After Three and Six Cycles|Percent Apoptosis in 34+36+71+ Cells at Baseline, Three Cycles and Six Cycles|BclXL Expression","Larry Cripe, MD|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C.|Walther Cancer Institute|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOG MDS04-85","September 2006","December 2008","December 2008","September 25, 2006","May 31, 2017","February 14, 2018","Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States|Arnett Cancer Care, Lafayette, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Center for Hematology-Oncology of S Michigan, Jackson, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00379912"
1003,"NCT00308178","Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Abraxane","To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.|To evaluate the feasibility of administering Abraxane on a dose dense schedule without G-CSF support|to estimate the percentage of patients with various grades of hematologic toxicity, neurotoxicity, and other non-hematologic toxicity associated with dose-dense Abraxane|to evaluate quality of life.","Harold J. Burstein, MD, PhD|Celgene Corporation|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-249","March 2006","September 2006","June 2008","March 29, 2006",,"February 18, 2013","Massacusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00308178"
1004,"NCT01191060","Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years","IFM/DFCI2009","Completed","No Results Available","Myeloma","Drug: Lenalidomide, Bortezomib","Progression Free Survival|Response Rates|Time To Progression|Toxicity comparison|Genetic prognostic groups definition|Best treatment examination in each GEP-defined prognostic group.","University Hospital, Toulouse|Dana-Farber Cancer Institute|Celgene Corporation|Janssen-Cilag Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","700","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09 110 01","October 2010","November 30, 2018","November 30, 2018","August 30, 2010",,"April 18, 2019","CH du Pays D'Aix, Aix-en-provence, France|CHRU - Hôpital Sud Amiens, AMIENS cedex 1, France|CHU d'Angers, ANGERS cedex 01, France|Centre Hospitalier Argenteuil Victor Dupouy, Argenteuil, France|Centre Hospitalier H.Duffaut, Avignon, France|Centre Hospitalier de la côte basque, Bayonne, France|Hôpital Jean Minjoz, Besançon, France|Centre Hospitalier de Blois, Blois, France|Hôpital Avicenne, Bobigny, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hôpital A.Morvan, Brest, France|CHU Caen Côte de Nacre, Caen, France|Centre François Baclesse, Caen, France|CH René Dubos, Cergy-Pontoise, France|Centre Hospitalier William Morey, Chalon-sur-saone, France|CH Chambéry, Chambéry, France|Hôpital Antoine Béclère, Clamart cedex, France|Hôpital d'instruction des armées Percy, Clamart cedex, France|Pole Santé République, Clermont - Ferrand, France|CHU d'Estaing, Clermont-Ferrand, France|CH Louis Pasteur - Colmar, Colmar, France|CH Sud Francilien, Corbeil-Essonnes, France|CHU Henri Mondor, Créteil, France|CHRU Dijon, Dijon, France|Centre Hospitalier Général - Dunkerque, Dunkerque, France|Hôpital A.Michallon, Grenoble, France|Centre hospitalier départemental - La Roche sur Yon cedex, La Roche sur Yon cedex, France|CH de Chartres - Hôpital Louis Pasteur, Le Coudray, France|Centre Jean Bernard, Le Mans, France|Centre hospitalier Le Mans, Le Mans, France|CHRU - Hôpital Claude Huriez, Lille, France|CHU de Limoges, Limoges, France|Centre hospitalier Bodelio, Lorient, France|CHU - Hôpital Edouard Herriot, Lyon, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|CH Meaux, Meaux, France|Hopital E Muller, Mulhouse, France|Hôpitaux de Brabois, Nancy, France|Centre Catherine de Sienne, Nantes, France|CHRU - Hôtel Dieu, Nantes, France|Hôpital Archet 1, NICE cedex 3, France|Hôpital de l'Archet, Nice cedex 3, France|Groupe Hospitalo-Universitaire Carémeau, Nîmes Cédex 9, France|Hôpital Saint-Louis, PARIS cedex 10, France|Hôpital St-Antoine, Paris cedex 12, France|Institut Curie, Paris, France|Hôpital Cochin, Paris, France|CH Saint Jean, Perpignan, France|CHRU - Hôpital du Haut Lévêque, Pessac, France|Centre Hospitalier Lyon sud, Pierre - Bénite cedex, France|CHRU - Hôpital Jean Bernard, Poitiers, France|Centre Hospitalier de la région d'Annecy, Pringy, France|Hôpital R.Debré, Reims, France|CHRU - Hôpital de Pontchaillou, Rennes, France|CHRU - Hôpital Sud, Rennes, France|Centre Henri Becquerel, Rouen, France|Groupe Hospitalier Sud Réunion, SAINT-PIERRE cedex, France|Centre René Huguenin, St Cloud, France|Centre Hospitalier Yves le Foll, St-Brieuc cedex 1, France|Centre Hospitalier Départemental - La réunion St Denis, St-denis, France|Institut de Cancérologie de la Loire, St-priest-en-jarez, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|University Hospital of Toulouse, Purpan, Toulouse, France|CHRU - Hôpital Bretonneau, Tours, France|Centre Hospitalier de Valence, Valence, France|CH Bretagne Atlantique Vannes et Auray, Vannes cedex, France|Institut Gustave Roussy, Villejuif cedex, France",,"https://ClinicalTrials.gov/show/NCT01191060"
1005,"NCT02382406","Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC",,"Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Carboplatin|Drug: Nab-paclitaxel|Drug: MK-3475 (Phase I)|Drug: MK-3475 (Phase II)","Phase I: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of Recommended Phase II Dose|Phase II: Disease Assessment for Progression-Free Survival (PFS) and Objective Response Rate|Phase I: Disease Assessment for Progression-Free Survival (PFS) and Objective Response Rate|Phase I: Disease Assessment for Anti-Tumor Activity|Phase I: Overall Survival (OS)|Phase I: Assessment of Association of PD-L1 Expression on PFS|Phase II: Overall Survival (OS)|Phase II: Disease Assessment for Anti-Tumor Activity|Phase II: Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Phase II: Assessment of Association of PD-L1 Expression on PFS","Nisha Mohindra, MD|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRN LUN13-175","June 2015","December 2019","December 2020","March 6, 2015",,"May 20, 2019","City of Hope, Duarte, California, United States|Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Center, Indianapolis, Indiana, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02382406"
1006,"NCT00777673","Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.",,"Unknown status","No Results Available","Breast Cancer","Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim","Pathological complete response (pCR) in the breast|Rate of near pCR/pCR of breast, axillary Ns & non axillary SNs cRR with nab-paclitaxel + carbo with bev cRR post neoadj Tx Rate of breast conserving surgery Safety & tolerability Disease free survival Identify gene(s) that may predict pCR to Tx","University of Tennessee Cancer Institute|National Comprehensive Cancer Network|Celgene Corporation|Genentech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRE 01-08","October 2008","January 2013","October 2013","October 22, 2008",,"January 4, 2013","University of Tennessee Cancer Institute, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders, Ft. Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00777673"
1007,"NCT00642759","Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer",,"Completed","Has Results","Non-small Cell Lung Cancer","Drug: carboplatin|Drug: Nab-paclitaxel|Drug: Bevacizumab","6-month Progression Free Survival Rate|Objective Response Rate to Carboplatin, Abraxane and Avastin|6 Month Survival Rate|Overall Survival","Massachusetts General Hospital|Dana-Farber Cancer Institute|Celgene Corporation|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-339","April 2008","April 2015","April 2015","March 25, 2008","December 12, 2016","April 7, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00642759"
1008,"NCT01702831","Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance","BuMelMCRN001","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Busulfan|Drug: Melphalan|Drug: Lenalidomide","• Minimal Residual Disease (MRD) negativity at day 100 post ASCT|• To determine the pattern, positivity (in terms of percentages) or negativity of MRD analysis during lenalidomide maintenance.|• To determine the response rate using conventional immunoglobulin and monoclonal protein-based markers at day 100 post ASCT and best response using lenalidomide maintenance.|• To determine the effectiveness of using the HevyLite Chain assay to assess anti-tumour response at day 100 post ASCT and during lenalidomide maintenance|• To determine the toxicity of busulfan and melphalan when used as a high-dose conditioning therapy for ASCT.|• To determine the toxicity of lenalidomide maintenance post busulfan and melphalan conditioning ASCT.|• To determine the progression free survival (PFS) and overall survival (OS) of this program.|• Identification of the type and frequencies of somatic abnormalities (point mutations, indels, and copy number abnormalities) and their evolution overtime.|• Assessment of using optional cell free DNA (cfDNA) in peripheral blood to monitor and correlate response assessments in multiple myeloma.","University Health Network, Toronto|Princess Margaret Hospital, Canada|Otsuka Pharmaceutical Development & Commercialization, Inc.|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCRN 001","October 1, 2013","July 2022","December 2022","October 8, 2012",,"April 17, 2019","Cross Cancer Institute 11560 University Ave, Edmonton, Alberta, Canada|Vancouver General Hospital, Centennial Pavilion, 6th Floor, Vancouver, British Columbia, Canada|Saint John Regional Hospital, 5DN Research Department, 400 University Ave, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre., Halifax, Nova Scotia, Canada|London Regional Cancer Program 790 Commissioners Road East, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hôpital Maisonneuve-Rosemont, 5415, boul. de l'Assomption, Montreal, Quebec, Canada|Royal Victoria Hospital, MUHC Glen Site, Cedars Cancer Centre, Montreal, Quebec, Canada|Saskatoon Cancer Centre 20 Campus Drive, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT01702831"
1009,"NCT01644799","Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma",,"Completed","No Results Available","Recurrent Follicular Lymphoma","Drug: idelalisib|Drug: lenalidomide","MTD based on the incidence of dose-limiting toxicity (DLT) assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Toxicity profile assessed by NCI CTCAE version 4.0|OR rate assessed up to 10 years|CR rate assessed up to 10 years|PFS assessed up to 10 years","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Gilead Sciences|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A051202|CDR0000736814|NCI-2012-01988|U10CA031946","July 2013","August 2014","May 2017","July 19, 2012",,"January 30, 2018","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Medical College of Cornell University, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01644799"
1010,"NCT01547260","Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer","LENAGEM","Completed","No Results Available","Pancreatic Carcinoma.","Drug: Gemzar|Drug: Revlimid","Safety (phase I).|Immunomodulatory effect (phase II).|Clinical efficacy","Maria Liljefors|Karolinska University Hospital|Karolinska Institutet|Celgene Corporation","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","34","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LENAGEM-PANC","October 2009","January 2014","November 2014","March 7, 2012",,"December 2, 2014","Karolinska University Hospital, Stockholm, Solna, Sweden",,"https://ClinicalTrials.gov/show/NCT01547260"
1011,"NCT01088815","Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas",,"Completed","Has Results","Metastatic Pancreatic Cancer","Drug: Gemcitabine, nab-Paclitaxel, GDC-0449","Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel.|Safety of Combination Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas as Assessed by Number of Grade 3 or 4 Adverse Events|Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Overall Survival|Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Tumor Response|Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Changes in Pancreatic Cancer Stem Cell|Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Hedgehog Signaling Pathway Downregulation","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Stand Up To Cancer|Genentech, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","98","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1013|NA_00036883","September 17, 2010","December 1, 2017","February 17, 2018","March 17, 2010","April 26, 2019","April 26, 2019","Translational Genomics Research Institute (TGen), Scottsdale, Arizona, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01088815/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01088815"
1012,"NCT00234000","Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes",,"Terminated","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: arsenic trioxide|Drug: azacitidine","Safety and tolerability as assessed by NCI CTCAE v3.0 (Phase I)|Time to disease progression|Overall survival","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|CTI BioPharma|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000442931|P30CA016042|UCLA-0408087","February 2007","February 2009",,"October 6, 2005",,"October 2, 2015","Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00234000"
1013,"NCT00098865","Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma",,"Completed","Has Results","Central Nervous System Tumor, Pediatric|Neuroblastoma","Drug: temozolomide|Drug: thalidomide","Therapy Completion Rate|Overall Response|Overall Survival","Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Boston Children’s Hospital|Celgene Corporation","All","up to 21 Years   (Child, Adult)","Phase 2","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-279 DFCI|P30CA006516|CDR0000396780","September 2002","June 2010","June 2010","December 9, 2004","September 25, 2014","October 7, 2014","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00098865"
1014,"NCT03815279","A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)","iStopMM","Enrolling by invitation","No Results Available","Multiple Myeloma|Smoldering Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Rate of MRD negativity|Progression free survival|Overall survival","Landspitali University Hospital|Amgen|Celgene|University of Iceland|Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LSH-17-001","June 24, 2019","January 2024","January 2028","January 24, 2019",,"August 16, 2019","Landspitali University Hospital, Reykjavík, Iceland",,"https://ClinicalTrials.gov/show/NCT03815279"
1015,"NCT02977780","INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)",,"Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Neratinib|Drug: CC-115|Drug: Abemaciclib","Overall Survival in Experimental Arms Compared with Standard Therapy|Incidence of Treatment-Emergent Adverse Events|Progression Free Survival Among Experimental Arms And Biomarker Groups|Overall Survival Among Experimental Arms And Biomarker Groups|Association Between Progression Free Survival and Overall Survival Effects Of Experimental Agents","Patrick Y. Wen, MD|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","280","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-443","February 9, 2017","February 2020","May 2021","November 30, 2016",,"August 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Lifespan / Rhode Island Hospital, Providence, Rhode Island, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02977780"
1016,"NCT03289299","Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant","ASCENT","Recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Daratumumab|Drug: Dexamethasone","Stringent complete response rate|MRD negativity after each treatment phase|MRD negativity at 1 year post treatment|Overall Survival|Progression-free survival|Adverse events","International Myeloma Foundation|Amgen|Janssen Scientific Affairs, LLC|Celgene|Trevie, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BS001|20159417|54767414MMY2009|RV-CL-MM-IMF-008479","May 25, 2018","June 1, 2022","June 1, 2026","September 20, 2017",,"December 4, 2018","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medicine, New York, New York, United States|Swedish Cancer Institute, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03289299"
1017,"NCT02733250","Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer","URCOH-PMS-001","Active, not recruiting","No Results Available","Lung Cancer","Biological: Pembrolizumab|Drug: Nab-Paclitaxel","Safety and tolerability of nab-paclitaxel in combination with pembrolizumab as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities.|Objective Response Rate (ORR)","Centre hospitalier de l'Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Merck Canada Inc.|Celgene|Jewish General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE15.274","March 13, 2017","April 2020","December 2020","April 11, 2016",,"June 20, 2018","Centre hospitalier de l'université de Montréal (CHUM), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02733250"
1018,"NCT01701076","Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma","BRd","Completed","No Results Available","Multiple Myeloma","Drug: Bendamustine","Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen|Objective response rates (sCR, CR, VGPR, PR, MR)|Best response (sCR, CR, VGPR, PR, MR)|Time to progression (TTP)|Overall survival (OS)|Safety and tolerability","Cantonal Hospital of St. Gallen|Celgene Corporation|Mundipharma Research GmbH & Co KG|Mundipharma Medical Company|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTU10.041/BRd|2010-022253-42","March 2012","February 2016","February 2016","October 4, 2012",,"August 24, 2016","Kantonsspital St. Gallen, St. Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT01701076"
1019,"NCT01838434","Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",,"Completed","No Results Available","Relapsed/Refractory Mantle Cell Lymphoma","Drug: lenalidomide|Drug: idelalisib","Maximum tolerated dose (MTD) of idelalisib and lenalidomide, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Progression Free Survival (PFS) of the combination of lenalidomide, with or without idelalisib (Phase II)|Overall survival (OS) (Phase II)|Overall response rate (partial or complete response) (Phase II)","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation|Gilead Sciences|Biologics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","106","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A051201|NCI-2012-01734|U10CA031946","July 2013","September 30, 2014","May 2017","April 24, 2013",,"January 30, 2018","University of Chicago, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01838434"
1020,"NCT00925821","Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Procedure: allogeneic stem cell transplant versus second autologous transplantation|Drug: RAD","Response rate to RAD induction and transplant (stringent CR, CR, very good PR)|Progression-free survival (PFS)|Incidence and relationship of severe adverse events","Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation|Amgen|medac GmbH","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSMM XII","June 2009",,,"June 22, 2009",,"June 28, 2012","Charité University Hospital - Virchow Klinikum, Berlin, Germany|Dresden University Hospital, Dresden, Germany|Erlangen University Hospital, Erlangen, Germany|Freiburg University Hospital, Freiburg, Germany|Jena University Hospital, Jena, Germany|Kiel University Hospital, Kiel, Germany|Munich Grosshadern University Hospital, Munich, Germany|University Hospital of Munich Technical University, Munich, Germany|Klinikum Nuremberg, Nuremberg, Germany|Regensburg University Hospital, Regensburg, Germany|Rostock University Hospital, Rostock, Germany|Ulm University Hospital, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00925821"
1021,"NCT02344472","Detect V / CHEVENDO (Chemo vs. Endo)",,"Recruiting","No Results Available","Metastatic Breast Cancer","Drug: pertuzumab|Drug: Trastuzumab|Drug: Capecitabine|Drug: Paclitaxel|Drug: Vinorelbine|Drug: Docetaxel|Drug: Exemestane|Drug: Letrozole|Drug: Anastrozole|Drug: Fulvestrant|Drug: Ribociclib|Drug: nab-Paclitaxel|Drug: eribulin|Drug: leuprorelin|Drug: goserelin","Number of Participants with Adverse Events|quality-adjusted survival|overall response rate (ORR)|incidence of central nervous system (CNS) metastases and their control rate|Analysis of Quality of life|presence and number of circulating tumor cell (CTC) at different time points|Evaluation of all reported events and all grades in both treatment arms (chemotherapy and endocrine therapy)|disease control rate (DCR)|progression-free survival (PFS)|overall survival (OS)","Prof. W. Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation|University of Ulm","Female","18 Years and older   (Adult, Older Adult)","Phase 3","270","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D-V|2014-002249-22","September 2015","September 2021","June 2023","January 26, 2015",,"October 25, 2019","University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT02344472"
1022,"NCT00378209","Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone","The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months|Objective Response Rate|Duration of Response|Progression Free Survival|Overall Survival","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-147","August 2006","October 2012","October 2016","September 19, 2006","June 9, 2014","November 17, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00378209"
1023,"NCT00142168","CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia",,"Terminated","Has Results","Waldenstrom's Macroglobulinemia","Drug: CC-5103 (lenalidomide)|Drug: Rituximab","Time to Progression|Overall Response|Major Response Rate|Minor Response Rate","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Celgene Corporation|Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-158","September 2004","May 2006","April 2008","September 2, 2005","December 16, 2015","April 21, 2016","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00142168"
1024,"NCT00543114","Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL",,"Terminated","No Results Available","Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia","Drug: Lenalidomide|Drug: Fludarabine|Drug: Rituximab","To evaluate the safety of lenalidomide in combination with fludarabine-rituximab (FR) and to determine the maximum tolerated dose in subjects with previously untreated CLL/SLL.|To determine the objective response rate and progression-free survival following lenalidomide/FR in this patient population|To determine the improvement in ORR following two months of consolidation lenalidomide after completion of combination therapy|To assess effects on immune function as measured by cytokine levels, T and NK cell subsets, T cell activation during therapy and DTH vaccine responses.","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-097|RV-0162","October 2007","June 2009","December 2012","October 12, 2007",,"May 27, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00543114"
1025,"NCT02279394","Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma",,"Active, not recruiting","No Results Available","Smoldering Myeloma|Smoldering Multiple Myeloma","Drug: Elotuzumab|Drug: Lenalidomide|Drug: Dexamethasone","Proportion of patients who are progression free at 2 years|Response rate|Safety of the combination therapy|Time to progression|Overall survival","Dana-Farber Cancer Institute|Bristol-Myers Squibb|Celgene|Blood Cancer Research Partnership|Multiple Myeloma Research Consortium|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-338","December 2014","January 2020","October 2023","October 31, 2014",,"January 7, 2019","Colorado Blood Cancer Institute, Denver, Colorado, United States|St Francis Hospital and Medical Center, Hartford, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Eastern Maine Medical Center, Brewer, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Levine Cancer Institute, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02279394"
1026,"NCT02819882","A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)","REGISTEM","Recruiting","No Results Available","Breast Neoplasms","Other: No intervention","Number of patients with the different breast cancer subtypes and real distribution of them.|Breast cancer and heredofamiliar risk according with the patient and tumor characteristics.|Differences in the development disease in the group of male vs female patients.|Evolution of number of patients by molecular subtypes of breast cancer.|Influence of primary tumor surgery in patient outcomes|Influence of timing of primary tumor surgery in patients with metastatic disease as first diagnosis|Influence of local therapy (surgery, radiotherapy and radiofrequency) in the outcome of patients with oligometasta|Prevalence (at entry) and incidence (during the observation period) of pregnancies, abortions and pregnancy outcomes.|Number of participants with specific biomarkers on tumor and blood samples.|IHC/ISH discrepancies between the primary tumor and the metastasis in patients with biopsy of the metastatic lesions.","Spanish Breast Cancer Research Group|Hoffmann-La Roche|Novartis|AstraZeneca|Pfizer|Celgene","All","18 Years and older   (Adult, Older Adult)",,"1400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GEICAM 2014-03","June 2016","June 2024","June 2024","June 30, 2016",,"January 11, 2018","Hospital General de Elche, Elche, Alicante, Spain|Althaia-Xarxa Assistencial de Manresa, Manresa, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Donostia, San Sebastián, Donostia, Spain|Hospital Dr. Negrín, Las Palmas de Gran Canaria, Gran Canaria, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain|Hospital Son Llatzer, Palma de Mallorca, Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Sagunto, Sagunto, Valencia, Spain|Hospital Universitario de Basurto, Bilbao, Vizcaya, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital San Juan de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital Moisés Broggi_institut Catalá D´Oncologia, Barcelona, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital de León, León, Spain|Hospital Lucus Augusti, Lugo, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario de Málaga, Málaga, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|IVO-Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hosital General de Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain",,"https://ClinicalTrials.gov/show/NCT02819882"
1027,"NCT01745588","Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Procedure: stem cell|Drug: Dexamethasone|Drug: Clarithromycin","overall response rate|safety analyses|overall survival|progression free survival|Determine the rates of ≥ Grade 3 toxicities","Memorial Sloan Kettering Cancer Center|Celgene Corporation|Weill Medical College of Cornell University|North Shore University Hospital|Rutgers Cancer Institute of New Jersey|State University of New York - Upstate Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-138","December 2012","December 2020","December 2020","December 10, 2012",,"October 29, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|North Shore LIJ, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT01745588"
1028,"NCT00165477","Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme",,"Completed","No Results Available","Glioblastoma|Gliosarcoma|Malignant Gliomas","Drug: lenalidomide|Radiation: Radiation","To determine the efficacy of lenalidomide with conventional radiation therapy in the treatment of patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.|To assess the proportion of patients treated with lenalidomide and radiation therapy surviving at 12 months|to evaluate the time to tumor progression|the radiologic response|to determine the safety and toxicity of the combination of lenalidomide and radiation therapy.","Dana-Farber Cancer Institute|Celgene Corporation|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital|University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-222","September 2005","November 2007","July 2009","September 14, 2005",,"March 10, 2010","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00165477"
1029,"NCT03537222","Quality of Life in Patients With Multiple Myeloma-validation Study",,"Recruiting","No Results Available","Multiple Myeloma","Diagnostic Test: Myeloma Patient Outcome Scale (MyPOS)","Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS)","Zurich University of Applied Sciences|Kantonsspital Münsterlingen|Kantonsspital Aarau|Klinik Hirslanden, Zurich|Celgene Corporation|King's College London","All","18 Years and older   (Adult, Older Adult)",,"210","Other|Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","97107155001701","October 10, 2018","October 2020","December 2020","May 25, 2018",,"August 14, 2019","Kantonsspital Münsterlingen, Münsterlingen, Thurgau, Switzerland|Kantonsspital Aarau, Aarau, Zurich, Switzerland|Onkozentrum Hirslanden, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03537222"
1030,"NCT01755975","Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma|Non-Hodgkin's Lymphoma","Drug: Romidepsin|Drug: Lenalidomide","define the maximum tolerated dose|safety and toxicity|assess the overall response rate (ORR)|assess clinical benefit rate (CBr)|assess the time to response (TTR)","Memorial Sloan Kettering Cancer Center|Saint Francis/Mount Sinai Regional Cancer Center|Weill Medical College of Cornell University|University of Nebraska|Celgene Corporation|Biologics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-170","December 2012","December 2019","December 2019","December 24, 2012",,"March 6, 2019","Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy, Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT01755975"
1031,"NCT00378105","Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Bortezomib|Drug: Lenalidomide|Drug: dexamethasone","Objective Response Rate of the Drug Combination in This Patient Populations.|Estimated 18-month Progression Free Survival (PFS) Rate|Percentage of Patients Who Remained in Response for More Than 18 Months|Estimated 18-month Overall Survival Rate","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","68","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-150","September 2006","July 2009","February 2021","September 19, 2006","August 19, 2014","June 11, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00378105"
1032,"NCT03498625","Crohn's Disease Endoscopic REmission Definition in an Objective Way","CREDO1","Recruiting","No Results Available","CD","Diagnostic Test: Colonoscopy","Building an objective definition of the depth or grade of endoscopic remission in relation to what is observed during endoscopy in CD patients presenting with clinical remission|Intra- and inter-observer variability of what is observed during endoscopy in CD|Intra- and inter-observer variability of depth and grade of endoscopic remission in CD","Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|AbbVie|Biogen|Celgene|Gilead Sciences|Roche Pharma AG|Takeda","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GETAID 2017-001|2017-003345-15","March 13, 2018","March 13, 2020","March 13, 2020","April 17, 2018",,"April 11, 2019","Leuven University Hospital, Leuven, Belgium|APHP- Hopital BEAUJON, Clichy, France",,"https://ClinicalTrials.gov/show/NCT03498625"
1033,"NCT03487900","Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up","CREDO2","Recruiting","No Results Available","CD","Diagnostic Test: Colonoscopy","Sustained clinical remission at week 104|Sustained clinical remission at week 52|Sustained clinical remission at week 26|Time to disease flare based on biomarker measurement|Sustained clinical remission according to treatment group as an exploratory endpoint","Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|AbbVie|Biogen|Celgene|Gilead Sciences|Roche Pharma AG|Takeda","All","18 Years and older   (Adult, Older Adult)","Not Applicable","320","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GETAID 2017-002|2017-003345-15","March 13, 2018","March 13, 2022","March 13, 2022","April 4, 2018",,"April 11, 2019","Leuven University Hospital, Leuven, Belgium|APHP- Hopital BEAUJON, Clichy, France",,"https://ClinicalTrials.gov/show/NCT03487900"
1034,"NCT01928576","Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","NA_00084192","Recruiting","No Results Available","Non-Small Lung Cancer, Epigenetic Therapy","Drug: Azacitidine|Drug: Entinostat|Drug: Nivolumab","Objective Response|Progression free survival|Time to Progression|Overall survival|Safety and tolerability as assessed by number of participants with adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Rising Tide Foundation|Stand Up To Cancer|Bristol-Myers Squibb|Celgene|Syndax Pharmaceuticals, Inc.|Rhone-Poulenc Rorer","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1353|NA_00084192|119134|117207|121445|CA209-117","August 2013","August 2022","August 2022","August 26, 2013",,"September 23, 2019","University of Southern California, Los Angeles, California, United States|Julie Brahmer, MD, Baltimore, Maryland, United States|Julie Brahmer, MD, Baltimore, Maryland, United States|UPMC Cancer Center- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01928576"
1035,"NCT03732703","Myeloma-Developing Regimens Using Genomics (MyDRUG)","MyDRUG","Recruiting","No Results Available","Relapsed Refractory Multiple Myeloma","Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomide|Drug: Enasidenib, dexamethasone, ixazomib, pomalidomide|Drug: Cobimetinib, dexamethasone, ixazomib, pomalidomide|Drug: Erdafitinib, dexamethasone, ixazomib, pomalidomide|Drug: Venetoclax, dexamethasone, ixazomib, pomalidomide|Drug: Daratumumab, dexamethasone, ixazomib, pomalidomide","Overall Response Rate - Actionable Genetic Alteration|Overall Response Rate - Non-Actionable Genetic Alteration","Multiple Myeloma Research Consortium|AbbVie|Celgene Corporation|Eli Lilly and Company|Genentech, Inc.|Janssen, LP|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","228","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MyDRUG (MMRC-085)","April 1, 2019","February 10, 2022","February 10, 2024","November 7, 2018",,"October 21, 2019","Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03732703"
1036,"NCT01380106","Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Lenalidomide 15mg|Drug: Lenalidomide 25mg","Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.|Duration of M-Protein response during combination therapy with Lenalidomide plus dexamethasone|Confirmed M-Protein response|Expression of angiogenic factors, cytokines, adhesion molecules, and myeloma biomarker expression","Boston VA Research Institute, Inc.|Celgene Corporation|Kansas City Veteran Affairs Medical Center|VA Pittsburgh Healthcare System|VA Greater Los Angeles Healthcare System|Michael Debakey Veterans Affairs Medical Center|Edward Hines Jr. VA Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RV-MM-PI-0345","August 2010","September 2016","December 2016","June 27, 2011",,"February 2, 2016","Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|West Los Angeles VA Medical Center, Los Angeles, California, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|VA Boston Healthcare System, Jamaica Plain, Massachusetts, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Pittsburgh VA Medical Center, Pittsburgh, Pennsylvania, United States|Houston VA Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01380106"
1037,"NCT03307148","Stromal TARgeting for PAncreatic Cancer (STAR_PAC)","STAR_PAC","Unknown status","No Results Available","Pancreatic Adenocarcinoma","Drug: ATRA|Drug: Gemcitabine|Drug: Nab-paclitaxel","Part 1: Dose Limiting Toxicities (DLT)|Part 2: Optimum Biological Dose (OBD)|Maximum concentration observed (Cmax)|Time of maximum concentration observed (Tmax)|Area under the curve (AUC)|Change in serum Vitamin A levels|Incidence of adverse events (AE)|Objective response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)","Barts & The London NHS Trust|Medical Research Council|Celgene Corporation|Cancer Research UK Cambridge Institute|King's College London|Royal Free Hospital NHS Foundation Trust|Imperial College Healthcare NHS Trust|Institute of Cancer Research, United Kingdom|Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010432QM|2015-002662-23","January 15, 2016","March 2018","March 2018","October 11, 2017",,"October 11, 2017","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Barts and The London NHS, St Bartholomew's Hospital, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03307148"
1038,"NCT02622581","Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients","CRISP","Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer (NSCLC)|Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage II|Non Small Cell Lung Cancer Stage III|Small-cell Lung Cancer","Other: data collection","biomarker|treatment|Response rate|progression free survival|overall survival|physician-reported factors|supportive therapies|changes during the project|general health-related and individual quality of life (QoL) patient-reported outcomes|physical and psychological well-being patient-reported outcomes|anxiety patient-reported outcomes","AIO-Studien-gGmbH|AstraZeneca|Celgene Corporation|Merck Sharp & Dohme Corp.|Novartis Pharmaceuticals|Pfizer|Boehringer Ingelheim|Bristol-Myers Squibb|iOMEDICO AG|Eli Lilly and Company|Roche Pharma AG|Takeda","All","18 Years and older   (Adult, Older Adult)",,"7500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AIO-TRK-0315","December 2015","September 2023","December 2025","December 4, 2015",,"October 30, 2019","Pius-Hospital, Oldenburg, Germany",,"https://ClinicalTrials.gov/show/NCT02622581"
1039,"NCT01208662","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","DFCI 10-106","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Bortezomib|Drug: Dexamethasone|Procedure: Autologous Stem Cell Transplant","Primary Outcome|Secondary Outcome|Secondary Outcomes","Paul G. Richardson, MD|Celgene Corporation|Millennium Pharmaceuticals, Inc.|Massachusetts General Hospital|Cape Cod Hospital|Beth Israel Deaconess Medical Center|Emory University|University of Michigan|Fox Chase Cancer Center|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Barbara Ann Karmanos Cancer Institute|Duke University|University of California, San Francisco|University of Chicago|M.D. Anderson Cancer Center|UNC Lineberger Comprehensive Cancer Center|Roswell Park Cancer Institute|Stanford University|University of Mississippi Medical Center|Icahn School of Medicine at Mount Sinai|Wake Forest University Health Sciences|University of Arizona|OHSU Knight Cancer Institute|Eastern Maine Medical Center|University of California, San Diego|University of Alabama at Birmingham|University of Pittsburgh Medical Center|Ochsner Health System|University of Texas Southwestern Medical Center|State University of New York - Downstate Medical Center|Newton-Wellesley Hospital|Baylor College of Medicine|City of Hope Medical Center|University of Florida|Northwell Health|H. Lee Moffitt Cancer Center and Research Institute|Vanderbilt University Medical Center|Ohio State University|Huntsman Cancer Institute|Columbia University|Dana-Farber Cancer Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","660","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-106","September 2010","September 2020","September 2020","September 24, 2010",,"June 3, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Comprehensive Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|University of California at San Diego, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Foundation Clinic, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Brewer, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Cape Cod Healthcare, Hyannis, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|New Hampshire Oncology and Hematology, Concord, New Hampshire, United States|New Hampshire Oncology and Hematology, Hooksett, New Hampshire, United States|New Hampshire Oncology and Hematology, Laconia, New Hampshire, United States|State University of New York Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore Long Island Jewish Health System, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health and Sciences, Portland, Oregon, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01208662"
1040,"NCT01848028","PsoBest - The German Psoriasis Registry",,"Recruiting","No Results Available","Psoriasis|Psoriatic-arthritis",,"Psoriasis Area Severity Index (PASI)|Dermatology Life Quality Index (DLQI)","Universitätsklinikum Hamburg-Eppendorf|Berufsverband der Deutschen Dermatologen e.V. (BVDD)|Deutsche Dermatologische Gesellschaft e.V. (DDG)|AbbVie|Biogen|Janssen-Cilag G.m.b.H|medac GmbH|Merck Sharp & Dohme Corp.|Novartis Pharmaceuticals|Pfizer Deutschland GmbH|Serono GmbH (former collaborator)|PsoNet.eu|Celgene Corporation|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,"3500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IVDP-085-07","January 2008","December 2025","July 2026","May 7, 2013",,"May 17, 2019","Nationwide group of dermatological centers, hospitals and medical offices, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01848028"
1041,"NCT01790737","First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02","FMG-MM02","Completed","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Filgrastim","Immunophenotypic response|Progression free survival","Kuopio University Hospital|Helsinki University Central Hospital|Tampere University Hospital|Turku University Hospital|Oulu University Hospital|Mikkeli Central Hospital|Kymenlaakso Central Hospital Kotka Finland|Jyväskylä Central Hospital|Central Hospital of Kanta-Hame|Satakunta Central Hospital|Kainuu Central Hospital, Kajaani|Celgene Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KUH5101424|2012-001051-39","January 2013","October 10, 2018","February 26, 2019","February 13, 2013",,"March 1, 2019","Kuopio University Hospital, Kuopio, North Savo, Finland|Tampere University Hospital, Tampere, Pirkanmaa, Finland|Helsinki University Hospital, Helsinki, Finland|Kanta-Häme Central Hospital, Hämeenlinna, Finland|Jyväskylä Central Finland Central Hospital, Jyväskylä, Finland|Kainuu Kajaani Central Hospital, Kajaani, Finland|Länsi-Pohja Central Hospital, Kemi, Finland|Kymenlaakso Central Hospital, Kotka, Finland|Mikkeli Southern-Savo Central Hospital, Mikkeli, Finland|Oulu University Hospital, Oulu, Finland|Satakunta Central Hospital, Pori, Finland|Turku University Central Hospital, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT01790737"
